var images_info;if (!images_info) images_info =[]; images_info["60"]={"60000":{"type":"graphic_table","displayName":"Symptoms of miliary TB","title":"Symptoms in patients with miliary tuberculosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms in patients with miliary tuberculosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">Maartens, 1990</td> <td class=\"subtitle1\">Kim, 1990</td> <td class=\"subtitle1\">Gelb, 1973</td> <td class=\"subtitle1\">Munt, 1971</td> <td class=\"subtitle1\">Proudfoot, 1969</td> <td class=\"subtitle1\">Biehl, 1957</td> </tr> <tr> <td>Fever and/or night sweats</td> <td>96*</td> <td>89</td> <td>85</td> <td>83</td> <td>83</td> <td>35</td> </tr> <tr> <td>Anorexia</td> <td>92</td> <td>78</td> <td>87</td> <td>91</td> <td>&nbsp;</td> <td>42</td> </tr> <tr> <td>Weight loss</td> <td>92</td> <td>66</td> <td>87</td> <td>85</td> <td>75</td> <td>61</td> </tr> <tr> <td>Weakness or malaise</td> <td>92</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>92</td> <td>78</td> <td>40</td> </tr> <tr> <td>Respiratory (cough, dsypnea, pleuritic chest pain)</td> <td>72</td> <td>55</td> <td>69</td> <td>78</td> <td>18</td> <td>91</td> </tr> <tr> <td>Gastrointestinal (abdominal pain, nausea, vomiting, diarrhea)</td> <td>21</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>12</td> <td>&nbsp;</td> <td>32</td> </tr> <tr> <td>Headache or central nervous system</td> <td>25</td> <td>5</td> <td>16</td> <td>10</td> <td>&nbsp;</td> <td>27</td> </tr> <tr> <td>Musculoskeletal</td> <td>13</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* All of the numbers recorded are percentages.</div><div class=\"graphic_reference\">Courtesy of Nesli Basgoz, MD.</div><div id=\"graphicVersion\">Graphic 60000 Version 2.0</div></div></div>"},"60002":{"type":"graphic_figure","displayName":"Modified Semont maneuver","title":"Modified Semont maneuver","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Modified Semont maneuver</div><div class=\"cntnt\"><img style=\"width:526px; height:344px;\" src=\"images/NEURO/60002_Modified_Semont_maneuver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The modified Semont maneuver is illustrated for left posterior canalithiasis. The seated patient begins by turning the head 45º to the right. The patient then quickly drops the trunk to the left side (1) with the head turned 45º to the right. This position is held for at least 30 seconds or until any provoked vertigo subsides. The patient then quickly sits up and lies down on the right side without stopping in the upright position (2), all the while keeping the head turned 45º to the right so that the head now faces partly down into the bed. This position is held for 30 seconds or until vertigo subsides. Then patient returns to the upright position (3). This maneuver is repeated three times a day until the patient is asymptomatic. For right posterior canalithiasis, the maneuver must be performed in the opposite direction, starting with the head turned toward the left.</div><div class=\"graphic_reference\">Modified from Radtke, A, von Brevern, M, Tiel-Wilck, K, et al. Self- treatment of benign paroxysmal positional vertigo. Neurology 2004; 63:150.</div><div id=\"graphicVersion\">Graphic 60002 Version 4.0</div></div></div>"},"60003":{"type":"graphic_picture","displayName":"Lip hemangioma","title":"Lip hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lip hemangioma</div><div class=\"cntnt\"><img style=\"width:370px; height:277px;\" src=\"images/PEDS/60003_Lip_hemangioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemangiomas in visible sites of the lip are particularly prone to disfigurement.</div><div class=\"graphic_reference\">Courtesy of Denise W Metry, MD.</div><div id=\"graphicVersion\">Graphic 60003 Version 3.0</div></div></div>"},"60004":{"type":"graphic_picture","displayName":"Superficial hemangioma","title":"Superficial hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial hemangioma</div><div class=\"cntnt\"><img style=\"width:225px; height:157px;\" src=\"images/PEDS/60004_Superficial_hemangioma_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superficial hemangiomas consist of a bright red papule, nodule, or plaque raised above clinically normal skin.</div><div class=\"graphic_reference\">Courtesy of Denise W Metry, MD.</div><div id=\"graphicVersion\">Graphic 60004 Version 2.0</div></div></div>"},"60005":{"type":"graphic_table","displayName":"Functional exercise progression for return to tennis","title":"Functional exercise progression for return to tennis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Functional exercise progression for return to tennis</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>1. Mini-tennis from service line, essentially point of contact &#8594; follow through</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>2. 2/3 court with a little more backswing and gentle spin if able</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>3. Full court with good leg drive but no heavy spin or pace</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>4. Throwing tennis ball from service line to other side</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>5. Serves from service line</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>6. Full groundstrokes &#8594; full serves &#8594; competition</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>7. Limit excessive/early spin; limit volume of play for 2 weeks until functioning normally</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_lgnd\">The progression described above is approximate. Steps one through five are performed 10 minutes daily for several days before moving to the next step.</div><div id=\"graphicVersion\">Graphic 60005 Version 2.0</div></div></div>"},"60006":{"type":"graphic_table","displayName":"Manifestations Turner syndrome","title":"Approximate incidence of major clinical abnormalities in Turner syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approximate incidence of major clinical abnormalities in Turner syndrome</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Abnormalities</td> <td class=\"subtitle1\">Frequency (percent)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Skeletal growth disturbances</td> </tr> <tr> <td class=\"indent1\">Short stature</td> <td>95 to 100</td> </tr> <tr> <td class=\"indent1\">Growth failure&nbsp;</td> <td>90 to 95</td> </tr> <tr> <td class=\"indent1\">Increased&nbsp;upper to low segment ratio&nbsp;</td> <td>&#62;90&nbsp;</td> </tr> <tr> <td class=\"indent1\">Defective dental development, malocclusion&nbsp;</td> <td>up to 75&nbsp;&nbsp;</td> </tr> <tr> <td class=\"indent1\">Characteristic facies with micrognathia&nbsp;</td> <td>60&nbsp;</td> </tr> <tr> <td class=\"indent1\">Cubitus valgus&nbsp;</td> <td>50&nbsp;</td> </tr> <tr> <td class=\"indent1\">Kyphosis&nbsp;&nbsp;</td> <td>50&nbsp;&nbsp;</td> </tr> <tr> <td class=\"indent1\">Short neck</td> <td>40</td> </tr> <tr> <td class=\"indent1\">Genu valgum</td> <td>35</td> </tr> <tr> <td class=\"indent1\">High arched palate&nbsp;</td> <td>35&nbsp;</td> </tr> <tr> <td class=\"indent1\">Widely spaced nipples, broad chest</td> <td>30 to 35</td> </tr> <tr> <td class=\"indent1\">Short metacarpals</td> <td>35</td> </tr> <tr> <td class=\"indent1\">Scoliosis&nbsp;</td> <td>10 to 20&nbsp;</td> </tr> <tr> <td class=\"indent1\">Madelung deformity</td> <td>5</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Lymphatic obstruction</td> </tr> <tr> <td class=\"indent1\">Low posterior hairline&nbsp;</td> <td>40&nbsp;</td> </tr> <tr> <td class=\"indent1\">Edema of hands/feet&nbsp;</td> <td>20 to 30&nbsp;</td> </tr> <tr> <td class=\"indent1\">Characteristic dermatoglyphics&nbsp;</td> <td>30&nbsp;</td> </tr> <tr> <td class=\"indent1\">Webbed neck</td> <td>25</td> </tr> <tr> <td class=\"indent1\">Earlobe anomalies (eg, rotated)</td> <td>15 to 20</td> </tr> <tr> <td class=\"indent1\">Nail dysplasia</td> <td>10</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Germ cell chromosomal defects</td> </tr> <tr> <td class=\"indent1\">Infertility&nbsp;&nbsp;&nbsp;</td> <td>95&nbsp;&nbsp;</td> </tr> <tr> <td class=\"indent1\">Ovarian&nbsp;failure&nbsp;&nbsp;</td> <td>90&nbsp;&nbsp;</td> </tr> <tr> <td class=\"indent1\">Gonadal dysgenesis&nbsp;&nbsp;&nbsp;&nbsp;</td> <td>85 to 90&nbsp;</td> </tr> <tr> <td class=\"indent1\">Gonadoblastoma&nbsp;</td> <td>5</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Abnormalities</td> <td class=\"subtitle1\">&nbsp;Frequency (percent)</td> </tr> <tr> <td class=\"subtitle2_left\">Other features&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td> <p class=\"indent1\">Cardiac malformations&nbsp;</p> </td> <td>up to 50</td> </tr> <tr> <td class=\"indent2\"><span class=\"indent2\"></span>Aortic valve abnormalities (primarily bicuspid aortic valve)</td> <td>15 to 30</td> </tr> <tr> <td class=\"indent2\">Elongated transverse aortic arch&nbsp;&nbsp;</td> <td>40 to 50&nbsp;&nbsp;</td> </tr> <tr> <td class=\"indent2\">Coarctation of the aorta&nbsp;</td> <td>up to 17</td> </tr> <tr> <td class=\"indent2\">Ventricular septal defects&nbsp;</td> <td>1 to 4</td> </tr> <tr> <td class=\"indent2\">Atrial septal defects&nbsp;</td> <td>1 to 2</td> </tr> <tr> <td class=\"indent2\">Systemic venous abnormalities (such as persistent left superior vena cava)</td> <td>8 to 13</td> </tr> <tr> <td class=\"indent2\">Pulmonary venous abnormalities&nbsp;</td> <td>13 to 15&nbsp;</td> </tr> <tr> <td class=\"indent1\"><span class=\"indent1\">Renal and renovascular anomalies</span>&nbsp;</td> <td>&#62;30</td> </tr> <tr> <td class=\"indent1\">Hypertension&nbsp;</td> <td>30&nbsp;</td> </tr> <tr> <td class=\"indent1\">Ocular abnormalities</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist3_start\">Myopia or hyperopia&nbsp;&nbsp;</td> <td>20 to 50&nbsp;&nbsp;</td> </tr> <tr> <td class=\"sublist3_start\">Strabismus &nbsp;</td> <td>15&nbsp;to 30&nbsp;</td> </tr> <tr> <td class=\"sublist3_start\">Amblyopia&nbsp;</td> <td>&#62;15</td> </tr> <tr> <td class=\"sublist3_start\">Ptosis &nbsp;</td> <td>10 to 30&nbsp;</td> </tr> <tr> <td class=\"indent1\">Ears and hearing</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist3_start\">Recurrent otitis media</td> <td>50 to 70&nbsp;&nbsp;</td> </tr> <tr> <td class=\"sublist3_start\">Sensorineural &nbsp;hearing loss&nbsp;</td> <td>50 (by adulthood)&nbsp;&nbsp;</td> </tr> <tr> <td class=\"sublist3_start\">Conductive hearing loss&nbsp;</td> <td>10 to 40&nbsp;</td> </tr> <tr> <td class=\"sublist3_start\">Cholesteatoma&nbsp;</td> <td> <p>5 </p> </td> </tr> <tr> <td class=\"indent1\">Skin </td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist3_start\">Multiple pigmented nevi&nbsp;</td> <td>25&nbsp;</td> </tr> <tr> <td class=\"sublist3_start\">Vitiligo&nbsp;</td> <td>5</td> </tr> <tr> <td class=\"sublist3_start\">Alopecia&nbsp;</td> <td>5&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Autoimmune</td> </tr> <tr> <td class=\"indent1\"> <p>Thyroiditis</p> <p>(rate increases with age)</p> </td> <td>15&nbsp;to 30</td> </tr> <tr> <td class=\"indent1\">Celiac disease</td> <td>&nbsp;6</td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease</td> <td>&nbsp;4</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>​Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. J Clin Epidemiol 1998; 51:147.</LI>&#xD;&#xA;<LI>Sylvén L, Hagenfeldt K, Bröndum-Nielsen K, von Schoultz B. Middle-aged women with Turner's syndrome. Medical status, hormonal treatment and social life. Acta Endocrinol (Copenh) 1991; 125:359.</LI>&#xD;&#xA;<LI>Lippe B. Turner syndrome. Endocrinol Metab Clin North Am 1991; 20:121.</LI>&#xD;&#xA;<LI>Gøtzsche CO, Krag-Olsen B, Nielsen J, et al. Prevalence of cardiovascular malformations and association with karyotypes in Turner's syndrome. Arch Dis Child 1994; 71:433.</LI>&#xD;&#xA;<LI>Kim HK, Gottliebson W, Hor K, et al. Cardiovascular anomalies in Turner syndrome: spectrum, prevalence, and cardiac MRI findings in a pediatric and young adult population. AJR Am J Roentgenol 2011; 196:454.</LI>&#xD;&#xA;<LI>Mortensen KH, Andersen NH, Gravholt CH. Cardiovascular phenotype in Turner syndrome--integrating cardiology, genetics, and endocrinology. Endocr Rev 2012; 33:677.</LI></OL></div><div id=\"graphicVersion\">Graphic 60006 Version 7.0</div></div></div>"},"60007":{"type":"graphic_picture","displayName":"Divert bleed endoclip endos","title":"Diverticular bleeding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diverticular bleeding</div><div class=\"cntnt\"><img style=\"width:396px; height:298px;\" src=\"images/GAST/60007_Divert_bleed_endoclip_endos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Closure of a diverticular bleed with two Resolution endoclips. Active bleeding was found initially in a hepatic flexure diverticulum in a patient presenting with severe hematochezia. The upper left image shows the bleeding diverticulum following injection with dilute epinephrine (1:20,000). Clockwise image show deployment of the two clips. The area was subsequently tattooed with India ink. There was no rebleeding with six months of follow-up.</div><div class=\"graphic_reference\">Courtesy of Dennis M. Jensen, MD.</div><div id=\"graphicVersion\">Graphic 60007 Version 1.0</div></div></div>"},"60008":{"type":"graphic_picture","displayName":"Preparation catheter sheath","title":"Preparation of the catheter sheath","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Preparation of the catheter sheath</div><div class=\"cntnt\"><img style=\"width:540px; height:359px;\" src=\"images/GAST/60008_Preparation_catheter_sheath.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pictures showing the correct preparation of the cathether sheath.</div><div class=\"graphic_reference\">Courtesy of Michael J Levy, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 60008 Version 1.0</div></div></div>"},"60009":{"type":"graphic_table","displayName":"Probability abnormal test","title":"Probability of an abnormal screening test result","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Probability of an abnormal screening test result</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Number of independent tests</td>\n<td class=\"subtitle1\">Probability of abnormal test</td>\n</tr>\n<tr>\n<td>1</td>\n<td>5 percent</td>\n</tr>\n<tr>\n<td>2</td>\n<td>10 percent</td>\n</tr>\n<tr>\n<td>4</td>\n<td>19 percent</td>\n</tr>\n<tr>\n<td>6</td>\n<td>26 percent</td>\n</tr>\n<tr>\n<td>10</td>\n<td>40 percent</td>\n</tr>\n<tr>\n<td>20</td>\n<td>64 percent</td>\n</tr>\n<tr>\n<td>50</td>\n<td>92 percent</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 60009 Version 1.0</div></div></div>"},"60010":{"type":"graphic_diagnosticimage","displayName":"Bronchial atresia CT II","title":"Left upper lobe bronchial atresia seen on an axial CT image","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left upper lobe bronchial atresia seen on an axial CT image</div><div class=\"cntnt\"><img style=\"width:360px; height:260px;\" src=\"images/PULM/60010_Bronchial_atresia_CT_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT scan with lung window settings shows marked hyperexpansion of the left upper lobe, a tubular branching hilar mass, and absence of the proximal left upper lobe bronchus.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 60010 Version 5.0</div></div></div>"},"60011":{"type":"graphic_figure","displayName":"Etiology of in-toeing","title":"Primary diagnosis in 202 children referred for evaluation of in-toeing","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Primary diagnosis in 202 children referred for evaluation of in-toeing</div><div class=\"cntnt\"><img style=\"width:463px; height:301px;\" src=\"images/PEDS/60011_Etiology_in-toeing.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">\"Normal/physiological/habitual\" in-toeing represents a diagnosis made on the basis of normal walking for the age of that child, or where the child in-toes as a result of habit. The three terms were used interchangeably in the notes. In all of these eventualities, there is no pathology to identify. \"Foot pathology\" represents pes planus, metatarsus adductus or pronation of the forefoot. \"Other\" represents leg-length discrepancy, reduced peroneal power, or in-toeing after an ankle injury.</div><div class=\"graphic_reference\">Reproduced with permission from: Blackmur JP, Murray AW. Do children who in-toe need to be referred to an orthopaedic clinic? J Pediatr Orthop B 2010; 19:415. Copyright © 2010 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60011 Version 12.0</div></div></div>"},"60012":{"type":"graphic_table","displayName":"Risk classific exercise class B","title":"Risk classification for exercise training: class B: presence of known, stable cardiovascular disease with low risk for complications with vigorous exercise, but slightly greater than for apparently healthy individuals","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk classification for exercise training: class B: presence of known, stable cardiovascular disease with low risk for complications with vigorous exercise, but slightly greater than for apparently healthy individuals</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">This classification includes individuals with any of the following diagnoses:</td> </tr> <tr> <td class=\"indent1\">1. Coronary artery disease (myocardial infarction, bypass surgery, angioplasty, angina pectoris, abnormal exercise test, and abnormal coronary angiograms) whose condition is stable and who have the clinical characteristics outlined below.</td> </tr> <tr> <td class=\"indent1\">2. Valvular heart disease, excluding severe valvular stenosis or regurgitation with the clinical characteristics as outlined below.</td> </tr> <tr> <td class=\"indent1\">3. Congenital heart disease; risk stratification for patients with congenital heart disease should be guided by the 36<sup>th</sup> Bethesda Conference recommendations.</td> </tr> <tr> <td class=\"indent1\">4. Cardiomyopathy: ejection fraction &#8804;30 percent; includes stable patients with heart failure with clinical characteristics as outlined below but not hypertrophic cardiomyopathy or recent myocarditis.</td> </tr> <tr> <td class=\"indent1\">5. Exercise test abnormalities that do not meet any of the high risk criteria outlined in class C below.</td> </tr> <tr> <td class=\"subtitle1_single\">Clinical characteristics (must include all of the following)</td> </tr> <tr> <td class=\"indent1\">1. New York Heart Association class 1 or 2.</td> </tr> <tr> <td class=\"indent1\">2. Exercise capacity &#8804;6 METs.</td> </tr> <tr> <td class=\"indent1\">3. No evidence of heart failure.</td> </tr> <tr> <td class=\"indent1\">4. No evidence of myocardial ischemia or angina at rest or on the exercise test at or below 6 METs.</td> </tr> <tr> <td class=\"indent1\">5. Appropriate rise in systolic blood pressure during exercise.</td> </tr> <tr> <td class=\"indent1\">6. Absence of sustained or nonsustained ventricular tachycardia at rest or with exercise.</td> </tr> <tr> <td class=\"indent1\">7. Ability to satisfactorily self-monitor intensity of activity.</td> </tr> <tr> <td class=\"subtitle1_single\">Activity guidelines:</td> </tr> <tr> <td class=\"indent1\">1. Activity should be individualized, with exercise prescription provided by qualified individuals and approved by primary healthcare provider.</td> </tr> <tr> <td class=\"subtitle1_single\">Supervision required:</td> </tr> <tr> <td class=\"indent1\">1. Medical supervision during initial prescription session is beneficial.</td> </tr> <tr> <td class=\"indent1\">2. Supervision by appropriate trained nonmedical personnel for other exercise sessions should occur until the individual understands how to monitor his or her activity.</td> </tr> <tr> <td class=\"indent1\">3. Medical personnel should be trained and certified in Advanced Cardiac Life Support. Nonmedical personnel should be trained and certified in Basic Life Support (which includes cardiopulmonary resuscitation).</td> </tr> <tr> <td class=\"subtitle1_single\">ECG and blood pressure monitoring:</td> </tr> <tr> <td class=\"indent1\">1. Useful during the early prescription phase of training, usually 6 to 12 sessions.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">METs: metabolic equivalents; ECG: electrocardiogram.</div><div class=\"graphic_reference\">Reproduced with permission from: Fletcher GF, Balady GJ, Amsterdam EA, et al. Circulation 2001; 104:1694. Copyright &copy; 2001 Lippincott Williams and Wilkins.</div><div id=\"graphicVersion\">Graphic 60012 Version 6.0</div></div></div>"},"60013":{"type":"graphic_picture","displayName":"Coronary artery after stent","title":"Coronary artery after stent implantation","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Coronary artery after stent implantation</div><div class=\"cntnt\"><img style=\"width:514px; height:514px;\" src=\"images/CARD/60013_Coronary_artery_after_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The individual stent struts can be recognized as signal rich, bright yellow structures casting a dorsal shadow on the vessel wall. (IC) OCT imaging catheter in the center of the lumen; asterisk indicates the angioplasty guide wire artefact.</div><div class=\"graphic_footnotes\">OCT: St. Jude/Lightlab Imaging C7XR.</div><div class=\"graphic_reference\">Courtesy of Dr. Evelyn Regar, Thoraxcenter.</div><div id=\"graphicVersion\">Graphic 60013 Version 2.0</div></div></div>"},"60014":{"type":"graphic_table","displayName":"Causes of pediatric syncope ","title":"Causes of syncope in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of syncope in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\"><span class=\"red\" style=\"color: #000000;\">Primary cardiac electrical disturbances</span></td> </tr> <tr> <td class=\"sublist1\"><span class=\"red\" style=\"color: #000000;\">Long QT syndrome*</span></td> </tr> <tr> <td class=\"sublist1\"><span class=\"red\" style=\"color: #000000;\">Brugada syndrome*</span></td> </tr> <tr> <td class=\"sublist1\"><span class=\"red\" style=\"color: #000000;\">Familial catecholaminergic polymorphic ventricular tachycardia*</span></td> </tr> <tr> <td class=\"sublist1\"><span class=\"red\" style=\"color: #000000;\">Short QT syndrome*</span></td> </tr> <tr> <td class=\"sublist1\"><span class=\"red\" style=\"color: #000000;\">Preexcitation syndromes (such as Wolff Parkinson White)*</span></td> </tr> <tr> <td class=\"sublist1\">Bradyarrhythmias (complete atrioventricular block, sinus node dysfunction)*</td> </tr> <tr> <td class=\"sublist1_start\"><span class=\"red\" style=\"color: #000000;\">Structural cardiac abnormalities</span></td> </tr> <tr> <td class=\"sublist1\"><span class=\"red\" style=\"color: #000000;\">Hypertrophic cardiomyopathy*</span></td> </tr> <tr> <td class=\"sublist1\"><span class=\"red\" style=\"color: #000000;\">Coronary artery anomalies*</span></td> </tr> <tr> <td class=\"sublist1\"><span class=\"red\" style=\"color: #000000;\">Arrhythmogenic right ventriclular dysplasia/cardiomyopathy*</span></td> </tr> <tr> <td class=\"sublist1\"><span class=\"red\" style=\"color: #000000;\">Valvar aortic stenosis*</span></td> </tr> <tr> <td class=\"sublist1\"><span class=\"red\" style=\"color: #000000;\">Dilated cardiomyopathy*</span></td> </tr> <tr> <td class=\"sublist1\"><span class=\"red\" style=\"color: #000000;\">Pulmonary hypertension*</span></td> </tr> <tr> <td class=\"sublist1\"><span class=\"red\" style=\"color: #000000;\">Acute myocarditis*</span></td> </tr> <tr> <td class=\"sublist1\"><span class=\"red\" style=\"color: #000000;\">Congenital heart disease*</span></td> </tr> <tr> <td>Heat illness*</td> </tr> <tr> <td>Anaphylaxis*</td> </tr> <tr> <td><span class=\"green\" style=\"color: #000000;\">Vasovagal (neurocardiogenic) syndrome, including situational syncope (eg, cough, micturation, hair combing, blood draw, intramuscular injection, or emotional stress)<sup>&#182;</sup></span></td> </tr> <tr> <td><span class=\"green\" style=\"color: #000000;\">Breath holding spell<sup>&#182;</sup></span></td> </tr> <tr> <td><span class=\"green\" style=\"color: #000000;\">Orthostatic hypotension due&nbsp;to volume depletion&nbsp;(hemorrhage, dehydration, pregnancy, anorexia nervosa)<sup>&#182;</sup></span></td> </tr> <tr> <td>Drug effects or toxic exposure (eg, clonidine, typical antipsychotic agents, carbon monoxide, ethanol intoxication)<sup>&#182;</sup></td> </tr> <tr> <td>Hypoglycemia*</td> </tr> <tr> <td class=\"sublist1_start\">Conditions that mimic syncope</td> </tr> <tr> <td class=\"sublist1\">Seizure</td> </tr> <tr> <td class=\"sublist1\">Migraine syndromes</td> </tr> <tr> <td class=\"sublist1\">Hysterical faint</td> </tr> <tr> <td class=\"sublist1\">Hyperventilation</td> </tr> <tr> <td class=\"sublist1\">Intentional strangulation (eg, the \"choking game\")</td> </tr> <tr> <td class=\"sublist1\">Narcolepsy&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">* Potentially life-threatening causes. <br />¶ Common causes.</div><div id=\"graphicVersion\">Graphic 60014 Version 9.0</div></div></div>"},"60015":{"type":"graphic_waveform","displayName":"Basic case 6","title":"Basic case 6","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Basic case 6</div><div class=\"cntnt\"><img style=\"width:540px; height:125px;\" src=\"images/CARD/60015_Basic_case_6.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 60015 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"60016":{"type":"graphic_picture","displayName":"Lepromatous leprosy","title":"Lepromatous leprosy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lepromatous leprosy</div><div class=\"cntnt\"><img style=\"width:288px; height:350px;\" src=\"images/ID/60016_Lepromatous_leprosy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Generalized skin disease with prominent nodules on the face and earlobes.</div><div class=\"graphic_reference\">Reproduced with permission from McDougall AC, Yuasa Y. A New Atlas of leprosy, Sasakawa Memorial Health Foundation, Tokyo, 2000, and Guinto RS, Abalos RM, Cellopna RV, Fajardo TT. An Atlas of Leprosy, Sasakawa Memorial Health Foundation, Tokyo, 1983.</div><div id=\"graphicVersion\">Graphic 60016 Version 2.0</div></div></div>"},"60019":{"type":"graphic_table","displayName":"RDA pregnancy and lactation","title":"Recommended Dietary Allowances (RDA) or Adequate Intake (AI) and Tolerable Upper Limits (UL) for adult pregnant and lactating women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended Dietary Allowances (RDA) or Adequate Intake (AI) and Tolerable Upper Limits (UL) for adult pregnant and lactating women</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">RDAs</td> <td class=\"subtitle1\" rowspan=\"2\">ULs for pregnant and lactating women</td> </tr> <tr> <td class=\"subtitle2\">Pregnant women*</td> <td class=\"subtitle2\">Lactating women*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Fat-soluble vitamins</td> </tr> <tr> <td class=\"indent1\">Vitamin A</td> <td>770 mcg</td> <td>1300 mcg</td> <td>3000 mcg</td> </tr> <tr> <td class=\"indent1\">Vitamin D</td> <td>600 international units (15 mcg)</td> <td>600 international units (15 mcg)</td> <td>4000 international units (100 mcg)</td> </tr> <tr> <td class=\"indent1\">Vitamin E</td> <td>15 mg</td> <td>19 mg</td> <td>1000 mg</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vitamin K<sup>&#182;</sup></td> <td>90 mcg</td> <td>90 mcg</td> <td>ND</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Water-soluble vitamins</td> </tr> <tr> <td class=\"indent1\">Vitamin C</td> <td>85 mg</td> <td>120 mg</td> <td>2000 mg</td> </tr> <tr> <td class=\"indent1\">Thiamin</td> <td>1.4 mg</td> <td>1.4 mg</td> <td>ND</td> </tr> <tr> <td class=\"indent1\">Riboflavin</td> <td>1.4 mg</td> <td>1.6 mg</td> <td>ND</td> </tr> <tr> <td class=\"indent1\">Niacin</td> <td>18 mg</td> <td>17 mg</td> <td>35 mg</td> </tr> <tr> <td class=\"indent1\">Vitamin B<sub>6</sub></td> <td>1.9 mg</td> <td>2 mg</td> <td>100 mg</td> </tr> <tr> <td class=\"indent1\">Folate</td> <td>600 mcg</td> <td>500 mcg</td> <td>1000 mcg</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vitamin B<sub>12</sub></td> <td>2.6 mcg</td> <td>2.8 mcg</td> <td>ND</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Minerals</td> </tr> <tr> <td class=\"indent1\">Calcium</td> <td>1000 mg</td> <td>1000 mg</td> <td>2500 mg</td> </tr> <tr> <td class=\"indent1\">Phosphorus</td> <td>700 mg</td> <td>700 mg</td> <td>4000 mg</td> </tr> <tr> <td class=\"indent1\">Iron</td> <td>27 mg</td> <td>9 mg</td> <td>45 mg</td> </tr> <tr> <td class=\"indent1\">Zinc</td> <td>11 mg</td> <td>12 mg</td> <td>40 mg</td> </tr> <tr> <td class=\"indent1\">Iodine</td> <td>220 mcg</td> <td>290 mcg</td> <td>1100 mcg</td> </tr> <tr> <td class=\"indent1\">Selenium</td> <td>60 mcg</td> <td>70 mcg</td> <td>400 mcg</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ND: Not determinable due to lack of data of adverse effects and concern with regard to lack of ability to handle excess amounts.<br />* Females over 18 years old.<br />¶ The requirement for vitamin K is given as an \"Adequate Intake (AI)\" rather than an RDA, because there was insufficient scientific evidence to calculate the RDA. </div><div class=\"graphic_reference\">Adapted from: Guidelines for Perinatal Care, sixth edition (2007); and Institute of Medicine Dietary Reference Intakes for Calcium and Vitamin D (2011), which can be accessed via <A href=\"http://www.nap.edu/\">www.nap.edu</A>. </div><div id=\"graphicVersion\">Graphic 60019 Version 8.0</div></div></div>"},"60020":{"type":"graphic_table","displayName":"Cytotoxic uses MTX","title":"Oncologic spectrum of methotrexate activity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oncologic spectrum of methotrexate activity</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\n\t\t\t\t<tr>\n\t\t\t\t\t<td>T-cell large granular lymphocytic leukemia</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Acute lymphoblastic leukemia</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Acute promyelocytic leukemia</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Choriocarcinoma/malignant trophoblastic disease</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Osteosarcoma</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Non-Hodgkin's lymphoma</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Breast cancer</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Gastric cancer</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Esophageal cancer</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Bladder cancer</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Desmoid tumors</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Head and neck cancer</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Leptomeningeal metastases (both intrathecal and high-dose parenteral)</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Courtesy of Crain Garrot, MD.</div><div id=\"graphicVersion\">Graphic 60020 Version 1.0</div></div></div>"},"60023":{"type":"graphic_figure","displayName":"Sartorius muscle flap","title":"Sartorius muscle flap transposed over femoral vessels at time of groin node dissection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sartorius muscle flap transposed over femoral vessels at time of groin node dissection</div><div class=\"cntnt\"><img style=\"width:233px; height:253px;\" src=\"images/OBGYN/60023_Sartorius_muscle_flap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The sartorius muscle is sutured to the inguinal ligament and over the femoral vessels at the end of the groin node dissection.</div><div id=\"graphicVersion\">Graphic 60023 Version 3.0</div></div></div>"},"60024":{"type":"graphic_table","displayName":"Response criteria AML","title":"Response criteria in acute myeloid leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Response criteria in acute myeloid leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Definition</td> </tr> <tr> <td>Complete remission (CR)*</td> <td>Bone marrow blasts &#60;5 percent; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count &#62;1.0 x 10<sup>9</sup>/L (1000/&#181;L); platelet count &#62;100 x 10<sup>9</sup>/L (100,000/&#181;L); independence of red cell transfusions</td> </tr> <tr> <td>CR with incomplete recovery (CRi)<sup>&#182;</sup></td> <td>All CR criteria except for residual neutropenia (&#60;1.0 x 10<sup>9</sup>/L (1000/&#181;L)) or thrombocytopenia (&#60;100 x 10<sup>9</sup>/L (100,000/&#181;L))</td> </tr> <tr> <td>Morphologic leukemia-free state<sup>&#916;</sup></td> <td>Bone marrow blasts &#60;5 percent; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required</td> </tr> <tr> <td>Partial remission (PR)</td> <td>Relevant in the setting of phase I and II clinical trials only; all hematologic criteria of CR; decrease of bone marrow blast percentage to 5 to 25 percent; and decrease of pretreatment bone marrow blast percentage by at least 50 percent</td> </tr> <tr> <td>Cytogenetic CR (CRc)<sup>&#9674;</sup></td> <td>Reversion to a normal karyotype at the time of morphologic CR (or CRi) in cases with an abnormal karyotype at the time of diagnosis; based on the evaluation of 20 metaphase cells from bone marrow</td> </tr> <tr class=\"divider_bottom\"> <td>Molecular CR (CRm)<sup>&#167;</sup></td> <td>No standard definition; depends on molecular target</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Treatment failure </td> </tr> <tr> <td class=\"indent1\">Resistant disease (RD)</td> <td>Failure to achieve CR or CRi (general practice; phase II/III trials), or failure to achieve CR, CRi or PR (phase I trials); only includes patients surviving &#8805;7 days following completion of initial treatment, with evidence of persistent leukemia by blood and/or bone marrow examination</td> </tr> <tr> <td class=\"indent1\">Death in aplasia</td> <td>Deaths occurring &#8805;7 days following completion of initial treatment while cytopenic; with an aplastic or hypoplastic bone marrow obtained within 7 days of death, without evidence of persistent leukemia</td> </tr> <tr> <td class=\"indent1\">Death from indeterminate cause</td> <td>Deaths occurring before completion of therapy, or &#60;7 days following its completion; or deaths occurring &#8805;7 days following completion of initial therapy with no blasts in the blood, but no bone marrow examination available</td> </tr> <tr> <td class=\"indent1\">Relapse<sup>&#165;</sup></td> <td>Bone marrow blasts &#8805;5 percent; or reappearance of blasts in the blood; or development of extramedullary disease</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Definitions of response criteria are based primarily on those given by Cheson et al<sup>[2]</sup>.</div><div class=\"graphic_footnotes\">* All criteria need to be fulfilled; marrow evaluation should be based on a count of 200 nucleated cells in an aspirate with spicules; if ambiguous, consider repeat exam after 5 to 7 days; flow cytometric evaluation may help to distinguish between persistent leukemia and regenerating normal marrow; a marrow biopsy should be performed in cases of dry tap, or if no spicules are obtained; no minimum duration of response required.<br />¶ The criterion of CRi is of value in protocols using intensified induction or double induction strategies, in which hematologic recovery is not awaited, but intensive therapy will be continued. In such protocols, CR may even not be achieved in the course of the entire treatment plan. In these instances, the overall remission rate should include CR and CRi patients. Some patients may not achieve complete hematologic recovery upon longer observation times.<br />Δ This category may be useful in the clinical development of novel agents within phase I clinical trials, in which a transient morphologic leukemia-free state may be achieved at the time of early response assessment.<br /><FONT class=lozenge>◊</FONT> Four studies showed that failure to convert to a normal karyotype at the time of CR predicts inferior outcome.<SUP>[3-6]</SUP><br />§ As an example, in CBF AML low-level PCR-positivity can be detected in patients even in long-term remission. Normalizing to 10<SUP>4</SUP> copies of ABL1 in accordance with standardized criteria, transcript levels below 10 to 12 copies appear to be predictive for long-term remission.<SUP>[7-9]</SUP><br />¥ In cases with low blast percentages (5 to 10 percent), a repeat marrow should be performed to confirm relapse. Appearance of new dysplastic changes should be closely monitored for emerging relapse. In a patient who has been recently treated, dysplasia or a transient increase in blasts may reflect a chemotherapy effect and recovery of hematopoiesis. Cytogenetics should be tested to distinguish true relapse from therapy-related MDS/AML.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>This research was originally published in Blood. Dohner, H, Estey, EH, Amadori, S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel on behalf of the European LeukemiaNet. Blood 2009. Copyright © American Society of Hematology.</LI>&#xD;&#xA;<LI>Cheson, BD, Bennett, JM, Kopecky, KJ, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21:4642.</LI>&#xD;&#xA;<LI>Freireich, EJ, Cork, A, Stass, SA, et al. Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia 1992; 6:500.</LI>&#xD;&#xA;<LI>Grimwade, D, Walker, H, Oliver, F, et al. What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML trial. Bone Marrow Transplant 1997; 19:1117.</LI>&#xD;&#xA;<LI>Marcucci, G, Mrózek, K, Ruppert, AS, et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B study 8461. J Clin Oncol 2004; 22:2410.</LI>&#xD;&#xA;<LI>Balleisen, S, Kuendgen, A, Hildebrandt, B, et al. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy. Leuk Res 2009; 33:1189.</LI>&#xD;&#xA;<LI>Freeman, SD, Jovanovic, JV, Grimwade, D. Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin Oncol 2008; 35:388.</LI>&#xD;&#xA;<LI>Perea, G, Lasa, A, Aventín, A, et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia 2006; 20:87.</LI>&#xD;&#xA;<LI>Martinelli, G, Rondoni, M, Buonamici, S, et al. Molecular monitoring to identify a threshold of CBFβ/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv(16) is likely [letter]. Haematologica 2004; 89:495.</LI></OL></div><div id=\"graphicVersion\">Graphic 60024 Version 3.0</div></div></div>"},"60025":{"type":"graphic_table","displayName":"Maternal blood lead follow-up testing during lactation","title":"Frequency of maternal blood lead follow-up testing during lactation to assess risk for infant lead exposure from maternal breast milk*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of maternal blood lead follow-up testing during lactation to assess risk for infant lead exposure from maternal breast milk*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Initial venous blood lead level<sup>&#182;</sup> (BLL; mcg/dL)</td> <td class=\"subtitle1\">Perform follow-up blood lead test(s)</td> </tr> <tr> <td>5 to 19</td> <td>Every&nbsp;three months, unless infant BLLs are rising or fail to decline.</td> </tr> <tr> <td>20 to 39</td> <td>Two&nbsp;weeks postpartum and then at one- to three-month intervals depending on direction/magnitude of trend in infant BLLs.</td> </tr> <tr> <td>&#8805;40</td> <td>Within 24 hours postpartum and then at frequent intervals depending on clinical interventions and trend in BLLs. Consultation with a clinician experienced in the management of lead poisoning is advised.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* If a woman becomes pregnant while lactating, she should be followed according to the schedule for pregnancy.<br />¶ Last BLL measured in pregnancy or at delivery (maternal or cord BLL).</div><div class=\"graphic_reference\">Reproduced from: Ettinger AS, Wengrovitz AG. Guidelines for the Identification and Management of Lead Exposure in Pregnant and Lactating Women. Centers for Disease Control and Prevention. November 2010.</div><div id=\"graphicVersion\">Graphic 60025 Version 8.0</div></div></div>"},"60026":{"type":"graphic_picture","displayName":"Cutaneous squamous cell carcinoma","title":"Cutaneous squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutaneous squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/60026_Cut_squamous_cell_carcin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous, hyperkeratotic papule is present on the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60026 Version 4.0</div></div></div>"},"60027":{"type":"graphic_picture","displayName":"Inducing blister","title":"How to induce a blister before biopsy for epidermolysis bullosa","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">How to induce a blister before biopsy for epidermolysis bullosa</div><div class=\"cntnt\"><img style=\"width:583px; height:281px;\" src=\"images/DERM/60027_Inducing_blister_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Rub the normal skin with twisting movements of a pencil eraser for a few seconds and repeat. The skin should not peel. Recheck the area intermittently for redness and vesiculation before performing the biopsy.<br> (B) This is the degree of redness and vesiculation needed before taking the 3 mm punch biopsy for immunofluorescence mapping in the vesiculated area. The 2 mm punch biopsy for electron microscopy may be taken from this area also.</div><div id=\"graphicVersion\">Graphic 60027 Version 1.0</div></div></div>"},"60028":{"type":"graphic_picture","displayName":"Paddle size","title":"Pediatric and adult electrode paddles","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pediatric and adult electrode paddles</div><div class=\"cntnt\"><img style=\"width:444px; height:348px;\" src=\"images/EM/60028_Paddlesize.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paddles and electrode pads designed for adults are recommended for children who weigh more than 10 kg (large circular paddles in picture). Of these, those 12 cm in diameter seem to be superior to those that are 8 cm in diameter. Infant paddles or pads are to be used for smaller infants weighing &lt;10 kg (small circular paddles above).</div><div class=\"graphic_reference\">Reproduced with permission from: Scarfone RJ, Cho CS. Cardioversion and Defibrillation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 60028 Version 11.0</div></div></div>"},"60029":{"type":"graphic_figure","displayName":"Long term GH in TS","title":"Efficacy of GH in Turner syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Efficacy of GH in Turner syndrome</div><div class=\"cntnt\"><img style=\"width:340px; height:459px;\" src=\"images/ENDO/60029_Long_term_GH_in_TS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long-term growth hormone (GH) dose-response results in Turner syndrome. Individual heights at the start of the study (white circles) and after seven years of GH treatment (red circles). Reference curves for healthy Dutch girls (solid lines) (3rd, 10th, 50th, 90th, and 97th percentiles) and for untreated girls with TS (dotted lines) (North European references; 3rd, 50th, and 97th percentiles) are given.</div><div class=\"graphic_reference\">Data from: Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, et al. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab 1999; 84:4607.</div><div id=\"graphicVersion\">Graphic 60029 Version 2.0</div></div></div>"},"60030":{"type":"graphic_table","displayName":"Differential diagnosis of small intestinal villous atrophy","title":"Causes of small intestinal villous atrophy other than celiac disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of small intestinal villous atrophy other than celiac disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Small intestinal bacterial overgrowth</td> </tr> <tr> <td>Crohn disease</td> </tr> <tr> <td>Cow's milk or soy protein intolerance (children)</td> </tr> <tr> <td>Eosinophilic gastroenteritis</td> </tr> <tr> <td>Giardiasis</td> </tr> <tr> <td>Intestinal lymphoma</td> </tr> <tr> <td>Peptic duodenitis</td> </tr> <tr> <td>Post-gastroenteritis</td> </tr> <tr> <td>Tropical sprue</td> </tr> <tr> <td>Zollinger-Ellison syndrome</td> </tr> <tr> <td>Common variable immunodeficiency</td> </tr> <tr> <td>Autoimmune enteropathy</td> </tr> <tr> <td>Other immunodeficiency states (usually apparent clinically, eg, AIDS enteropathy, hypogammaglobulinemic sprue)</td> </tr> <tr> <td>Medications (eg, olmesartan)</td> </tr> <tr> <td>Whipple disease</td> </tr> <tr> <td>Malnutrition</td> </tr> <tr> <td>Intestinal tuberculosis</td> </tr> <tr> <td>Graft-versus-host disease</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 60030 Version 7.0</div></div></div>"},"60032":{"type":"graphic_picture","displayName":"Mediastinal benign schwannoma 1","title":"Mediastinal benign schwannoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mediastinal benign schwannoma</div><div class=\"cntnt\"><img style=\"width:360px; height:227px;\" src=\"images/PULM/60032_Mediastinal_benign_schwanno.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spindle cell neoplasm demonstrates hypercellular areas (Antoni A on the left) and edematous, hypocellular areas (Antoni B on the right). Verocay bodies composed of two parallel rows of palisading nuclei are seen within the hypercellular areas. (Hematoxylin and eosin, magnification 50x).</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 60032 Version 1.0</div></div></div>"},"60035":{"type":"graphic_picture","displayName":"Typical facial features in a patient with fragile X syndrome","title":"Typical facial features in a patient with fragile X syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Typical facial features in a patient with fragile X syndrome</div><div class=\"cntnt\"><img style=\"width:365px; height:432px;\" src=\"images/ALLRG/60035_Typ_fac_feat_Fragile_X_synd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A&nbsp;four-year-old boy with fragile X syndrome displays some of the typical facial features of the disorder including:<br /><UL>&#xD;&#xA;<LI>A long and narrow face with prominent forehead and chin (prognathism) </LI>&#xD;&#xA;<LI>Large ears </LI>&#xD;&#xA;<LI>Midface hypoplasia with sunken eyes </LI>&#xD;&#xA;<LI>Strabismus </LI></UL></div><div id=\"graphicVersion\">Graphic 60035 Version 4.0</div></div></div>"},"60037":{"type":"graphic_picture","displayName":"Light microscopy of adult type granulosa cell tumor","title":"Adult type granulosa cell tumor","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Adult type granulosa cell tumor</div><div class=\"cntnt\"><img style=\"width:720px; height:540px;\" src=\"images/ONC/60037_Lght_mcrscp_adlt_grnls_cll_tmr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of an adult type granulosa cell tumor from the testis.</div><div class=\"graphic_reference\">Courtesy of Dr. Michelle S. Hirsch, Department of Pathology, Brigham and Womens Hospital, Boston, MA.</div><div id=\"graphicVersion\">Graphic 60037 Version 2.0</div></div></div>"},"60039":{"type":"graphic_figure","displayName":"Nasal fracture","title":"Nasal fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nasal fracture</div><div class=\"cntnt\"><img style=\"width:244px; height:418px;\" src=\"images/PEDS/60039_Nasal_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Postinjury edema may mask underlying nasal bone deformity. <br />(B) Nasal deformity becomes manifest as edema subsides.</div><div id=\"graphicVersion\">Graphic 60039 Version 2.0</div></div></div>"},"60042":{"type":"graphic_figure","displayName":"Upper abdominal anatomy","title":"Upper abdominal anatomy","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Upper abdominal anatomy</div><div class=\"cntnt\"><img style=\"width:538px; height:470px;\" src=\"images/SURG/60042_Upper-abdominal-anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Illustration of upper abdominal anatomy showing the relationship of the stomach (rotated to show its posterior aspect) to the pancreas and spleen, and their blood supply.</div><div id=\"graphicVersion\">Graphic 60042 Version 3.0</div></div></div>"},"60046":{"type":"graphic_picture","displayName":"IgM deposits in mixed cryo IF","title":"IgM deposits in mixed cryoglobulinemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">IgM deposits in mixed cryoglobulinemia</div><div class=\"cntnt\"><img style=\"width:377px; height:238px;\" src=\"images/NEPH/60046_CryoglobulinemiaIF.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Immunofluorescence microscopy showing almost pathognomonic diffuse deposition of IgM in the capillary loops in mixed cryoglobulinemia. The subendothelial location of these deposits is suggested by the relatively smooth outer portions (arrows) due to their pressing against the inner aspect of the glomerular basement membrane.</div><div class=\"graphic_footnotes\">IgM: immunoglobulin G.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 60046 Version 4.0</div></div></div>"},"60048":{"type":"graphic_figure","displayName":"Stroke risk in carotid stenosis","title":"Severity of carotid stenosis predicts stroke risk","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severity of carotid stenosis predicts stroke risk</div><div class=\"cntnt\"><img style=\"width:383px; height:280px;\" src=\"images/NEURO/60048_Stroke_risk_in_carotid_sten.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation between the degree of carotid artery stenosis and the annual risk of stroke.</div><div class=\"graphic_reference\">Data from Barnett, HJ, Eliasziw, M, Meldrum, HE, Taylor, DW, Neurology 1996; 46:603.</div><div id=\"graphicVersion\">Graphic 60048 Version 1.0</div></div></div>"},"60049":{"type":"graphic_table","displayName":"Androgens in PCOS","title":"Sources of serum androgens in women with PCOS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sources of serum androgens in women with PCOS</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Androgen</td> <td class=\"subtitle1\">Ovary</td> <td class=\"subtitle1\">Adrenal</td> <td class=\"subtitle1\">Peripheral conversion</td> </tr> <tr> <td>DHEA-S</td> <td class=\"centered\">&#60;5</td> <td class=\"centered\">&#62;95</td> <td>0</td> </tr> <tr> <td>Androstenedione (A)</td> <td class=\"centered\">60</td> <td class=\"centered\">35</td> <td>5 (from DHEA-S)</td> </tr> <tr> <td>Testosterone (T)</td> <td class=\"centered\">60</td> <td class=\"centered\">5</td> <td>35 (from A)</td> </tr> <tr> <td>DHT</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td>100 (from A and T)</td> </tr> <tr> <td>3-Androstanediol glucuronide</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td>100 (from DHT)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Values are percent of total production at the different sites.</div><div class=\"graphic_footnotes\">A: androstenedione; DHEA-S: dehydroepiandrosterone sulfate; DHT: dihydrotestosterone; PCOS: polycystic ovarian syndrome; T: testosterone.</div><div id=\"graphicVersion\">Graphic 60049 Version 3.0</div></div></div>"},"60050":{"type":"graphic_table","displayName":"ESWL technical results","title":"Technical results of ESWL for pancreatic stones","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Technical results of ESWL for pancreatic stones</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author (year)</td> <td class=\"subtitle1\">SW system*</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Fragmentation (percent)</td> <td class=\"subtitle1\">Complete clearance (percent)</td> <td class=\"subtitle1\">Decrease in MPD diameter (percent)</td> </tr> <tr> <td>Delhaye 1992</td> <td>EM</td> <td>123</td> <td>99</td> <td>59</td> <td>90</td> </tr> <tr> <td>Sauerbruch 1992</td> <td>EH</td> <td>24</td> <td>87.5</td> <td>42</td> <td>96</td> </tr> <tr> <td>Schneider 1994</td> <td>P</td> <td>50</td> <td>86</td> <td>60</td> <td>ND</td> </tr> <tr> <td>Van der Hul 1994</td> <td>EM</td> <td>17</td> <td>76.5</td> <td>41</td> <td>ND</td> </tr> <tr> <td>Johanns 1996</td> <td>EH</td> <td>35</td> <td>100</td> <td>46</td> <td>83</td> </tr> <tr> <td>Ohara 1996</td> <td>EM</td> <td>32</td> <td>100</td> <td>75</td> <td>ND</td> </tr> <tr> <td>Schreiber 1996</td> <td>EH</td> <td>10</td> <td>100</td> <td>70</td> <td>ND</td> </tr> <tr> <td>Costamagna 1997</td> <td>EM-EH</td> <td>35</td> <td>100</td> <td>74</td> <td>86</td> </tr> <tr> <td>Adamek 1999</td> <td>P</td> <td>80</td> <td>54</td> <td>ND</td> <td>ND</td> </tr> <tr> <td>Brand 2000</td> <td>EM</td> <td>48</td> <td>60</td> <td>44</td> <td>ND</td> </tr> <tr> <td>Kozarek 2002</td> <td>EH</td> <td>40</td> <td>100</td> <td>ND</td> <td>ND</td> </tr> <tr> <td>Farnbacher 2002</td> <td>P</td> <td>114</td> <td>82</td> <td>39</td> <td>ND</td> </tr> <tr> <td>Inui 2005</td> <td>EH-EM-P</td> <td>555</td> <td>92</td> <td>73</td> <td>ND</td> </tr> <tr> <td>Tadenuma 2005</td> <td>P</td> <td>117</td> <td>97</td> <td>56</td> <td>ND</td> </tr> <tr> <td>Ong 2006</td> <td>EM</td> <td>250</td> <td>ND</td> <td>60</td> <td>70</td> </tr> <tr> <td>Tandan 2010</td> <td>EM</td> <td>1006</td> <td>93</td> <td>76</td> <td>ND</td> </tr> <tr> <td>Suzuki 2013</td> <td>EH-EM-P</td> <td>479</td> <td>92</td> <td>74</td> <td>ND</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* SW: shock wave; EM: electromagnetic; EH: electrohydraulic; P: piezoelectric; ND: not determined.</div><div id=\"graphicVersion\">Graphic 60050 Version 4.0</div></div></div>"},"60051":{"type":"graphic_picture","displayName":"Squamous cell carcinoma esophagus Light","title":"Histologic appearance of a squamous cell carcinoma of the esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic appearance of a squamous cell carcinoma of the esophagus</div><div class=\"cntnt\"><img style=\"width:360px; height:269px;\" src=\"images/GAST/60051_Squamous_cell_CA_esoph_Ligh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a mucosal biopsy specimen demonstrating squamous cell carcinoma. The invasive portion of the tumor in the lamina propria shows squamous differentiation with cells having eosinophilic cytoplasm and keratinization (arrow).</div><div class=\"graphic_reference\">Courtesy of Donald Antonioli, MD.</div><div id=\"graphicVersion\">Graphic 60051 Version 3.0</div></div></div>"},"60052":{"type":"graphic_table","displayName":"Known Gla-containing proteins","title":"Known gamma-Carboxyglutamic acid-containing proteins","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Known gamma-Carboxyglutamic acid-containing proteins</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\">\n\t<tr>\n\t\t<td class=\"container\">\n\t\t\t<table cellspacing=\"0\">\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Blood clotting and regulatory proteins</td>\n\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t<td>Prothrombin</td>\n\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t<td>Factor VII</td>\n\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t<td>Factor IX</td>\n\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t<td>Factor X</td>\n\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t<td>Protein C</td>\n\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t<td>Protein S</td>\n\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t<td>Protein Z</td>\n\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Other proteins</td>\n\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t<td>Gas6</td>\n\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t<td>PRGP1</td>\n\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t<td>PRGP2</td>\n\t\t\t\t\t</tr>\n\t\t\t\t</table>\n\t\t\t</td>\n\t\t\t<td class=\"container\">\n\t\t\t\t<table cellspacing=\"0\">\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1_single\">Bone proteins</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Osteocalcin</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Matrix Gla protein</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td class=\"subtitle1_single\">Conopeptides</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Conantokin G</td>\n\t\t\t\t\t</tr>\n\t\t\t\t\t<tr>\n\t\t\t\t\t\t<td>Conantokin T</td>\n\t\t\t\t\t</tr>\n\t\t\t\t</table>\n\t\t\t</td>\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n\n</table></div><div class=\"graphic_reference\">Data reproduced with permission from Furie, B, et al. Blood 1999; 93:1798.</div><div id=\"graphicVersion\">Graphic 60052 Version 1.0</div></div></div>"},"60053":{"type":"graphic_table","displayName":"Discharge plan PI","title":"What a discharge plan should include","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">What a discharge plan should include</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">When you leave the hospital, the staff should give you:</td> </tr> <tr> <td>A written description of why you were in the hospital</td> </tr> <tr> <td>A written list of all the medicines you are supposed to take, and instructions on how to take them and how to get them</td> </tr> <tr> <td>Written instructions on what to do if your condition changes or you have warning signs</td> </tr> <tr> <td>Written details about all the medical appointments you have after you leave the hospital</td> </tr> <tr> <td>Written instructions on how to get the results of any tests that were done that have not yet come back by the time you leave the hospital</td> </tr> <tr> <td>The contact information for a staff member at the hospital who can answer your questions</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: the Components of Re-Engineered Discharge. Available at: <a href=\"https://www.bu.edu/fammed/projectred/components.html\" target=\"_blank\">https://www.bu.edu/fammed/projectred/components.html</a>.</div><div id=\"graphicVersion\">Graphic 60053 Version 2.0</div></div></div>"},"60054":{"type":"graphic_picture","displayName":"Rosacea papules and pustules PI","title":"Rosacea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rosacea</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PI/60054_Rosacea_paps_pustules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This person with rosacea has raised, red bumps (called &quot;papules&quot;) and raised, red bumps with pus in them (called &quot;pustules&quot;) on the nose and cheeks.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60054 Version 4.0</div></div></div>"},"60055":{"type":"graphic_figure","displayName":"Lip anatomy","title":"Lip anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lip anatomy</div><div class=\"cntnt\"><img style=\"width:376px; height:656px;\" src=\"images/EM/60055_LipanatomyPR2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Attia MW, Loiselle J. Management of soft-tissue injuries of the mouth. In: Textbook of Pediatric Emergency Procedures, 2nd Edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 60055 Version 6.0</div></div></div>"},"60056":{"type":"graphic_picture","displayName":"Ingrown toenail 1","title":"Ingrown toenail","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ingrown toenail</div><div class=\"cntnt\"><img style=\"width:396px; height:338px;\" src=\"images/DERM/60056_Ingrowntoenail1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The nail plate is entering the lateral nail groove, causing erythema, granulation tissue, and discomfort.</div><div class=\"graphic_reference\">Reproduced with permission from: Stedman's Medical Dictionary. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60056 Version 2.0</div></div></div>"},"60057":{"type":"graphic_diagnosticimage","displayName":"Elbow posterior lateral view","title":"Normal elbow, AP view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal elbow, AP view</div><div class=\"cntnt\"><img style=\"width:342px; height:540px;\" src=\"images/EM/60057_Elbow_posterior_lateral_vie.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 60057 Version 2.0</div></div></div>"},"60058":{"type":"graphic_figure","displayName":"Orbital bones","title":"Bones of the orbit","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Bones of the orbit</div><div class=\"cntnt\"><img style=\"width:534px; height:340px;\" src=\"images/EM/60058_Orbital_bones.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing depicts the major bones of the orbit.</div><div id=\"graphicVersion\">Graphic 60058 Version 2.0</div></div></div>"},"60059":{"type":"graphic_diagnosticimage","displayName":"Erosive lesion in MCTD","title":"Erosive lesion in mixed connective tissue disease (MCTD)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erosive lesion in mixed connective tissue disease (MCTD)</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/RHEUM/60059_Erosive_lesion_in_MCTD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain radiograph showing a small, well-demarcated digital erosion (arrow) in mixed connective tissue disease. These erosions are seen most commonly in the hands and feet.</div><div class=\"graphic_reference\">Courtesy of Robert M Bennett, MD.</div><div id=\"graphicVersion\">Graphic 60059 Version 2.0</div></div></div>"},"60060":{"type":"graphic_picture","displayName":"T cruzi trypomastigote and amastigote forms","title":"<em>Trypanosoma cruzi</em> trypomastigote and amastigote forms","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><em>Trypanosoma cruzi</em> trypomastigote and amastigote forms</div><div class=\"cntnt\"><img style=\"width:442px; height:222px;\" src=\"images/ID/60060_Tcruzi.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The trypomastigote form of <em>Trypanosoma cruzi</em> in a Giemsa stained peripheral blood smear from a patient with acute Chagas disease.<br> (B) The amastigote form of <em>T. cruzi</em> in a hematoxylin and eosin stained slide of heart muscle tissue.</div><div class=\"graphic_reference\">Division of Parasitic Diseases, Centers for Disease Control and Prevention.</div><div id=\"graphicVersion\">Graphic 60060 Version 2.0</div></div></div>"},"60063":{"type":"graphic_diagnosticimage","displayName":"Ultrasound atrophic triceps and deltoid","title":"Ultrasound of atrophic triceps and deltoid muscles","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound of atrophic triceps and deltoid muscles</div><div class=\"cntnt\"><img style=\"width:442px; height:269px;\" src=\"images/NEURO/60063_US_atrophic_triceps_deltoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These are axial images through the triceps (left) and deltoid (right) showing the humerus (H) in both images. Note that both muscles are atrophic and have increased echogenicity (more so in the deltoid) that reduces the distinction of the bone edge. These images are from a 72 year old man with limb girdle dystrophy and prominent proximal weakness (MRC grade 3 of 5) in these muscles. Note the similarities of the changes to those seen in old polio, a pure neurogenic disorder. (See text for link to the figure &quot;Ultrasound of the tibialis anterior after polio&quot;).</div><div class=\"graphic_reference\">Courtesy of Francis O Walker, MD.</div><div id=\"graphicVersion\">Graphic 60063 Version 4.0</div></div></div>"},"60064":{"type":"graphic_figure","displayName":"Diagnostic paracentesis needles","title":"Diagnostic paracentesis needles","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagnostic paracentesis needles</div><div class=\"cntnt\"><img style=\"width:383px; height:534px;\" src=\"images/GAST/60064_Diagnostic-paracentesis-needles.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 60064 Version 2.0</div></div></div>"},"60065":{"type":"graphic_figure","displayName":"Clock locating lesion","title":"Clock position in locating a lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clock position in locating a lesion</div><div class=\"cntnt\"><img style=\"width:364px; height:230px;\" src=\"images/PC/60065_Clock_locating_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The location can also be indicated as a clock position. Each breast is divided into clock positions with the nipple as the center.</div><div id=\"graphicVersion\">Graphic 60065 Version 1.0</div></div></div>"},"60068":{"type":"graphic_table","displayName":"Clinical setting NSIP","title":"Clinical conditions associated with nonspecific interstitial pneumonia histologic pattern","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical conditions associated with nonspecific interstitial pneumonia histologic pattern</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>No detectable cause (idiopathic NSIP)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Collagen vascular disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hypersensitivity pneumonitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Drug-induced pneumonitis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Infection</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Immunodeficiency including HIV infection</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 60068 Version 1.0</div></div></div>"},"60070":{"type":"graphic_table","displayName":"Radiologic Ddx IIP","title":"Radiologic features and differential diagnosis of idiopathic interstitial pneumonias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Radiologic features and differential diagnosis of idiopathic interstitial pneumonias</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Clinical diagnosis</td> <td class=\"subtitle1\">Histologic pattern</td> <td class=\"subtitle1\">Radiographic features</td> <td class=\"subtitle1\">Typical distribution</td> <td class=\"subtitle1\">Typical CT findings</td> <td class=\"subtitle1\">Differential diagnosis</td> </tr> <tr> <td>IPF/CFA</td> <td>UIP</td> <td>Basal-predominant reticular abnormality with volume loss</td> <td>Peripheral, subpleural, basal</td> <td>Reticular, honeycombing, traction bronchiectasis/bronchiolectasis; architectural distortion. Focal ground glass</td> <td>Asbestosis, collagen vascular disease, hypersensitivity pneumonitis, sarcoidosis</td> </tr> <tr> <td>NSIP</td> <td>NSIP</td> <td>Ground glass and reticular opacity</td> <td>Peripheral, basal, symmetric</td> <td>Ground glass attenuation, irregular lines, consolidation</td> <td>UIP, DIP, COP, hypersensitivity pneumonitis</td> </tr> <tr> <td>COP</td> <td>OP</td> <td>Patchy bilateral consolidation</td> <td>Subpleural/peribronchial</td> <td>Patchy consolidation and/or nodules</td> <td>Infection, vasculitis, sarcoidosis, alveolar carcinoma, lymphoma, eosinophilic pneumonia, NSIP</td> </tr> <tr> <td>AIP</td> <td>DAD</td> <td>Progressive diffuse ground glass density/consolidation</td> <td>Diffuse</td> <td>Consolidation and ground glass opacity, often with lobular sparing. Traction bronchiectasis later</td> <td>Hydrostatic edema, pneumonia, acute eosinophilic pneumonia</td> </tr> <tr> <td>DIP</td> <td>DIP</td> <td>Ground glass opacity</td> <td>Lower zone, peripheral predominance in most</td> <td>Ground glass attenuation, reticular lines</td> <td>RB-ILD, hypersensitivity pneumonitis, sarcoidosis, PCP</td> </tr> <tr> <td>RB-ILD</td> <td>RB</td> <td>Bronchial wall thickening; ground glass opacity</td> <td>Diffuse</td> <td>Bronchial wall thickening, cenrilobular nodules, patchy ground glass opacity</td> <td>DIP, NSIP, Hypersensitivity pneumonitis</td> </tr> <tr> <td>LIP</td> <td>LIP</td> <td>Reticular opacities, nodules</td> <td>Diffuse</td> <td>Centrilobular nodules, ground glass attenuation, septal and bronchovascular thickening, thin-walled cysts</td> <td>Sarcoidosis, lymphangitic carcinoma, Langerhans' cell histiocytosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AIP: acute interstitial pneumonia; CFA: cryptogenic fibrosing alveolitis; COP: cryptogenic OP (also called idiopathic bronchiolitis obliterans organizing pneumonia [BOOP]); DAD: diffuse alveolar damage; DIP: desquamative interstitial pneumonia; IPF: idiopathic pulmonary fibrosis; LIP: lymphoid interstitial pneumonia; NSIP: nonspecific interstitial pneumonia; OP: organizing pneumonia; PCP: Pneumocystis jirovecii (carinii) pneumonia; RB-ILD: respiratory bronchiolitis-associated intersitial lung disease: UIP: usual interstitial pneumonia.</div><div id=\"graphicVersion\">Graphic 60070 Version 3.0</div></div></div>"},"60072":{"type":"graphic_table","displayName":"NCI CTCAE v5 fatigue","title":"NCI CTCAE v5.0 fatigue","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 fatigue</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Fatigue</td> <td>Fatigue relieved by rest</td> <td>Fatigue not relieved by rest; limiting instrumental ADL*</td> <td>Fatigue not relieved by rest; limiting self-care ADL*</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Fatigue is characterized by a state of generalized weakness with a pronounced inability to summon sufficient energy to accomplish daily activities.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; ADL: activities of daily living.<br />* Instrumental ADLs include preparing meals, shopping, using the telephone, managing money. Self-care ADLs include bathing, dressing/undressing, using the toilet, taking medications, and not bedridden.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <A spellcheck=true href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=_blank>https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</A> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 60072 Version 9.0</div></div></div>"},"60074":{"type":"graphic_picture","displayName":"CMV retinitis in pediatric AIDS","title":"Funduscopic examination of an HIV-infected 16-year-old girl with cytomegalovirus retinitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Funduscopic examination of an HIV-infected 16-year-old girl with cytomegalovirus retinitis</div><div class=\"cntnt\"><img style=\"width:367px; height:283px;\" src=\"images/PEDS/60074_CMV_retinitis_in_pediatric.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There are extensive areas of hemorrhage with white retinal exudates. Children with cytomegalovirus retinitis usually present with painless visual impairment.</div><div class=\"graphic_reference\">Courtesy of Dr. David Coats, Houston, Texas.</div><div id=\"graphicVersion\">Graphic 60074 Version 2.0</div></div></div>"},"60075":{"type":"graphic_table","displayName":"HepB vaccine doses US","title":"Recommended doses of formulations of hepatitis B vaccines licensed in the United States, by age group and vaccine type","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended doses of formulations of hepatitis B vaccines licensed in the United States, by age group and vaccine type</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Age group</td> <td class=\"subtitle1\" colspan=\"4\">Single-antigen vaccine</td> <td class=\"subtitle1\" colspan=\"4\">Combination vaccine</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Recombivax HB</td> <td class=\"subtitle2\" colspan=\"2\">Engerix-B</td> <td class=\"subtitle2\" colspan=\"2\">Pediarix (combined HepB-DTaP-IPV)</td> <td class=\"subtitle2\" colspan=\"2\">Twinrix (combined HepA-HepB)</td> </tr> <tr> <td class=\"subtitle3\">Dose HBsAg, mcg</td> <td class=\"subtitle3\">Volume, mL</td> <td class=\"subtitle3\">Dose HBsAg, mcg</td> <td class=\"subtitle3\">Volume, mL</td> <td class=\"subtitle3\">Dose HBsAg, mcg</td> <td class=\"subtitle3\">Volume, mL</td> <td class=\"subtitle3\">Dose HBsAg, mcg</td> <td class=\"subtitle3\">Volume, mL</td> </tr> <tr> <td>&#60;6 weeks</td> <td class=\"centered\">5</td> <td class=\"centered\">0.5</td> <td class=\"centered\">10</td> <td class=\"centered\">0.5</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> </tr> <tr> <td>6 weeks through 6 years</td> <td class=\"centered\">5</td> <td class=\"centered\">0.5</td> <td class=\"centered\">10</td> <td class=\"centered\">0.5</td> <td class=\"centered\">10</td> <td class=\"centered\">0.5</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> </tr> <tr> <td>7&nbsp;through 10 years</td> <td class=\"centered\">5</td> <td class=\"centered\">0.5</td> <td class=\"centered\">10</td> <td class=\"centered\">0.5</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> </tr> <tr> <td rowspan=\"2\">11&nbsp;through&nbsp;15 years</td> <td class=\"centered\">10*</td> <td class=\"centered\">1</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> </tr> <tr> <td class=\"centered\">5</td> <td class=\"centered\">0.5</td> <td class=\"centered\">10</td> <td class=\"centered\">0.5</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> </tr> <tr> <td>16&nbsp;through 17 years</td> <td class=\"centered\">5</td> <td class=\"centered\">0.5</td> <td class=\"centered\">10</td> <td class=\"centered\">0.5</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> </tr> <tr> <td>18 through 19 years</td> <td class=\"centered\">5</td> <td class=\"centered\">0.5</td> <td class=\"centered\">10</td> <td class=\"centered\">0.5</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">20</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td>&#8805;20 years</td> <td class=\"centered\">10</td> <td class=\"centered\">1</td> <td class=\"centered\">20</td> <td class=\"centered\">1</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">20</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Hemodialysis patients and other immunocompromised persons</td> </tr> <tr> <td class=\"indent1\">&#60;20 years</td> <td class=\"centered\">5</td> <td class=\"centered\">0.5</td> <td class=\"centered\">10</td> <td class=\"centered\">0.5</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> </tr> <tr> <td class=\"indent1\">&#8805;20 years</td> <td class=\"centered\">40<sup>&#182;</sup></td> <td class=\"centered\">1</td> <td class=\"centered\">40</td> <td class=\"centered\">2<sup>&#916;</sup></td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HepB: hepatitis B; DTaP: diphtheria, tetanus, acellular pertussis; IPV: inactivated poliovirus; HepA: hepatitis A; HBsAg: hepatitis B surface antigen; NA: not applicable.<br />* Adult formulation administered on a two-dose schedule at 0 and 4 to 6 months. Both doses must be administered before the 16<SUP>th</SUP> birthday.<br />¶&nbsp;Dialysis formulation administered on a three-dose schedule at 0, 1, and 6 months.<br />Δ&nbsp;Two 1 mL doses administered at one site, on a four-dose schedule at 0, 1, 2, and 6 months.</div><div class=\"graphic_reference\">Adapted from: Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018; 67:1.</div><div id=\"graphicVersion\">Graphic 60075 Version 14.0</div></div></div>"},"60076":{"type":"graphic_diagnosticimage","displayName":"Ureterocele cystoscopy US","title":"Ureterocele cystoscopy and ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ureterocele cystoscopy and ultrasound</div><div class=\"cntnt\"><img style=\"width:391px; height:170px;\" src=\"images/PEDS/60076_Ureterocele_cystoscopy_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ureterocele demonstrated by cystoscopy and ultrasound.</div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 60076 Version 3.0</div></div></div>"},"60078":{"type":"graphic_figure","displayName":"Female pelvis","title":"Superior view of female pelvis","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Superior view of female pelvis</div><div class=\"cntnt\"><img style=\"width:543px; height:359px;\" src=\"images/OBGYN/60078_Female_pelvic_bones.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 60078 Version 3.0</div></div></div>"},"60080":{"type":"graphic_figure","displayName":"FEV1 growth curves in girls","title":"FEV1 growth curves for girls","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">FEV1 growth curves for girls</div><div class=\"cntnt\"><img style=\"width:408px; height:351px;\" src=\"images/PULM/60080_FEV1_growth_curves_I.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The smoothed percentiles of FEV<SUB>1</SUB> by height for white girls; six cities, United States.</div><div class=\"graphic_footnotes\">FEV<sub>1</sub>: forced expiratory volume in one second.</div><div class=\"graphic_reference\">Data from: Wang X, Dockery DW, Wypij D, et al. Pediatric Pulmonology 1993; 15:75.</div><div id=\"graphicVersion\">Graphic 60080 Version 3.0</div></div></div>"},"60081":{"type":"graphic_figure","displayName":"Adjustable gastric band","title":"Adjustable gastric band","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Adjustable gastric band</div><div class=\"cntnt\"><img style=\"width:350px; height:454px;\" src=\"images/SURG/60081_Adjustable_gastric_band.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Laparoscopic gastric banding is a purely restrictive procedure that compartmentalizes the upper stomach by placing a tight, adjustable prosthetic band around the entrance to the stomach. The gastric band consists of a soft, locking silicone ring connected to an infusion port placed in the subcutaneous tissue. The port may be accessed with relative ease by a syringe and needle. Injection of saline into the port leads to reduction in the band diameter, resulting in an increased degree of restriction.</div><div class=\"graphic_reference\">Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury, Connecticut 2010. Copyright &#169; 2010 Cine-Med.</div><div id=\"graphicVersion\">Graphic 60081 Version 3.0</div></div></div>"},"60082":{"type":"graphic_picture","displayName":"Dupuytrens contracture PI","title":"Dupuytren's contracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dupuytren's contracture</div><div class=\"cntnt\"><img style=\"width:306px; height:305px;\" src=\"images/PI/60082_Dupuytrens_contracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When people have Dupuytren's contracture, the tissue under the skin in the palm of the hand gets thick. Over time, this makes the fingers (usually the ring and little fingers) stiff and keeps them from straightening all the way.</div><div class=\"graphic_reference\">Reproduced with permission from: Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996. Copyright © 1996 Lippincott Williams &amp; Wilkins.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 60082 Version 7.0</div></div></div>"},"60086":{"type":"graphic_figure","displayName":"Episodic cortisol in Cushing's","title":"Episodic cortisol secretion in Cushing's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Episodic cortisol secretion in Cushing's syndrome</div><div class=\"cntnt\"><img style=\"width:372px; height:311px;\" src=\"images/ENDO/60086_Episodic_cortisol_in_Cushin.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serum cortisol concentrations throughout the day in patients with different forms of Cushing's syndrome. There is episodic hormone release in both ACTH-dependent and ACTH-independent (adrenal adenoma) forms of the syndrome. To convert serum cortisol to nmol/L, multiply by 27.6.</div><div class=\"graphic_footnotes\">ACTH: corticotropin.</div><div class=\"graphic_reference\">Data from: Sederberg-Olsen P, Binder C, Kehlet H, et al. Episodic variation in plasma corticosteroids in subjects with Cushing's syndrome of differing etiology.&nbsp;J Clin Endocrinol Metab 1973; 36:906.</div><div id=\"graphicVersion\">Graphic 60086 Version 5.0</div></div></div>"},"60087":{"type":"graphic_diagnosticimage","displayName":"Apical four chamber view of PPCM with thrombus","title":"Apical four chamber echocardiographic view showing thrombus in peripartum cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Apical four chamber echocardiographic view showing thrombus in peripartum cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:378px; height:298px;\" src=\"images/CARD/60087_2-D_Echo_peripartum_CM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical four-chamber echocardiographic view in a patient with peripartum cardiomyopathy showing left ventricular and left atrial dilatation. There is thrombus at the left ventricular apex.</div><div id=\"graphicVersion\">Graphic 60087 Version 11.0</div></div></div>"},"60088":{"type":"graphic_picture","displayName":"IDUS pancreatic duct mucin","title":"Guidewire placement for intraductal ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Guidewire placement for intraductal ultrasound</div><div class=\"cntnt\"><img style=\"width:257px; height:268px;\" src=\"images/GAST/60088_IDUS_pancreatic_duct_mucin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Placement of a guidewire, for intraductal ultrasound, into the pancreatic duct in a patient with a widely patent papilla that is extruding mucus as a result of an intraductal papillary mucinous neoplasm.</div><div class=\"graphic_reference\">Courtesy of Michael J Levy, MD, Enrique Vazquez-Sequeiros, MD, and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 60088 Version 2.0</div></div></div>"},"60089":{"type":"graphic_picture","displayName":"Medication esophagitis Endosc","title":"Medication-induced esophagitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Medication-induced esophagitis</div><div class=\"cntnt\"><img style=\"width:300px; height:300px;\" src=\"images/GAST/60089_Medication_esophagitis_Endo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic endoscopic appearance of medication-induced esophagitis showing a discrete ulcer in the distal esophagus with normal appearing adjacent mucosa.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 60089 Version 2.0</div></div></div>"},"60090":{"type":"graphic_waveform","displayName":"EP study tracings bidirectional isthmus block","title":"Intracardiac and surface electrocardiogram (ECG) recordings during electrophysiologic study and radiofrequency catheter ablation of atrial flutter showing bidirectional isthmus block","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Intracardiac and surface electrocardiogram (ECG) recordings during electrophysiologic study and radiofrequency catheter ablation of atrial flutter showing bidirectional isthmus block</div><div class=\"cntnt\"><img style=\"width:524px; height:382px;\" src=\"images/CARD/60090_Bidirectional_isthmus_block.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are three surface ECG leads (I, aVF, V1) and intracardiac recordings from the high right atrium (HRA), eight recordings from a catheter extending from the lateral right atrial wall through the tricuspid valve-inferior vena cava (TV-IVC) isthmus and into the ostium of the coronary sinus (CS15-16 through CS1-2), and right ventricular apex (RVA3-4) in a patient who has undergone ablation for atrial flutter. Left panel shows pacing (PA) from the lateral right atrial wall; the impulse is propagated down the lateral wall of the high right atrium, generating an atrial electrogram (A), to the lateral TV-IVC isthmus region (CS13-14, CS11-12, CS9-10) where conduction is blocked. The medial aspect of the isthmus is not depolarized until a wavefront of activation comes down the interatrial septum or from the low left atrium; the distal poles of the catheter are therefore depolarized late and in the opposite direction, from the coronary sinus ostium back towards the medial TV-IVC isthmus (CS3-4, CS5-6, CS7-8). Right panel shows pacing from the coronary sinus ostium. In this case, the medial isthmus is depolarized promptly (CS3-4, CS5-6), but conduction is blocked within the isthmus (CS7-8). Thus, activation of the lateral wall of the right atrium is delayed until a wavefront travels up the septum and across the roof of the right atrium. Activation of the proximal poles of the catheter is therefore delayed and occurs from high to low (CS15-16, CS13-14, CS11-12, CS9-10). Patients with bidirectional block across the TC-IVC isthmus have a low rate of atrial flutter recurrence.</div><div id=\"graphicVersion\">Graphic 60090 Version 4.0</div></div></div>"},"60094":{"type":"graphic_figure","displayName":"Medication positions PI","title":"Positions for administering sinus medications","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Positions for administering sinus medications</div><div class=\"cntnt\"><img style=\"width:562px; height:558px;\" src=\"images/PI/60094_Medication_positions_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These positions allow nasal medications to penetrate into the sinuses (highlighted in green in the right-hand column). To give the medications, first&nbsp;get into the head-down forward position, and put the medication into the<STRONG> righ</STRONG>t nostril. Stay in the position for the amount of time specified by your health care provider. This will treat the frontal and ethmoid sinuses. Then, roll onto&nbsp;your right side to treat the right maxillary sinus. After that, roll on your back to treat the sphenoid sinus. In this way, all the sinuses on&nbsp;the right&nbsp;side are treated with a single application of the nasal medication. Once you have finished with the right side, get into the head-down forward position and put the medication into the<STRONG> left</STRONG> nostril. This will treat the left frontal and ethmoid sinuses. Then, roll on your left side to treat the left maxillary sinus. Finally, roll on your back to treat the left sphenoid sinus.<STRONG> NOTE</STRONG>: Lying on your back is optional and should not be done if it causes the nasal medication to get into your inner ear. </div><div class=\"graphic_reference\">Courtesy of Daniel L Hamilos, MD.</div><div id=\"graphicVersion\">Graphic 60094 Version 6.0</div></div></div>"},"60095":{"type":"graphic_table","displayName":"Normal ranges for TFTs in children","title":"Normal ranges for thyroid function tests in infants and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal ranges for thyroid function tests in infants and children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Free T4*<br /> (ng/dL)</td> <td class=\"subtitle1\">T4<br /> (&#181;g/dL)</td> <td class=\"subtitle1\">Free T3<br /> (pg/mL)</td> <td class=\"subtitle1\">T3<br /> (ng/dL)</td> <td class=\"subtitle1\">TSH<br /> (mU/L)</td> <td class=\"subtitle1\">TBG<br /> (mg/dL)</td> </tr> <tr> <td>Cord blood</td> <td>0.9-2.2</td> <td>7.8-13.1</td> <td>0.2-2.4</td> <td>15-75</td> <td>2.2-10.7</td> <td>1.4-9.4</td> </tr> <tr> <td>1 to 4 days</td> <td>2.2-5.3</td> <td>9.3-20.9</td> <td>1.8-7.6</td> <td>100-740</td> <td>2.7-26.5</td> <td>&nbsp;</td> </tr> <tr> <td>4 to 30 days</td> <td>0.9-3.4</td> <td>8.0-21.8</td> <td>2.93-5.08</td> <td>105-387</td> <td>1.2-13.1</td> <td>1.9-4.5</td> </tr> <tr> <td>1 to 12 months</td> <td>0.9-2.3</td> <td>7.2-15.7</td> <td>2.67-5.21</td> <td>105-245</td> <td>0.6-7.3</td> <td>1.9-4.4</td> </tr> <tr> <td>1 to 5 years</td> <td>0.8-1.8</td> <td>6.4-13.5</td> <td>2.73-4.95</td> <td>105-269</td> <td>0.7-6.6</td> <td>1.6-4.2</td> </tr> <tr> <td>6 to 10 years</td> <td>1.0-2.1</td> <td>6.0-12.8</td> <td>2.73-4.69</td> <td>94-241</td> <td>0.8-6.0</td> <td>1.4-3.7</td> </tr> <tr> <td>11 to 18 years</td> <td>0.8-1.9</td> <td>4.7-12.4</td> <td>2.67-4.62</td> <td>80-210</td> <td>0.6-5.8</td> <td>1.2-2.9</td> </tr> <tr> <td>&#62;18 years</td> <td>0.9-2.5</td> <td>5.3-10.5</td> <td>2.10-4.40</td> <td>70-204</td> <td>0.4-4.2</td> <td>1.5-3.4</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Because the normal free T4 reference range varies according to the assay method, clinicians need to determine the range for their specific laboratory, which may differ from the data presented in the table.</div><div class=\"graphic_reference\">Data adapted from the following sources:<br /><ol>&#xD;&#xA;    <li>Nelson JC, Clark SJ, Bonut DL, et al. Age-related changes in serum free thyroxine during childhood and adolescence. J Pediatr 1993; 123:899.</li>&#xD;&#xA;    <li>Elmlinger MW, K&uuml;hnel W, Lambrecht HG, et al. Reference intervals from birth to adulthood for serum thyroxine (T4), triiodothyronine (T3), free T3, free T4, thyroxine binding globulin (TBG) and thyrotropin (TSH). Clin Chem Lab Med 2001; 39:973.</li>&#xD;&#xA;    <li>Mutlu M, Karag&uuml;zel G, Alıyazicioğlu Y, et al. Reference intervals for thyrotropin and thyroid hormones and ultrasonographic thyroid volume during the neonatal period. J Matern Fetal Neonatal Med 2012; 25:120.</li>&#xD;&#xA;    <li>Strich D, Edri S, Gillis D. Current normal values for TSH and FT3 in children are too low: evidence from over 11,000 samples. J Pediatr Endocrinol Metab 2012; 25:245.</li>&#xD;&#xA;    <li>Lem AJ, de Rijke YB, van Toor H, et al. Serum thyroid hormone levels in healthy children from birth to adulthood and in short children born small for gestational age. J Clin Endocrinol Metab 2012; 97:3170.</li>&#xD;&#xA;    <li>Esoterix (Endocrine Sciences).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 60095 Version 9.0</div></div></div>"},"60097":{"type":"graphic_figure","displayName":"Dense RBCs in beta thalassemia","title":"Dense red cells in beta thalassemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dense red cells in beta thalassemia</div><div class=\"cntnt\"><img style=\"width:340px; height:358px;\" src=\"images/HEME/60097_Dense_RBCs_in_beta_thalasse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Analysis of the density distribution of normal erythrocytes (A), erythrocytes from a nonsplenectomized individual with beta-thalassemia intermedia (B), erythrocytes from a splenectomized individual with beta thalassemia intermedia (C), and HbH erythrocytes (D) on discontinuous Stractan density gradients. The more dense cells are at the bottom of the gradient; dense populations are present only in the nonsplenectomized and splenectomized subjects with beta thalassemia.</div><div class=\"graphic_reference\">Reproduced with permission from Schrier, SL, Rachmilevitz, E, Mohandas, N. Cellular and membrane properties of alpha and beta thalassemic erythrocytes are different: Implication for differences in clinical manifestations. Blood 1989; 6:2194. Copyright &#169; 1989 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 60097 Version 1.0</div></div></div>"},"60099":{"type":"graphic_figure","displayName":"Effect on dyspnea","title":"Effect of pulmonary rehabilitation on dyspnea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Effect of pulmonary rehabilitation on dyspnea</div><div class=\"cntnt\"><img style=\"width:421px; height:271px;\" src=\"images/PULM/60099_Effect_on_dyspnea.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of exercise training on dyspnea compared with bronchodilators and oxygen.</div><div class=\"graphic_reference\">Data from Am J Respir Crit Care Med 1999; 159:321.</div><div id=\"graphicVersion\">Graphic 60099 Version 2.0</div></div></div>"},"60100":{"type":"graphic_diagnosticimage","displayName":"Calcinosis and scleroderma","title":"Calcinosis in scleroderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calcinosis in scleroderma</div><div class=\"cntnt\"><img style=\"width:389px; height:263px;\" src=\"images/RHEUM/60100_Calcinosis_and_scleroderma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph showing calcium deposits in the thumb and index finger of patient with systemic sclerosis (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Nalebuff EA. Surgery in patients with systemic sclerosis of the hand. Clin Orthop Rel Res 1999; 91:366. Copyright © 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60100 Version 9.0</div></div></div>"},"60101":{"type":"graphic_diagnosticimage","displayName":"MRI of femoral head avascular necrosis","title":"MRI of femoral head avascular necrosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">MRI of femoral head avascular necrosis</div><div class=\"cntnt\"><img style=\"width:504px; height:504px;\" src=\"images/RADIOL/60101_Osteonecrosis_hip_STIR_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Femoral head avascular necrosis. MRI coronal&nbsp;inversion recovery&nbsp;image of the pelvis shows a low signal intensity lesion of the left femoral head (arrow) with surrounding bright signal from bone marrow edema consistent with avascular necrosis.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD.</div><div id=\"graphicVersion\">Graphic 60101 Version 4.0</div></div></div>"},"60102":{"type":"graphic_picture","displayName":"Dermatophyte potassium hydroxide","title":"Dermatophyte potassium hydroxide preparation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermatophyte potassium hydroxide preparation</div><div class=\"cntnt\"><img style=\"width:432px; height:323px;\" src=\"images/DERM/60102_TineacorporisKOH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Septate hyphae are visible on a background of squamous cells in this potassium hydroxide preparation taken from a lesion of tinea corporis. Potassium hydroxide preparations from tinea pedis and tinea cruris have a similar appearance.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60102 Version 5.0</div></div></div>"},"60103":{"type":"graphic_picture","displayName":"Wearable defibrillator","title":"Wearable cardioverter-defibrillator","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wearable cardioverter-defibrillator</div><div class=\"cntnt\"><img style=\"width:390px; height:504px;\" src=\"images/CARD/60103_Wear_defibrillator.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The wearable cardioverter-defibrillator consists of a vest incorporating two defibrillation electrodes and four sensing electrocardiographic electrodes connected to a waist unit containing the monitoring and defibrillation electronics.</div><div class=\"graphic_reference\">Reproduced with permission from: ZOLL Medical Corporation. Copyright © 2012. All rights reserved.</div><div id=\"graphicVersion\">Graphic 60103 Version 3.0</div></div></div>"},"60104":{"type":"graphic_diagnosticimage","displayName":"4 chamber view LV mass","title":"Determination of left ventricular myocardial mass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Determination of left ventricular myocardial mass</div><div class=\"cntnt\"><img style=\"width:373px; height:323px;\" src=\"images/CARD/60104_4_chamber_view_LV_mass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Orthogonal apical echocardiographic&nbsp;views are digitized in systole and diastole and the computer analyzes the tracings according to two volume algorithms and, using the truncate ellipsoid method, computes the internal dimensions used in the calculation of mass. By this method the ejection fraction is borderline normal at 55 percent and the mass is increased at 220 g; assuming a body surface area of 2 msq, the mass is 110 g/msq, well over two standard deviations from the mean of 95 g/msq. The end systolic volume index is 33 ml/msq and also exceeds the bounds for normality. By comparing the diastolic to the systolic area tracings it can be seen that the descent of the base is less than 14 mm. Since increased left ventricular mass imparts a lower wall stress and afterload, the borderline ejection fraction becomes clearly abnormal (unless blood pressure is greatly elevated).</div><div id=\"graphicVersion\">Graphic 60104 Version 3.0</div></div></div>"},"60105":{"type":"graphic_figure","displayName":"Peripheral artery disease PI","title":"Peripheral artery disease","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Peripheral artery disease</div><div class=\"cntnt\"><img style=\"width:518px; height:449px;\" src=\"images/PI/60105_Periph_artery_disease_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 60105 Version 6.0</div></div></div>"},"60106":{"type":"graphic_figure","displayName":"Sept asthma epidemic","title":"The number of asthma hospitalizations by age group (in multiples of the mean) in Canada graphed by the week of the year","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">The number of asthma hospitalizations by age group (in multiples of the mean) in Canada graphed by the week of the year</div><div class=\"cntnt\"><img style=\"width:461px; height:343px;\" src=\"images/ALLRG/60106_Sept_asthma_epidemic.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Johnston NW, Johnston SL, Norman GR, et al. The September epidemic of asthma hospitalization: School children as disease vectors. J Allergy Clin Immunol 2006; 117:557. Copyright © 2006. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 60106 Version 2.0</div></div></div>"},"60109":{"type":"graphic_picture","displayName":"Chondrosarcoma Gross","title":"Chondrosarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chondrosarcoma</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/ONC/60109_Chondrosarcoma_Gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross appearance of a chondro-sarcoma.</div><div id=\"graphicVersion\">Graphic 60109 Version 1.0</div></div></div>"},"60110":{"type":"graphic_picture","displayName":"Spinal hemangioblastoma","title":"Hemangioblastoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hemangioblastoma</div><div class=\"cntnt\"><img style=\"width:504px; height:188px;\" src=\"images/ONC/60110_Spinal_hemangioblastoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The intraoperative photograph of a spinal hemangioblastoma shows enlarged vessels (arrowhead) feeding the strawberry-like exophytic mass (arrow).<br> (B) A cross-section from a resected cerebellar hemangioblastoma illustrates the tumor's reddish color due to its vascularity (arrow) compared to the normal cerebellar gray and white matter (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Julian Wu, MD and Jeffrey Joseph, MD.</div><div id=\"graphicVersion\">Graphic 60110 Version 4.0</div></div></div>"},"60112":{"type":"graphic_picture","displayName":"TT granulation tissue","title":"Tympanostomy tube surrounded by granulation tissue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tympanostomy tube surrounded by granulation tissue</div><div class=\"cntnt\"><img style=\"width:253px; height:249px;\" src=\"images/PEDS/60112_TTgranulationtissue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long-term tympanostomy tube occluded and surrounded by granulation tissue.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 93, Pages 924-9, Copyright © 1994 by the AAP.</div><div id=\"graphicVersion\">Graphic 60112 Version 13.0</div></div></div>"},"60113":{"type":"graphic_table","displayName":"Pharmacokinetic comparison of digoxin and digitoxin","title":"Pharmacokinetic comparison of digoxin and digitoxin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacokinetic comparison of digoxin and digitoxin</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Digoxin</td> <td class=\"subtitle1\">Digitoxin</td> </tr> <tr> <td>Bioavailability (percent)</td> <td>70</td> <td>90</td> </tr> <tr> <td>Plasma binding (percent)</td> <td>25</td> <td>95</td> </tr> <tr> <td>VD (L/kg)</td> <td>5.6 L/kg</td> <td>0.56 L/kg</td> </tr> <tr> <td>Half life (hours)*</td> <td>50</td> <td>161</td> </tr> <tr> <td>Desired therapeutic concentrations</td> <td>0.5 to 0.8&nbsp;ng/mL</td> <td>----</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Assumes normal renal function.</div><div class=\"graphic_reference\">Data from:<br> <ol> <li>Lapostolle F, Baud FJ, Borron SW, Mégarbane B. Digitalis glycosides. In: Critical Care Toxicology: Diagnosis and Management of the Critically Poisoned Patient, Brent J, Wallace KL, Burkhart K, et al (Eds), Elsevier Mosby, Philadelphia 2004. p.393.</li> <li>Holford NHG. Pharmacokinetics and pharmacodynamics: Rational dosing and the time course of drug action. In: Basic and Clinical Pharmacology, 8th ed, Katzung BG (Ed), McGraw Hill, New York 2001. p.35.</li> </ol></div><div id=\"graphicVersion\">Graphic 60113 Version 5.0</div></div></div>"},"60116":{"type":"graphic_figure","displayName":"CIN terminology and histology","title":"Terminology and histology of cervical intraepithelial neoplasia","html":"<div class=\"graphic\"><div style=\"width: 633px\" class=\"figure\"><div class=\"ttl\">Terminology and histology of cervical intraepithelial neoplasia</div><div class=\"cntnt\"><img style=\"width:613px; height:384px;\" src=\"images/OBGYN/60116_CIN_terminology_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Terminology regarding cytologic and histologic precancerous changes of the uterine cervix. The corresponding terminology from the previous classification systems is shown. Images of the histologic correlates for each category are also shown.</div><div class=\"graphic_footnotes\">LAST: lower anogenital squamous terminology; LSIL: low-grade squamous intraepithelial lesions; HSIL: high-grade squamous intraepithelial lesions; CIN: cervical intraepithelial neoplasia.<br />* CIN 2 that is p16-positive is classified as HSIL. CIN 2 that is p16-negative is classified as LSIL.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Darragh TM, Colgan TJ, Thomas Cox J, et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 2013; 32:76.</LI>&#xD;&#xA;<LI>Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114.</LI></OL></div><div id=\"graphicVersion\">Graphic 60116 Version 7.0</div></div></div>"},"60117":{"type":"graphic_table","displayName":"Evaluation for end-organ damage from iron overload","title":"Suggested evaluation for organ damage based on signs and symptoms in patients with iron overload","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested evaluation for organ damage based on signs and symptoms in patients with iron overload</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Abnormality</td> <td class=\"subtitle1\">Indicated evaluations</td> </tr> <tr> <td>Weakness, fatigue, malaise</td> <td>Evaluation for liver, endocrinologic, and cardiac disorders and for anemia</td> </tr> <tr> <td>Elevated hepatic enzyme&nbsp;concentrations</td> <td>Evaluation for hepatitis B, hepatitis C, and other liver diseases (such as drug-related hepatopathy, alpha-1-antitrypsin deficiency, or metastatic cancer); liver biopsy</td> </tr> <tr> <td>Hepatomegaly or hepatic&nbsp;pain</td> <td>Evaluation for hepatitis B, hepatitis C,&nbsp;and other liver diseases; liver biopsy;&nbsp;measurement of alpha-fetoprotein&nbsp;concentration; hepatic imaging&nbsp;procedures; liver MRI*</td> </tr> <tr> <td>Arthralgias or arthropathy</td> <td>Radiography of affected joints; evaluation for other arthropathies</td> </tr> <tr> <td>Thyroid dysfunction</td> <td>Measurement of thyroid-stimulating hormone, thyroxine, and antithyroid antibody concentration if hypothyroid</td> </tr> <tr> <td>Impotence, premature&nbsp;amenorrhea</td> <td>Measurement of luteinizing hormone follicle-stimulating hormone, and sex hormone concentrations;&nbsp;CT of anterior pituitary to evaluate for possible pituitary tumor</td> </tr> <tr> <td>Cardiac symptoms</td> <td>Electrocardiography; echocardiographic assessment of ventricular ejection fraction and exercise tolerance; cardiac MRI*</td> </tr> <tr> <td>Hyperglycemia or diabetes mellitus</td> <td>Fasting serum glucose and glycosylated hemoglobin levels</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate for&nbsp;the approach to the evaluation.</div><div class=\"graphic_footnotes\">MRI: Magnetic resonance imaging; CT: computed tomography.<br />* Combined liver and heart MRI is available in some institutions.<br /></div><div class=\"graphic_reference\">Adapted from: Barton JC, McDonnell SM, Adams PC. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 1998; 129:932.</div><div id=\"graphicVersion\">Graphic 60117 Version 7.0</div></div></div>"},"60120":{"type":"graphic_picture","displayName":"CMV retinitis","title":"Cytomegalovirus retinitis","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Cytomegalovirus retinitis</div><div class=\"cntnt\"><img style=\"width:463px; height:314px;\" src=\"images/RHEUM/60120_CMV_retinitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retinitis along a vascular distribution as is typical of cytomegalovirus infection.</div><div class=\"graphic_reference\">Courtesy of James T Rosenbaum, MD.</div><div id=\"graphicVersion\">Graphic 60120 Version 1.0</div></div></div>"},"60121":{"type":"graphic_table","displayName":"Evaluation of anemia when ESA use is considered","title":"Evaluation for other causes of anemia in patients being considered for an erythropoiesis-stimulating agent","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation for other causes of anemia in patients being considered for an erythropoiesis-stimulating agent</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"indent1\">Thorough drug exposure history</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Review of a peripheral blood smear, and in some cases, bone marrow examination</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Analysis for iron, folate, or vitamin B12 deficiency, where indicated</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Assessment of reticulocyte count, occult blood loss, and renal insufficiency</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"subtitle2_left\">May also include:</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Coombs' testing for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, or a history of autoimmune disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Assessment of endogenous erythropoetin levels for patients with myelodysplastic syndrome (MDS)</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_reference\">Data from: Rizzo JD, Brouwers M, Hurley P, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Oncol Pract. 2010; 6:317.</div><div id=\"graphicVersion\">Graphic 60121 Version 3.0</div></div></div>"},"60122":{"type":"graphic_diagnosticimage","displayName":"CT of preinvasive lesion - AAH or AIS","title":"CT of preinvasive lesion - AAH or AIS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT of preinvasive lesion - AAH or AIS</div><div class=\"cntnt\"><img style=\"width:333px; height:353px;\" src=\"images/ONC/60122_CT_preinvas_lesion_AAH_AIS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT of preinvasive lesion (AAH or AIS). Axial 2-mm image through the left upper lobe shows a 5-mm pure ground-glass nodule (GGN), which has remained stable for eight years (arrow). AAH and AIS can be single or multiple.</div><div class=\"graphic_footnotes\">CT: computed tomography; AHH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ.</div><div class=\"graphic_reference\">Reproduced with permission from: Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6:244. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60122 Version 10.0</div></div></div>"},"60123":{"type":"graphic_picture","displayName":"Type 1 reaction in leprosy","title":"Type 1 reaction (RR) in leprosy","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Type 1 reaction (RR) in leprosy</div><div class=\"cntnt\"><img style=\"width:469px; height:279px;\" src=\"images/ID/60123_Type_1_leprosy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The initial lesions (panel A) became highly erythematous and indurated during a type 1 reaction (panel B) that occurred after 12 months of multidrug treatment.</div><div id=\"graphicVersion\">Graphic 60123 Version 3.0</div></div></div>"},"60124":{"type":"graphic_diagnosticimage","displayName":"Porcelain gallbladder CT","title":"Porcelain gallbladder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Porcelain gallbladder</div><div class=\"cntnt\"><img style=\"width:285px; height:353px;\" src=\"images/GAST/60124_Porcelain_gallbladder_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Porcelain gallbladder seen on computed tomography (arrow). Note the characteristic calcific gallbladder wall with the bile filled gallbladder lumen appearing dark.</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD.</div><div id=\"graphicVersion\">Graphic 60124 Version 2.0</div></div></div>"},"60126":{"type":"graphic_table","displayName":"Chemicals associated with immune dysfunction","title":"Chemicals associated with immune system dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chemicals associated with immune system dysfunction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Chemical </td> <td class=\"subtitle1\">Immunologic effects </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Polycyclic aromatic hydrocarbons </td> </tr> <tr> <td class=\"indent1\">Benzopyrenes</td> <td>Reduced antibody production</td> </tr> <tr> <td class=\"indent1\">Benzanthracene</td> <td>Reduced T cell cytotoxicity, carcinogenesis</td> </tr> <tr> <td class=\"indent1\">Benzene</td> <td>Lymphopenia, marrow suppression, carcinogenesis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Polyhalogenated aromatic hydrocarbons </td> </tr> <tr> <td class=\"indent1\">Polychlorinated biphenyls </td> <td>Altered lymphocyte populations, decreased delayed-type hypersensitivity, increased respiratory infections</td> </tr> <tr> <td class=\"indent1\">Polybrominated biphenyls </td> <td>Decreased T cell number and function</td> </tr> <tr> <td class=\"indent1\">Polychlorinated dibenzofurans </td> <td>Depressed cellular immunity</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Aromatic amines </td> </tr> <tr> <td class=\"indent1\">Benzidine </td> <td>Depressed cellular immunity, bladder carcinomas</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Estrogenic xenobiotics </td> </tr> <tr> <td class=\"indent1\">DDT </td> <td>Thymic atrophy</td> </tr> <tr> <td class=\"indent1\">Zearalenol </td> <td>Myelotoxicity</td> </tr> <tr> <td class=\"indent1\">Tetrahydrocannabinol </td> <td>Depressed cellular immunity</td> </tr> <tr> <td class=\"indent1\">Diethylstilbestrol </td> <td>Reduced natural killer activity, reduced antibody synthesis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pesticides </td> </tr> <tr> <td class=\"indent1\">Organochlorines (including DDT) </td> <td>Lymphopenia</td> </tr> <tr> <td class=\"indent1\">Organophosphates </td> <td>Thymic atrophy, reduced T cell cytotoxicity, reduced antibody synthesis</td> </tr> <tr> <td class=\"indent1\">Methyl isocyanate </td> <td>Increased CD4+ T cells, decreased mitogen response</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Organometals </td> </tr> <tr> <td class=\"indent1\">Organotins </td> <td>Impaired generation of&nbsp;cytotoxic lymphocytes,&nbsp;thymic atrophy</td> </tr> <tr> <td class=\"indent1\">Methylmercury </td> <td>Inhibition of complement</td> </tr> <tr> <td class=\"indent1\">Dimethylnitrosamine </td> <td>Reduced antibody production, carcinogenic</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Heavy metals </td> </tr> <tr> <td class=\"indent1\">Arsenic, cadmium, copper, gold, iron, lead, zinc </td> <td>Bone marrow suppression, lymphopenia, carcinogenesis</td> </tr> <tr> <td class=\"indent1\">Asbestos </td> <td>Reduced&nbsp;natural killer&nbsp;function, reduced CD4/CD8 ratio, cytotoxic to alveolar macrophages, depressed cellular immunity, polyclonal B cell activation, autoimmunity</td> </tr> <tr> <td class=\"indent1\">Silica production </td> <td>Decreased antibody, prolonged allograft rejection, cytotoxic to alveolar macrophages, depressed cellular immunity, polyclonal B cell activation, autoimmunity</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Air pollutants </td> </tr> <tr> <td class=\"indent1\">Ozone </td> <td>Decrease resistance to experimental infections</td> </tr> <tr> <td class=\"indent1\">Sulfur dioxide </td> <td>Respiratory tract infections</td> </tr> <tr> <td class=\"indent1\">Nitrogen dioxide </td> <td>Decreased alveolar macrophage phagocytosis and bacterial capacity</td> </tr> <tr> <td class=\"indent1\">Nanoparticles (organic or inorganic, naturally-occurring or man-made)</td> <td>Induction of proinflammatory cytokines, altered responses to allergens, altered function of antigen-presenting cells</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Fungal toxins </td> </tr> <tr> <td class=\"indent1\">Ochratoxin </td> <td>Depressed antibody production</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Trichothecenes </td> <td>Decreased T and B cell mitogen responses, leukopenia, delayed skin graft rejection</td> </tr> <tr> <td>Inhibition of macrophage activation, hepatic carcinoma</td> </tr> <tr> <td class=\"indent1\">Ethanol </td> <td>Reduced T cell function, reduced macrophage function, reduced antibody production, impaired neutrophil chemotaxis, increased respiratory tract infection</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DDT: dichlorodiphenyltrichloroethane.</div><div id=\"graphicVersion\">Graphic 60126 Version 3.0</div></div></div>"},"60127":{"type":"graphic_diagnosticimage","displayName":"Angiomyolipoma renal bleed CT","title":"CT scan showing renal angiomyolipoma with hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan showing renal angiomyolipoma with hemorrhage</div><div class=\"cntnt\"><img style=\"width:346px; height:288px;\" src=\"images/NEPH/60127_Angiomyolipomarenalbleed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT scan demonstrates a large fat-containing mass arising from the posterior aspect of the left kidney (arrow) which is displaced anteriorly by the mass. The mass has ruptured producing a hematoma in the perirenal space (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 60127 Version 5.0</div></div></div>"},"60129":{"type":"graphic_diagnosticimage","displayName":"Endomyocard fibrosis echo","title":"Endomyocardial fibrosis echo","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Endomyocardial fibrosis echo</div><div class=\"cntnt\"><img style=\"width:491px; height:181px;\" src=\"images/CARD/60129_Endomyocard_fibrosis_echo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Surface echocardiogram with fibrosis and thrombus in the left ventricular apex. <br />(B) Transesophageal echocardiogram with biventricular apical fibrosis with involvement of the posterior mitral papillary muscle and a small pericardial effusion.</div><div class=\"graphic_reference\">Reproduced with permission from Berenstein CS, Pineiro D, Marcotegui M, et al. Usefulness of echocardiography and doppler echocardiography in endomyocardial fibrosis. J Am Soc Echocardiogr 2000; 13:385. Copyright ©2000 The American Society of Echocardiography.</div><div id=\"graphicVersion\">Graphic 60129 Version 4.0</div></div></div>"},"60130":{"type":"graphic_diagnosticimage","displayName":"Primary CNS lymphoma MRI II","title":"Magnetic resonance imaging of primary central nervous system lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging of primary central nervous system lymphoma</div><div class=\"cntnt\"><img style=\"width:407px; height:252px;\" src=\"images/HEME/60130_Primary_CNS_lymphoma_MRI_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A shows a gadolinium-enhanced cranial magnetic resonance image (MRI) of an immunocompetent patient with a homogeneously enhancing, single periventricular mass (yellow arrow). Pathologic examination revealed this to be a diffuse large B-cell non-Hodgkin lymphoma. Panel B is a MRI of the same patient after four cycles (2 months) of high-dose methotrexate, showing resolution of the mass lesion.</div><div class=\"graphic_reference\">Reproduced with permission from: Batchelor, T, Carson, K, O'Neill, A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07. J Clin Oncol 2003; 21:1044. Copyright © 2003 American Society of Clinical Oncology.</div><div id=\"graphicVersion\">Graphic 60130 Version 4.0</div></div></div>"},"60132":{"type":"graphic_figure","displayName":"Mechanism of acromioclavicular joint injury","title":"Mechanism of acromioclavicular joint injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mechanism of acromioclavicular joint injury</div><div class=\"cntnt\"><img style=\"width:438px; height:497px;\" src=\"images/EM/60132_Mechanism_of_AC_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Injury to the acromioclavicular (AC) joint usually occurs from direct trauma to the superior or lateral aspect of the shoulder with the arm adducted, such as falling onto the shoulder. Greater force increases the risk of injury.</div><div id=\"graphicVersion\">Graphic 60132 Version 3.0</div></div></div>"},"60133":{"type":"graphic_figure","displayName":"FSH threshold","title":"FSH threshold and follicular development","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">FSH threshold and follicular development</div><div class=\"cntnt\"><img style=\"width:344px; height:298px;\" src=\"images/ENDO/60133_FSH_threshold.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The intercycle rise in serum FSH concentrations exceeds the threshold for recruitment of follicles for further development. The number of follicles recruited is determined by the time (&quot;window&quot;) in which the serum FSH is above the threshold at which recruitment occurs.</div><div class=\"graphic_footnotes\">FSH: follicle-stimulating hormone.</div><div id=\"graphicVersion\">Graphic 60133 Version 2.0</div></div></div>"},"60134":{"type":"graphic_figure","displayName":"Vent responses to hypoxia","title":"Ventilatory responses to hypoxia in patients with mild and severe hypothyroidism","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Ventilatory responses to hypoxia in patients with mild and severe hypothyroidism</div><div class=\"cntnt\"><img style=\"width:530px; height:336px;\" src=\"images/ENDO/60134_Vent_responses_to_hypoxia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ventilatory responses are shown as the relationships between alveolar oxygen tension (PAO2) and VE (STPD).</div><div class=\"graphic_footnotes\">PAO2: partial pressure of oxygen; STPD: standard temperature and pressure dry; VE: minute ventilation.</div><div class=\"graphic_reference\">Data from: Zwillich AA, Pierson DJ, Hofeldt FD. Ventilatory control in myxedema and hypothyroidism. N Engl J Med 1975; 292:662.</div><div id=\"graphicVersion\">Graphic 60134 Version 3.0</div></div></div>"},"60135":{"type":"graphic_diagnosticimage","displayName":"Herpes esophagitis Ba swallow","title":"Herpes esophagitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Herpes esophagitis</div><div class=\"cntnt\"><img style=\"width:193px; height:288px;\" src=\"images/GAST/60135_Herpes_esophagitis_Ba_swall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Barium swallow in a patient with Herpes simplex esophagitis shows a single aphthous ulcer in the distal esophagus (arrow) on a background of normal esophageal mucosa. Other viruses, such as cytomegalovirus and HIV, and medications may also produce this appearance.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 60135 Version 2.0</div></div></div>"},"60136":{"type":"graphic_picture","displayName":"Radical vulvectomy","title":"Radical vulvectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radical vulvectomy</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/OBGYN/60136_Radical_vulvectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dissection is being taken down the deep fascia of the medial thigh. Vulvar specimen is being retracted to the left.</div><div class=\"graphic_reference\">Courtesy of C. William Helm, MD.</div><div id=\"graphicVersion\">Graphic 60136 Version 2.0</div></div></div>"},"60137":{"type":"graphic_picture","displayName":"Infil UC sarcomatoid","title":"Infiltrating urothelial carcinoma, sarcomatoid variant with heterologous elements","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Infiltrating urothelial carcinoma, sarcomatoid variant with heterologous elements</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ONC/60137_Infil_UC_sarcomatoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sarcomatoid urothelial carcinoma showing an undifferentiated high-grade spindle cell neoplasm with heterologous elements of chondrosarcoma (right).</div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 60137 Version 1.0</div></div></div>"},"60138":{"type":"graphic_picture","displayName":"Cebocephaly","title":"Cebocephaly","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cebocephaly</div><div class=\"cntnt\"><img style=\"width:268px; height:373px;\" src=\"images/PEDS/60138_Cebocephaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The closely-approximated nostrils, small mouth, and hypotelorism in this infant are clinical manifestations of holoprosencephaly.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 60138 Version 2.0</div></div></div>"},"60139":{"type":"graphic_picture","displayName":"Breast abscess with skin necrosis","title":"Breast abscess with skin necrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Breast abscess with skin necrosis</div><div class=\"cntnt\"><img style=\"width:360px; height:363px;\" src=\"images/PC/60139_Breast_abscess_w_necrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When the overlying skin is thinned or necrotic, the optimal&nbsp;procedure is excision of&nbsp;the necrotic skin, which allows the abscess to drain.</div><div class=\"graphic_reference\">Courtesy of Michael J Dixon, MD.</div><div id=\"graphicVersion\">Graphic 60139 Version 4.0</div></div></div>"},"60143":{"type":"graphic_diagnosticimage","displayName":"CMV and Legionella PA","title":"Combined pulmonary infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Combined pulmonary infection</div><div class=\"cntnt\"><img style=\"width:311px; height:344px;\" src=\"images/ID/60143_CMV_and_Legionella_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows extensive bilateral pulmonary infiltrates in a patient on high-dose glucocorticoids for granulomatosis with polyangiitis (Wegener’s) who developed acute fever and dyspnea. Lung biopsy demonstrated dual infection with cytomegalovirus and <EM>Legionella pneumophila</EM>.</div><div class=\"graphic_reference\">Courtesy of Jay Fishman, MD.</div><div id=\"graphicVersion\">Graphic 60143 Version 5.0</div></div></div>"},"60144":{"type":"graphic_picture","displayName":"Cutaneous larva migrans","title":"Skin lesion of cutaneous larva migrans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin lesion of cutaneous larva migrans</div><div class=\"cntnt\"><img style=\"width:405px; height:288px;\" src=\"images/ID/60144_Cutaneous_larva_migrans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic elevated, serpiginous, reddish-brown lesion of cutaneous larva migrans as the larvae migrate at a rate of several millimeters per day.</div><div class=\"graphic_reference\">Courtesy of Peter F Weller, MD.</div><div id=\"graphicVersion\">Graphic 60144 Version 1.0</div></div></div>"},"60145":{"type":"graphic_table","displayName":"Per-act risk of HIV","title":"Estimated per-act risk for acquisition of HIV, by exposure route","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated per-act risk for acquisition of HIV, by exposure route</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"14%\"></colgroup><colgroup span=\"2\" width=\"43%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Exposure route</td> <td class=\"subtitle1\">Risk per 10,000 exposures to an infected source (risk)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Blood-borne exposure</td> <td>Blood transfusion</td> <td class=\"centered\">9000 (9/10)</td> </tr> <tr> <td>Needle-sharing injection drug use</td> <td class=\"centered\">67 (1/150)</td> </tr> <tr> <td>Percutaneous needle stick</td> <td class=\"centered\">23 (1/435)</td> </tr> <tr class=\"divider_bottom\"> <td>Mucous membrane exposure to blood (eg, splash to eye)</td> <td class=\"centered\">10 (1/1,000)</td> </tr> <tr> <td rowspan=\"5\">Sexual exposure</td> <td>Receptive anal intercourse</td> <td class=\"centered\">138 (1/72)</td> </tr> <tr> <td>Insertive anal intercourse</td> <td class=\"centered\">11 (1/900)</td> </tr> <tr> <td>Receptive penile-vaginal intercourse</td> <td class=\"centered\">8 (1/1250)</td> </tr> <tr> <td>Insertive penile-vaginal intercourse</td> <td class=\"centered\">4 (1/2500)</td> </tr> <tr> <td>Receptive or insertive penile-oral intercourse</td> <td class=\"centered\">0-4</td> </tr> <tr> <td>Other</td> <td>Biting, spitting, throwing body fluids (including semen and saliva), sharing sex toys</td> <td class=\"centered\">Negligible&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">There are scant empiric data on per contact risk of exposure. This table lists the estimated risk by exposure type in the absence of antiretroviral treatment of the HIV-infected source and in the absence of amplifying factors. Most of these estimates are derived through modeling studies of different cohorts. Clinicians need to be aware that estimates of sexual risk are often based on studies of monogamous couples among whom amplifying factors have been treated and repeated exposure may offer as yet unexplained protection from infection. Using a single value for assessing risk of HIV transmission based on route of sexual exposure fails to reflect the variation associated with important cofactors. A variety of amplifying factors and conditions have been identified, and these factors can be expected to increase transmission probability. </div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Donegan E, Stuart M, Niland JC, et al. Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations. Ann Intern Med 1990; 113:733-9.</LI>&#xD;&#xA;<LI>Baggaley RF, Boily MC, White RG, Alary M. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: A systematic review and meta-analysis. AIDS 2006; 20:805.</LI>&#xD;&#xA;<LI>Kaplan EH, Heimer R. HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. J Acquir Immune Defic Syndr 1995; 10:175-6.</LI>&#xD;&#xA;<LI>Patel P, Borkowf CB, Brooks JT, et al. Estimating per-act HIV transmission risk: A systematic review. AIDS 2014; 28:1509-19.</LI>&#xD;&#xA;<LI>Cohen MS. Amplified transmission of HIV-1: Missing link in the HIV pandemic. Trans Am Clin Climatol Assoc 2006; 117: 213–225.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention, US Department of Health and Human Services. Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016.</LI></OL></div><div id=\"graphicVersion\">Graphic 60145 Version 5.0</div></div></div>"},"60146":{"type":"graphic_figure","displayName":"Association of increasing plasma cholesterol and coronary risk","title":"Association of increasing plasma cholesterol and coronary risk","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Association of increasing plasma cholesterol and coronary risk</div><div class=\"cntnt\"><img style=\"width:364px; height:238px;\" src=\"images/CARD/60146_Cholesterol_and_coronary_ri.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation between plasma cholesterol concentration and six-year coronary heart disease risk in 361,662 men (ages 35 to 57) screened during the MRFIT study. There is a continuous, positive, graded correlation between the plasma cholesterol concentration and coronary risk. To convert plasma cholesterol to mmol/L, divide by 38.5.</div><div class=\"graphic_reference\">Data from: Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256:2823.</div><div id=\"graphicVersion\">Graphic 60146 Version 7.0</div></div></div>"},"60148":{"type":"graphic_table","displayName":"Neuro complications of hyperthy","title":"Summary of the more common neurologic manifestations of hyperthyroidism and Graves' disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of the more common neurologic manifestations of hyperthyroidism and Graves' disease</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n<tbody>\r\n\r\n\t<tr>\r\n\t\t\t\t\t<td class= \"subtitle1\">&nbsp;</td>\r\n\t\t\t\t\t<td class= \"subtitle1\">Cardinal features</td>\r\n\t\t\t\t\t<td class= \"subtitle1\">Relative frequency</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Cognitive dysfunction</td>\r\n\t\t\t\t\t<td>Ranges from mild inattention and anxiety to agitated delirium, rarely coma</td>\r\n\t\t\t\t\t<td>Common, especially with acute and more severe thyrotoxicosis</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Seizures</td>\r\n\t\t\t\t\t<td>Usually generalized tonic clonic seizures that usually occur with encephalopathy in acute thyrotoxicosis</td>\r\n\t\t\t\t\t<td>Uncommon</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Tremor</td>\r\n\t\t\t\t\t<td>High frequency, low amplitude</td>\r\n\t\t\t\t\t<td>Common</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Chorea</td>\r\n\t\t\t\t\t<td>Unifocal or multifocal, sustained or paroxysmal</td>\r\n\t\t\t\t\t<td>Rare</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Stroke</td>\r\n\t\t\t\t\t<td>Usually cardioembolic, associated with thyrotoxic-induced atrial fibrillation</td>\r\n\t\t\t\t\t<td>Rare</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Myopathy</td>\r\n\t\t\t\t\t<td>Usually mild proximal muscle weakness with normal serum CK</td>\r\n\t\t\t\t\t<td>Common, but may be subclinical</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Polyneuropathy</td>\r\n\t\t\t\t\t<td><p>Usually an axonal sensory polyneuropathy</p>\r\n\t\t\t\t\t\t<p>Rare demyelinating polyneuropathy</p></td>\r\n\t\t\t\t\t<td>Approximately 25 percent, but may be subclinical</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Myasthenia gravis</td>\r\n\t\t\t\t\t<td>Perhaps more likely to be ocular rather than generalized</td>\r\n\t\t\t\t\t<td>Uncommon</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Periodic paralysis</td>\r\n\t\t\t\t\t<td>Usually associated with hypokalemia</td>\r\n\t\t\t\t\t<td>Rare</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>Graves' ophthalmopathy</td>\r\n\t\t\t\t\t<td>Proptosis, restricted eye movements</td>\r\n\t\t\t\t\t<td>Approximately 25 percent of patients with Graves' disease</td>\r\n\t\t\t\t</tr>\r\n</tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 60148 Version 1.0</div></div></div>"},"60149":{"type":"graphic_figure","displayName":"Echinococcal cyst series","title":"Hepatic echinococcal cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatic echinococcal cyst</div><div class=\"cntnt\"><img style=\"width:382px; height:267px;\" src=\"images/GAST/60149_Echinococcal_cyst_series.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: ERCP demonstrating external compression of the hepatic duct by the cyst. Panel B: CT scan shows a complex septated cyst and a heavily calcified daughter-cyst in the right hepatic lobe (arrowhead), in a 38-year old man. Panel C: Post resection. Panel D: Histologic appearance of a degenerated cyst containing fragments of the germinal membrane (hematoxylin and eosin, original magnification: x 2000).</div><div class=\"graphic_reference\">Reproduced with permission from: Regev, A, Reddy, KR, Berho, M, et al. Large cystic lesions of the liver in adults: A 15-year experience in a tertiary center. J Am Coll Surg 2001; 193:36. Copyright &#169; 2001 American College of Surgeons.</div><div id=\"graphicVersion\">Graphic 60149 Version 2.0</div></div></div>"},"60151":{"type":"graphic_table","displayName":"Risk factors and proposed screening recs for gastric cancer","title":"Risk factors and proposed screening recommendations for gastric cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors and proposed screening recommendations for gastric cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Risk factors</td> <td class=\"subtitle1\">Risk for developing gastric cancer</td> <td class=\"subtitle1\">Recommendation</td> <td class=\"subtitle1\">Reference</td> </tr> <tr> <td rowspan=\"2\">Helicobacter pylori (HP) infection</td> <td rowspan=\"2\">Odds ratio (OR): 2.3</td> <td>High risk area - mass screening possible benefit</td> <td rowspan=\"2\">Huang 1998</td> </tr> <tr> <td>Low risk area - mass screening not cost-effective</td> </tr> <tr class=\"divider_top\"> <td>1. HP without atrophic gastritis</td> <td>1. Hazard ratio 7.13 (compared with no HP)</td> <td>See above</td> <td rowspan=\"3\">Ohata 2004</td> </tr> <tr> <td>2. HP with atrophic gastritis</td> <td>2. Hazard ratio 14.5</td> <td>HP eradication</td> </tr> <tr> <td>3. Atrophic gastritis and extensive intestinal metaplasia</td> <td>3. Hazard ratio 61.9</td> <td>HP eradication</td> </tr> <tr class=\"divider_top\"> <td>Pernicious anemia</td> <td>Standardized incidence ratio: 5</td> <td>Screening by upper endoscopy (UE) recommended</td> <td>Kokkola 1998</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Partial gastrectomy</td> <td>15-24 years, RR = 9.4</td> <td rowspan=\"2\">Screening by UE recommended</td> <td rowspan=\"2\"> <p>Lundegardh 1988</p> <p>Tersmette 1991</p> </td> </tr> <tr> <td>25-46 years, RR = 55.6</td> </tr> <tr class=\"divider_top\"> <td>Sporadic adenomas</td> <td>Not available</td> <td>Surveillance post polypectomy for established dysplasia</td> <td>Ming 1965</td> </tr> <tr class=\"divider_top\"> <td>Familial adenomatous polyposis</td> <td>Not available</td> <td>Screening by UE recommended</td> <td>Alexander 1989</td> </tr> <tr class=\"divider_top\"> <td>Hereditary nonpolyposis colorectal cancer</td> <td>Not available</td> <td>Screening by UE recommended</td> <td>Aarnio 1997</td> </tr> <tr class=\"divider_top\"> <td>Positive family history of gastric cancer</td> <td>OR: 2.5-5.1</td> <td>HP eradication +/- UE screening</td> <td> <p>Yatsuya 2004</p> <p>Chen 2004</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Annie O O Chan, MD, and Benjamin C Y Wong, MD.</div><div id=\"graphicVersion\">Graphic 60151 Version 3.0</div></div></div>"},"60152":{"type":"graphic_figure","displayName":"VWF mRNA and functional domains","title":"The structure of von Willebrand factor including common mutations and binding sites","html":"<div class=\"graphic\"><div style=\"width: 702px\" class=\"figure\"><div class=\"ttl\">The structure of von Willebrand factor including common mutations and binding sites</div><div class=\"cntnt\"><img style=\"width:682px; height:387px;\" src=\"images/HEME/60152_VWF_mRNA_functional_domains.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type 1 and 3 VWD mutations are not shown in the figure because they are distributed widely throughout the VWF sequence. Please refer to UpToDate topics on von Willebrand factor and von Willebrand disease for details and additional information about D domain assemblies.</div><div class=\"graphic_footnotes\">VWF: von Willebrand factor; VWD: von Willebrand disease.</div><div id=\"graphicVersion\">Graphic 60152 Version 5.0</div></div></div>"},"60153":{"type":"graphic_diagnosticimage","displayName":"Multiple nerve root metastases","title":"Multiple nerve root metastases","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple nerve root metastases</div><div class=\"cntnt\"><img style=\"width:336px; height:504px;\" src=\"images/NEURO/60153_Mult_nerve_root_metast_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T2-weighted sagittal MRI of the lower thoracic, lumbar, and sacral spine shows abnormal hyperintensity of multiple nerve roots in a patient with leptomeningeal metastases.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Seward Rutkove, MD and Andrew Tarulli, MD.</div><div id=\"graphicVersion\">Graphic 60153 Version 3.0</div></div></div>"},"60155":{"type":"graphic_picture","displayName":"Circumferential thrombosed hemorrhoids","title":"Circumferential thrombosed hemorrhoids - Hemorrhoidal crisis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Circumferential thrombosed hemorrhoids - Hemorrhoidal crisis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/SURG/60155_Circum_thromb_hemorrhoid_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows thrombosis of multiple external hemorrhoids, a hemorrhoidal crisis.</div><div class=\"graphic_reference\">Courtesy of W Brian Sweeney, MD.</div><div id=\"graphicVersion\">Graphic 60155 Version 1.0</div></div></div>"},"60156":{"type":"graphic_diagnosticimage","displayName":"Hydrocephalus due to a choroid plexus papilloma","title":"Hydrocephalus due to a choroid plexus papilloma","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Hydrocephalus due to a choroid plexus papilloma</div><div class=\"cntnt\"><img style=\"width:463px; height:184px;\" src=\"images/PEDS/60156_Hydro_choroid_plex_pap_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance imaging in a 10-month-old male infant, showing a papilloma of the choroid plexus in the right lateral ventricle. There is associated hydrocephalus, caused by overproduction of cerebrospinal fluid (CSF).</div><div class=\"graphic_reference\">Courtesy of Drs. Abilash Haridas and Tadanori Tomita.</div><div id=\"graphicVersion\">Graphic 60156 Version 2.0</div></div></div>"},"60160":{"type":"graphic_table","displayName":"Safe use of cyclophosphamide","title":"Guidelines for the safe use of daily cyclophosphamide","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for the safe use of daily cyclophosphamide</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Limit duration of CYC use (ideally 6 to 12 months or less, for remission induction)</td> </tr> <tr> <td>Administer medication in morning</td> </tr> <tr> <td>Instruct the patient to drink eight 8-oz glasses of water daily</td> </tr> <tr> <td>Adjust dose to maintain the total white blood cell count &#62;3500 mm<sup>3</sup></td> </tr> <tr> <td>Decrease the dose in the setting of renal dysfunction</td> </tr> <tr> <td>Check complete blood counts (with differential) and serum creatinine levels every&nbsp;two weeks (more frequently for those with borderline counts)</td> </tr> <tr> <td>Monthly urinalyses</td> </tr> <tr> <td>Use prophylaxis for <em>Pneumocystis jiroveci (carinii)</em> pneumonia infection</td> </tr> <tr> <td>Long-term surveillance for CYC-induced bladder injury</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CYC: cyclophosphamide.</div><div class=\"graphic_reference\">Reproduced with permission from: Rheumatic Disease Clinics of North America 2001. 27(4):863. Copyright © 2001 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 60160 Version 3.0</div></div></div>"},"60161":{"type":"graphic_table","displayName":"Recommendations for tilt testing","title":"Recommendations for tilt testing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for tilt testing</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Recommendations</td> <td class=\"subtitle1\">Class*</td> <td class=\"subtitle1\">Level<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Methodology</td> </tr> <tr> <td class=\"indent1\">Supine pre-tilt phase of at least 5 min, when no venous cannulation, and of at least 20 min, when cannulation is undertaken, is recommended</td> <td>I</td> <td>C</td> </tr> <tr> <td class=\"indent1\">Tilt angle between 60 and 70&#176; is recommended</td> <td>I</td> <td>B</td> </tr> <tr> <td class=\"indent1\">Passive phase of a minimum of 20 min and a maximum of 45 min is recommended</td> <td>I</td> <td>B</td> </tr> <tr> <td class=\"indent1\">For nitroglycerin, a fixed dose of 300 to 400 micrograms sublingually administered in the upright position is recommended</td> <td>I</td> <td>B</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">For isoproterenol, an incremental infusion rate from 1 up to 3 micrograms/min in order to increase average heart rate by ~20 to 25 percent over baseline is recommended</td> <td>I</td> <td>B</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Indications</td> </tr> <tr> <td class=\"indent1\">Tilt testing is indicated in the case of an unexplained single syncopal episode in high risk settings (eg, occurrence of, or potential risk of physical injury or with occupational implications), or recurrent episodes in the absence of organic heart disease, or in the presence of organic heart disease, after cardiac causes of syncope have been excluded</td> <td>I</td> <td>B</td> </tr> <tr> <td class=\"indent1\">Tilt testing is indicated when it is of clinical value to demonstrate susceptibility to reflex syncope to the patient</td> <td>I</td> <td>C</td> </tr> <tr> <td class=\"indent1\">Tilt testing should be considered to discriminate between relfex and OH syncope</td> <td>IIa</td> <td>C</td> </tr> <tr> <td class=\"indent1\">Tilt testing may be considered for differentiating syncope with jerking movements from epilepsy</td> <td>IIb</td> <td>C</td> </tr> <tr> <td class=\"indent1\">Tilt testing may be indicated for evaluating patients with recurrent unexplained falls</td> <td>IIb</td> <td>C</td> </tr> <tr> <td class=\"indent1\">Tilt testing may be indicated for evaluating patients with frequent syncope and psychiatric disease</td> <td>IIb</td> <td>C</td> </tr> <tr> <td class=\"indent1\">Tilt testing is not recommended for assessment of treatment</td> <td>III</td> <td>B</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Isoproterenol tilt testing is contraindicated in patients with ischaemic heart disease</td> <td>III</td> <td>C</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Diagnostic criteria</td> </tr> <tr> <td class=\"indent1\">In patients without structural heart disease the induction of reflex hypotension/bradycardia with reproduction of syncope or progressive OH (with or without symptoms) are diagnostic of reflex syncope and OH, respectively</td> <td>I</td> <td>B</td> </tr> <tr> <td class=\"indent1\">In patients without structural heart disease the induction of reflex hypotension/bradycardia without reproduction of syncope may be diagnostic of reflex syncope</td> <td>IIa</td> <td>B</td> </tr> <tr> <td class=\"indent1\">In patients with structural heart disease, arrhythmia, or other cardiovascular cause of syncope should be excluded prior to considering positive tilt test results as diagnostic</td> <td>IIa</td> <td>C</td> </tr> <tr> <td class=\"indent1\">Induction of LOC in absence of hypotension and/or bradycardia should be considered diagnostic of psychogenic pseudosyncope</td> <td>IIa</td> <td>C</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BP: blood pressure; CSM: carotid sinus massage; HR: heart rate; LOC: loss of consciousness; OH: orthostatic hypotension; TIA: transient ischaemic attack; µg: micrograms.<br />* Class of recommendation.<br />¶ Level of evidence.</div><div class=\"graphic_reference\">Reproduced with permission from: European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009; 30:2631. Copyright &copy; 2009 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 60161 Version 10.0</div></div></div>"},"60162":{"type":"graphic_picture","displayName":"AIDS-related Kaposis sarcoma - ulcerating","title":"AIDS-related Kaposi's sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AIDS-related Kaposi's sarcoma</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/60162_Kaposis_sarc_ulcerating.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An ulcerating plaque is present on the sole of the foot.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60162 Version 3.0</div></div></div>"},"60163":{"type":"graphic_picture","displayName":"Genital lesions chancroid","title":"The genital lesions of chancroid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The genital lesions of chancroid</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ID/60163_Genital_lesions_chancroid.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60163 Version 3.0</div></div></div>"},"60164":{"type":"graphic_figure","displayName":"MUNE multiple point stimulation","title":"Motor unit number estimation (MUNE) by the multiple point stimulation method","html":"<div class=\"graphic\"><div style=\"width: 649px\" class=\"figure\"><div class=\"ttl\">Motor unit number estimation (MUNE) by the multiple point stimulation method</div><div class=\"cntnt\"><img style=\"width:629px; height:441px;\" src=\"images/NEURO/60164_MPS_MUNE.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A group of single motor unit action potential (S-MUAP) waveforms recorded from the thenar muscles of an ALS patient using low intensity multiple point stimulation. The amplitudes of these potentials can be averaged to obtain the representative S-MUAP amplitude for calculation of the MUNE. Note the higher amplitude motor unit (waveform 2, left column, middle row) in this patient with motor neuron disease, a correlate of the collateral reinnervation. The following waveform data appears above each tracing (left to right): Waveform number (1 to 10), onset latency (milliseconds; time base varies from tracing to tracing with settings at 5, 10 or 20 milliseconds/division), peak-to-peak amplitude (microvolts; sensitivity 100 microvolts per division), negative peak amplitude (microvolts) and area (microvolts-milliseconds).&#160;</div><div class=\"graphic_reference\">Courtesy of Clifton Gooch, MD.</div><div id=\"graphicVersion\">Graphic 60164 Version 1.0</div></div></div>"},"60165":{"type":"graphic_picture","displayName":"Reinkes edema","title":"Reinke's edema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reinke's edema</div><div class=\"cntnt\"><img style=\"width:322px; height:255px;\" src=\"images/PC/60165_Reinkes_edema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reinke's edema (polypoid corditis) of bilateral true vocal folds. In this view, the patient is inspiring forcefully; note the soft, gelatinous appearing quality of the medial vocal folds. Note also the thickened, irregular appearance of the interarytenoid mucosa posteriorly, representing changes consistent with laryngopharyngeal reflux.</div><div id=\"graphicVersion\">Graphic 60165 Version 1.0</div></div></div>"},"60169":{"type":"graphic_table","displayName":"SPECT myocardial perfusion agents","title":"Characteristics of various SPECT myocardial perfusion agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of various SPECT myocardial perfusion agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Thallium</td> <td class=\"subtitle1\">Sestamibi</td> <td class=\"subtitle1\">Tetrofosmin</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Class</strong></td> <td>Element</td> <td>Isonitrite</td> <td>Diphospine</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Charge</strong></td> <td>Positive</td> <td>Positive</td> <td>Positive</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Lipophilic</strong></td> <td>No</td> <td>No</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Extraction</strong></td> <td>Mod-high</td> <td>Moderate</td> <td>Moderate</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Retention</strong></td> <td>Moderate</td> <td>High</td> <td>High</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Redistribution</strong></td> <td>Yes</td> <td>Minimal</td> <td>Minimum</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Start time</strong>*</td> <td>&#60;15 min</td> <td>15-60 min</td> <td>15-30 min</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Imaging protocol</strong></td> <td>1 day</td> <td>1 or 2 days</td> <td>1 or 2 days</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Gated SPECT</strong></td> <td>Possible</td> <td>Yes</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td><strong>First pass</strong></td> <td>No</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td><strong>Viability assessment</strong></td> <td>Yes</td> <td>Yes</td> <td>Yes?</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Start time is the time from injection of tracer to the start of imaging after stress.</div><div class=\"graphic_reference\">Adapted from: Stewart RE, Schwaiger M, Hutchins GD, et al, J Nucl Med 1990; 31:1183.</div><div id=\"graphicVersion\">Graphic 60169 Version 4.0</div></div></div>"},"60170":{"type":"graphic_picture","displayName":"Lymphatic stomata in pleura","title":"Lymphatic stomata in parietal pleura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphatic stomata in parietal pleura</div><div class=\"cntnt\"><img style=\"width:369px; height:273px;\" src=\"images/PULM/60170_Lymphatic_stomata_in_pleura.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scanning electron micrograph showing a lymphatic stoma on the surface of the parietal pleura (arrow). The stomata are holes in the otherwise continuous mesothelial layer that open onto the pleural space; they are the primary site of removal of pleural liquid from the pleural space.</div><div class=\"graphic_reference\">Courtesy of Kurt H Albertine, MD.</div><div id=\"graphicVersion\">Graphic 60170 Version 2.0</div></div></div>"},"60171":{"type":"graphic_picture","displayName":"Fundus in central retinal artery occlusion","title":"Fundus in central retinal artery occlusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fundus in central retinal artery occlusion</div><div class=\"cntnt\"><img style=\"width:432px; height:370px;\" src=\"images/NEURO/60171_Retinal_ischemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient presented acutely with painless loss of vision in the left eye. Visual acuity was 20/20 OD, 1/200 OS, and there was a dense left relative afferent pupillary defect. The fundus shows retinal whitening (edema of the nerve fiber layer) in the macular region (arrow), with a &quot;cherry-red&quot; spot in the fovea, the classic appearance of a central retinal artery occlusion.</div><div id=\"graphicVersion\">Graphic 60171 Version 2.0</div></div></div>"},"60172":{"type":"graphic_diagnosticimage","displayName":"Peritoneal calcification","title":"Focal peritoneal calcification","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Focal peritoneal calcification</div><div class=\"cntnt\"><img style=\"width:380px; height:266px;\" src=\"images/OBGYN/60172_Peritoneal_calcification.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left parasagittal view of fetus at 22 weeks gestational age shows a focal calcification in the peritoneal cavity with shadowing.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 60172 Version 3.0</div></div></div>"},"60173":{"type":"graphic_figure","displayName":"Actions of the ankle","title":"Actions of the ankle","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Actions of the ankle</div><div class=\"cntnt\"><img style=\"width:539px; height:674px;\" src=\"images/PEDS/60173_Actions_of_the_ankle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The actions of the ankle include dorsiflexion, plantarflexion, eversion, and inversion. </div><div id=\"graphicVersion\">Graphic 60173 Version 5.0</div></div></div>"},"60174":{"type":"graphic_table","displayName":"Etiology of sore throat by age","title":"Etiology of sore throat by age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of sore throat by age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cause</td> <td class=\"subtitle1\">Infants &#38; young children</td> <td class=\"subtitle1\">Older children and adolescents</td> </tr> <tr class=\"divider_bottom\"> <td>Viral pharyngitis*</td> <td> <p>Respiratory viruses</p> Herpangina (enterovirus)*</td> <td> <p>Epstein-Barr virus (infectious mononucleosis)*</p> <p>Respiratory viruses*</p> <p>HIV</p> <p>Herpangina (enterovirus)</p> HSV</td> </tr> <tr class=\"divider_bottom\"> <td>Bacterial pharyngitis</td> <td> <p>Group A <em>streptococcus</em></p> <p><em>Fusobacterium necrophorum </em>and other anaerobic bacteria (&#177; Lemierre's syndrome<sup>&#182;</sup>)</p> Other bacteria<sup>&#916;</sup></td> <td> <p>Group A <em>streptococcus</em>*</p> <p><em>Neisseria gonorrhoeae</em></p> <p><em>Fusobacterium necrophorum </em>and other anaerobic bacteria (&#177; Lemierre's syndrome<sup>&#182;</sup>)</p> Other bacteria<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Other infections</td> <td> <p>Retropharyngeal abscess<sup>&#182;</sup></p> <p>Lateral pharyngeal abscess<sup>&#182;</sup></p> Epiglottitis<sup>&#182;</sup></td> <td> <p>Peritonsillar abscess<sup>&#182;</sup></p> <p>Retropharyngeal abscess<sup>&#182;</sup></p> <p>Lateral pharyngeal abscess<sup>&#182;</sup></p> Epiglottitis<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Miscellaneous conditions</td> <td> <p>Steven-Johnson syndrome</p> <p>Kawasaki disease</p> <p>Beh&#231;et syndrome</p> PFAPA syndrome</td> <td> <p>Psychogenic pharyngitis</p> <p>Referred pain</p> <p>Steven-Johnson syndrome</p> <p>Kawasaki disease</p> <p>Beh&#231;et syndrome</p> PFAPA syndrome</td> </tr> <tr> <td>Traumatic injury</td> <td> <p>Foreign body</p> Chemical exposure</td> <td>Irritation of the mucosa*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: Human immunodeficiency virus; HSV: herpes simplex virus; PFAPA: periodic fever with aphthous stomatitis, pharyngitis, and adenitis.<br />* Common causes of sore throat in children.<br />¶ Life-threatening causes of sore throat in children.<br />Δ Other bacteria that can cause acute pharyngitis include group C and G <EM>Streptococcus</EM>, <EM>Arcanobacterium hemolyticum</EM>, <EM>Mycoplasma pneumoniae</EM>, <EM>Chlamydia pneumoniae</EM>, <EM>Francisella tularensis</EM>, <EM>Corynebacterium diphtheriae</EM>, and <EM>Neisseria gonorrhoeae</EM>.</div><div id=\"graphicVersion\">Graphic 60174 Version 16.0</div></div></div>"},"60175":{"type":"graphic_table","displayName":"Findings - Henoch Schonlein purpura","title":"Frequencies of clinical features of children with Henoch-Schonlein purpura (HSP) at presentation and during their disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequencies of clinical features of children with Henoch-Schonlein purpura (HSP) at presentation and during their disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Taiwan<sup>[1]</sup> (percent)</td> <td class=\"subtitle1\">Italy<sup>[2]</sup> (percent)</td> <td class=\"subtitle1\">United States<sup>[3]</sup> (percent)</td> </tr> <tr> <td>Purpura</td> <td class=\"centered\">100</td> <td class=\"centered\">100</td> <td class=\"centered\">100</td> </tr> <tr> <td>Arthralgia/arthritis</td> <td class=\"centered\">43</td> <td class=\"centered\">74</td> <td class=\"centered\">82</td> </tr> <tr> <td class=\"sublist1_start\">Abdominal pain</td> <td class=\"sublist_other_start_centered\">58</td> <td class=\"sublist_other_start_centered\">51</td> <td class=\"sublist_other_start_centered\">63</td> </tr> <tr> <td class=\"sublist1\">Gastrointestinal bleeding</td> <td class=\"sublist_other_centered\">18</td> <td class=\"sublist_other_centered\">18</td> <td class=\"sublist_other_centered\">33</td> </tr> <tr> <td class=\"sublist1\">Intussusception</td> <td class=\"sublist_other_centered\">0.4</td> <td class=\"sublist_other_centered\">0.6</td> <td class=\"sublist_other_centered\">&nbsp;</td> </tr> <tr> <td>Renal involvement</td> <td class=\"centered\">21</td> <td class=\"centered\">54</td> <td class=\"centered\">40</td> </tr> <tr> <td>Edema</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">52</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Encephalopathy</td> <td class=\"centered\">1</td> <td class=\"centered\">3</td> <td class=\"centered\">2</td> </tr> <tr> <td>Orchitis</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">13</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Recurrence</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">33</td> <td class=\"centered\">33</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Chang WL, Yang YH, Lin YT, Chiang BL. Gastrointestinal manifestations in Henoch-Schönlein purpura: a review of 261 patients. Acta Paediatr 2004; 93:1427. </LI>&#xD;&#xA;<LI>Chang WL, Yang YH, Wang LC, et al. Renal manifestations in Henoch-Schönlein purpura: a 10-year clinical study. Pediatr Nephrol 2005; 20:1269.</LI>&#xD;&#xA;<LI>Trapani S, Micheli A, Grisolia F, et al. Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum 2005; 35:143.</LI>&#xD;&#xA;<LI>Saulsbury FT. Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore) 1999; 78:395.</LI></OL></div><div id=\"graphicVersion\">Graphic 60175 Version 5.0</div></div></div>"},"60176":{"type":"graphic_figure","displayName":"Pivot shift test","title":"Pivot shift test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pivot shift test</div><div class=\"cntnt\"><img style=\"width:374px; height:481px;\" src=\"images/PEDS/60176_Pivot_shift_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pivot shift test assesses the presence of an anterior cruciate ligament injury.<br />(A) The 45 degrees of the flexed knee is reduced with external tibial rotation.<br />(B) Knee is allowed to extend with strong valgus pressure. A positive test is a definite \"thud\" as the tibia becomes subluxated and internally rotates between 20 and 10 degrees.<br />(C) Complete extension reduces the knee as the posterior capsule tightens.This test may be more sensitive than the anterior drawer or Lachman test but is difficult to perform in the acutely injured athlete because of guarding and apprehension.</div><div class=\"graphic_reference\">Reproduced with permission from: Reid DC. Sports Injury Assessment and Rehabilitation. Churchill Livingstone, New York 1992. p.471. Copyright &copy; 1992 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 60176 Version 4.0</div></div></div>"},"60177":{"type":"graphic_figure","displayName":"Bile acids in PBC","title":"Role of bile acids in primary biliary cholangitis","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Role of bile acids in primary biliary cholangitis</div><div class=\"cntnt\"><img style=\"width:479px; height:398px;\" src=\"images/GAST/60177_Bile_acids_in_PBC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The immunologically mediated T cell attack on bile ducts in primary biliary cholangitis leads to the retention of bile acids. Bile acids eventually accumulate in high enough concentrations in the liver to cause chemical damage to hepatocytes.</div><div id=\"graphicVersion\">Graphic 60177 Version 2.0</div></div></div>"},"60178":{"type":"graphic_figure","displayName":"Weight loss and fall in blood pressure","title":"Weight loss-induced reduction in diastolic blood pressure","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Weight loss-induced reduction in diastolic blood pressure</div><div class=\"cntnt\"><img style=\"width:465px; height:219px;\" src=\"images/NEPH/60178_Weight_loss_and_fall_in_BP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship between the quantity of weight lost and the fall in diastolic blood pressure in 308 moderately obese patients given a weight reduction regimen for 18 months. The patients began with a diastolic pressure between 80 and 89 mmHg; those who lost the most weight had the largest reduction in diastolic pressure. The decreases in the systolic pressure were similar.</div><div class=\"graphic_footnotes\">BP: blood pressure.</div><div class=\"graphic_reference\">Data from: Stevens VJ, Corrigan SA, Obarzanek E, et al. Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. Arch Intern Med 1993; 153:849.</div><div id=\"graphicVersion\">Graphic 60178 Version 6.0</div></div></div>"},"60182":{"type":"graphic_table","displayName":"Pharmacologic properties of antiseizure drugs","title":"Pharmacologic properties of antiseizure drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacologic properties of antiseizure drugs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"4\" width=\"21%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Metabolism and clearance</td> <td class=\"subtitle1\">Enzyme induction/inhibition</td> <td class=\"subtitle1\">Protein binding (%)*</td> <td class=\"subtitle1\">Half-life in adults (hours)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Brivaracetam</strong>&nbsp;</td> <td> <p>Metabolized primarily by CYP-independent hydrolysis (60%) and CYP2C19 (30%)</p> <p>Dose adjustment is needed in hepatic impairment</p> </td> <td> <p>Inhibits CYP2C19 (minor)</p> <p>Inhibits epoxide hydroxylase<sup>&#182;</sup></p> </td> <td>&#8804;20&nbsp;</td> <td>9&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Carbamazepine</strong></td> <td> <p>&#62;90% metabolized by CYPs 3A4 (major) and 1A2/2C8 (minor) to active (epoxide) and inactive metabolites</p> Dose adjustment is needed in severe renal impairment; use is not recommended in moderate or severe hepatic impairment</td> <td>Potent and broad-spectrum inducer of CYP, UGT-glucuronidation, and P-gp</td> <td>75</td> <td> <p>25-65 (initial use, enzyme-inducing naive patient)</p> 8-22 (after several weeks due to auto-induction)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Clobazam</strong></td> <td> <p>&#62;90% metabolized by CYPs 3A4, 2C19, 2B6 and non-CYP transformations to active (N-desmethylclobazam) and inactive metabolites</p> <p>Active metabolite is primarily metabolized by CYP2C19</p> Dose adjustment is needed in hepatic impairment</td> <td> <p>Inhibits CYP2D6 (moderate)</p> </td> <td> <p>80-90 (clobazam, parent drug)</p> <p>70 (N-desmethylclobazam, active&nbsp;metabolite)</p> </td> <td> <p>36-42 (clobazam, parent drug)</p> 71-82 (N-desmethylclobazam, active&nbsp;metabolite)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Eslicarbazepine</strong></td> <td> <p>Prodrug; &#60;33% of active form undergoes UGT-glucuronidation (including &#60;5% metabolized to oxcarbazepine); 66% is excreted renally as unchanged drug</p> Dose adjustment is needed for renal impairment; not recommended in patients with severe hepatic impairment</td> <td> <p>Induces CYP3A4 and UGT1A1 glucuronidation (weak) but does not induce its own metabolism</p> Inhibits CYP2C19 (moderate)</td> <td>&#60;40</td> <td>13-20 (prolonged in renal insufficiency)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Ethosuximide</strong></td> <td>~80% metabolized by CYP3A4 (major) and non-CYP transformations to inactive metabolites</td> <td>None</td> <td>&#60;5</td> <td>40-60</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Felbamate</strong></td> <td> <p>50% metabolized by CYPs 3A4, 2E1 (minor); ~50% renally excreted as unchanged drug</p> Dose adjustment is needed in renal impairment</td> <td> <p>Inhibits CYP2C19 (minor)</p> <p>Increases conversion of carbamazepine to active epoxide metabolite; mechanism not established</p> </td> <td>25</td> <td>13-22 (prolonged in renal insufficiency)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Gabapentin</strong></td> <td> <p>&#62;95% renally excreted as unchanged drug (ie, does not undergo hepatic metabolism)</p> Dose adjustment is needed in renal impairment</td> <td>None</td> <td>&#60;5</td> <td>5-7 (prolonged in renal insufficiency; &#62;130 hours in anuria)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Lacosamide</strong></td> <td> <p>40% renally excreted as unchanged drug; 30% metabolized by non-CYP transformations (including methylation) to inactive metabolite</p> Dose adjustment is needed in hepatic and renal impairment</td> <td>Inhibits CYP2C19 (minor)</td> <td>&#60;15</td> <td>13</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Lamotrigine</strong></td> <td> <p>&#62;90% metabolized by UGT-glucuronidation and other non-CYP transformations to inactive metabolites</p> Dose adjustment is needed in moderate to severe renal or hepatic impairment</td> <td>May induce its own metabolism by UGT-glucuronidation (minor)</td> <td>55</td> <td>12-62</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Levetiracetam</strong></td> <td> <p>&#62;65% renally excreted as unchanged drug; 24% metabolized by non-CYP transformation (including amidase hydrolysis) to inactive metabolites</p> Dose adjustment is needed in renal impairment</td> <td>None</td> <td>&#60;10</td> <td>6-8</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Oxcarbazepine</strong></td> <td> <p>Prodrug; 70% of active (MHD) form undergoes UGT-glucuronidation; 30% is renally excreted as unchanged active drug</p> Dose adjustment is needed in severe renal impairment</td> <td>Induces CYP3A4 (moderate to severe) and UGT-glucuronidation but does not induce its own metabolism</td> <td>40</td> <td>9 (active metabolite, prolonged in renal insufficiency)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Perampanel</strong></td> <td> <p>&#62;70% metabolized by CYPs 3A4, 3A5 and non-CYP transformations to inactive metabolites</p> Dose adjustment is needed in mild or moderate hepatic impairment</td> <td>Appears to induce metabolism of progestin-containing hormonal contraceptives</td> <td>95</td> <td>105</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Phenobarbital</strong></td> <td> <p>75% metabolized by CYPs 2C19, 2C9 (minor) and glucosidase hydrolysis and 2E1 (minor) to inactive metabolites; 25% excreted renally as unchanged drug</p> Dose adjustment is needed in severe renal or hepatic impairment</td> <td>Potent and broad-spectrum inducer of CYP and UGT-glucuronidation</td> <td>55</td> <td>75-110</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Phenytoin</strong></td> <td> <p>&#62;90% metabolized by CYPs 2C9, 2C19, 3A4 (minor) and non-CYP transformations to inactive metabolites; clearance is dose dependent, saturable, and may be subject to genetic polymorphism</p> Dose adjustment is needed in severe renal or hepatic insufficiency; monitoring of free (unbound) concentrations also suggested</td> <td>Potent and broad-spectrum inducer of CYP and UGT-glucuronidation</td> <td>90-95</td> <td>9 to&nbsp;&#62;42 (dose dependent)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pregabalin</strong></td> <td> <p>&#62;95% excreted renally as unchanged drug</p> Dose adjustment is needed in renal impairment</td> <td>None</td> <td>&#60;5</td> <td>6</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Primidone</strong></td> <td> <p>75% metabolized by CYPs 2C19, 2C9 (minor) and 2E1 (minor) to active intermediates; ~25% excreted renally as unchanged drug</p> Dose adjustment is needed in moderate and severe renal or hepatic impairment; close monitoring of plasma levels suggested</td> <td>Potent and broad-spectrum inducer of CYP</td> <td>0-20</td> <td> <p>10-15 (parent)</p> 29-100 (active metabolite)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Rufinamide</strong></td> <td>&#62;90% metabolized by non-CYP transformations (hydrolysis) to inactive metabolites</td> <td> <p>Induces CYP3A4 (minor)</p> Inhibits CYP2E1 (minor)</td> <td>35</td> <td>6-10</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Tiagabine</strong></td> <td>&#62;90% metabolized by CYP3A4 and non-CYP transformations to inactive metabolites</td> <td>None</td> <td>95</td> <td> <p>7-9</p> 2-5 (with enzyme-inducing antiseizure drugs)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Topiramate</strong></td> <td> <p>&#62;65% excreted renally as unchanged drug; &#60;30% metabolized by non-CYP transformations to inactive metabolites; extent of metabolism is increased ~50% in patients receiving enzyme-inducing antiseizure drugs</p> Dose adjustment is needed in moderate and severe renal or hepatic impairment</td> <td> <p>Inhibits CYP2C19 (minor)</p> Induces CYP3A4 (minor)</td> <td>9-17</td> <td>12-24</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Valproate</strong></td> <td> <p>&#62;95% undergoes complex transformations including CYPs 2C9, 2C19, 2A6, UGT-glucuronidation and other non-CYP transformation</p> Dose adjustment is needed in hepatic impairment</td> <td> <p>Moderate broad-spectrum inhibitor including CYPs 2A6, 2B6, 2C9, 2C19, 2E1 and UGT-glucuronidation</p> Minor or moderate inducer of CYP2A6</td> <td>80-95</td> <td>7-16</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Vigabatrin</strong></td> <td> <p>&#62;90% excreted renally as unchanged drug</p> Dose adjustment is needed in renal impairment</td> <td>Induces CYP2C9</td> <td>0</td> <td>5-13 (unrelated to duration of action)</td> </tr> <tr> <td><strong>Zonisamide</strong></td> <td> <p>&#62;65% metabolized by CYPs 3A4, 2C19 (minor) and non-CYP transformations</p> Dose adjustment and/or slower titration is needed in mild renal impairment or hepatic impairment; not recommended in patients with moderate or severe renal impairment</td> <td>None</td> <td>50</td> <td>63</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CYP: cytochrome P450; MHD: monohydroxy derivative active form of oxcarbazepine; P-gp: membrane P-glycoprotein multidrug resistance transporter; UGT-glucuronidation: metabolism by uridine 5'diphosphate-glucuronyltransferases.<br />* Highly protein-bound antiseizure drugs exhibit altered pharmacokinetics, including greater therapeutic and toxic effects and drug interactions, when given in usual doses to patients with low serum albumin or protein-binding affinity (eg, due to nephrotic syndrome or acidosis). Dose alteration is needed and monitoring of unbound (free)&nbsp;antiseizure drug&nbsp;serum concentrations is suggested. Refer to UpToDate topic for additional information.<br />¶ Inhibitors of epoxide hydroxylase (eg, brivaracetam) can decrease metabolism of phenytoin and active metabolite of carbamazepine; refer to UpToDate topic.</div><div class=\"graphic_reference\">Modified from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Bazil CW. Antiepileptic drugs in the 21st century. CNS Spectr 2001; 6:756.</LI>&#xD;&#xA;<LI>Lacerda G, Krummel T, Sabourdy C, et al. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006; 67:S28.</LI></OL>Additional data from: Anderson GD and Hakimian S. Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment. Clin Pharmacokinet 2014; 53:29 and Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 60182 Version 23.0</div></div></div>"},"60183":{"type":"graphic_picture","displayName":"Barretts methylene blue","title":"Chromoendoscopy of Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chromoendoscopy of Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:443px; height:221px;\" src=\"images/GAST/60183_Barretts_methylene_blue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic views of short-segment Barrett's esophagus (left panel) and long-segment Barrett's esophagus (right panel) seen after staining with methylene blue.</div><div class=\"graphic_reference\">Courtesy of Marcia I Canto, MD, MHS.</div><div id=\"graphicVersion\">Graphic 60183 Version 2.0</div></div></div>"},"60185":{"type":"graphic_figure","displayName":"Two day method chart","title":"Cervical secretion variations during a menstrual cycle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cervical secretion variations during a menstrual cycle</div><div class=\"cntnt\"><img style=\"width:295px; height:586px;\" src=\"images/OBGYN/60185_Two_day_method_chart.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: The Institute for Reproductive Health, Georgetown University.</div><div id=\"graphicVersion\">Graphic 60185 Version 1.0</div></div></div>"},"60186":{"type":"graphic_picture","displayName":"Positioning for puncture of hip joint","title":"Positioning for ultrasound-guided puncture of hip joint","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Positioning for ultrasound-guided puncture of hip joint</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/RHEUM/60186_Position_puncture_hip_joint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient and needle positioning for puncture of hip joint.</div><div class=\"graphic_reference\">Reproduced with permission from: Introductory Guide to Musculoskeletal Ultrasound for the Rheumatologist, Second Edition. ISBN 978-90-313-9206-3; Bohn Stafleu van Loghum, Houten 2012. Copyright &#169; 2012.</div><div id=\"graphicVersion\">Graphic 60186 Version 2.0</div></div></div>"},"60187":{"type":"graphic_picture","displayName":"Pemphigus vegetans","title":"Pemphigus vegetans, axilla","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pemphigus vegetans, axilla</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/60187_Pemphigus_vegetans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In pemphigus vegetans, blisters and erosions develop in intertriginous areas and evolve in vegetating plaques due to excessive granulation tissue formation.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60187 Version 6.0</div></div></div>"},"60188":{"type":"graphic_table","displayName":"Distinction between parasomnias and nocturnal seizures","title":"Distinction between parasomnias and nocturnal seizures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinction between parasomnias and nocturnal seizures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Feature</td> <td class=\"subtitle1\">Parasomnias*</td> <td class=\"subtitle1\">Nocturnal seizures</td> </tr> <tr> <td>Age of onset</td> <td>Preschool age and childhood</td> <td>Infancy, preschool age, childhood, and adolescence</td> </tr> <tr> <td>Family history of similar events</td> <td>May be positive</td> <td>May or may not be positive</td> </tr> <tr> <td>Time of occurrence</td> <td>First third of night sleep (usually)</td> <td>Randomly through the night</td> </tr> <tr> <td>Most common sleep stage at occurrence</td> <td>Stage N3 sleep<sup>&#182;</sup></td> <td>Stage N1 or N2 sleep</td> </tr> <tr> <td>Duration of event</td> <td>5 to 30 minutes</td> <td>0.5 to 5 minutes</td> </tr> <tr> <td>Multiple events on a single night</td> <td>Less likely</td> <td>More likely</td> </tr> <tr> <td>Polysomnogram (with EEG)</td> <td>Rhythmic theta or delta activity</td> <td>Normal, OR spikes or sharp waves over a focal or generalized distribution</td> </tr> <tr> <td>Usual daytime behavior</td> <td>Normal (unless complicated by sleep related breathing disturbance or restless legs/periodic limb movement disorder)</td> <td>May be irritable and sleepy; seizures may also occur during the day</td> </tr> <tr> <td>Pharmacologic therapy</td> <td>Benzodiazepine at bedtime</td> <td>Daytime and bedtime administration of oxcarbazepine, lamotrigine, levetiracetam, carbamazepine, or phenytoin</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EEG: electroencephalogram.<br />* The most common parasomnias in children are sleepwalking, confusional arousals, and sleep terrors, which occur upon partial arousal from non-rapid eye movement (NREM) sleep.<br />¶ NREM sleep is divided into stages N1, N2, and N3. Stage N3&nbsp;was previously known as \"slow wave sleep.\"&nbsp;</div><div class=\"graphic_reference\">Reproduced with permission from: Kotagal S. Parasomnias of childhood. Curr Opin Pediatr 2008; 20:659. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60188 Version 9.0</div></div></div>"},"60189":{"type":"graphic_picture","displayName":"Pyogenic granuloma lip","title":"Pyogenic granuloma of the lip","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pyogenic granuloma of the lip</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/60189_Pyogenic_granuloma_lip.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60189 Version 3.0</div></div></div>"},"60190":{"type":"graphic_picture","displayName":"PIP extension","title":"Examination of finger PIP joint extension","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Examination of finger PIP joint extension</div><div class=\"cntnt\"><img style=\"width:504px; height:302px;\" src=\"images/EM/60190_PIP_extension.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 60190 Version 1.0</div></div></div>"},"60193":{"type":"graphic_movie","displayName":"Ultrasound benign fasciculations","title":"Ultrasound benign fasciculations","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound benign fasciculations</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/NEURO/60193_USbenignfascicconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:442px; height:327px;\" src=\"images/NEURO/60193_USbenignfasciculations.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a real-time axial image of the abductor hallucis muscle in an individual with benign fasciculations of the feet. Note the random focal twitching in muscle that contrasts with the whole movement of muscle that occurs in normal voluntary contraction (see text for link to movie 'Ultrasound biceps contraction and relaxation'). A combined B-mode and M-mode recording of the same muscle follows this image. M-mode refers to motion, and in this image, one vertical line of the B-mode image, as indicated by the white line, is recorded in the M-mode image and followed over time (the large tick marks at the bottom of the screen represent one second). Note that initially the bulk of fasciculations occur to the left of the white line, so the probe is moved to center the recording line over this area. A single fasciculation is then captured and measured. Note that the M-mode image captures the contraction (110ms) phase of the muscle twitch and its total contraction and relaxation phase (230ms), which are much longer than the action potential duration of a motor unit. Ultrasound measures the mechanical activity of the muscle, rather than the change in membrane potential that is recorded by EMG.</div><div class=\"graphic_reference\">Courtesy of Francis O Walker, MD.</div><div id=\"graphicVersion\">Graphic 60193 Version 4.0</div></div></div>"},"60194":{"type":"graphic_picture","displayName":"Laparoscopic mobilization of the intra-abdominal esophagus","title":"Laparoscopic mobilization of the intra-abdominal esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laparoscopic mobilization of the intra-abdominal esophagus</div><div class=\"cntnt\"><img style=\"width:432px; height:298px;\" src=\"images/SURG/60194_Lapar_mobil_intra_abd_esoph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This intraoperative photograph shows the mobilized intra-abdominal esophagus (large arrow) and the crura of the diaphragm (smaller arrows). The esophagus is mobilized without tension.</div><div class=\"graphic_reference\">Courtesy of Michael Rosen, MD.</div><div id=\"graphicVersion\">Graphic 60194 Version 2.0</div></div></div>"},"60196":{"type":"graphic_figure","displayName":"Repair of common bile duct injury over a T tube","title":"Repair of common bile duct injury over a T-tube","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Repair of common bile duct injury over a T-tube</div><div class=\"cntnt\"><img style=\"width:492px; height:573px;\" src=\"images/SURG/60196_Common-bile-duct-drainage-using-a-T-tube.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A T-tube may be placed after laparoscopic or open common bile duct exploration. The largest caliber T-tube the duct will accomodate should be selected. Tapering the ends of the T-tube&nbsp;catheter with&nbsp;scissors facilitates intraductal placement. In addition, opening the intraductal portion of the T-tube along its length opposite the junction of the intraabdominal&nbsp;portion will&nbsp;allow the catheter to collapse when it is removed. The catheter should be secured in the bile duct using fine monofilament sutures, taking care not to suture into&nbsp;the catheter. A completion T-tube cholangiogram is performed prior to abdominal closure.</div><div id=\"graphicVersion\">Graphic 60196 Version 2.0</div></div></div>"},"60197":{"type":"graphic_diagnosticimage","displayName":"Ultrasound fetal hydranencephaly","title":"Hydranencephaly","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Hydranencephaly</div><div class=\"cntnt\"><img style=\"width:480px; height:392px;\" src=\"images/OBGYN/60197_US_fetal_hydranencephaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial section of the fetal head.&nbsp;Except for the midlike falx, no brain structures are seen.&nbsp;They are replaced by cerebro-spinal fluid.</div><div id=\"graphicVersion\">Graphic 60197 Version 3.0</div></div></div>"},"60203":{"type":"graphic_table","displayName":"Language delay red flags","title":"Red flags* for language delay","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Red flags* for language delay</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Red flag</td> <td class=\"subtitle1\">Type of skill</td> </tr> <tr class=\"divider_bottom\"> <td>Birth or any age</td> <td>Does not respond to sounds, particularly parent's voice</td> <td>Receptive language</td> </tr> <tr class=\"divider_bottom\"> <td>6 to 9 months</td> <td>Does not babble</td> <td>Expressive language</td> </tr> <tr class=\"divider_bottom\"> <td>12 months</td> <td>Does not use \"mama,\" \"dada,\" or \"papa\"&nbsp;to call parent</td> <td>Expressive language</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">15 months</td> <td>Does not use specific single word or word approximation other than \"mama,\" \"dada,\"&nbsp;or \"papa\" to request or comment</td> <td>Expressive language</td> </tr> <tr class=\"divider_bottom\"> <td>Does not use a point to request something out of reach</td> <td>Gestural communication</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">18 months</td> <td>Does not have at least five words used spontaneously to make requests or to comment on or label objects (assessed by asking: \"How does she let you know what she wants?\" or \"What words does she use to ask for things?\")</td> <td>Expressive language</td> </tr> <tr> <td>Does not follow familiar one-step direction without gesture</td> <td>Receptive language</td> </tr> <tr class=\"divider_bottom\"> <td>Does not point to something in order to share enjoyment or excitement with another person (joint attention)</td> <td>Gestural communication</td> </tr> <tr> <td rowspan=\"2\">24 months</td> <td>Uses fewer than 50 words</td> <td>Expressive language</td> </tr> <tr> <td>Does not combine two words together to create new meaning. (See caution below.)<sup>&#182;</sup></td> <td>Expressive language</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Typically the age at which 90 percent of typically developing children have attained the skill.<br />¶ Parents may report <STRONG>stock phrases</STRONG> (eg, \"let's go,\" \"all done,\" \"good job\") or <STRONG>compound nouns</STRONG> (\"dump truck,\" \"Tyrannosaurus rex,\" \"baby doll\") as examples of this skill. <STRONG>These do not count as novel two-word combinations</STRONG>. Ask parents for specific examples, and probe further if these types of examples are the only ones provided.</div><div id=\"graphicVersion\">Graphic 60203 Version 5.0</div></div></div>"},"60204":{"type":"graphic_picture","displayName":"Dorsal ganglion","title":"Dorsal ganglion of the wrist","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dorsal ganglion of the wrist</div><div class=\"cntnt\"><img style=\"width:367px; height:279px;\" src=\"images/EM/60204_Dorsal_ganglion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The wrist is placed in a partially flexed position. The cyst is palpated for tension, fluctuance, and mobility. Passive movement of the fingers is performed to determine if the cyst is attached to the tenosynovial sheath.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 60204 Version 2.0</div></div></div>"},"60205":{"type":"graphic_figure","displayName":"Memorial symptom assessment","title":"Memorial Symptom Assessment Scale - Short Form [MSAS-SF]","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Memorial Symptom Assessment Scale - Short Form [MSAS-SF]</div><div class=\"cntnt\"><img style=\"width:484px; height:788px;\" src=\"images/PC/60205_Memorial_symptom_assessment.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 60205 Version 1.0</div></div></div>"},"60206":{"type":"graphic_picture","displayName":"Scabies infant foot","title":"Scabies, infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scabies, infant</div><div class=\"cntnt\"><img style=\"width:432px; height:243px;\" src=\"images/PC/60206_Scabies_infant_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The rash of scabies may be more diffuse in infants, spreading to the trunk and scalp in addition to the extremities.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR, Ludwig S, Baskin MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright ©2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60206 Version 3.0</div></div></div>"},"60208":{"type":"graphic_diagnosticimage","displayName":"Arc welders lung PA","title":"Arc welder's lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arc welder's lung</div><div class=\"cntnt\"><img style=\"width:359px; height:357px;\" src=\"images/PULM/60208_Arc_welders_lung_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows coarse reticular changes with preserved lung volumes in this patient with siderosis. Incidental note is made of an azygos fissure in the right upper lobe.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 60208 Version 3.0</div></div></div>"},"60210":{"type":"graphic_table","displayName":"Frequency fetal arrhythmias","title":"Type and distribution of arrythmias in 1384 fetuses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Type and distribution of arrythmias in 1384 fetuses</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Type</td>\n<td class=\"subtitle1\">Number</td>\n</tr>\n<tr>\n<td>Premature atrial contractions</td>\n<td>1213</td>\n</tr>\n<tr>\n<td>Supraventricular tachycardia</td>\n<td>69</td>\n</tr>\n<tr>\n<td>Complete heart block</td>\n<td>39</td>\n</tr>\n<tr>\n<td>Atrial flutter</td>\n<td>21</td>\n</tr>\n<tr>\n<td>2nd degree AV block</td>\n<td>10</td>\n</tr>\n<tr>\n<td>Sinus tachycardia</td>\n<td>8</td>\n</tr>\n<tr>\n<td>Ventricular tachycardia</td>\n<td>7</td>\n</tr>\n<tr>\n<td>Atrial fibrillation</td>\n<td>4</td>\n</tr>\n<tr>\n<td>Junctional tachycardia</td>\n<td>2</td>\n</tr>\n<tr>\n<td>Sinus bradycardia</td>\n<td>2</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: Kleinman, CS, Nehgme, R, Copel, JA. Maternal-Fetal Medicine, Principles and Practice, 5th edition, Saunders, 2004, p 466.</div><div id=\"graphicVersion\">Graphic 60210 Version 1.0</div></div></div>"},"60211":{"type":"graphic_picture","displayName":"Mucoepidermoid carcinoma light micro","title":"Mucoepidermoid carcinoma","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Mucoepidermoid carcinoma</div><div class=\"cntnt\"><img style=\"width:512px; height:766px;\" src=\"images/ONC/60211_Mucoepidermoid_carcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Low-grade mucoepidermoid carcinoma. Cystic spaces with variably sized solid nests of tumor, all composed of a mixture of squamous, mucinous, and intermediate epithelial neoplastic cells.<br />(B) Low-grade mucoepidermoid carcinoma. Solid tumor nests with an ectatic center showing squamous differentiation, surrounded by mucin-containing glandular cells and polygonal intermediate cells.</div><div id=\"graphicVersion\">Graphic 60211 Version 6.0</div></div></div>"},"60212":{"type":"graphic_figure","displayName":"Anatomic etiologic risk","title":"Anatomy and etiology of risk factors for brain injury resulting in neonatal encephalopathy","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Anatomy and etiology of risk factors for brain injury resulting in neonatal encephalopathy</div><div class=\"cntnt\"><img style=\"width:550px; height:213px;\" src=\"images/PEDS/60212_Anatomic_etiologic_risk.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Sidhartha Tan, MD.</div><div id=\"graphicVersion\">Graphic 60212 Version 2.0</div></div></div>"},"60213":{"type":"graphic_figure","displayName":"Crossed renal ectopia","title":"Crossed renal ectopia","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Crossed renal ectopia</div><div class=\"cntnt\"><img style=\"width:540px; height:292px;\" src=\"images/PEDS/60213_Crossed_renal_ectopia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Different forms of crossed renal ectopia. Fused: Ectopic kidney moves across the midline and fuses to the lower pole of the normally positioned contralateral kidney. Nonfused: Ectopic kidney moves across the midline without fusion and is positioned at the rim of the pelvis (pelvic kidney). Bilateral: Both kidneys are ectopic and cross the midline with the ureters maintaining their normal bladder insertion.</div><div id=\"graphicVersion\">Graphic 60213 Version 3.0</div></div></div>"},"60214":{"type":"graphic_picture","displayName":"Mixed gonadal dysgenesis 1","title":"Mixed gonadal dysgenesis (45,X/46,XY mosaicism)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Mixed gonadal dysgenesis (45,X/46,XY mosaicism)</div><div class=\"cntnt\"><img style=\"width:504px; height:236px;\" src=\"images/PEDS/60214_Mix_gonad_dysgenesi_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mixed gonadal dysgenesis is characterized by 45,X/46,XY mosaicism, typically with hypospadias (often severe), a descended testis on the right side and a streak gonad with retained Müllerian remnants on the contralateral side. The phenotype of patients with 45,X/46,XY mosaicism is highly variable, ranging from phenotypically normal males to those with female genitalia and Turner syndrome-like features. </div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 60214 Version 4.0</div></div></div>"},"60215":{"type":"graphic_table","displayName":"Cullens definition IEI","title":"Cullen's definition of idiopathic environmental intolerance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cullen's definition of idiopathic environmental intolerance</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n    <td>1. A disorder acquired after a documented environmental exposure, insult, or illness.</td>\n  </tr>\n  <tr>\n    <td>2. Symptoms involving more than one organ system.</td>\n  </tr>\n  <tr>\n    <td>3. Symptoms that recur and abate in response to predictable stimuli.</td>\n  </tr>\n  <tr>\n    <td>4. Symptoms elicited by exposures to chemical of diverse structural class and toxicologic modes of action.</td>\n  </tr>\n  <tr>\n    <td>5. Symptoms that are elicited by exposures that are demonstrable.</td>\n  </tr>\n  <tr>\n    <td>6. Exposures that elicit symptoms are generally lower than 1 percent of established threshold limit values.</td>\n  </tr>\n  <tr>\n    <td>7. No single widely available test of organ system function can explain symptoms.</td>\n  </tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 60215 Version 1.0</div></div></div>"},"60216":{"type":"graphic_figure","displayName":"Serum markers acute HBV HDV","title":"Serum markers of acute, self-limiting HBV/HDV coinfection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Serum markers of acute, self-limiting HBV/HDV coinfection</div><div class=\"cntnt\"><img style=\"width:296px; height:392px;\" src=\"images/GAST/60216_Serum_markers_acute_HBV_HDV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the typical serologic response to acute HBV/HDV infection. Patients should be positive for HBsAg and have high titer IgM anti-HBc; serum HDAg and/or HDV RNA are usually positive at presentation.</div><div id=\"graphicVersion\">Graphic 60216 Version 2.0</div></div></div>"},"60218":{"type":"graphic_picture","displayName":"SLE proliferative","title":"Light micrograph showing proliferative lupus nephritis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Light micrograph showing proliferative lupus nephritis</div><div class=\"cntnt\"><img style=\"width:377px; height:262px;\" src=\"images/NEPH/60218_SLE_Proliferative.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph showing a proliferative pattern in lupus nephritis, characterized by areas of cellular proliferation (arrows) and by thickening of the glomerular capillary wall (due to immune deposits) that may be prominent enough to form a \"wire loop\" (arrowheads). Although proliferative changes can be focal (affecting less than 50 percent of glomeruli), disease of this severity is usually diffuse.</div><div class=\"graphic_reference\">Courtesy of Helmut G&nbsp;Rennke, MD.</div><div id=\"graphicVersion\">Graphic 60218 Version 7.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal glomerulus</div><div class=\"cntnt\"><img style=\"width:396px; height:253px;\" src=\"images/NEPH/75094_Normal_glomerulus_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph of a normal glomerulus. There are only 1 or 2 cells per capillary tuft, the capillary lumens are open, the thickness of the glomerular capillary wall (long arrow) is similar to that of the tubular basement membranes (short arrow), and the mesangial cells and mesangial matrix are located in the central or stalk regions of the tuft (arrows).</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 75094 Version 4.0</div></div></div>"},"60219":{"type":"graphic_figure","displayName":"Breast cancer with tamoxifen","title":"Cumulative rates per 1000 women of invasive and noninvasive breast cancer in NSABP P-1 participants by treatment group","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Cumulative rates per 1000 women of invasive and noninvasive breast cancer in NSABP P-1 participants by treatment group</div><div class=\"cntnt\"><img style=\"width:525px; height:265px;\" src=\"images/ONC/60219_Breast_cancer_with_tamoxife.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Fisher B, Costantino JP, Lawrence D, et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P- 1 study. JNCI 2005; 97:1652. Copyright &#169; 2005 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 60219 Version 2.0</div></div></div>"},"60221":{"type":"graphic_diagnosticimage","displayName":"Chondromyxoid fibroma femur","title":"Chondromyxoid fibroma of the proximal femur","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chondromyxoid fibroma of the proximal femur</div><div class=\"cntnt\"><img style=\"width:420px; height:491px;\" src=\"images/PEDS/60221_Chondromyxoid_fibroma_femur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ovoid, eccentric metaphyseal lucency with thinning of the overlying cortex and a sclerotic inner margin.</div><div class=\"graphic_reference\">Reproduced with permission from: Eisenberg RL. An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60221 Version 2.0</div></div></div>"},"60222":{"type":"graphic_diagnosticimage","displayName":"Clavicle fracture with nonunion","title":"Clavicle fracture with nonunion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clavicle fracture with nonunion</div><div class=\"cntnt\"><img style=\"width:396px; height:315px;\" src=\"images/EM/60222_Clav_fx_nonunion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Several months after sustaining a clavicle fracture, the patient continued to have daily pain with arm movement. Gentle manipulation of the proximal clavicle produced palpable motion at the fracture site. Careful scrutiny of the radiograph reveals a subtle lucency through the callus (arrow).</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 60222 Version 2.0</div></div></div>"},"60223":{"type":"graphic_figure","displayName":"Acute HCV clearance","title":"Time course of acute HCV infection with recovery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Time course of acute HCV infection with recovery</div><div class=\"cntnt\"><img style=\"width:434px; height:363px;\" src=\"images/GAST/60223_Acute_HCV_clearance.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Figure adapted from: the Centers for Disease Control and Prevention.</div><div id=\"graphicVersion\">Graphic 60223 Version 1.0</div></div></div>"},"60224":{"type":"graphic_picture","displayName":"Erosive lichen planus","title":"Vulvar erosive lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar erosive lichen planus</div><div class=\"cntnt\"><img style=\"width:349px; height:293px;\" src=\"images/OBGYN/60224_Erosive_lichen_planus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema and erosions on the vulvar labial mucosa in a patient with erosive lichen planus.</div><div class=\"graphic_reference\">Reproduced with permission from Ridley CM, Neill SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright © 1999 Blackwell Science. <A spellcheck=true href=\"http://www.wiley.com/wiley-blackwell\" target=_blank>http://www.blackwell-science.com</A>.</div><div id=\"graphicVersion\">Graphic 60224 Version 5.0</div></div></div>"},"60225":{"type":"graphic_figure","displayName":"Testicular volume and sexual maturity rating","title":"Testicular volume in each pubertal stage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Testicular volume in each pubertal stage</div><div class=\"cntnt\"><img style=\"width:419px; height:311px;\" src=\"images/PEDS/60225_Testicular_volume_v_Tanner.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Testicular volume in adolescents as a function of pubertal stage.&nbsp;These data are from serial&nbsp;evaluations of 539 boys, ages 10 to 15 years; the subjects were evaluated every 6 months over 3 years. Pubertal stage&nbsp;represents the&nbsp;sexual maturity rating (Tanner stage of pubertal development).</div><div class=\"graphic_reference\">Reproduced with permission from: Biro FM. Physical growth and development. In: Principles of Adolescent Medicine, Friedman SB, Fisher M, Schonberg SK. Mosby-Year Book, Inc, 1997. Figure 6-3, p.31. Copyright ©1997 Elsevier.</div><div id=\"graphicVersion\">Graphic 60225 Version 4.0</div></div></div>"},"60226":{"type":"graphic_picture","displayName":"Wet AMD with disciform scar","title":"Wet type age-related macular degeneration (AMD) with disciform scar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Wet type age-related macular degeneration (AMD) with disciform scar</div><div class=\"cntnt\"><img style=\"width:346px; height:294px;\" src=\"images/PC/60226_Wet_AMD_with_disciform_scar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Areas of blood vessel leakage are present, with a large disciform scar (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from the Massachusetts Eye &amp; Ear Infirmary, Photographer, David Walsh.</div><div id=\"graphicVersion\">Graphic 60226 Version 2.0</div></div></div>"},"60229":{"type":"graphic_diagnosticimage","displayName":"Volar (palmar) lip fracture of the base of the middle phalanx","title":"Volar (palmar) lip fracture of the base of the middle phalanx","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Volar&nbsp;(palmar)&nbsp;lip fracture of the base of the middle phalanx</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/SURG/60229_Palmar_lip_finger_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Volar&nbsp;(ie, palmar) lip fractures are the most common type of fracture of the base of the middle phalanx and result from a combination of proximal interphalangeal (PIP) joint hyperextension and axial loading. Patients present with swelling, pain, limited motion at the PIP joint, and a flexed finger posture. The radiograph shows a dorsal subluxation of the PIP joint, noted by the V-sign, in addition to a lip fracture involving greater than 50 percent of the articular surface.</div><div id=\"graphicVersion\">Graphic 60229 Version 9.0</div></div></div>"},"60230":{"type":"graphic_picture","displayName":"Bullous arthropod bite","title":"Bullous arthropod (insect) bite","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bullous arthropod (insect) bite</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/60230_Bullous_arthropod_bite.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A bulla is present in the site of an insect bite.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60230 Version 1.0</div></div></div>"},"60231":{"type":"graphic_waveform","displayName":"ECG torsades de pointes and ventricular flutter","title":"Example of torsades de pointes and ventricular flutter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Example of torsades de pointes and ventricular flutter</div><div class=\"cntnt\"><img style=\"width:434px; height:514px;\" src=\"images/CARD/60231_ECG_torsades_vent_flutter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are three ECG leads (I, II, III); bradycardia and prolongation of the QT interval are present. Several runs of polymorphic ventricular tachycardia, called torsades de pointes (TdP) when associated with QT prolongation are seen (panel A); after several minutes, a rapid sustained ventricular tachycardia, sometimes called ventricular flutter, occurs (panel B). This is closely related to ventricular fibrillation.</div><div class=\"graphic_reference\">Reproduced with permission by Samuel Levy, MD.</div><div id=\"graphicVersion\">Graphic 60231 Version 3.0</div></div></div>"},"60232":{"type":"graphic_diagnosticimage","displayName":"Left atrial myxoma TTE TEE I","title":"Left atrial myxoma on transthoracic and transesophageal echocardiography","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Left atrial myxoma on transthoracic and transesophageal echocardiography</div><div class=\"cntnt\"><img style=\"width:462px; height:253px;\" src=\"images/CARD/60232_Left_atrial_myxoma_TTE_TEE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A four chamber view from a transthoracic echocardiography (panel A) suggests a well encapsulated mass within the left atrium (arrow). The consistence is fairly uniform although there may be a few rarefactions. Transesophageal echocardiography (panel B) shows the details of the tumor attachment to the lower limbus of the foraminal portion of the interatrial septum. The implied irregularity on transthoracic echocardiography are clearly seen cysts that are also typical of these tumors.</div><div id=\"graphicVersion\">Graphic 60232 Version 2.0</div></div></div>"},"60233":{"type":"graphic_figure","displayName":"Changes in IgE and IgG from subcutaneous allergen immunotherapy","title":"Changes in IgE and IgG resulting from subcutaneous allergen immunotherapy ","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Changes in IgE and IgG resulting from subcutaneous allergen immunotherapy </div><div class=\"cntnt\"><img style=\"width:527px; height:482px;\" src=\"images/ALLRG/60233_Ab_changes_w_SCIT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Profile of a typical patient illustrating the dose regimens for immunotherapy and the IgE and IgG antibody responses. Plotted are the relationships between time expressed in days, individual and cumulative doses of ragweed pollen extract expressed in nanograms of antigen E (AgE), and serum levels of ragweed specific-IgE (RW-IgE), ragweed specific-IgG (RW-IgG), and total IgE.<br />(A) RW-IgE, RW IgG, total IgE data.<br />(B) Progressive cumulative dose (line) over respective single doses (bars) over time in days.</div><div class=\"graphic_footnotes\">ng: nanograms; LL: large local reaction; E Th: threshold dose for IgE response, or that single dose of RW extract that subsequently initiated a significant (&gt;25%) and persistent sise in serum levels of RW-specific IgE molecules; G Th: threshold dose for IgG response, or that single dose of RW extract that subsequently initiated a significant (&gt;25%) and persistent sise in serum levels of RW-specific IgG molecules; E Max: observations at maximum IgE response; G Max: observations at maximum IgG response; RW: ragweed.</div><div class=\"graphic_reference\">Reproduced from: Creticos PS, Van Metre TE, Mardiney MR, et al. Dose response of IgE and IgG antibodies during ragweed immunotherapy. J Allergy Clin Immunol 1984; 73:94. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 60233 Version 4.0</div></div></div>"},"60234":{"type":"graphic_diagnosticimage","displayName":"AP forearm","title":"AP view of normal forearm in 9-year-old","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AP view of normal forearm in 9-year-old</div><div class=\"cntnt\"><img style=\"width:192px; height:443px;\" src=\"images/EM/60234_AP_forearm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This anteroposterior (AP) view of the forearm has minimal superimposition of the radial tuberosity (located at the proximal radius) over the proximal ulna and similar radiographic density for the proximal and distal forearm.</div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD</div><div id=\"graphicVersion\">Graphic 60234 Version 3.0</div></div></div>"},"60235":{"type":"graphic_figure","displayName":"Intraosseous blood supply","title":"Intraosseous blood supply of the fifth metatarsal","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Intraosseous blood supply of the fifth metatarsal</div><div class=\"cntnt\"><img style=\"width:497px; height:222px;\" src=\"images/EM/60235_Intraosseous_blood_supply.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The three principal arteries are: the metaphyseal arteries, periosteal arteries, and nutrient artery. High rates of nonunion among acute and stress fractures of the proximal diaphysis may be attributable to its relatively poor blood supply via the nutrient artery.</div><div id=\"graphicVersion\">Graphic 60235 Version 1.0</div></div></div>"},"60236":{"type":"graphic_diagnosticimage","displayName":"Thyroid ultrasound showing thyroid anatomy","title":"Thyroid ultrasound showing thyroid anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thyroid ultrasound showing thyroid anatomy</div><div class=\"cntnt\"><img style=\"width:301px; height:304px;\" src=\"images/ENDO/60236_Thyroid_anatomy_Echo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sonogram of the thyroid region in the transverse plane that shows the local anatomy.</div><div class=\"graphic_footnotes\">L: thyroid lobe; I: isthmus; T: tracheal ring (dense white arc is calcification, distal to it is artifact); C: carotid artery (note the enhanced echoes deep to the fluid-filled blood vessel); J: jugular vein: S: sternocleidomastoid muscle; M: strap muscle; E: esophagus.</div><div class=\"graphic_reference\">Courtesy of Manfred Blum, MD.</div><div id=\"graphicVersion\">Graphic 60236 Version 4.0</div></div></div>"},"60237":{"type":"graphic_picture","displayName":"Crohns v pseudom colitis Endosc","title":"Pseudomembranous colitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pseudomembranous colitis</div><div class=\"cntnt\"><img style=\"width:367px; height:183px;\" src=\"images/GAST/60237_Crohns_v_pseudom_colitis_En.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endsocopy of pseudomembranous colitis reveals small groups of pseudomembranes (left panel) that may be confused grossly with the aphthous ulcers of Crohn's disease (right panel). These lesions can be distinguished since pseudomembranes are present on top of the mucosa and do not result in ulceration of the underlying tissue.</div><div class=\"graphic_reference\">Courtesy of James B McGee, MD.</div><div id=\"graphicVersion\">Graphic 60237 Version 2.0</div></div></div>"},"60238":{"type":"graphic_table","displayName":"Colposcopy equipment supplies","title":"Colposcopy equipment and supplies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Colposcopy equipment and supplies</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">General colposcopy equipment</td> </tr> <tr> <td>Colposcope</td> </tr> <tr> <td>Speculums (variable sizes)</td> </tr> <tr> <td>Cervical punch biopsy instruments</td> </tr> <tr> <td>Endocervical curettes</td> </tr> <tr> <td>Tenaculum</td> </tr> <tr> <td>Endometrial sampling devices</td> </tr> <tr> <td class=\"subtitle1_single\">Additional equipment and supplies</td> </tr> <tr> <td>Ring or sponge forceps</td> </tr> <tr> <td>Needle holder</td> </tr> <tr> <td>Long Debakey forceps</td> </tr> <tr> <td>Anoscope, clear plastic</td> </tr> <tr> <td>Vulvar biopsy supplies (consent form, povidone-iodine, 1 percent lidocaine, small syringe with 27-gauge needle, 3 to 5 mm punch biopsy instruments, suture removal kit, silver nitrate sticks)</td> </tr> <tr> <td class=\"subtitle1_single\">Written material</td> </tr> <tr> <td>Consent forms</td> </tr> <tr> <td>Documentation forms</td> </tr> <tr> <td>Post-biopsy instructions</td> </tr> <tr> <td>Educational materials</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Supplies</td> </tr> <tr> <td>Pap test supplies (liquid based cytology or glass slide and fixative, spatula, cytobrush)</td> </tr> <tr> <td>3 to 5 percent acetic acid</td> </tr> <tr> <td>Schiller's solution</td> </tr> <tr> <td>Large and small cotton swabs</td> </tr> <tr> <td>Silver nitrate sticks</td> </tr> <tr> <td>Monsel's solution</td> </tr> <tr> <td>Small histology jars with permanent fixative and labels</td> </tr> <tr> <td>Povidone-iodine</td> </tr> <tr> <td>1 percent lidocaine (with and without epinephrine)</td> </tr> <tr> <td>22-gauge spinal needle and 10-cc syringe</td> </tr> <tr> <td>Pantiliners</td> </tr> <tr> <td>Suture material</td> </tr> <tr> <td>Chux pads</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 60238 Version 2.0</div></div></div>"},"60242":{"type":"graphic_figure","displayName":"VF temp crescent sparing HH","title":"Temporal crescent-sparing homonymous hemianopia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Temporal crescent-sparing homonymous hemianopia</div><div class=\"cntnt\"><img style=\"width:504px; height:223px;\" src=\"images/NEURO/60242_VF_temp_crescent_sparing_HH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Goldmann visual field showing a right temporal crescent-sparing homonymous hemianopia in a patient with a left occipital infarction.</div><div id=\"graphicVersion\">Graphic 60242 Version 1.0</div></div></div>"},"60243":{"type":"graphic_picture","displayName":"Heliotrope rash in DM PI","title":"Heliotrope rash in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heliotrope rash in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:360px; height:232px;\" src=\"images/PI/60243_Heliotrope_rash_in_DM_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A reddish-purple eruption on the upper eyelid (the heliotrope rash), accompanied by swelling of the eyelid in a patient with dermatomyositis (DM).&nbsp;This is the most specific rash in DM, although it is only present in a minority of patients.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD, MPH</div><div id=\"graphicVersion\">Graphic 60243 Version 3.0</div></div></div>"},"60244":{"type":"graphic_figure","displayName":"Foregut formation","title":"Foregut formation","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Foregut formation</div><div class=\"cntnt\"><img style=\"width:465px; height:457px;\" src=\"images/PEDS/60244_Foregut_formation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Formation of a ventral mesentery in the foregut region. The accessory organs of digestion (liver, pancreas, and gallbladder) derive from the foregut only. Like the gut tube, they rest in a &quot;sling&quot; of mesoderm, but because the gut tube already occupies the dorsal mesentery, these organs need a mesentery of their own. The ventral mesentery appears to form from thinning of the overlying mesoderm of the septum transversum.</div><div class=\"graphic_reference\">Reproduced with permission from: Sadler TW. Langman's Medical Embryology, 9th Edition Image Bank. Baltimore: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60244 Version 1.0</div></div></div>"},"60245":{"type":"graphic_figure","displayName":"Nucleotides building blocks","title":"Chemical structure of nitogenous bases in DNA and RNA","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Chemical structure of nitogenous bases in DNA and RNA</div><div class=\"cntnt\"><img style=\"width:488px; height:480px;\" src=\"images/PC/60245_Nucleotides_building_blocks.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 60245 Version 1.0</div></div></div>"},"60246":{"type":"graphic_picture","displayName":"Concentric exercise elbow epicondylitis","title":"Concentric exercise for elbow epicondylitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Concentric exercise for elbow epicondylitis</div><div class=\"cntnt\"><img style=\"width:432px; height:317px;\" src=\"images/EM/60246_Epicondy_concentric_rehab.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a concentric exercise for strengthening the wrist extensors. Concentric exercise involves the application of a load during the shortening of a muscle. Here the wrist extensors are contracting concentrically against the resistance of an exercise band.</div><div class=\"graphic_reference\">Courtesy of Neeru Jayanthi, MD.</div><div id=\"graphicVersion\">Graphic 60246 Version 2.0</div></div></div>"},"60247":{"type":"graphic_picture","displayName":"Hemoclips after polypectomy","title":"Use of hemoclips after colonic polypectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Use of hemoclips after colonic polypectomy</div><div class=\"cntnt\"><img style=\"width:317px; height:332px;\" src=\"images/GAST/60247_Hemoclips_after_polypectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Large sessile polyp in the right colon in a patient who requires Warfarin anticoagulation; (B) Polypectomy site after polyp removal; (C) Polypectomy defect closed with clips to ensure against further bleeding.</div><div class=\"graphic_reference\">Courtesy of Jerome D Waye, MD.</div><div id=\"graphicVersion\">Graphic 60247 Version 2.0</div></div></div>"},"60250":{"type":"graphic_table","displayName":"Conditions with inflammation in respiratory bronchioles","title":"Conditions associated with inflammation in the respiratory bronchioles","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with inflammation in the respiratory bronchioles</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Cigarette smokers</td>\n</tr>\n<tr>\n<td>Hypersensitivity reactions</td>\n</tr>\n<tr>\n<td>Inhalation of mineral dusts (asbestos, silica, iron oxide, aluminum oxide, talc, mica, coal)</td>\n</tr>\n<tr>\n<td>Viral infection</td>\n</tr>\n<tr>\n<td>Connective tissue disease, especially rheumatoid arthritis</td>\n</tr>\n<tr>\n<td>Drug reaction</td>\n</tr>\n<tr>\n<td>Chronic rejection in heart-lung and bone marrow transplant recipients</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 60250 Version 4.0</div></div></div>"},"60253":{"type":"graphic_figure","displayName":"Alleles genotypes and haplotypes","title":"Alleles, genotypes, and haplotypes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Alleles, genotypes, and haplotypes</div><div class=\"cntnt\"><img style=\"width:378px; height:346px;\" src=\"images/PC/60253_Alleles-genotypes-haplotypes.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Individual A has genotypes CG, AA and TC at SNPs 1, 2, and 3, respectively. Individual A has haplotypes 1 and 6.</div><div id=\"graphicVersion\">Graphic 60253 Version 2.0</div></div></div>"},"60254":{"type":"graphic_table","displayName":"Effect of drugs on calcineurin inhibitor concentrations","title":"Effect of drugs on calcineurin inhibitor concentrations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effect of drugs on calcineurin inhibitor concentrations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Increase CNIs</td> <td class=\"subtitle1\">Decrease CNIs</td> </tr> <tr> <td>Diltiazem (potent)</td> <td>Carbamazepine</td> </tr> <tr> <td>Verapamil (potent)</td> <td>Rifabutin</td> </tr> <tr> <td>Fluconazole (potent)</td> <td>Phenobarbital</td> </tr> <tr> <td>Erythromycin</td> <td>Caspofungin</td> </tr> <tr> <td>Ketoconazole (potent)</td> <td>Phenytoin</td> </tr> <tr> <td>Voriconazole (potent)</td> <td>Rifampin</td> </tr> <tr> <td>Nicardipine</td> <td>St. John's Wort</td> </tr> <tr> <td>Clotrimazole</td> <td>Sirolimus</td> </tr> <tr> <td>Nifedipine (mild effect)</td> <td rowspan=\"4\">&nbsp;</td> </tr> <tr> <td>Itraconazole</td> </tr> <tr> <td>Troleandomycin</td> </tr> <tr> <td>Clarithromycin</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">9</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=93663&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">CNI: calcineurin inhibitor.</div><div class=\"graphic_reference\">Courtesy of Anil Chandraker, MD.</div><div id=\"graphicVersion\">Graphic 60254 Version 3.0</div></div></div>"},"60255":{"type":"graphic_table","displayName":"Generalized cutaneous blistering disorders","title":"Examples of generalized cutaneous blistering disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of generalized cutaneous blistering disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Pathology</td> <td class=\"subtitle1\">Laboratory findings</td> </tr> <tr> <td>Bullous pemphigoid</td> <td>Tense bullae, urticarial papules and plaques; mucous membrane involvement in up to 30 percent of cases</td> <td>H&#38;E: subepidermal blister with eosinophils; DIF: linear basement membrane zone deposition of IgG and C3</td> <td>IIF: IgG anti-BP antigen 180 and 230</td> </tr> <tr class=\"divider_top\"> <td>Pemphigus vulgaris</td> <td>Flaccid vesicles and erosions on skin and mucous membranes, desquamative gingivitis; scalp involvement common</td> <td>H&#38;E: intraepidermal blister formation, acantholysis; DIF: intercellular epidermal IgG deposition involving lower epidermis</td> <td>IIF: intercellular IgG staining of skin substrate, anti-desmoglein 3 IgG</td> </tr> <tr class=\"divider_top\"> <td>Pemphigus foliaceus</td> <td>Flaccid vesicles and erosions; no mucous membrane involvement</td> <td>H&#38;E: intraepidermal vesicle and acantholysis (blister is subcorneal); DIF: intercellular IgG deposition in upper epidermis</td> <td>IIF: intercellular IgG staining of skin substrate; anti-desmoglein 1 IgG</td> </tr> <tr class=\"divider_top\"> <td>Stevens-Johnson syndrome and toxic epidermal necrolysis</td> <td>Exudative erosions of lips, oral mucosa, eyes, genital mucosa; targetoid papulovesicles of skin, skin sloughing, and skin pain</td> <td>H&#38;E: vacuolar interface dermatitis or epidermal necrosis</td> <td>None</td> </tr> <tr class=\"divider_top\"> <td>Paraneoplastic pemphigus</td> <td>Targetoid papulovesicles, erythema multiforme-like cutaneous lesions; exudative erosions of lips, oral mucosal, eyes, genital mucosa</td> <td>H&#38;E: mixed histology with overlapping features of pemphigus vulgaris, erythema multiforme, and lichen planus; DIF: staining of transitional epithelium (rodent bladder)</td> <td>IIF: antibodies to multiple antigens (desmoplakins, desmogleins, bullous pemphigoid antigen 1, etc)</td> </tr> <tr class=\"divider_top\"> <td>Dermatitis herpetiformis</td> <td>Grouped papulovesicles on elbows, knees, buttocks, scalp; intense pruritus</td> <td>H&#38;E: subepidermal blister with neutrophils in dermal papillae; DIF: IgA in dermal papillae</td> <td>Elevation of serum IgA anti-epidermal transglutaminase antibodies</td> </tr> <tr class=\"divider_top\"> <td>Disseminated HSV/VZV</td> <td>Fever, hepatitis, CNS involvement; grouped and scattered monomorphic vesicles</td> <td>Intraepidermal blister; ballooning of keratinocyte cytoplasm and margination of chromatin to form intranuclear inclusion bodies; mixed inflammatory infiltrate</td> <td>Viral culture, Tzanck smear, DFA, PCR</td> </tr> <tr class=\"divider_top\"> <td>Linear IgA bullous dermatosis</td> <td>Annular or arcuate vesicles and bullae; can have mucous membrane involvement </td> <td>H&#38;E: subepidermal blister with predominance of neutrophils; DIF: linear IgA along basement membrane zone</td> <td>IIF: circulating IgA antibasement membrane antibodies</td> </tr> <tr class=\"divider_top\"> <td>Epidermolysis bullosa acquisita</td> <td>Tense blisters and erosions with scarring and milia</td> <td>H&#38;E: subepidermal blisters with mixed inflammatory infiltrate of neutrophils, eosinophils, lymphocytes; DIF: broad, linear IgG along the basement membrane zone; in salt-split skin, IgG stains dermal side</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td>Staphylococcal scalded skin syndrome</td> <td>Widespread erythema, flaccid bullae, erosions, desquamation of skin</td> <td>H&#38;E: subcorneal blister (split within the granular cell layer)</td> <td>Toxin-mediated condition; culture often negative at sites of blistering</td> </tr> <tr class=\"divider_top\"> <td>Bullous systemic lupus erythematosus</td> <td>Other skin findings of SLE: nail fold telangiectasias, malar erythema, discoid or subacute cutaneous lupus</td> <td>H&#38;E: similar to dermatitis herpetiformis; DIF: mixed features similar to bullous pemphigoid and lupus</td> <td>Antinuclear antibody test</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">H&amp;E: hematoxylin and eosin pathology stain; DIF: direct immunofluorescence; IIF: indirect immunofluorescence; IgG: immunoglobulin G; IgA: immunoglobulin A; HSV: herpes simplex virus; VZV: varicella zoster virus; CNS: central nervous system; DFA: direct fluorescent antibody test; PCR: polymerase chain reaction; SLE: systemic lupus erythematosus.</div><div id=\"graphicVersion\">Graphic 60255 Version 2.0</div></div></div>"},"60256":{"type":"graphic_picture","displayName":"STARI rash","title":"Erythema migrans-like rash of STARI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythema migrans-like rash of STARI</div><div class=\"cntnt\"><img style=\"width:324px; height:243px;\" src=\"images/ID/60256_Erythema_migrans_STARI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Circular erythema migrans-like lesion with central clearing on the lower leg of a patient with STARI. The central papule was the site of a recent tick bite.</div><div class=\"graphic_footnotes\">STARI: Southern tick-associated rash illness.</div><div class=\"graphic_reference\">Courtesy of Edwin Masters, MD.</div><div id=\"graphicVersion\">Graphic 60256 Version 4.0</div></div></div>"},"60257":{"type":"graphic_table","displayName":"Core components rehab A","title":"Core components of cardiac rehabilitation/secondary prevention programs: Patient assessment, nutritional counseling, and weight management","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Core components of cardiac rehabilitation/secondary prevention programs: Patient assessment, nutritional counseling, and weight management</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Patient assessment </td> </tr> <tr> <td class=\"subtitle2_left\">Evaluation </td> </tr> <tr> <td class=\"indent1\">Medical history: Review current and prior cardiovascular medical and surgical diagnoses and procedures (including assessment of left ventricular function); comorbidities (including peripheral arterial disease, cerebral vascular disease, pulmonary disease, kidney disease, diabetes mellitus, musculoskeletal and neuromuscular disorders, depression, and other pertinent diseases); symptoms of cardiovascular disease; medications (including dose, frequency, and compliance); date of most recent influenza vaccination; cardiovascular risk profile; and educational barriers and preferences. Refer to each core component of care for relevant assessment measures. </td> </tr> <tr> <td class=\"indent1\">Physical examination: Assess cardiopulmonary systems (including pulse rate and regularity, blood pressure, auscultation of heart and lungs, palpation and inspection of lower extremities for edema and presence of arterial pulses); post-cardiovascular procedure wound sites; orthopedic and neuromuscular status; and cognitive function. Refer to each core component for respective additional physical measures. </td> </tr> <tr> <td class=\"indent1\">Testing: Obtain resting 12-lead ECG; assess patient's perceived health-related quality of life or health status. Refer to each core component for additional specified tests. </td> </tr> <tr> <td class=\"subtitle2_left\">Interventions </td> </tr> <tr> <td class=\"indent1\">Document the patient assessment information that reflects the patient's current status and guides the development and implementation of (1) a patient treatment plan that prioritizes goals and outlines intervention strategies for risk reduction, and (2) a discharge/follow-up plan that reflects progress toward goals and guides long-term secondary prevention plans. </td> </tr> <tr> <td class=\"indent1\">Interactively, communicate the treatment and follow-up plans with the patient and appropriate family members/domestic partners in collaboration with the primary healthcare provider. </td> </tr> <tr> <td class=\"indent1\">In concert with the primary care provider and/or cardiologist, ensure that the patient is taking appropriate doses of aspirin, clopidogrel, <sub>&#946; </sub>-blockers, lipid-lowering agents, and ACE inhibitors or angiotensin receptor blockers as per the ACC/AHA, and that the patient has had an annual influenza vaccination. </td> </tr> <tr> <td class=\"subtitle2_left\">Expected outcomes </td> </tr> <tr> <td class=\"indent1\">Patient treatment plan: Documented evidence of patient assessment and priority short-term (ie, weeks-months) goals within the core components of care that guide intervention strategies. Discussion and provision of the initial and follow-up plans to the patient in collaboration with the primary healthcare provider. </td> </tr> <tr> <td class=\"indent1\">Outcome report: Documented evidence of patient outcomes within the core components of care that reflects progress toward goals, including whether the patient is taking appropriate doses of aspirin, clopidogrel, <sub>&#946; </sub>-blockers, and ACE inhibitors or angiotensin receptor blockers as per the ACC/AHA, and whether the patient has had an annual influenza vaccination (and if not, documented evidence for why not), and identifies specific areas that require further intervention and monitoring. </td> </tr> <tr> <td class=\"indent1\">Discharge plan: Documented discharge plan summarizing long-term goals and strategies for success. </td> </tr> <tr> <td class=\"subtitle1_single\">Nutritional counseling </td> </tr> <tr> <td class=\"subtitle2_left\">Evaluation </td> </tr> <tr> <td class=\"indent1\">Obtain estimates of total daily caloric intake and dietary content of saturated fat, trans fat, cholesterol, sodium, and nutrients. </td> </tr> <tr> <td class=\"indent1\">Assess eating habits, including fruit and vegetable, whole grain, and fish consumption; number of meals and snacks; frequency of dining out; and alcohol consumption. </td> </tr> <tr> <td class=\"indent1\">Determine target areas for nutrition intervention as outlined in the core components of weight, hypertension, diabetes, as well as heart failure, kidney disease, and other comorbidities. </td> </tr> <tr> <td class=\"subtitle2_left\">Interventions </td> </tr> <tr> <td class=\"indent1\">Prescribe specific dietary modifications aiming to at least attain the saturated fat and cholesterol content limits of the Therapeutic Lifestyle Change diet. Individualize diet plan according to specific target areas as outlined in the core components of weight, hypertension, and diabetes (as outlined in this table), as well as heart failure and other comorbidities. Recommendations should be sensitive and relevant to cultural preferences. </td> </tr> <tr> <td class=\"indent1\">Educate and counsel patient (and appropriate family members/domestic partners) on dietary goals and how to attain them. </td> </tr> <tr> <td class=\"indent1\">Incorporate behavior change models and compliance strategies into counseling sessions. </td> </tr> <tr> <td class=\"subtitle2_left\">Expected outcomes </td> </tr> <tr> <td class=\"indent1\">Patient adheres to prescribed diet. </td> </tr> <tr> <td class=\"indent1\">Patient understands basic principles of dietary content, such as calories, fat, cholesterol, and nutrients. </td> </tr> <tr> <td class=\"indent1\">A plan has been provided to address eating behavior problems. </td> </tr> <tr> <td class=\"subtitle1_single\">Weight management </td> </tr> <tr> <td class=\"subtitle2_left\">Evaluation </td> </tr> <tr> <td class=\"indent1\">Measure weight, height, and waist circumference. Calculate body mass index (BMI). </td> </tr> <tr> <td class=\"subtitle2_left\">Interventions </td> </tr> <tr> <td class=\"sublist2_start\">In patients with BMI &#62;25 kg/m<sup>2</sup> and/or waist &#62;40 inches in men (102 cm) and &#62;35 inches (88 cm) in women*: </td> </tr> <tr> <td class=\"sublist2\">&#8226; Establish reasonable short-term and long-term weight goals individualized to the patient and his or her associated risk factors (eg, reduce body weight by at least 5 percent and preferably by &#62;10 percent at a rate of 1 to 2 lb/wk over a period of time up to sixmonths). </td> </tr> <tr> <td class=\"sublist2\">&#8226; Develop a combined diet, physical activity/exercise, and behavioral program designed to reduce total caloric intake, maintain appropriate intake of nutrients and fiber, and increase energy expenditure. The exercise component should strive to include daily, longer distance/duration walking (eg, 60 to 90 minutes). </td> </tr> <tr> <td class=\"sublist2\">&#8226; Aim for an energy deficit tailored to achieve weight goals (eg, 500 to 1000 kcal/day). </td> </tr> <tr> <td class=\"subtitle2_left\">Expected outcomes </td> </tr> <tr> <td class=\"indent1\">Short-term: Continue to assess and modify interventions until progressive weight loss is achieved. Provide referral to specialized, validated nutrition weight loss programs if weight goals are not achieved. </td> </tr> <tr> <td class=\"indent1\">Long-term: Patient adheres to diet and physical activity/exercise program aimed toward attainment of established weight goal. </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* BMI definitions for overweight and obesity may differ by race/ethnicity and region of the world. Relevant definitions, when available, should be respectively applied.</div><div class=\"graphic_reference\">Reproduced with permission from: Balady GJ, Williams MA, Ades PA, et al.&nbsp;Circulation 2007;115:2675. Copyright 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60257 Version 4.0</div></div></div>"},"60258":{"type":"graphic_picture","displayName":"Abruptio placentae gross","title":"Abruptio placenta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abruptio placenta</div><div class=\"cntnt\"><img style=\"width:403px; height:284px;\" src=\"images/OBGYN/60258_Abruptio_placentae_gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large retroplacental hematoma derived from rupture of a spiral artery separates the placenta from the underlying uterus and indents the basal plate of the placenta.</div><div class=\"graphic_reference\">Courtesy of Raymond W. Redline, MD.</div><div id=\"graphicVersion\">Graphic 60258 Version 1.0</div></div></div>"},"60259":{"type":"graphic_picture","displayName":"Anti Yo cerebellar degeneration","title":"Paraneoplastic cerebellar degeneration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paraneoplastic cerebellar degeneration</div><div class=\"cntnt\"><img style=\"width:360px; height:243px;\" src=\"images/ONC/60259_Anti_Yo_cerebellar_degenera.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph shows paraneoplastic cerebellar degeneration in a patient with anti-Yo antibodies, which are directed against Purkinje cell antigens. There is total absence of Purkinje cells and Bergmann gliosis.</div><div class=\"graphic_reference\">Courtesy of Josep Dalmau, MD, PhD.</div><div id=\"graphicVersion\">Graphic 60259 Version 1.0</div></div></div>"},"60261":{"type":"graphic_table","displayName":"Fluoride content bottled water","title":"Fluoride content of some bottled water","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fluoride content of some bottled water</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type of water</td> <td class=\"subtitle1\">Number of specimens</td> <td class=\"subtitle1\">Range of fluoride content (mg/L*)</td> </tr> <tr> <td>Artesian</td> <td class=\"centered\">4</td> <td>&#60;0.10 to 0.25</td> </tr> <tr> <td>Distilled</td> <td class=\"centered\">6</td> <td>&#60;0.10</td> </tr> <tr> <td>Drinking</td> <td class=\"centered\">8</td> <td>&#60;0.10 to 0.94 (four samples had &#60;0.10 mg/L and&nbsp;four had &#8805;0.65 mg/L)</td> </tr> <tr> <td>Purified</td> <td class=\"centered\">3</td> <td>&#60;0.10</td> </tr> <tr> <td>Spring</td> <td class=\"centered\">36</td> <td>&#60;0.10 to 0.73 (34 of 36 specimens had &#60;0.3 mg/L; only&nbsp;two had &#62;0.3 mg/L)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* 1 mg/L = 1 part per million.</div><div class=\"graphic_reference\">Data from: Lalumandier JA, Ayers LW. Fluoride and bacterial content of bottled water vs tap water. Arch Fam Med 2000; 9:246.</div><div id=\"graphicVersion\">Graphic 60261 Version 3.0</div></div></div>"},"60262":{"type":"graphic_figure","displayName":"Hiatus hernia and LES pressure on reflux","title":"Interaction of hiatus hernia size and LES pressure on reflux","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Interaction of hiatus hernia size and LES pressure on reflux</div><div class=\"cntnt\"><img style=\"width:519px; height:296px;\" src=\"images/GAST/60262_HH_LES_press_reflux_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Model showing the relationship between hiatus hernia size, lower esophageal sphincter (LES) pressure, and reflux score. The reflux score increased with increasing hernia size and lower LES pressure, both of which were required for marked reflux.</div><div class=\"graphic_reference\">Reproduced with permission from: Sloan S, Rademaker AW, Kahrilas PJ. Determinants of gastroesophageal junction incompetence: hiatal hernia, lower esophageal sphincter, or both? Ann Intern Med 1992; 117:977.</div><div id=\"graphicVersion\">Graphic 60262 Version 4.0</div></div></div>"},"60263":{"type":"graphic_diagnosticimage","displayName":"HSG showing synechiae","title":"Hysterosalpingogram showing a filling defect due to synechiae","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Hysterosalpingogram showing a filling defect due to synechiae</div><div class=\"cntnt\"><img style=\"width:468px; height:306px;\" src=\"images/OBGYN/60263_HSG_showing_synechiae.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Baramki TA. Hysterosalpingography. Fertil Steril 2005; 83:1595. Copyright © 2005 Elsevier Science, Inc.</div><div id=\"graphicVersion\">Graphic 60263 Version 3.0</div></div></div>"},"60265":{"type":"graphic_figure","displayName":"CFTR gene and CF","title":"CFTR gene","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">CFTR gene</div><div class=\"cntnt\"><img style=\"width:546px; height:337px;\" src=\"images/PULM/60265_CFTR_gene_and_CF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the CFTR gene and its encoded polypeptide. &#916;F508 refers to the site of the&nbsp;most common&nbsp;mutation&nbsp;causing cystic fibrosis.</div><div class=\"graphic_footnotes\">CFTR: cystic fibrosis transmembrane conductance regulator</div><div class=\"graphic_reference\">Redrawn from Welsh, MJ, Tsui, L-C, Boat, T, Beaudet, AL. Cystic fibrosis. In: The Metabolic and Molecular Basis of Inherited Disease, Scriver, CR, Beaudet, AL, Sly, WS, et al (Eds), McGraw-Hill, New York, 1995, p. 3801.</div><div id=\"graphicVersion\">Graphic 60265 Version 2.0</div></div></div>"},"60266":{"type":"graphic_picture","displayName":"Occupational asthma Light","title":"Occupational asthma","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Occupational asthma</div><div class=\"cntnt\"><img style=\"width:303px; height:242px;\" src=\"images/PULM/60266_Occupational_asthma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bronchial biopsy of a patient with occupational asthma after removal from exposure, showing partial desquamation of the epithelium, thickened basement membrane, and some cellular infiltration.</div><div class=\"graphic_reference\">Courtesy of Lemiere, C, Malo, JL, Boulet, M.</div><div id=\"graphicVersion\">Graphic 60266 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lung</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/PULM/54820_Normal_lung_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph of normal lung tissue shows open alveoli with thin, capillary- containing interstitial spaces. An artery (A) is identifiable by its thick, muscular wall; the accompanying bronchus (B) contains mucoid material and is lined by columnar respiratory epithelial cells.</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 54820 Version 1.0</div></div></div>"},"60268":{"type":"graphic_figure","displayName":"Protocol adenosine stress Tc99m SPECT","title":"Protocol adenosine stress 99m-technetium (Tc99m) SPECT imaging*<SUP>¶</SUP>","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Protocol adenosine&nbsp;stress 99m-technetium (Tc99m)&nbsp;SPECT imaging*<SUP>¶</SUP></div><div class=\"cntnt\"><img style=\"width:460px; height:221px;\" src=\"images/CARD/60268_Protcladenosinestressed1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SPECT: single photon emission computed tomography.<br />* Low level exercise is optional throughout.<br />¶ Imaging should occur 15 to 45 minutes after protocol.</div><div id=\"graphicVersion\">Graphic 60268 Version 3.0</div></div></div>"},"60269":{"type":"graphic_algorithm","displayName":"ESCC management algorithm","title":"Suggested algorithm for the management of epidural spinal cord compression (ESCC)","html":"<div class=\"graphic\"><div style=\"width: 696px\" class=\"figure\"><div class=\"ttl\">Suggested algorithm for the management of epidural spinal cord compression (ESCC)</div><div class=\"cntnt\"><img style=\"width:676px; height:598px;\" src=\"images/ONC/60269_ESCC_mgmt_algorithm_edit3.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ESCC: epidural spinal cord compression; EBRT: external beam radiation therapy; SBRT: stereotactic body radiation therapy.<br />​* Spine stability is primarily determined by imaging. Spinal Instability Neoplastic Score (SINS) scores &ge;7 are generally considered to indicate high risk for spinal instability and warrant surgical consultation; pain caused by movement suggests spinal instability unless proven otherwise. Refer to topic review for further details.<br />&para; Relatively radioresistant neoplasms include renal cell, sarcoma, melanoma, non-small cell lung, and gastrointestinal; relatively radiosensitive neoplasms include lymphoma, myeloma, germ cell tumors, breast, ovarian, prostate, and small cell lung cancer.<br />&Delta; High-grade ESCC is defined as compression of the spinal cord or deformation of the thecal sac with spinal cord abutment. Signs and symptoms of myelopathy or cauda equine syndrome include limb weakness or spasticity (often bilateral), sensory changes (eg, sensory level, saddle anesthesia), and loss of bowel or bladder control.<br /><span class=\"lozenge\">&loz;</span> Patients who are not suitable candidates for surgery or decline surgery may be treated by EBRT, preceded by noninvasive stabilization if spine is unstable.<br />&sect; Stabilization options include percutaneous cement augmentation, percutaneous pedicle screw instrumentation, and open instrumentation.</div><div id=\"graphicVersion\">Graphic 60269 Version 6.0</div></div></div>"},"60270":{"type":"graphic_diagnosticimage","displayName":"Color Doppler image of velamentous umbilical cord","title":"Color Doppler image of velamentous umbilical cord","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Color Doppler image of velamentous umbilical cord</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/OBGYN/60270_C_Doppler_velam_umbilical.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color Doppler shows flow in the umbilical vessels separate from the cord and extending to the placenta.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 60270 Version 1.0</div></div></div>"},"60271":{"type":"graphic_movie","displayName":"Airway stent deployment","title":"Airway stent deployment","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Airway stent deployment</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/60271_airstentconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:231px; height:205px;\" src=\"images/CARD/60271_airstent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Video shows the bronchoscopic deployment of a studded silicone stent using rigid grasping forceps into a right main bronchus that has been narrowed by tumor.</div><div class=\"graphic_reference\">Courtesy of Henri G Colt, MD and Praveen Mathur, MD.</div><div id=\"graphicVersion\">Graphic 60271 Version 2.0</div></div></div>"},"60273":{"type":"graphic_table","displayName":"Genital and nipple piercings","title":"Genital and nipple piercings*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genital and nipple piercings*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Site </td> <td class=\"subtitle1\">Healing time </td> <td class=\"subtitle1\">Comments </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Male genitalia</td> </tr> <tr> <td class=\"indent1\"> <p>Vertical pin through the glans (Apadravya)</p> <p>Horizontal pin through the glans (Ampallang or \"crossbar\")</p> </td> <td>6 to 9 months or longer</td> <td> <p>Relatively uncommon</p> <p>May bleed until healing is complete</p> </td> </tr> <tr> <td class=\"indent1\">Rim of glans (Dydoe)</td> <td>3 to 4 months or longer</td> <td>Reportedly only worn by circumcised men</td> </tr> <tr> <td class=\"indent1\">Enters through the urethra and exits through the juncture of the glans and shaft or the dorsum of the penis (Prince Albert or reverse Prince Albert)</td> <td>1 to 2 months&nbsp;or longer</td> <td> <p>Popular piercing</p> <p>Has the most complications cited in the medical literature, but the total number of citations is few</p> </td> </tr> <tr> <td class=\"indent1\">Juncture of the shaft and pubic mound (Pubic or \"rhinoceros horn\")</td> <td>3 to 4 months or longer</td> <td>Less painful than other types</td> </tr> <tr> <td class=\"indent1\">Frenum/frenulum </td> <td>3 to 4 months or longer</td> <td>Easier to execute and less painful than other penis piercings</td> </tr> <tr> <td class=\"indent1\">Between testis and base of penis (Hafada)</td> <td>3 to 4 months or longer</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Foreskin (Oetang)</td> <td>2&nbsp;to&nbsp;3 months or longer</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Between the scrotum and anus, behind the testes (Guiche)</td> <td>3 to 4 months or longer</td> <td>Sitting may be painful during healing</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Female genitalia&nbsp;and nipple</td> </tr> <tr> <td class=\"indent1\">Outer labia </td> <td>4 to 10 weeks</td> <td>Often placed for appearance rather than sexual stimulation</td> </tr> <tr> <td class=\"indent1\">Inner labia </td> <td>Short if post-piercing instructions are followed</td> <td>Piercing hole vanishes quickly after removal of ring</td> </tr> <tr> <td class=\"indent1\">Clitoris (horizontal placement)</td> <td>4 to 10 weeks</td> <td> <p>Most frequent choice for females</p> <p>Typically placed above clitoris for sexual stimulation (actual piercing of the clitoris is difficult and painful)</p> </td> </tr> <tr> <td class=\"indent1\">Between vagina and anus (Fourchette)</td> <td>&nbsp;</td> <td>Requires scrupulous hygiene</td> </tr> <tr> <td class=\"indent1\">Nipple</td> <td>6 weeks to 6 months</td> <td> <p>Breastfeeding is not normally constrained if milk ducti remain intact; whether&nbsp;the jewelry is left intact during breastfeeding depends on the type of jewelry and the \"latch-on\" of the infant; any jewelry that poses a risk of aspiration in the infant should be removed</p> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">* <STRONG>These piercings should only be performed by experienced piercers.</STRONG></div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Stirn A. Body piercing: medical consequences and psychological motivations. Lancet 2003; 361:1205.</LI>&#xD;&#xA;<LI>Nelius T, Armstrong ML, Rinard K, et al. Genital piercings: diagnostic and therapeutic implications for urologists. Urology 2011; 78:998.</LI></OL></div><div id=\"graphicVersion\">Graphic 60273 Version 5.0</div></div></div>"},"60274":{"type":"graphic_diagnosticimage","displayName":"Standing teleogram","title":"Standing teleogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Standing teleogram</div><div class=\"cntnt\"><img style=\"width:340px; height:514px;\" src=\"images/PEDS/60274_Standing_teleogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Standing teleogram of bilateral lower extremities from hips to feet with patellas pointed straight ahead.</div><div class=\"graphic_reference\">Courtesy of Scott Rosenfeld, MD.</div><div id=\"graphicVersion\">Graphic 60274 Version 2.0</div></div></div>"},"60277":{"type":"graphic_diagnosticimage","displayName":"Hysterosc microinsert HSG","title":"Hysteroscopic sterilization microinsert: Post-procedure hysterosalpingogram","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Hysteroscopic sterilization microinsert: Post-procedure hysterosalpingogram</div><div class=\"cntnt\"><img style=\"width:504px; height:331px;\" src=\"images/OBGYN/60277_Hysterosc_microinsert_HSG.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Essure. Copyright ©2009 Conceptus, Inc.</div><div id=\"graphicVersion\">Graphic 60277 Version 2.0</div></div></div>"},"60278":{"type":"graphic_figure","displayName":"Mobilization of rectum","title":"Mobilization of the rectum and detachment from the posterior uterus during hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mobilization of the rectum and detachment from the posterior uterus during hysterectomy</div><div class=\"cntnt\"><img style=\"width:404px; height:462px;\" src=\"images/OBGYN/60278_Mobilization_of_rectum.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 60278 Version 2.0</div></div></div>"},"60280":{"type":"graphic_table","displayName":"Substances removed apheresis","title":"Pathologic substances removed by therapeutic apheresis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pathologic substances removed by therapeutic apheresis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Pathologic substance</td> <td class=\"subtitle1\">Diseases</td> </tr> <tr> <td rowspan=\"3\">Immunoglobulins</td> <td>Hyperviscosity syndrome</td> </tr> <tr> <td>Waldenstr&#246;m macroglobulinemia</td> </tr> <tr> <td>Multiple myeloma</td> </tr> <tr> <td rowspan=\"6\">Autoantibodies</td> <td>Myasthenia gravis</td> </tr> <tr> <td>Anti-GBM antibody disease</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Systemic vasculitis</td> </tr> <tr> <td>Factor VIII inhibitors</td> </tr> <tr> <td>Thrombotic thrombocytopenic purpura</td> </tr> <tr> <td>Lipoproteins</td> <td>Hypercholesterolemia</td> </tr> <tr> <td>Leukocytes</td> <td>Hyperleukemic leukostasis</td> </tr> <tr> <td>Platelets</td> <td>Severe thrombocytosis</td> </tr> <tr> <td>Abnormal red cells</td> <td>Sickle cell disease (pain crisis, acute chest syndrome, stroke)</td> </tr> <tr> <td rowspan=\"3\">Circulating immune complexes</td> <td>Immune complex glomerulonephritis</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Systemic vasculitis</td> </tr> <tr> <td rowspan=\"2\">Protein-bound substances and toxins</td> <td>Thyroid storm</td> </tr> <tr> <td>Amanita phalloides toxins</td> </tr> <tr> <td>Hyperparasitemia</td> <td>Malaria, babesiosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 60280 Version 4.0</div></div></div>"},"60282":{"type":"graphic_diagnosticimage","displayName":"Coronal CT of hamate fracture","title":"Coronal CT of hamate fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coronal CT of hamate fracture</div><div class=\"cntnt\"><img style=\"width:314px; height:334px;\" src=\"images/EM/60282_Fracture_of_hamate_CT_coron.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This coronal CT of the wrist shows two larger comminuted fragments (arrows) and some smaller pieces, resulting from a fracture of the hamate (H). The base of the adjacent fifth metacarpal is also indicated (dashed arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 60282 Version 7.0</div></div></div>"},"60284":{"type":"graphic_figure","displayName":"Shearing forces and pressure ulcers","title":"Shearing forces and pressure ulcers","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shearing forces and pressure ulcers</div><div class=\"cntnt\"><img style=\"width:425px; height:486px;\" src=\"images/SURG/60284_Ulcer_shearing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shearing forces can occur when a patient is moved carelessly or slides down the bed.</div><div class=\"graphic_reference\">Reproduced with permission from: Taylor CR, Lillis C, LeMone P, Lynn P. Fundamentals of Nursing: The Art And Science Of Nursing Care, Sixth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2008. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60284 Version 2.0</div></div></div>"},"60285":{"type":"graphic_diagnosticimage","displayName":"Unilateral facet dislocation CT","title":"Unilateral facet dislocation (C5/C6)","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Unilateral facet dislocation (C5/C6)</div><div class=\"cntnt\"><img style=\"width:560px; height:285px;\" src=\"images/EM/60285_Facet_dislocatn_unilat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Unilateral facet dislocations involve flexion and rotation. Rotation occurs around one of the facet joints; dislocation occurs at the contralateral facet joint, with the superior facet moving over the inferior facet. In the CT images above note the normal juxtaposition of the facets on the right and the dislocation on the left.</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD</div><div id=\"graphicVersion\">Graphic 60285 Version 2.0</div></div></div>"},"60286":{"type":"graphic_picture","displayName":"Hürthle cell lesion FNA","title":"Hürthle cell thyroid lesion: Findings on fine-needle aspirate","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hürthle cell thyroid lesion: Findings on fine-needle aspirate</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/ENDO/60286_Hurthle_cell_lesion_FNA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">FNA of a thyroid nodule showing sheets of large, polygonal Hürthle cells (also called oncocytes, Askanazy cells, or oxyphil cells) with abundant oxyphilic cytoplasm. The nodule is benign if there is no evidence of vascular or capsular invasion after surgical excision.</div><div class=\"graphic_footnotes\">FNA: fine-needle aspirate.</div><div id=\"graphicVersion\">Graphic 60286 Version 7.0</div></div></div>"},"60288":{"type":"graphic_diagnosticimage","displayName":"Tumefactive pediatric MS","title":"Tumefactive pediatric multiple sclerosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tumefactive pediatric multiple sclerosis</div><div class=\"cntnt\"><img style=\"width:504px; height:249px;\" src=\"images/NEURO/60288_Tumefactive_pediatric_MS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Axial FLAIR MRI demonstrating large tumefactive areas of demyelination. B) Axial T1 with gadolinium contrast demonstrating enhancement of the lesion margins.</div><div class=\"graphic_footnotes\">FLAIR: fluid-attenuated inversion recovery; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 60288 Version 2.0</div></div></div>"},"60290":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph of a child with pneumomediastinum","title":"Chest radiograph of a child with pneumomediastinum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of a child with pneumomediastinum</div><div class=\"cntnt\"><img style=\"width:396px; height:353px;\" src=\"images/PEDS/60290_SPM_cont_diaphragm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this radiograph of a child with pneumomediastinum, the following characteristic signs are seen:<br />1) The \"continuous diaphragm sign\", in which the mediastinal gas is seen as a thin lucent line outlining the superior surface of the diaphragm and separating it from the heart (white arrows).<br />2) \"Naclerio's V sign\", in which the gas outlines the lateral margin of the descending aorta and extends laterally over left hemidiaphragm (black arrows).</div><div class=\"graphic_reference\">Courtesy of Ibrahim Janahi and Ammar Saadoon.</div><div id=\"graphicVersion\">Graphic 60290 Version 4.0</div></div></div>"},"60292":{"type":"graphic_figure","displayName":"Oxygen flow rate and FiO2","title":"Oxygen delivery via nasal cannula and FiO2","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Oxygen delivery via nasal cannula and FiO2</div><div class=\"cntnt\"><img style=\"width:461px; height:279px;\" src=\"images/PULM/60292_Oxygen_flow_rate_and_FiO2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relation between oxygen flow rate via nasal cannula and the fraction of inspired oxygen (FiO2). Each additional L/min in oxygen flow increases the FiO2 by about 4 percent (shown as a separate block on each sequential column).</div><div id=\"graphicVersion\">Graphic 60292 Version 1.0</div></div></div>"},"60293":{"type":"graphic_table","displayName":"Indications for progestin only contraception","title":"Conditions in which a progestin-only contraceptive may be desirable","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions in which a progestin-only contraceptive may be desirable</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Migraine headaches</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Age over 35 years and smoker or obese</td>\n\n    </tr>\n\n    <tr>\n\n      <td>History of thromboembolic disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiac disease, especially coronary artery disease or heart failure</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cerebrovascular disease</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Early postpartum period</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hypertension with vascular disease or older than 35 years of age</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Systemic lupus erythematosus with vascular disease, nephritis, or antiphospholipid antibodies</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Hypertriglyceridemia</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from: the American College of Obstetricians and Gynecologists. The use of hormonal contraception in women with coexisting medical conditions. ACOG practice bulletin #73, 2006.</div><div id=\"graphicVersion\">Graphic 60293 Version 2.0</div></div></div>"},"60294":{"type":"graphic_figure","displayName":"Marsupialization Bartholin cyst/abscess","title":"Marsupialization of Bartholin gland cyst or abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Marsupialization of Bartholin gland cyst or abscess</div><div class=\"cntnt\"><img style=\"width:387px; height:462px;\" src=\"images/OBGYN/60294_Marsupialization_Bartholin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A vertical oval incision is made over the center of the cyst/abscess where it protrudes at the vestibule and outside the hymenal ring. The cyst cavity can be irrigated with saline solution and loculations can be broken up with a hemostat, as needed. The cyst wall is then everted and sutured onto the edge of the vestibular mucosa with interrupted 2-0 absorbable suture.</div><div id=\"graphicVersion\">Graphic 60294 Version 2.0</div></div></div>"},"60295":{"type":"graphic_table","displayName":"Prognostic factors AML","title":"Risk factors for outcome in adults with acute myeloid leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for outcome in adults with acute myeloid leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Favorable factors</td> <td class=\"subtitle1\">Unfavorable factors</td> </tr> <tr> <td>Age &#60;50</td> <td>Age &#62;60</td> </tr> <tr> <td>Karnofsky score &#62;60 percent</td> <td>Karnofsky score &#60;60 percent</td> </tr> <tr> <td>MDR 1-negative phenotype</td> <td>MDR 1-positive phenotype</td> </tr> <tr> <td>No antecedent hematologic disorder or prior chemo/radiotherapy</td> <td>Therapy-related AML, prior myelodysplastic syndrome, myeloproliferative or other hematologic disorder</td> </tr> <tr> <td>t(8;21), inv(16)/t(16;16), t(15;17)</td> <td>Complex karyotypic abnormalities, -5, -7, 3q26 aberrations, t(6;9), 11q23 aberrations except for t(9;11), \"monosomal karyotype\"</td> </tr> <tr> <td>NPM1 mutation, CEBPA mutation</td> <td>FLT3/ITD mutation, MLL partial tandem duplication, BAALC overexpression, mutations in IDH1 and/or IDH2</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">7</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=26372&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n<mso:Media_Notes msdt:dt=\"string\"></mso:Media_Notes>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">AML: acute myeloid leukemia. </div><div id=\"graphicVersion\">Graphic 60295 Version 6.0</div></div></div>"},"60296":{"type":"graphic_table","displayName":"Sources of quinine","title":"Commercially available sources of quinine","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commercially available sources of quinine</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Available forms of quinine: </td> </tr> <tr> <td>Quinine sulfate capsules/tablets (as anti-malarial therapy or for leg cramps)</td> </tr> <tr> <td>Quinine-containing beverages (eg, quinine water, tonic water, bitter lemon, gin and tonic)</td> </tr> <tr> <td>Quinine is also added to other popular beverages because of its fluorescent properties (eg, \"jello shots,\" \"shocktails\")</td> </tr> <tr> <td>Herbal preparations containing quinine or bark from the Cinchona tree*</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In the United States, quinine&nbsp;tablets are&nbsp;available only by prescription for the treatment of malaria (as Qualaquin). In other countries, quinine may be available for leg cramps by prescription or over-the-counter. We believe all of the products listed above have the potential for causing drug-induced immune thrombocytopenia (DITP)&nbsp;and/or immune-mediated drug-induced thrombotic microangiopathy (DITMA).</div><div class=\"graphic_reference\">Adapted from: Liles NW, Page EE, Liles AL, et al. Diversity and severity of adverse reactions to quinine: a systematic review. Am J Hematol&nbsp;2016; 91:461. </div><div id=\"graphicVersion\">Graphic 60296 Version 5.0</div></div></div>"},"60298":{"type":"graphic_table","displayName":"Diagnostic criteria for DISH","title":"Published classification criteria for DISH","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Published classification criteria for DISH</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Criteria of Resnick and Niwayama</td> </tr> <tr> <td>1. The presence of flowing calcification and ossification along the anterolateral aspect of at least four contiguous vertebral bodies with or without associated localized pointed excrescences at the intervening vertebral body-intervertebral disc junctions.</td> </tr> <tr> <td>2. The presence of relative preservation of intervertebral disc height in the involved vertebral segment and the absence of extensive radiographic changes of \"degenerative\" disc disease, including vacuum phenomena and vertebral body marginal sclerosis.</td> </tr> <tr> <td>3. The absence of apophyseal joint bony ankylosis and sacroiliac joint erosion, sclerosis, or intraarticular osseous fusion.</td> </tr> <tr> <td class=\"subtitle1_single\">Criteria of Utsinger</td> </tr> <tr> <td>1. Continuous ossification along the anterolateral aspect of at least four contiguous vertebral bodies, primarily in the thoracolumbar spine. Ossification begins as a fine, ribbon-like wave of bone but commonly develops into a broad, bumpy, buttress-like band of bone.</td> </tr> <tr> <td>2. Continuous ossification along the anterolateral aspect of at least two contiguous vertebral bodies.</td> </tr> <tr> <td>3. Symmetrical and peripheral enthesopathy involving the posterior heel, superior patella, or olecranon, with the entheseal new bone having a well-defined cortical margin.</td> </tr> <tr> <td class=\"sublist1_start\">Exclusions:</td> </tr> <tr> <td class=\"sublist1\">i) Abnormal disc space height in the involved areas</td> </tr> <tr> <td class=\"sublist1\">ii) Apophyseal joint ankylosis</td> </tr> <tr> <td class=\"sublist1_start\">Categories of DISH according to the Utsinger criteria are:</td> </tr> <tr> <td class=\"sublist1\">Definite = criterion 1 </td> </tr> <tr> <td class=\"sublist1\">Probable = criteria 2 and 3</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DISH: diffuse idiopathic skeletal hyperostosis.</div><div class=\"graphic_reference\">Data from: Resnick D, Niwayama G. Radiographic and pathologic features of spinal involvement in diffuse idiopathic skeletal hyperostosis (DISH). Radiology 1976;119:559; and Utsinger PD. Diffuse idiopathic skeletal hyperostosis. Clin Rheum Dis 1985; 11:325.</div><div id=\"graphicVersion\">Graphic 60298 Version 6.0</div></div></div>"},"60300":{"type":"graphic_figure","displayName":"Pathogenesis perinatal arterial ischemic stroke","title":"Pathogenesis of perinatal arterial ischemic stroke","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of perinatal arterial ischemic stroke</div><div class=\"cntnt\"><img style=\"width:542px; height:544px;\" src=\"images/PEDS/60300_Patho_peri_art_isch_stroke.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">DIC: disseminated intravascular coagulation; ECMO: extracorporeal membrane oxygenation; PFO: patent foramen ovale; PHACES: Posterior fossa brain malformations, Hemangiomas, Arterial anomalies, Cardiac anomalies/coarctation of the aorta, Eye abnormalities/endocrine abnormalities, Sternal cleft, supraumbilical raphe, or both.</div><div class=\"graphic_reference\">Courtesy of Rebecca Ichord, MD.</div><div id=\"graphicVersion\">Graphic 60300 Version 2.0</div></div></div>"},"60301":{"type":"graphic_picture","displayName":"Fibroblast on electron microscopy","title":"Fibroblast on electron microscopy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Fibroblast on electron microscopy</div><div class=\"cntnt\"><img style=\"width:504px; height:356px;\" src=\"images/SURG/60301_Fibroblast_elect_microsc_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fibroblast viewed by electron microscopy. This elongated cell, with multiple, delicate cell processes and an oval nucleus, is an active fibroblast. During the repair reaction, fibroblasts secrete extracellular matrix components. This activity is manifested by the distended cisternae of the rough endoplasmic reticulum (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60301 Version 1.0</div></div></div>"},"60302":{"type":"graphic_figure","displayName":"Endotracheal intubation position child","title":"Endotracheal intubation position in a child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endotracheal intubation position in a child</div><div class=\"cntnt\"><img style=\"width:414px; height:375px;\" src=\"images/EM/60302_ETIpositionchild.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Positioning the head and neck for insertion of the laryngoscope blade. Posterior pressure on the forehead extends the neck and usually causes the mouth to open.</div><div class=\"graphic_reference\">Reproduced with permission from: King C, Rappaport LD. Emergent endotracheal intubation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 60302 Version 10.0</div></div></div>"},"60303":{"type":"graphic_table","displayName":"Causes of stroke in pregnancy","title":"Causes of stroke in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of stroke in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Hematologic </td> </tr> <tr> <td>Sickle cell disease</td> </tr> <tr> <td>Polycythemia</td> </tr> <tr> <td>Thrombocytosis</td> </tr> <tr> <td>Thrombophilias, inherited or acquired</td> </tr> <tr> <td>Thrombotic thrombocytopenic purpura</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiac </td> </tr> <tr> <td>Valvular abnormalities</td> </tr> <tr> <td>Arrhythmias, especially atrial fibrillation</td> </tr> <tr> <td>Cardiomyopathy</td> </tr> <tr> <td>Infective&nbsp;endocarditis</td> </tr> <tr> <td>Patent foramen ovale</td> </tr> <tr> <td>Atrial septal defect</td> </tr> <tr> <td class=\"subtitle1_single\">Vascular </td> </tr> <tr> <td>Aneurysms</td> </tr> <tr> <td>Arteriovenous malformations</td> </tr> <tr> <td>Vasculopathy (eg, moyamoya disease or syndrome, Takayasu arteritis)</td> </tr> <tr> <td>Cerebral venous thrombosis</td> </tr> <tr> <td>Cervical artery dissection</td> </tr> <tr> <td>Cocaine use</td> </tr> <tr> <td>Atherosclerosis</td> </tr> <tr> <td>Postpartum angiopathy (Reversible cerebral vasoconstriction syndromes)</td> </tr> <tr> <td class=\"subtitle1_single\">Pregnancy related disorders </td> </tr> <tr> <td>Preeclampsia, eclampsia, and HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome</td> </tr> <tr> <td>Amniotic fluid embolism</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 60303 Version 5.0</div></div></div>"},"60304":{"type":"graphic_table","displayName":"Chemotherapy skin pigment abnormalities","title":"Cytotoxic chemotherapy agents causing pigmentation changes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cytotoxic chemotherapy agents causing pigmentation changes</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Diffuse </td> </tr> <tr> <td>Methotrexate</td> </tr> <tr> <td>Busulfan</td> </tr> <tr> <td>Liposomal doxorubicin</td> </tr> <tr> <td>Hydroxyurea</td> </tr> <tr> <td>Procarbazine</td> </tr> <tr> <td class=\"subtitle1_single\">Local </td> </tr> <tr> <td>Bleomycin</td> </tr> <tr> <td>Cyclophosphamide</td> </tr> <tr> <td>Busulfan</td> </tr> <tr> <td>Doxorubicin (nonencapsulated)</td> </tr> <tr> <td>Ifosfamide</td> </tr> <tr> <td>Tegafur</td> </tr> <tr> <td>Mitoxantrone</td> </tr> <tr> <td>Daunorubicin</td> </tr> <tr> <td>Fluorouracil</td> </tr> <tr> <td>Cisplatin</td> </tr> <tr> <td>Carmustine</td> </tr> <tr> <td>Mechlorethamine</td> </tr> <tr> <td>Thiotepa</td> </tr> <tr> <td>Docetaxel</td> </tr> <tr> <td>Hydroxyurea</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Hair </td> </tr> <tr> <td>Cisplatin</td> </tr> <tr> <td>Cyclophosphamide</td> </tr> <tr> <td>Methotrexate</td> </tr> <tr> <td>Combination regimens</td> </tr> <tr> <td class=\"subtitle1_single\">Special patterns* </td> </tr> <tr> <td>Fluorouracil</td> </tr> <tr> <td>Vinorelbine</td> </tr> <tr> <td>Fotemustine</td> </tr> <tr> <td>Vincristine</td> </tr> <tr> <td>Bromodeoxyuridine</td> </tr> <tr> <td>Docetaxel</td> </tr> <tr> <td>Bleomycin</td> </tr> <tr> <td>Combination regimens</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Supravenous serpentine hyperpigmentation, flagellate hyperpigmentation, or hypopigmentation.</div><div id=\"graphicVersion\">Graphic 60304 Version 6.0</div></div></div>"},"60305":{"type":"graphic_table","displayName":"WHO thin melanoma trial","title":"WHO thin melanoma trial","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO thin melanoma trial</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Thickness, mm</td> <td class=\"subtitle1\" rowspan=\"2\">n</td> <td class=\"subtitle1\">Narrow margin (1 cm)</td> <td class=\"subtitle1\" rowspan=\"2\">n</td> <td class=\"subtitle1\">Wide margin (3 cm)</td> </tr> <tr> <td class=\"subtitle2\">Rate of local recurrence</td> <td class=\"subtitle2\">Rate of local recurrence</td> </tr> <tr> <td>0 to 1.0</td> <td>186</td> <td>3 (1.6%)</td> <td>173</td> <td>1 (0.6%)</td> </tr> <tr> <td>1.1 to 2.0</td> <td>119</td> <td>5 (4.2%)</td> <td>134</td> <td>2 (1.5%)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WHO: World Health Organization.</div><div class=\"graphic_reference\">Cascinelli Sem Surg Onc 1998.</div><div id=\"graphicVersion\">Graphic 60305 Version 3.0</div></div></div>"},"60306":{"type":"graphic_table","displayName":"Intravenous antimicrobial treatment regimens for epiglottitis","title":"Intravenous antimicrobial treatment regimens for epiglottitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intravenous antimicrobial treatment regimens for epiglottitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Pediatric dose</td> <td class=\"subtitle1\">Adult dose</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Two-drug regimens</td> </tr> <tr> <td class=\"indent2\">Ceftriaxone <strong>OR</strong></td> <td> <p>50 to 100 mg/kg per day once daily or in two divided doses</p> Maximum daily dose 2 g</td> <td>2 g every 24 hours</td> </tr> <tr> <td class=\"indent2\">Cefotaxime</td> <td> <p>150 to 200 mg/kg per day in four divided doses</p> Maximum daily dose 10 g</td> <td>2 g every 4 to 8 hours</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\"><span class=\"red\"><strong>PLUS</strong> </span></td> </tr> <tr> <td class=\"indent2\">Vancomycin* <strong>OR</strong></td> <td> <p>40 to 60 mg/kg per day in three to four divided doses</p> Maximum daily dose 2 g</td> <td>1 g every 12 hours (or 15 mg/kg every 12 hours if weight-based dosing is preferred)</td> </tr> <tr> <td class=\"indent2\">Clindamycin <strong>OR</strong></td> <td> <p>30 to 40 mg/kg per day in three divided doses</p> Maximum daily dose 2.7 g</td> <td>600 to 900 mg every 8 hours</td> </tr> <tr> <td class=\"indent2\">Oxacillin<sup>&#182;</sup> <strong>OR</strong></td> <td> <p>150 to 200 mg/kg per day in four divided doses</p> Maximum daily dose 12 g</td> <td>1 to 2 g every 4 to 6 hours</td> </tr> <tr> <td class=\"indent2\">Nafcillin<sup>&#182;</sup> <strong>OR</strong></td> <td> <p>150 to 200 mg/kg per day in four divided doses</p> Maximum daily dose 12 g</td> <td>2 g every 4 hours</td> </tr> <tr> <td class=\"indent2\">Cefazolin<sup>&#182;</sup></td> <td> <p>75 to 100 mg/kg per day in three divided doses</p> Maximum daily dose 6 g</td> <td>1 to 2 g every 6 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Vancomycin is indicated in patients with moderate to severe sepsis, patients who may have concomitant meningitis, and patients from areas with an increased prevalence of clindamycin-resistant and/or methicillin-resistant <EM>Staphylococcal aureus </EM>isolates.<br />¶ Oxacillin, nafcillin, and cefazolin should only be used as part of combination therapy in patients for whom methicillin-resistant <EM>S. aureus </EM>is <STRONG>not </STRONG>a consideration.</div><div id=\"graphicVersion\">Graphic 60306 Version 4.0</div></div></div>"},"60307":{"type":"graphic_diagnosticimage","displayName":"Paraseptal emphysema II","title":"Paraseptal emphysema with bullae","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paraseptal emphysema with bullae</div><div class=\"cntnt\"><img style=\"width:375px; height:343px;\" src=\"images/PULM/60307_Paraseptal_emphysema_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Paraseptal emphysema in the periphery of both upper lobes and in the left lower lobe on a background of centrilobular emphysema. Several large subpleural bullae are visible in both lungs and are the result of paraseptal emphysema.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 60307 Version 2.0</div></div></div>"},"60308":{"type":"graphic_picture","displayName":"Digital pitting scars in SSc","title":"Digital pitting scars in scleroderma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Digital pitting scars in scleroderma</div><div class=\"cntnt\"><img style=\"width:396px; height:263px;\" src=\"images/RHEUM/60308_Digital_pitting_scars_in_SS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Digital pitting scars in a patient with limited cutaneous systemic sclerosis.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 60308 Version 1.0</div></div></div>"},"60309":{"type":"graphic_figure","displayName":"Insulin processing in beta cell","title":"Processing of insulin within the beta cell","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Processing of insulin within the beta cell</div><div class=\"cntnt\"><img style=\"width:527px; height:461px;\" src=\"images/ENDO/60309_Insulin_processing_in_beta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Insulin is synthesized as preproinsulin in the ribosomes of the rough endoplasmic reticulum. The preproinsulin is then cleaved to proinsulin, which is transported to the Golgi apparatus where it is packaged into secretory granules located close to the cell membrane. Most of the proinsulin is cleaved into equimolar amounts of insulin and C-peptide in the secretory granules.</div><div class=\"graphic_reference\">Courtesy of David K McCulloch, MD.</div><div id=\"graphicVersion\">Graphic 60309 Version 2.0</div></div></div>"},"60310":{"type":"graphic_table","displayName":"Extra-abdominal causes abdominal pain","title":"Selected extra-abdominal causes of acute abdominal pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected extra-abdominal causes of acute abdominal pain</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Cardiac</td> </tr> <tr> <td>Myocardial ischemia and infarction</td> </tr> <tr> <td>Myocarditis</td> </tr> <tr> <td>Endocarditis</td> </tr> <tr> <td>Heart failure</td> </tr> <tr> <td class=\"subtitle1_single\">Thoracic</td> </tr> <tr> <td>Pneumonitis</td> </tr> <tr> <td>Pleurodynia, Bornholm's disease</td> </tr> <tr> <td>Pulmonary embolism and infarction</td> </tr> <tr> <td>Pneumothorax</td> </tr> <tr> <td>Empyema</td> </tr> <tr> <td>Esophagitis</td> </tr> <tr> <td>Esophageal spasm</td> </tr> <tr> <td>Esophageal rupture (Boerhaave's syndrome)</td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic</td> </tr> <tr> <td>Radiculitis: spinal cord or peripheral nerve tumors, degenerative arthritis of spine</td> </tr> <tr> <td>Abdominal epilepsy</td> </tr> <tr> <td>Tabes dorsalis (tertiary syphilis)</td> </tr> <tr> <td class=\"subtitle1_single\">Metabolic</td> </tr> <tr> <td>Uremia</td> </tr> <tr> <td>Diabetes mellitus (ketoacidosis)</td> </tr> <tr> <td>Porphyria</td> </tr> <tr> <td>Acute adrenal insufficiency</td> </tr> <tr> <td>Hyperlipidemia</td> </tr> <tr> <td>Hyperparathyroidism</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Hematologic</td> </tr> <tr> <td>Sickle cell anemia</td> </tr> <tr> <td>Hemolytic anemia</td> </tr> <tr> <td>Henoch-Sch&#246;nlein purpura</td> </tr> <tr> <td>Acute leukemia</td> </tr> <tr> <td class=\"subtitle1_single\">Toxins</td> </tr> <tr> <td>Hypersensitivity reactions: insect bites, reptile venoms</td> </tr> <tr> <td>Heavy metals and corrosives (eg, lead or iron)</td> </tr> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td>Herpes zoster</td> </tr> <tr> <td>Osteomyelitis</td> </tr> <tr> <td>Typhoid fever</td> </tr> <tr> <td class=\"subtitle1_left\">Miscellaneous</td> </tr> <tr> <td>Muscular contusion, hematoma, or tumor</td> </tr> <tr> <td>Narcotic withdrawal</td> </tr> <tr> <td>Familial Mediterranean fever</td> </tr> <tr> <td>Psychiatric disorders</td> </tr> <tr> <td>Heat stroke</td> </tr> </tbody> </table> </td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">6</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">perm requested 1/12/99. Only print media granted, will try again 2/24/99. 3/24/99-CD perm granted. 3/22/2000-Internet perm req, ar. 5/3-Internet perm granted.</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=18634&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Reproduced with permission from: Glasgow RE, Mulvihill SJ. Abdominal pain, including the acute abdomen. In: Gastrointestinal and Liver Disease, Feldman M, Scharschmidt BF, Sleisenger MH (Eds), W.B. Saunders, Philadelphia 1998. p.80. Copyright © 1998 W.B. Saunders.</div><div id=\"graphicVersion\">Graphic 60310 Version 7.0</div></div></div>"},"60311":{"type":"graphic_picture","displayName":"Los Angeles grade A esophagitis","title":"Los Angeles grade A esophagitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Los Angeles grade A esophagitis</div><div class=\"cntnt\"><img style=\"width:298px; height:282px;\" src=\"images/GAST/60311_LA_grade_A_esophagitis_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Los Angeles grade A esophagitis: One or more mucosal breaks no longer than 5 mm, not bridging the tops of mucosal folds. Mucosal breaks are defined as an area of slough or erythema with a discrete line of demarcation from the adjacent, more normal looking mucosa.</div><div id=\"graphicVersion\">Graphic 60311 Version 4.0</div></div></div>"},"60313":{"type":"graphic_picture","displayName":"Papular secondary syphilis","title":"Secondary syphilis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Secondary syphilis</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/60313_Papular_secondary_syphilis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple slightly scaly erythematous papules are present on the trunk of this patient with papular secondary syphilis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60313 Version 3.0</div></div></div>"},"60314":{"type":"graphic_picture","displayName":"Septal rupture post MI","title":"Septal rupture after MI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Septal rupture after MI</div><div class=\"cntnt\"><img style=\"width:360px; height:265px;\" src=\"images/CARD/60314_Septal_rupture_post_MI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pathologic specimen showing rupture of the interventricular septum (arrow) after a myocardial infarction.</div><div class=\"graphic_reference\">From Edwards, WD, Pathology of myocardial infarction and reperfusion. In: Acute Myocardial Infarction, Gersh, BJ, Rahimtoola, SH (Eds), Elsevier, New York 1991, pp, 14-48. By permission.</div><div id=\"graphicVersion\">Graphic 60314 Version 1.0</div></div></div>"},"60315":{"type":"graphic_picture","displayName":"Hypoechoic nodule with microcalcifications","title":"Hypoechoic nodule with microcalcifications","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypoechoic nodule with microcalcifications</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/ENDO/60315_Hypoechoic_nod_microcal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A transverse image of the neck shows a nodule (N) in the anterio-medial part of the left thyroid lobe that is hypoechoic when compared to the right thyroid lobe (RTL). There are bright tiny spots, which are microcalcifications (microC) (arrow) in the nodule and are strongly suggestive of papillary thyroid cancer. The trachea (T) has been displaced to the right by the nodule. The sternocleidomastoid muscles (SCM) are seen lateral to the nodule. A 12.0 MHz transducer was used to achieve high resolution.</div><div id=\"graphicVersion\">Graphic 60315 Version 2.0</div></div></div>"},"60316":{"type":"graphic_figure","displayName":"Sources of sodium in your diet PI","title":"Sources of sodium in your diet","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sources of sodium in your diet</div><div class=\"cntnt\"><img style=\"width:430px; height:558px;\" src=\"images/PI/60316_Sources_sodium_diet_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Original data from: He FJ, MacGregor GA. Reducing population salt intake worldwide: from evidence to implementation. Prog Cardiovasc Dis 2010; 52:363.</div><div id=\"graphicVersion\">Graphic 60316 Version 2.0</div></div></div>"},"60318":{"type":"graphic_diagnosticimage","displayName":"Garden type I hip fracture","title":"Garden type I hip fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Garden type I hip fracture</div><div class=\"cntnt\"><img style=\"width:432px; height:343px;\" src=\"images/EM/60318_HipfxGarden1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type I fractures can be incomplete, but much more typically they are impacted with a valgus and retroverted orientation.</div><div class=\"graphic_reference\">Reproduced with permission from: Baumgaertner MR, Higgins TF. Femoral neck fractures. In: Rockwood and Green's Fractures in Adults, 5th ed, Bucholz RW, Heckman JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 60318 Version 12.0</div></div></div>"},"60319":{"type":"graphic_figure","displayName":"Leaded gasoline","title":"Marked reduction in consumption of tetraethyl lead following the phase-out of leaded gasoline in the United States","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Marked reduction in consumption of tetraethyl lead following the phase-out of leaded gasoline in the United States</div><div class=\"cntnt\"><img style=\"width:517px; height:306px;\" src=\"images/NEPH/60319_Leaded_gasoline.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">US Department of the Interior, Bureau of Mines, \"Lead,\" in Minerals Yearbook 1920 to 1989 (Washington: GPO, 1921-90). No statistics for tetraethyl lead were published prior to 1941.</div><div class=\"graphic_reference\">Reproduced with permission from: Warren C. Childhood Lead Poisoning before 1930. In: Brush with Death: A Social History of Lead Poisoning, The John Hopkins University Press, Baltimore 2000. p.32.</div><div id=\"graphicVersion\">Graphic 60319 Version 2.0</div></div></div>"},"60320":{"type":"graphic_figure","displayName":"Calcitrol PTH change pregnancy","title":"Changes in serum concentrations of calcitriol and intact-PTH in non-pregnant (NP) and pregnant women (P1: first trimester; P2: second trimester; P3: third trimester), at term and 6 weeks postpartum (PP)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Changes in serum concentrations of calcitriol and intact-PTH in non-pregnant (NP) and pregnant women (P1: first trimester; P2: second trimester; P3: third trimester), at term and 6 weeks postpartum (PP)</div><div class=\"cntnt\"><img style=\"width:325px; height:522px;\" src=\"images/OBGYN/60320_Calcitrol_PTH_change_pregna.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Points shown represent means ± SD. The shaded area represents the reference range obtained in non-pregnant women (n = 280).</div><div class=\"graphic_footnotes\">* Denotes statistical significance as described in the text.</div><div class=\"graphic_reference\">Reproduced with permission from: Ardawi MS, Nasrat HA, BA'Aqueel HS. Calcium-regulating hormones and parathyroid hormone-related peptide in normal human pregnancy and postpartum: a longitudinal study. Eur J Endocrinol 1997; 137:402. Copyright © 1997 Society for the European Journal of Endocrinology.</div><div id=\"graphicVersion\">Graphic 60320 Version 10.0</div></div></div>"},"60322":{"type":"graphic_table","displayName":"Etiology high tyrosine levels","title":"Etiology of elevated blood tyrosine levels","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of elevated blood tyrosine levels</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Hepatocellular dysfunction</td> </tr> <tr> <td>2. Transient tryosinemia of the newborn</td> </tr> <tr> <td class=\"sublist1_start\">3. Genetic enzyme deficiencies in tyrosine degradation</td> </tr> <tr> <td class=\"sublist1\">Hepatorenal tyrosinemia (hereditary tyrosinemia type 1, HT1)</td> </tr> <tr> <td class=\"sublist1\">Oculocutaneous tyrosinemia (hereditary tyrosinemia type 2,&nbsp;HT2)</td> </tr> <tr> <td class=\"sublist1\">4-OH-phenylpyruvate dioxygenase deficiency (hereditary tyrosinemia type 3,&nbsp;HT3)</td> </tr> <tr> <td class=\"sublist1_start\">4. Miscellaneous</td> </tr> <tr> <td class=\"sublist1\">Scurvy</td> </tr> <tr> <td class=\"sublist1\">Hyperthyroidism</td> </tr> <tr> <td class=\"sublist1\">Postprandial sample</td> </tr> <tr> <td class=\"sublist1\">Nitisinone&nbsp;therapy</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Markus Grompe, MD.</div><div id=\"graphicVersion\">Graphic 60322 Version 2.0</div></div></div>"},"60323":{"type":"graphic_picture","displayName":"Drug induced skin vasculitis","title":"Drug-induced cutaneous vasculitis with palpable purpura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Drug-induced cutaneous vasculitis with palpable purpura</div><div class=\"cntnt\"><img style=\"width:216px; height:142px;\" src=\"images/RHEUM/60323_Drug_induced_skin_vasculiti.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dense palpable purpura on the lower extremity of a patient with drug-induced cutaneous vasculitis.</div><div class=\"graphic_reference\">Courtesy of Leonard Calabrese, MD.</div><div id=\"graphicVersion\">Graphic 60323 Version 2.0</div></div></div>"},"60325":{"type":"graphic_table","displayName":"Increased T4 requirement","title":"Factors that increase the requirement for T4","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors that increase the requirement for T4</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Pregnancy</td> </tr> <tr> <td>Estrogen therapy</td> </tr> <tr> <td>Weight gain</td> </tr> <tr> <td class=\"sublist1_start\">Drugs which increase catabolism of T4 </td> </tr> <tr> <td class=\"sublist1\">Rifampin </td> </tr> <tr> <td class=\"sublist1\">Carbamazepine </td> </tr> <tr> <td class=\"sublist1\">Phenytoin </td> </tr> <tr> <td class=\"sublist1\">Phenobarbital </td> </tr> <tr> <td class=\"sublist1\">Imatinib </td> </tr> <tr> <td class=\"sublist1_start\">Malabsorption or increased excretion of T4 </td> </tr> <tr> <td class=\"sublist1\">Gastrointestinal disorders (eg, celiac disease) </td> </tr> <tr> <td class=\"sublist1\">Impaired acid secretion </td> </tr> <tr> <td class=\"sublist1\">Drugs that interfere with T4 absorption </td> </tr> <tr> <td class=\"sublist2\">Ferrous sulfate </td> </tr> <tr> <td class=\"sublist2\">Cholestyramine or colestipol </td> </tr> <tr> <td class=\"sublist2\">Sucralfate </td> </tr> <tr> <td class=\"sublist2\">Aluminum hydroxide gels </td> </tr> <tr> <td class=\"sublist2\">Calcium carbonate </td> </tr> <tr> <td class=\"sublist2\">Sertraline </td> </tr> <tr> <td class=\"sublist2\">Raloxifene </td> </tr> <tr> <td class=\"sublist2\">Omeprazole </td> </tr> <tr> <td class=\"sublist1\">Nephrotic syndrome </td> </tr> <tr> <td class=\"sublist1_start\">Progressive thyroid dysfunction </td> </tr> <tr> <td class=\"sublist1\">Autoimmune thyroiditis </td> </tr> <tr> <td class=\"sublist1\">Previous thyroid irradiation </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">T4: thyroxine.</div><div class=\"graphic_reference\">Modified with permission from: Roberts, CG, Ladenson, PW. Hypothyroidism. Lancet 2004; 363:793. Copyright © 2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 60325 Version 2.0</div></div></div>"},"60326":{"type":"graphic_figure","displayName":"Method of penile self injection","title":"Method of administering intrapenile injection","html":"<div class=\"graphic\"><div style=\"width: 497px\" class=\"figure\"><div class=\"ttl\">Method of administering intrapenile injection</div><div class=\"cntnt\"><img style=\"width:477px; height:526px;\" src=\"images/ENDO/60326_Method_of_penile_self_injection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To be fully effective, the medications must be injected directly into one of the penile erectile bodies, the corporus cavernosum. The medication will diffuse over to the other side of the penis so that symmetrical erection is achieved. A cross section of the penis shows the relationship of the site of injection to the corpora cavernosae. Most men use an insulin syringe with a 26 to 30 gauge 1/2 inch needle.</div><div id=\"graphicVersion\">Graphic 60326 Version 2.0</div></div></div>"},"60327":{"type":"graphic_picture","displayName":"Jejunal leiomyoma Gross","title":"Jejunal leiomyoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Jejunal leiomyoma</div><div class=\"cntnt\"><img style=\"width:266px; height:324px;\" src=\"images/GAST/60327_Jejunal_leiomyoma_Gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical specimen of a large jejunal leiomyoma that caused a small bowel obstruction.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 60327 Version 1.0</div></div></div>"},"60328":{"type":"graphic_figure","displayName":"LAV hysterectomy PI","title":"Laparoscopically assisted vaginal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Laparoscopically assisted vaginal hysterectomy</div><div class=\"cntnt\"><img style=\"width:544px; height:423px;\" src=\"images/PI/60328_LAV_hysterectomy_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In laparoscopically assisted vaginal hysterectomy, three small incisions are made in the abdomen. The laparoscope is inserted through these incisions. The uterus and cervix are removed through the vagina. The top of the vagina is then sewn together. The ovaries and fallopian tubes may also be removed (called salpingo-oophorectomy) at the same time.</div><div id=\"graphicVersion\">Graphic 60328 Version 5.0</div></div></div>"},"60330":{"type":"graphic_table","displayName":"Gemcitabine for metastatic pancreatic and biliary tract cancer","title":"Gemcitabine for metastatic pancreatic and biliary tract cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gemcitabine for metastatic pancreatic and biliary tract cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 8 weeks for first cycle, then 4 weeks.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr class=\"divider_bottom\"> <td>Gemcitabine*</td> <td>1000 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline (concentration no greater than 40 mg/mL) and administer over 30 to 60 minutes.</td> <td>Weekly for seven weeks followed by one week of rest in the first cycle, then weekly for three weeks followed by one week of rest in all subsequent cycles</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>LOW. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with granulocyte colony stimulating factors not indicated (incidence of neutropenic fever &#60;1%<sup>[1-4]</sup>). </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>A lower starting dose may be needed for patients with liver impairment. </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count weekly during treatment. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess basic metabolic panel (including serum creatinine) and liver function tests prior to each cycle and otherwise as indicated during treatment. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>This regimen should not be initiated unless the white blood cell count is &#62;3500 cells/microL and platelets are &#8805;100,000/microL.<sup>[1]</sup> During therapy, the dose of gemcitabine should be decreased by 25% if the absolute neutrophil count decreases to &#60;1000 cells/microL but &#8805;500 cells/microL, or the platelets decrease to &#60;100,000/microL and &#8805;50,000/microL.<sup>[5]</sup> The United States Prescribing Information recommends holding gemcitabine for an absolute neutrophil count &#60;500 cells/microL or platelets &#60;50,000/microL.<sup>[5]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Hepatotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear dose recommendations in these patients. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Thrombotic microangiopathy</strong></td> <td colspan=\"3\"> <ul> <li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose.<sup>[5]</sup> Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP. </li> <li>Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>A variety of manifestations of pulmonary toxicity have been reported. Discontinue gemcitabine immediately and permanently. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; CBC: complete blood count.<br />* In the original protocol, the gemcitabine dose could be increased by 25% up to, but not exceeding, a dose of 1250 mg/m<SUP>2</SUP> after the first cycle, provided the absolute neutrophil count and platelets exceed 1500 cells/mm<SUP>3</SUP> and 100,000/mm<SUP>3</SUP>, respectively, and nonhematologic toxicity was less than or equal to WHO Grade 1.<SUP>[1]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Burris HA, et al. J Clin Oncol 1997; 15:2403.</LI>&#xD;&#xA;<LI>Oettle H, et al. Ann Oncol 2005; 16:1639.</LI>&#xD;&#xA;<LI>Stathopoulos GP, et al. Br J Cancer 2006; 95:587.</LI>&#xD;&#xA;<LI>Herrmann R, et al. J Clin Oncol 2007; 25:2212.</LI>&#xD;&#xA;<LI>Gemcitabine hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 28, 2011).</LI></OL></div><div id=\"graphicVersion\">Graphic 60330 Version 22.0</div></div></div>"},"60331":{"type":"graphic_picture","displayName":"Traction alopecia hairline","title":"Traction alopecia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traction alopecia</div><div class=\"cntnt\"><img style=\"width:324px; height:432px;\" src=\"images/DERM/60331_Traction_alopecia_hairline.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hair loss on the anterior scalp is evident in this patient with traction alopecia.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60331 Version 3.0</div></div></div>"},"60332":{"type":"graphic_picture","displayName":"Lichen sclerosus on the chest","title":"Extragenital lichen sclerosus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Extragenital lichen sclerosus</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/60332_Lichen_sclerosus_chest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple white, atrophic plaques are present on the chest.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60332 Version 3.0</div></div></div>"},"60333":{"type":"graphic_figure","displayName":"Finger extension","title":"Finger extension","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Finger extension</div><div class=\"cntnt\"><img style=\"width:552px; height:242px;\" src=\"images/EM/60333_Finger_extension.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the muscles and tendons involved in finger extension.</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company, General Anatomy. Copyright &#169;2008 Anatomical Chart Company.</div><div id=\"graphicVersion\">Graphic 60333 Version 1.0</div></div></div>"},"60334":{"type":"graphic_figure","displayName":"Traumatic hyphema - Grading and prognosis","title":"Traumatic hyphema: Grading and prognosis","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Traumatic hyphema: Grading and prognosis</div><div class=\"cntnt\"><img style=\"width:537px; height:504px;\" src=\"images/EM/60334_Hyphema_grading_table.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from Brandt MT, Haug RH. Traumatic hyphema: a comprehensive review. J Oral Maxillofac Surg 2001;59:1492.</div><div id=\"graphicVersion\">Graphic 60334 Version 7.0</div></div></div>"},"60335":{"type":"graphic_figure","displayName":"Base of skull anatomy","title":"Base of skull anatomy","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Base of skull anatomy</div><div class=\"cntnt\"><img style=\"width:501px; height:347px;\" src=\"images/ONC/60335_Base_of_skull_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Co. Copyright &#169; 2009 Wolters Kluwer.</div><div id=\"graphicVersion\">Graphic 60335 Version 1.0</div></div></div>"},"60337":{"type":"graphic_picture","displayName":"Urothelial dysplasia A","title":"Urothelial dysplasia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Urothelial dysplasia</div><div class=\"cntnt\"><img style=\"width:504px; height:229px;\" src=\"images/ONC/60337_Urothelial_dysplasia_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Cristina Magi-Galluzzi, MD, PhD.</div><div id=\"graphicVersion\">Graphic 60337 Version 1.0</div></div></div>"},"60338":{"type":"graphic_table","displayName":"Enuresis alarms PI","title":"Enuresis alarms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Enuresis alarms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Device</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Dri-Sleeper</p> <p>Canada</p> <p>www.DRI-Sleeper.com</p> </td> <td>Detector is clipped to standard disposable panty liner; beeper unit worn on shoulder.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Enurad</p> <p>UK Electronic</p> <p>Sweden</p> <p>www.enurad.com</p> </td> <td>Wireless moisture alarm with radio transmission to an alarm clock. (Approved for use in Europe, but not in the US).</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Malem Medical*</p> <p>Nottingham, England</p> <p>www.malem.co.uk</p> </td> <td>Sensor pad in underwear; alarm unit on child's shoulder. Available with both auditory and vibratory alarms, or as a wireless unit.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Nighthawk</p> <p>Bed Wetting Global Limited</p> <p>www.nighthawkbedwetting.com</p> <p>&nbsp;</p> </td> <td>&nbsp;Vibratory alarm with buzzer that can be silenced.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Nite Train'r</p> <p>Koregon Enterprises</p> <p>Beaverton, OR</p> <p>www.nitetrain-r.com</p> </td> <td>Moisture sensor in underwear or bed pad.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Nytone Enuretic Alarm*</p> <p>Nytone Medical Products</p> <p>Bluffdale, UT</p> <p>www.nytone.com</p> </td> <td>Sensor clips on underwear; moisture alarm on wrist.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Sleep Dry</p> <p>Star Child Labs</p> <p>www.sleepdryalarm.com</p> </td> <td>Beeper unit can be clipped to child's bedclothes near the ear.</td> </tr> <tr> <td> <p>Wet-Stop*</p> <p>Palco Labs</p> <p>Santa Cruz, CA</p> <p>www.wetstop.com</p> </td> <td>Sensor patch sewn into underwear (position can be adjusted for boys and girls); beeper unit attached by velcro to child's bedclothes near the ear. Available with both auditory and vibratory alarms.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Also available from The Bedwetting Store (www.bedwettingstore.com).</div><div id=\"graphicVersion\">Graphic 60338 Version 11.0</div></div></div>"},"60339":{"type":"graphic_table","displayName":"Manifestations of fibromyalgia","title":"Manifestations of fibromyalgia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Manifestations of fibromyalgia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">History</td> </tr> <tr> <td>More common in women,&nbsp;age 20 to 65</td> </tr> <tr> <td>Chronic, generalized pain</td> </tr> <tr> <td>Fatigue</td> </tr> <tr> <td>Sleep and mood disturbances</td> </tr> <tr> <td>Headaches</td> </tr> <tr> <td>Irritable bowel syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Physical examination</td> </tr> <tr> <td>Multiple tender areas of muscle and tendons</td> </tr> <tr> <td>No inflammatory muscle or joint disease</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory tests</td> </tr> <tr> <td>Unremarkable</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 60339 Version 2.0</div></div></div>"},"60341":{"type":"graphic_picture","displayName":"Riedels thyroiditis Gross","title":"Riedel's thyroiditis: Surgical specimen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Riedel's thyroiditis: Surgical specimen</div><div class=\"cntnt\"><img style=\"width:343px; height:288px;\" src=\"images/ENDO/60341_Riedels_thyroiditis_Gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross thyroid specimen from a patient with Riedel's thyroiditis is characterized by a pale color due to replacement of the thyroid parenchyma with dense, avascular fibrous tissue. The surface of the specimen is covered with ink to indicate the surgical margin.</div><div class=\"graphic_reference\">Courtesy of Stephanie L Lee, MD, PhD.</div><div id=\"graphicVersion\">Graphic 60341 Version 2.0</div></div></div>"},"60342":{"type":"graphic_picture","displayName":"Food impaction CPC Endosc","title":"Food impaction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Food impaction</div><div class=\"cntnt\"><img style=\"width:252px; height:257px;\" src=\"images/GAST/60342_Food_impaction_CPC_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of the distal esophagus showing a round food bolus, which was successfully extracted using a basket and an overtube.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD and Helen M. Shields, MD.</div><div id=\"graphicVersion\">Graphic 60342 Version 1.0</div></div></div>"},"60343":{"type":"graphic_figure","displayName":"Intestinal lesions celiac","title":"Intestinal lesions in celiac disease","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Intestinal lesions in celiac disease</div><div class=\"cntnt\"><img style=\"width:540px; height:200px;\" src=\"images/GAST/60343_Intestlesionsceliacedt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the five main lesions associated with gluten sensitivity. The lesions range in histologic severity from a mild alteration characterized by increased intraepithelial lymphocytes (type 0 lesion) to a flat mucosa with total mucosal atrophy, complete loss of villi, enhanced epithelial apoptosis, and crypt hyperplasia (type 3 lesion). The type 4 lesion is seen in T cell lymphoma.</div><div class=\"graphic_reference\">Adapted from: Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology 1992; 102:330.</div><div id=\"graphicVersion\">Graphic 60343 Version 4.0</div></div></div>"},"60344":{"type":"graphic_table","displayName":"Potential candidates for fertility preservation interventions","title":"Diseases in which affected individuals may benefit from fertility preservation interventions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diseases in which affected individuals may benefit from fertility preservation interventions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Malignant diseases</td> </tr> <tr> <td class=\"subtitle2_single\">Childhood cancers*</td> </tr> <tr> <td class=\"indent2\">Hodgkin and non-Hodgkin lymphoma</td> </tr> <tr> <td class=\"indent2\">Ewing sarcoma</td> </tr> <tr> <td class=\"indent2\">Pelvic osteosarcoma</td> </tr> <tr> <td class=\"indent2\">Wilms tumor</td> </tr> <tr> <td class=\"indent2\">Genital rhabdomyosarcoma<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent2\">Burkitt lymphoma<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent2\">Leukemia<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Neuroblastoma<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_single\">Adult cancers</td> </tr> <tr> <td class=\"sublist3_start\">Breast cancer<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist3\">Infiltrative ductal</td> </tr> <tr> <td class=\"sublist3\">Stage I-III</td> </tr> <tr> <td class=\"sublist3\">Infiltrative lobular<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist3\">Stage IV</td> </tr> <tr> <td class=\"sublist3_start\">Cancer of the cervix<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist3\">Squamous cell carcinoma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">Adeno-/adenosquamous carcinoma<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_single\">Malignancies of the gastrointestinal tract<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Autoimmune and hematologic diseases</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"indent1\">Beh&#231;et syndrome</td> </tr> <tr> <td class=\"indent1\">Steroid-resistant glomerulonephritis</td> </tr> <tr> <td class=\"indent1\">Rheumatoid arthritis</td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease</td> </tr> <tr> <td class=\"indent1\">Progressive systemic sclerosis</td> </tr> <tr> <td class=\"indent1\">Juvenile idiopathic arthritis</td> </tr> <tr> <td class=\"indent1\">Multiple sclerosis</td> </tr> <tr> <td class=\"indent1\">Pemphigus vulgaris</td> </tr> <tr> <td class=\"indent1\">Autoimmune thrombocytopenia</td> </tr> <tr> <td class=\"indent1\">Sickle cell disease</td> </tr> <tr> <td class=\"indent1\">Aplastic anemia</td> </tr> <tr> <td class=\"subtitle1_single\">Benign ovarian disease</td> </tr> <tr> <td class=\"indent1\">Benign ovarian masses requiring radical surgery</td> </tr> <tr> <td class=\"subtitle1_single\">Patients receiving pelvic radiation</td> </tr> <tr> <td class=\"sublist2_start\">Solid organ tumors presenting in the pelvis</td> </tr> <tr> <td class=\"sublist2\">Ewing's sarcoma</td> </tr> <tr> <td class=\"sublist2\">Osteosarcoma</td> </tr> <tr> <td class=\"sublist2\">Tumors of the spinal cord</td> </tr> <tr> <td class=\"sublist2\">Retroperitoneal sarcoma</td> </tr> <tr> <td class=\"indent1\">Rectal cancer</td> </tr> <tr> <td class=\"indent1\">Idiopathic bone disease requiring radiation</td> </tr> <tr> <td class=\"subtitle1_single\">Prophylactic oophorectomy</td> </tr> <tr> <td class=\"indent1\">BRCA I and II germline mutation carriers</td> </tr> <tr> <td class=\"subtitle1_single\">Hematopoietic stem cell transplantation</td> </tr> <tr> <td class=\"indent1\">Malignant diseases</td> </tr> <tr> <td class=\"indent1\">Genetic, hematological, and autoimmune disorders</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Cryopreservation of the ovarian tissue is the only option in children.<br />&para; If ovarian tissue is cryopreserved, ovarian metastases should be ruled because of the moderate or high risk of ovarian involvement.</div><div class=\"graphic_reference\">Modified with permission from: Sonmezer M, Shamonki MI, Oktay K. Ovarian tissue cryopreservation: benefits and risks. Cell Tissue Res 2005; 322:125. Copyright &copy; 2005 Springer Verlag.</div><div id=\"graphicVersion\">Graphic 60344 Version 6.0</div></div></div>"},"60345":{"type":"graphic_figure","displayName":"Cell damage release cytochrome C","title":"Initiation of apoptosis by extrinsic and intrinsic pathways leads to caspase activation","html":"<div class=\"graphic\"><div style=\"width: 646px\" class=\"figure\"><div class=\"ttl\">Initiation of apoptosis by extrinsic and intrinsic pathways leads to caspase activation</div><div class=\"cntnt\"><img style=\"width:626px; height:360px;\" src=\"images/RHEUM/60345_Cell_dama_release_cytochr_C.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Keith Elkon, MD.</div><div id=\"graphicVersion\">Graphic 60345 Version 4.0</div></div></div>"},"60346":{"type":"graphic_picture","displayName":"AIDS-related Kaposis sarcoma - nose","title":"AIDS-related Kaposi's sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AIDS-related Kaposi's sarcoma</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/60346_Kaposis_sarcoma_nose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous to violaceous plaque is present on the nose.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60346 Version 3.0</div></div></div>"},"60347":{"type":"graphic_picture","displayName":"Thumb spica cast 2","title":"Thumb spica cast: Step 2","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Thumb spica cast: Step 2</div><div class=\"cntnt\"><img style=\"width:504px; height:207px;\" src=\"images/EM/60347_Thumb_spica_cast_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Place a stockinette or similar material over the hand and forearm. Minimize wrinkles as much as possible.</div><div class=\"graphic_reference\">Courtesy of Kevin E Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 60347 Version 3.0</div></div></div>"},"60348":{"type":"graphic_picture","displayName":"Linear morphea - arm","title":"Linear morphea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Linear morphea</div><div class=\"cntnt\"><img style=\"width:76px; height:504px;\" src=\"images/DERM/60348_Linear_morphea_multip_sites.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sclerotic, hyperpigmented, linear plaques are present on the arm.</div><div id=\"graphicVersion\">Graphic 60348 Version 1.0</div></div></div>"},"60350":{"type":"graphic_figure","displayName":"Nasal vs intramuscular calcitonin bone pain","title":"Nasal versus intramuscular calcitonin for bone pain","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Nasal versus intramuscular calcitonin for bone pain</div><div class=\"cntnt\"><img style=\"width:459px; height:257px;\" src=\"images/ENDO/60350_Nasal_CT_better_for_bone_pa.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of salmon calcitonin on spontaneous bone pain in patients with recent osteoporotic fractures treated with either intranasal (100 international units) or intramuscular (100 international units) calcitonin. The intranasal calcitonin led to more effective pain relief.</div><div class=\"graphic_footnotes\">sCT: salmon calcitonin.</div><div class=\"graphic_reference\">Data from: Gennari C, Agnusdei D, Camporeale A. Use of calcitonin in the treatment of bone pain associated with osteoporosis. Calcif Tissue Int 1991; 49 Suppl 2:S9.</div><div id=\"graphicVersion\">Graphic 60350 Version 4.0</div></div></div>"},"60351":{"type":"graphic_picture","displayName":"Paraneoplastic brainstem encephalitis","title":"Paraneoplastic brainstem encephalitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paraneoplastic brainstem encephalitis</div><div class=\"cntnt\"><img style=\"width:377px; height:252px;\" src=\"images/ONC/60351_Brainstem_encephalitis_Ligh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light micrograph from a section of brainstem from a patient with colon cancer and paraneoplastic brainstem encephalitis associated with anti-Ma2 antibodies. There is a perivascular lymphocytic infiltrate on the right side (large arrow), while the middle shows several reactive astrocytes (gliosis) and a neuron undergoing degeneration (small arrow). Parenchymal infiltrates of mononuclears cells are more apparent on the left side of the picture.</div><div class=\"graphic_reference\">Courtesy of Josep Dalmau, MD, PhD.</div><div id=\"graphicVersion\">Graphic 60351 Version 2.0</div></div></div>"},"60352":{"type":"graphic_diagnosticimage","displayName":"Clear cell carcinoma CT","title":"Computed tomographic (CT) image of large clear cell carcinoma of the kidney","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomographic (CT) image of large clear cell carcinoma of the kidney</div><div class=\"cntnt\"><img style=\"width:432px; height:291px;\" src=\"images/ONC/60352_Clear_cell_carcinoma_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial contrast-enhanced CT image shows a large enhancing mass in the left kidney with central necrosis (asterisk). A patent left renal vein (arrow) is noted medially. A low grade (Furhman nuclear grade 2) clear-cell renal cell carcinoma was identified pathologically after nephrectomy.</div><div class=\"graphic_reference\">Courtesy of Ivan Pedrosa, MD.</div><div id=\"graphicVersion\">Graphic 60352 Version 3.0</div></div></div>"},"60354":{"type":"graphic_table","displayName":"Continuous birth control PI","title":"Hormonal birth control pills that are packaged for continuous dosing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hormonal birth control pills that are packaged for continuous dosing</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Brand name </td> <td class=\"subtitle1\">Number of pills in pack </td> </tr> <tr> <td>Seasonale*</td> <td>120</td> </tr> <tr> <td>Quasense*</td> <td>120</td> </tr> <tr> <td>Jolessa*</td> <td>120</td> </tr> <tr> <td>Seasonique<sup>&#182;</sup></td> <td>120</td> </tr> <tr> <td>Lybrel<sup>&#916;</sup></td> <td>365</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Taking continuous hormonal birth control means that you will have less frequent menstrual periods. However, many women have irregular spotting or bleeding when starting this regimen. This spotting and bleeding may be inconvenient but does not mean that you are more likely to get pregnant (unless you miss a dose of pills).</div><div class=\"graphic_footnotes\">* These pills are designed so that you will have a menstrual period once every 3 months. The pack includes 83 pills that contain two hormones (estrogen and progestin) and 7 pills that are placebo (sugar) pills. During the placebo pill week, you will have menstrual bleeding.<br />¶ Seasonique includes 83 pills that contain two hormones (estrogen and progestin) and 7 pills that contain one hormone (estrogen). This regimen may be helpful for women who develop headaches related to a low estrogen level during the last week of pills.<br />Δ Lybrel includes 365 pills, so you will not have menstrual bleeding for a full year.</div><div id=\"graphicVersion\">Graphic 60354 Version 2.0</div></div></div>"},"60355":{"type":"graphic_diagnosticimage","displayName":"Angulated metacarpal neck fractures","title":"Angulated metacarpal neck fractures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angulated metacarpal neck fractures</div><div class=\"cntnt\"><img style=\"width:324px; height:347px;\" src=\"images/SM/60355_Metacarpal_neck_fx_angulate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A significantly angulated fifth metacarpal and slightly angulated fourth metacarpal neck fracture are seen on the anteroposterior (AP) plain radiograph above. The measurement of&nbsp;fracture angulation is performed&nbsp;using the lateral view.</div><div id=\"graphicVersion\">Graphic 60355 Version 4.0</div></div></div>"},"60356":{"type":"graphic_figure","displayName":"Mood disorders brain PI","title":"Mood disorders caused by problems in the brain ","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Mood disorders caused by problems in the brain </div><div class=\"cntnt\"><img style=\"width:470px; height:556px;\" src=\"images/PI/60356_Mood_disorders_brain_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mood disorders, such as depression and bipolar disorder, are caused by chemical imbalances in the brain. Treatments for these conditions work by changing the chemistry of the brain.</div><div id=\"graphicVersion\">Graphic 60356 Version 3.0</div></div></div>"},"60361":{"type":"graphic_picture","displayName":"Didelphus uterus","title":"Didelphus uterus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Didelphus uterus</div><div class=\"cntnt\"><img style=\"width:432px; height:256px;\" src=\"images/OBGYN/60361_Didelphus_uterus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The two cervices are easily visualized in this hysterectomy specimen. Both tubes and ovaries are present, as well as an intraligamentous leiomyoma (right side of photograph).</div><div class=\"graphic_reference\">Reproduced with permission from: Robert MLellan, MD and Aron Schuftan, MD; Lahey Clinic Foundation. Copyright &#169; Robert McLellan, MD and Aron Schuftan, MD.</div><div id=\"graphicVersion\">Graphic 60361 Version 1.0</div></div></div>"},"60363":{"type":"graphic_form","displayName":"Hamilton Rating Scale - page 2","title":"Hamilton Rating Scale for Depression, page 2","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Hamilton Rating Scale for Depression, page 2</div><div class=\"cntnt\"><img style=\"width:593px; height:685px;\" src=\"images/PSYCH/60363_Hamilton_p2.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Hamilton, M. A rating scale for depression. J Neurosurg Psychiatry 1960; 23:56.</div><div id=\"graphicVersion\">Graphic 60363 Version 2.0</div></div></div>"},"60365":{"type":"graphic_table","displayName":"Classification of neuroendocrine neoplasms GI tract","title":"2010 ENETS/WHO nomenclature and classification for neuroendocrine neoplasms arising in the gastrointestinal (GI) tract","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2010 ENETS/WHO nomenclature and classification for neuroendocrine neoplasms arising in the gastrointestinal (GI) tract</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Differentiation</td> <td class=\"subtitle1\">Grade</td> <td class=\"subtitle1\">Mitotic count<sup>*</sup></td> <td class=\"subtitle1\">Ki-67 index<sup>&#182;</sup></td> <td class=\"subtitle1\">Traditional</td> <td class=\"subtitle1\">ENETS, WHO</td> </tr> <tr> <td rowspan=\"2\">Well differentiated</td> <td>Low grade (G1)</td> <td>&#60;2 per 10 HPF</td> <td>&#60;3%</td> <td>Carcinoid, islet cell, pancreatic (neuro)endocrine tumor</td> <td>Neuroendocrine tumor, G1</td> </tr> <tr> <td>Intermediate grade (G2)</td> <td>2 to 20 per 10 HPF</td> <td>3 to 20%</td> <td>Carcinoid, atypical carcinoid<sup>&#916;</sup>, islet cell, pancreatic (neuro)endocrine tumor</td> <td>Neuroendocrine tumor, G2</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Poorly differentiated</td> <td rowspan=\"2\">High grade (G3)</td> <td rowspan=\"2\">&#62;20 per 10 HPF</td> <td rowspan=\"2\">&#62;20%</td> <td>Small cell carcinoma</td> <td>Neuroendocrine carcinoma, G3, small cell</td> </tr> <tr> <td>Large cell neuroendocrine carcinoma</td> <td>Neuroendocrine carcinoma, G3, large cell</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ENETS: European Neuroendocrine Tumor Society; WHO: World Health Organization; HPF: high-power fields.<br />* Counted in 10 HPF. 10 HPF = 2 mm<SUP>2</SUP>, at least 40 fields (at 400x magnification) evaluated in areas of highest mitotic density. Cut-offs per American Joint Commission on Cancer Staging Manual, 8th edition.<br />¶&nbsp;Ki-67 index as assessed by MIB1 antibody staining: percent positive after count of 2000 cells in area of highest nuclear labeling. Cut-offs per American Joint Commission on Cancer Staging Manual, 8th edition.<br />Δ The term \"atypical carcinoid\" only applies to intermediate-grade neuroendocrine tumors of the lung.</div><div id=\"graphicVersion\">Graphic 60365 Version 13.0</div></div></div>"},"60366":{"type":"graphic_figure","displayName":"Ketone response to treatment DKA","title":"Ketone response to treatment of diabetic ketoacidosis","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Ketone response to treatment of diabetic ketoacidosis</div><div class=\"cntnt\"><img style=\"width:570px; height:438px;\" src=\"images/ENDO/60366_Ketone_response_to_tx.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparative data in 37 patients with diabetic ketoacidosis with regard to plasma acetoacetic acid (AA) and β-hydroxybutyric acid (βOH) (top left); ratio of AA to βOH (bottom left); and ketone bodies (nitroprusside reaction) in the urine (top right) and plasma (bottom right) before and during low-dose intravenous infusion of insulin for 48 hours.</div><div class=\"graphic_reference\">Reproduced with permission from: Kitabchi AE, Fisher JN, Murphy MB, et al. Diabetic ketoacidosis and the hyperglycemic hyperosmolar nonketotic state. In: Joslin's Diabetes Mellitus, 13th edition, Kahn CR, Weir GC (Eds), Lea and Febiger, Philadelphia 1994. Copyright © 1994 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 60366 Version 10.0</div></div></div>"},"60367":{"type":"graphic_figure","displayName":"N telopeptide crosslinks","title":"N-telopeptide crosslinks and bone collagen","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">N-telopeptide crosslinks and bone collagen</div><div class=\"cntnt\"><img style=\"width:542px; height:333px;\" src=\"images/ENDO/60367_N_telopeptide_crosslinks.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pyridinoline crosslinks occur in many types of collagen outside of bone. One type of pyridinoline crosslink that is more common in bone collagen is the pyridinoline crosslink in the N-telopeptide region (NTX). These crosslinks joins alpha-1 molecules to alpha-2 molecules (lower right) in bone collagen; in other tissues, these crosslinks join alpha-1 to alpha-1 molecules (upper left).</div><div id=\"graphicVersion\">Graphic 60367 Version 1.0</div></div></div>"},"60368":{"type":"graphic_picture","displayName":"Acute liver TPL rejection II","title":"Acute hepatic allograft rejection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute hepatic allograft rejection</div><div class=\"cntnt\"><img style=\"width:448px; height:288px;\" src=\"images/GAST/60368_Acute_liver_TPL_rejection1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of a liver transplant biopsy shows dense lymphocytic infiltrate (cellular rejection) and endotheliitis.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 60368 Version 1.0</div></div></div>"},"60369":{"type":"graphic_waveform","displayName":"EPS tracing AVNRT dual AVN pathways I","title":"Electrophysiologic study (EPS) in a patient with atrioventricular nodal reentrant tachycardia and dual AV nodal pathways","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Electrophysiologic study (EPS) in a patient with atrioventricular nodal reentrant tachycardia and dual AV nodal pathways</div><div class=\"cntnt\"><img style=\"width:577px; height:448px;\" src=\"images/CARD/60369_AVNRT_dual_AVN_pathways_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tracing shows three surface ECG leads (I, II, V1) and intracardiac recordings from the high right atrium (HRA), bundle of His (HIS), right ventricular apex (RVA), and coronary sinus (CS). During atrial pacing (S1) at a cycle length of 600 ms (100 beats per minute); the AH interval is 120 ms. An atrial premature beat (S2) is added at a coupling cyle of 420 ms; this results in a prolongation of the PR interval and increase in the AH interval to 184 ms.</div><div class=\"graphic_reference\">Courtesy of Martin Burke, DO.</div><div id=\"graphicVersion\">Graphic 60369 Version 3.0</div></div></div>"},"60370":{"type":"graphic_table","displayName":"Suppurative parotitis rx","title":"Usual causative organisms and initial empiric antimicrobial regimens for suppurative parotitis in adults*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Usual causative organisms and initial empiric antimicrobial regimens for suppurative parotitis in adults*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Usual causative organisms</td> <td class=\"subtitle1\" colspan=\"2\">Initial antimicrobial regimens</td> </tr> <tr> <td class=\"subtitle2\">Immunocompetent host</td> <td class=\"subtitle2\">Immunocompromised host</td> </tr> <tr> <td rowspan=\"10\">Staphylococcus aureus, viridans and other streptococci, Bacteroides spp, Peptostreptococcus spp, and other oral anaerobes<sup>&#916;</sup></td> <td class=\"centered\"> <p>Nafcillin 1.5 g IV Q 4 h<sup>&#9674;&#167;</sup></p> <p><strong>or</strong></p> <p>Vancomycin 15-20 mg/kg IV Q 8-12 h<sup>&#165;</sup></p> <p><strong>or</strong></p> Linezolid 600 mg orally or IV Q 12 h</td> <td rowspan=\"3\">Vancomycin 15-20 mg/kg IV Q 8-12 h<sup>&#165;</sup> or linezolid 600 mg orally or IV Q 12 h <strong>PLUS</strong> one of the following regimens: <ul> <li>Cefepime 2 g IV Q 12 h <strong>PLUS</strong> metronidazole 500 mg IV Q 6-8 h <strong>or</strong> </li> <li>Imipenem 500 mg IV Q 6 h <strong>or</strong> </li> <li>Meropenem 1 g IV Q 8 h<strong> or</strong> </li> <li>Piperacillin-tazobactam 4.5 g IV Q 6 h </li> </ul> </td> </tr> <tr> <td class=\"centered\"><strong>PLUS</strong></td> </tr> <tr> <td class=\"centered\"> <p>Either metronidazole 500 mg IV Q 6-8 h</p> <p><strong>or</strong></p> Clindamycin 600 mg IV Q 6-8 h</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Oral step-down regimens</td> </tr> <tr> <td class=\"subtitle2\">Immunocompetent host</td> <td class=\"subtitle2\">Compromised host</td> </tr> <tr> <td class=\"centered\">Clindamycin 450 mg orally Q 8 h <strong>plus</strong> ciprofloxacin 500 or 750 mg orally Q 12 h<sup>&#135;</sup></td> <td class=\"centered\">Clindamycin 450 mg orally Q 8 h <strong>plus</strong> ciprofloxacin 750 mg orally Q 12 h</td> </tr> <tr> <td class=\"centered\"><strong>OR</strong></td> <td class=\"centered\"><strong>OR</strong></td> </tr> <tr> <td class=\"centered\">Amoxicillin-clavulanate 875 mg orally Q 12 h +/&ndash; linezolid 600 mg orally Q 12 h<sup>&#167;&#134;</sup></td> <td class=\"centered\" rowspan=\"3\">Linezolid 600 mg orally Q 12 h <strong>plus</strong> moxifloxacin** 400 mg orally Q 24 h</td> </tr> <tr> <td class=\"centered\"><strong>OR</strong></td> </tr> <tr> <td class=\"centered\">Linezolid 600 mg orally Q 12 h <strong>plus</strong> moxifloxacin 400 mg orally Q 24 h</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The doses recommended in this table are intended for patients with normal renal and hepatic function.<BR>Δ Immunocompromised hosts are at increased risk for facultative gram-negative bacilli, including extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae and Pseudomonas aeruginosa.<BR><FONT class=lozenge>◊</FONT> In patients with risk factors for methicillin-resistant Staphylococcus aureus (MRSA) infection, vancomycin 15 to 20 mg/kg IV Q 8-12 h or linezolid 600 mg orally or IV Q 8-12 h should be substituted for nafcillin.<BR>§ Risk factors for MRSA infection include a history of intravenous drug use, comorbid disease (eg, diabetes mellitus), or residing in a community or hospital where there is a substantial incidence of MRSA.<BR>¥ Not to exceed 2 g per dose.<BR>‡ The higher dose of ciprofloxacin should be used when Pseudomonas aeruginosa is suspected.<BR>† Linezolid should be included if MRSA is suspected.<BR>** Moxifloxacin lacks adequate activity against P. aeruginosa, so it should not be used when this organism is suspected or proven to be the etiologic agent.</div><div id=\"graphicVersion\">Graphic 60370 Version 12.0</div></div></div>"},"60373":{"type":"graphic_figure","displayName":"Pathway frailty","title":"Hypothesized model of frailty and adverse health outcomes","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Hypothesized model of frailty and adverse health outcomes</div><div class=\"cntnt\"><img style=\"width:597px; height:310px;\" src=\"images/PC/60373_Pathway_frailty.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CRP: C-reactive protein; IL: interleukin; IGF: insulin-like growth factor; DHEA-S: dehydroepiandrosterone sulfate.</div><div class=\"graphic_reference\">Reproduced with permission from: Walston J, Hadley EC, Ferrucci L, et al. Research Agenda for Frailty in Older Adults: Towards a Better Understanding of Physiology and Etiology. J Am Geriatr Soc 2006; 54:991. Copyright &copy; 2006 Wiley-Blackwell.</div><div id=\"graphicVersion\">Graphic 60373 Version 3.0</div></div></div>"},"60375":{"type":"graphic_picture","displayName":"Necrobiotic nodule Low","title":"Pulmonary parenchymal involvement in Crohn's disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary parenchymal involvement in Crohn's disease</div><div class=\"cntnt\"><img style=\"width:348px; height:229px;\" src=\"images/PULM/60375_Necrobiotic_nodule_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power photomicrograph demonstrating a necrobiotic nodule adjacent to normal lung tissue in a patient with Crohn's disease.</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 60375 Version 1.0</div></div></div>"},"60377":{"type":"graphic_table","displayName":"DSM-IV-TR criteria for agoraphobia","title":"DSM-IV-TR criteria for agoraphobia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-IV-TR criteria for agoraphobia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Anxiety about being in places or situations from which escape might be difficult (or embarrassing) or in which help may not be available in the event of having an unexpected or situationally predisposed panic attack or panic-like symptoms. Agoraphobic fears typically involve characteristic clusters of situations that include being outside the home alone; being in a crowd or standing in a line; being on a bridge; and traveling in a bus, train, or automobile.</td> </tr> <tr> <td>The situations are avoided (eg, travel is restricted) or else are endured with marked distress or with anxiety about having a panic attack or panic-like symptoms, or require the presence of a companion.</td> </tr> <tr> <td>The anxiety or phobic avoidance is not better accounted for by another mental disorder such as social phobia (eg, avoidance limited to social situations because of fear of embarrassment), specific phobia (eg, avoidance limited to a single situation like elevators), obsessive-compulsive disorder (eg, avoidance of dirt in someone with an obsession about contamination), posttraumatic stress disorder (eg, avoidance of stimuli associated with a severe stressor), or separation anxiety disorder (eg, avoidance of leaving home or relatives).</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">22.0000000000000</mso:Specialty>\r\n<mso:Publishable_Version msdt:dt=\"string\">0</mso:Publishable_Version>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=85613&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>DSM-IV-TR_criteria_for_agoraphobia.htm</title></head></div><div class=\"graphic_reference\">Reprinted with permission from: the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, (Copyright 2000). American Psychiatric Association.</div><div id=\"graphicVersion\">Graphic 60377 Version 7.0</div></div></div>"},"60378":{"type":"graphic_table","displayName":"Seven-point checklist","title":"The seven-point checklist of dermoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The seven-point checklist of dermoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Criteria</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Score*</td> </tr> <tr> <td rowspan=\"3\"><strong>Major criteria</strong></td> <td>Atypical pigment network</td> <td>Prominent (hyperpigmented or thick) and irregular network.</td> <td>2</td> </tr> <tr> <td>White-blue areas</td> <td>Irregular, structureless white-blue area with an overlying \"ground-glass\" film. It cannot occupy the entire lesion.</td> <td>2</td> </tr> <tr> <td>Atypical vascular pattern</td> <td>Linear irregular or dotted vessels, irregularly distributed outside areas of regression.</td> <td>2</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\"><strong>Minor criteria</strong></td> <td>Radial streaming (streaks)</td> <td>Radial and asymmetric linear or bulbous projections at the edge of the lesion.</td> <td>1</td> </tr> <tr> <td>Irregular blotches</td> <td>Black, brown and/or gray structureless areas with irregular shape or distribution.</td> <td>1</td> </tr> <tr> <td>Irregular dots and globules</td> <td>Black or brown round structures irregularly distributed.</td> <td>1</td> </tr> <tr> <td>Regression structures</td> <td>White scar-like depigmentation and/or \"peppering\".</td> <td>1</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For the diagnosis of melanoma, a total score of 3 or more is required.</div><div class=\"graphic_footnotes\">* In the Revised 7-point checklist (Argenziano G, et al. Br J Dermatol 2011; 164:785), all scores have a value of 1 and the threshold for excision is 1 instead of 3.</div><div class=\"graphic_reference\">Original table modified for this publication. Argenziano G, Soyer HP, Chimenti S, et al. Dermoscopy of pigmented skin lesions: Results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 60378 Version 3.0</div></div></div>"},"60379":{"type":"graphic_algorithm","displayName":"Middle ear causes otalgia in children","title":"Middle ear causes of ear pain in children","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Middle ear causes of ear pain in children</div><div class=\"cntnt\"><img style=\"width:391px; height:384px;\" src=\"images/EM/60379_Middle_ear_causes_otalgia.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Referred ear pain from parotitis, TMJ dysfunction syndrome, stomatitis, pharyngitis, dental abscess, or maxillary sinusitis (see text).</div><div id=\"graphicVersion\">Graphic 60379 Version 3.0</div></div></div>"},"60382":{"type":"graphic_movie","displayName":"Normal leukocyte movement: No inflammatory stimulus","title":"Normal leukocyte movement: No inflammatory stimulus","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal leukocyte movement: No inflammatory stimulus</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/60382_nlconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:304px; height:233px;\" src=\"images/CARD/60382_nl.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Amos Etzioni, MD.</div><div id=\"graphicVersion\">Graphic 60382 Version 6.0</div></div></div>"},"60383":{"type":"graphic_table","displayName":"Spinal cord injury grading scale","title":"American Spinal Injury Association (ASIA) impairment scale (AIS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Spinal Injury Association (ASIA) impairment scale (AIS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">American Spinal Injury Association Scale (ASIA)</td> </tr> <tr> <td class=\"centered\">A</td> <td>Complete cord injury. No motor or sensory function is preserved in the sacral segments S4-5.</td> </tr> <tr> <td class=\"centered\">B</td> <td>Sensory incomplete.&nbsp;Sensory but not motor function is preserved below the neurologic level and includes the sacral segmments (light touch or pin prick at S4-5 or deep anal pressure) AND no motor function is preserved more than three levels below the motor level on either side of the body.</td> </tr> <tr> <td class=\"centered\">C</td> <td>Motor incomplete. Motor function is preserved below the neurologic level and more than half of key muscle functions&nbsp;below the neurologic level of injury have a muscle grade&nbsp;&#60;3 (Grades 0 to 2).</td> </tr> <tr> <td class=\"centered\">D</td> <td>Motor incomplete. Motor function is preserved below the neurologic level and at least half (half or more) of key muscle functions below the neurologic level of injury have a muscle grade &#8805;3.</td> </tr> <tr> <td class=\"centered\">E</td> <td>Normal. Sensation and motor function are graded as normal&nbsp;in all segments and the patient had prior deficits.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Muscle function is graded using the International Standards for Neurologic Classification of Spinal Cord Injury.<br />For an individual to receive a grade of C or D (ie, motor incomplete status),&nbsp;he or she&nbsp;must have either (1) voluntary anal sphincter contraction or (2) sacral sensory sparing with sparing of motor function more than three levels below the motor level for that side of the body. <br />Patients without an initial spinal cord injury do not receive an AIS grade.</div><div class=\"graphic_reference\">American Spinal Injury Association: International Standards for Neurological Classification of Spinal Cord Injury, revised 2013; Atlanta, GA. Reprinted 2013. Used with permission. Copyright © 2013 American Spinal Injury Association. American Spinal Injury Association (ASIA) impairment scale (AIS) remained unchanged in the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) (Updated 2015). To download a PDF version of the ISNCSCI worksheet: <A spellcheck=true href=\"http://asia-spinalinjury.org/wp-content/uploads/2016/02/International_Stds_Diagram_Worksheet.pdf\" target=_blank>http://asia-spinalinjury.org/wp-content/uploads/2016/02/International_Stds_Diagram_Worksheet.pdf</A>.</div><div id=\"graphicVersion\">Graphic 60383 Version 8.0</div></div></div>"},"60384":{"type":"graphic_waveform","displayName":"Doppler derived AV gradient","title":"Continuous wave Doppler in aortic stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Continuous wave Doppler in aortic stenosis</div><div class=\"cntnt\"><img style=\"width:331px; height:266px;\" src=\"images/CARD/60384_Doppler_derived_AV_gradient.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The peak velocity, recorded by continuous wave Doppler obtained from the right upper sternal border, is 4.3 m/sec. By the Bernoulli equation, this represents a peak pressure across the valve of 74 mmHg.</div><div id=\"graphicVersion\">Graphic 60384 Version 4.0</div></div></div>"},"60387":{"type":"graphic_figure","displayName":"Megakaryocyte mass platelet production","title":"Megakaryocyte mass and effective platelet production in megakaryocyte disorders","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Megakaryocyte mass and effective platelet production in megakaryocyte disorders</div><div class=\"cntnt\"><img style=\"width:506px; height:277px;\" src=\"images/HEME/60387_Megak_mass_platelet_product.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow analysis was performed in normal subjects and patients with a variety of hematological conditions: hypoplastic bone marrow states (Hypo), B12 deficiency (B12 def), congestive splenomegaly (Congest), immune thrombocytopenia (ITP), chronic inflammation (Inflam), and essential thrombocythemia (ET). Left panel: The megakaryocyte mass was markedly reduced in hypoplastic bone marrow states but variably increased in all other conditions. Right panel: Effective platelet production, as determined by platelet kinetic study, was significantly reduced only in hypoplastic bone marrow states and B12 deficiency and variably increased in all other conditions.</div><div class=\"graphic_reference\">Data from: Harker LA, Finch CA. J Clin Invest 1969; 48:963.</div><div id=\"graphicVersion\">Graphic 60387 Version 3.0</div></div></div>"},"60388":{"type":"graphic_table","displayName":"Risk of cardiac catheterization and coronary angiography","title":"Risk of cardiac catheterization and coronary angiography (based on 59,792 patients)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk of cardiac catheterization and coronary angiography (based on 59,792 patients)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Percent</td> </tr> <tr> <td>Mortality</td> <td>0.11</td> </tr> <tr> <td>Myocardial infarction</td> <td>0.05</td> </tr> <tr> <td>Cerebrovascular accident</td> <td>0.07</td> </tr> <tr> <td>Arrhythmia</td> <td>0.38</td> </tr> <tr> <td>Vascular complications</td> <td>0.43</td> </tr> <tr> <td>Contrast reaction</td> <td>0.37</td> </tr> <tr> <td>Hemodynamic complications</td> <td>0.26</td> </tr> <tr> <td class=\"sublist1_start\">Perforation of heart chamber</td> <td class=\"sublist_other_start\">0.28</td> </tr> <tr> <td class=\"sublist1\">Other complications</td> <td class=\"sublist_other\">0.28</td> </tr> <tr> <td>Total of major complications</td> <td>1.70</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Noto, TJ Jr, Johnson, LW, Krone, R, et al. Cardiac catheterization 1990: A report of the Registry of the Society for Cardiac Angiography and Interventions (SCA&amp;I). Cathet Cardiovasc Diagn 1991; 24:75. Copyright &#169; Wiley-Liss, Inc.</div><div id=\"graphicVersion\">Graphic 60388 Version 2.0</div></div></div>"},"60390":{"type":"graphic_picture","displayName":"Perioral dermatitis papules","title":"Perioral dermatitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Perioral dermatitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/60390_Perioral_dermatitis_papules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small erythematous papules are present around the mouth.</div><div id=\"graphicVersion\">Graphic 60390 Version 1.0</div></div></div>"},"60391":{"type":"graphic_figure","displayName":"Exercise in T1DM","title":"Metabolic effects of exercise in type 1 diabetes","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Metabolic effects of exercise in type 1 diabetes</div><div class=\"cntnt\"><img style=\"width:497px; height:253px;\" src=\"images/ENDO/60391_Exercise_in_IDDM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparison of the effects of exercise in normal subjects and patients with type 1 diabetes who are in control or poorly controlled (ketotic). Exercise modestly lowered blood glucose concentrations and raised blood ketone concentrations in the normal subjects and in well-controlled diabetic patients. In the latter group, the fall in blood glucose is somewhat more prominent since exogenous insulin prevents plasma insulin concentrations from falling, thereby maintaining both muscle glucose utilization and inhibition of hepatic glucose output. In comparison, the lack of availability of insulin in poorly controlled diabetic patients prevents the fall in blood glucose and augments the increase in ketogenesis. To convert blood glucose values to mmol/L, multiply by 0.056.</div><div class=\"graphic_reference\">Data from: Berger M, Berchtold P, Cuppers HJ, et al. Metabolic and hormonal effects of muscular exercise in juvenile type diabetics. Diabetologia 1977; 13:355.</div><div id=\"graphicVersion\">Graphic 60391 Version 3.0</div></div></div>"},"60393":{"type":"graphic_table","displayName":"Eligibility med abortion","title":"Eligibility criteria for medical termination of pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Eligibility criteria for medical termination of pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody><tr>\n<td>Pregnancy up to 49 days of gestation</td>\n</tr><tr>\n<td>Agreement to undergo surgical abortion if the procedure fails</td>\n</tr><tr>\n<td>Absence of a contraindication to surgical abortion</td>\n</tr><tr>\n<td>Agreement to complete therapy and all clinic visits</td>\n</tr><tr>\n<td>A means of reaching an emergency facility within one hour if\nproblems occur</td>\n</tr><tr>\n<td>Legally competent to sign a consent form for obtaining an\nabortion</td>\n</tr></tbody>\n</table></div><div class=\"graphic_reference\">Per manufacturer Danco Laboratories.</div><div id=\"graphicVersion\">Graphic 60393 Version 1.0</div></div></div>"},"60394":{"type":"graphic_figure","displayName":"Plaque rupture MI PI","title":"Heart attack","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Heart attack</div><div class=\"cntnt\"><img style=\"width:538px; height:426px;\" src=\"images/PI/60394_Plaque_rupture_MI_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plaques inside the coronary arteries sometimes break open or \"rupture.\" This is what causes most heart attacks. When a plaque breaks open, it causes a blood clot to form inside the artery. As the clot grows, it can completely block off the flow of blood through the artery. That means that the tissue on the other end of the clogged artery does not get the blood and oxygen it needs, so it gets damaged or dies.</div><div id=\"graphicVersion\">Graphic 60394 Version 6.0</div></div></div>"},"60395":{"type":"graphic_table","displayName":"Percent of median classification of malnutrition","title":"Methods for classification of the severity of malnutrition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Methods for classification of the severity of malnutrition</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"4\" width=\"10%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Method</td> <td class=\"subtitle1\"> <p>0</p> Normal</td> <td class=\"subtitle1\"> <p>1</p> Mild</td> <td class=\"subtitle1\"> <p>2</p> Moderate</td> <td class=\"subtitle1\"> <p>3</p> Severe</td> <td class=\"subtitle1\">Nutritional implications</td> </tr> <tr> <td>Weight-for-height, percent expected*<sup>[1,2]</sup></td> <td>&#8805;90</td> <td>&#60;90</td> <td>&#60;80</td> <td>&#60;70</td> <td>Wasting</td> </tr> <tr> <td>Height-for-age, percent expected*<sup>[1,2]</sup></td> <td>&#8805;95</td> <td>&#60;95</td> <td>&#60;90</td> <td>&#60;85</td> <td>Stunting</td> </tr> <tr> <td>MUAC/FOC<sup>&#182;</sup><sup>[3]</sup></td> <td>&#8805;0.31</td> <td>&#60;0.31</td> <td>&#60;0.28</td> <td>&#60;0.25</td> <td>Wasting</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><SPAN style=\"COLOR: black\">These methods are presented here for completeness, but they are no longer recommended for the assessment of the severity of malnutrition. Instead, the World Health Organization (WHO) recommends use of Z-scores for length/height and weight, and clinical assessment of edema&nbsp;(refer to topic text for details).</SPAN> </div><div class=\"graphic_footnotes\">WT: weight; HT: height; MUAC: mid-upper arm circumference; FOC: fronto-occipital-circumference.<br />* The percent of median method is also known as a modified Waterlow method.<br />¶ This is also known as the McLaren method; it is used to assess acute malnutrition in children younger than three years of age when accurate measures of height and weight cannot be obtained.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Waterlow JC. Classification and definition of protein-calorie malnutrition. Br Med J 1972; 3:566.</li>&#xD;&#xA;    <li>Waterlow JC. Note on the assessment and classification of protein-energy malnutrition in children. Lancet 1973; 2:87.</li>&#xD;&#xA;    <li>Kanawati AA, McLaren DS. Assessment of marginal malnutrition. Nature 1970; 228:573.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 60395 Version 12.0</div></div></div>"},"60398":{"type":"graphic_table","displayName":"Localized scleroderma","title":"Classification of localized scleroderma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of localized scleroderma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Circumscribed (plaque) morphea</td> </tr> <tr> <td>One or more circumscribed patches of skin with sclerotic changes in one anatomic site</td> </tr> <tr> <td>Involvement is confined to the superificial panniculus (subcutaneous tissue)</td> </tr> <tr> <td class=\"subtitle1_single\">Generalized morphea</td> </tr> <tr> <td>Four or more plaques that affect at least two anatomic sites</td> </tr> <tr> <td>Often located on the trunk or limbs</td> </tr> <tr> <td>Similar clinical and histologic features as circumscribed morphea</td> </tr> <tr> <td class=\"subtitle1_single\">Bullous morphea</td> </tr> <tr> <td>Bullous involvement</td> </tr> <tr> <td>May occur in other forms of morphea</td> </tr> <tr> <td class=\"subtitle1_single\">Linear morphea</td> </tr> <tr> <td>Most common form of morphea in children</td> </tr> <tr> <td>One or more elongated sclerotic areas of skin</td> </tr> <tr> <td>Lesions are typically asymmetric and oriented along the affected limb</td> </tr> <tr> <td>Associated with growth impairment of the involved extremity</td> </tr> <tr> <td>Lesions on the face or scalp are called en coup de sabre</td> </tr> <tr> <td class=\"subtitle1_single\">Deep morphea</td> </tr> <tr> <td>Least common form of morphea in children</td> </tr> <tr> <td>Most disabling form of morphea</td> </tr> <tr> <td>Primary site of involvement is the panniculus (subcutaneous tissue)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 60398 Version 4.0</div></div></div>"},"60399":{"type":"graphic_table","displayName":"Vaccine schedule age 0 to 6 years PI","title":"Standard recommended vaccine schedule for children age 0 to 6 years (United States, 2018)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Standard recommended vaccine schedule for children age 0 to 6 years (United States, 2018)</div><div class=\"cntnt\"><table cellspacing=\"0\"><span style=\"color: black;\"><colgroup span=\"3\" width=\"15%\"></colgroup><colgroup width=\"55%\"></colgroup></span> <tbody> <tr> <td class=\"subtitle1\"><span style=\"color: black;\">Age</span></td> <td class=\"subtitle1\"><span style=\"color: black;\">Vaccine</span></td> <td class=\"subtitle1\"><span style=\"color: black;\">Dose</span></td> <td class=\"subtitle1\"><span style=\"color: black;\">Notes</span></td> </tr> <tr class=\"divider_bottom\"> <td><span style=\"color: black;\">Birth</span></td> <td><span style=\"color: black;\">Hepatitis B (HepB)</span></td> <td><span style=\"color: black;\">1 of 3 <strong>or </strong>1 of 4</span></td> <td><span style=\"color: black;\">Depending on which type of HepB vaccine they get, some infants need 4 doses in all, while others need 3.</span></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><span style=\"color: black;\">2 months</span></td> <td><span style=\"color: black;\">Hepatitis B (HepB)</span></td> <td><span style=\"color: black;\">2 of 3 <strong>or </strong>2 of 4</span></td> <td><span style=\"color: black;\">This dose can be given from 1 to 2 months old.</span></td> </tr> <tr> <td><span style=\"color: black;\">Diphtheria, tetanus, pertussis (DTaP)</span></td> <td><span style=\"color: black;\">1 of 5</span></td> <td><span style=\"color: black;\">&nbsp;</span></td> </tr> <tr> <td><span style=\"color: black;\">H. influenzae type b (Hib)</span></td> <td><span style=\"color: black;\">1 of 3 <strong>or</strong> 1 of 4</span></td> <td><span style=\"color: black;\">&nbsp;</span></td> </tr> <tr> <td><span style=\"color: black;\">Polio (IPV)</span></td> <td><span style=\"color: black;\">1 of 4</span></td> <td><span style=\"color: black;\">&nbsp;</span></td> </tr> <tr> <td><span style=\"color: black;\">Pneumococcal (PCV)</span></td> <td><span style=\"color: black;\">1 of 4</span></td> <td><span style=\"color: black;\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td><span style=\"color: black;\">Rotavirus</span></td> <td><span style=\"color: black;\">1 of 2 or 3</span></td> <td><span style=\"color: black;\">&nbsp;</span></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><span style=\"color: black;\">4 months</span></td> <td><span style=\"color: black;\">Hepatitis B (HepB)</span></td> <td><span style=\"color: black;\">3&nbsp;of 4 (if using a combination vaccine)</span></td> <td><span style=\"color: black;\">&nbsp;</span></td> </tr> <tr> <td><span style=\"color: black;\">Diphtheria, tetanus, pertussis (DTaP)&nbsp;</span></td> <td><span style=\"color: black;\">2 of 5</span></td> <td><span style=\"color: black;\">&nbsp;</span></td> </tr> <tr> <td><span style=\"color: black;\">H. influenzae type b (Hib)</span></td> <td><span style=\"color: black;\">2 of 3 <strong>or</strong> 2 of 4</span></td> <td><span style=\"color: black;\">&nbsp;</span></td> </tr> <tr> <td><span style=\"color: black;\">Polio (IPV)</span></td> <td><span style=\"color: black;\">2 of 4</span></td> <td><span style=\"color: black;\">&nbsp;</span></td> </tr> <tr> <td><span style=\"color: black;\">Pneumococcal (PCV)</span></td> <td><span style=\"color: black;\">2 of 4</span></td> <td><span style=\"color: black;\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td><span style=\"color: black;\">Rotavirus</span></td> <td><span style=\"color: black;\">2 of 2 <strong>or</strong> 2 of 3</span></td> <td><span style=\"color: black;\">This dose is not needed with 1 type of vaccine.</span></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\"><span style=\"color: black;\">6 months</span></td> <td><span style=\"color: black;\">Hepatitis B (HepB)</span></td> <td><span style=\"color: black;\">3 of 3 <strong>or </strong>4 of 4</span></td> <td><span style=\"color: black;\">This can be given from 6 to 18 months old.</span></td> </tr> <tr> <td><span style=\"color: black;\">Diphtheria, tetanus, pertussis (DTaP)</span></td> <td><span style=\"color: black;\">3 of 5</span></td> <td><span style=\"color: black;\">&nbsp;</span></td> </tr> <tr> <td><span style=\"color: black;\">H. influenzae type b (Hib)</span></td> <td><span style=\"color: black;\">3 of 4 (if needed)</span></td> <td><span style=\"color: black;\">This dose is not needed with 1 type of vaccine.</span></td> </tr> <tr> <td><span style=\"color: black;\">Polio (IPV)</span></td> <td><span style=\"color: black;\">3 of 4</span></td> <td><span style=\"color: black;\">This can be given from 6 to 18 months old.</span></td> </tr> <tr> <td><span style=\"color: black;\">Pneumococcal (PCV)</span></td> <td><span style=\"color: black;\">3 of 4</span></td> <td><span style=\"color: black;\">&nbsp;</span></td> </tr> <tr> <td><span style=\"color: black;\">Influenza (flu)</span></td> <td><span style=\"color: black;\">Every year</span></td> <td><span style=\"color: black;\">Children get 1 dose each year up to age 18. Children younger than 9 who are getting the flu vaccine for the first time need 2 doses. These doses are given at least 4 weeks apart.</span></td> </tr> <tr class=\"divider_bottom\"> <td><span style=\"color: black;\">Rotavirus</span></td> <td><span style=\"color: black;\">3 of 3 (if needed)</span></td> <td><span style=\"color: black;\">&nbsp;</span></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><span style=\"color: black;\">12 months</span></td> <td><span style=\"color: black;\">H. influenzae type b (Hib)</span></td> <td> <p><span style=\"color: black;\">3 of 3 <strong>or</strong>&nbsp;4 of 4</span></p> </td> <td><span style=\"color: black;\">This can be given from 12 to 15 months old.</span></td> </tr> <tr> <td><span style=\"color: black;\">Pneumococcal (PCV)</span></td> <td><span style=\"color: black;\">4 of 4</span></td> <td><span style=\"color: black;\">This can be given from 12 to 15 months old.</span></td> </tr> <tr> <td><span style=\"color: black;\">Chickenpox (varicella)</span></td> <td><span style=\"color: black;\">1 of 2</span></td> <td><span style=\"color: black;\">This can be given from 12 to 15 months old.</span></td> </tr> <tr> <td><span style=\"color: black;\">Measles, mumps, rubella (MMR)</span></td> <td><span style=\"color: black;\">1 of 2</span></td> <td><span style=\"color: black;\">This can be given from 12 to 15 months old.</span></td> </tr> <tr class=\"divider_bottom\"> <td><span style=\"color: black;\">Hepatitis A (HepA)</span></td> <td><span style=\"color: black;\">1 of 2</span></td> <td><span style=\"color: black;\">This can be given from 12 to 24 months old.</span></td> </tr> <tr class=\"divider_bottom\"> <td><span style=\"color: black;\">15 months</span></td> <td><span style=\"color: black;\">Diphtheria, tetanus, pertussis (DTaP)</span></td> <td><span style=\"color: black;\">4 of 5</span></td> <td><span style=\"color: black;\">This can be given from 15 to 18 months old. It can also be given earlier starting at 12 months old, but it needs to be at least 6 months after the third dose.</span></td> </tr> <tr class=\"divider_bottom\"> <td><span style=\"color: black;\">18 months</span></td> <td><span style=\"color: black;\">Hepatitis A (HepA)</span></td> <td><span style=\"color: black;\">2 of 2</span></td> <td><span style=\"color: black;\">This needs to be at least 6 months after the first dose.</span></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><span style=\"color: black;\">2 years and older</span></td> <td><span style=\"color: black;\">Hepatitis A (HepA)</span></td> <td><span style=\"color: black;\">2 doses</span></td> <td><span style=\"color: black;\">This is given to some children who did <strong>not</strong> get the hepatitis A vaccine when younger.</span></td> </tr> <tr class=\"divider_bottom\"> <td><span style=\"color: black;\">Pneumococcal (PPSV)</span></td> <td><span style=\"color: black;\">1 dose</span></td> <td><span style=\"color: black;\">This is given to children who have certain medical conditions.</span></td> </tr> <tr> <td rowspan=\"4\"><span style=\"color: black;\">4 years</span></td> <td><span style=\"color: black;\">Diphtheria, tetanus, pertussis (DTaP)</span></td> <td><span style=\"color: black;\">5 of 5</span></td> <td><span style=\"color: black;\">This can be given from ages 4 to 6 years. But DTaP should not be given to children age 7 or older.</span></td> </tr> <tr> <td><span style=\"color: black;\">Polio (IPV)</span></td> <td><span style=\"color: black;\">4 of 4</span></td> <td><span style=\"color: black;\">This can be given from ages 4 to 6 years.</span></td> </tr> <tr> <td><span style=\"color: black;\">Measles, mumps, rubella (MMR)</span></td> <td><span style=\"color: black;\">2 of 2</span></td> <td><span style=\"color: black;\">This can be given from ages 4 to 6 years. It can also be given earlier, but it needs to be at least 4 weeks after the first dose.</span></td> </tr> <tr> <td><span style=\"color: black;\">Chickenpox (varicella)</span></td> <td><span style=\"color: black;\">2 of 2</span></td> <td><span style=\"color: black;\">This can be given from ages 4 to 6 years. It can also be given earlier, but it needs to be at least 3 months after the first dose.</span></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Note: Children who fall behind schedule should get all the vaccines and doses they need, even if they are older than the recommended age. Some children might need other vaccines, too. The exact schedule depends on where they live and travel, and whether they have certain medical problems.</div><div id=\"graphicVersion\">Graphic 60399 Version 13.0</div></div></div>"},"60401":{"type":"graphic_picture","displayName":"Measurement levator function","title":"Measurement of levator function of the upper lid with the patient in downgaze (left) and upgaze (right)","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Measurement of levator function of the upper lid with the patient in downgaze (left) and upgaze (right)</div><div class=\"cntnt\"><img style=\"width:540px; height:271px;\" src=\"images/NEURO/60401_Measurement_levator_functio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The brow should be better fixated to prevent frontalis action on the eyelid.</div><div id=\"graphicVersion\">Graphic 60401 Version 2.0</div></div></div>"},"60402":{"type":"graphic_diagnosticimage","displayName":"Annular pancreas","title":"Annular pancreas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Annular pancreas</div><div class=\"cntnt\"><img style=\"width:432px; height:357px;\" src=\"images/PEDS/60402_Annular_pancreas.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography (ERCP) shows a branch of the pancreatic duct surrounding the descending duodenum. A short ventral pancreas is found.</div><div class=\"graphic_reference\">Reproduced with permission from: ERCP in Paediatric Practice: Diagnosis and Treatment, Isis Medical Media LTD, Oxford University Press, UK 1997. Copyright ©1997 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 60402 Version 3.0</div></div></div>"},"60403":{"type":"graphic_figure","displayName":"Inguinal anatomy","title":"Inguinal anatomy","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Inguinal anatomy</div><div class=\"cntnt\"><img style=\"width:516px; height:474px;\" src=\"images/PEDS/60403_Inguinal_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inguinal anatomy is illustrated in the panels above, progressing from anterior (A) to posterior (D) views. The inguinal canal is formed by the aponeurosis of the external oblique muscle anteriorly (A) and the transversalis fascia and the transversus abdominus muscle posteriorly (B,C). The external inguinal ring is formed by the external oblique muscle (A). The internal inguinal ring is located in the transversalis fascia and composed of the transversus abdominus and internal oblique muscles (B,C). The femoral vessels exit the abdomen posterior to the inguinal canal (D).</div><div class=\"graphic_reference\">Adapted from O'Rahilly. Abdominal walls. In: Basic Human Anatomy, W.B. Saunders Company, Philadelphia 1983. p.232.</div><div id=\"graphicVersion\">Graphic 60403 Version 1.0</div></div></div>"},"60404":{"type":"graphic_table","displayName":"Causes of muscle injury (rhabdomyolysis)","title":"Causes of muscle injury (rhabdomyolysis)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of muscle injury (rhabdomyolysis)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Traumatic or compression</td> </tr> <tr> <td class=\"indent1\">Multiple trauma</td> </tr> <tr> <td class=\"indent1\">Crush injuries</td> </tr> <tr> <td class=\"indent1\">Vascular or orthopedic surgery</td> </tr> <tr> <td class=\"indent1\">Coma</td> </tr> <tr> <td class=\"indent1\">Immobilization</td> </tr> <tr> <td class=\"subtitle1_single\">Nontraumatic</td> </tr> <tr> <td class=\"subtitle2_single\">Exertional</td> </tr> <tr> <td class=\"subtitle3_single\">Normal muscle</td> </tr> <tr> <td class=\"indent2\">Extreme exertion</td> </tr> <tr> <td class=\"indent2\">Environmental heat illness</td> </tr> <tr> <td class=\"indent2\">Sickle cell trait</td> </tr> <tr> <td class=\"indent2\">Seizures</td> </tr> <tr> <td class=\"indent2\">Hyperkinetic states</td> </tr> <tr> <td class=\"subtitle3_single\">Abnormal muscle</td> </tr> <tr> <td class=\"indent2\">Metabolic myopathies</td> </tr> <tr> <td class=\"indent2\">Mitochondrial myopathies</td> </tr> <tr> <td class=\"indent2\">Malignant hyperthermia</td> </tr> <tr> <td class=\"indent2\">Neuroleptic malignant syndrome</td> </tr> <tr> <td class=\"subtitle2_single\">Nonexertional</td> </tr> <tr> <td class=\"indent1\">Alcoholism</td> </tr> <tr> <td class=\"indent1\">Drugs and toxins</td> </tr> <tr> <td class=\"indent1\">Infections (including HIV)</td> </tr> <tr> <td class=\"indent1\">Electrolyte abnormalities</td> </tr> <tr> <td class=\"indent1\">Endocrinopathies</td> </tr> <tr> <td class=\"indent1\">Inflammatory myopathies</td> </tr> <tr> <td class=\"indent1\">Miscellaneous</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 60404 Version 4.0</div></div></div>"},"60405":{"type":"graphic_figure","displayName":"Breastfeeding positions PI","title":"Different holds for breastfeeding","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Different holds for breastfeeding</div><div class=\"cntnt\"><img style=\"width:612px; height:662px;\" src=\"images/PI/60405_Breastfeeding_positions_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These drawings show different ways you can hold your baby for breastfeeding.</div><div id=\"graphicVersion\">Graphic 60405 Version 5.0</div></div></div>"},"60407":{"type":"graphic_picture","displayName":"Dermoscopy melanoma 2","title":"Dermoscopic image of thin melanoma","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of thin melanoma</div><div class=\"cntnt\"><img style=\"width:540px; height:302px;\" src=\"images/DERM/60407_Dermoscopy_melanoma_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superficial spreading melanoma 0.5 mm. Atypical globules (solid square) and atypical vessels, including serpentine vessels and dotted vessels (solid arrow).</div><div class=\"graphic_reference\">Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 60407 Version 2.0</div></div></div>"},"60408":{"type":"graphic_picture","displayName":"Arterial catheter with continuous flush","title":"Arterial catheter with continuous flush","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Arterial catheter with continuous flush</div><div class=\"cntnt\"><img style=\"width:504px; height:359px;\" src=\"images/EM/60408_ArtercathcontinflushPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The catheter is secured with suture and a sterile, transparent dressing and attached to a system that consists of flushed tubing, a stopcock, and a syringe on a pump set at a low rate that provides continuous flushing of the catheter.</div><div class=\"graphic_reference\">Reproduced with permission from: Torrey SB, Saladino RA. Arterial puncture and catheterization. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 60408 Version 6.0</div></div></div>"},"60409":{"type":"graphic_figure","displayName":"Log-roll technique","title":"Log-roll procedure","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Log-roll procedure</div><div class=\"cntnt\"><img style=\"width:528px; height:415px;\" src=\"images/EM/60409_Log-roll_technique.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 60409 Version 2.0</div></div></div>"},"60410":{"type":"graphic_diagnosticimage","displayName":"MRCP and ERC versus EUS","title":"Comparison of MRCP/ERCP and EUS for the detection of common bile duct stones","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Comparison of MRCP/ERCP and EUS for the detection of common bile duct stones</div><div class=\"cntnt\"><img style=\"width:497px; height:442px;\" src=\"images/GAST/60410_MRCP_and_ERC_versus_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small bile duct stone missed by magnetic resonance cholangiopancreatography (MRCP) and endoscopic retrograde cholangiopancreatography (ERCP), but shown by endoscopic ultrasound (EUS). This demonstrates the superior sensitivity of EUS for small bile duct stones. A) MRCP showing dilated bile duct with no apparent stone, incidental pancreas divisum. B) EUS in same patient showing very small bile duct stone (&lt;5 mm) (arrow). C) ERCP in same patient showing dilated common bile duct without apparent stone. D) Endoscopic view of extracted stone after biliary sphincterotomy (arrow).</div><div class=\"graphic_reference\">Courtesy of ML Freeman, MD.</div><div id=\"graphicVersion\">Graphic 60410 Version 3.0</div></div></div>"},"60413":{"type":"graphic_movie","displayName":"TR subcostal with color Doppler echo","title":"Tricuspid regurgitation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tricuspid regurgitation</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/60413_subctrreconv.mp4\" style=\"width:328px;height:248px\"></div><img style=\"width:258px; height:217px;\" src=\"images/CARD/60413_subctrre.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subcostal view from a 2-D echocardiogram with color flow Doppler shows retrograde flow into dilated hepatic veins as a result of severe tricuspid regurgitation.</div><div class=\"graphic_reference\">Provided by Thomas Binder, MD, et al. Interactive Echocardiography. A Clinical Atlas. Futura, 1997.</div><div id=\"graphicVersion\">Graphic 60413 Version 2.0</div></div></div>"},"60416":{"type":"graphic_figure","displayName":"Posterior cerebral artery territory","title":"Posterior cerebral artery distribution and signs and symptoms of occlusion","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Posterior cerebral artery distribution and signs and symptoms of occlusion</div><div class=\"cntnt\"><img style=\"width:571px; height:695px;\" src=\"images/NEURO/60416_Post_cerebral_artery_territ.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Kistler, JP, et al, Cerebrovascular Diseases, Harrison's Principles of Internal Medicine, 13th ed. McGraw-Hill, New York 1994. Copyright 1994 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 60416 Version 2.0</div></div></div>"},"60417":{"type":"graphic_picture","displayName":"Superficial burn PI","title":"Superficial burn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Superficial burn</div><div class=\"cntnt\"><img style=\"width:272px; height:319px;\" src=\"images/PI/60417_Superficial_burn_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superficial burns are red, and they turn white when you press them.</div><div class=\"graphic_reference\">Courtesy of Eric D Morgan and William F Miser, MD.</div><div id=\"graphicVersion\">Graphic 60417 Version 3.0</div></div></div>"},"60419":{"type":"graphic_diagnosticimage","displayName":"Nerve root lymphoma","title":"Lymphomatous nerve root involvement","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Lymphomatous nerve root involvement</div><div class=\"cntnt\"><img style=\"width:451px; height:405px;\" src=\"images/HEME/60419_Nerve_root_lymphoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This coronal T1-weighted MRI of the lumbar spine shows diffuse thickening of the nerve roots (arrows) suggestive of lymphomatous involvement.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 60419 Version 3.0</div></div></div>"},"60420":{"type":"graphic_figure","displayName":"Pelvic circulation","title":"Pelvic circulation","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Pelvic circulation</div><div class=\"cntnt\"><img style=\"width:542px; height:509px;\" src=\"images/SURG/60420_Pelvic-circulation.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Illustration modified with permission from: Uflacker R. Atlas Of Vascular Anatomy: An Angiographic Approach, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60420 Version 1.0</div></div></div>"},"60421":{"type":"graphic_picture","displayName":"Digital subcutaneous abscess","title":"Digital subcutaneous abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Digital subcutaneous abscess</div><div class=\"cntnt\"><img style=\"width:439px; height:583px;\" src=\"images/SURG/60421_Digital_subcutan_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A subcutaneous abscess of the finger presents with localized swelling, erythema, and restricted motion at the adjacent joints. The digit is usually in a flexed posture, and there may be evidence of an inflamed puncture wound from a penetrating injury. In late presentations, the abscess may be pointing or discharging through a sinus.<br />(A) Palmar digital subcutaneous abscess.<br />(B) Dorsal digital subcutaneous abscess.<br />(C) Lateral digital subcutaneous abscess.</div><div id=\"graphicVersion\">Graphic 60421 Version 5.0</div></div></div>"},"60422":{"type":"graphic_picture","displayName":"Contact dermatitis neomycin","title":"Allergic contact dermatitis induced by neomycin ointment","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Allergic contact dermatitis induced by neomycin ointment</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/60422_Contact_dermatitis_neomycin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A red, rectangular, scaly, and excoriated 2 cm plaque with surrounding scattered red papules and intac wound with sutures in place. An 8-year-old girl developed an acute allergic contact dermatitis following the application of neomycin to prevent infection after excision of a congenital pigmented nevus.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 60422 Version 3.0</div></div></div>"},"60423":{"type":"graphic_figure","displayName":"Impedance-pH monitoring and laparoscopic Nissen fundoplication","title":"Impedance-pH monitoring before and after laparoscopic Nissen fundoplication","html":"<div class=\"graphic\"><div style=\"width: 646px\" class=\"figure\"><div class=\"ttl\">Impedance-pH monitoring before and after laparoscopic Nissen fundoplication</div><div class=\"cntnt\"><img style=\"width:626px; height:304px;\" src=\"images/GAST/60423_Imped_pH_mon_lap_Niss_fund.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Pre-OP: pre-operation; Post-OP: post-operation.</div><div class=\"graphic_reference\">Data from: del Genio G, Tolone S, del Genio F, et al. Total fundoplication controls acid and nonacid reflux: Evaluation by pre- and postoperative 24-h pH-multichannel intraluminal impedance. Surg Endosc 2008; 22:2518.</div><div id=\"graphicVersion\">Graphic 60423 Version 1.0</div></div></div>"},"60424":{"type":"graphic_table","displayName":"Critical physical findings of trauma","title":"Physical findings strongly associated with critical injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical findings strongly associated with critical injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\">Vital signs and level of consciousness</td> </tr> <tr> <td class=\"indent1\">GCS &#60;14</td> </tr> <tr> <td class=\"indent1\">Shock (compensated or uncompensated)*</td> </tr> <tr> <td class=\"indent1\">RR lower or higher than normal for age<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle1_left\">Anatomy of injury</td> </tr> <tr> <td class=\"indent1\">Airway trauma with respiratory distress, anterior neck tenderness, or deformity </td> </tr> <tr> <td class=\"indent1\">Chest trauma with persistent tachycardia, chest tenderness, or deformity with respiratory distress</td> </tr> <tr> <td class=\"indent1\">Abdominal tenderness or distension with persistent tachycardia</td> </tr> <tr> <td class=\"indent1\">Pelvic fracture</td> </tr> <tr> <td class=\"indent1\">Two or more proximal long-bone fractures</td> </tr> <tr> <td class=\"indent1\">Amputation proximal to wrist or ankle</td> </tr> <tr> <td class=\"indent1\">Crushed, mangled, or degloved extremity</td> </tr> <tr> <td class=\"indent1\">Open or depressed skull fracture</td> </tr> <tr> <td class=\"indent1\">Paralysis</td> </tr> <tr> <td class=\"indent1\">Penetrating trauma to head, neck, chest, abdomen, or proximal extremities</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GCS: Glasgow coma scale.<br />* Compensated shock presents with tachycardia and poor perfusion but normal blood pressure. Uncompensated shock manifests as tachycardia and signs of inadequate perfusion with hypotension for age (See text entitled \"Unique pediatric considerations\" for discussion of vital signs in children and shock).<br />¶ See Unique pediatric considerations, section on pediatric physiology.</div><div class=\"graphic_reference\">Reference: American College of Surgeons Committee on Trauma. Resources for optimal care of the injured patient 2006. American College of Surgeons, Chicago, IL, 2006, p. 22.</div><div id=\"graphicVersion\">Graphic 60424 Version 4.0</div></div></div>"},"60425":{"type":"graphic_picture","displayName":"Hawkins Kennedy test for shoulder impingement","title":"Hawkins Kennedy test for shoulder impingement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hawkins Kennedy test for shoulder impingement</div><div class=\"cntnt\"><img style=\"width:432px; height:320px;\" src=\"images/EM/60425_Hawkins_Kennedy_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Hawkins Kennedy test is used to assess shoulder impingement. In this test the clinician stabilizes the shoulder with one hand and, with the patient's elbow flexed at 90 degrees, internally rotates the shoulder using the other hand. Shoulder pain elicited by internal rotation represents a positive test.</div><div class=\"graphic_reference\">Courtesy of Stephen Simons, MD, J Bryan Dixon, MD, and David Kruse, MD.</div><div id=\"graphicVersion\">Graphic 60425 Version 4.0</div></div></div>"},"60426":{"type":"graphic_figure","displayName":"Eval metatarsus adductus","title":"Evaluation of metatarsus adductus","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Evaluation of metatarsus adductus</div><div class=\"cntnt\"><img style=\"width:484px; height:575px;\" src=\"images/PEDS/60426_Eval_metatarsus_adductus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flexibility is determined by whether adduction can be corrected with manipulation back to the normal position.</div><div id=\"graphicVersion\">Graphic 60426 Version 2.0</div></div></div>"},"60427":{"type":"graphic_diagnosticimage","displayName":"Hip effusion US","title":"Ultrasonography left hip effusion","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Ultrasonography left hip effusion</div><div class=\"cntnt\"><img style=\"width:609px; height:424px;\" src=\"images/PEDS/60427_Hip_effusion_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anechoic fluid collection at the lateral aspect of the left hip adjacent to the femoral neck is a joint effusion (Panel A). The effusion causes lateral bowing of the gluteus minimus muscle, which can sometimes be seen on plain film as displacement of the gluteal fat pad. Ultrasound of the right hip shows no such collection (Panel B).</div><div class=\"graphic_reference\">Courtesy of Michael Rosenthal, MD, PhD.</div><div id=\"graphicVersion\">Graphic 60427 Version 2.0</div></div></div>"},"60428":{"type":"graphic_table","displayName":"Safety resources CSHCN","title":"Resources for the promotion of safety of children with disabilities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Resources for the promotion of safety of children with disabilities</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Transportation safety</td> </tr> <tr> <td class=\"indent1\"> <p>The Indiana University School of Medicine Automotive Safety Program provides a state-by-state listing of child safety passenger technicians</p> <p><a href=\"http://www.preventinjury.org/Special-Needs-Transportation\" target=\"_blank\">www.preventinjury.org/Special-Needs-Transportation</a></p> </td> </tr> <tr> <td class=\"indent1\"> <p>The American Academy of Pediatrics (AAP) policy statement on school bus transportation of children with special needs</p> <p><a href=\"http://pediatrics.aappublications.org/content/108/2/516.full\" target=\"_blank\">pediatrics.aappublications.org/content/108/2/516.full</a></p> </td> </tr> <tr> <td class=\"indent1\"> <p>The National Highway Traffic Safety Administration provides information on child safety seats and federal motor vehicle safety standards and regulations</p> <p><a href=\"http://www.nhtsa.dot.gov/\" target=\"_blank\">www.nhtsa.dot.gov</a></p> </td> </tr> <tr> <td class=\"subtitle1_single\">Wheelchair transportation</td> </tr> <tr> <td class=\"indent1\"> <p>The University of Pittsburgh's School of Health and Rehabilitation Science, the Rehabilitation Engineering Research Center on Wheeled Mobility, and the National Institute on Disability and Rehabilitation Research provides information about wheelchair transportation</p> <p><a href=\"http://www.wheelchairnet.org/\" target=\"_blank\">www.wheelchairnet.org</a></p> </td> </tr> <tr> <td class=\"subtitle1_single\">Home safety</td> </tr> <tr> <td class=\"indent1\"> <p>Easter Seals provides information about home safety for individuals with disabilities</p> <p><a href=\"http://www.easterseals.com/site/PageServer?pagename=ntl_resource_room&#38;s_esLocation=res\" target=\"_blank\">www.easterseals.com/site/PageServer?pagename=ntl_resource_room&#38;s_esLocation=res</a></p> </td> </tr> <tr> <td class=\"subtitle1_single\">Fire safety</td> </tr> <tr> <td class=\"indent1\"> <p>Centers for Disease Control and Prevention</p> <p><a href=\"http://www.cdc.gov/HomeandRecreationalSafety/Fire-Prevention\" spellcheck=\"true\" target=\"_blank\">www.cdc.gov/HomeandRecreationalSafety/Fire-Prevention</a></p> </td> </tr> <tr> <td class=\"indent1\"> <p>The US Fire Administration provides information on fire safety for people with disabilities</p> <p><a href=\"http://www.usfa.fema.gov/prevention/outreach/disabilities.html\" spellcheck=\"true\" target=\"_blank\">www.usfa.fema.gov/prevention/outreach/disabilities.html</a></p> </td> </tr> <tr> <td class=\"subtitle1_single\">Respite</td> </tr> <tr> <td class=\"indent1\"> <p>The National Respite Network helps caregivers find respite services in their local area</p> <p><a href=\"http://archrespite.org/respitelocator\" target=\"_blank\">http://archrespite.org/respitelocator</a></p> </td> </tr> <tr> <td class=\"subtitle1_single\">Prevention of maltreatment</td> </tr> <tr> <td class=\"indent1\"> <p>The AAP provides a listing of state child abuse programs (which can provide additional evaluation and management or help with decisions about reporting)</p> <p><a href=\"http://www.aap.org/sections/childabuseneglect/MedicalDiagnostic.cfm\" target=\"_blank\">www.aap.org/sections/childabuseneglect/MedicalDiagnostic.cfm</a></p> </td> </tr> <tr> <td class=\"indent1\"> <p>The AAP clinical report on maltreatment of children with disabilities</p> <p><a href=\"http://pediatrics.aappublications.org/content/119/5/1018.full\" target=\"_blank\">pediatrics.aappublications.org/content/119/5/1018.full</a></p> </td> </tr> <tr> <td class=\"indent1\"> <p>The state of Florida Agency for Persons with Disabilities provides information on prevention of abuse, neglect, and exploitation of individuals with disabilities</p> <p><a href=\"http://apd.myflorida.com/zero-tolerance/\" target=\"_blank\">apd.myflorida.com/zero-tolerance/</a></p> </td> </tr> <tr> <td class=\"indent1\"> <p>The Disability &#38; Abuse Project provides a list of resources on abuse and disabilities </p> <p><a href=\"http://disability-abuse.com/resources/index.htm\" target=\"_blank\">http://disability-abuse.com/resources/index.htm</a></p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 60428 Version 9.0</div></div></div>"},"60431":{"type":"graphic_figure","displayName":"SAECG predicts atrial fibrillation post CABG","title":"Signal averaged electrocardiogram predicts atrial fibrillation after coronary artery bypass graft (CABG) surgery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Signal averaged electrocardiogram predicts atrial fibrillation after coronary artery bypass graft (CABG) surgery</div><div class=\"cntnt\"><img style=\"width:441px; height:259px;\" src=\"images/CARD/60431_SAECG_AF_post_CABG.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The incidence of atrial fibrillation (AF) after coronary artery bypass graft surgery is directly related to the duration of the P wave on a signal averaged ECG.</div><div class=\"graphic_reference\">Data from Zaman AG, Archbold RA, Helft G, et al. Circulation 2000; 101:1403.</div><div id=\"graphicVersion\">Graphic 60431 Version 4.0</div></div></div>"},"60432":{"type":"graphic_table","displayName":"Description of genital ulcer I","title":"Characteristics of sexually transmitted genital ulcers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of sexually transmitted genital ulcers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>&nbsp;</td> <td class=\"subtitle1\">Primary syphilis</td> <td class=\"subtitle1\">Genital herpes</td> <td class=\"subtitle1\">Chancroid</td> <td class=\"subtitle1\">Lymphogranuloma venereum</td> <td class=\"subtitle1\">Donovanosis</td> </tr> <tr> <td class=\"subtitle2_left\">Etiology</td> <td><em>Treponema pallidum</em> </td> <td>Herpes simplex</td> <td><em>Haemophilus ducreyi</em></td> <td><em>Chlamydia trachomatis</em></td> <td><em>Calymmatobacterium granulomatis</em></td> </tr> <tr> <td class=\"subtitle2_left\">Incubation period</td> <td>9&nbsp;to 90 days; average 2&nbsp;to 4 weeks</td> <td>2&nbsp;to 7 days</td> <td>Range 1&nbsp;to 35 days; average 3&nbsp;to 7 days</td> <td>3 days&nbsp;to 3 weeks; average 10 to 14 days</td> <td>Precise data unavailable; probably a few days to several months</td> </tr> <tr> <td class=\"subtitle2_left\">Number of lesions</td> <td>Usually single lesion, but multiple lesions may occur</td> <td>Multiple; may coalesce; more lesions appear in primary episodes than in recurrences</td> <td>Usually 1 to 3, but multiple lesions may occur</td> <td>Usually single</td> <td>Single or multiple</td> </tr> <tr> <td class=\"subtitle2_left\">Appearance of genital ulcers</td> <td>Sharply demarcated round or oval ulcer with slightly elevated edges; may be irregular or symmetrical (\"kissing chancre\").</td> <td>Small superficial grouped vesicles and/or erosions; lesions may coalesce, forming bullae or large areas of ulceration; lesions have irregular borders.</td> <td>Deep, sharply demarcated ulcer; irregular ragged undermined edge; ranges in diameter from a few ml to 2 cm.</td> <td>Papule, pustule, vesicle, or ulcer; discrete and transient; frequently overlooked.</td> <td>Sharply defined irregular ulcerations or hypertrophic, verrucous, necrotic, or cicatrical granulomas.</td> </tr> <tr> <td class=\"subtitle2_left\">Base</td> <td>Red, smooth and shiny, or crusted; serous exudate occurs when squeezed. </td> <td>Bright, red, and smooth.</td> <td>Rough, uneven, yellow to gray in color.</td> <td>Variable.</td> <td>Usually friable, rough, beefy granulations; can be necrotic, verrucous, or cicatrical.</td> </tr> <tr> <td class=\"subtitle2_left\">Induration</td> <td>Firm; does not change shape with pressure.</td> <td>None.</td> <td>Soft; changes shape with pressure.</td> <td>None.</td> <td>Firm granulation tissue.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Martin DH, Mroczkowski TF. Sexually transmitted diseases. In: The Skin and Infection: A Color Atlas and Text,&nbsp;Sanders CV,&nbsp;Nesbitt LT (Eds), Williams &amp; Wilkins, Baltimore&nbsp;1995. p.95.</div><div id=\"graphicVersion\">Graphic 60432 Version 3.0</div></div></div>"},"60436":{"type":"graphic_picture","displayName":"Local injection for lateral epicondylitis","title":"Local injection for lateral epicondylitis","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Local injection for lateral epicondylitis</div><div class=\"cntnt\"><img style=\"width:500px; height:318px;\" src=\"images/EM/60436_Local_anesthetic_lat_epicon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For short-term relief of severe symptoms, glucorticoid injection is a reasonable treatment option when used as part of a comprehensive management program including physical therapy.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 60436 Version 4.0</div></div></div>"},"60437":{"type":"graphic_table","displayName":"Bacterial pneumonia in HIV","title":"Causes of bacterial pneumonia in HIV-infected patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of bacterial pneumonia in HIV-infected patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><em>Streptococcus pneumoniae</em></td> </tr> <tr> <td class=\"sublist1_start\"><em>Haemophilus influenzae</em></td> </tr> <tr> <td class=\"sublist1\">Non-typeable</td> </tr> <tr> <td class=\"sublist1\">Type B</td> </tr> <tr> <td><em>Staphylococcus aureus</em></td> </tr> <tr> <td><em>Streptococcus</em>, Group B</td> </tr> <tr> <td><em>Streptococcus milleri</em></td> </tr> <tr> <td><em>Moraxella catarrhalis</em></td> </tr> <tr> <td><em>Klebsiella pneumoniae</em></td> </tr> <tr> <td><em>Pseudomonas aeruginosa</em></td> </tr> <tr> <td><em>Legionella </em>species</td> </tr> <tr> <td><em>Mycoplasma pneumoniae</em></td> </tr> <tr> <td><em>Rhodococcus equi</em></td> </tr> <tr> <td><em>Bordetella pertussis</em></td> </tr> <tr> <td><em>Nocardia asteroides</em></td> </tr> <tr> <td><em>Pasteurella multocida</em></td> </tr> <tr> <td><em>Chlamydophila pneumoniae</em></td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 60437 Version 3.0</div></div></div>"},"60438":{"type":"graphic_diagnosticimage","displayName":"Buckle fracture tibia","title":"Buckle fracture of the tibia","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Buckle fracture of the tibia</div><div class=\"cntnt\"><img style=\"width:494px; height:448px;\" src=\"images/EM/60438_Buckle_fx_tibia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distal tibial buckle fracture in a 14-month-old toddler with a limp.</div><div class=\"graphic_reference\">Courtesy of Eglal Shalaby-Rana, MD.</div><div id=\"graphicVersion\">Graphic 60438 Version 3.0</div></div></div>"},"60440":{"type":"graphic_table","displayName":"Causes of osteoporosis men","title":"Causes of osteoporosis in men","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of osteoporosis in men</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Endocrine diseases</td> </tr> <tr> <td class=\"sublist1_start\">Hypogonadism</td> </tr> <tr> <td class=\"sublist1\">Primary</td> </tr> <tr> <td class=\"sublist1\">Secondary</td> </tr> <tr> <td>Delayed puberty</td> </tr> <tr> <td>Estrogen deficiency</td> </tr> <tr> <td>Hypercortisolism</td> </tr> <tr> <td>Hyperthyroidism</td> </tr> <tr> <td>Hyperparathyroidism</td> </tr> <tr> <td>Vitamin D deficiency</td> </tr> <tr> <td>Growth hormone deficiency</td> </tr> <tr> <td>Diabetes mellitus (type 1 and 2)</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal diseases</td> </tr> <tr> <td>Malabsorption syndromes (eg, celiac disease, postoperative states)</td> </tr> <tr> <td>Inflammatory bowel disease</td> </tr> <tr> <td>Cirrhosis</td> </tr> <tr> <td class=\"subtitle1_single\">Hematologic disorders</td> </tr> <tr> <td>Multiple myeloma</td> </tr> <tr> <td>Chronic hemolytic anemia</td> </tr> <tr> <td>Systemic mastocytosis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Connective tissue diseases</td> </tr> <tr> <td>Osteogenesis imperfecta</td> </tr> <tr> <td>Ehlers-Danlos syndrome</td> </tr> <tr> <td>Marfan's syndrome</td> </tr> <tr> <td>Homocystinuria</td> </tr> <tr> <td class=\"subtitle1_single\">Drugs</td> </tr> <tr> <td>Alcohol</td> </tr> <tr> <td>Heparin</td> </tr> <tr> <td>Glucocorticoids</td> </tr> <tr> <td>Thyroxine suppressive therapy</td> </tr> <tr> <td>Anticonvulsant drugs</td> </tr> <tr> <td>Gonadotropin-releasing hormone analogs</td> </tr> <tr> <td>Cyclosporine</td> </tr> <tr> <td>Chemotherapy</td> </tr> <tr> <td>HIV medications (eg, tenofovir)</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous causes</td> </tr> <tr> <td>Eating disorders (eg, anorexia nervosa)</td> </tr> <tr> <td>Hypercalciuria</td> </tr> <tr> <td>Immobilization</td> </tr> <tr> <td>Rheumatoid arthritis</td> </tr> <tr> <td>Renal disease</td> </tr> <tr> <td>Hepatic disease</td> </tr> <tr> <td>Tobacco</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 60440 Version 6.0</div></div></div>"},"60442":{"type":"graphic_table","displayName":"Contraindications to NPPV","title":"Contraindications to noninvasive positive pressure ventilation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications to noninvasive positive pressure ventilation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Cardiac or respiratory arrest</td> </tr> <tr> <td class=\"sublist1_start\">Nonrespiratory organ failure that is acutely life-threatening</td> </tr> <tr> <td class=\"sublist1\">Severe encephalopathy (eg, GCS &#60;10)</td> </tr> <tr> <td class=\"sublist1\">Severe upper gastrointestinal bleeding</td> </tr> <tr> <td class=\"sublist1\">Hemodynamic instability or unstable cardiac arrhythmia</td> </tr> <tr> <td>Facial or neurological surgery, trauma, or deformity</td> </tr> <tr> <td>Upper airway obstruction</td> </tr> <tr> <td>Inability to cooperate/protect airway</td> </tr> <tr> <td>Inability to clear secretions</td> </tr> <tr> <td>High risk for aspiration</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">GCS: Glasgow Coma Score.</div><div class=\"graphic_reference\">Adapted with permission from: International Consensus Conferences in Intensive Care Medicine: Noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 2001; 163:283. Copyright © 2001 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 60442 Version 3.0</div></div></div>"},"60444":{"type":"graphic_figure","displayName":"Pill splitter PI","title":"Pill splitter","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Pill splitter</div><div class=\"cntnt\"><img style=\"width:493px; height:556px;\" src=\"images/PI/60444_Pill_splitter_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Always use a pill splitter when splitting a pill. Do not use a knife. To use a pill splitter correctly, it helps to have good vision and good use of your hands.</div><div id=\"graphicVersion\">Graphic 60444 Version 4.0</div></div></div>"},"60446":{"type":"graphic_table","displayName":"CML prognostic models","title":"Prognostic scoring systems for newly diagnosed chronic myeloid leukemia*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prognostic scoring systems for newly diagnosed chronic myeloid leukemia*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"4\" width=\"22%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Scoring system</td> <td class=\"subtitle1\">Variables</td> <td class=\"subtitle1\">Equation for relative risk of progression</td> <td class=\"subtitle1\">Calculator</td> <td class=\"subtitle1\">Risk groups</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">EUTOS score<sup>[1]</sup></td> <td>Percentage basophils<sup>&#182;</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">Relative risk calculated as 7 (basophils) + 4 (spleen size)</td> <td class=\"divider_bottom\" rowspan=\"2\">A EUTOS score calculator is available online at: <a href=\"http://www.leukemia-net.org/content/leukemias/cml/eutos_score/\" target=\"_blank\">http://www.leukemia-net.org/content/leukemias/cml/eutos_score/</a></td> <td>Low risk: sum &#8804;87</td> </tr> <tr class=\"divider_bottom\"> <td>Spleen size<sup>&#916;</sup>: measured in centimeters below the costal margin</td> <td>High risk: &#62;87</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Euro (Hasford) score<sup>[2]</sup></td> <td>Spleen size<sup>&#916;</sup>: 0.042(spleen in cm below costal margin)</td> <td class=\"divider_bottom\" rowspan=\"6\">Relative risk calculated as the total obtained from the variables adjusted by weight and then multiplied by 1000.</td> <td class=\"divider_bottom\" rowspan=\"6\">A Euro and Sokal score calculator is available online at: <a href=\"http://www.leukemia-net.org/content/leukemias/cml/euro__and_sokal_score/index_eng.html\" spellcheck=\"true\">http://www.leukemia-net.org/content/leukemias/cml/euro__and_sokal_score/index_eng.html</a></td> <td>Low risk: score &#8804;780</td> </tr> <tr> <td>Percentage blasts<sup>&#182;</sup>: 0.0584 (myeloblasts)</td> <td>Intermediate risk: score &#62;780 and &#8804;1480</td> </tr> <tr> <td>Age: 0.666 when age &#8805;50 years</td> <td class=\"divider_bottom\" rowspan=\"4\">High risk: score &#62;1480</td> </tr> <tr> <td>Platelet count: 1.0956 when &#8805;1500 x 10<sup>9</sup>/L</td> </tr> <tr> <td>Percentage eosinophils<sup>&#182;</sup>: 0.0413 (eosinophils)</td> </tr> <tr class=\"divider_bottom\"> <td>Percentage basophils<sup>&#182;</sup>: 0.20399 when basophils &#8805;3 percent</td> </tr> <tr> <td rowspan=\"4\">Sokal score<sup>[3]</sup></td> <td>Spleen size<sup>&#916;</sup>: 0.0345 (spleen &ndash; 7.51 cm)</td> <td rowspan=\"4\"> <p>Relative risk calculated as the exponential of the total obtained from the variables adjusted by weight.</p> &#955;<sub>i</sub>(t)/&#955;<sub>o</sub>(t) = EXP 0.0116 (age &ndash; 43.4) + 0.0345 (spleen &ndash; 7.51) + 0.188 [(platelets/700)<sup>2</sup> &ndash; 0.563] + 0.0887 (blasts &ndash; 2.1)</td> <td rowspan=\"4\">&nbsp;</td> <td>Low risk: relative risk &#60;0.8</td> </tr> <tr> <td>Percentage blasts<sup>&#182;</sup>: 0.887 (myeloblasts &ndash; 2.1)</td> <td>Intermediate risk: relative risk 0.8 to 1.2</td> </tr> <tr> <td>Age: 0.116 (age &ndash; 43.4 years)</td> <td rowspan=\"2\">High risk: relative risk &#62;1.2</td> </tr> <tr> <td>Platelet count: 0.118 [(platelets/700)<sup>2</sup> &ndash; 0.563]</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These scoring systems were designed for patients with newly diagnosed chronic myeloid leukemia (CML) who have not yet received any treatment, including hydroxyurea. In addition, the EUTOS score was specifically designed to predict outcomes among patients undergoing initial treatment with imatinib.<br />¶ Percentage blasts, basophils, and eosinophils are measured from peripheral blood.<br />Δ Spleen size as assessed by physical examination.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118:686. </LI>&#xD;&#xA;<LI>Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90:850. </LI>&#xD;&#xA;<LI>Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in \"good-risk\" chronic granulocytic leukemia. Blood 1984; 63:789. </LI></OL></div><div id=\"graphicVersion\">Graphic 60446 Version 7.0</div></div></div>"},"60447":{"type":"graphic_picture","displayName":"Lentigo maligna histology","title":"Lentigo maligna","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lentigo maligna</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/60447_Lentigo_maligna_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atypical melanocytes grow largely at the dermal-epidermal interface (straight arrow), with extension down the external root sheath of follicles (curved arrow). Upward growth of melanocytes is much less prominent than in intraepidermal malignant melanoma of the superficial spreading type.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin R, Strayer DS. Rubin's Pathology: Clinicopathologic Foundations of Medicine, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &#169; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60447 Version 1.0</div></div></div>"},"60449":{"type":"graphic_table","displayName":"Comparison IIV LAIV","title":"Live attenuated influenza vaccine (LAIV) compared with inactivated influenza vaccine (IIV) for seasonal influenza, United States formulations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Live attenuated influenza vaccine (LAIV) compared with inactivated influenza vaccine (IIV) for seasonal influenza, United States formulations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Factor</td> <td class=\"subtitle1\">LAIV</td> <td class=\"subtitle1\">IIV</td> </tr> <tr> <td>Recommended by the ACIP for use during&nbsp;2017-2018 northern hemisphere influenza season in the United States</td> <td><strong>&nbsp;No</strong></td> <td><strong>&nbsp;Yes</strong></td> </tr> <tr> <td>Route of administration</td> <td>Intranasal spray</td> <td>Intramuscular injection, intradermal injection </td> </tr> <tr> <td>Type of vaccine</td> <td>Live virus</td> <td>Killed virus</td> </tr> <tr> <td>Number of included virus strains</td> <td>Four (two influenza A, two influenza B)</td> <td>Three (two influenza A, one influenza B) or four (two influenza A, two influenza B)</td> </tr> <tr> <td>Vaccine virus strains updated</td> <td>Annually*</td> <td>Annually*</td> </tr> <tr> <td>Frequency of administration</td> <td>Annually<sup>&#182;</sup></td> <td>Annually<sup>&#182;</sup></td> </tr> <tr> <td>Approved age</td> <td>Persons aged 2 to 49 years<sup>&#916;</sup></td> <td>Persons aged &#8805;6 months<sup>&#9674;</sup></td> </tr> <tr> <td>Interval between two doses recommended for children aged &#8805;6 months to 8 years who require two doses<sup>&#182;</sup></td> <td>&#8805;4 weeks</td> <td>&#8805;4 weeks</td> </tr> <tr> <td>Can be given to persons with risk factors for influenza-related complications<sup>&#916;</sup></td> <td><span style=\"color: black;\">Depends upon the risk factor<sup>&#916;</sup></span></td> <td>Yes</td> </tr> <tr> <td>Can be given to children with asthma or children aged&nbsp;two to&nbsp;four years with wheezing in the past year<sup>&#167;</sup></td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Can be administered to family members or close contacts of immunosuppressed persons not requiring a protected environment</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>Can be administered to family members or close contacts of immunosuppressed persons requiring a protected environment (eg, hematopoietic cell transplant recipient)</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Can be administered to family members or close contacts of persons with risk factors for influenza-related complications <strong>other than </strong>immunosuppression requiring a protected environment, as described in the previous row</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>Can be administered simultaneously with other vaccines</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>If not administered simultaneously, can be administered within&nbsp;four weeks of another live vaccine</td> <td>Prudent to space &#8805;4 weeks apart</td> <td>Yes</td> </tr> <tr> <td>If not administered simultaneously, can be administered within&nbsp;four weeks of an inactivated vaccine</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td>Can be given to persons who have been given influenza antiviral medications within the previous 48 hours</td> <td>No</td> <td>Yes&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* A decision is made annually regarding which virus strains will be targeted in the vaccine for the upcoming influenza season. Even in years in which the vaccine composition is the same as the previous season, annual vaccination is necessary since immunity wanes.<br />¶ Refer to UpToDate topic on seasonal influenza vaccination in children for details of the schedule for children&nbsp;six months through&nbsp;eight years.<br />Δ <FONT color=black>Contraindications to LAIV include pregnancy, immune suppression from any cause (including </FONT><FONT color=red><FONT color=black>medications&nbsp;or HIV infection), and,</FONT> <FONT color=black>in children and adolescents</FONT><FONT color=black><FONT color=black>,&nbsp;concomitant</FONT> aspirin or salicylate-containing therapy. Other medical conditions that may predispose to complications&nbsp;of influenza are a precaution for LAIV. These conditions include&nbsp;chronic pulmonary (including asthma), cardiovascular (except hypertension), renal, hepatic, neurologic (including disorders of the brain and spinal cord, cerebral palsy, epilepsy, stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy, spinal cord injury), hematologic, or metabolic (including diabetes mellitus) disorders.</FONT></FONT><br /><FONT class=lozenge>◊</FONT> Approval varies by formulation.<br />§ Clinicians and vaccination programs should screen for possible reactive airways diseases when considering use of LAIV for children aged&nbsp;two through&nbsp;four years and should avoid use of this vaccine in children with asthma or a recent wheezing episode. Health care providers should consult the medical record, when available, to identify children aged&nbsp;two through&nbsp;four years with asthma or recurrent wheezing that might indicate asthma. In addition, to identify children who might be at greater risk for asthma and possibly at increased risk for wheezing after receiving LAIV, parents or caregivers of children aged&nbsp;two through&nbsp;four years should be asked: \"In the past 12 months, has a health care provider ever told you that your child had wheezing or asthma?\" Children whose parents or caregivers answer \"yes\" to this question and children who have asthma or who had a wheezing episode noted in the medical record within the preceding 12 months should not receive LAIV.</div><div class=\"graphic_reference\">Data from:<br /><br /><OL>&#xD;&#xA;<LI>Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2017–18 influenza season. MMWR Recomm Rep 2017; 66:1.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention. People at high risk of developing flu-related complications. <A spellcheck=true href=\"http://www.cdc.gov/flu/about/disease/high_risk.htm \" target=_blank>http://www.cdc.gov/flu/about/disease/high_risk.htm </A>(Accessed on August 24, 2017.)</LI></OL></div><div id=\"graphicVersion\">Graphic 60449 Version 17.0</div></div></div>"},"60451":{"type":"graphic_picture","displayName":"Urine sample with chyluria","title":"Urine sample with chyluria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urine sample with chyluria</div><div class=\"cntnt\"><img style=\"width:432px; height:363px;\" src=\"images/ID/60451_Urine_sample_with_chyuria.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Photo Quiz. A woman from British Guyana with recurrent back pain and fever. Clin Infect Dis 2006; 42:1297. Copyright © 2006 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 60451 Version 3.0</div></div></div>"},"60452":{"type":"graphic_table","displayName":"IP ABX intermittent dosing","title":"Intraperitoneal antibiotic dosing recommendations for intermittent administration in peritoneal dialysis patients (adult)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intraperitoneal antibiotic dosing recommendations for intermittent administration in peritoneal dialysis patients (adult)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr class=\"highlight_gray_text;\" style=\"font-size:1.2em;\"> <td style=\"border-bottom: black 3px solid; padding-bottom: 0.3em; padding-top:0.5em;\">&nbsp;</td> <td style=\"border-bottom: black 3px solid; padding-bottom: 0.3em; padding-top:0.5em;\"> <p><strong>IP dose instilled in the longest dwell of the day of at least six hours</strong></p> For patients with residual renal function (defined as greater than 100 mL per day urine output): Empirically increase dose shown by 25%.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Aminoglycosides*</td> </tr> <tr> <td class=\"indent1\">Amikacin</td> <td>2 mg/kg in one exchange per day<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Gentamicin</td> <td>0.6 mg/kg in one exchange per day<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Netilmicin<sup>&#916;</sup></td> <td>0.6 mg/kg in one exchange per day<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tobramycin</td> <td>0.6 mg/kg in one exchange per day<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Carbapenems</td> </tr> <tr> <td class=\"indent1\">Imipenem</td> <td>500 mg in alternate exchanges</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Meropenem</td> <td>1 gram in one exchange per day</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cephalosporins<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Cefazolin</td> <td>15 to 20 mg/kg in one exchange per day</td> </tr> <tr> <td class=\"indent1\">Cefepime</td> <td>1 gram in one exchange per day</td> </tr> <tr> <td class=\"indent1\">Cefotaxime</td> <td>500 to 1000 mg in one exchange per day</td> </tr> <tr> <td class=\"indent1\">Ceftazidime</td> <td>1 to 1.5 grams in one exchange per day</td> </tr> <tr> <td class=\"indent1\">Ceftizoxime</td> <td>1 gram in one exchange per day</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ceftriaxone</td> <td>1 gram in one exchange per day</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Glycopeptides</td> </tr> <tr> <td class=\"indent1\">Vancomycin</td> <td>25 mg/kg ideal body weight; re-dose once serum level is &#8804;15 mcg/mL<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Teicoplanin<sup>&#916;</sup></td> <td>15 mg/kg in one exchange every five days</td> </tr> <tr> <td style=\"border-bottom: #555555 1px solid; padding-bottom: 0.3em; padding-top:0.4em;\" colspan=\"2\"><strong>Penicillins</strong><br /> NOTE: For dosing of most penicillins for IP administration, refer to separately available table for continuous administration of IP antibiotics.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ampicillin-sulbactam</td> <td>3 grams every 12 hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other</td> </tr> <tr> <td class=\"indent1\">Aztreonam</td> <td>2 grams in one exchange per day</td> </tr> <tr> <td class=\"indent1\">Quinupristin-dalfopristin</td> <td>25 mg per liter of dialysate in alternate exchanges<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Ciprofloxacin<sup>&#165;</sup></td> <td>ORAL: 250 mg once or twice per day depending on residual renal function</td> </tr> <tr> <td class=\"indent1\">Linezolid</td> <td>ORAL: 600 mg twice per day</td> </tr> <tr> <td class=\"indent1\">Moxifloxacin<sup>&#165;</sup></td> <td>ORAL: 400 mg once per day</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trimethoprim-sulfamethoxazole (co-trimoxazole)</td> <td>ORAL: One double-strength tablet (trimethoprim 160 mg and sulfamethoxazole 800 mg) two times per day</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Antifungal</td> </tr> <tr> <td class=\"indent1\">Fluconazole</td> <td>200 mg in one exchange every 24 to 48 hours</td> </tr> <tr> <td class=\"indent1\">Voriconazole</td> <td>2.5 mg/kg in one exchange per day</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table shows the suggested dose of antibiotics for intermittent IP administration (except where noted as \"oral\") in peritoneal dialysate for continuous ambulatory peritoneal dialysis-associated peritonitis without signs of systemic infection. Intermittent IP-administered regimens are preferred over continuous administration (ie, antibiotics in all exchanges) for initial therapy and should be used for the duration of treatment of two to three weeks or more in patients who are responding clinically. In patients who are not improving on intermittent therapy with agent(s) that should be effective based on microbiologic data, it is reasonable to increase frequency of intermittent dosing or switch to a continuous IP dosing regimen as listed on a separately available table. Refer to UpToDate topic on microbiology and therapy of peritonitis in continuous peritoneal dialysis for considerations in selection of antimicrobials and dosing strategy.</div><div class=\"graphic_footnotes\">IP: intraperitoneal.<br />* To determine weight-based dose of aminoglycosides in patients who are overweight, use \"ideal body weight\"; if obese, use \"dosing weight.\" A calculator for determining \"ideal body weight\" and \"dosing weight\" based on inputs of actual body weight and height is available in UpToDate.<br />&para; Loss of residual renal function is not generally associated with a brief course of an IP-administered aminoglycoside. However, systemic toxicity can occur with prolonged or repeated course(s), but serum concentration monitoring is of limited utility for preventing toxicity and assuring efficacy. Once culture and sensitivity results are available, early switch to another appropriate class of antibiotic (eg, third-generation cephalosporin) is suggested to decrease the risk of toxicity. Refer to UpToDate topics on microbiology and therapy of peritonitis in peritoneal dialysis.<br />&Delta; Not available in United States.<br /><span class=\"lozenge\">&loz;</span> Obtain daily vancomycin serum levels. Re-dose once the serum level reaches &le;15 mcg/mL, which usually occurs within four to seven days following an IP-administered dose. If serum levels are available only once every two to three days, it is reasonable to re-dose once the level reaches &le;20 mcg/mL. Supplemental doses may be needed in patients receiving machine-assisted automated peritoneal dialysis.<br />&sect; Given in conjunction with 500 mg intravenous twice daily.<br />&yen; Empiric use of oral fluoroquinolones is not recommended, unless local resistance patterns show &gt;90% susceptibility of common gram-negative pathogens. We generally avoid IP administration of fluoroquinolones. Refer to UpToDate topics on microbiology and therapy of peritonitis in peritoneal dialysis.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Li PK, Szeto CC, Piraino B, et al. Peritoneal Dialysis-Related Infections Recommendations: 2010 Update. Perit Dial Int 2010; 30:393.</li>&#xD;&#xA;    <li>Li PK, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int 2016; 36:481.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 60452 Version 7.0</div></div></div>"},"60454":{"type":"graphic_picture","displayName":"Urticaria annular lesions","title":"Urticaria","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Urticaria</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/60454_Urticaria_annular_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular, edematous, mildly erythematous plaques are present on the trunk.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60454 Version 3.0</div></div></div>"},"60456":{"type":"graphic_table","displayName":"Common antipsychotic medications","title":"Common antipsychotic medications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common antipsychotic medications</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">Brand name*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">First generation agents</td> </tr> <tr> <td class=\"indent1\">Chlorpromazine</td> <td>Thorazine</td> </tr> <tr> <td class=\"indent1\">Droperidol</td> <td>Inapsine</td> </tr> <tr> <td class=\"indent1\">Fluphenazine</td> <td>Prolixin</td> </tr> <tr> <td class=\"indent1\">Haloperidol</td> <td>Haldol</td> </tr> <tr> <td class=\"indent1\">Loxapine</td> <td>Adasuve, Loxitane</td> </tr> <tr> <td class=\"indent1\">Perphenazine</td> <td>Trilafon</td> </tr> <tr> <td class=\"indent1\">Thioridazine</td> <td>Mellaril</td> </tr> <tr> <td class=\"indent1\">Thiothixene</td> <td>Navane</td> </tr> <tr> <td class=\"indent1\">Trifluoperazine</td> <td>Stelazine</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Generic name</td> <td class=\"subtitle1\">Brand name<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Second generation agents</td> </tr> <tr> <td class=\"indent1\">Aripiprazole</td> <td>Abilify</td> </tr> <tr> <td class=\"indent1\">Asenapine</td> <td>Saphris</td> </tr> <tr> <td class=\"indent1\">Brexipiprazole</td> <td>Rexulti</td> </tr> <tr> <td class=\"indent1\">Clozapine</td> <td>Clozaril, Fazaclo, Versacloz</td> </tr> <tr> <td class=\"indent1\">Iloperidone</td> <td>Fanapt</td> </tr> <tr> <td class=\"indent1\">Lurasidone</td> <td>Latuda</td> </tr> <tr> <td class=\"indent1\">Olanzapine</td> <td>Zyprexa, Zyprexa Relprevv, Zyprexa Zydis</td> </tr> <tr> <td class=\"indent1\">Paliperidone</td> <td>Invega, Invega Sustenna, Invega Trinza</td> </tr> <tr> <td class=\"indent1\">Quetiapine</td> <td>Seroquel</td> </tr> <tr> <td class=\"indent1\">Ziprasidone</td> <td>Geodon, Zeldox</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Most first generation antipsychotics are available only as generic versions in United States (US).<br />&para; Brand names of second generation agents available in US, Canada, and many other countries.</div><div id=\"graphicVersion\">Graphic 60456 Version 6.0</div></div></div>"},"60457":{"type":"graphic_diagnosticimage","displayName":"SIS abn ut bleeding3","title":"Saline infusion sonography of a patient with uterine bleeding","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Saline infusion sonography of a patient with uterine bleeding</div><div class=\"cntnt\"><img style=\"width:372px; height:276px;\" src=\"images/OBGYN/60457_SIS_abn_ut_bleeding3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Saline infusion sonography of a patient with uterine bleeding reveals fluffy endometrial tissue occupying the right lateral half of the endometrial cavity while the left side is thin.</div><div class=\"graphic_reference\">Courtesy of Steven Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 60457 Version 3.0</div></div></div>"},"60460":{"type":"graphic_form","displayName":"Quebec back pain scale","title":"Quebec back pain disability scale*","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Quebec back pain disability scale*</div><div class=\"cntnt\"><img style=\"width:595px; height:780px;\" src=\"images/PC/60460_Quebec_back_pain_scale.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Minimum detectable change (90% confidence): 15 points.</div><div class=\"graphic_reference\">Reproduced with permission from: Kopec JA, Esdaile JM, Abrahamowicz M, et al. The Quebec Back Pain Disability Scale: Measurement properties. Spine 1995; 20:341. Copyright © 1995 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60460 Version 10.0</div></div></div>"},"60461":{"type":"graphic_diagnosticimage","displayName":"Dependent airspace disease CT","title":"Dependent airspace disease","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Dependent airspace disease</div><div class=\"cntnt\"><img style=\"width:582px; height:212px;\" src=\"images/PULM/60461_Dependent_airspace_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical supine chest CT scans in a patient with the acute respiratory distress syndrome (ARDS) reveal areas of dependent airspace disease in a patient with left lower lobe pneumonia. In the scan on the left, airway pressure (P<sub>aw</sub>) = 0 cmH<sub>2</sub>0; in the scan on the right, (P<sub>aw</sub>) = 40 cmH<sub>2</sub>0.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of David Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 60461 Version 3.0</div></div></div>"},"60462":{"type":"graphic_algorithm","displayName":"MCT flowchart","title":"Methacholine challenge testing sequence","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Methacholine challenge testing sequence</div><div class=\"cntnt\"><img style=\"width:456px; height:657px;\" src=\"images/PULM/60462_MCT_flowchart.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* The choice of the FEV1 value considered a contraindication may vary from 60 to 70 percent of predicted.<br> • The final dose may vary depending on the dosing schedule used. Final doses discussed in this statement are 16, 25 and 32 mg/mL.</div><div id=\"graphicVersion\">Graphic 60462 Version 2.0</div></div></div>"},"60463":{"type":"graphic_figure","displayName":"Vocal cord palsy flow volume","title":"Cricoarytenoid disease in rheumatoid arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cricoarytenoid disease in rheumatoid arthritis</div><div class=\"cntnt\"><img style=\"width:182px; height:237px;\" src=\"images/PULM/60463_Vocal_cord_palsy_flow_volum.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inspiratory and expiratory flow volume loop in a patient with bilateral vocal cord palsy secondary to cricoarytenoid disease. Both forced inspiratory and forced expiratory flow are decreased, but there is more marked reduction in inspiratory flow.</div><div id=\"graphicVersion\">Graphic 60463 Version 1.0</div></div></div>"},"60464":{"type":"graphic_waveform","displayName":"Hyperacute  or peaked T waves","title":"Hyperacute (peaked) T waves","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Hyperacute (peaked) T waves</div><div class=\"cntnt\"><img style=\"width:500px; height:131px;\" src=\"images/CARD/60464_Peaked_T_waves_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperacute T waves are &gt;5 mm in the limb leads, and usually &gt;10 mm in the precordial leads. They have a peaked, symmetric morphology.</div><div id=\"graphicVersion\">Graphic 60464 Version 4.0</div></div></div>"},"60466":{"type":"graphic_table","displayName":"Vancomycin dosing in adults not receiving HD","title":"Approach to initial empiric dosing of parenteral vancomycin in adults who are not receiving hemodialysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to initial empiric dosing of parenteral vancomycin in adults who are not receiving hemodialysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td colspan=\"7\"><strong>1. Loading dose for critically ill patient or severe infection:</strong>* <strong>25 mg/kg (rounded to nearest 250 mg)</strong></td> </tr> <tr> <td colspan=\"7\"><strong>2. Initial maintenance dose and interval: Based on target trough, patient weight, and estimated creatinine clearance</strong><sup>&#182;</sup> <strong>as follows:</strong></td> </tr> <tr> <td class=\"subtitle1\" rowspan=\"2\">Creatinine clearance in mL/minute<br /> (Cockcroft Gault equation)<sup>&#182;</sup></td> <td class=\"subtitle1\" colspan=\"6\">Weight (actual)<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2\">50 to 59 kg</td> <td class=\"subtitle2\">60 to 69 kg</td> <td class=\"subtitle2\">70 to 79 kg</td> <td class=\"subtitle2\">80 to 89 kg</td> <td class=\"subtitle2\">90 to 99 kg</td> <td class=\"subtitle2\">100 kg<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Severe or deep-seated infection:<sup>&#9674;</sup> Target trough 15 to 20 mcg/mL</td> </tr> <tr> <td class=\"indent1\">&#60;10 (not receiving hemodialysis)<sup>&#167;</sup></td> <td colspan=\"6\">Repeat dose when spot (random) serum concentration &#8804;20 mcg/mL</td> </tr> <tr> <td class=\"indent1\">10 to 19 (not receiving hemodialysis)<sup>&#167;</sup></td> <td>750 mg every 48 hours</td> <td>1000 mg every 48 hours</td> <td>1000 mg every 48 hours</td> <td>1250 mg every 48 hours</td> <td>1250 mg every 48 hours</td> <td>1500 mg every 48 hours</td> </tr> <tr> <td class=\"indent1\">20 to 29</td> <td>500 mg every 24 hours</td> <td>750 mg every 24 hours</td> <td>1000 mg every 36 hours</td> <td>1250 mg every 36 hours</td> <td>1250 mg every 36 hours</td> <td>1250 mg every 36 hours</td> </tr> <tr> <td class=\"indent1\">30 to 39</td> <td>750 mg every 24 hours</td> <td>750 mg every 24 hours</td> <td>1000 mg every 24 hours</td> <td>1250 mg every 24 hours</td> <td>1250 mg every 24 hours</td> <td>1250 mg every 24 hours</td> </tr> <tr> <td class=\"indent1\">40 to 49</td> <td>750 mg every 18 hours</td> <td>750 mg every 18 hours</td> <td>1000 mg every 18 hours</td> <td>1250 mg every 18 hours</td> <td>1250 mg every 18 hours</td> <td>1250 mg every 18 hours</td> </tr> <tr> <td class=\"indent1\">50 to 59</td> <td>750 mg every 18 hours</td> <td>1000 mg every 18 hours</td> <td>1000 mg every 18 hours</td> <td>1250 mg every 18 hours</td> <td>1250 mg every 18 hours</td> <td>1500 mg every 18 hours</td> </tr> <tr> <td class=\"indent1\">60 to 69</td> <td>750 mg every 12 hours</td> <td>750 mg every 12 hours</td> <td>1000 mg every 12 hours</td> <td>1000 mg every 12 hours</td> <td>1250 mg every 12 hours</td> <td>1250 mg every 12 hours</td> </tr> <tr> <td class=\"indent1\">70 to 79</td> <td>750 mg every 12 hours</td> <td>1000 mg every 12 hours</td> <td>1000 mg every 12 hours</td> <td>1250 mg every 12 hours</td> <td>1250 mg every 12 hours</td> <td>1500 mg every 12 hours</td> </tr> <tr> <td class=\"indent1\">80 to 89</td> <td>750 mg every 12 hours</td> <td>1000 mg every 12 hours</td> <td>1250 mg every 12 hours</td> <td>1250 mg every 12 hours</td> <td>1500 mg every 12 hours</td> <td>1500 mg every 12 hours</td> </tr> <tr> <td class=\"indent1\">90 to 99</td> <td>1000 mg every 12 hours</td> <td>1000 mg every 12 hours</td> <td>1250 mg every 12 hours</td> <td>1500 mg every 12 hours</td> <td>1500 mg every 12 hours</td> <td>1500 mg every 12 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;100 <strong>and</strong> &#60;60 years old<sup>&#182;</sup></td> <td>750 mg every 8 hours</td> <td>750 mg every 8 hours</td> <td>1000 mg every 8 hours</td> <td>1250 mg every 8 hours</td> <td>1250 mg every 8 hours</td> <td>1250 mg every 8 hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Nonsevere and superficial infection:<sup>&#9674;</sup> Target trough 10 to 15 mcg/mL</td> </tr> <tr> <td class=\"indent1\">&#60;10 (not receiving hemodialysis)<sup>&#167;</sup></td> <td colspan=\"6\">Repeat dose when spot (random) serum concentration &#8804;15 mcg/mL</td> </tr> <tr> <td class=\"indent1\">10 to 19 (not receiving hemodialysis)<sup>&#167;</sup></td> <td>1000 mg every 72 hours</td> <td>1250 mg every 72 hours</td> <td>1250 mg every 72 hours</td> <td>1500 mg every 72 hours</td> <td>1500 mg every 72 hours</td> <td>1750 mg every 72 hours</td> </tr> <tr> <td class=\"indent1\">20 to 29</td> <td>1000 mg every 48 hours</td> <td>1000 mg every 48 hours</td> <td>1250 mg every 48 hours</td> <td>1500 mg every 48 hours</td> <td>1500 mg every 48 hours</td> <td>1750 mg every 48 hours</td> </tr> <tr> <td class=\"indent1\">30 to 39</td> <td>1000 mg every 36 hours</td> <td>1000 mg every 36 hours</td> <td>1250 mg every 36 hours</td> <td>1500 mg every 36 hours</td> <td>1500 mg every 36 hours</td> <td>1750 mg every 36 hours</td> </tr> <tr> <td class=\"indent1\">40 to 49</td> <td>1000 mg every 24 hours</td> <td>1000 mg every 24 hours</td> <td>1250 mg every 24 hours</td> <td>1250 mg every 24 hours</td> <td>1500 mg every 24 hours</td> <td>1500 mg every 24 hours</td> </tr> <tr> <td class=\"indent1\">50 to 59</td> <td>1000 mg every 24 hours</td> <td>1250 mg every 24 hours</td> <td>1250 mg every 24 hours</td> <td>1500 mg every 24 hours</td> <td>1500 mg every 24 hours</td> <td>1750 mg every 24 hours</td> </tr> <tr> <td class=\"indent1\">60 to 69</td> <td>1000 mg every 18 hours</td> <td>1250 mg every 18 hours</td> <td>1250 mg every 18 hours</td> <td>1500 mg every 18 hours</td> <td>1500 mg every 18 hours</td> <td>1750 mg every 18 hours</td> </tr> <tr> <td class=\"indent1\">70 to 79</td> <td>1000 mg every 18 hours</td> <td>1250 mg every 18 hours</td> <td>1250 mg every 18 hours</td> <td>1500 mg every 18 hours</td> <td>1500 mg every 18 hours</td> <td>1750 mg every 18 hours</td> </tr> <tr> <td class=\"indent1\">80 to 89</td> <td>1000 mg every 18 hours</td> <td>1250 mg every 18 hours</td> <td>1250 mg every 12 hours</td> <td>1250 mg every 12 hours</td> <td>1500 mg every 12 hours</td> <td>1500 mg every 12 hours</td> </tr> <tr> <td class=\"indent1\">90 to 99</td> <td>1000 mg every 12 hours</td> <td>1000 mg every 12 hours</td> <td>1250 mg every 12 hours</td> <td>1500 mg every 12 hours</td> <td>1500 mg every 12 hours</td> <td>1500 mg every 12 hours</td> </tr> <tr> <td class=\"indent1\">&#8805;100 <strong>and</strong> &#60;60 years old<sup>&#182;</sup></td> <td>1000 mg every 12 hours</td> <td>1000 mg every 12 hours</td> <td>1250 mg every 12 hours</td> <td>1500 mg every 12 hours</td> <td>1500 mg every 12 hours</td> <td>1500 mg every 12 hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>This is a sample nomogram to guide determination of initial empiric dose and interval of IV vancomycin in hospitalized adults who are not receiving hemodialysis. Use of vancomycin dosing nomograms typically produces steady-state serum concentrations within the targeted range in approximately 44 to 76% of patients.<sup>[1]</sup> For dosing recommendations in patients receiving hemodialysis, refer to accompanying text and a separate table available in UpToDate.</li>&#xD;&#xA;    <li>Subsequent dosing is guided by vancomycin serum trough concentrations when indicated, daily assessments of renal function, and clinical response to therapy.</li>&#xD;&#xA;    <li>Patients who exhibit highly variable vancomycin pharmacokinetics (eg, critically ill, burn injured &gt;20% body surface, rapidly changing renal function, pregnant, liver failure/ascites, extremes of weight, acutely post-transplant, cystic fibrosis) were excluded from the population in which this nomogram was validated; individualized pharmacokinetic dose regimen calculations may be warranted. Refer to accompanying UpToDate text for detail.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">* If the patient is critically ill or has severe infection, a one-time intravenous (IV) loading dose of 25 mg/kg actual body weight is warranted. The loading dose is not adjusted for altered renal function. A maximum loading dose of 3 grams may be given; however, we generally use a loading dose of no more than 2 grams in older patients and patients with risk factors for acute kidney injury. The above nomogram was developed with a 25 mg/kg loading dose; the 2009 Infectious Diseases Society of America vancomycin guideline suggests a range of 25 to 30 mg/kg.<br />&para; Creatinine clearance estimates provided by the Cockcroft Gault equation may overestimate renal clearance of vancomycin in patients with low muscle mass and in older adults (eg, &ge;60 years). Consider more conservative (ie, less frequent) initial dosing in those patients and/or the use of an alternate method of renal function assessment. A calculator for determination of creatinine clearance by Cockcroft Gault equation is available in UpToDate.<br />&Delta; For patients who weigh up to 125% of their ideal body weight (IBW), vancomycin dosing is based on actual body weight. For patients who weigh more than 125% of their ideal body weight, an adjusted dosing weight is used for scaling initial maintenance dose. A calculator is available in UpToDate to determine ideal body weight and adjusted dosing weight. Individual maintenance doses over 2 grams per dose or 4 grams per day should only be given on documentation of sub-therapeutic serum concentrations due to concern for renal injury. The above nomogram has not been validated in patients weighing more than 100 kg. Refer to topic discussion for approach to initial dosing of vancomycin in patients weighing more than 100 kg.<br /><span class=\"lozenge\">&loz;</span> A target serum trough concentration of 15 to 20 mcg/mL is warranted for patients with severe or deep-seated infection (such as bacteremia, endocarditis, osteomyelitis, prosthetic joint infection, pneumonia warranting hospitalization, and infections involving the central nervous system). A target trough of 10 to 15 mcg/mL is warranted for patients with nonsevere infection (such as soft tissue infection).<br />&sect; In patients with advanced renal disease (eg, creatinine clearance [CrCl] &lt;29 mL/minute and not receiving dialysis) or unstable renal function, the dosing following the initial vancomycin dose can be determined by measurement of timed \"spot\" (non-steady state) levels. Refer to UpToDate topic discussion for detail.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Elyasi S, Hossein K. Vancomycin dosing nomographs targeting high serum trough levels in different populations: pros and cons. Eur J Clin Pharmacol (2016) 72:777.</li>&#xD;&#xA;</ol>&#xD;&#xA;Adapted from: Duke University Hospital Adult Pharmacokinetics Policy, Department of Pharmacy (June 2014). Courtesy of Richard H Drew, PharmD.</div><div id=\"graphicVersion\">Graphic 60466 Version 10.0</div></div></div>"},"60471":{"type":"graphic_picture","displayName":"Anaplasmosis peripheral smear","title":"Morulae of anaplasmosis in circulating neutrophils","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Morulae of anaplasmosis in circulating neutrophils</div><div class=\"cntnt\"><img style=\"width:294px; height:656px;\" src=\"images/HEME/60471_Anaplasmosis_periph_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 51-year-old man with no significant past medical history presented with a five-day history of fever, malaise, and diffuse myalgias with no recollection of a tick bite. He was found to have thrombocytopenia, elevated transaminase levels, and renal insufficiency. Examination of the peripheral smear suggested the diagnosis of anaplasmosis. He was started on a course of doxycycline with eventual complete resolution of symptoms.<br> The peripheral smear (1000x, &quot;feather edge&quot;) shows morulae of anaplasmosis in the patient's granulocytes. Photomicrographs B and C were taken from the extreme feather edge, and show exploded neutrophils containing well-delineated morulae.</div><div class=\"graphic_reference\">Peripheral smear and patient information kindly provided by Dr. Eddy J Chen and Dr. German Pihan, Departments of Medicine and Pathology, Beth Israel Deaconess Medical Center, Boston, MA.</div><div id=\"graphicVersion\">Graphic 60471 Version 3.0</div></div></div>"},"60472":{"type":"graphic_figure","displayName":"Depressive episodes over five-years by age group","title":"Mean proportions of weeks in depressive episodes over five-year periods by age group","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Mean proportions of weeks in depressive episodes over five-year periods by age group</div><div class=\"cntnt\"><img style=\"width:544px; height:370px;\" src=\"images/PSYCH/60472_Depr_ep_over_five_years_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Height of rectangle indicates the mean proportion, and error bar indicates +/- 1.00 standard error.</div><div class=\"graphic_reference\">Reproduced with permission from: Coryell W, Solomon D, Leon A, et al. Does major depressive disorder change with age? Psychol Med 2009; 39:1689. Copyright &copy; 2009 Cambridge University Press.</div><div id=\"graphicVersion\">Graphic 60472 Version 1.0</div></div></div>"},"60473":{"type":"graphic_table","displayName":"Infections that warrant evaluation of antibody-mediated immunity","title":"Infections that warrant an evaluation of antibody-mediated immunity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infections that warrant an evaluation of antibody-mediated immunity</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Indications</td> <td class=\"subtitle1\" colspan=\"2\">Number of episodes</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Allergy/Immunology Clinic LSUHSC, New Orleans</td> </tr> <tr> <td class=\"subtitle3\">2 to 5 years of age</td> <td class=\"subtitle3\">&#62;5 years of age</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Respiratory infections</td> </tr> <tr> <td class=\"indent1\">URI treated with antibiotics in last 12 months</td> <td>&#8805;4</td> <td>&#8805;2</td> </tr> <tr> <td class=\"indent1\">Otitis treated with antibiotics (per year)</td> <td>&#8805;3*<sup></sup></td> <td>&#8805;2</td> </tr> <tr> <td class=\"indent1\">Sinusitis episodes (per year)</td> <td>&#8805;2</td> <td>&#8805;2</td> </tr> <tr> <td class=\"indent1\">Chronic, treatment-resistant sinusitis (&#62;1 month)</td> <td>&#8805;1</td> <td>&#8805;1</td> </tr> <tr> <td class=\"indent1\">Pneumonias (per year)</td> <td>&#8805;2</td> <td>&#8805;2</td> </tr> <tr> <td class=\"indent1\">Invasive infections (sepsis, meningitis, osteomyelitis)</td> <td>&#8805;2</td> <td>&#8805;2</td> </tr> <tr> <td class=\"indent1\">Severe invasive infections</td> <td>&#8805;1</td> <td>&#8805;1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Gastrointestinal infections</td> </tr> <tr> <td class=\"indent1\">Chronic diarrhea due to rotavirus, other</td> <td>&#8805;1</td> <td>&#8805;1</td> </tr> <tr> <td class=\"indent1\">Chronic/recurrent <em>Giardia lamblia </em>infection</td> <td>&#8805;1</td> <td>&#8805;1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antibiotic use</td> </tr> <tr> <td class=\"indent1\">Need for preventive antibiotic use</td> <td>&#8805;1</td> <td>&#8805;1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LSUHSC: Louisiana State University Health Sciences Center; URI: upper respiratory tract infection.<br />* After placement of ventilation tubes.</div><div class=\"graphic_reference\">Adapted from: Sorensen RU, Moore C. Peds Clin N A 2000; 42:1225.</div><div id=\"graphicVersion\">Graphic 60473 Version 10.0</div></div></div>"},"60474":{"type":"graphic_figure","displayName":"Baumann angle","title":"Anteroposterior radiograph angles of the elbow","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anteroposterior radiograph angles of the elbow</div><div class=\"cntnt\"><img style=\"width:392px; height:306px;\" src=\"images/EM/60474_Baumannangle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Baumann's angle (α).</div><div class=\"graphic_reference\">Reproduced with permission from: Beaty JH, Kasser JR. Evaluation of Pediatric Distal Humeral Fractures. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Lippincott Williams &amp; Wilkins 2014. Copyright © 2014 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 60474 Version 12.0</div></div></div>"},"60476":{"type":"graphic_picture","displayName":"COP lung biopsy high power","title":"Cryptogenic organizing pneumonia: High power view","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cryptogenic organizing pneumonia: High power view</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/PULM/60476_BOOP_Light_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of specimen from open lung biopsy in a patient with cryptogenic organizing pneumonia. A polypoid mass of granulation tissue is filling the lumen of an alveolar duct (Masson body).</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 60476 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lung</div><div class=\"cntnt\"><img style=\"width:360px; height:330px;\" src=\"images/PULM/80140_Normal_lung_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph shows alveoli containing capillaries within a narrow interstitium. The alveoli are lined with thin, elongated type I pneumocytes (arrow) and smaller numbers of cuboidal type II pneumocytes (dashed arrow).</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 80140 Version 2.0</div></div></div>"},"60478":{"type":"graphic_waveform","displayName":"Nonspecific ST changes tutorial","title":"Nonspecific ST and T wave changes","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Nonspecific ST and T wave changes</div><div class=\"cntnt\"><img style=\"width:518px; height:211px;\" src=\"images/CARD/60478_Nonspecific_ST_changes_tuto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The types of abnormalities include ST segment depression or elevation (leads I, aVL, V4-V6), flattening of the T wave (leads I, aVR, aVL, V5, V6), or T wave inversion (I, V2-V4).</div><div id=\"graphicVersion\">Graphic 60478 Version 2.0</div></div></div>"},"60481":{"type":"graphic_picture","displayName":"GB cholesterolosis Light","title":"Gallbladder cholesterolosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gallbladder cholesterolosis</div><div class=\"cntnt\"><img style=\"width:403px; height:252px;\" src=\"images/GAST/60481_GB_cholesterolosis_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microscopic appearance of the gallbladder wall from a specimen demonstrating cholesterolosis. The villi are elongated and contain lipid-laden macrophages.</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD, FACP.</div><div id=\"graphicVersion\">Graphic 60481 Version 2.0</div></div></div>"},"60482":{"type":"graphic_diagnosticimage","displayName":"Aortic intramural hematoma on TEE and CT","title":"Aortic intramural hematoma on TEE and CT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic intramural hematoma on TEE and CT</div><div class=\"cntnt\"><img style=\"width:367px; height:277px;\" src=\"images/CARD/60482_Aortic_intramural_hematoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representative transesophageal echocardiograms (panels A and B) and computed tomograms (panels C and D) of a section of the descending aorta in a patient with intramural hemorrhage. Panels A and C reveal a crescentic thickening of the aortic wall without any evidence of flow communication or intimal tear (arrows). Panels B and D show complete normalization at follow-up.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiogram; CT: computed tomography.</div><div class=\"graphic_reference\">With permission from Song, JK, Kang, DH, Lim, TH, et al. Am J Cardiol 1999; 83:937.</div><div class=\"contractual\"><br/><a href=\"http://www.elsevier.com/locate/jacc\">http://www.elsevier.com/locate/jacc</a><br/><a href=\"http://www.sciencedirect.com/\"> http://www.sciencedirect.com</a></div><div id=\"graphicVersion\">Graphic 60482 Version 6.0</div></div></div>"},"60486":{"type":"graphic_table","displayName":"Treatment of blastomycosis","title":"Treatment of blastomycosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of blastomycosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Manifestation </td> <td class=\"subtitle1\">Preferred treatment </td> <td class=\"subtitle1\">Comments </td> </tr> <tr> <td>Moderately severe to severe pulmonary</td> <td>Lipid AmB 3 to 5 mg/kg per day or deoxycholate AmB 0.7 to 1 mg/kg per day for 1 to 2 weeks, followed by itraconazole 200 mg&nbsp;twice per day&nbsp;for 6 to 12 months</td> <td>The entire course of therapy can be given with deoxycholate AmB to a total of 2 g; however, most clinicians prefer to use step-down itraconazole therapy after the patient's condition improves. The lipid formulations of AmB have fewer adverse effects.</td> </tr> <tr> <td>Mild to moderate pulmonary</td> <td>Itraconazole, 200 mg once or twice per day for 6 to 12 months</td> <td>&nbsp;</td> </tr> <tr> <td>Moderately severe to severe disseminated</td> <td>Lipid AmB 3 to 5 mg/kg per day or deoxycholate AmB 0.7 to 1 mg/kg per day for 1 to 2 weeks, followed by itraconazole 200 mg&nbsp;twice per day&nbsp;for 12 months</td> <td>The entire course of therapy can be given with deoxycholate AmB to a total of 2 g; however, most clinicians prefer to use step-down itraconazole therapy after the patient's condition improves. The lipid formulations of AmB have fewer adverse effects. Treat osteoarticular disease for 12 months.</td> </tr> <tr> <td>Mild to moderate disseminated</td> <td>Itraconazole 200 mg once or twice per day for 6 to 12 months</td> <td>Treat osteoarticular disease for 12 months.</td> </tr> <tr> <td>CNS disease</td> <td>Lipid AmB 5 mg/kg per day for 4 to 6 weeks is preferred,* followed by an oral azole for at least 1 year</td> <td>Step-down therapy can be with fluconazole 800 mg per day, itraconazole 200 mg 2 to 3 times per day, or voriconazole 200 to 400 mg twice per day. Longer treatment may be required for immunosuppressed patients.</td> </tr> <tr> <td>Immunosuppressed patients</td> <td>Lipid AmB 3 to 5 mg/kg per day or deoxycholate AmB&nbsp;0.7 to 1 mg/kg per day for 1 to 2 weeks, followed by itraconazole 200 mg&nbsp;twice per day&nbsp;for 12 months</td> <td>Life-long suppressive treatment may be required if immunosuppression cannot be reversed.</td> </tr> <tr> <td>Pregnant women</td> <td>Lipid AmB 3 to 5 mg/kg per day</td> <td>Azoles should not be used during pregnancy.</td> </tr> <tr> <td>Children with moderately severe to severe disease</td> <td>Deoxycholate AmB 0.7 to 1 mg/kg per day or lipid AmB 3 to 5 mg/kg per day for 1 to 2 weeks, followed by itraconazole 10 mg/kg per day for 12 months</td> <td>Children tolerate deoxycholate AmB better than adults do; maximum dose of itraconazole should be 400 mg per day.</td> </tr> <tr> <td>Children with mild to moderate disease</td> <td>Itraconazole 10 mg/kg per day for 6 to 12 months</td> <td>Maximum dose 400 mg per day</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AmB: amphotericin; CNS: central nervous system.<br />* In animal models of fungal meningitis, liposomal AmB achieves higher CNS levels than do other lipid formulations. Hence, many infectious diseases experts recommend liposomal AmB as the preferred lipid formulation for the treatment of CNS fungal infections.</div><div class=\"graphic_reference\">Reproduced with permission from: Chapman SW, Dismukes WE, Proia LA, et al. Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:1801. Copyright ©2008 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 60486 Version 2.0</div></div></div>"},"60487":{"type":"graphic_picture","displayName":"Exogenous mold endophthalmitis","title":"Exogenous mold endophthalmitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Exogenous mold endophthalmitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ID/60487_Exogenous_mold_endophthalm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Exogenous mold endophthalmitis following eye trauma.</div><div class=\"graphic_reference\">Courtesy of Marlene Durand, MD.</div><div id=\"graphicVersion\">Graphic 60487 Version 1.0</div></div></div>"},"60488":{"type":"graphic_figure","displayName":"Primary pain pathways","title":"Central perception of pain","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Central perception of pain</div><div class=\"cntnt\"><img style=\"width:485px; height:474px;\" src=\"images/PC/60488_Primary_pain_pathways.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The transmission of incoming nociceptive impulses is modulated by dorsal horn circuitry that receives input from peripheral touch receptors and from descending pathways that involve the limbic cortical systems (orbital frontal cortex, amygdala, and hypothalamus), periaqueductal endogenous analgesic center in the midbrain, pontine noradrenergic neurons, and the nucleus raphe magnus (NRM) in the medulla. Dashed lines indicate inhibition or modulation.</div><div class=\"graphic_footnotes\">* Location of opioid receptors.</div><div class=\"graphic_reference\">Reproduced with permission from: Wolters Kluwer. Copyright &#169;2008.</div><div id=\"graphicVersion\">Graphic 60488 Version 1.0</div></div></div>"},"60489":{"type":"graphic_figure","displayName":"Metoprolol hospitaliz HF","title":"Metoprolol reduces the number of heart failure patients requiring hospitalization","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metoprolol reduces the number of heart failure patients requiring hospitalization</div><div class=\"cntnt\"><img style=\"width:394px; height:555px;\" src=\"images/CARD/60489_Metoprolol_hospitaliz_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the MERIT-HF trial of 3991 patients, metoprolol CR/XL reduced the number of patients requiring hospitalization for any reason by 18 percent compared to placebo (p = 0.004), the number admitted for a cardiovascular cause by 25 percent (p &lt;0.001), and the number admitted for worsening heart failure by 35 percent (p &lt;0.001) (Panel A). There was an equivalent reduction in the number of hospital days (Panel B).</div><div class=\"graphic_reference\">Data from: Hjalmarson A, Goldstein S, Fagerberg B, et al. JAMA 2000; 283:1245.</div><div id=\"graphicVersion\">Graphic 60489 Version 2.0</div></div></div>"},"60491":{"type":"graphic_table","displayName":"Causes eosinophilic pneumonia","title":"Causes of eosinophilic pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of eosinophilic pneumonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Idiopathic (acute or chronic)</td> </tr> <tr> <td>Tropical filarial eosinophilia</td> </tr> <tr> <td>Parasitic infections</td> </tr> <tr> <td>Allergic bronchopulmonary aspergillosis</td> </tr> <tr> <td>Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)&nbsp;</td> </tr> <tr> <td>Hypereosinophilic syndrome</td> </tr> <tr> <td>Acquired immunodeficiency syndrome</td> </tr> <tr> <td>Drugs (eg, aspirin, nonsteroidal antiinflammatory drugs, nitrofurantoin, sulfonamides, ampicillin, cocaine)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 60491 Version 3.0</div></div></div>"},"60493":{"type":"graphic_figure","displayName":"Plagiocephaly comparison","title":"Common presentation of deformational plagiocephaly compared with synostotic plagiocephaly","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Common presentation of deformational plagiocephaly compared with synostotic plagiocephaly</div><div class=\"cntnt\"><img style=\"width:504px; height:312px;\" src=\"images/ALLRG/60493_Plagiocephaly-comparison.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ear is often anteriorly displaced on the affected side in deformational plagiocephaly, although this finding is not always consistent.</div><div id=\"graphicVersion\">Graphic 60493 Version 3.0</div></div></div>"},"60494":{"type":"graphic_table","displayName":"Causes dilated cardiomyopathy","title":"Major causes of dilated cardiomyopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of dilated cardiomyopathy</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Infectious diseases </td> </tr> <tr> <td class=\"sublist1_start\">Viral </td> </tr> <tr> <td class=\"sublist1\">Adenovirus</td> </tr> <tr> <td class=\"sublist1\">Coxsackie virus</td> </tr> <tr> <td class=\"sublist1\">Cytomegalovirus </td> </tr> <tr> <td class=\"sublist1\">HIV </td> </tr> <tr> <td class=\"sublist1\">Influenza virus</td> </tr> <tr> <td class=\"sublist1\">Varicella </td> </tr> <tr> <td class=\"sublist1\">Hepatitis </td> </tr> <tr> <td class=\"sublist1\">Epstein-Barr </td> </tr> <tr> <td class=\"sublist1\">Echovirus </td> </tr> <tr> <td class=\"sublist1\">Parvovirus</td> </tr> <tr> <td class=\"sublist1\">Other </td> </tr> <tr> <td class=\"sublist1_start\">Bacterial </td> </tr> <tr> <td class=\"sublist1\">Streptococci-rheumatic fever </td> </tr> <tr> <td class=\"sublist1\">Typhoid fever </td> </tr> <tr> <td class=\"sublist1\">Diphtheria </td> </tr> <tr> <td class=\"sublist1\">Brucellosis </td> </tr> <tr> <td class=\"sublist1\">Psitticosis </td> </tr> <tr> <td class=\"sublist1\">Mycobacteria</td> </tr> <tr> <td>Rickettsial </td> </tr> <tr> <td>Spirochetal&nbsp;</td> </tr> <tr> <td><span class=\"subtitle4\">&nbsp;&nbsp; Leptospirosis</span></td> </tr> <tr> <td>&nbsp;&nbsp; Syphilis</td> </tr> <tr> <td>&nbsp;&nbsp; Lyme disease</td> </tr> <tr> <td class=\"sublist1_start\">Fungal&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Histoplasmosis </td> </tr> <tr> <td class=\"sublist1\">Cryptococcosis </td> </tr> <tr> <td class=\"sublist1_start\">Parasitic </td> </tr> <tr> <td class=\"sublist1\">Toxoplasmosis </td> </tr> <tr> <td class=\"sublist1\">Trypanosomiasis (Chagas disease)</td> </tr> <tr> <td class=\"sublist1\">Shistosomiasis </td> </tr> <tr> <td class=\"sublist1\">Trichinosis </td> </tr> <tr> <td class=\"subtitle1_single\">Deposition diseases </td> </tr> <tr> <td>Hemochromatosis</td> </tr> <tr> <td>Amyloidosis</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Medications </td> </tr> <tr> <td class=\"sublist1_start\">Chemotherapeutic agents </td> </tr> <tr> <td class=\"sublist1\">Anthracyclines </td> </tr> <tr> <td class=\"sublist1\">Cyclophosphamide </td> </tr> <tr> <td class=\"sublist1\">Trastuzumab </td> </tr> <tr> <td>Antiretroviral drugs</td> </tr> <tr> <td class=\"sublist1\">Zidovudine </td> </tr> <tr> <td class=\"sublist1\">Didanosine </td> </tr> <tr> <td class=\"sublist1\">Zalcitabine </td> </tr> <tr> <td>Phenothiazines</td> </tr> <tr> <td>Chloroquine</td> </tr> <tr> <td>Clozapine</td> </tr> <tr> <td class=\"subtitle1_single\">Toxins </td> </tr> <tr> <td>Ethanol</td> </tr> <tr> <td>Cocaine</td> </tr> <tr> <td>Amphetamines</td> </tr> <tr> <td>Cobalt</td> </tr> <tr> <td>Lead</td> </tr> <tr> <td>Lithium&nbsp;</td> </tr> <tr> <td>Mercury</td> </tr> <tr> <td>Carbon monoxide</td> </tr> <tr> <td>Beryllium</td> </tr> <tr> <td>Methysergide</td> </tr> <tr> <td class=\"subtitle1_single\">Electrolyte and renal&nbsp;abnormalities </td> </tr> <tr> <td>Hypocalcemia</td> </tr> <tr> <td>Hypophosphatemia</td> </tr> <tr> <td>Uremia</td> </tr> <tr> <td class=\"subtitle1_single\">Nutritional deficiencies </td> </tr> <tr> <td>Thiamine</td> </tr> <tr> <td>Selenium</td> </tr> <tr> <td>Carnitine</td> </tr> <tr> <td>Niacin (pellagra)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Inflammatory/autoimmune </td> </tr> <tr> <td>Systemic lupus erythematosis</td> </tr> <tr> <td>Dermatomyositis</td> </tr> <tr> <td>Scleroderma</td> </tr> <tr> <td>Rheumatoid arthritis</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Hypersensitivity myocarditis</td> </tr> <tr> <td>Other autoimmune myocarditis</td> </tr> <tr> <td>Giant cell arteritis</td> </tr> <tr> <td>Kawasaki disease</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrinologic disorders </td> </tr> <tr> <td><span class=\"sublist1_start\"></span>Thyroid hormone excess or deficiency</td> </tr> <tr> <td>Growth hormone excess or deficiency</td> </tr> <tr> <td>Diabetes mellitus</td> </tr> <tr> <td>Cushing's syndrome</td> </tr> <tr> <td>Pheochromocytoma or other catecholamine excess</td> </tr> <tr> <td class=\"subtitle1_single\">Genetic with or without neuromuscular disease </td> </tr> <tr> <td>Familial (and sporadic) genetic&nbsp;cardiomyopathies</td> </tr> <tr> <td>Duchenne's muscular dystrophy</td> </tr> <tr> <td>Myotonic dystrophy</td> </tr> <tr> <td>Friedreich's ataxia</td> </tr> <tr> <td>Arrhythmogenic right ventricular cardiomyopathy</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous </td> </tr> <tr> <td>Peripartum cardiomyopathy</td> </tr> <tr> <td>Tachycardia</td> </tr> <tr> <td>Heat stroke</td> </tr> <tr> <td>Hypothermia&nbsp;</td> </tr> <tr> <td>Sleep apnea</td> </tr> <tr> <td>Radiation</td> </tr> <tr> <td><em>(Calcium overload)</em></td> </tr> <tr> <td><em>(Oxygen free radical damage)</em></td> </tr> <tr> <td><strong>Differential diagnosis</strong></td> </tr> <tr> <td>Ischemic heart disease</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 60494 Version 4.0</div></div></div>"},"60496":{"type":"graphic_waveform","displayName":"Dextrocardia tutorial","title":"Dextrocardia","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Dextrocardia</div><div class=\"cntnt\"><img style=\"width:539px; height:189px;\" src=\"images/CARD/60496_Dextrocardia_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic changes of dextrocardia include a negative P wave and QRS complex in lead 1, since atrial and ventricular depolarization begin on the left and spread to the right. There is also reverse R wave progression across the precordium; the R wave is tallest in V1, and progressively decreases in amplitude in leads V2 to V6.</div><div id=\"graphicVersion\">Graphic 60496 Version 2.0</div></div></div>"},"60497":{"type":"graphic_picture","displayName":"Diascopy","title":"Diascopy of urticarial vasculitis skin lesion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diascopy of urticarial vasculitis skin lesion</div><div class=\"cntnt\"><img style=\"width:357px; height:540px;\" src=\"images/ALLRG/60497_Diascopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(1) Lesion of urticarial vasculitis on the neck. (2) Diascopy causes erythematous halo to disappear, revealing clinically inapparent purpura.</div><div class=\"graphic_reference\">Reproduced with permission from: Dahl MV. Clinical pearl: diascopy helps diagnose urticarial vasculitis. J Am Acad Dermatol 1994; 30:481. Copyright © 1994 American Academy of Dermatology.</div><div id=\"graphicVersion\">Graphic 60497 Version 3.0</div></div></div>"},"60498":{"type":"graphic_form","displayName":"Adult ADHD screening tool","title":"Adult ADHD screening tool","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Adult ADHD screening tool</div><div class=\"cntnt\"><img style=\"width:608px; height:493px;\" src=\"images/PC/60498_Adult_ADHD_screening_tool.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>Grading:</strong> Add the number of checkmarks that appear in the darkly shaded areas. Four or more checkmarks indicate that your symptoms may be consistent with Adult ADHD. It may be beneficial for you to talk with your family physician about an evaluation.</div><div class=\"graphic_reference\">Adapted with permission from the World Health Organization.</div><div id=\"graphicVersion\">Graphic 60498 Version 5.0</div></div></div>"},"60500":{"type":"graphic_table","displayName":"Brucella postexposure recs","title":"Recommendations for surveillance and postexposure prophylaxis (PEP) after laboratory exposure to <em>Brucella</em> isolates","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for surveillance and postexposure prophylaxis (PEP) after laboratory exposure to <em>Brucella</em> isolates</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Evaluate all workers exposed to <em>Brucella</em> isolates* and classify exposures as either high risk or low risk<sup>&#182;</sup>.</td> </tr> <tr> <td class=\"sublist1_start\">Recommend PEP for workers with high-risk exposures to <em>Brucella</em> isolates. PEP should be offered as soon as <em>Brucella</em> exposure has been identified and be administered for six months following exposure.</td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Administer doxycycline (100 mg twice daily) and rifampin (600 mg once daily) for&nbsp;three weeks. </li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>For individuals with exposure to <em>Brucella abortus </em>RB51 strain (which is resistant to rifampin), administer doxycycline (100 mg twice daily) and trimethoprim-sulfamethoxazole (160 mg/800 mg twice daily) for three weeks. </li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>For patients with contraindications to doxycycline or rifampin, trimethoprim-sulfamethoxazole may be used. </li> </ul> </td> </tr> <tr> <td class=\"sublist1\"> <ul> <li>Pregnant&nbsp;women with high-risk exposures should be considered for PEP in consultation with their obstetricians. </li> </ul> </td> </tr> <tr> <td>Discuss potential PEP with workers who have low-risk exposures to <em>Brucella</em> isolates; PEP may be warranted for patients who are immunocompromised or pregnant.</td> </tr> <tr> <td>Obtain baseline serum samples from all workers exposed to <em>Brucella</em>, unless exposed to <em>B. abortus </em>RB51 strain or <em>B. canis </em>(these strains do not elicit a measurable serologic response using available assays). </td> </tr> <tr> <td>Arrange for periodic serologic testing on all workers exposed to <em>Brucella </em>(6, 12, 18, and 24 weeks post exposure) using agglutination testing (eg, tube or <em>Brucella </em>microagglutination testing) at the state public health laboratory or CDC; serologic testing is not recommended for workers exposed to <em>B. abortus </em>RB51 strain or <em>B. canis</em>.</td> </tr> <tr> <td>Among workers with <em>Brucella</em> exposure, arrange for weekly symptom monitoring and daily temperature monitoring for six months following exposure. </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PEP: postexposure prophylaxis; CDC: United States Centers for Disease Control and Prevention.<br />* A <EM>Brucella</EM>-exposed worker is defined as any worker present in the microbiology laboratory during workup and identification of a <EM>Brucella</EM> isolate, from the time the culture is first manipulated until all culture isolates are destroyed or removed from the laboratory.<br />¶ A high-risk exposure is defined as (1) having direct personal exposure to <EM>Brucella</EM> (eg, sniffing bacteriologic cultures, direct skin contact, pipetting by mouth, inoculation, or spraying into the eyes, nose, or mouth), (2) performing work on an open bench (ie, outside of biosafety level 3 containment equipment) with an open culture plate containing a <EM>Brucella</EM> isolate or being in close proximity to such work (eg, across an open bench top or within 5 feet), or (3) presence in the laboratory during any procedure conducted on a <EM>Brucella</EM> isolate that might result in generation of aerosolized organisms and inhalational exposure (eg, vortexing or catalase testing). A low-risk exposure is defined as being present in the laboratory during an exposure but not meeting the definition for a high-risk exposure.</div><div class=\"graphic_reference\">Data from:&nbsp;<br /><br /><OL>&#xD;&#xA;<LI>Yoder J, Roberts V, Craun GF, et al. Surveillance for waterborne disease and outbreaks associated with drinking water and water not intended for drinking--United States, 2005-2006. MMWR Surveill Summ 2008; 57:39.</LI>&#xD;&#xA;<LI>​Traxler RM, Guerra MA, Morrow MG,&nbsp;et al. Review of brucellosis cases from laboratory exposures in the United States in 2008 to 2011 and improved strategies for disease prevention. J Clin Microbiol 2013; 51:3132.</LI></OL></div><div id=\"graphicVersion\">Graphic 60500 Version 4.0</div></div></div>"},"60501":{"type":"graphic_picture","displayName":"Ixodes pacificus","title":"An adult female <EM>Ixodes pacificus</EM> (Western blacklegged tick)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">An adult female <EM>Ixodes pacificus</EM> (Western blacklegged tick)</div><div class=\"cntnt\"><img style=\"width:179px; height:178px;\" src=\"images/ID/60501_Ixodes_pacificus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Champman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever, Ehrlichoioses, and Anaplasmosis-United States: A practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55(RR-4):1.</div><div id=\"graphicVersion\">Graphic 60501 Version 3.0</div></div></div>"},"60502":{"type":"graphic_table","displayName":"Findings that increase the certainty of dx of preeclampsia","title":"Findings which increase the certainty of the diagnosis of preeclampsia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Findings which increase the certainty of the diagnosis of preeclampsia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Systolic blood pressure &#8805;160 mm Hg</td> </tr> <tr> <td>Diastolic blood pressure &#8805;110 mm Hg </td> </tr> <tr> <td>Proteinuria occurring for the first time during pregnancy, especially if &#8805;2 g in 24 hours. A qualitative result of 2+ or 3+ is also suggestive.</td> </tr> <tr> <td>Serum creatinine &#62;1.2 mg/dL (106 mmol/L)</td> </tr> <tr> <td>Platelet count &#60;100,000 cells per cubic millimeter</td> </tr> <tr> <td>Evidence of microangiopathic hemolytic anemia (eg, elevated indirect bilirubin or lactic acid dehydrogenase)</td> </tr> <tr> <td>Elevated liver&nbsp;chemistries (eg, alanine aminotransferase or aspartate aminotransferase)</td> </tr> <tr> <td>Persistent headache or other cerebral or visual disturbances</td> </tr> <tr> <td>Persistent epigastric pain</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Working group report on high blood pressure in pregnancy. National Instititutes of Health, Washington, DC 2000.</div><div id=\"graphicVersion\">Graphic 60502 Version 3.0</div></div></div>"},"60503":{"type":"graphic_table","displayName":"Likelihood of pregnancy by findings on history and physical exam","title":"Summary of studies reporting likelihood ratios for prediction of pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of studies reporting likelihood ratios for prediction of pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">History</td> <td class=\"subtitle1\">Positive likelihood ratio<br /> (95% confidence interval)</td> </tr> <tr> <td rowspan=\"4\">Delayed menses</td> <td>2.06 (95% CI 1.65-2.57)</td> </tr> <tr> <td>1.04 (95% CI 0.38-2.87)</td> </tr> <tr> <td>1.13 (95% CI 1.05-2.92)</td> </tr> <tr> <td>1.56 (95% CI 1.4-1.74)</td> </tr> <tr> <td rowspan=\"2\">No birth control</td> <td>1.31 (95% CI 1.14-1.5)</td> </tr> <tr> <td>1.53 (95% CI 1.06-2.18)</td> </tr> <tr> <td rowspan=\"4\">Patient suspects that she is pregnant</td> <td>1.6 (95% CI 1.39-1.85)</td> </tr> <tr> <td>3.15 (95% CI 2.37-4.2)</td> </tr> <tr> <td>1.6 (95% CI 1.39-1.85)</td> </tr> <tr> <td>2.11 (95% CI 1.97-2.27)</td> </tr> <tr> <td>Morning sickness</td> <td>2.7 (95% CI 2.19-3.33)</td> </tr> <tr> <td>Any pregnancy symptoms (defined as morning sickness, breast tenderness and fullness, urinary frequency, or fatigue)</td> <td>2.43 (95% CI 1.71-3.44)</td> </tr> <tr> <td>Characteristic breast changes on physical examination</td> <td>2.71 (95% CI 2.3-3.2)</td> </tr> <tr> <td>Palpable fundus on physical examination</td> <td>2.77 (95% CI 1.7-4.51)</td> </tr> <tr> <td>Chadwick sign present</td> <td>3.17 (95% CI 2.22-4.51)</td> </tr> <tr> <td>Uterine artery pulsations present</td> <td>10.98 (95% CI 5.63-21.4)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 60503 Version 3.0</div></div></div>"},"60504":{"type":"graphic_picture","displayName":"Bilateral 4th nerve palsy","title":"Bilateral superior oblique palsy","html":"<div class=\"graphic\"><div style=\"width: 508px\" class=\"figure\"><div class=\"ttl\">Bilateral superior oblique palsy</div><div class=\"cntnt\"><img style=\"width:488px; height:303px;\" src=\"images/PEDS/60504_Bilateral_4th_nerve_palsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A patient with a bilateral fourth nerve palsy demonstrates a reversing hypertropia (left hypertropia in right gaze and a right hypertropia in left gaze in the middle panels right and left). The primary position deviation is not readily apparent because of the bilateral palsy (middle row center panel). There is underaction of both superior oblique muscles (right lower and left lower panels). There is overaction of the inferior oblique muscle bilaterally (right upper and left upper panels).</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2001. Copyright &#169;2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60504 Version 3.0</div></div></div>"},"60507":{"type":"graphic_picture","displayName":"3 3 2 rule for identifying a difficult airway","title":"The 3-3-2 rule for identifying a difficult airway","html":"<div class=\"graphic\"><div style=\"width: 583px\" class=\"figure\"><div class=\"ttl\">The 3-3-2 rule for identifying a difficult airway</div><div class=\"cntnt\"><img style=\"width:563px; height:186px;\" src=\"images/EM/60507_3_3_2_rule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The spatial relationships depicted here are important determinants of successful direct laryngoscopy. <br />(A) The patient can open his/her mouth sufficiently to admit three of his/her own fingers. <br />(B) The distance between the mentum and the neck/mandible junction (near the hyoid bone) is the length of three of the patient's fingers. <br />(C) The space between the superior notch of the thyroid cartilage and the neck/mandible junction, near the hyoid bone, is the length of two of the patient's fingers.</div><div id=\"graphicVersion\">Graphic 60507 Version 5.0</div></div></div>"},"60508":{"type":"graphic_diagnosticimage","displayName":"Acute ulcerative colitis BE","title":"Acute ulcerative colitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute ulcerative colitis</div><div class=\"cntnt\"><img style=\"width:220px; height:360px;\" src=\"images/GAST/60508_Acute_ulcerative_colitis_BE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Double contrast barium enema demonstrates extensive mucosal ulceration and inflammation throughout the colon.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD</div><div id=\"graphicVersion\">Graphic 60508 Version 2.0</div></div></div>"},"60512":{"type":"graphic_diagnosticimage","displayName":"Adult shoulder hemiarthroplast","title":"Shoulder hemiarthroplasty","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shoulder hemiarthroplasty</div><div class=\"cntnt\"><img style=\"width:432px; height:373px;\" src=\"images/EM/60512_Adult_shoulder_hemiarthropl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This postoperative anteroposterior radiograph shows a prosthesis that replaces the native humeral head. The shoulder hemiarthroplasty was necessitated by a complex proximal humerus fracture (categorized as &quot;three-part&quot; in the Neer system).</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 60512 Version 2.0</div></div></div>"},"60513":{"type":"graphic_figure","displayName":"Pathways of complement activation","title":"Pathways of complement activation","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Pathways of complement activation</div><div class=\"cntnt\"><img style=\"width:467px; height:317px;\" src=\"images/ALLRG/60513_Pathways_complement_act_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The three pathways of complement activation are shown. Each leads to generation of activated C3b. The classical pathway is triggered by antibody interacting with antigen, and the lectin pathway by a lectin binding to a sugar. The alternative pathway turns over continuously. Activation of the complement system leads to inflammation (release of anaphylatoxins C3a and C5a), membrane perturbation and lysis (via the membrane attack complex, C5b-9), and opsonization (deposition of C3b and C4b).</div><div class=\"graphic_footnotes\">MASP: mannose-binding lectin (MBL)-associated serine protease.</div><div id=\"graphicVersion\">Graphic 60513 Version 5.0</div></div></div>"},"60514":{"type":"graphic_figure","displayName":"Psoas hitch ureteral reimplantation","title":"Psoas hitch ureteral reimplantation","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Psoas hitch ureteral reimplantation</div><div class=\"cntnt\"><img style=\"width:539px; height:420px;\" src=\"images/SURG/60514_Psoas-hitch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A)&nbsp;represents mobilization of the bladder, with fingers inserted into the bladder to assist with anchoring the bladder to the psoas muscle with nonabsorbable sutures. The cystostomy is performed away from the dome. The ureter is reimplanted into the dome of the bladder.<br />(B) represents the reimplanted ureter, anchored bladder, and the closed cystostomy.</div><div id=\"graphicVersion\">Graphic 60514 Version 3.0</div></div></div>"},"60515":{"type":"graphic_table","displayName":"Stepwise FM therapy","title":"Stepwise fibromyalgia therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stepwise fibromyalgia therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Initial approach in every patient</td> </tr> <tr> <td>Confirm the diagnosis</td> </tr> <tr> <td>Education: explain the condition</td> </tr> <tr> <td>Evaluate and treat comorbidities, such as mood and sleep disturbances</td> </tr> <tr> <td class=\"subtitle1_single\">Most patients</td> </tr> <tr> <td>Trial with low-dose tricyclic antidepressants or selected antidepressants or anticonvulsants proven effective in fibromyalgia</td> </tr> <tr> <td>Exercise program</td> </tr> <tr> <td class=\"subtitle1_single\">Patients not responding to above</td> </tr> <tr> <td>Specialty referral (eg, rheumatologist, physiatrist, psychiatrist, pain management)</td> </tr> <tr> <td>Combinations of drug therapies</td> </tr> <tr> <td>Physical therapy measures</td> </tr> <tr> <td>Psychological interventions, such as cognitive behavioral therapy</td> </tr> <tr> <td>Multidisciplinary programs</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004; 292:2388.</div><div id=\"graphicVersion\">Graphic 60515 Version 2.0</div></div></div>"},"60519":{"type":"graphic_figure","displayName":"Etonogestrel levels","title":"ENG decline after Implanon removal","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">ENG decline after Implanon removal</div><div class=\"cntnt\"><img style=\"width:505px; height:435px;\" src=\"images/OBGYN/60519_Etonogestrel_levels_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Etonogestrel levels undetectable within one week. &gt;90 percent of subjects ovulated within one month of post-removal; 44 of 47 women who were studied with ultrasound and hormone levels.</div><div class=\"graphic_reference\">Data from: Davies GC, Feng LX, Newton JR, et al. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel. Contraception 1993; 47:251 and Croxatto HB, Makarainen L. The pharmacodynamics and efficacy of Implanon&#174;: An overview of the data. Contraception 1998; 58:91S.</div><div id=\"graphicVersion\">Graphic 60519 Version 3.0</div></div></div>"},"60520":{"type":"graphic_algorithm","displayName":"Diagnosis of adrenal insufficiency in children","title":"Diagnosis of adrenal insufficiency in children","html":"<div class=\"graphic\"><div style=\"width: 656px\" class=\"figure\"><div class=\"ttl\">Diagnosis of adrenal insufficiency in children</div><div class=\"cntnt\"><img style=\"width:636px; height:406px;\" src=\"images/PEDS/60520_Diagnosis_adrenal_insuff.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CNS: central nervous system; ACTH: adrenocorticotropic hormone; CAH: congenital adrenal hyperplasia; AHC: adrenal hypoplasia congenita; ALD: adrenoleukodystrophy; AMN: adrenomyeloneuropathy; PRA: plasma renin activity.<br />* ACTH resistance is a characteristic of familial glucocorticoid deficiency (usually caused by a mutation in the melanocortin 2 receptor [MCR2]), and of \"triple A syndrome\" (Allgrove syndrome).</div><div id=\"graphicVersion\">Graphic 60520 Version 4.0</div></div></div>"},"60521":{"type":"graphic_figure","displayName":"A1C pramlin vs Pbo B","title":"Mean change ± standard deviation in A1c and body weight in patients with type 2 diabetes treated with insulin plus either pramlintide or placebo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mean change ± standard deviation in A1c and body weight in patients with type 2 diabetes treated with insulin plus either pramlintide or placebo</div><div class=\"cntnt\"><img style=\"width:433px; height:446px;\" src=\"images/ENDO/60521_A1C_pramlin_vs_Pbo_B.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HbA1c: glycated hemoglobin.<br />* p&lt;0.05.<br />• p&lt;0.001.</div><div class=\"graphic_reference\">Reproduced with permission from: Buse J, Weyer C, Maggs D. Amylin replacement with pramlintide in type 1 and type 2 diabetes: A physiological approach to overcome barriers with insulin therapy. Clinical Diabetes 2002; 20:137. Copyright © 2002 The American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 60521 Version 3.0</div></div></div>"},"60522":{"type":"graphic_algorithm","displayName":"Pediatric oropharyngeal trauma algorithm","title":"Evaluation and management of oropharyngeal trauma in children","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Evaluation and management of oropharyngeal trauma in children</div><div class=\"cntnt\"><img style=\"width:538px; height:424px;\" src=\"images/EM/60522_OP_trauma_eval_mng_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CTA: computed tomography angiography.<br />* Internal carotid artery abnormality, tissue disruption or air near carotid sheath.<br />&#182; Admission is warranted if social concerns prevent home observation.</div><div id=\"graphicVersion\">Graphic 60522 Version 3.0</div></div></div>"},"60524":{"type":"graphic_diagnosticimage","displayName":"Cumulus oophorus","title":"Cumulus oophorus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cumulus oophorus</div><div class=\"cntnt\"><img style=\"width:385px; height:264px;\" src=\"images/ENDO/60524_Cumulus_oophorus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasonography of an ovary near the end of the follicular phase of the menstrual cycle. The red arrow points to the dissociating cumulus oophorus.</div><div class=\"graphic_reference\">Courtesy of Judith Adams, DMU.</div><div id=\"graphicVersion\">Graphic 60524 Version 2.0</div></div></div>"},"60525":{"type":"graphic_figure","displayName":"Overview T cell activation","title":"Overview of T cell activation and proliferation showing the site of action of available and experimental immunomodulatory agents","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Overview of T cell activation and proliferation showing the site of action of available and experimental immunomodulatory agents</div><div class=\"cntnt\"><img style=\"width:597px; height:390px;\" src=\"images/GAST/60525_Overview_T_cell_activation.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Vierling, JM. Clinical Use of Immunosuppressive Drugs to Control the Immune Response. In: Liver Immunology: Principles and Practice, Gershwin, ME, Vierling, JM, Manns, MP (Eds), Humana Press, Totowa 2007. Copyright &#169;2007 Springer-Verlag.</div><div id=\"graphicVersion\">Graphic 60525 Version 1.0</div></div></div>"},"60526":{"type":"graphic_table","displayName":"Sedative herbal ingredients","title":"Sedative herbal ingredients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sedative herbal ingredients</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Drug</td>\n<td class=\"subtitle1\">Effect</td>\n</tr>\n<tr>\n<td>Calamus</td>\n<td>Potentiation barbituate sleeping time</td>\n</tr>\n<tr>\n<td>Celery</td>\n<td>In vivo</td>\n</tr>\n<tr>\n<td>Chamomile, German</td>\n<td>Human</td>\n</tr>\n<tr>\n<td>Couchgrass</td>\n<td>In vivo</td>\n</tr>\n<tr>\n<td>Elecampane</td>\n<td>In vivo</td>\n</tr>\n<tr>\n<td>Ginseng</td>\n<td>CNS depressant and stimulant</td>\n</tr>\n<tr>\n<td>Goldenseal</td>\n<td>In vivo</td>\n</tr>\n<tr>\n<td>Hops</td>\n<td>In vivo</td>\n</tr>\n<tr>\n<td>Hydrocotyle</td>\n<td>In vivo</td>\n</tr>\n<tr>\n<td>Jamaica Dogwood</td>\n<td>In vivo</td>\n</tr>\n<tr>\n<td>Nettle</td>\n<td>CNS depression, in vivo</td>\n</tr>\n<tr>\n<td>Passionflower</td>\n<td>In vivo</td>\n</tr>\n<tr>\n<td>Sage</td>\n<td>In vivo</td>\n</tr>\n<tr>\n<td>Scullcap</td>\n<td>Reputed action</td>\n</tr>\n<tr>\n<td>Shepherd's Purse</td>\n<td>Potentiation barbituate sleeping time</td>\n</tr>\n<tr>\n<td>St. John's Wort</td>\n<td>Traditional use, bioflavonoids</td>\n</tr>\n<tr>\n<td>Valerian</td>\n<td>Human, in vivo</td>\n</tr>\n<tr>\n<td>Wild carrot</td>\n<td>In vivo</td>\n</tr>\n<tr>\n<td>Wild lettuce</td>\n<td>In vivo, related species</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted with permission from Newall CA, Anderson LA, Phillipson JD. Herbal Medicines: A Guide for Health-Care Professionals, The Pharmaceutical Press, London 1996. p.283.</div><div id=\"graphicVersion\">Graphic 60526 Version 2.0</div></div></div>"},"60528":{"type":"graphic_figure","displayName":"Extravasation of circulating leukocytes","title":"Schematic representation showing extravasation of circulating leukocytes","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Schematic representation showing extravasation of circulating leukocytes</div><div class=\"cntnt\"><img style=\"width:548px; height:344px;\" src=\"images/RHEUM/60528_Steps_in_leukocyte_migratio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Physiologic mechanisms which underlie hematopoietic cell movement into extravascular tissue. A sequential multistep process, which involves margination, rolling, adherence, and diapedesis, is utilized by circulating leukocytes to migrate out of the vasculature and move directionally into areas of inflammation and infection. Each discrete step requires the actions of different adhesion molecules. Selectins primarily mediate cellular margination and rolling, while integrins and their receptors (immunoglobulin superfamily of adhesion molecules) are used for adherence to and diapedesis through endothelial cells.</div><div id=\"graphicVersion\">Graphic 60528 Version 2.0</div></div></div>"},"60529":{"type":"graphic_table","displayName":"Safe food handling PI","title":"Tips for safe food handling","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tips for safe food handling</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Purchase</td> </tr> <tr> <td>Do not buy already-cooked food that is stored next to raw food, even if it is stored on ice.</td> </tr> <tr> <td>Do not buy food in cans that are dented, cracked, or have a bulging lid.</td> </tr> <tr> <td class=\"subtitle1_single\">Storage</td> </tr> <tr> <td>Make sure meat and poultry products are refrigerated when bought.</td> </tr> <tr> <td>Use plastic bags to keep juices from meat and fish from touching other foods.</td> </tr> <tr> <td>Store perishable items (that can go bad quickly) in the refrigerator within an hour of buying.</td> </tr> <tr> <td>Keep refrigerator temperature between 32 and 40&#176;F (0 and 4&#176;C) and freezer temperature at or below 0&#176;F (-18&#176;C).</td> </tr> <tr> <td>Freeze meat and poultry that will not be cooked within 48 hours.</td> </tr> <tr> <td>Freeze tuna, bluefish, and mahi-mahi that will not be cooked within 24 hours. Other fish can be stored in the refrigerator for 48 hours.</td> </tr> <tr> <td>Do not store eggs on the refrigerator door (since that is the warmest part of the refrigerator).</td> </tr> <tr> <td>Put leftovers in the refrigerator within 2 hours of cooking them.</td> </tr> <tr> <td>Divide leftovers into parts and store in small containers.</td> </tr> <tr> <td>Reheat leftovers to 165&#176;F (74&#176;C) before eating.</td> </tr> <tr> <td class=\"subtitle1_single\">Preparation</td> </tr> <tr> <td>Wash hands with soap and water before cooking and after handling raw meat, poultry, fish, or raw eggs.</td> </tr> <tr> <td>Thaw frozen meats and fish in the refrigerator or microwave, not by leaving them out.</td> </tr> <tr> <td>Marinate foods in the refrigerator, not at room temperature.</td> </tr> <tr> <td>Avoid contact of cooked foods with forks, spoons, knives, plates, or areas that&nbsp;might not be clean.</td> </tr> <tr> <td>Wash forks, spoons, knives, plates, and cutting areas with soap and water after they have touched raw meat, poultry, fish, or eggs.</td> </tr> <tr> <td>Avoid letting the juices from uncooked meat, poultry, or fish touch cooked foods or foods that will be eaten raw.</td> </tr> <tr> <td>Carefully wash all fresh fruits and vegetables.</td> </tr> <tr> <td>Avoid recipes that include raw eggs.</td> </tr> <tr> <td class=\"subtitle1_single\">Cooking</td> </tr> <tr> <td> <p>Use a meat thermometer.</p> <ul> <li>Cook beef, veal, and lamb (steaks, roasts, chops) to 145&#176;F (63&#176;C) and rest for&nbsp;3 minutes. </li> <li>Cook ground beef, pork, veal, and lamb&nbsp;to 160&#176;F (71&#176;C). </li> <li>Cook poultry (chicken, turkey) to 165&#176;F (74&#176;C). </li> <li>Cook fresh pork (roasts, chops, ham that is not precooked)&nbsp;to 145&#176;F (63&#176;C) and rest for 3 minutes. </li> <li>Cook precooked ham to 140&#176;F (60&#176;C). </li> <li>Cook fish until the flesh is firm and separates easily with a fork. </li> <li>Cook shellfish&nbsp;until the flesh is firm. </li> </ul> </td> </tr> <tr> <td>Cook eggs until the yolk and white are firm.</td> </tr> <tr> <td>Boil juices from raw meat or fish before using on cooked food.</td> </tr> <tr> <td class=\"subtitle1_single\">Serving</td> </tr> <tr> <td>Serve cooked foods on clean plates with clean forks, spoons, and knives.</td> </tr> <tr> <td>Keep hot foods at 140&#176;F (60&#176;C) and cold foods below 40&#176;F (4&#176;C).</td> </tr> <tr> <td>Never leave foods at room temperature longer than 2 hours, or 1 hour if the room is hotter than 90&#176;F (32&#176;C).</td> </tr> <tr> <td>Use coolers and ice packs to take perishable foods (that might go bad) away from home.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">United States Department of Agriculture. Food Safety. Available at <A href=\"http://www.foodsafety.gov/\">http://www.foodsafety.gov</A>&nbsp;(Accessed on January 19, 2016).</div><div id=\"graphicVersion\">Graphic 60529 Version 6.0</div></div></div>"},"60530":{"type":"graphic_picture","displayName":"Pemphigus foliaceus scalp","title":"Pemphigus foliaceus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pemphigus foliaceus</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/60530_Pemphigusfoliaceousscalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The scalp and periauricular lesions resemble those of seborrheic dermatitis in this patient with pemphigus foliaceus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60530 Version 6.0</div></div></div>"},"60534":{"type":"graphic_picture","displayName":"Histologic appearance of meningioma grades I-III","title":"Histologic appearance of meningioma, WHO grades I-III","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Histologic appearance of meningioma, WHO grades I-III</div><div class=\"cntnt\"><img style=\"width:468px; height:151px;\" src=\"images/ONC/60534_Lightmicroscopymeningioma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: transitional meningioma (grade I) showing characteristic cellular whorls; intranuclear pseudo-inclusions are visible in some cells. Middle panel: Chordoid meningioma (grade II) with cohesive epithelial-like cords of cells; small foci of more typical arachnoidal differentiation are found in most of these tumors. Right panel: anaplastic meningioma (grade III) consisting of pleomorphic arachnoidal cells with a high mitotic rate; foci of necrosis are widely distributed throughout most anaplastic meningiomas.</div><div class=\"graphic_reference\">Reproduced with permission from: Whittle IR, Smith C, Navoo P, Collie D. Meningiomas. The Lancet 2004; 363:1536. Copyright ©2004 Elsevier.</div><div id=\"graphicVersion\">Graphic 60534 Version 4.0</div></div></div>"},"60535":{"type":"graphic_table","displayName":"Prevalence of dyspnea in advanced illness","title":"Prevalence of dyspnea in select advanced illnesses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of dyspnea in select advanced illnesses</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Population</td> <td class=\"subtitle1\">Prevalence of dyspnea (percent)</td> <td class=\"subtitle1\">References</td> </tr> <tr> <td>Cancer (mixed)</td> <td>10 to 70</td> <td>Solano 2006<sup>[1]</sup></td> </tr> <tr> <td>AIDS</td> <td>11 to 62</td> <td>Solano 2006<sup>[1]</sup></td> </tr> <tr> <td>Lung cancer (primary or metastatic)</td> <td>62 to 95</td> <td>Currow 2010<sup>[2]</sup></td> </tr> <tr> <td>Heart disease</td> <td>60 to 88</td> <td>Solano 2006<sup>[1]</sup></td> </tr> <tr> <td>COPD</td> <td>90 to 95</td> <td>Solano 2006<sup>[1]</sup></td> </tr> <tr> <td>Renal disease</td> <td>11 to 62</td> <td>Solano 2006<sup>[1]</sup></td> </tr> <tr> <td>Stroke</td> <td>37</td> <td>Addington-Hall 1995<sup>[3]</sup></td> </tr> <tr> <td>ALS</td> <td>47 to 50</td> <td>O'Brien 1992<sup>[4]</sup>, Hicks 1993<sup>[5]</sup></td> </tr> <tr> <td>Dementia</td> <td>70</td> <td>Lloyd-Williams 1996<sup>[6]</sup></td> </tr> <tr> <td>No cardiorespiratory disease (ie, no primary or secondary lung malignancy, cardiac failure, or respiratory disease)</td> <td>45 to 81</td> <td>Currow 2010<sup>[2]</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AIDS: acquired immunodeficiency syndrome; COPD: chronic obstructive pulmonary disease; ALS: amyotrophic lateral sclerosis.</div><div class=\"graphic_reference\">References:<br> <ol> <li>Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 2006; 31:58. </li> <li>Currow DC, Smith J, Davidson PM, et al. Do the trajectories of dyspnea differ in prevalence and intensity by diagnosis at the end of life? A consecutive cohort study. J Pain Symptom Manage 2010; 39:680. </li> <li>Addington-Hall J, Lay M, Altmann D, et al. Symptom control, communication with health professionals, and hospital care of stroke patients in the last year of life as reported by surviving family, friends and officials. Stroke 1995; 26:2242. </li> <li>O'Brien T, Kelly M, Saunders C. Motor neuron disease: a hospice perspective. BMJ 1992; 304:471. </li> <li>Hicks F, Corcoran G. Should hospices offer respite admissions to patient with motor neurone disease? Palliat Med 1993; 7:145. </li> <li>Lloyd-Williams M. A survey of palliative care given to patients with end-stage dementia (abstract). Palliat Med 1996; 10:63. </li> </ol></div><div id=\"graphicVersion\">Graphic 60535 Version 4.0</div></div></div>"},"60537":{"type":"graphic_table","displayName":"Plain film signs appendicitis","title":"Plain radiographic signs of acute appendicitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Plain radiographic signs of acute appendicitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td> Right lower quadrant fecalith</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Localized ileus with air/fluid levels</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Paucity of gas in the right lower quadrant</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Scoliosis concave to the right</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Loss of the psoas shadow</td>\n\n    </tr>\n\n    <tr>\n\n      <td> Soft tissue mass</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 60537 Version 1.0</div></div></div>"},"60538":{"type":"graphic_figure","displayName":"FPLD type 2","title":"Patient with familial partial lipodystrophy type 2","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patient with familial partial lipodystrophy type 2</div><div class=\"cntnt\"><img style=\"width:371px; height:603px;\" src=\"images/ENDO/60538_CongenitallipodysB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">FPLD&nbsp;of the Dunnigan variety resulting from a missense mutation in the<EM> LMNA</EM> gene that encodes lamins A and C. Note the loss of fat from the extremities and trunk and excess accumulation of fat in the face and neck.</div><div class=\"graphic_footnotes\">FPLD: familial partial lipodystrophy.</div><div id=\"graphicVersion\">Graphic 60538 Version 6.0</div></div></div>"},"60540":{"type":"graphic_figure","displayName":"Interphase FISH","title":"Interphase FISH","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Interphase FISH</div><div class=\"cntnt\"><img style=\"width:433px; height:300px;\" src=\"images/HEME/60540_Interphase_FISH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Interphase fluorescence in situ hybridization (FISH) is a modification of FISH analysis that allows high resolution analysis because probes are hybridized to minimally condensed interphase chromosomes. In the interphase nucleus, chromosomal structures cannot be discerned and only the hybridized probe will light up. The cell nucleus in this figure was hybridized with a probe for a region on the X chromosome (red) and one for an area on the Y chromosome (green). The presence of three separate signals indicates that this individual has two X chromosomes (red) and one Y chromosome (green). This chromosomal abnormality causes Klinefelter syndrome.</div><div id=\"graphicVersion\">Graphic 60540 Version 1.0</div></div></div>"},"60541":{"type":"graphic_table","displayName":"Fitzpatrick skin phototypes","title":"Fitzpatrick skin phototypes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fitzpatrick skin phototypes</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1\">Skin type </td>\r\n                    <td class=\"subtitle1\">Unexposed skin color </td>\r\n                    <td class=\"subtitle1\">Reaction to sun exposure* </td>\r\n                </tr>\r\n                <tr>\r\n                    <td>I</td>\r\n                    <td>White</td>\r\n                    <td>Always burns, never tans</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>II</td>\r\n                    <td>White</td>\r\n                    <td>Always burns, minimal tan</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>III</td>\r\n                    <td>White to olive</td>\r\n                    <td>Burns minimally, gradually tans</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>IV</td>\r\n                    <td>Light brown</td>\r\n                    <td>Burns minimally, tans well</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>V</td>\r\n                    <td>Brown</td>\r\n                    <td>Very rarely burns, tans profusely</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>VI</td>\r\n                    <td>Dark brown to black</td>\r\n                    <td>Never burns, tans deeply</td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=58854&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_lgnd\">Note: Slight variations on the definitions of the phototypes appear in the literature.</div><div class=\"graphic_footnotes\">* After the first one hour of sun exposure on untanned skin on the first day of spring.</div><div id=\"graphicVersion\">Graphic 60541 Version 4.0</div></div></div>"},"60543":{"type":"graphic_table","displayName":"Pulm tox neoplastic agents","title":"Clinical syndromes of pulmonary toxicity caused by antineoplastic agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical syndromes of pulmonary toxicity caused by antineoplastic agents</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Syndromes\n   </td>\n   <td  class=\"subtitle1\">\n   Description\n   </td>\n   </tr>\n   <tr>\n   <td>Acute bronchoconstriction</td>\n   <td>Evidence of airflow limitation (eg, wheezing, prolonged expiratory phase, reduced FEV1)</td>\n   </tr>\n   <tr>\n   <td>Infusion reaction</td>\n   <td>\t<p>Acute onset of symptoms/signs (eg, angioedema, flushing, itching, urticaria, arthralgias, bronchoconstriction, dyspnea, hypotension, hypoxemia, nausea, or back pain) during or shortly after infusion</p>\n\t<p>May be caused by mast cell/basophil activation or cytokine release in a systemic inflammatory reaction</p>\n</td>\n   </tr>\n   <tr>\n   <td>Alveolar hemorrhage</td>\n   <td>Dyspnea, sometimes hemoptysis, diffuse radiographic opacities, hypoxemia, BAL fluid with evidence of hemorrhage</td>\n   </tr>\n   <tr>\n   <td>Eosinophilic pneumonia</td>\n   <td>Dyspnea, diffuse radiographic pulmonary opacities, hypoxemia, and BAL fluid eosinophilia (&#62;20 percent eosinophils), sometimes with peripheral eosinophilia</td>\n   </tr>\n   <tr>\n   <td>Hypersensitivity pneumonitis</td>\n   <td>\t<p>Dyspnea and radiographic pulmonary opacities developing within hours to days of treatment due to a cell-mediated (Type IV) delayed hypersensitivity reaction</p>\n\t<p>May be associated with pulmonary eosinophilia</p>\n</td>\n   </tr>\n   <tr>\n   <td>Interstitial pneumonitis (includes nonspecific interstitial pneumonia, usual interstitial pneumonia, and organizing pneumonia)</td>\n   <td>Dyspnea, cough, sometimes fever, diffuse or focal radiographic opacities (eg, septal thickening, ground glass opacities, consolidation) and nonspecific BAL findings</td>\n   </tr>\n   <tr>\n   <td>Radiation recall lung injury</td>\n   <td>\t<p>Appearance of radiographic opacities in areas of prior irradiation in response to treatment with a cytotoxic agent</p>\n\t<p>Often associated with cough and dyspnea</p>\n</td>\n   </tr>\n   <tr>\n   <td>Noncardiogenic pulmonary edema</td>\n   <td>Pulmonary edema without evidence of heart failure or increase in left atrial pressure</td>\n   </tr>\n   <tr>\n   <td>Capillary leak syndrome</td>\n   <td>Noncardiogenic pulmonary edema associated with diffuse peripheral edema and sometimes intravascular hypovolemia</td>\n   </tr>\n   <tr>\n   <td>Acute lung injury/ARDS</td>\n   <td>Noncardiogenic pulmonary edema PLUS evidence of acute inflammation (eg, fever, elevated neutrophils in BAL fluid)</td>\n   </tr>\n </table></div><div class=\"graphic_footnotes\">FEV1: forced expiratory volume in one second; BAL: bronchoalveolar lavage; ARDS: acute respiratory distress syndrome.</div><div id=\"graphicVersion\">Graphic 60543 Version 1.0</div></div></div>"},"60544":{"type":"graphic_picture","displayName":"Trigeminal nerve danger zones","title":"Danger zones for supraorbital, supratrochlear, infraorbital, and mental branches of the trigeminal nerve","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Danger zones for supraorbital, supratrochlear, infraorbital, and mental branches of the trigeminal nerve</div><div class=\"cntnt\"><img style=\"width:469px; height:635px;\" src=\"images/DERM/60544_Trigeminal_nerve_danger_zones.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trigeminal nerve danger zones. The supraorbital and supratrochlear nerves (area 1). The infraorbital nerve (area 2). The mental nerve (area 3).</div><div id=\"graphicVersion\">Graphic 60544 Version 2.0</div></div></div>"},"60545":{"type":"graphic_table","displayName":"Medicare resources PI","title":"Help with understanding and choosing a Medicare Part D plan","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Help with understanding and choosing a Medicare Part D plan</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">These websites are only for people on Medicare</td> </tr> <tr> <td><strong>Medicare:</strong> This is the official government website that lists the different drug plans Medicare offers. Here you can compare the plans offered in your state and view each plan's formulary (list of covered drugs). <ul> <li>General site: <a href=\"http://www.medicare.gov/\" spellcheck=\"true\" target=\"_blank\">www.medicare.gov</a> </li> <li>Site with information on state help with drug payment (how to contact each program, who is eligible, and other details you should know): <a href=\"https://www.medicare.gov/pharmaceutical-assistance-program/state-programs.aspx\" spellcheck=\"true\" target=\"_blank\">https://www.medicare.gov/pharmaceutical-assistance-program/state-programs.aspx</a> </li> <li>Phone:1-800-MEDICARE (1-800-633-4227) </li> </ul> </td> </tr> <tr> <td><strong>Medicare Rights Center:</strong> This is an independent non-profit consumer advocacy group that helps people navigate the Medicare system. The group offers a hotline with counselors who can answer questions and help you make the most out of your Medicare coverage. <ul> <li>Website: <a href=\"http://www.medicarerights.org/\" spellcheck=\"true\" target=\"_blank\">www.medicarerights.org</a> </li> <li>Phone: 1-800-333-4114 </li> </ul> </td> </tr> <tr> <td><strong>Social Security Extra Help Program:</strong> Only for people with Medicare, this official government site has information about the Extra Help program. The Extra Help program helps people pay for the costs<span style=\"color: black;\"> (monthly premiums, annual deductibles, and prescription co-payments)</span><span style=\"color: black;\"> related </span>to a Medicare prescription drug plan. <ul> <li>Website: <a href=\"http://www.ssa.gov/prescriptionhelp\" spellcheck=\"true\" target=\"_blank\">www.ssa.gov/prescriptionhelp</a> </li> <li>Site with information about applying to the Extra Help program: <a href=\"http://www.ssa.gov/pubs/10525.html\" spellcheck=\"true\" target=\"_blank\">www.ssa.gov/pubs/10525.html</a> </li> </ul> </td> </tr> <tr> <td><strong>SHIP: State Health Insurance Assistance Program:</strong> SHIP is a national program that offers counseling and help to people with Medicare and their families. This site can help you find a counselor in your area who will meet with you one on one and talk to you about your Medicare options. <ul> <li>Website: <a href=\"https://www.shiptacenter.org/\" spellcheck=\"true\" target=\"_blank\">https://www.shiptacenter.org/</a> </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 60545 Version 7.0</div></div></div>"},"60548":{"type":"graphic_picture","displayName":"Motility medium Shigella","title":"Motility testing on nonlactose fermenting gram negative rods","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Motility testing on nonlactose fermenting gram negative rods</div><div class=\"cntnt\"><img style=\"width:221px; height:274px;\" src=\"images/ID/60548_Motility_medium_Shigella.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left tube: The nonmotile Shigella does not migrate away from the central stab line in the agar. Right tube: Motile Proteus produces visible opacification of the agar away from the central stab line. The color difference between the two samples is unrelated to the motility test.</div><div class=\"graphic_reference\">Courtesy of Michael S Glickman, MD.</div><div id=\"graphicVersion\">Graphic 60548 Version 1.0</div></div></div>"},"60550":{"type":"graphic_table","displayName":"Causes of light near dissociation","title":"Etiologies of light-near dissociation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologies of light-near dissociation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Bilateral anterior afferent visual pathway disease (retina, optic nerve, chiasm, tract)</td>\n</tr>\n<tr>\n<td>Dorsal midbrain lesions (eg, vascular, neoplastic, traumatic, demyelinating, toxic, ischemic, inflammatory)</td>\n</tr>\n<tr>\n<td>Argyll Robertson pupil</td>\n</tr>\n<tr>\n<td>Diabetes (autonomic neuropathy)</td>\n</tr>\n<tr>\n<td>Tonic pupils (eg, local orbital disease, systemic neuropathic disorders, Adie's tonic pupil)</td>\n</tr>\n<tr>\n<td>Aberrant third nerve regeneration of the third nerve</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Lee AG, Brazis PW. Clinical Pathways in Neuro-ophthalmology, Thieme, NY, 2002. Copyright © 2002 Thieme Medical Publishers, Inc.</div><div id=\"graphicVersion\">Graphic 60550 Version 7.0</div></div></div>"},"60551":{"type":"graphic_figure","displayName":"Lung ca II PI","title":"Stage II lung cancer","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Stage II lung cancer</div><div class=\"cntnt\"><img style=\"width:544px; height:398px;\" src=\"images/PI/60551_Lung_ca_II_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts a stage II cancer. In stage II cancer, the tumor is bigger than in stage I or it has spread to nearby lymph nodes or it has spread into the large bronchial tubes.</div><div id=\"graphicVersion\">Graphic 60551 Version 5.0</div></div></div>"},"60552":{"type":"graphic_figure","displayName":"Position of safety hand","title":"Position of safety of the hand","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Position of safety of the hand</div><div class=\"cntnt\"><img style=\"width:427px; height:279px;\" src=\"images/PEDS/60552_Position_of_function_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The safe position shows the wrist extended 20 degrees, MCP joints flexed at 90 degrees, and the PIP and DIP joints fully extended.</div><div class=\"graphic_footnotes\">MCP: metacarpophalangeal; PIP: proximal interphalangeal; DIP: distal interphalangeal.</div><div class=\"graphic_reference\">Reproduced with permission from: Harrison, BP, Hilliard, MW. Emergency department evaluation and treatment of hand injuries. Emerg Med Clin North Am 1999; 17:793. Copyright © 1999 Elsevier.</div><div id=\"graphicVersion\">Graphic 60552 Version 4.0</div></div></div>"},"60553":{"type":"graphic_table","displayName":"Stages of pediatric heart failure and therapy","title":"Stages of heart failure in infants and children and recommended therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stages of heart failure in infants and children and recommended therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Examples</td> <td class=\"subtitle1\">Therapy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">A</td> <td>Patients with increased risk of developing HF, but with normal cardiac function and chamber size</td> <td> <ul> <li>Exposure to cardiotoxic agents </li> <li>Family history of heritable cardiomyopathy </li> <li>Univentricular heart </li> <li>Congenitally corrected transposition of the great arteries </li> </ul> </td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">B</td> <td>Patients with abnormal cardiac morphology or function, with no symptoms of HF, past or present</td> <td> <ul> <li>Aortic insufficiency with LV enlargement </li> <li>History of anthracycline exposure with decreased LV systolic function </li> </ul> </td> <td> <ul> <li>ACE inhibitor for patients with systemic ventricular dysfunction</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">C</td> <td>Patients with structural or functional heart disease, and past or current symptoms of HF</td> <td> <ul> <li>Symptomatic cardiomyopathy </li> <li>Congenital heart defect with ventricular pump dysfunction </li> </ul> </td> <td> <ul> <li>ACE inhibitor and an aldosterone antagonist; oral diuretic therapy&nbsp;as needed for fluid overload;&nbsp;low-dose digoxin if needed for additional symptom relief </li> <li>After a few weeks of stability, a beta blocker is added in patients with persistent LV dilation and dysfunction </li> </ul> </td> </tr> <tr> <td class=\"centered\">D</td> <td>Patients with end-stage HF requiring specialized interventions</td> <td> <ul> <li>Marked symptoms at rest despite maximal medical therapy</li> </ul> </td> <td> <ul> <li>Pharmacologic therapy consists of intravenous diuretics and/or inotropes </li> <li>Other interventions may include positive pressure ventilation, cardiac resynchronization therapy, mechanical circulatory support, and heart transplantation </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HF: heart failure; LV: left ventricular; ACE: angiotensin-converting enzyme.</div><div class=\"graphic_reference\">Original table modified for this publication. Rosenthal D, Chrisant MR, Edens E, et al. International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. J Heart Lung Transplant 2004; 23:1313. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 60553 Version 7.0</div></div></div>"},"60554":{"type":"graphic_table","displayName":"Causes pediatric earache","title":"Causes of pediatric earache","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of pediatric earache</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Traumatic injuries to the ear </td> </tr> <tr> <td class=\"indent1\">Abrasions or lacerations*</td> </tr> <tr> <td class=\"indent1\">Auricular hematoma</td> </tr> <tr> <td class=\"indent1\">Traumatic perforation of the TM</td> </tr> <tr> <td class=\"indent1\">Disruption of the ossicles<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Hemotympanum (blunt or barotrauma)</td> </tr> <tr> <td class=\"sublist2_start\">Basilar skull fracture<sup>&#182;</sup> </td> </tr> <tr> <td class=\"sublist2\">Associated intracranial injury<sup>&#182;</sup> </td> </tr> <tr> <td class=\"indent1\">Inner ear injury (blunt or barotrauma)<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Diseases of the auricle </td> </tr> <tr> <td class=\"indent1\">Cellulitis of the auricle*</td> </tr> <tr> <td class=\"indent1\">Perichondritis</td> </tr> <tr> <td class=\"indent1\">Herpes zoster oticus</td> </tr> <tr> <td class=\"indent1\">Local allergic reaction (bug bite)*</td> </tr> <tr> <td class=\"indent1\">Contact dermatitis*</td> </tr> <tr> <td class=\"indent1\">Sunburn*</td> </tr> <tr> <td class=\"indent1\">Frostbite</td> </tr> <tr> <td class=\"subtitle1_single\">Diseases of the ear canal </td> </tr> <tr> <td class=\"sublist2_start\">Otitis externa </td> </tr> <tr> <td class=\"sublist2\">Bacterial </td> </tr> <tr> <td class=\"sublist2\">Fungal </td> </tr> <tr> <td class=\"sublist2\">Malignant otitis externa<sup>&#182;</sup> </td> </tr> <tr> <td class=\"indent1\">Furunculosis</td> </tr> <tr> <td class=\"indent1\">Cerumen impaction*</td> </tr> <tr> <td class=\"indent1\">Foreign bodies*</td> </tr> <tr> <td class=\"indent1\">Granuloma</td> </tr> <tr> <td class=\"indent1\">Malignant tumor<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Contact dermatitis</td> </tr> <tr> <td class=\"indent1\">Eczema*</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Diseases of the middle and inner ear </td> </tr> <tr> <td class=\"indent1\">Acute otitis media*</td> </tr> <tr> <td class=\"indent1\">Otitis media with effusion*</td> </tr> <tr> <td class=\"indent1\">Otitis media with perforation*</td> </tr> <tr> <td class=\"indent1\">Otitis media with tympanostomy tubes*</td> </tr> <tr> <td class=\"indent1\">Myringitis</td> </tr> <tr> <td class=\"indent1\">Cholesteatoma<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Malignant tumor<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist2_start\">Complications of otitis media </td> </tr> <tr> <td class=\"sublist2\">Mastoiditis<sup>&#182;</sup> </td> </tr> <tr> <td class=\"sublist2\">Meningitis<sup>&#182;</sup> </td> </tr> <tr> <td class=\"sublist2\">Brain abscess<sup>&#182;</sup> </td> </tr> <tr> <td class=\"sublist2\">Venous sinus thrombosis<sup>&#182;</sup> </td> </tr> <tr> <td class=\"sublist2\">Inner ear infection<sup>&#182;</sup> </td> </tr> <tr> <td class=\"sublist2\">Facial nerve palsy<sup>&#182;</sup> </td> </tr> <tr> <td class=\"subtitle1_single\">Secondary otalgia </td> </tr> <tr> <td class=\"indent1\">Pharyngitis</td> </tr> <tr> <td class=\"indent1\">Stomatitis*</td> </tr> <tr> <td class=\"indent1\">Dental infection*</td> </tr> <tr> <td class=\"indent1\">Sinusitis (maxillary)</td> </tr> <tr> <td class=\"indent1\">Parotitis</td> </tr> <tr> <td class=\"indent1\">TMJ arthritis*</td> </tr> <tr> <td class=\"indent1\">Facial nerve palsy</td> </tr> <tr> <td class=\"indent1\">Psychogenic</td> </tr> <tr> <td class=\"indent1\">Sinusitis*</td> </tr> <tr> <td class=\"indent1\">Cervical spine injury<sup>&#182;</sup></td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Common diagnosis.<br />¶ Life-threatening or associated with permanent injury.<br /></div><div id=\"graphicVersion\">Graphic 60554 Version 3.0</div></div></div>"},"60555":{"type":"graphic_table","displayName":"Classification system of drug-induced acute pancreatitis","title":"Classification system of drug-induced acute pancreatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification system of drug-induced acute pancreatitis</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Class Ia drugs</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>At least 1 case report with positive rechallenge, excluding all other causes, such as alcohol, hypertriglyceridemia, gallstones, and other drugs</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Class Ib drugs</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>At least 1 case report with positive rechallenge; however, other causes, such as alcohol, hypertriglyceridemia, gallstones, and other drugs were not ruled out</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Class II drugs</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>At least 4 cases in the literature</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Consistent latency (&#8805;75 percent of cases)</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Class III drugs</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>At least 2 cases in the literature</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>No consistent latency among cases</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>No rechallenge</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1_single\">Class IV drugs</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Drugs not fitting into the earlier-described classes, single case report published in medical literature, without rechallenge</td>\n\t\t\t\t</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Badalov N, Baradarian R, Kadirawel I, et al. Drug-Induced Acute Pancreatitis: An Evidence-Based Review. Clin Gastroenterol Hepatol 2007; 5:648. Copyright &copy; 2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 60555 Version 3.0</div></div></div>"},"60560":{"type":"graphic_picture","displayName":"Sturge-Weber syndrome - bilateral PWS infant","title":"Sturge-Weber syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sturge-Weber syndrome</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/60560_SW_syndrome_bilateral_PWS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral port wine stains involving V1 are present on this infant with Sturge-Weber syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60560 Version 3.0</div></div></div>"},"60561":{"type":"graphic_figure","displayName":"Laser penetration into skin","title":"Laser penetration into skin","html":"<div class=\"graphic\"><div style=\"width: 482px\" class=\"figure\"><div class=\"ttl\">Laser penetration into skin</div><div class=\"cntnt\"><img style=\"width:462px; height:493px;\" src=\"images/DERM/60561_Laser-penetration-into-skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the range of visible light and near infrared light (400 to 1200 nm), lasers that emit long wavelengths of light penetrate more deeply into the skin than lasers that emit shorter wavelengths of light.<br> Mid-infrared (eg, Er:YAG) and far-infrared (eg, CO<sub>2</sub>) lasers do not follow this rule. Heavy absorption by water in the skin greatly limits the penetration of these lasers.</div><div id=\"graphicVersion\">Graphic 60561 Version 5.0</div></div></div>"},"60564":{"type":"graphic_figure","displayName":"Sacral neuromodulation PI","title":"Sacral neuromodulation device","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sacral neuromodulation device</div><div class=\"cntnt\"><img style=\"width:432px; height:432px;\" src=\"images/PI/60564_Interstim_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Illustrated depiction of device placement.</div><div class=\"graphic_reference\">Courtesy of Medtronic, Inc.</div><div id=\"graphicVersion\">Graphic 60564 Version 4.0</div></div></div>"},"60567":{"type":"graphic_table","displayName":"Common herbal therapies","title":"Commonly used herbal therapies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly used herbal therapies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Herb</td> <td class=\"subtitle1\">Common uses</td> </tr> <tr> <td>Aloe</td> <td>Burns, minor wounds, skin irritations, aphthous stomatitis, constipation, gastric and duodenal ulcers</td> </tr> <tr> <td>Calendula</td> <td>Skin soother</td> </tr> <tr> <td>Cascara</td> <td>Constipation</td> </tr> <tr> <td>Cayenne</td> <td>Topical treatment for pain, postherpetic neuralgia, nasal spray for migraines and cluster headaches</td> </tr> <tr> <td>Chamomile</td> <td>Sedative, colic, anti-inflammatory, antispasmodic</td> </tr> <tr> <td>Clove oil</td> <td>Teething pain</td> </tr> <tr> <td>Coffee</td> <td>Stimulant, ADHD, bronchodilator</td> </tr> <tr> <td>Dandelion</td> <td>Mild diuretic, liver tonic</td> </tr> <tr> <td>Dill</td> <td>Antispasmodic, colic, decrease flatulence</td> </tr> <tr> <td>Echinacea</td> <td>Immune stimulation, anti-inflammatory</td> </tr> <tr> <td>Feverfew</td> <td>Migraine headaches, rheumatoid arthritis</td> </tr> <tr> <td>Garlic</td> <td>Antimicrobial, cholesterol lowering</td> </tr> <tr> <td>Ginger</td> <td>Antiemetic, antinausea</td> </tr> <tr> <td>Ginseng</td> <td>Stimulant, enhance endurance and performance, adaptogen</td> </tr> <tr> <td>Hops</td> <td>Sedative</td> </tr> <tr> <td>Lavender</td> <td>Sedative</td> </tr> <tr> <td>Licorice</td> <td>Anti-inflammatory, demulcent</td> </tr> <tr> <td>Milk thistle</td> <td>Hepatoprotection; cirrhosis, hepatitis</td> </tr> <tr> <td>Oats</td> <td>Antipruritic; eczema, varicella</td> </tr> <tr> <td>Pine bark extract</td> <td>Antioxidant promoted to treat ADHD</td> </tr> <tr> <td>Rhubarb root</td> <td>Constipation, chronic renal failure</td> </tr> <tr> <td>Saint John's wort</td> <td>Depression, antiviral</td> </tr> <tr> <td>Slippery elm bark</td> <td>Demulcent; pharyngitis</td> </tr> <tr> <td>Tea tree oil</td> <td>Antimicrobial; acne; minor skin infections, including fungal and yeast infections</td> </tr> <tr> <td>Thyme</td> <td>Antimicrobial; colds, sore throats; cough; expectorant</td> </tr> <tr> <td>Valerian</td> <td>Sedative</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADHD: attention deficit hyperactivity disorder.</div><div id=\"graphicVersion\">Graphic 60567 Version 6.0</div></div></div>"},"60568":{"type":"graphic_table","displayName":"Radiographic signs malrotation","title":"Radiographic signs of intestinal malrotation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Radiographic signs of intestinal malrotation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Imaging modality</td> <td class=\"subtitle1\">Findings suggestive of intestinal malrotation</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Plain radiograph</td> <td>Nasogastric or orogastric tube that extends into an abnormally positioned duodenum</td> </tr> <tr class=\"divider_bottom\"> <td>The \"double-bubble\" sign of duodenal obstruction</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Upper GI contrast study*</td> <td>A clearly misplaced duodenum (ie, ligament of Treitz on the right side of the abdomen) that has a \"corkscrew\" appearance</td> </tr> <tr> <td>Duodenal obstruction, which may appear similar to that seen with duodenal atresia or may have more of a \"beak\" appearance if a volvulus is present</td> </tr> <tr class=\"divider_bottom\"> <td>Entire small bowel located in the right abdomen</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Barium enema</td> <td>Complete obstruction of the transverse colon, particularly if the head of the barium column has a beaked appearance</td> </tr> <tr class=\"divider_bottom\"> <td>Entire colon located in the left abdomen</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Ultrasonography</td> <td>Abnormal position of the superior mesenteric vein (anterior or to the left of the SMA)</td> </tr> <tr> <td>Third part of the duodenum does not pass between the SMA and the aorta</td> </tr> <tr> <td>Dilated duodenum (indicating duodenal obstruction)</td> </tr> <tr class=\"divider_bottom\"> <td>The \"whirlpool\" sign of volvulus (twisting of&nbsp;vessels around the base of the mesenteric pedicle)</td> </tr> <tr> <td rowspan=\"4\">Computed tomography with intravenous contrast<sup>&#182;</sup></td> <td>Third part of duodenum does not pass between the SMA and aorta</td> </tr> <tr> <td>Proximal bowel is mostly to the right of midline</td> </tr> <tr> <td>The \"whirlpool\" sign of volvulus (twisting of&nbsp;vessels around the base of the mesenteric pedicle)&nbsp;</td> </tr> <tr> <td>Abnormal position of the superior mesenteric vein (anterior or to the left of the SMA)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GI: gastrointestional; SMA: superior mesenteric artery. <br />* An upper GI contrast study is the preferred diagnostic study in infants and children with suspected intestinal malrotation.<br />¶ Computed tomography with intravenous contrast should not be the initial test for intestinal malrotation in infants and children.</div><div id=\"graphicVersion\">Graphic 60568 Version 7.0</div></div></div>"},"60570":{"type":"graphic_picture","displayName":"Collagenous colitis Light I","title":"Collagenous colitis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Collagenous colitis</div><div class=\"cntnt\"><img style=\"width:434px; height:252px;\" src=\"images/GAST/60570_Collagenous_colitis_Light_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of a colonic biopsy from a patient with collagenous colitis. There is a thickened subepithelial collagenous band (arrow) associated with increased mononuclear cell infiltration and epithelial degeneration.</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD.</div><div id=\"graphicVersion\">Graphic 60570 Version 1.0</div></div><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Normal colon</div><div class=\"cntnt\"><img style=\"width:518px; height:172px;\" src=\"images/GAST/81083_Normal_colon_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low (left) and high (right) power views of a biopsy of a normal colon. Low power reveals straight crypts and mild lamina propria mononuclear cell infiltration. High power shows the surface enterocytes with interspersed goblet cells (arrows).</div><div class=\"graphic_reference\">Courtesy of Robert Odze, MD</div><div id=\"graphicVersion\">Graphic 81083 Version 1.0</div></div></div>"},"60572":{"type":"graphic_table","displayName":"Excretion patterns in the porphyrias","title":"Excretion patterns for porphyrins, porphyrin precursors, and porphyrin metabolites; and deficient erythrocyte enzymes in the porphyrias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Excretion patterns for porphyrins, porphyrin precursors, and porphyrin metabolites; and deficient&nbsp;erythrocyte enzymes&nbsp;in the porphyrias</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of porphyria</td> <td class=\"subtitle1\">Specific porphyria</td> <td class=\"subtitle1\">Urine</td> <td class=\"subtitle1\">Stool</td> <td class=\"subtitle1\">Erythrocytes</td> <td class=\"subtitle1\">Plasma</td> </tr> <tr> <td>Acute neurovisceral</td> <td>ADP</td> <td>ALA, coproporphyrin III</td> <td>*</td> <td> <p>Zinc protoporphyrin</p> <p>Markedly decreased ALAD activity</p> </td> <td>ALA*</td> </tr> <tr> <td>Acute neurovisceral</td> <td>AIP</td> <td>ALA, PBG, uroporphyrin, coproporphyrin</td> <td>*</td> <td>Decreased PBGD activity by approximately 50%&nbsp;(most cases)*</td> <td> <p>ALA, PBG*</p> [~620 nm]<sup>&#182;</sup></td> </tr> <tr> <td>Acute neurovisceral, rarely cutaneous</td> <td>HCP</td> <td>ALA, PBG, coproporphyrin III</td> <td>Coproporphyrin III</td> <td>*</td> <td> <p>&#916;</p> [~620 nm]<sup>&#182;</sup></td> </tr> <tr> <td>Acute neurovisceral, commonly cutaneous</td> <td>VP</td> <td>ALA, PBG, coproporphyrin III</td> <td>Coproporphyrin III, protoporphyrin</td> <td>*</td> <td> <p>Porphyrin-peptide conjugate</p> [~626 to 628 nm]<sup>&#182;</sup> </td> </tr> <tr> <td>Cutaneous, blistering</td> <td>PCT and HEP</td> <td>Uroporphyrin, heptacarboxyl porphyrin</td> <td>Heptacarboxyl porphyrin, isocoproporphyrins</td> <td>Zinc protoporphyrin (markedly elevated in HEP, normal or mildly elevated in PCT)</td> <td> <p>Uroporphyrin, heptacarboxyl porphyrin</p> [~620 nm]<sup>&#182;</sup></td> </tr> <tr> <td>Cutaneous, blistering</td> <td>CEP</td> <td>Uroporphyrin I; coproporphyrin I</td> <td>Coproporphyrin I</td> <td>Uroporphyrin I; coproporphyrin I</td> <td> <p>Uroporphyrin I, coproporphyrin I</p> [~620 nm]<sup>&#182;</sup> </td> </tr> <tr> <td>Cutaneous, nonblistering</td> <td>EPP and XLP</td> <td>&#9674;</td> <td>Protoporphyrin*</td> <td>Metal-free protoporphyrin<sup>&#167;</sup></td> <td> <p>Protoporphyrin</p> [~634 nm]<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on individual porphyrias for additional information.</div><div class=\"graphic_footnotes\">ADP: ALA dehydratase porphyria; AIP: acute intermittent porphyria; CEP: congenital erythropoietic porphyria; PCT: porphyria cutanea tarda; HEP: hepatoerythropoietic porphyria; HCP: hereditary coproporphyria; VP: variegate porphyria; EPP: erythropoietic protoporphyria; ALA: delta-aminolevulinic acid; PBG: porphobilinogen; ALAD: ALA dehydratase; PBGD: porphobilinogen deaminase; XLP: X-linked protoporphyria.<br />* Porphyrin levels normal or slightly increased.<br />¶ Fluorescence emission peak of diluted plasma at neutral pH.<br />Δ Plasma porphyrins usually normal, but increased when blistering skin lesions develop.<br /><FONT class=lozenge>◊</FONT> Urine porphyrins (especially coproporphyrin) increase only with hepatopathy.<br />§ Zinc protoporphyrin ≤5 percent of total in classic EPP, but 15 to 50 percent in variant form (XLP).</div><div class=\"graphic_reference\">Provided by Karl Anderson, MD, FACP.</div><div id=\"graphicVersion\">Graphic 60572 Version 10.0</div></div></div>"},"60573":{"type":"graphic_diagnosticimage","displayName":"RLL atelectasis CT","title":"CT scan of right lower lobe atelectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of right lower lobe atelectasis</div><div class=\"cntnt\"><img style=\"width:360px; height:253px;\" src=\"images/PULM/60573_RLL_atelectasis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan of right lower lobe atelectasis showing a nearly triangular opacity in the right paraspinal region (arrow). In this patient with bronchogenic carcinoma, a mucoid bronchogram in the atelectatic lobe is evidence of the bronchial obstruction.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 60573 Version 3.0</div></div></div>"},"60574":{"type":"graphic_picture","displayName":"Pars planitis","title":"Pars planitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pars planitis</div><div class=\"cntnt\"><img style=\"width:401px; height:274px;\" src=\"images/RHEUM/60574_Pars_planitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The peripheral retinal vessels have a whitish exudate adjacent to them. This periphlebitis is sometimes seen in an inflammatory condition known as pars planitis.</div><div class=\"graphic_reference\">Courtesy of James T Rosenbaum, MD.</div><div id=\"graphicVersion\">Graphic 60574 Version 1.0</div></div></div>"},"60575":{"type":"graphic_picture","displayName":"Paget disease of the breast presentation","title":"Paget disease of the breast presentation","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Paget disease of the breast presentation</div><div class=\"cntnt\"><img style=\"width:509px; height:449px;\" src=\"images/SURG/60575_Paget_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Various presentations of Paget disease of the breast are represented here. Paget disease is typified by erythematous, scaly, and weeping \"eczema\" that involves the nipple. Discoloration, depigmentation, and desquamation of the nipple and areola are sometimes seen.</div><div class=\"graphic_reference\">(A) Weber J, Kelley J. Health Assessment in Nursing, Second Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003.<BR>(B) Rubin E, Farber JL. Pathology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999.<BR>(C) Mulholland MW, Maier RV, et al. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006.<BR>(D) Stedman's Medical Dictionary. Philadelphia: Lippincott Williams &amp; Wilkins, 2008.<BR>All figures reproduced with permission. Copyright © Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60575 Version 7.0</div></div></div>"},"60577":{"type":"graphic_picture","displayName":"Common hepatic duct mass on cholangioscopy","title":"Cholangioscopic view of common hepatic duct mass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cholangioscopic view of common hepatic duct mass</div><div class=\"cntnt\"><img style=\"width:390px; height:376px;\" src=\"images/GAST/60577_Com_hep_duct_mass_cholan_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cholangioscopy showing a mass of the common hepatic duct near the bifurcation.</div><div id=\"graphicVersion\">Graphic 60577 Version 2.0</div></div></div>"},"60584":{"type":"graphic_table","displayName":"ADHD resources","title":"Resources for families of children with attention deficit hyperactivity disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Resources for families of children with attention deficit hyperactivity disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Children and Adults with Attention Deficit/Hyperactivity Disorder (CHADD)</td> </tr> <tr> <td>CHADD is a national advocacy organization for individuals affected by AD/HD and organizes local chapters for information and support.</td> </tr> <tr> <td><a href=\"http://www.chadd.org/\" target=\"_blank\">www.chadd.org</a></td> </tr> <tr> <td class=\"subtitle1_single\">National Alliance for the Mentally Ill (NAMI)</td> </tr> <tr> <td>NAMI is a national advocacy organization for individuals affected by mental illness. NAMI provides general information and support opportunities for many mental illnesses.</td> </tr> <tr> <td><a href=\"http://www.nami.org/\" target=\"_blank\">www.nami.org</a></td> </tr> <tr> <td class=\"subtitle1_single\">National Attention Deficit Disorder Association (ADDA)</td> </tr> <tr> <td>ADDA is a non-profit, national organization that advocates for the needs of ADHD individuals and their families. ADDA is a resource for a variety of information and current research and policy updates.</td> </tr> <tr> <td><a href=\"http://www.add.org/\" target=\"_blank\">www.add.org</a></td> </tr> <tr> <td class=\"subtitle1_single\">National Institute of Mental Health (NIMH)</td> </tr> <tr> <td>The NIMH provides a number of booklets about ADHD that can be downloaded free of charge.</td> </tr> <tr> <td><a href=\"http://www.nimh.nih.gov/health/publications/adhd-listing.shtml\" target=\"_blank\">www.nimh.nih.gov/health/publications/adhd-listing.shtml</a></td> </tr> <tr> <td class=\"subtitle1_single\">The United States Department of Education</td> </tr> <tr> <td>The United States Department of Education, Office of Special Education Programs provides information on educational policy and research related to ADHD.</td> </tr> <tr> <td><a href=\"http://www2.ed.gov/about/offices/list/osers/index.html\" target=\"_blank\">www2.ed.gov/about/offices/list/osers/index.html</a></td> </tr> <tr> <td class=\"subtitle1_single\">The American Academy of Child and Adolescent Psychiatry (AACAP)</td> </tr> <tr> <td>The American Academy of Child and Adolescent Psychiatry provides fact sheets about AD/HD.</td> </tr> <tr> <td><a href=\"http://www.aacap.org/AACAP/Families_and_Youth/Facts_for_Families/FFF-Guide/Children-Who-Cant-Pay-Attention-Attention-Deficit-Hyperactivity-Disorder-006.aspx\" spellcheck=\"true\" target=\"_blank\">www.aacap.org/AACAP/Families_and_Youth/Facts_for_Families/FFF-Guide/Children-Who-Cant-Pay-Attention-Attention-Deficit-Hyperactivity-Disorder-006.aspx</a></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADHD: Attention deficit hyperactivity disorder.</div><div id=\"graphicVersion\">Graphic 60584 Version 5.0</div></div></div>"},"60585":{"type":"graphic_picture","displayName":"Infantile seborrheic dermatitis multiple sites PI","title":"Seborrheic dermatitis involving multiple skin folds","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seborrheic dermatitis involving multiple skin folds</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PI/60585_Infan_sebor_derm_mult_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Moist, glistening, erythematous plaques involving multiple intertriginous areas in this infant with seborrheic dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60585 Version 5.0</div></div></div>"},"60587":{"type":"graphic_algorithm","displayName":"Sphincter of Oddi algorithm","title":"Approach to suspected sphincter of Oddi dysfunction","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Approach to suspected sphincter of Oddi dysfunction</div><div class=\"cntnt\"><img style=\"width:486px; height:586px;\" src=\"images/GAST/60587_Sphincter_of_Oddi_algo_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SO: sphincter of Oddi.<br />* SO manometry and sphincterotomy should be performed in these patients only as part of a research protocol.</div><div id=\"graphicVersion\">Graphic 60587 Version 3.0</div></div></div>"},"60588":{"type":"graphic_picture","displayName":"Howell-Jolly bodies","title":"Howell-Jolly bodies following splenectomy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Howell-Jolly bodies following splenectomy</div><div class=\"cntnt\"><img style=\"width:360px; height:238px;\" src=\"images/HEME/60588_Howell_Jolly_bodies.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This peripheral blood smear shows two red blood cells (RBCs) that contain Howell-Jolly bodies (black arrows). Howell-Jolly bodies are remnants of RBC nuclei that are normally removed by the spleen. Thus, they are seen in patients who have undergone splenectomy (as in this case) or who have functional asplenia (eg, from sickle cell disease). Target cells (blue arrows) are another consequence of splenectomy.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 60588 Version 6.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"60589":{"type":"graphic_figure","displayName":"ICE technique","title":"The x-ray picture shows an intracardiac ultrasound catheter in the right ventricle and pointed at the mitral valve","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">The x-ray picture shows an intracardiac ultrasound catheter in the right ventricle and pointed at the mitral valve</div><div class=\"cntnt\"><img style=\"width:467px; height:250px;\" src=\"images/CARD/60589_ICE_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The right panel shows a 3-D model of the heart with the imaging plane produced by the ICE catheter.</div><div id=\"graphicVersion\">Graphic 60589 Version 1.0</div></div></div>"},"60590":{"type":"graphic_table","displayName":"Provocative testing of the elbow","title":"Provocative testing of the elbow","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Provocative testing of the elbow</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Positive Maneuver</td> <td class=\"subtitle1\">Diagnosis</td> </tr> <tr> <td rowspan=\"2\">Valgus testing of medial complex</td> <td>Elbow at 15 degrees flexion</td> <td rowspan=\"2\">Ulnar collateral ligament insufficiency</td> </tr> <tr> <td>Shoulder externally rotated</td> </tr> <tr> <td>Moving valgus stress test</td> <td>With the shoulder abducted to 90 degrees and fully externally rotated and the elbow fully flexed, valgus force to the elbow during its extension causes pain at 70<sup> </sup>to 120 degrees of elbow flexion</td> <td>Ulnar collateral ligament insufficiency&nbsp;</td> </tr> <tr> <td rowspan=\"2\">Varus testing of medial complex</td> <td>Elbow at 15 degrees flexion </td> <td rowspan=\"2\">Lateral collateral ligament insufficiency</td> </tr> <tr> <td>Shoulder internally rotated</td> </tr> <tr> <td>Tinel sign</td> <td>Reproduction of pain/numbness in the fourth and fifth fingers with tapping on the groove between medial epicondyle and the olecranon process with the elbow flexed at 90 degrees&nbsp;and the arm externally rotatied</td> <td>Ulnar neuritis</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Median compressive neuropathies</td> </tr> <tr> <td class=\"sublist1\">Pronator compression</td> <td class=\"sublist_other\">Reproduction of pain and altered sensation by direct pressure over the pronator teres </td> <td class=\"sublist_other\">Pronator teres syndrome</td> </tr> <tr> <td class=\"sublist1\">Prolonged resisted pronation</td> <td class=\"sublist_other\">Digital pressure on proximal lateral edge of pronator teres for 30 seconds with resisted forearm supination</td> <td class=\"sublist_other\">Lacertus fibrosis syndrome</td> </tr> <tr> <td class=\"sublist1\">OK sign</td> <td class=\"sublist_other\">Decreased strength or pincer grasp with flattening of the distal interphalangeal joint</td> <td class=\"sublist_other\">Anterior interosseous syndrome</td> </tr> <tr> <td class=\"sublist1\">Long finger PIP flexion</td> <td class=\"sublist_other\">Resisted PIP flexion of the long finger</td> <td class=\"sublist_other\">Flexor digitorum superficialis syndrome</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Radial compressive neuropathies</td> </tr> <tr> <td class=\"sublist1\">Superficial radial nerve tenderness</td> <td class=\"sublist_other\">Superficial radial nerve tenderness over extensors 8 cm distal to lateral epicondyle</td> <td class=\"sublist_other\">Superficial radial nerve</td> </tr> <tr> <td class=\"sublist1\">Long finger extension</td> <td class=\"sublist_other\">Pain with resisted long finger flexion at the metacarpophalangeal joint with wrist in 30 degrees flexion and fingers extended</td> <td class=\"sublist_other\">Superficial radial nerve</td> </tr> <tr> <td class=\"sublist1\">Radial deviation</td> <td class=\"sublist_other\">Radial deviation of the wrist with active wrist extension</td> <td class=\"sublist_other\">Posterior interosseous syndrome</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PIP: proximal interphalangeal.</div><div id=\"graphicVersion\">Graphic 60590 Version 5.0</div></div></div>"},"60591":{"type":"graphic_diagnosticimage","displayName":"Flock workers lung CT - Micronodular pattern","title":"Flock worker's lung CT - Micronodular pattern","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flock worker's lung CT - Micronodular pattern</div><div class=\"cntnt\"><img style=\"width:255px; height:240px;\" src=\"images/PULM/60591_Flock_workers_lung_CT_IV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prone CT of the chest shows a micronodular pattern.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of David Kern, MD and Robert Crausman, MD.</div><div id=\"graphicVersion\">Graphic 60591 Version 5.0</div></div></div>"},"60593":{"type":"graphic_diagnosticimage","displayName":"Vertebral compression fx Lat","title":"Thoracolumbar vertebral compression fractures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracolumbar vertebral compression fractures</div><div class=\"cntnt\"><img style=\"width:286px; height:413px;\" src=\"images/ENDO/60593_Vertebral_compression_fx_La.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiographic features of spinal osteoporosis include wedging of the vertebra anteriorly with vertebral collapse (arrows), vertebral end-plate irregularity, and general demineralization.</div><div class=\"graphic_reference\">Courtesy of Toledo Hospital.</div><div id=\"graphicVersion\">Graphic 60593 Version 3.0</div></div></div>"},"60594":{"type":"graphic_table","displayName":"Prolonged exposure therapy session outline","title":"Prolonged exposure therapy session outline","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prolonged exposure therapy session outline</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Session</td> <td class=\"subtitle1\">Session outline</td> </tr> <tr> <td rowspan=\"6\">1</td> <td>Present an overview of the program (10 to 15 minutes)</td> </tr> <tr> <td>Discuss the treatment procedures that will be used in the program</td> </tr> <tr> <td>Explain that the focus of the program is on PTSD symptoms</td> </tr> <tr> <td>Collect information relevant to the trauma using the Trauma Interview (45 minutes)</td> </tr> <tr> <td>Introduce breathing retraining (10 to 15 minutes)</td> </tr> <tr> <td>Assign homework (5 minutes)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">2</td> <td>Review homework (5 to 10 minutes)</td> </tr> <tr> <td>Present agenda for the session (5 minutes)</td> </tr> <tr> <td>Educate client about PTSD symptoms by discussing common reactions to trauma (25 to 30 minutes)</td> </tr> <tr> <td>Discuss the rationale for exposure with emphasis on in vivo (10 minutes)</td> </tr> <tr> <td>Introduce the Subjective Units of Discomfort Scale (SUDS) (5 minutes)</td> </tr> <tr> <td>Construct in vivo hierarchy (20 minutes)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">3</td> <td>Review homework (10 to 15 minutes)</td> </tr> <tr> <td>Present agenda for the session (5 minutes)</td> </tr> <tr> <td>Present rationale for imaginal exposure (10 to 15 minutes)</td> </tr> <tr> <td>Conduct imaginal exposure on entire trauma memory (45 to 60 minutes)</td> </tr> <tr> <td>Process imaginal exposure (15 to 20 minutes)</td> </tr> <tr> <td>Assign homework (5 minutes)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">4</td> <td>Review homework (10 to 15 minutes)</td> </tr> <tr> <td>Present agenda for the session (5 minutes)</td> </tr> <tr> <td>Conduct imaginal exposure (45 to 60 minutes)</td> </tr> <tr> <td>Process imaginal exposure (15 to 20 minutes)</td> </tr> <tr> <td>Assign homework (5 minutes)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">5-9</td> <td>Review homework (10 minutes)</td> </tr> <tr> <td>Present agenda for the session (3 minutes)</td> </tr> <tr> <td>Conduct imaginal exposure to \"hot spots\" progressively more as therapy advances (45 to 60 minutes)</td> </tr> <tr> <td>Process imaginal exposure (15 to 20 minutes)</td> </tr> <tr> <td>Discuss in vivo exposure (10 to 15 minutes)</td> </tr> <tr> <td>Assign homework (5 minutes)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">10</td> <td>Review homework (10 minutes)</td> </tr> <tr> <td>Present agenda for the session (3 minutes)</td> </tr> <tr> <td>Conduct imaginal exposure to entire trauma memory (20 to 30 minutes)</td> </tr> <tr> <td>Review progress and make suggestions for continued practice (30 minutes)</td> </tr> <tr> <td>Terminate therapy; saying good-bye (5 minutes)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PTSD: posttraumatic stress disorder.</div><div class=\"graphic_reference\">Reproduced with permission from: Foa EB, Hembree E, Rothbaum BO. In: Prolonged Exposure Therapy for PTSD: Emotional Processing of Traumatic Experiences, Therapist Guide, Oxford University Press, New York 2007. Copyright © 2007 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 60594 Version 4.0</div></div></div>"},"60597":{"type":"graphic_table","displayName":"NCI CTCAE v5 mucositis oral","title":"NCI CTCAE v5.0 mucositis oral","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 mucositis oral</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Mucositis oral</td> <td>Asymptomatic or mild symptoms; intervention not indicated</td> <td>Moderate pain or ulcer that does not interfere with oral intake; modified diet indicated</td> <td>Severe pain, interfering with oral intake</td> <td>Life-threatening consequences; urgent intervention indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Mucositis oral is characterized by ulceration or inflammation of the oral mucosa.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 60597 Version 10.0</div></div></div>"},"60598":{"type":"graphic_figure","displayName":"SEER surv adeno rectum","title":"Observed survival rates for 9,860 cases with adenocarcinoma of the rectum","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Observed survival rates for 9,860 cases with adenocarcinoma of the rectum</div><div class=\"cntnt\"><img style=\"width:549px; height:497px;\" src=\"images/ONC/60598_SEER_surv_adeno_rectum.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data from the SEER 1973-2005 Public Use File diagnosed in years 1998-2000. Stage I includes 3470; Stage IIA, 2752; Stage IIB, 165; Stage IIC, 268; Stage IIIA, 595; Stage IIIB, 615; Stage IIIC, 761; and Stage IV, 1234.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 60598 Version 12.0</div></div></div>"},"60599":{"type":"graphic_table","displayName":"DSM IV criteria Asperger disorder","title":"Diagnostic criteria for Asperger disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for Asperger disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">A. Qualitative impairment in social interaction, as manifested by at least two of the following:</td> </tr> <tr> <td class=\"sublist2\">1. Marked impairments in the use of multiple nonverbal behaviors such as eye-to-eye gaze, facial expression, body postures, and gestures to regulate social interaction</td> </tr> <tr> <td class=\"sublist2\">2. Failure to develop peer relationships appropriate to developmental level</td> </tr> <tr> <td class=\"sublist2\">3. A lack of spontaneous seeking to share enjoyment, interests, or achievements with other people (eg, by a lack of showing, bringing, or pointing out objects of interest to other people)</td> </tr> <tr> <td class=\"sublist2\">4. Lack of social or emotional reciprocity</td> </tr> <tr> <td class=\"sublist1_start\">B. Restricted repetitive and stereotyped patterns of behavior, interests, and activities, as manifested by at least one of the following:</td> </tr> <tr> <td class=\"sublist2\">1. Encompassing preoccupation with one or more stereotyped and restricted patterns of interest that are abnormal either in intensity or focus</td> </tr> <tr> <td class=\"sublist2\">2. Apparently inflexible adherence to specific, nonfunctional routines or rituals</td> </tr> <tr> <td class=\"sublist2\">3. Stereotyped and repetitive motor mannerisms (eg, hand or finger flapping or twisting, or complex whole-body movements)</td> </tr> <tr> <td class=\"sublist2\">4. Persistent preoccupation with parts of objects</td> </tr> <tr> <td>C. The disturbance causes clinically significant impairment in social, occupational, or other important areas of functioning</td> </tr> <tr> <td>D. There is no clinically significant general delay in language (eg, single words used by age two years, communicative phrases used by age three years)</td> </tr> <tr> <td>E. There is no clinically significant delay in cognitive development or in the development of age-appropriate self-help skills, adaptive behavior (other than social interaction), and curiosity about the environment in childhood</td> </tr> <tr> <td>F. Criteria are not met for another specific pervasive developmental disorder or schizophrenia</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">13</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">8/11/2006 perm requested 8/11/2006 perm granted 8/3/2007 -r enewal requested.mt 9/24/2007 -bug.mn 9/27/2007 - Granted. We're now being charged a total of $450 for these two tables ($75 per table x three editions = $475). We should look into an alternative next time these are up for renewal. 8/12/2008--Requested renewal (JD). 9/15/2008--Renewal granted, invoice to Susan (JD). 10/1/2009--Renewal requested (JD). 10/2/2009--Renewal granted; invoice to Catherine (JD). The total fee of $&amp;quot;200.00&amp;quot;was originally charged to DSM_IV_criteria_autism DSM_IV_criteria_Asperger_syndr</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=51795&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_reference\">Reprinted with permission from: the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (Copyright 2000). American Psychiatric Association.</div><div id=\"graphicVersion\">Graphic 60599 Version 9.0</div></div></div>"},"60600":{"type":"graphic_figure","displayName":"Optotype recognition tests","title":"Optotype recognition tests for visual acuity testing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Optotype recognition tests for visual acuity testing</div><div class=\"cntnt\"><img style=\"width:241px; height:502px;\" src=\"images/PEDS/60600_Optotype_recognition_tests.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Snellen letters, (B) tumbling E game, (C) HOTV test, (D) Landolt ring test, (E) Lea figures, (F) Allen figures, (G) single optotypes surrounded by crowding bars.</div><div class=\"graphic_reference\">Adapted with permission of American Academy of Ophthalmology. Coats DK, Jenkins RH. Refinements: Vision assessment of the patient 1:1. San Francisco: American Academy of Ophthalmology 1997.</div><div id=\"graphicVersion\">Graphic 60600 Version 4.0</div></div></div>"},"60601":{"type":"graphic_figure","displayName":"Saphenous vein cutdown cannula in place","title":"Saphenous vein cutdown cannula in place","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Saphenous vein cutdown cannula in place</div><div class=\"cntnt\"><img style=\"width:540px; height:396px;\" src=\"images/EM/60601_Saphenous_cutdown_techniq2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Secure the cannula in place and apply a protective dressing.</div><div id=\"graphicVersion\">Graphic 60601 Version 2.0</div></div></div>"},"60605":{"type":"graphic_figure","displayName":"Sacroiliac tenderness III","title":"Testing for sacroiliac pain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Testing for sacroiliac pain</div><div class=\"cntnt\"><img style=\"width:360px; height:228px;\" src=\"images/RHEUM/60605_Sacroiliac_tenderness_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the patient lying supine, he or she is instructed to flex one of the knees and then abduct as well as externally rotate the corresponding hip. Pressure on the flexed knee causes pain at the corresponding sacroiliac joint.</div><div class=\"graphic_reference\">Courtesy of Craig W Wiesenhutter, MD.</div><div id=\"graphicVersion\">Graphic 60605 Version 2.0</div></div></div>"},"60606":{"type":"graphic_figure","displayName":"Trochanteric bursa","title":"Trochanteric bursa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trochanteric bursa</div><div class=\"cntnt\"><img style=\"width:441px; height:402px;\" src=\"images/RHEUM/60606_Trochanteric_bursa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomy of the trochanteric bursa. In patients with bursitis, corticosteroid-local anesthetic injections can be made into the site.</div><div class=\"graphic_reference\">Reproduced with permission from: Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 60606 Version 4.0</div></div></div>"},"60607":{"type":"graphic_table","displayName":"Congenital syphilis case definition-CDC","title":"US Centers for Disease Control and Prevention (CDC) surveillance case definition for congenital syphilis*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">US Centers for Disease Control and Prevention (CDC) surveillance case definition for congenital syphilis*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Laboratory criteria for diagnosis</td> </tr> <tr> <td>Demonstration of <em>Treponema pallidum</em> by darkfield microscopy, fluorescent antibody, or other specific stains in specimens from lesions, placenta, umbilical cord, or autopsy material</td> </tr> <tr> <td class=\"subtitle1_single\">Case classification</td> </tr> <tr> <td class=\"subtitle2_single\">Probable</td> </tr> <tr> <td class=\"indent1\">Infant whose mother had untreated or inadequately<sup>&#182;</sup> treated syphilis at delivery, regardless of signs in the infant, or</td> </tr> <tr> <td class=\"sublist2_start\">Infant or child who has a reactive treponemal test for syphilis and any one of the following:</td> </tr> <tr> <td class=\"sublist3_start\"> <ul> <li>Any evidence of congenital syphilis on physical examination:</li> </ul> </td> </tr> <tr> <td class=\"sublist3\">For children 0 to 2 years: Hepatosplenomegaly, rash, condyloma lata, snuffles, jaundice, pseudoparalysis, edema</td> </tr> <tr> <td class=\"sublist3\">For children &#62;2 years: Interstitial keratitis, sensorineural hearing loss, \"saber shins\"<sup>&#916;</sup>, frontal bossing, Hutchinson teeth<sup>&#916;</sup>, mulberry molars<sup>&#916;</sup>, saddle nose, rhagades<sup>&#916;</sup>, Clutton joints<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Any evidence of congenital syphilis on radiographs of long bones<sup>&#916;</sup></li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>A reactive cerebrospinal fluid (CSF) venereal disease research laboratory (VDRL) test</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>An elevated CSF cell count or protein (without other cause)</li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Confirmed</td> </tr> <tr> <td class=\"indent1\">Case that is laboratory confirmed</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For reporting purposes, congenital syphilis includes cases of congenitally acquired syphilis among infants and children, as well as syphilitic stillbirths (death of a fetus weighing &gt;500 g or having a gestational age &gt;20 weeks in which the mother had untreated or inadequately treated syphilis at delivery).<br />¶ For the purpose of the CDC case definition, inadequate treatment is defined by any non-penicillin therapy or any therapy (including penicillin) given less than 30 days before delivery. Other definitions of inadequate treatment may also include undocumented therapy, subtherapeutic or undocumented treatment response, and inappropriate dose for maternal stage of disease.<br />Δ Please refer to UpToDate topic on clinical features of congential syphilis for description.</div><div class=\"graphic_reference\">Adapted from: Centers for Disease Control and Prevention. STD Surveillance case definitions. <a href=\"http://www.cdc.gov/std/stats/CaseDefinitions-2014.pdf\" target=\"_blank\">http://www.cdc.gov/std/stats/CaseDefinitions-2014.pdf</a> (Accessed on March 21, 2014).</div><div id=\"graphicVersion\">Graphic 60607 Version 6.0</div></div></div>"},"60608":{"type":"graphic_picture","displayName":"Skin metastasis of squamous cell carcinoma","title":"Squamous cell carcinoma metastasizing to the skin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Squamous cell carcinoma metastasizing to the skin</div><div class=\"cntnt\"><img style=\"width:432px; height:412px;\" src=\"images/DERM/60608_Skin_metast_squam_cell_carc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Renal transplant recipient with locally recurrent squamous cell carcinoma and in transit metastasis.</div><div id=\"graphicVersion\">Graphic 60608 Version 2.0</div></div></div>"},"60609":{"type":"graphic_diagnosticimage","displayName":"Leak and stricture after sleeve gastrectomy","title":"Leak and stricture after sleeve gastrectomy","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Leak and stricture after sleeve gastrectomy</div><div class=\"cntnt\"><img style=\"width:464px; height:461px;\" src=\"images/SURG/60609_Leak_stricture_sleeve_gastr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The upper arrow shows a leak and the lower arrow shows a stricture in a sleeve gastrectomy.</div><div id=\"graphicVersion\">Graphic 60609 Version 4.0</div></div></div>"},"60610":{"type":"graphic_table","displayName":"Oxygen delivery systems","title":"Oxygen delivery systems","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oxygen delivery systems</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">System </td> <td class=\"subtitle1\">Percent oxygen delivered* </td> <td class=\"subtitle1\">Indications </td> <td class=\"subtitle1\">Comments </td> </tr> <tr> <td>Blow by</td> <td>Less than 30 percent</td> <td>Use for spontaneously breathing children who require low doses of oxygen and do not tolerate a mask</td> <td>Monitor pulse oximetry</td> </tr> <tr> <td>Nasal cannula (1 to 4 L/min)</td> <td>25 to 40 percent</td> <td>Use to deliver low dose oxygen to spontaneously breathing patients</td> <td>Percent oxygen delivered affected by respiratory rate, tidal volume, and extent of mouth breathing. Flow rate 2 L/min or less for infants</td> </tr> <tr> <td>Simple mask</td> <td>35 to 50 percent</td> <td>Use to deliver low dose oxygen to spontaneously breathing patients</td> <td>Percent oxygen delivered affected by mask fit and respiratory rate</td> </tr> <tr> <td>Partial rebreather mask</td> <td>50 to 60 percent</td> <td>Use to conserve oxygen</td> <td>&nbsp;</td> </tr> <tr> <td>Nonrebreather mask</td> <td>65 to 95 percent</td> <td>Use to deliver high dose oxygen to spontaneously breathing patients</td> <td>Tight mask fit required to deliver higher concentrations of oxygen</td> </tr> <tr> <td>Hood</td> <td>30 to 90 percent</td> <td>Infants less than one year of age</td> <td>Noisy for patient</td> </tr> <tr> <td>Tent</td> <td>25 to 50 percent</td> <td>Use for children who require 30 percent oxygen or less</td> <td>Mist may obscure view of patient. Noisy for patient.</td> </tr> <tr> <td>Self-inflating ventilation bag</td> <td>95 to 100 percent, with reservoir</td> <td>Use to provide assisted ventilation and oxygen</td> <td>Do not use to provide blow by. Must use with a reservoir to provide higher oxygen concentrations.</td> </tr> <tr> <td>Flow-inflating ventilation bag</td> <td>100 percent</td> <td>Use to provide assisted ventilation and oxygen</td> <td>May use to provide blow by. Requires experience to use reliably.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*Actual percent oxygen delivered may vary widely depending on the type of delivery device, device manufacturer, oxygen flow rate provided to the device, and, for oxygen masks, mask fit.</div><div id=\"graphicVersion\">Graphic 60610 Version 7.0</div></div></div>"},"60611":{"type":"graphic_figure","displayName":"Signal transduction in T cells","title":"Signal transduction pathways involved in T cell activation","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Signal transduction pathways involved in T cell activation</div><div class=\"cntnt\"><img style=\"width:593px; height:593px;\" src=\"images/NEPH/60611_Signal_transduction_in_T_ce.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The provision of antigen specific, costimulatory, and cytokine signals leads to T cell activation. A number of pathways exist that transduce signals from the surface of the T cell to the nucleus. The end result of signal transduction is the transcription of mRNAs that code for a variety of pro-inflammatory proteins. The numbered steps depict sites at which various immunosuppressive agents act: 1, Cyclosporine; 2, Tacrolimus (FK506); 3, Rapamycin; 4, Corticosteroid.</div><div class=\"graphic_footnotes\">APC: antigen-presenting cell; MHC: major histocompatibility complex; TCR: T-cell receptor; LPS: lipopolysaccharide; TNF: tumor necrosis factor; IkappaB: inhibitors of kB; JAK-STAT: Janus kinase-signal transducer and activator of transcription; TK: tyrosine kinase; PLC-gamma: phospholipase C gamma; ER: endoplasmic reticulum; NFAT: nuclear factor of activated T cells; PIP: phosphatidylinositol 4,5-bisphosphate; IP3: inositol triphosphate; DAG: diacylglycerol; PKC: protein kinase C; FKBP: FK506 binding protein; IL-2r: interleukin-2R.</div><div id=\"graphicVersion\">Graphic 60611 Version 2.0</div></div></div>"},"60613":{"type":"graphic_table","displayName":"Gene mutations causing CRC","title":"Genetic mutations that are associated with an increased risk of colorectal cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genetic mutations that are associated with an increased risk of colorectal cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Syndrome/disease</td> <td class=\"subtitle1\">Responsible gene</td> <td class=\"subtitle1\">Mode of acquisition</td> </tr> <tr> <td>FAP</td> <td>APC</td> <td rowspan=\"8\">Germline (inherited)</td> </tr> <tr> <td rowspan=\"7\">HNPCC (Lynch syndrome)</td> <td class=\"sublist1_start\">MMR</td> </tr> <tr> <td class=\"sublist1\">hMSH2</td> </tr> <tr> <td class=\"sublist1\">hMLH1</td> </tr> <tr> <td class=\"sublist1\">hPMS1</td> </tr> <tr> <td class=\"sublist1\">hPMS2</td> </tr> <tr> <td class=\"sublist1\">hMSH3</td> </tr> <tr> <td class=\"sublist1\">hMSH6</td> </tr> <tr> <td rowspan=\"10\">Sporadic tumor</td> <td class=\"sublist1_start\">Tumor suppressor genes</td> <td rowspan=\"10\">Somatic (acquired)</td> </tr> <tr> <td class=\"sublist1\">p53</td> </tr> <tr> <td class=\"sublist1\">DCC</td> </tr> <tr> <td class=\"sublist1\">APC</td> </tr> <tr> <td class=\"sublist1_start\">Oncogenes</td> </tr> <tr> <td class=\"sublist1\">myc</td> </tr> <tr> <td class=\"sublist1\">ras</td> </tr> <tr> <td class=\"sublist1\">src</td> </tr> <tr> <td class=\"sublist1\">erbB2</td> </tr> <tr> <td>MMR genes (epigenetic change)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FAP: familial adenomatous polyposis; APC: adenomatous polyposis coli gene; DCC: deleted in colorectal carcinoma gene; HNPCC: hereditary nonpolyposis colorectal cancer; MMR: mismatch repair gene.</div><div id=\"graphicVersion\">Graphic 60613 Version 6.0</div></div></div>"},"60614":{"type":"graphic_picture","displayName":"Sinonasal polyp Light","title":"Sinonasal polyp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sinonasal polyp</div><div class=\"cntnt\"><img style=\"width:385px; height:265px;\" src=\"images/ONC/60614_Sinonasal_polyp_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These nonneoplastic polypoid lesions consist of an inflamed and edematous stroma covered by respiratory or metaplastic squamous epithelium. They are often allergy related.</div><div class=\"graphic_reference\">Courtesy of G Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 60614 Version 2.0</div></div></div>"},"60615":{"type":"graphic_figure","displayName":"Doppler interrogation VSD","title":"Doppler interrogation for ventricular septal defects","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Doppler interrogation for ventricular septal defects</div><div class=\"cntnt\"><img style=\"width:468px; height:280px;\" src=\"images/PEDS/60615_Doppler_interrogation_VSD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Planes of Doppler interrogation for different ventricular septal defects as seen in parasternal short axis.</div><div class=\"graphic_footnotes\">PV: pulmonary valve; AoV: aortic valve; TV: tricuspid valve; MV: mitral valve.</div><div class=\"graphic_reference\">Drawing by Emily McIntosh.</div><div id=\"graphicVersion\">Graphic 60615 Version 3.0</div></div></div>"},"60616":{"type":"graphic_picture","displayName":"Ochronotic pigmentation 2","title":"Ochronotic pigmentation of ear cartilage and sclera","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ochronotic pigmentation of ear cartilage and sclera</div><div class=\"cntnt\"><img style=\"width:304px; height:500px;\" src=\"images/PEDS/60616_Ochronotic_pigmentation_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Bluish-gray auricular cartilage in a patient with alkaptonuria. B) Ocular ochronosis with scleral pigmentation.</div><div class=\"graphic_reference\">Reproduced with permission from: Gold DH,&nbsp;Weingeist TA. Color Atlas of the Eye in Systemic Disease. Baltimore: Lippincott Williams &amp; Wilkins, 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60616 Version 2.0</div></div></div>"},"60619":{"type":"graphic_figure","displayName":"Cervicovaginal incision","title":"Incision into the anterior vaginal mucosa during vaginal hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incision into the anterior vaginal mucosa during vaginal hysterectomy</div><div class=\"cntnt\"><img style=\"width:424px; height:377px;\" src=\"images/OBGYN/60619_Cervicovaginal_incision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is performed at the level of the cervicovaginal mucosa.</div><div id=\"graphicVersion\">Graphic 60619 Version 2.0</div></div></div>"},"60620":{"type":"graphic_picture","displayName":"Birbeck granules","title":"Birbeck granules","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Birbeck granules</div><div class=\"cntnt\"><img style=\"width:446px; height:419px;\" src=\"images/HEME/60620_Birbeck_granules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This electron micrograph of a Langerhans' cell shows a number of typical Birbeck granules (arrow). (39,000 X).</div><div class=\"graphic_reference\">Electron micrograph courtesy of Dr. Dominic V. Spagnolo, Perth, Western Australia. From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 60620 Version 1.0</div></div></div>"},"60621":{"type":"graphic_diagnosticimage","displayName":"Scimitar syndrome I","title":"Scimitar syndrome with partial anomalous pulmonary venous return to the inferior vena cava","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scimitar syndrome with partial anomalous pulmonary venous return to the inferior vena cava</div><div class=\"cntnt\"><img style=\"width:360px; height:343px;\" src=\"images/PULM/60621_Scimitar_syndrome_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph shows a slightly smaller right lung, an aberrant right basal pulmonary vein, and dilated central pulmonary arteries due to left-to-right shunting.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 60621 Version 3.0</div></div></div>"},"60622":{"type":"graphic_picture","displayName":"Squamous CA cavitation Gross","title":"Cavitary squamous cell carcinoma of the lung","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cavitary squamous cell carcinoma of the lung</div><div class=\"cntnt\"><img style=\"width:401px; height:284px;\" src=\"images/PULM/60622_Squamous_CA_cavitation_Gros.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripherally located squamous cell carcinoma with extensive central necrosis and cavitation.</div><div class=\"graphic_reference\">Courtesy of Jeffrey Myers, MD.</div><div id=\"graphicVersion\">Graphic 60622 Version 1.0</div></div></div>"},"60624":{"type":"graphic_table","displayName":"Dosage and pharmacology of antipsychotics","title":"Pharmacology of antipsychotics: Dosing (adult), formulations, kinetics and potential for drug interactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacology of antipsychotics: Dosing (adult), formulations, kinetics and potential for drug interactions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"9%\"></colgroup><colgroup width=\"19%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Usual oral dose range (mg/day)</td> <td class=\"subtitle1\">Initial oral dose (mg/day)</td> <td class=\"subtitle1\">Adjustment of oral dose in older* or medically compromised patients<sup>&#182;</sup></td> <td class=\"subtitle1\">Usual maximum oral dose<br /> <span style=\"white-space: nowrap;\">(mg/day)<sup>&#916;</sup></span></td> <td class=\"subtitle1\">Formulations</td> <td class=\"subtitle1\">Half-life after oral administration (hours)</td> <td class=\"subtitle1\">Primary metabolism<sup>&#9674;</sup></td> <td class=\"subtitle1\">Enzyme(s) inhibited<br /> <span style=\"white-space: nowrap;\">(see note)<sup>&#167;</sup></span></td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">First-generation antipsychotics (FGAs)</td> </tr> <tr> <td class=\"indent1\">Chlorpromazine</td> <td>400 to 600</td> <td>25 to 200</td> <td>Use low initial dose and increase more gradually</td> <td>800</td> <td>Tab, IM</td> <td>30</td> <td>CYP2D6, other CYPs and UGT-glucuronidation to active and inactive metabolites</td> <td>CYP2D6</td> <td> <p>Oral absorption is variable and may require dose adjustment based on patient response.</p> Older adults and medically ill patients are unlikely to tolerate cardiovascular, sedating, and anticholinergic side effects.</td> </tr> <tr> <td class=\"indent1\">Fluphenazine</td> <td>2 to 15</td> <td>2 to 10</td> <td>1 to 2.5 mg daily initially, adjust dose gradually based on response</td> <td>12</td> <td>Tab, IM, LAI, oral solution</td> <td>33</td> <td>CYP2D6</td> <td>CYP2D6</td> <td>Oral absorption is highly variable and dose must be individualized based on patient response.</td> </tr> <tr> <td class=\"indent1\">Haloperidol</td> <td>2 to 20</td> <td>2 to 10</td> <td>1 to 5 mg daily; adjust dose gradually based on response</td> <td>30</td> <td>Tab, IM, LAI, oral solution</td> <td>20</td> <td>CYPs 2D6, 3A4 and UGT-glucuronidation; some metabolites potentially active or toxic</td> <td>CYPs 2D6, 3A4 (moderate)</td> <td> <p>The US labeled maximum recommended dose of 100 mg/day (oral) is considerably higher than more recent practice supports.</p> <p>Bioavailability with oral dosing is about 60%; dose adjustments between oral and parenteral administration should be made accordingly.</p> Intravenous use has not been approved by the US Food and Drug Administration and is associated with increased risk of QT prolongation; refer to accompanying text.</td> </tr> <tr> <td class=\"indent1\">Loxapine</td> <td>20 to 80</td> <td>20</td> <td>Generally follows standard adult dosing, although a dose reduction may be indicated in some cases</td> <td>100</td> <td> <p>Capsule; oral inhalation for use in healthcare settings as alternative to IM injection.</p> Oral solution and IM injection available in countries other than United States.</td> <td> <p>6 to 8 (parent drug)</p> 12 (active metabolites)</td> <td>CYPs 1A2, 2D6, 3A4 and UGT-glucuronidation to active and inactive metabolites</td> <td>None</td> <td>Onset of oral (swallowed capsule) and IM within 30 minutes.</td> </tr> <tr> <td class=\"indent1\">Perphenazine</td> <td>12 to 24</td> <td>8 to 16</td> <td>Initiate dose at 8 mg/day and titrate more gradually to the usual adult range</td> <td>24 (a higher daily dose may be acceptable, refer to notes)</td> <td>Tab</td> <td> <p>9 to 12 (parent drug)</p> 10 to 19 (active metabolite)</td> <td>CYPs 2D6, 3A4 and other CYPs to active and inactive metabolites</td> <td>CYP2D6</td> <td> <p>Bioavailability is variable (60 to 80%).</p> <p>Higher daily doses, eg, up to 32 mg per day were shown to be similar in tolerability and efficacy to some SGAs<sup>[1] </sup>and in practice up to 64 mg per day total may be acceptable in some circumstances. </p> </td> </tr> <tr> <td class=\"indent1\">Pimozide<sup>&#165;</sup></td> <td>8 to 10</td> <td>1 to 2</td> <td>1 mg/day initially and titrate more gradually to the usual adult range</td> <td> <p>10</p> 4 (CYP2D6 poor metabolizer)</td> <td>Tab</td> <td> <p>55</p> 150 (CYP2D6 poor metabolizers)</td> <td>CYPs 1A2, 2D6, 3A4 and others</td> <td>CYP2D6</td> <td>Bioavailability is variable due to extensive hepatic first-pass metabolism.</td> </tr> <tr> <td class=\"indent1\">Thiothixene<sup>&#165;</sup> (tiotixene)</td> <td>10 to 20</td> <td>5 to 10</td> <td>Use low initial dose and titrate more gradually to the usual adult dose range</td> <td>30</td> <td>Capsule</td> <td>34</td> <td>CYP1A2 and other CYPs</td> <td>None</td> <td>Oral absorption is variable and dose must be individualized based on patient response.</td> </tr> <tr> <td class=\"indent1\">Thioridazine</td> <td>200 to 600</td> <td>150</td> <td>Use low initial dose and titrate more gradually to the usual adult dose range</td> <td>600</td> <td>Tab</td> <td> <p>4 to 10 (parent drug)</p> 21 to 25 (active metabolites)</td> <td>CYP2D6 and other CYPs to active (mesoridazine) and inactive metabolites</td> <td>CYP2D6</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trifluoperazine<sup>&#165;</sup></td> <td>15 to 20</td> <td>4 to 10</td> <td>Initiate dose at 4 mg/day and titrate more gradually to the usual adult range</td> <td>40</td> <td>Tab</td> <td> <p>3 to 12 (parent drug)</p> 22 (active metabolites)</td> <td>CYP1A2 and other CYPs to active and inactive metabolites</td> <td>None</td> <td>Bioavailability is variable.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Second-generation antipsychotics (SGAs)</td> </tr> <tr> <td class=\"indent1\">Aripiprazole</td> <td>10 to 15</td> <td>10 to 15</td> <td>None</td> <td>30</td> <td> <p>Tab, ODT, LAI, oral solution</p> Aripiprazole lauroxil LAI</td> <td>75 to 94</td> <td>CYPs 2D6 and 3A4 to active and inactive metabolites</td> <td>None</td> <td>For augmentation of antidepressant, a lower daily dose of 2 to 5 mg is useful.</td> </tr> <tr> <td class=\"indent1\">Asenapine<sup>&#165;</sup></td> <td>10 to 20</td> <td>10</td> <td> <p>None.</p> Exception: Use contraindicated in severe hepatic impairment.</td> <td>20</td> <td>Sublingual tab</td> <td>24</td> <td>CYP1A2 and UGT-glucuronidation</td> <td>None</td> <td> <p>Patient should not eat or drink within 10 minutes of sublingual (SL) administration.</p> SL preparation should not be swallowed due to poor gastrointestinal absorption.</td> </tr> <tr> <td class=\"indent1\">Brexpiprazole</td> <td>2 to 4</td> <td>0.5 to 1</td> <td>Dose adjustments are needed in renal or hepatic impairment<sup>&#135;</sup></td> <td>4</td> <td>Tab</td> <td>91</td> <td>CYP2D6 and 3A4</td> <td>None</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Cariprazine</td> <td>1.5 to 6</td> <td>1.5</td> <td>Not recommended in severe renal or hepatic impairment</td> <td>6</td> <td>Capsule</td> <td> <p>48 to 96 (parent drug)</p> 7 to 21 <strong>days</strong> (active metabolites)<sup>&#134;</sup></td> <td>CYP3A4 to active<sup>&#134;</sup> and inactive metabolites</td> <td>None</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Clozapine<sup>&#165;</sup></td> <td>150 to 600</td> <td>25 to 50</td> <td> <p>Titrate gradually to reduced maintenance range of 100 to 150 mg/day; maximum 300 mg/day.</p> Lower doses advised in renal or hepatic impairment; specific dose adjustment recommendations are not available.</td> <td>900</td> <td>Tab, ODT, oral suspension</td> <td>12</td> <td>CYP1A2, other CYPs, and UGT-glucuronidation</td> <td>CYP2D6 (moderate)</td> <td> <p>Hypotension is the most frequent dose limiting factor during titration.</p> <p>Other side effects requiring monitoring include agranulocytosis, sedation, and sialorrhea.</p> Once titrated to 300 to 450 mg daily, rate of titration may be increased to 100 mg once or twice weekly.</td> </tr> <tr> <td class=\"indent1\">Iloperidone</td> <td>12 to 24</td> <td>2</td> <td>Not recommended in severe hepatic impairment</td> <td> <p>24</p> 12 (CYP2D6 poor metabolizer or receiving 2D6 inhibitor cotreatment)</td> <td>Tab</td> <td>18 to 26</td> <td>CYP2D6 and other CYPs to active and inactive metabolites</td> <td>CYP3A4 (moderate)</td> <td>Orthostatic hypotension is usually the dose limiting factor in titration.</td> </tr> <tr> <td class=\"indent1\">Lurasidone</td> <td>40 to 80</td> <td> <p>40</p> 20 (renal or hepatic insufficiency)</td> <td>Dose adjustments are needed in renal and hepatic impairment<sup>&#135;</sup></td> <td> <p>160</p> <p>80 (moderate or severe renal impairment, moderate hepatic impairment)</p> 40 (severe hepatic insufficiency)</td> <td>Tab</td> <td>29 to 37 (at steady state)</td> <td>CYP3A4 to active and inactive metabolites</td> <td>None</td> <td>Needs to be taken with a meal to be adequately absorbed.</td> </tr> <tr> <td class=\"indent1\">Olanzapine<sup>&#165;</sup></td> <td>10 to 20</td> <td>5 to 10</td> <td>Initially 1.25 to 2.5 mg/day; typical maintenance 5 mg/day; maximum 10 mg/day</td> <td>30</td> <td>Tab, ODT, IM, LAI</td> <td>30 to 38</td> <td>CYP1A2 and UGT-glucuronidation</td> <td>None</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Paliperidone</td> <td>6 to 12</td> <td>6</td> <td>Older adults or renal impairment: 3 mg/day<sup>&#135;</sup></td> <td>12</td> <td>ER tab, LAI</td> <td>23</td> <td>Paliperidone is excreted mainly unchanged in urine necessitating dose reduction in renal insufficiency<sup>&#135;</sup></td> <td>None</td> <td>Tablets need to be swallowed whole.</td> </tr> <tr> <td class=\"indent1\">Pimavanserin</td> <td>34</td> <td>34</td> <td>Not recommended in hepatic impairment or severe renal impairment (not studied)</td> <td>34</td> <td>Tab</td> <td>57 parent drug (200 for active metabolite)</td> <td>CYP3A4 and 3A5 to active metabolite</td> <td>None</td> <td> <p>Approved for reducing Parkinson disease related psychosis.</p> <p>Dose adjustment needed if used with strong inhibitors of CYP3A. Efficacy may be reduced if used with strong inducers of CYP3A. Refer to separate table of CYP3A inhibitors and inducers available in UpToDate.</p> </td> </tr> <tr> <td class=\"indent1\">Quetiapine</td> <td> <p>150 to 750 (immediate release)</p> 400 to 800 (extended release)</td> <td>50</td> <td> <p>Initially 25 to 50 mg/day; use substantially lower maintenance dose.</p> Dose adjustment needed in hepatic impairment<sup>&#135;</sup>.</td> <td> <p>750 (immediate release)</p> 800 (extended release)</td> <td>Tab, ER tab</td> <td>6 to 12</td> <td>CYP3A4</td> <td>None</td> <td>Titration most often limited by excessive sedation or orthostatic hypotension which should be monitored.</td> </tr> <tr> <td class=\"indent1\">Risperidone</td> <td>2 to 6</td> <td>1 to 2</td> <td> <p>Initially 0.25 to 0.5 mg/day; typical maintenance 1 mg/day; maximum 2 mg/day.</p> Dose adjustments are needed in renal and hepatic impairment<sup>&#135;</sup>.</td> <td>8</td> <td>Tab, ODT, LAI, oral solution</td> <td>20</td> <td>CYP2D6 to active (paliperidone) and inactive metabolites; P-gp substrate</td> <td>CYP2D6 (moderate)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Ziprasidone</td> <td>40 to 160</td> <td>40 to 80</td> <td>Lower doses advised in hepatic impairment; specific adjustment recommendations are not available</td> <td>200</td> <td>Capsule, IM</td> <td> <p>7 oral</p> 2 to 5 IM</td> <td>CYP3A4</td> <td>None</td> <td>Oral preparation is not dependent on renal function for clearance but a component of the IM injection is cleared by the kidney.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Important note: Doses shown are total daily dose, oral administration, for maintenance treatment of schizophrenia in otherwise healthy adults. The dosing and other information provided in this table differs from dosing used in management of behavioral symptoms of dementia in older adults; in general these medications are not recommended for that use. For additional information, refer to the relevant UpToDate clinical topics and the Lexicomp drug monographs included within UpToDate.</div><div class=\"graphic_footnotes\">ODT: orally dissolving tablet; Tab: tablet; ER tab: extended-release tablet; IM: short-acting intramuscular injection; LAI: long-acting injectable (eg, depot); CYP: cytochrome P-450; P-gp: membrane P-glycoprotein transporters; UGT-glucuronidation: uridine 5'diphosphate-glucuronyltransferases.<br />* First- and second-generation antipsychotics are included on the Beers list of medications to be used with caution in older adults and should in general be avoided except for schizophrenia and bipolar disorder.<SUP>[2]</SUP><br />¶ First-generation antipsychotics (FGAs) undergo extensive hepatic metabolism; levels may be elevated in hepatic impairment necessitating dose reduction and more gradual dose titration to avoid toxicity. FGAs should be used with caution at significantly reduced doses or avoided in severe hepatic impairment.<br />Δ Usual maximum total oral daily dose for maintenance treatment of schizophrenia in adult patients without significant comorbidity. Doses shown may not be the maximum dose used in some clinical trials or in exceptional patients.<br /><FONT class=lozenge>◊</FONT> Dose adjustments of several antipsychotic medications listed in this table are recommended in presence of strong or moderate inhibitors or inducers of CYP drug metabolism; for specific recommendations refer to the individual Lexicomp drug monographs.<br />§ Only potent to moderate inhibitor effects are listed in this table. For additional information including moderate to weak inhibitor or inducer effects, and to determine specific drug interactions, refer to individual drug monographs section on drug interactions and the Lexi-Interact program included with UpToDate.<br />¥ Smoking may decrease blood concentrations of antipsychotics primarily metabolized by CYP1A2.<br />‡ For specific dose adjustments in setting of renal or hepatic impairment, refer to Lexicomp drug monograph.<br />† Active metabolites of cariprazine are equipotent to cariprazine. Due to the long half-life of cariprazine and active metabolites, changes in dose will not reach plasma steady-state for several weeks or months.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.&nbsp;N Engl J Med 2005; 353:1209.</LI>&#xD;&#xA;<LI>American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2015; 63:2227.</LI></OL>Prepared with data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>US product information (available online at <A href=\"http://dailymed.nlm.nih.gov/dailymed/about.cfm\" target=_blank>http://dailymed.nlm.nih.gov/dailymed/about.cfm</A>) and Health Canada product monograph.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI>&#xD;&#xA;<LI>Wynn GH, et al (eds) Clinical Manual of Drug Interaction Principles for Medical Practice APA publishing, Washington DC. Copyright © 2009.</LI></OL></div><div id=\"graphicVersion\">Graphic 60624 Version 31.0</div></div></div>"},"60625":{"type":"graphic_figure","displayName":"Arterial switch operation","title":"Arterial switch operation for transposition of the great arteries","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Arterial switch operation for transposition of the great arteries</div><div class=\"cntnt\"><img style=\"width:504px; height:656px;\" src=\"images/PEDS/60625_Arterial_switch_operation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical technique of the arterial switch operation.<br> (A) Aortic cannula is positioned distally in the ascending aorta, the ductus arteriosus is divided between suture ligatures, and the branch pulmonary arteries are dissected out to the hilum to provide adequate mobility for anterior translocation. The broken lines represent the levels of transection of the aorta and the main pulmonary artery. Marking sutures are placed in the anticipated sites of coronary transfer.<br> (B) Transection of the great arteries. The left ventricular outflow tract, neoaortic valve, and coronary arteries are thoroughly inspected.<br> (C) The coronary arterial buttons are excised from the free edge of the aorta to the base of the sinus of Valsalva.<br> (D) The coronary buttons are anastomosed to V-shaped excisions made in the neoaorta.<br> (E) The pulmonary artery is brought anterior to the aorta (Lecompte maneuver). Anastomosis of the proximal neoaorta is shown.<br> (F) The coronary donor sites are filled with autologous pericardial patches. A single U-shaped patch (F) or two separate patches (G) may be used.<br> (H) Anastomosis of the proximal neopulmonary artery and the distal pulmonary artery.</div><div class=\"graphic_reference\">Reproduced from: Castaneda AR. Anatomic correction of the transposition of the great arteries at the arterial level. In: Surgery of the Chest, Sabiston DC Jr, Spencer FC (Eds), WB Saunders, Philadelphia 1990. Illustrations used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 60625 Version 3.0</div></div></div>"},"60627":{"type":"graphic_table","displayName":"Serologic markers HBV","title":"Serologic markers for the different phases of acute and chronic hepatitis B virus infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Serologic markers for the different phases of acute and chronic hepatitis B virus infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">HBsAg</td> <td class=\"subtitle1\">HBeAg</td> <td class=\"subtitle1\">IgM anti-HBc</td> <td class=\"subtitle1\">IgG anti-HBc</td> <td class=\"subtitle1\">Anti-HBs</td> <td class=\"subtitle1\">Anti-HBe</td> <td class=\"subtitle1\">HBV DNA</td> <td class=\"subtitle1\">Interpretation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Acute HBV infection</td> </tr> <tr> <td class=\"indent1\">+</td> <td>+</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+++</td> <td>Early phase</td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>Window phase</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>+</td> <td>+</td> <td>&#177;</td> <td>Recovery phase</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Chronic HBV infection</td> </tr> <tr> <td class=\"indent1\">+</td> <td>+</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>-</td> <td>+++</td> <td>HBeAg+ high replicative phase (immune tolerance or immune clearance)</td> </tr> <tr> <td class=\"indent1\">+</td> <td>-</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>+</td> <td>&#177;</td> <td>HBeAg- low replicative or inactive phase</td> </tr> <tr> <td class=\"indent1\">+</td> <td>&#177;</td> <td>&#177;</td> <td>+</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>+</td> <td>Flare of chronic HBV</td> </tr> <tr> <td class=\"indent1\">+</td> <td>-</td> <td>&nbsp;</td> <td>+</td> <td>&nbsp;</td> <td>+</td> <td>++</td> <td>HBeAg- replicative phase (HBeAg- chronic hepatitis, precore/core promoter variants)</td> </tr> <tr> <td class=\"indent1\">-</td> <td>-</td> <td>&nbsp;</td> <td>&#177; (generally +)</td> <td>&#177;</td> <td>&#177;</td> <td>+</td> <td>Occult HBV</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Anti-HBc: antibody to hepatitis B core antigen; anti-HBe: antibody to hepatitis B e antigen; anti-HBs: antibody to hepatitis B surface antigen; HBeAg: hepatitis B e antigen; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus.</div><div id=\"graphicVersion\">Graphic 60627 Version 5.0</div></div></div>"},"60628":{"type":"graphic_diagnosticimage","displayName":"Potts disease in child","title":"Pott's disease in a young child","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Pott's disease in a young child</div><div class=\"cntnt\"><img style=\"width:532px; height:279px;\" src=\"images/ID/60628_Potts_disease_in_a_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A gibbous deformity has occurred as a consequence of collapse of the 8th, 9th, and 10th thoracic vertebral bodies with sparing of the posterior vertebral elements. The paravertebral abscess is extensive projecting laterally and anteriorly (arrows). Bony debris is present in the abscess.</div><div class=\"graphic_reference\">Courtesy of Charles E Putnam, MD.</div><div id=\"graphicVersion\">Graphic 60628 Version 5.0</div></div></div>"},"60631":{"type":"graphic_table","displayName":"DSMIV Endicott sympt depres","title":"DSM-IV* Symptoms of major depressive syndrome and substitute symptoms recommended by Endicott","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">DSM-IV* Symptoms of major depressive syndrome and substitute symptoms recommended by Endicott</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Symptom*</td>\n\t\t\t\t\t<td class=\"subtitle1\">Substitute&#8226;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>&#916;Depressed mood most of the day</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>&#916;Markedly diminished interest or pleasure in all, or almost all, activities most of the day</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Weight loss or gain (eg, more than 5 percent of body weight in a month) or decrease or increase in appetite</td>\n\t\t\t\t\t<td>Depressed appearance</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Insomnia or hypersomnia</td>\n\t\t\t\t\t<td>Social withdrawal or decreased talkativeness</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Psychomotor agitation or retardation</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Fatigue or loss of energy</td>\n\t\t\t\t\t<td>Brooding, self-pity, or pessimism</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Feelings of worthlessness or excessive or inappropriate guilt</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Diminished ability to think or concentrate, or indecisiveness</td>\n\t\t\t\t\t<td>Lack of reactivity; cannot be cheered up</td>\t\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>Recurrent thoughts of death, or suicidal ideation or planning, or a suicide attempt</td>\n\t\t\t\t\t<td>&nbsp;</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div class=\"graphic_lgnd\">One of the symptoms marked by a delta (&#916;) must be present for a diagnosis of major depressive syndrome. Each symptom must also meet severity (eg, &quot;most of the day, nearly every day&quot; and duration (greater than 2 weeks) criteria. Finally, the symptoms must be judged to cause clinically significant distress or impairment; they must not be due to the direct physiological effects of a medication or general medial condition; and they must not be better accounted for by bereavement.</div><div class=\"graphic_reference\">* DSM-IV, Amer Psych Assoc, 1994. Diagnostic and statistical manual, 4th ed (DSM-IV).<br>&#8226; Endicott, J. Cancer 1984; 53:2243.</div><div id=\"graphicVersion\">Graphic 60631 Version 1.0</div></div></div>"},"60632":{"type":"graphic_table","displayName":"Taxonomy of aging","title":"Taxonomy of aging","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Taxonomy of aging</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Group</td>\n\n      <td class=\"subtitle1\">Characteristics</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Primary</td>\n\n      <td>No functional dependence; negligible comorbidity</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Intermediate</td>\n\n      <td>Dependence in one or more IADLs; stable comorbidity\n(eg, stable angina, chronic renal insufficiency, etc)</td>\n\n    </tr>\n\n    <tr>\n\n      <td colspan=\"1\" rowspan=\"4\">Secondary or frail\n\n      </td>\n\n      <td>One of the following criteria:</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>(i) Dependence in one or more ADLS;</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>(ii) Three or more comorbid conditions or one poorly\ncontrolled comorbid condition;</td>\n\n    </tr>\n\n    <tr>\n\n      \n\n      <td>(iii) One or more geriatric syndromes\n(delirium, dementia, depression, falls, incontinence, spontaneous bone\nfractures, neglect or abuse, failure to thrive)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Near death</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">ADLs: activities of daily living; IADLs: instrumental activities of daily living.</div><div class=\"graphic_reference\">Reproduced with permission from: Balducci L. Geriatric oncology. Crit Rev Oncol Hematol 2003; 46:212. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 60632 Version 2.0</div></div></div>"},"60633":{"type":"graphic_figure","displayName":"Reduction of metacarpal neck fracture","title":"Reduction of metacarpal neck fracture","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Reduction of metacarpal neck fracture</div><div class=\"cntnt\"><img style=\"width:524px; height:326px;\" src=\"images/SURG/60633_Reduct_meta_neck_fing_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A metacarpal neck fracture often develops an apex dorsal angulation deformity because the thin volar cortex is frequently comminuted, which leads to flexion of the metacarpal head. The flexion is maintained by the intrinsic muscles that cross volar to the axis of the metacarpophalangeal joint (MCPJ).<br> The Jahss maneuver shown here is an effective technique for closed reduction of metacarpal neck fractures: <ul> <li>After suitable anesthesia, the metacarpophalangeal joint (MCPJ) and distal interphalangeal joint (DIPJ) are flexed to 90 degrees </li> <li>Force is exerted upwards through the flexed proximal phalanx and downwards on the metacarpal shaft to correct the flexion deformity at the metacarpal neck </li> <li>The proximal interphalangeal joint (PIPJ) is extended and a splint is applied to maintain the wrist in extension, the MCPJ in maximal flexion, and the PIPJ in extension. An adjacent stable finger should be included in the splint. </li> </ul></div><div id=\"graphicVersion\">Graphic 60633 Version 8.0</div></div></div>"},"60634":{"type":"graphic_figure","displayName":"Erratic CHO intake in IDDM","title":"Erratic carbohydrate intake prevents glycemic control","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Erratic carbohydrate intake prevents glycemic control</div><div class=\"cntnt\"><img style=\"width:498px; height:211px;\" src=\"images/ENDO/60634_Erratic_CHO_intake_in_IDDM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Carbohydrate profiles from 6 AM to 12 AM on two consecutive days in a 57-year-old woman with fluctuating blood glucose concentrations (shown, in mg/dL, by the numbers in the graphs). Each column represents the&nbsp;carbohydrate intake at a meal or snack. Both the total carbohydrate intake and the distribution of carbohydrate intake vary markedly, a change that was even more marked on the day 3 when total carbohydrate intake was 267 grams (not shown). To convert blood glucose values to mmol/L, multiply by 0.056.</div><div class=\"graphic_footnotes\">CHO: carbohydrate.<br />* Mild hypoglycemic symptoms.</div><div id=\"graphicVersion\">Graphic 60634 Version 3.0</div></div></div>"},"60637":{"type":"graphic_table","displayName":"Nutrient requirements premature infants","title":"Recommended daily parenteral and enteral requirements for premature infants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended daily parenteral and enteral requirements for premature infants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Component (unit)</td> <td class=\"subtitle1\">Parenteral intake, unit/kg</td> <td class=\"subtitle1\">Enteral intake, unit/kg</td> </tr> <tr> <td>Water (mL)</td> <td>150</td> <td>150</td> </tr> <tr> <td>Energy (kcal)</td> <td>80 to 100</td> <td>120 to 130</td> </tr> <tr> <td>Protein (g)</td> <td>3 to 3.5</td> <td>3.5</td> </tr> <tr> <td>Fat (g)</td> <td>1 to 4</td> <td>5 to 7</td> </tr> <tr> <td>Carbohydrate (g)</td> <td>16</td> <td>12 to 14</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Electrolytes, minerals, and trace elements</td> </tr> <tr> <td class=\"sublist1\">Sodium (meq)</td> <td class=\"sublist_other\">2 to 4</td> <td class=\"sublist_other\">2 to 8</td> </tr> <tr> <td class=\"sublist1\">Potassium (meq)</td> <td class=\"sublist_other\">2 to 3</td> <td class=\"sublist_other\">2 to 3</td> </tr> <tr> <td class=\"sublist1\">Chloride (meq)</td> <td class=\"sublist_other\">2 to 3</td> <td class=\"sublist_other\">2 to 3</td> </tr> <tr> <td class=\"sublist1\">Calcium (mg)</td> <td class=\"sublist_other\">80 to 120</td> <td class=\"sublist_other\">200 to 220</td> </tr> <tr> <td class=\"sublist1\">Phosphorus (mg)</td> <td class=\"sublist_other\">60 to 90</td> <td class=\"sublist_other\">100 to 110</td> </tr> <tr> <td class=\"sublist1\">Magnesium (mg)</td> <td class=\"sublist_other\">9 to 10</td> <td class=\"sublist_other\">7 to 10</td> </tr> <tr> <td class=\"sublist1\">Zinc (mcg)</td> <td class=\"sublist_other\">350 to 450</td> <td class=\"sublist_other\">1000 to 2000</td> </tr> <tr> <td class=\"sublist1\">Copper (mcg)</td> <td class=\"sublist_other\">65</td> <td class=\"sublist_other\">65 to 300</td> </tr> <tr> <td class=\"sublist1\">Chromium (mcg)</td> <td class=\"sublist_other\">0.4</td> <td class=\"sublist_other\">0.1 to 0.4</td> </tr> <tr> <td class=\"sublist1\">Manganese (mcg)</td> <td class=\"sublist_other\">1</td> <td class=\"sublist_other\">7.5</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Vitamins</td> </tr> <tr> <td class=\"sublist1\">Vitamin A (int. unit)</td> <td class=\"sublist_other\">500</td> <td class=\"sublist_other\">700 to 1500</td> </tr> <tr> <td class=\"sublist1\">Vitamin D (int. unit)</td> <td class=\"sublist_other\">160</td> <td class=\"sublist_other\">400*</td> </tr> <tr> <td class=\"sublist1\">Vitamin E (int. unit)</td> <td class=\"sublist_other\">2.8</td> <td class=\"sublist_other\">6 to 12</td> </tr> <tr> <td class=\"sublist1\">Vitamin K<sup>&#182;</sup> (mcg)</td> <td class=\"sublist_other\">80</td> <td class=\"sublist_other\">8 to 10</td> </tr> <tr> <td class=\"sublist1\">Folic acid (mcg)</td> <td class=\"sublist_other\">56</td> <td class=\"sublist_other\">25 to 50</td> </tr> <tr> <td class=\"sublist1\">Niacin (mg)</td> <td class=\"sublist_other\">16.8</td> <td class=\"sublist_other\">3.6 to 4.8</td> </tr> <tr> <td class=\"sublist1\">Pyridoxine (mcg)</td> <td class=\"sublist_other\">180</td> <td class=\"sublist_other\">150 to 210</td> </tr> <tr> <td class=\"sublist1\">Riboflavin (mcg)</td> <td class=\"sublist_other\">150</td> <td class=\"sublist_other\">250 to 360</td> </tr> <tr> <td class=\"sublist1\">Thiamine (mcg)</td> <td class=\"sublist_other\">350</td> <td class=\"sublist_other\">180 to 240</td> </tr> <tr> <td class=\"sublist1\">Vitamin B12 (mcg)</td> <td class=\"sublist_other\">0.3</td> <td class=\"sublist_other\">0.1 to 0.5</td> </tr> <tr> <td class=\"sublist1\">Vitamin C (mg)</td> <td class=\"sublist_other\">15 to 25</td> <td class=\"sublist_other\">18 to 24</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Intake is not adjusted for weight.<br />¶ Does not include 0.5 to 1 mg vitamin K given at birth.</div><div class=\"graphic_reference\">Adapted from:&nbsp;<br /><OL>&#xD;&#xA;<LI>Greene HL, Hambidge KM, Schanler RJ, Tsang RC. Guidelines for the use of vitamins, trace elements, calcium, magnesium, and phosphorus in infants and children receiving total parenteral nutrition: report of the Subcommittee on Pediatric Parenteral Nutrient Requirements from the Committee on Clinical Practice Issues of The American Society for Clinical Nutrition. Am J Clin Nutr 1988; 48:1324. </LI>&#xD;&#xA;<LI>American Academy of Pediatrics, Committee on Nutrition. Nutritional needs of low-birth-weight infants. Pediatrics 1985; 75:976. </LI>&#xD;&#xA;<LI>Wharton BA. Wharton BA. Nutrition and feeding of preterm infants. Oxford: Blackwell Scientific Publications, 1987. </LI>&#xD;&#xA;<LI>Tsang RC, Lucas A, Uauy R, Zlotkin S. Nutritional needs of the preterm infant. Williams &amp; Wilkins, Baltimore, 1993. p.288.</LI></OL></div><div id=\"graphicVersion\">Graphic 60637 Version 9.0</div></div></div>"},"60638":{"type":"graphic_diagnosticimage","displayName":"Scheuermann kyphosis x-ray","title":"Scheuermann kyphosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scheuermann kyphosis</div><div class=\"cntnt\"><img style=\"width:334px; height:504px;\" src=\"images/PEDS/60638_Scheuermann_kyphosis_x-ray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This lateral radiograph of the thoracic spine demonstrates moderate endplate irregularity, preserved vertebral disc spaces, and mild anterior wedging of the vertebral bodies, all of which are consistent with Scheuermann kyphosis.</div><div class=\"graphic_reference\">Courtesy of Jeanne Chow, MD, and Children's Hospital Boston.</div><div id=\"graphicVersion\">Graphic 60638 Version 2.0</div></div></div>"},"60640":{"type":"graphic_diagnosticimage","displayName":"Infected pleural hematoma CT","title":"Infected pleural hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infected pleural hematoma</div><div class=\"cntnt\"><img style=\"width:333px; height:339px;\" src=\"images/PULM/60640_Infected_pleural_hematoma_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loculated collection of blood with fresh thrombus exhibiting higher attenuation. Bubbles of gas are likely due to gas-forming organisms.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 60640 Version 2.0</div></div></div>"},"60641":{"type":"graphic_table","displayName":"Lab studies musculoskeletal CP","title":"Potentially useful laboratory studies in musculoskeletal chest pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potentially useful laboratory studies in musculoskeletal chest pain</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">General</td>\n</tr>\n<tr>\n<td>Complete blood count</td>\n</tr>\n<tr>\n<td>Liver enzymes</td>\n</tr>\n<tr>\n<td>Renal function tests</td>\n</tr>\n<tr>\n<td>Urinalysis</td>\n</tr>\n<tr>\n<td>Chest radiography</td>\n</tr>\n<tr>\n<td>Electrocardiogram</td>\n</tr>\n<tr>\n<td>Other cardiac studies</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Rheumatologic</td>\n</tr>\n<tr>\n<td>Erythrocyte sedimentation rate (ESR)</td>\n</tr>\n<tr>\n<td>Rheumatoid factor (for true inflammatory joint disease)</td>\n</tr>\n<tr>\n<td>Sacroiliac radiographs with or without HLA-B27</td>\n</tr>\n<tr>\n<td>Synovial fluid analysis and culture (for true inflammatory joint disease)</td>\n</tr>\n<tr>\n<td>Synovial with or without bone biopsy and culture</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Chest wall</td>\n</tr>\n<tr>\n<td>Rib radiographs</td>\n</tr>\n<tr>\n<td>Sternoclavicular, manubriosternal joint radiographs</td>\n</tr>\n<tr>\n<td>Scintigraphy</td>\n</tr>\n<tr>\n<td>Computerized tomography</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 60641 Version 1.0</div></div></div>"},"60642":{"type":"graphic_diagnosticimage","displayName":"Balloon extraction of common bile duct stones","title":"Balloon extraction of common bile duct stones","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Balloon extraction of common bile duct stones</div><div class=\"cntnt\"><img style=\"width:484px; height:347px;\" src=\"images/GAST/60642_Balloon_extraction_CBD_ston.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel shows a balloon catheter being threaded over a guidewire within the common bile duct (arrows). At least two gallstones are visible in the distal common bile duct (arrowheads), which is dilated. In the right panel, the balloon has been inflated above a gallstone (arrow), which permits the balloon to drag the gallstone out of the duct.</div><div class=\"graphic_reference\">Courtesy of Isaac Raijman, MD.</div><div id=\"graphicVersion\">Graphic 60642 Version 4.0</div></div></div>"},"60646":{"type":"graphic_table","displayName":"Mgmt opioid constipation","title":"Common strategies for managing opioid-induced constipation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common strategies for managing opioid-induced constipation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">1. Nonpharmacologic approaches for all patients, unless contraindicated by medical status </td> </tr> <tr> <td class=\"indent1\">Increase fluid intake </td> </tr> <tr> <td class=\"indent1\">Increase dietary soluble fiber (avoid if severely debilitated or bowel obstruction is suspected) </td> </tr> <tr> <td class=\"indent1\">Encourage mobility </td> </tr> <tr> <td class=\"indent1\">Ensure comfort and privacy for defecation </td> </tr> <tr> <td class=\"subtitle2_left\">2. Select a pharmacologic strategy*</td> </tr> <tr> <td class=\"indent1\">Intermittent use of a rectal therapy, either a suppository such as bisacodyl or glycerin, or mineral oil and/or sodium phosphate&nbsp;enema </td> </tr> <tr> <td class=\"indent1\">Intermittent use (every 2-3 days) of an osmotic laxative, such as polyethylene glycol, magnesium hydroxide, or magnesium citrate</td> </tr> <tr> <td class=\"indent1\">Trial of a daily softening agent (docusate) </td> </tr> <tr> <td class=\"indent1\">Intermittent use (every 2-3 days) of a contact cathartic, such as senna or bisacodyl </td> </tr> <tr> <td class=\"indent1\">Daily use of a contact cathartic (with or without a concurrent softening agent) </td> </tr> <tr> <td class=\"indent1\">Daily use of lactulose (unless lactose-intolerant) or sorbitol </td> </tr> <tr> <td class=\"indent1\">Daily use of polyethylene glycol </td> </tr> <tr> <td class=\"subtitle2_left\">3. Adjust dose and dosing schedule of selected therapy to optimize effects </td> </tr> <tr> <td class=\"subtitle2_left\">4. Switch or combine conventional approaches if initial therapy is inadequate </td> </tr> <tr> <td class=\"subtitle2_left\">5. Consider adding a peripheral opioid antagonist&nbsp;(eg, methylnaltrexone, naloxegol, or an opioid-naloxone fixed combination)&nbsp;or lubiprostone; if constipation continues to be refractory, consider alternative drugs, eg, metoclopramide. </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*Fiber supplements and/or bulk-forming laxatives (eg, psyllium) are an option for treating non-debilitated patients who maintain good oral hydration; however, efficacy is generally modest in patients with slow transit constipation, who are also more likely to experience bloating and distention. If used, patients should start with small amounts of fiber or bulking laxatives and increase gradually as tolerated.</div><div id=\"graphicVersion\">Graphic 60646 Version 5.0</div></div></div>"},"60647":{"type":"graphic_table","displayName":"Outcomes of Rx male breast Ca","title":"Outcomes of treatment for male breast cancer in 1986 men in the SEER* database, 1988-2001","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outcomes of treatment for male breast cancer in 1986 men in the SEER* database, 1988-2001</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Disease stage</td>\n<td colspan=\"2\" rowspan=\"1\" class=\"subtitle1\">Disease specific survival, percent</td>\n\n<td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">Overall survival, percent</td>\n\n</tr>\n<tr>\n\n<td class=\"subtitle2\">5 yr</td>\n<td class=\"subtitle2\">10 yr</td>\n<td class=\"subtitle2\">5 yr</td>\n<td class=\"subtitle2\">10 yr</td>\n</tr>\n<tr>\n<td>I</td>\n<td>96</td>\n<td>93</td>\n<td>78</td>\n<td>55</td>\n</tr>\n<tr>\n<td>II</td>\n<td>88</td>\n<td>74</td>\n<td>66</td>\n<td>39</td>\n</tr>\n<tr>\n<td>III</td>\n<td>60</td>\n<td>44</td>\n<td>39</td>\n<td>21</td>\n</tr>\n<tr>\n<td>IV</td>\n<td>23</td>\n<td>21</td>\n<td>14</td>\n<td>5</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">* Calculated from the SEER database.</div><div class=\"graphic_reference\">Data from Giordano, S et al. Oncologist 2005; 10:471.</div><div id=\"graphicVersion\">Graphic 60647 Version 1.0</div></div></div>"},"60648":{"type":"graphic_figure","displayName":"Survival in asymptomatic LVD","title":"Survival in HF and disease severity","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Survival in HF and disease severity</div><div class=\"cntnt\"><img style=\"width:479px; height:229px;\" src=\"images/CARD/60648_SurvivalinasymptomaticLV.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Impact of severity of disease on mortality in patients with heart failure. Patients with symptomatic heart failure had a two-year survival rate of 50 percent in the Mayo study and 63 percent in the Framingham study.&nbsp;By contrast, asymptomatic patients had survival rates of 82 percent in the SAVE trial and 85 percent in the SOLVD trial.</div><div class=\"graphic_footnotes\">HF: heart failure.</div><div class=\"graphic_reference\">Data from: Rodeheffer RJ, Jacobsen SJ, Gersh BJ, et al. Mayo Clinic Proc 1993; 68:1143; Ho, KK, Anderson, KM, Kannel, WB, et al, Circulation 1993; 88:107; Pfeffer, MA, Braunwald, E, Moye, LA, et al, N Engl J Med 1992; 327:669; The SOLVD Investigators, N Engl J Med 1992; 327:685.</div><div id=\"graphicVersion\">Graphic 60648 Version 3.0</div></div></div>"},"60649":{"type":"graphic_table","displayName":"CARG risk score versus physician-rated KPS chemo toxicity","title":"Ability of CARG risk score versus physician-rated Karnofsky performance status (KPS) to predict chemotherapy toxicity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ability of CARG risk score versus physician-rated Karnofsky performance status (KPS) to predict chemotherapy toxicity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"4\" width=\"9%\"></colgroup><colgroup span=\"3\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Risk strata</td> <td class=\"subtitle1\" colspan=\"2\">No toxicity</td> <td class=\"subtitle1\" colspan=\"2\">Toxicity</td> <td class=\"subtitle1\" rowspan=\"2\">Total</td> <td class=\"subtitle1\" rowspan=\"2\">p</td> <td class=\"subtitle1\" rowspan=\"2\">ROC</td> </tr> <tr> <td class=\"subtitle2\">No.</td> <td class=\"subtitle2\">Percent</td> <td class=\"subtitle2\">No.</td> <td class=\"subtitle2\">Percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">By total score</td> </tr> <tr> <td class=\"indent1\">0-5 (low)</td> <td class=\"centered\">89</td> <td class=\"centered\">70</td> <td class=\"centered\">39</td> <td class=\"centered\">30</td> <td class=\"centered\">128</td> <td class=\"centered\" rowspan=\"3\">&#60;0.001</td> <td class=\"centered\" rowspan=\"3\">0.72*</td> </tr> <tr> <td class=\"indent1\">6-9 (mid)</td> <td class=\"centered\">110</td> <td class=\"centered\">48</td> <td class=\"centered\">117</td> <td class=\"centered\">52</td> <td class=\"centered\">227</td> </tr> <tr> <td class=\"indent1\">10-19 (high)</td> <td class=\"centered\">19</td> <td class=\"centered\">17</td> <td class=\"centered\">90</td> <td class=\"centered\">83</td> <td class=\"centered\">109</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">By physician-rated KPS (percent)</td> </tr> <tr> <td class=\"indent1\">90-100</td> <td class=\"centered\">125</td> <td class=\"centered\">49</td> <td class=\"centered\">128</td> <td class=\"centered\">51</td> <td class=\"centered\">253</td> <td class=\"centered\" rowspan=\"3\">0.19</td> <td class=\"centered\" rowspan=\"3\">0.53*</td> </tr> <tr> <td class=\"indent1\">80</td> <td class=\"centered\">73</td> <td class=\"centered\">49</td> <td class=\"centered\">76</td> <td class=\"centered\">51</td> <td class=\"centered\">149</td> </tr> <tr> <td class=\"indent1\">&#8804;70</td> <td class=\"centered\">33</td> <td class=\"centered\">38</td> <td class=\"centered\">53</td> <td class=\"centered\">62</td> <td class=\"centered\">86</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CARG: Cancer and Aging Research Group; ROC: receiver operating characteristic; KPS: Karnofsky performance status.<br />* Risk score and physician-rated KPS were treated as continuous to calculate the ROC.</div><div class=\"graphic_reference\">From: Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011; 29:3457. Reprinted with permission. Copyright &copy; 2011 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 60649 Version 6.0</div></div></div>"},"60650":{"type":"graphic_picture","displayName":"Mycosis fungoides patches","title":"Mycosis fungoides - patch stage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mycosis fungoides - patch stage</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/60650_Mycosis_fungoides_patch_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous patches on the trunk and proximal extremities.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60650 Version 6.0</div></div></div>"},"60652":{"type":"graphic_figure","displayName":"Urea cycle","title":"Urea cycle (UC)","html":"<div class=\"graphic\"><div style=\"width: 574px\" class=\"figure\"><div class=\"ttl\">Urea cycle (UC)</div><div class=\"cntnt\"><img style=\"width:554px; height:383px;\" src=\"images/PEDS/60652_Urea_cycle.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The flow of nitrogen intermediates in the urea cycle (UC) is depicted above. The UC converts nitrogen, derived from dietary protein intake and the breakdown of endogenous protein (catabolism), into urea, which can be excreted from the body. The steps of this cycle, and the six enzymes involved, are indicated in red. The dashed red arrow depicts the overflow of excess carbamyl phosphate (CP) into pyrimidine synthesis and, hence, to orotic acid, which is excreted in the urine. The dashed green arrow depicts the generation of nitric oxide (NO) when arginine is converted into citrulline by nitric oxide synthase (NOS). The green cylinders denote the ornithine and citrulline transporter (ORNT1; SLC25A15), and the blue cylinders represent the cationic amino-acid transporter found on intestinal- and kidney-epithelial cells (SLC7A7). The pink cylinder denotes citrin, a mitochondrial aspartate and glutamate transporter (SLC25A13).</div><div class=\"graphic_footnotes\">ARG1: arginase; ASL: argininosuccinate lyase; ASS: argininosuccinate synthetase; CPS-I: carbamyl-phosphate-synthetase-I; NAG: N-acetylglutamate; NAGS: N-acetyl-glutamate synthase; OTC: ornithine transcarbamylase.</div><div class=\"graphic_reference\">Courtesy of Brendan Lee, MD, PhD.</div><div id=\"graphicVersion\">Graphic 60652 Version 2.0</div></div></div>"},"60654":{"type":"graphic_table","displayName":"Histologic features of OP","title":"Histologic features of organizing pneumonia pattern","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histologic features of organizing pneumonia pattern</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Key histologic features</td> </tr> <tr> <td>Organizing pneumonia: intraluminal organizing fibrosis in distal airspaces (bronchioles, alveolar ducts, and alveoli)</td> </tr> <tr> <td>Patchy and peribronchiolar distribution</td> </tr> <tr> <td>Preservation of lung architecture</td> </tr> <tr> <td>Uniform and recent temporal appearance</td> </tr> <tr> <td>Mild interstitial chronic inflammation (eg, lymphocytes and edema)</td> </tr> <tr> <td>Foamy macrophages are common in alveolar spaces, likely due to bronchiolar obstruction</td> </tr> <tr> <td class=\"subtitle1_single\">Pertinent negative findings</td> </tr> <tr> <td>Absence of severe fibrotic changes (eg, honeycombing); incidental scars or apical fibrosis may be present</td> </tr> <tr> <td>Granulomas are absent; giant cells are rare or absent</td> </tr> <tr> <td>Lack of prominent infiltration of eosinophils or neutrophils</td> </tr> <tr> <td>Absence of necrosis or abscess</td> </tr> <tr> <td>Absence of vasculitis</td> </tr> <tr> <td>Lack of hyaline membranes or prominent airspace fibrin*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Intra-alveolar fibrin deposition is seen in acute fibrinous and organizing pneumonia; it is unclear whether this is a separate entity or a variant of organizing pneumonia.</div><div id=\"graphicVersion\">Graphic 60654 Version 5.0</div></div></div>"},"60657":{"type":"graphic_algorithm","displayName":"Neutropenic fever initial treatment","title":"Initial management of fever and neutropenia","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Initial management of fever and neutropenia</div><div class=\"cntnt\"><img style=\"width:604px; height:467px;\" src=\"images/ID/60657_Febrile_neutro_init_edt_4.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ANC: absolute neutrophil count; <em>C. difficile</em>: <em>Clostridium difficile</em>.<br />* Fever in a neutropenic patient is defined as a single temperature &gt;38.3&deg;C (101&deg;F) or a sustained temperature &gt;38.0&deg;C (100.4&deg;F) for &gt;1 hour.<br />&para; The authors consider patients with an ANC &lt;500 cells/microL for &gt;7 days to be at high risk for serious complications. It should be noted that in the Infectious Diseases Society of America guidelines, patients with an absolute neutrophil count &le;100 cells/microL for &gt;7 days are considered to be at high risk for serious complications.<br />&Delta; Although ceftazidime monotherapy has been used for many years, we typically recommend using an alternative. Refer to the UpToDate topic review for details.</div><div class=\"graphic_reference\">Adapted with permission from: Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:e56. Copyright © 2011 Oxford University Press. Available at: <A spellcheck=true href=\"http://www.idsociety.org/\" target=_blank>www.idsociety.org</A>.</div><div id=\"graphicVersion\">Graphic 60657 Version 18.0</div></div></div>"},"60661":{"type":"graphic_figure","displayName":"Shoulder anat anterior PI","title":"Anterior view of shoulder anatomy","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Anterior view of shoulder anatomy</div><div class=\"cntnt\"><img style=\"width:593px; height:462px;\" src=\"images/PI/60661_Shoulder_anat_anterior_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 60661 Version 3.0</div></div></div>"},"60662":{"type":"graphic_figure","displayName":"Etiology of bacterial meningitis in children","title":"Etiology of bacterial meningitis in 231 children from 20 pediatric emergency departments, United States 2001-2004","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Etiology of bacterial meningitis in 231 children from 20 pediatric emergency departments, United States 2001-2004</div><div class=\"cntnt\"><img style=\"width:610px; height:616px;\" src=\"images/PEDS/60662_Etio_bact_mening_child.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">%: percent.<br> * <em>Citrobacter diversus</em>, <em>Enterobacter cloacae</em>, <em>Klebsiella</em> spp, <em>Pasteurella multocida</em>, <em>Pseudomonas aeruginosa</em>, <em>Salmonella</em> spp.<br> <span class=bullet>&#8226;</span> <em>Listeria monocytogenes</em> (2 percent); group A streptococcus (2 percent), <em>Moraxella catarrhalis</em> (0.4 percent).</div><div class=\"graphic_reference\">Data from: Nigrovic LE, Kuppermann N, Malley R. Children with bacterial meningitis presenting to the emergency department during the pneumococcal conjugate vaccine era. Acad Emerg Med 2008; 15:522.</div><div id=\"graphicVersion\">Graphic 60662 Version 4.0</div></div></div>"},"60663":{"type":"graphic_figure","displayName":"Comparison statin drugs","title":"Comparison of the efficacy of statin drugs","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Comparison of the efficacy of statin drugs</div><div class=\"cntnt\"><img style=\"width:518px; height:392px;\" src=\"images/PC/60663_Comparisonstatindrugs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparison of the percent reduction in serum LDL cholesterol with various statin drugs.</div><div class=\"graphic_footnotes\">LDL: low-density lipoprotein.</div><div id=\"graphicVersion\">Graphic 60663 Version 3.0</div></div></div>"},"60664":{"type":"graphic_picture","displayName":"Choledochoscope for lithotripsy","title":"Choledochoscope","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Choledochoscope</div><div class=\"cntnt\"><img style=\"width:396px; height:255px;\" src=\"images/GAST/60664_Choledochoscope_for_lithotr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A choledochoscope can be introduced via the working channel of a therapeutic side-viewing duodenoscope for retrograde access to the biliary system. The system can be worked by one endoscopist and one endoscopy nurse.</div><div class=\"graphic_reference\">Courtesy of Thomas Lingenfelser, MD, PhD.</div><div id=\"graphicVersion\">Graphic 60664 Version 2.0</div></div></div>"},"60665":{"type":"graphic_diagnosticimage","displayName":"Dissection of the abdominal aorta on transverse ultrasound","title":"Dissection of the abdominal aorta on transverse ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dissection of the abdominal aorta on transverse ultrasound</div><div class=\"cntnt\"><img style=\"width:248px; height:254px;\" src=\"images/CARD/60665_Abdominal_aorta_dissectio1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The short axis view shows a dissection (Dis) of the abdominal aorta (AoAb) and a spiral flap (arrows).</div><div id=\"graphicVersion\">Graphic 60665 Version 3.0</div></div></div>"},"60666":{"type":"graphic_picture","displayName":"Normal human PMN","title":"Normal human neutrophil","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal human neutrophil</div><div class=\"cntnt\"><img style=\"width:385px; height:261px;\" src=\"images/HEME/60666_Normal_human_PMN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear shows a normal polymorphonuclear neutrophil (PMN). The nucleus is segmented into four lobes connected by thin chromatin strands. The cytoplasm is pink with fine, azure bluish granules. The predominant specific secondary granules are finely dispersed and stains the cytoplasm faintly pink.</div><div class=\"graphic_reference\">Courtesy of Robert L Baehner, MD.</div><div id=\"graphicVersion\">Graphic 60666 Version 2.0</div></div></div>"},"60667":{"type":"graphic_figure","displayName":"Research designs","title":"Clinical research designs, questions and measures","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Clinical research designs, questions and measures</div><div class=\"cntnt\"><img style=\"width:526px; height:730px;\" src=\"images/PC/60667_Research_designs_edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted from Fletcher SW. Principles of Epidemiology. In: Textbook of Internal Medicine, Kelley WN (Ed), JB Lippincott, Philadelpia 1988.</div><div id=\"graphicVersion\">Graphic 60667 Version 3.0</div></div></div>"},"60668":{"type":"graphic_figure","displayName":"Talking tracheostomy tube","title":"Talking tracheostomy tube","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Talking tracheostomy tube</div><div class=\"cntnt\"><img style=\"width:349px; height:330px;\" src=\"images/PULM/60668_Talking_tracheostomy_tube.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representation of the talking tracheostomy tube. Air is passed proximally beyond the vocal cords and phonation occurs when the port shown is manually occluded.</div><div class=\"graphic_reference\">Redrawn from Current Respiratory Care 1988; BC Decker, Philadelphia, PA.</div><div id=\"graphicVersion\">Graphic 60668 Version 1.0</div></div></div>"},"60670":{"type":"graphic_figure","displayName":"Comparison of ESRD patients receiving ICDs","title":"Comparison of peritoneal dialysis, hemodialysis and transplant patients with ICDs","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Comparison of peritoneal dialysis, hemodialysis and transplant patients with ICDs</div><div class=\"cntnt\"><img style=\"width:498px; height:319px;\" src=\"images/NEPH/60670_Percent_ESRDs_ICDs.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Period prevalent ESRD patients.</div><div class=\"graphic_footnotes\">ICD: implantable cardioverter-defibrillator; ESRD: end-stage renal disease.</div><div class=\"graphic_reference\">Reproduced from: US Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010. Full report available at: <a href=\"http://www.usrds.org/adr.htm\" target=\"_blank\">http://www.usrds.org/adr.htm</a>.</div><div id=\"graphicVersion\">Graphic 60670 Version 5.0</div></div></div>"},"60672":{"type":"graphic_table","displayName":"Carbon monoxide poisoning - Rapid overview","title":"Carbon monoxide poisoning: Rapid overview","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Carbon monoxide poisoning: Rapid overview</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><span style=\"color: #ff0000;\">To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (</span><a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html</a><span style=\"color: #ff0000;\">).</span></td> </tr> <tr> <td class=\"subtitle1_single\">History</td> </tr> <tr> <td>Duration and mechanism of exposure</td> </tr> <tr> <td>Assess for major symptoms: loss of consciousness, confusion, symptoms consistent with hypoxia (ie, chest pain)</td> </tr> <tr> <td>Assess for minor symptoms: headache, nausea/vomiting</td> </tr> <tr> <td>Assess pregnancy status</td> </tr> <tr> <td class=\"subtitle1_single\">Physical examination</td> </tr> <tr> <td>Careful evaluation of mental status</td> </tr> <tr> <td>Physical examination usually unremarkable</td> </tr> <tr> <td class=\"subtitle1_single\">Diagnostic evaluation</td> </tr> <tr> <td>Check CO level with co-oximetry of arterial or venous blood</td> </tr> <tr> <td>Check acid-base status using (preferably arterial) blood gas</td> </tr> <tr> <td>Obtain ECG in all patients; measure cardiac biomarkers in patients &#8805;65, patients with significant cardiac risk factors, and younger patients with chest pain or symptoms suggestive of ischemia</td> </tr> <tr> <td>Consider CNS imaging (head CT) in patients with altered mental status to rule out other etiologies</td> </tr> <tr> <td>Measure blood cyanide concentration; consider empiric treatment for cyanide poisoning in patients with smoke inhalation</td> </tr> <tr> <td class=\"subtitle1_single\">Treatment</td> </tr> <tr> <td class=\"sublist1_start\">Secure airway, breathing, and circulation</td> </tr> <tr> <td class=\"sublist1\">Intubate as clinically indicated</td> </tr> <tr> <td class=\"sublist1\">Apply high-flow oxygen to <strong>ALL</strong> CO poisoned patients regardless of pulse oximetry or arterial pO2</td> </tr> <tr> <td>Direct fire department to assess for environmental exposure and remove victims</td> </tr> <tr> <td class=\"sublist1_start\">We suggest hyperbaric oxygen (HBO) for:</td> </tr> <tr> <td class=\"sublist1\">CO level &#62;25 percent (&#62;20 percent if pregnant)</td> </tr> <tr> <td class=\"sublist1\">Loss of consciousness</td> </tr> <tr> <td class=\"sublist1\">Severe metabolic acidosis (pH &#60;7.1)</td> </tr> <tr> <td class=\"sublist1\">Concern for end-organ ischemia (chest pain, ECG changes, altered mental status)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; CO: carbon monoxide; CT: computed tomography; ECG: electrocardiogram; HBO: hyperbaric oxygen.</div><div id=\"graphicVersion\">Graphic 60672 Version 10.0</div></div></div>"},"60673":{"type":"graphic_picture","displayName":"Nodular lesions bartonellos","title":"Nodular lesions (eruptive-phase bartonellosis)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Nodular lesions (eruptive-phase bartonellosis)</div><div class=\"cntnt\"><img style=\"width:504px; height:327px;\" src=\"images/ID/60673_Nodular_lesions_bartonellos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous irregularly shaped, subdermal nodular lesions, with normal-appearing overlying skin, on the lower extremity of a 30-year-old patient from Peru.</div><div class=\"graphic_reference\">Reproduced with permission from Maguina C, Garcia PJ, Gotuzzo E, et al. Bartonellosis (Carrion's disease) in the modern era. Clin Infect Dis 2001; 33:772. Copyright ©2001 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 60673 Version 4.0</div></div></div>"},"60674":{"type":"graphic_table","displayName":"Parenteral rx VRE","title":"Parenteral therapy for infections due to vancomycin-resistant enterococci in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parenteral therapy for infections due to vancomycin-resistant enterococci in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Dose* and route</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Ampicillin-susceptible enterococci</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Monotherapy:</strong></td> </tr> <tr> <td class=\"indent2\">Ampicillin (+/&ndash; sulbactam)<sup>&#182;</sup></td> <td>6 to 12 g per 24 hours in six equally divided doses</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Combination therapy:</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"><strong>Above plus one of the following:</strong> (for bactericidal activity)<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent2\">Gentamicin<sup>&#9674;</sup></td> <td>3 mg/kg per 24 hours in three equally divided doses</td> </tr> <tr> <td class=\"indent2\">Streptomycin<sup>&#167;</sup></td> <td>15 mg/kg per 24 hours in two equally divided doses</td> </tr> <tr> <td class=\"indent3\" colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td class=\"indent2\">Ampicillin<sup>&#182;</sup></td> <td>12 g per 24 hours intravenously in six equally divided doses</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\"><strong>PLUS</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Ceftriaxone</td> <td>4 g per 24 hours in two equally divided doses</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Ampicillin-resistant <em>E. faecium</em>: One of the following</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Daptomycin<sup>&#134;</sup></td> <td>For <em>E. faecalis</em>: 4 mg/kg every 24 hours (approved dose for complicated skin and soft tissue infection)</td> </tr> <tr> <td>Higher dosing (8 to 12 mg/kg every 24 hours)&nbsp;is recommended for bacteremia or life-threatening infections due to <em>E. faecalis</em> or <em>E. faecium</em> with or without another agent (aminoglycoside, ampicillin or ceftaroline, tigecycline)</td> </tr> <tr> <td class=\"indent1\">High-dose ampicillin<sup><span style=\"font-size: 13px;\">&#165;</span></sup></td> <td>18 to 30 g per day<sup><span style=\"font-size: 13px;\">&#135; </span></sup>(if MIC 16, 32 or 64 ug/mL)&nbsp;</td> </tr> <tr> <td class=\"indent1\">Linezolid</td> <td>1200 mg per 24 hours in two equally divided doses</td> </tr> <tr> <td class=\"indent1\">Tigecycline**</td> <td>100 mg loading dose followed by maintenance dosing of 50 mg every 12 hours (if source is an intraabdominal infection)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Doses recommended are for patients with normal renal function.<br />¶ Infections due to beta-lactamase-producing enterococci may be treated with ampicillin-sulbactam.<br />Δ Synergistic activity of an active&nbsp;cell wall-active agent (eg, ampicillin)&nbsp;in combination with gentamicin, streptomycin, or ceftriaxone is required for bactericidal activity, which is warranted in the setting of invasive infections such as endocarditis, meningitis, and bacteremia in the setting of valvulopathy and/or critical illness.<br /><FONT class=lozenge>◊</FONT> In patients with normal renal function, gentamicin dosing should be adjusted to achieve a one-hour post-dose&nbsp;serum concentration of 3 mcg/mL and a trough concentration of &lt;1 mcg/mL.<br />§ In patients with normal renal function, streptomycin dosing should be adjusted to achieve a one-hour post-dose serum concentration of 20 to 35 mcg/mL and a trough concentration of &lt;10 mcg/mL.<br />¥ Some <EM>E. faecium</EM> are ampicillin sensitive. If minimum inhibitory concentration (MIC) is&nbsp;16 to 64 mcg/mL, <EM>E. faecium</EM> may be treated with high-dose ampicillin.<br />‡ With or without aminoglycoside (gentamicin or streptomycin).<br />† Although daptomycin has approval only for vancomycin-sensitive <EM>E. faecalis</EM>, many favor using this agent for treatment of infections due to isolates that are resistant to approved agents (including vancomycin-resistant <EM>E. faecalis</EM> and <EM>E. faecium</EM>). Approved dosing for soft tissue infections due to vancomycin-sensitive <EM>E. faecalis</EM> is 4 mg/kg intravenously once daily. Approved dosing for bloodstream infections due to <EM>S. aureus</EM> is 6 mg/kg intravenously once daily; some routinely use doses of 8 to 10&nbsp;mg/kg intravenously once daily. Doses of up to 12 mg/kg appeared to be safe in a small number of volunteers and could be considered for life-threatening VRE infections with relatively high MICs.<br />** Although tigecycline has approval only for soft tissue and intraabdominal infections due to vancomycin-sensitive <EM>E. faecalis</EM>, some favor using this agent for treatment of&nbsp;skin and soft tissue&nbsp;enterococcal infections due to isolates that are resistant to approved agents (including vancomycin-resistant <EM>E. faecalis</EM> and <EM>E. faecium</EM>) or adding it to daptomycin.</div><div id=\"graphicVersion\">Graphic 60674 Version 10.0</div></div></div>"},"60675":{"type":"graphic_figure","displayName":"Motor unit","title":"The motor unit","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">The motor unit</div><div class=\"cntnt\"><img style=\"width:535px; height:478px;\" src=\"images/NEURO/60675_Motor_unit.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 60675 Version 2.0</div></div></div>"},"60676":{"type":"graphic_table","displayName":"GA and BW characteristics of US singleton twin triplet births","title":"Gestational age and birthweight characteristics of United States singleton, twin, and triplet live births, 2006","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gestational age and birthweight characteristics of United States singleton, twin, and triplet live births, 2006</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Singletons<br /> </td> <td class=\"subtitle1\">Twins<br /> </td> <td class=\"subtitle1\">Triplets<br /> </td> </tr> <tr> <td><strong>No. of births</strong></td> <td class=\"centered\">4,121,930</td> <td class=\"centered\">137,085</td> <td class=\"centered\">6118</td> </tr> <tr> <td><strong>Mean gestational age (weeks)</strong></td> <td class=\"centered\">38.7</td> <td class=\"centered\">35.2</td> <td class=\"centered\">32.0</td> </tr> <tr> <td><strong>Percent very preterm (&#60;32 weeks)</strong></td> <td class=\"centered\">1.6</td> <td class=\"centered\">12.1</td> <td class=\"centered\">36.3</td> </tr> <tr> <td><strong>Percent preterm (&#60;37 weeks)</strong></td> <td class=\"centered\">11.1</td> <td class=\"centered\">60.4</td> <td class=\"centered\">92.6</td> </tr> <tr> <td><strong>Birthweight (grams)</strong></td> <td class=\"centered\">3298</td> <td class=\"centered\">2323</td> <td class=\"centered\">1655</td> </tr> <tr> <td><strong>Percent very low birthweight (&#60;1500 grams)</strong></td> <td class=\"centered\">1.1</td> <td class=\"centered\">10.2</td> <td class=\"centered\">34.8</td> </tr> <tr> <td><strong>Percent low birthweight (&#60;2500 grams)</strong></td> <td class=\"centered\">6.5</td> <td class=\"centered\">57.5</td> <td class=\"centered\">95.4</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2006. Natl Vital Stat Rep 2009; 57:1.</div><div id=\"graphicVersion\">Graphic 60676 Version 4.0</div></div></div>"},"60677":{"type":"graphic_diagnosticimage","displayName":"Endomyocard fibrosis surg","title":"Endomyocardial fibrosis surgery","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Endomyocardial fibrosis surgery</div><div class=\"cntnt\"><img style=\"width:513px; height:197px;\" src=\"images/CARD/60677_Endomyocard_fibrosis_surg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Surface echocardiogram with left ventricular apical fibrosis and severe left and right atrial enlargement.<br />(B) Postoperative.</div><div class=\"graphic_reference\">Reproduced with permission from Schneider U, Jenni R, Turina J, et al. Long term follow up of patients with endomyocardial fibrosis: effects of surgery. Heart 1998; 79:362. Copyright &copy;1998 BMJ Publishing Group.</div><div id=\"graphicVersion\">Graphic 60677 Version 4.0</div></div></div>"},"60678":{"type":"graphic_table","displayName":"Carpal ossification","title":"Ossification centers and epiphyseal growth plate maturation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ossification centers and epiphyseal growth plate maturation</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\t<tr>\n\t\t\t\t<td class=\"subtitle1\">Bone</td>\n\t\t\t\t<td class=\"subtitle1\">Appearance</td>\n\t\t\t\t<td class=\"subtitle1\">Closure</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Capitate</td>\n\t\t\t\t<td>2 months</td>\n\t\t\t\t<td>13 to 15 years</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Hamate</td>\n\t\t\t\t<td>3 to 4 months</td>\n\t\t\t\t<td>13 to 15 years</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Radius</td>\n\t\t\t\t<td>10 to 12 montsh</td>\n\t\t\t\t<td>16 to 17 years</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Triquetrum</td>\n\t\t\t\t<td>2 to 3 years</td>\n\t\t\t\t<td>13 to 15 years</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Lunate</td>\n\t\t\t\t<td>3 years</td>\n\t\t\t\t<td>13 to 16 years</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Scaphoid</td>\n\t\t\t\t<td>4 to 5 years</td>\n\t\t\t\t<td>13 to 16 years</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Trapezium</td>\n\t\t\t\t<td>4 to 6 years</td>\n\t\t\t\t<td>13 to 16 years</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Trapezoid</td>\n\t\t\t\t<td>4 to 6 years</td>\n\t\t\t\t<td>13 to 16 years</td>\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td>Ulna</td>\n\t\t\t\t<td>6 years</td>\n\t\t\t\t<td>15 to 17 years</td>\n\t\t\t</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 60678 Version 1.0</div></div></div>"},"60679":{"type":"graphic_table","displayName":"Differential diagnosis of low back pain","title":"Differential diagnosis of low back pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of low back pain</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Mechanical low back pain</td> </tr> <tr> <td>Lumbar strain</td> </tr> <tr> <td>Degenerative disease <br /> <ul> <li>Discs (spondylosis) </li> <li>Facet joints (osteoarthritis) </li> </ul> </td> </tr> <tr> <td>Spondylolisthesis</td> </tr> <tr> <td>Herniated disc</td> </tr> <tr> <td>Spinal stenosis</td> </tr> <tr> <td>Osteoporosis</td> </tr> <tr> <td>Fractures</td> </tr> <tr> <td>Congenital disease<br /> <ul> <li>Severe kyphosis </li> <li>Severe scoliosis </li> <li>Possible type II or type IV&nbsp;transitional vertebra* </li> </ul> </td> </tr> <tr> <td>Possible spondylolysis</td> </tr> <tr> <td>Possible facet joint asymmetry</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Nonmechanical spine disease</td> </tr> <tr> <td>Neoplasia<br /> <ul> <li>Multiple myeloma </li> <li>Metastatic carcinoma </li> <li>Lymphoma and leukemia </li> <li>Spinal cord tumors </li> <li>Retroperitoneal tumors </li> </ul> </td> </tr> <tr> <td>Infection<br /> <ul> <li>Osteomyelitis </li> <li>Septic discitis </li> <li>Paraspinous abscess </li> <li>Epidural abscess </li> </ul> </td> </tr> <tr> <td>Inflammatory arthritis (often HLA-B27-associated)<br /> <ul> <li>Ankylosing spondylitis </li> <li>Psoriatic spondylitis </li> <li>Reactive arthritis </li> <li>Inflammatory bowel disease </li> </ul> </td> </tr> <tr> <td>Scheuermann disease (osteochondrosis)</td> </tr> <tr> <td>Paget disease</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\">Visceral disease</td> </tr> <tr> <td>Pelvic organs<br /> <ul> <li>Prostatitis </li> <li>Endometriosis </li> <li>Chronic pelvic inflammatory disease </li> </ul> </td> </tr> <tr> <td>Renal disease<br /> <ul> <li>Nephrolithiasis </li> <li>Pyelonephritis </li> <li>Perinephric abscess </li> </ul> </td> </tr> <tr> <td>Aortic aneurysm</td> </tr> <tr> <td>Gastrointestinal disease<br /> <ul> <li>Pancreatitis </li> <li>Cholecystitis </li> <li>Penetrating ulcer </li> </ul> </td> </tr> <tr> <td>Fat herniation of lumbar space</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HLA: human leukocyte antigen.<br />* A transitional vertebra is a congenital anomaly in which there is a naturally occurring articulation or bony fusion between the transverse processes of L5 and the sacrum, but there is still a small remnant disc space between L5 and the sacrum. Type II means that one or both transverse processes appear to form a diarthrodial joint with the sacrum, but there is no bony fusion. Type IV means that there is a type II abnormality on one side and a complete bony fusion on the opposite side.</div><div class=\"graphic_reference\">Reproduced from: Deyo RA. Early diagnostic evaluation of low back pain. J Gen Intern Med 1986; 1:328, with kind permission from Springer Science + Business Media B.V. Copyright © 1986.</div><div id=\"graphicVersion\">Graphic 60679 Version 11.0</div></div></div>"},"60681":{"type":"graphic_figure","displayName":"Wound eversion A","title":"Needle insertion for eversion technique","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Needle insertion for eversion technique</div><div class=\"cntnt\"><img style=\"width:392px; height:366px;\" src=\"images/EM/60681_Wound_eversion_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For proper healing, the edges of the wound must be everted. To accomplish this, the needle should penetrate the skin at a 90 degree angle to its surface.</div><div id=\"graphicVersion\">Graphic 60681 Version 4.0</div></div></div>"},"60682":{"type":"graphic_figure","displayName":"Anatomy abdominal aortic aneurysm","title":"Anatomy abdominal aortic aneurysm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy abdominal aortic aneurysm</div><div class=\"cntnt\"><img style=\"width:447px; height:591px;\" src=\"images/SURG/60682_AAA_anatomy-edit2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 60682 Version 13.0</div></div></div>"},"60683":{"type":"graphic_table","displayName":"Pre-liver transplant evaluation","title":"Pre-liver transplantation evaluation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pre-liver transplantation evaluation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Laboratory testing</td> </tr> <tr> <td class=\"indent1\">ABO-Rh blood typing</td> </tr> <tr> <td class=\"indent1\">Liver biochemical and function tests (ALT, AST, alkaline phosphatase, bilirubin, INR)</td> </tr> <tr> <td class=\"indent1\">Sodium&nbsp;</td> </tr> <tr> <td class=\"indent1\">CBC with differential</td> </tr> <tr> <td class=\"indent1\">Creatinine clearance</td> </tr> <tr> <td class=\"indent1\">Serum alpha-fetoprotein</td> </tr> <tr> <td class=\"indent1\">Calcium and vitamin D levels</td> </tr> <tr> <td class=\"indent1\">Serologies for CMV, EBV, varicella, HIV, HAV, HBV, HCV, RPR</td> </tr> <tr> <td class=\"indent1\">Urinalysis</td> </tr> <tr> <td class=\"indent1\">Urine drug screen</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiopulmonary evaluation</td> </tr> <tr> <td class=\"indent1\">ECG</td> </tr> <tr> <td class=\"indent1\">Cardiac stress test (exercise or pharmacologic) if over the age of 40 years or if there are multiple risk factors for coronary artery disease (followed by cardiac catheterization if positive)</td> </tr> <tr> <td class=\"indent1\">Contrast-enhanced echocardiography</td> </tr> <tr> <td class=\"indent1\">Pulse oximetry</td> </tr> <tr> <td class=\"indent1\">Arterial blood gas</td> </tr> <tr> <td class=\"indent1\">Chest radiography</td> </tr> <tr> <td class=\"indent1\">Contrast-enhanced chest CT</td> </tr> <tr> <td class=\"indent1\">Pulmonary function tests with DLCO</td> </tr> <tr> <td class=\"subtitle1_single\">Cancer screening</td> </tr> <tr> <td class=\"indent1\">Contrast-enhanced abdominal CT scan or MRI to look for hepatocellular carcinoma</td> </tr> <tr> <td class=\"indent1\">Skin examination</td> </tr> <tr> <td class=\"indent1\">Colonoscopy (patients &#8805;50 years old or with a history of primary sclerosing cholangitis)</td> </tr> <tr> <td class=\"indent1\">Upper endoscopy</td> </tr> <tr> <td class=\"indent1\">Cervical cancer screening and breast cancer screening for women (if indicated based on patient's age)</td> </tr> <tr> <td class=\"indent1\">Prostate cancer screening for men (if indicated based on patient's age)</td> </tr> <tr> <td class=\"subtitle1_single\">Infectious disease evaluation</td> </tr> <tr> <td class=\"indent1\">Skin testing or interferon-gamma release assay for tuberculosis</td> </tr> <tr> <td class=\"indent1\">Dental evaluation</td> </tr> <tr> <td class=\"indent1\">Screening for coccidioidomycosis or strongyloides (for patients from endemic areas)</td> </tr> <tr> <td class=\"subtitle1_single\">Psychosocial evaluation</td> </tr> <tr> <td class=\"indent1\">Psychiatric evaluation</td> </tr> <tr> <td class=\"indent1\">Social work evaluation</td> </tr> <tr> <td class=\"indent1\">Patient education seminars</td> </tr> <tr> <td class=\"indent1\">Evaluation for substance use disorders (drugs or alcohol)</td> </tr> <tr> <td class=\"subtitle1_single\">Other testing</td> </tr> <tr> <td class=\"indent1\">Bone density scan</td> </tr> <tr> <td class=\"indent1\">Transabdominal ultrasound with Doppler imaging to assess the hepatic vasculature (if not already assessed with cross-sectional imaging)</td> </tr> <tr> <td class=\"indent1\">Upper endoscopy in patients with cirrhosis or portal hypertension</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALT: alanine aminotransferase; AST: aspartate aminotransferase; CBC: complete blood count; CMV: cytomegalovirus; CT: computed tomography; DLCO: diffusing capacity of the lungs for carbon monoxide; EBV: Epstein-Barr virus; ECG: electrocardiogram; HIV: human immunodeficiency virus; HAV: hepatitis A virus; HBV: hepatitis B virus; HCV: hepatitis C virus; INR: international normalized ratio; MRI: magnetic resonance imaging; RPR: rapid plasma reagin.</div><div class=\"graphic_reference\">Courtesy of Lorna Dove, MD, MPH and Robert Brown, MD, MPH.</div><div id=\"graphicVersion\">Graphic 60683 Version 7.0</div></div></div>"},"60684":{"type":"graphic_figure","displayName":"Partial septate uterus","title":"Septate uterus: partial","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Septate uterus: partial</div><div class=\"cntnt\"><img style=\"width:354px; height:223px;\" src=\"images/OBGYN/60684_Partialseptateuterus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 60684 Version 13.0</div></div></div>"},"60685":{"type":"graphic_picture","displayName":"Infant ankyloglossia","title":"Ankyloglossia in a newborn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ankyloglossia in a newborn</div><div class=\"cntnt\"><img style=\"width:396px; height:336px;\" src=\"images/PEDS/60685_Infant_ankyloglossia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abnormally short frenulum, inserting at the tip of the tongue in a neonate.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 60685 Version 1.0</div></div></div>"},"60686":{"type":"graphic_figure","displayName":"Toxicodendron radicans world","title":"Worldwide range of toxicodendron radicans subspecies","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Worldwide range of toxicodendron radicans subspecies</div><div class=\"cntnt\"><img style=\"width:432px; height:322px;\" src=\"images/PC/60686_Toxicodendron_radicans_worl.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Bolognia, J, et al. Dermatology. Elsevier, Boston 2003. Copyright &#169; 2003 Elsevier.</div><div id=\"graphicVersion\">Graphic 60686 Version 1.0</div></div></div>"},"60689":{"type":"graphic_figure","displayName":"Pylorus-preserving pancreaticoduodenectomy","title":"Pylorus-preserving pancreaticoduodenectomy ","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Pylorus-preserving pancreaticoduodenectomy </div><div class=\"cntnt\"><img style=\"width:537px; height:334px;\" src=\"images/SURG/60689_Pylorus-preserving_whipple.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 60689 Version 2.0</div></div></div>"},"60690":{"type":"graphic_figure","displayName":"Clotting factor consumption and hypofibrinogenemia","title":"Clotting factor consumption and hypofibrinogenemia","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Clotting factor consumption and hypofibrinogenemia</div><div class=\"cntnt\"><img style=\"width:593px; height:273px;\" src=\"images/SURG/60690_Clotting_hypofibrinogenemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Citrated rapid-TEG reflecting clotting factor consumption and hypofibrinogenemia. The red line indicates a normal study.<br> This study shows a prolonged ACT, R time, and K time, reflecting enzymatic hypocoagulability; markedly low alpha angle, MA, and G, reflecting platelet hypocoagulability and poor fibrin deposition; normal LY30.</div><div class=\"graphic_footnotes\">R (reaction time): time from sample placement or activation until the tracing amplitude reaches 2 mm; K (clot formation time): time elapsed between the R-time and the point where the tracing amplitude reaches 20 mm; alpha angle: angle between the middle line of the tracing and a tangential line to the developing &quot;body&quot; of the tracing; MA (maximal amplitude): the maximal amplitude reached after clot initiation; G: a calculated measure of total clot strength based on amplitude; LY30: the amount of clot lysis detected 30 minutes after the maximal amplitute (MA) is reached; SP (split point): time from sample placement (or activation with an exogenous procoagulant) until the earliest detectable resistance.</div><div id=\"graphicVersion\">Graphic 60690 Version 3.0</div></div></div>"},"60691":{"type":"graphic_picture","displayName":"Coryneform bacteria","title":"<EM>Corynebacterium matruchotii</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\"><EM>Corynebacterium matruchotii</EM></div><div class=\"cntnt\"><img style=\"width:396px; height:335px;\" src=\"images/ID/60691_Coryneform_bacteria.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Funke G, Bernard K. Coryneform Gram-positive rods. In: Manual of Clinical Microbiology, Murray PR, Baron EJ, Jorgenson JH, et al (Eds), 9th ed, Vol 1, ASM Press, Washington, DC, 2007. p. 488. Copyright © 2007 American Society for Microbiology.</div><div id=\"graphicVersion\">Graphic 60691 Version 6.0</div></div></div>"},"60692":{"type":"graphic_table","displayName":"HCW prophylaxis recs II","title":"Postexposure prophylaxis for vaccine-preventable diseases in health care workers - II","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Postexposure prophylaxis for vaccine-preventable diseases in health care workers - II</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Disease</td> <td class=\"subtitle1\" colspan=\"2\">Definition of</td> <td class=\"subtitle1\" rowspan=\"2\">Prophylaxis</td> <td class=\"subtitle1\" rowspan=\"2\">Work restrictions</td> </tr> <tr> <td class=\"subtitle2\">Susceptible</td> <td class=\"subtitle2\">Exposed</td> </tr> <tr> <td>Varicella zoster</td> <td>None of the following: history of varicella, serologic evidence of immunity, two doses of varicella vaccine</td> <td>Cohabiting confined air space or face-to-face contact in open area with a patient who has active lesions or in the 48 hours before onset of primary infection</td> <td>Varicella zoster immune globulin (125 U/10 kg intramuscularly) for immunocompromised or pregnant health care workers or varicella vaccine if no contraindications</td> <td>Furlough from health care facility until all lesions are dry and crusted or from day 8 after first exposure to day 21 after last exposure (extend to day 28 if VZIG given)</td> </tr> <tr> <td>Hepatitis A</td> <td>None of the following: history of hepatitis A, serologic evidence of immunity, two doses of hepatitis A vaccine</td> <td>Ingestion of contaminated food, contact with feces from a patient infected with hepatitis A</td> <td>Immune globulin 0.02 mL/kg&nbsp;intramuscularly in gluteal or deltoid within 14 days of exposure; consider concurrent hepatitis A vaccination</td> <td>Relieve from direct patient contact and food handling until&nbsp;seven days after onset of jaundice</td> </tr> <tr> <td>Pertussis</td> <td>All health care workers</td> <td>Direct contact with respiratory secretions or droplets from infected person</td> <td> <p>Azithromycin&nbsp;500 mg&nbsp;orally&nbsp;on day one followed by 250 mg&nbsp;orally&nbsp;daily&nbsp;on days two to five (trimethoprim-sulfamethoxazole is an alternative)</p> </td> <td> <p><strong>Active disease or symptomatic postexposure</strong> - furlough from health care facility from beginning of catarrhal stage to&nbsp;third week after onset of paroxysms or&nbsp;five days after effective therapy</p> </td> <td> <p><strong>Asymptomatic postexposure</strong> - no restriction providing antibiotic therapy is taken</p> </td> </tr> <tr> <td>Neisseria meningitidis</td> <td>All health care workers</td> <td>Direct contact with respiratory secretions from infected person</td> <td>Ciprofloxacin 500 mg&nbsp;orally x 1 or ceftriaxone 250 mg&nbsp;intramuscularly x 1 or rifampin 600 mg&nbsp;orally&nbsp;twice daily&nbsp;for&nbsp;two&nbsp;days</td> <td>No restriction</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 60692 Version 2.0</div></div></div>"},"60693":{"type":"graphic_figure","displayName":"Collecting tubule transport","title":"Ion transport in collecting tubule principal cells","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Ion transport in collecting tubule principal cells</div><div class=\"cntnt\"><img style=\"width:541px; height:387px;\" src=\"images/NEPH/60693_Collectingtubuletransport.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of sodium (Na) and potassium (K) transport in the sodium-reabsorbing principal cells in the collecting tubules. The entry of filtered sodium into these cells is mediated by selective sodium channels in the apical (luminal) membrane; the energy for this process is provided by the favorable electrochemical gradient for sodium (cell interior electronegative and low cell sodium concentration). Reabsorbed sodium is pumped out of the cell by the Na-K-ATPase pump in the basolateral (peritubular) membrane. The reabsorption of cationic sodium makes the lumen electronegative, thereby creating a favorable gradient for the secretion of potassium into the lumen via potassium channels in the apical membrane. Aldosterone (Aldo), after combining with the cytosolic mineralocorticoid receptor (Aldo-R), leads to enhanced sodium reabsorption and potassium secretion by increasing both the number of open sodium channels and the number of Na-K-ATPase pumps. The potassium-sparing diuretics (amiloride and triamterene) act by directly inhibiting the epithelial sodium channel; spironolactone acts by competing with aldosterone for binding to the mineralocorticoid receptor.</div><div id=\"graphicVersion\">Graphic 60693 Version 14.0</div></div></div>"},"60694":{"type":"graphic_table","displayName":"Parkinson vs essential tremor","title":"Differentiating Parkinson disease and essential tremor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differentiating Parkinson disease and essential tremor</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Parkinson disease tremor</td> <td class=\"subtitle1\">Essential tremor</td> </tr> <tr> <td>Age at onset</td> <td>&#62;50 years</td> <td>Bimodal 2nd and 6th decade</td> </tr> <tr> <td>Gender</td> <td>Male &#8805; Female</td> <td>Male = Female</td> </tr> <tr> <td>Family history</td> <td>~10 to 15 percent</td> <td>~50 percent</td> </tr> <tr> <td>Asymmetry</td> <td>+++</td> <td>+</td> </tr> <tr> <td>Frequency</td> <td>4 to 6 Hz</td> <td>6&nbsp;to 12 Hz</td> </tr> <tr> <td rowspan=\"2\">Character</td> <td>At rest</td> <td>Postural, kinetic</td> </tr> <tr> <td>Supination-pronation</td> <td>Flexion-extension</td> </tr> <tr> <td>Distribution</td> <td>Hands, legs, chin, tongue</td> <td>Hands, head, voice</td> </tr> <tr> <td>Associated features</td> <td>Bradykinesia, rigidity, postural instability, micrographia</td> <td>Mild&nbsp;gait disorder or cerebellar signs in a minority</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Modified with permission from: Jankovic J. Essential tremor: clinical characteristics. Neurology 2000; 54(11 Suppl 4):S21. Copyright © 2000 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60694 Version 16.0</div></div></div>"},"60695":{"type":"graphic_table","displayName":"Mailed geriatric assessment","title":"Mailed geriatric assessment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mailed geriatric assessment</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody><tr>\n<td class=\"subtitle1\">Domain</td>\n<td class=\"subtitle1\">Measures</td>\n</tr><tr>\n<td colspan=\"1\" rowspan=\"3\">Functional status</td>\n<td>1) Activities of Daily Living [Subscale of the EORTC QLQ-C30]</td>\n</tr><tr><td>2) Instrumental Activities of Daily Living [Subscale of the OARS]</td></tr><tr><td>3)\nExercise scale</td></tr><tr>\n<td>Comorbidity</td>\n<td>Physical Health Section [Subscale of the OARS]</td>\n</tr><tr>\n<td>Pain</td>\n<td>Visual Analog Pain Thermometer Scale</td>\n</tr><tr>\n<td>Psychological</td>\n<td>Hospital Anxiety and Depression Scale</td>\n</tr><tr>\n<td>Financial well-being</td>\n<td>Subscale of the OARS</td>\n</tr><tr>\n<td>Social support</td>\n<td>Medical Outcomes Study Social Support Survey</td>\n</tr><tr>\n<td>Spiritual well-being</td>\n<td>Symptoms of Belief Inventory</td>\n</tr><tr>\n<td>Quality of life</td>\n<td>EORTC QLQ-C30</td>\n</tr></tbody>\n</table></div><div class=\"graphic_lgnd\">Also captures information on demographics.</div><div class=\"graphic_footnotes\">OARS: Older American Resources and Services.</div><div id=\"graphicVersion\">Graphic 60695 Version 2.0</div></div></div>"},"60696":{"type":"graphic_picture","displayName":"PIN basal cells IHC light","title":"Basal cells in high-grade prostatic intraepithelial neoplasia (PIN)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Basal cells in high-grade prostatic intraepithelial neoplasia (PIN)</div><div class=\"cntnt\"><img style=\"width:359px; height:285px;\" src=\"images/ONC/60696_PIN_basal_cells_IHC_light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This high-power magnification photomicrograph demonstrates the presence of basal cells (arrowheads) in an area of PIN by immunohistochemical staining using 34bE12.</div><div class=\"graphic_reference\">Courtesy of Ximing Yang, MD.</div><div id=\"graphicVersion\">Graphic 60696 Version 1.0</div></div></div>"},"60697":{"type":"graphic_figure","displayName":"Construction of a colostomy - suture to abdominal wall","title":"Construction of a colostomy - suture to abdominal wall","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Construction of a colostomy - suture to abdominal wall</div><div class=\"cntnt\"><img style=\"width:466px; height:494px;\" src=\"images/SURG/60697_Colostomy-suture-to-abd-wall.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts suturing the proximal colon limb to the dermis of&#160;the abdominal wall.</div><div id=\"graphicVersion\">Graphic 60697 Version 1.0</div></div></div>"},"60698":{"type":"graphic_figure","displayName":"Post-cleavage complex","title":"Post-cleavage complex","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Post-cleavage complex</div><div class=\"cntnt\"><img style=\"width:492px; height:318px;\" src=\"images/ALLRG/60698_Post_cleavage_complex.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">V: variable segment; J: joining segment; DNA PKcs: DNA-dependent protein kinase catalytic subunit; XRCC4: x-ray repair cross-complementing protein 4; OH: hydroxy; TdT: terminal deoxytransferase; WRN: Werner syndrome protein.</div><div id=\"graphicVersion\">Graphic 60698 Version 3.0</div></div></div>"},"60699":{"type":"graphic_picture","displayName":"Anterior shoulder dislocation appearance","title":"Anterior right shoulder dislocation in a young man","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior right shoulder dislocation in a young man</div><div class=\"cntnt\"><img style=\"width:432px; height:305px;\" src=\"images/EM/60699_Shoulder_ant_DL_external.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the prominent acromion, loss of the the normal rounded appearance of the shoulder, and the slightly abducted and externally rotated position of the right arm.</div><div id=\"graphicVersion\">Graphic 60699 Version 3.0</div></div></div>"},"60701":{"type":"graphic_picture","displayName":"Holoprosencephaly brain section","title":"Holoprosencephaly on brain section","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Holoprosencephaly on brain section</div><div class=\"cntnt\"><img style=\"width:344px; height:291px;\" src=\"images/PEDS/60701_Holoprosencephaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal brain section in holoprosencephaly demonstrating single ventricle.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 60701 Version 2.0</div></div></div>"},"60702":{"type":"graphic_table","displayName":"Alpha-1-receptor antagonist","title":"Alpha-1-receptor antagonist for BPH*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Alpha-1-receptor antagonist for BPH*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Dose titration schedule to reduce orthostatic effects<sup>[1]</sup> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Terazosin standard (appropriate for most patients) </td> </tr> <tr> <td class=\"indent1\">Days 1 to 3 </td> <td>1 mg</td> </tr> <tr> <td class=\"indent1\">Days 4 to 14 </td> <td>2 mg</td> </tr> <tr> <td class=\"indent1\">Weeks 2 to 6 </td> <td>5 mg</td> </tr> <tr> <td class=\"indent1\">Weeks 7 and thereafter </td> <td>10 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Terazosin rapid (for selected patients) </td> </tr> <tr> <td class=\"indent1\">Days 1 to 3 </td> <td>1 mg</td> </tr> <tr> <td class=\"indent1\">Days 4 to 14 </td> <td>2 mg</td> </tr> <tr> <td class=\"indent1\">Weeks 2 to 3 </td> <td>5 mg</td> </tr> <tr> <td class=\"indent1\">Weeks 4 and thereafter </td> <td>10 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Doxazosin (immediate release) </td> </tr> <tr> <td class=\"indent1\">Days 1 to 3 </td> <td>1 mg</td> </tr> <tr> <td class=\"indent1\">Days 4 to 14 </td> <td>2 mg</td> </tr> <tr> <td class=\"indent1\">Weeks 2 to 6 </td> <td>4 mg</td> </tr> <tr> <td class=\"indent1\">Weeks 7 and thereafter </td> <td>8 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Doxazosin (extended release preparation only) </td> </tr> <tr> <td class=\"indent1\">Days 1 to 21 </td> <td>4 mg</td> </tr> <tr> <td class=\"indent1\">Week 4 and thereafter </td> <td>8 mg</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Uroselective alpha-1 receptor antagonists<sup>&#182;[2]</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Alfuzosin </td> </tr> <tr> <td class=\"indent1\">Initial and maintenance </td> <td>10 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Tamsulosin </td> </tr> <tr> <td class=\"indent1\">Initial and maintenance </td> <td>0.4 mg</td> </tr> <tr> <td class=\"indent1\">If inadequate response after&nbsp;two&nbsp;to four&nbsp;weeks </td> <td>0.8 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Silodosin </td> </tr> <tr> <td class=\"indent1\">Initial and maintenance </td> <td>8 mg</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BPH: benign prostatic hyperplasia.<br />* Titrate dose as tolerated and as needed for effect. Oral administration for all medications is once daily at bedtime. Peak effect of a given dose on BPH symptoms may not be fully evident until&nbsp;four to six&nbsp;weeks. If therapy is interrupted for three or more days, reinitiate at lowest dose and re-titrate according to schedule.<br />¶&nbsp;Due to lower risk of orthostatic hypotension and syncope, uroselective agents do not require gradual dose titration. Oral administration for all medications is once daily at bedtime.</div><div class=\"graphic_reference\">1. Data from: US FDA approved product information accessed at http://dailymed.nlm.nih.gov/dailymed/about.cfm and Lee, M Management of benign prostatic hyperplasia chap 87 in Pharmacotherapy 7th ed Dipiro, JT, Talbert, RL, Yee, GC et al. 2008; McGraw Hill Medical.<br />2. Data from: US FDA approved product information accessed at http://dailymed.nlm.nih.gov/dailymed/about.cfm.</div><div id=\"graphicVersion\">Graphic 60702 Version 3.0</div></div></div>"},"60706":{"type":"graphic_diagnosticimage","displayName":"Left iliac artery aneurysm on abdominal CT","title":"Left iliac artery aneurysm on abdominal CT","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Left iliac artery aneurysm on abdominal CT</div><div class=\"cntnt\"><img style=\"width:540px; height:411px;\" src=\"images/SURG/60706_Iliac_art_aneurysm_abd_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial image through the pelvis on computed tomography showing a left common iliac artery aneurysm.</div><div id=\"graphicVersion\">Graphic 60706 Version 3.0</div></div></div>"},"60707":{"type":"graphic_table","displayName":"Bacterial meningitis adult antibiotic dosing","title":"Recommended intravenous dosages of antimicrobial therapy for adults with bacterial meningitis who have normal renal and hepatic function","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended intravenous dosages of antimicrobial therapy for adults with bacterial meningitis who have normal renal and hepatic function</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antimicrobial agent</td> <td class=\"subtitle1\">Dose (adult)</td> </tr> <tr> <td>Amikacin</td> <td>5 mg/kg every&nbsp;8 hours*</td> </tr> <tr> <td>Ampicillin</td> <td>2 g every&nbsp;4 hours</td> </tr> <tr> <td>Aztreonam</td> <td>2 g every&nbsp;6 to&nbsp;8 hours</td> </tr> <tr> <td>Cefepime</td> <td>2 g every&nbsp;8 hours</td> </tr> <tr> <td>Cefotaxime</td> <td>2 g every&nbsp;4 to&nbsp;6 hours</td> </tr> <tr> <td>Ceftazidime</td> <td>2 g every&nbsp;8 hours</td> </tr> <tr> <td>Ceftriaxone</td> <td>2 g every 12 hours</td> </tr> <tr> <td>Chloramphenicol</td> <td>1 to 1.5 g every&nbsp;6 hours<sup>&#182;</sup></td> </tr> <tr> <td>Ciprofloxacin</td> <td>400 mg every 8 to 12 hours</td> </tr> <tr> <td>Gentamicin</td> <td>1.7 mg/kg every&nbsp;8 hours*</td> </tr> <tr> <td>Meropenem</td> <td>2 g every&nbsp;8 hours</td> </tr> <tr> <td>Moxifloxacin</td> <td>400 mg every 24 hours<sup>&#916;</sup></td> </tr> <tr> <td>Nafcillin</td> <td>2 g IV every&nbsp;4 hours</td> </tr> <tr> <td>Oxacillin</td> <td>2 g IV&nbsp;every&nbsp;4 hours</td> </tr> <tr> <td>Penicillin G potassium</td> <td>4 million units every&nbsp;4 hours</td> </tr> <tr> <td>Rifampin</td> <td>600 mg every 24 hours<sup>&#9674;</sup></td> </tr> <tr> <td>Tobramycin</td> <td>1.7 mg/kg every&nbsp;8 hours*</td> </tr> <tr> <td>Trimethoprim-sulfamethoxazole (cotrimoxazole)</td> <td>5 mg/kg every 6 to 12 hours<sup>&#167;</sup><sup>&#165;</sup></td> </tr> <tr> <td>Vancomycin</td> <td>15 to 20 mg/kg every 8 to 12 hours<sup>&#135;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenously; MRSA: methicillin-resistant <EM>Staphylococcus aureus</EM>.<br />* Dose based on ideal body weight or dosing weight except in underweight patients. A calculator for ideal body weight and dosing weight is available in UpToDate. Dosage and interval must be individualized to produce a peak serum concentration of 7 to 9 mg/L and trough &lt;1 to 2 mg/L for gentamicin or tobramycin and a peak of 25 to 40 mg/L and trough &lt;4 to 8 mg/L for amikacin. For additional information,&nbsp;refer to the UpToDate&nbsp;topic on aminoglycosides.<br />¶ The higher dose is recommended for patients with pneumococcal meningitis.<br />Δ No data on optimal dosage needed in patients with bacterial meningitis.<br /><FONT class=lozenge>◊</FONT> For the treatment of MRSA meningitis, the Infectious Diseases Society of America (IDSA) suggests a rifampin dose of 600 mg orally once daily or 300 to 450 mg twice daily.<SUP>[1]</SUP> <br />§ Dosage is based on the trimethoprim component.<br />¥ For the treatment of MRSA meningitis, the IDSA suggests a trimethoprim-sulfamethoxazole dose of 5 mg/kg (based on the trimethoprim component) intravenously twice or three times daily.<SUP>[1]</SUP><br />‡ The vancomycin dose should not exceed 2 g per dose or a total daily dose of 60 mg/kg. Adjust dose to achieve vancomycin serum trough concentrations of 15 to 20 mcg/mL.<SUP>[1]</SUP></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children: Executive Summary. Clin Infect Dis 2011; 52:285.</li>&#xD;&#xA;</ol>&#xD;&#xA;Modified with permission from: Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267. Copyright &copy; 2004 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 60707 Version 13.0</div></div></div>"},"60709":{"type":"graphic_movie","displayName":"Flail mitral valve four chamber echocardiogram","title":"Flail mitral valve","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flail mitral valve</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/60709_4chfmitvconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:271px; height:430px;\" src=\"images/CARD/60709_4chfmitv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The four chamber view from a 2-D echocardiogram shows a flail posterior mitral valve leaflet which has exaggerated motion in diastole and prolapses into the left atrium during systole. There is a bright echo seen at the tip of the valve, suggesting papillary muscle rupture as the etiology. Enlargement of the left atrium and ventricle is present, suggesting significant mitral regurgitation.</div><div class=\"graphic_reference\">Courtesy of Thomas Binder, MD. University of Vienna.</div><div id=\"graphicVersion\">Graphic 60709 Version 4.0</div></div></div>"},"60713":{"type":"graphic_figure","displayName":"Patterns of allergic crossreactivity between latex and food","title":"Patterns of allergic crossreactivity between latex and food","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Patterns of allergic crossreactivity between latex and food</div><div class=\"cntnt\"><img style=\"width:534px; height:328px;\" src=\"images/ALLRG/60713_Latexfoodcrossrxn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The numeric risks cited here are based upon findings in limited series of patients and may not be generalizable to all populations. Foods that uncommonly cause reactions in latex-allergic patients include carrot, coconut, apricot, strawberry, loquat, spinach, pineapple, cherimoya, passion fruit, papaya, mango, and celery.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Rodriguez J, Crespo JF, Lopez-Rubio, et al. Clinical cross-reactivity among foods of the Rosaceae family. J Allergy Clin Immunol 2000; 106:183.</li>&#xD;&#xA;    <li>Garcia Ortiz JC, Moyano JC, Alvarez M, et al. Latex allergy in fruit-allergic patients. Allergy 1998; 53:532.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 60713 Version 6.0</div></div></div>"},"60715":{"type":"graphic_figure","displayName":"Turner-Warwick incision","title":"Turner-Warwick incision","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Turner-Warwick incision</div><div class=\"cntnt\"><img style=\"width:552px; height:428px;\" src=\"images/SURG/60715_Turner-Warwick_incision.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse skin incision. Subcutaneous tissue is dissected from the anterior sheath to a point at least 2 cm below the pubis. The sheath is incised 2 cm below the pubis and at least 4 cm in length. The incision is extended cephalad along the borders of the rectus muscles. Peritoneum is incised longitudinally.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 60715 Version 3.0</div></div></div>"},"60716":{"type":"graphic_table","displayName":"Differential diagnosis of diffuse myalgia","title":"Differential diagnosis and distinguishing features of diffuse myalgia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis and distinguishing features of diffuse myalgia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Diagnosis </td> <td class=\"subtitle1\">Distinguishing features </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Infection </td> </tr> <tr> <td class=\"indent1\">Viral infection </td> <td>Fever, respiratory or gastrointestinal symptoms, viral diagnostic testing</td> </tr> <tr> <td class=\"indent1\">Bacterial infection </td> <td>Hypotension, rash, heart murmur, leukocytosis, bacteremia</td> </tr> <tr> <td class=\"indent1\">Spirochetal infection </td> <td>Rash, Lyme or RPR serology</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Noninflammatory pain syndrome </td> </tr> <tr> <td class=\"indent1\">Fibromyalgia </td> <td>Tender points, nonrestorative sleep, normal test results</td> </tr> <tr> <td class=\"indent1\">Chronic fatigue syndrome, also&nbsp;known as systemic exertion intolerance disease&nbsp;</td> <td>Longstanding, profound fatigue without other explanation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Systemic rheumatic disease and autoinflammatory disease</td> </tr> <tr> <td class=\"indent1\">Polymyalgia rheumatica </td> <td>Acute onset of proximal myalgia, morning stiffness, over age 55, high ESR, prompt improvement with low-dose glucocorticoids</td> </tr> <tr> <td class=\"indent1\">Polymyositis/dermatomyositis </td> <td>Proximal weakness, rash, elevated CK, myopathic EMG, muscle histology</td> </tr> <tr> <td class=\"indent1\">Rheumatoid arthritis </td> <td>Chronic, symmetric polyarthritis, positive RF, and/or anti-cyclic citrullinated peptide antibody</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus </td> <td>Polyarthritis, rash, nephritis, serositis, positive ANA antibody, anti-double-stranded DNA antibody, and/or anti-Smith antibody</td> </tr> <tr> <td class=\"indent1\">Spondyloarthropathy </td> <td>History of psoriasis, colitis, conjunctivitis, urethritis, low back pain</td> </tr> <tr> <td class=\"indent1\">Vasculitis </td> <td>Multisystem inflammatory disease, palpable purpura, paresthesias, focal neurologic deficit, cavitary pulmonary nodules, active urinary sediment, positive ANCA</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Metabolic </td> </tr> <tr> <td class=\"indent1\">Osteomalacia </td> <td>Reduced 25-hydroxy vitamin D</td> </tr> <tr> <td class=\"indent1\">Metabolic myopathy </td> <td>Exercise intolerance, family history, muscle weakness, muscle biopsy results</td> </tr> <tr> <td class=\"indent1\">Scurvy </td> <td>Petechiae, ecchymoses, follicular hyperkeratosis, corkscrew hairs, vitamin C deficiency</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Endocrinologic </td> </tr> <tr> <td class=\"indent1\">Familial Mediterranean fever</td> <td>Episodic fever, serositis, arthralgia, abdominal pain, onset during childhood</td> </tr> <tr> <td class=\"indent1\">Neuropathic </td> <td>Paresthesias, focal neurologic deficits</td> </tr> <tr> <td class=\"indent1\">Hypothyroidism </td> <td>Elevated TSH, decreased free T4</td> </tr> <tr> <td class=\"indent1\">Adrenal insufficiency </td> <td>Low-serum cortisol, 24-hour urine cortisol, and/or abnormal ACTH stimulation test</td> </tr> <tr> <td><strong>Medications</strong></td> <td>History of new medication use, especially statins</td> </tr> <tr> <td><strong>Psychiatric</strong></td> <td>Prior history of mood disorder, depressed affect</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RPR: rapid plasma regain; ESR: erythrocyte sedimentation rate; CK: creatine kinase; EMG: electromyogram; RF: rheumatoid factor; ANA: anti-nuclear antibody; ANCA: anti-neutrophilic cytoplasmic antibodies; TSH: thyroid-stimulating hormone; T4: thyroxine;&nbsp;ACTH: adrenocorticotropic hormone.</div><div id=\"graphicVersion\">Graphic 60716 Version 6.0</div></div></div>"},"60717":{"type":"graphic_figure","displayName":"Levels of prevention","title":"Levels of prevention","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Levels of prevention</div><div class=\"cntnt\"><img style=\"width:370px; height:176px;\" src=\"images/PC/60717_Levelsofprevention.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Primary prevention prevents disease from occurring. Secondary prevention detects and cures disease in the asymptomatic phase. Tertiary prevention reduces complications of disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Fletcher RH, Fletcher SW, Fletcher GS. Clinical Epidemiology: The Essentials, 5th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 60717 Version 11.0</div></div></div>"},"60719":{"type":"graphic_figure","displayName":"Glucocorticoids outpt COPD","title":"Kaplan-Meier estimates of the probability of remaining relapse-free at 30 days for outpatients with acute exacerbations of COPD treated with prednisone or placebo","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Kaplan-Meier estimates of the probability of remaining relapse-free at 30 days for outpatients with acute exacerbations of COPD treated with prednisone or placebo</div><div class=\"cntnt\"><img style=\"width:493px; height:351px;\" src=\"images/PULM/60719_Glucocorticoids_outpt_COPD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tick marks represent censored data. p=0.04 by the log-rank test.</div><div class=\"graphic_reference\">Data from: N Engl J Med 2003; 348:2623.</div><div id=\"graphicVersion\">Graphic 60719 Version 1.0</div></div></div>"},"60726":{"type":"graphic_diagnosticimage","displayName":"CT acute traumatic epidural hematoma","title":"Non contrast head CT demonstrates an acute traumatic epidural hematoma over the left parietal region","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Non contrast head CT demonstrates an acute traumatic epidural hematoma over the left parietal region</div><div class=\"cntnt\"><img style=\"width:396px; height:520px;\" src=\"images/NEURO/60726_CT_acute_trauma_EDH.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Neuroradiology Department, Thomas Jefferson University, Philadelphia, PA.</div><div id=\"graphicVersion\">Graphic 60726 Version 4.0</div></div></div>"},"60727":{"type":"graphic_figure","displayName":"Leopolds maneuvers","title":"Diagnosis of transverse lie by abdominal palpation using Leopold's maneuvers","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Diagnosis of transverse lie by abdominal palpation using Leopold's maneuvers</div><div class=\"cntnt\"><img style=\"width:541px; height:610px;\" src=\"images/OBGYN/60727_Leopolds_maneuvers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The four Leopold maneuvers systematically examine the fundus, sides of the uterus, presenting part at the symphysis pubis, and lower uterine segment to determine fetal presentation and the location of the back. The&nbsp;fetal&nbsp;head is hard, round, and moves independently of the trunk&nbsp;whereas the&nbsp;buttocks&nbsp;are soft and&nbsp;move with the&nbsp;trunk. The fetal back is a broad, smooth, firm, resistant surface, whereas the&nbsp;elbows, knees, hands and feet&nbsp;are small irregularities and protrusions.</div><div id=\"graphicVersion\">Graphic 60727 Version 2.0</div></div></div>"},"60730":{"type":"graphic_figure","displayName":"Mechanism of HCO3 reabsorption and generation","title":"Mechanisms of bicarbonate reabsorption and bicarbonate generation","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Mechanisms of bicarbonate reabsorption and bicarbonate generation</div><div class=\"cntnt\"><img style=\"width:533px; height:367px;\" src=\"images/NEPH/60730_MechanismofHCO3reabsorptionandgeneration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>The major cellular and luminal events in bicarbonate reabsorption in proximal tubules (left panel) and bicarbonate reabsorption and generation in the collecting tubules (right panel). Intracellular H<SUB>2</SUB>O dissociates into H<SUP>+</SUP> and OH<SUP>–</SUP> ions. The OH<SUP>–</SUP> combines with CO<SUB>2</SUB> to form HCO<SUB>3</SUB><SUP>–</SUP> via a reaction catalyzed by carbonic anhydrase (CA) II.</LI>&#xD;&#xA;<LI>In the proximal tubule, the steep electrochemical gradient for sodium, created by Na-K-ATPase, allows H<SUP>+</SUP> ions to be secreted into the lumen in exchange for sodium via the Na<SUP>+</SUP>-H<SUP>+</SUP> exchanger. The HCO<SUB>3</SUB><SUP>–</SUP> ions that are generated in these cells move into the peritubular capillary primarily via a Na<SUP>+</SUP>-3HCO<SUB>3</SUB><SUP>–</SUP> cotransporter. The H<SUP>+</SUP> ions, which enter the proximal tubule lumen, combine with filtered HCO<SUB>3</SUB><SUP>–</SUP> to form carbonic acid (H<SUB>2</SUB>CO<SUB>3</SUB>). The dissociation of the carbonic acid is facilitated by intraluminal CA IV, which is tethered to the membrane. The CO<SUB>2</SUB> and H<SUB>2</SUB>O that form are passively reabsorbed. Secretion of H<SUP>+</SUP> is matched by equimolar addition of HCO<SUB>3</SUB><SUP>–</SUP> to the extracellular fluid. Note that the HCO<SUB>3</SUB><SUP>–</SUP> ions that enter the peritubular capillaries are not actually the filtered ions; however, the net effect is to reclaim filtered HCO<SUB>3</SUB><SUP>–</SUP> and return it to the circulation. In addition, a smaller component of the H<SUP>+</SUP> secretion in the proximal tubule is accomplished via a V-type H<SUP>+</SUP>-ATPase pump. Approximately 90% of the filtered bicarbonate is reclaimed in the proximal tubule.</LI>&#xD;&#xA;<LI>In the type A intercalated cells of the distal convoluted connecting and collecting tubules, H<SUP>+</SUP> and HCO<SUB>3</SUB><SUP>–</SUP> are generated by a similar intracellular process catalyzed by CA II (right panel). However, a number of the pumps and transporters that move these ions into the lumen and peritubular capillary differ from those in proximal tubule cells. A V-type H<SUP>+</SUP>-ATPase pump in the luminal membrane drives H<SUP>+</SUP> secretion, and, driven by their electrochemical concentration gradients, cellular bicarbonate enters the peritubular capillary in exchange for extracellular chloride via a Cl<SUP>–</SUP>-HCO<SUB>3</SUB><SUP>–</SUP> exchanger in the basolateral membrane (the AE-1 or anion exchanger-1). The remaining 10% of filtered bicarbonate enters the distal tubule where it combines with hydrogen ions in the tubular lumen, completing the process of reclaiming all of the filtered bicarbonate. Additional secreted H<SUP>+</SUP> ions combine with NH<SUB>3</SUB> to form NH<SUB>4</SUB><SUP>+</SUP> and with HPO<SUB>4</SUB><SUP>–2</SUP> to form H<SUB>2</SUB>PO<SUB>4</SUB><SUP>–</SUP>, and this generates new HCO<SUB>3</SUB><SUP>–</SUP> (beyond that which was filtered) for transport to the peritubular capillaries. The type A intercalated cells also have H<SUP>+</SUP>-K<SUP>+</SUP>-ATPase pumps in the luminal membrane that are involved in both acid secretion and, perhaps more importantly, K<SUP>+</SUP> reabsorption.</LI></UL></div><div id=\"graphicVersion\">Graphic 60730 Version 10.0</div></div></div>"},"60731":{"type":"graphic_picture","displayName":"Biologic control of imported fire ants by decapitating flies","title":"Biologic control of imported fire ants by decapitating flies","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Biologic control of imported fire ants by decapitating flies</div><div class=\"cntnt\"><img style=\"width:468px; height:229px;\" src=\"images/ALLRG/60731_Decapitated_head_IFA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows several ants whose heads have detached as a result of parasitism by larvae of decapitating flies. The introduction of decapitating flies is one potential approach to biologic control of imported fire ants.</div><div class=\"graphic_reference\">Reproduced with permission from: Williams DF, deShazo RD. Biological control of fire ants: an update on new techniques. Ann Allergy Asthma Immunol 2004; 93:15. Copyright © 2004 American Academy of Allergy, Asthma, and Immunology.</div><div id=\"graphicVersion\">Graphic 60731 Version 5.0</div></div></div>"},"60732":{"type":"graphic_table","displayName":"Clinical features tyrosine disorders","title":"Clinical manifestations of enzyme deficiencies in tyrosine catabolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of enzyme deficiencies in tyrosine catabolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Defective enzyme </td> <td>Tyrosine aminotransferase</td> <td>4-hydroxy-phenylpyruvate dioxygenase</td> <td>Homogentisate dioxygenase</td> <td>Maleylaceto-acetate isomerase</td> <td>Fumarylaceto-acetate hydrolase</td> </tr> <tr> <td class=\"subtitle1_single\">Disease name(s)</td> <td> <p>Tyrosinemia type II</p> <p>Oculocutaneous tyrosinemia</p> <p>Richner-Hanhardt syndrome</p> </td> <td>Tyrosinemia type III</td> <td>Alkaptonuria</td> <td>No human patients described</td> <td> <p>Tyrosinemia type I</p> <p>Hepatorenal tyrosinemia</p> </td> </tr> <tr> <td class=\"subtitle1_single\">Elevated blood tyrosine</td> <td>+++</td> <td>++</td> <td>&empty;</td> <td>?</td> <td>++</td> </tr> <tr> <td class=\"subtitle1_single\">Corneal ulcers</td> <td>+++</td> <td>+/-</td> <td>&empty;</td> <td>?</td> <td>&empty;</td> </tr> <tr> <td class=\"subtitle1_single\">Hyper-keratosis</td> <td>++</td> <td>+/-</td> <td>&empty;</td> <td>?</td> <td>&empty;</td> </tr> <tr> <td class=\"subtitle1_single\">Mental retardation</td> <td>+/-</td> <td>+/-</td> <td>&empty;</td> <td>?</td> <td>&empty;</td> </tr> <tr> <td class=\"subtitle1_single\">Arthritis</td> <td>&empty;</td> <td>&empty;</td> <td>+++</td> <td>?</td> <td>&empty;</td> </tr> <tr> <td class=\"subtitle1_single\">Liver failure</td> <td>&empty;</td> <td>&empty;</td> <td>&empty;</td> <td>?</td> <td>+++</td> </tr> <tr> <td class=\"subtitle1_single\">Renal Fanconi syndrome</td> <td>&empty;</td> <td>&empty;</td> <td>&empty;</td> <td>?</td> <td>++</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Markus Grompe, MD.</div><div id=\"graphicVersion\">Graphic 60732 Version 3.0</div></div></div>"},"60733":{"type":"graphic_figure","displayName":"Pediatric lumbar puncture technique","title":"Spinal needle placement using one or two hands","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spinal needle placement using one or two hands</div><div class=\"cntnt\"><img style=\"width:422px; height:505px;\" src=\"images/PEDS/60733_LP_technique.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 60733 Version 2.0</div></div></div>"},"60734":{"type":"graphic_table","displayName":"Diet recommendations for toddlers to early-school-age children","title":"Dietary recommendations for toddlers to early-school-age children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary recommendations for toddlers to early-school-age children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"3\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Food groups and number of daily servings</td> <td class=\"subtitle1\">Age 12 to 23 months</td> <td class=\"subtitle1\">Age 2 to 3 years</td> <td class=\"subtitle1\">Age 4 to 8 years</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Milk and milk products*</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\"><em>Low-fat or fat-free milk or milk products</em>.</td> <td>2 cups/day (whole milk or milk products)</td> <td>2 to 2.5 cups/day</td> <td>2.5 to 3 cups/day</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\" colspan=\"4\"> <p>1 cup equivalent =</p> <p>1 cup of milk or yogurt, 1&#189; ounces of natural cheese, 2 ounces of processed cheese, 1/3 cup of shredded cheese</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Meat and other protein foods</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\"><em>Includes beef, chicken, pork, poultry, fish, eggs, peanut butter, and legumes.</em></td> <td>1&#189; ounces/day</td> <td>2 ounces/day</td> <td>3 to 4 ounces/day</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\" colspan=\"4\"> <p>1 ounce equivalent =</p> <p>1 ounce of beef, poultry, or fish, &#188; cup cooked beans, 1 egg, 1 tablespoon peanut butter<sup>&#182;</sup>, &#189; ounce of nuts<sup>&#182;</sup></p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Breads, cereals and starches</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\"><em>Includes whole-grain breads, infant and cooked cereals, rice, pasta, ready-to-eat cereals. Half of all starches should be whole grains.</em></td> <td>2 ounces/day</td> <td>3 ounces/day</td> <td>4 to 5 ounces/day</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\" colspan=\"4\"> <p>1 ounce equivalent =</p> <p>1 slice whole-grain bread, &#189; cup cooked cereal, rice or pasta, 1 cup dry cereal</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Fruits</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\"><em>Includes one source of vitamin C daily (citrus fruits and juices, strawberries) and one source of vitamin A every other day (dark green and yellow fruits, melons).</em></td> <td>1 cup/day</td> <td>1 cup/day</td> <td>1 to 1&#189; cups/day</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\" colspan=\"4\"> <p>1 cup equivalent =</p> <p>1 cup of fruit or 100 percent fruit juice<sup>&#916;</sup>, &#189; cup of dried fruit</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Vegetables</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\"><em>Includes one source of vitamin C daily (broccoli and tomatoes) and one source of vitamin A every other day (spinach, sweet potatoes, corn, squash).</em></td> <td>&#190; cup/day</td> <td>1 cup/day</td> <td>1&#189; cups/day</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\" colspan=\"4\"> <p>1 cup equivalent =</p> <p>1 cup of raw or cooked vegetables or vegetable juice, 2 cups of raw leafy greens</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Fats and oils</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\"><em>Includes margarine, butter, oils</em>.</td> <td>Do not limit*</td> <td>3 teaspoons/day</td> <td>4 teaspoons/day</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\" colspan=\"4\"> <p>1 teaspoon equivalent =</p> <p>1 teaspoon oil, margarine, butter or mayonnaise, 1 tablespoon salad dressing, sour cream or light mayonnaise</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\"><em>Desserts, sweets, soft drinks, candy, jams and jelly.</em></td> <td colspan=\"4\">Limit to small amount, use sparingly</td> </tr> <tr> <td>Limit intake</td> <td>100 discretionary kilocalories<sup>&#9674;</sup></td> <td>100&nbsp;discretionary kilocalories<sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: For more details, go to <a href=\"http://www.choosemyplate.gov/\" target=\"_blank\">www.choosemyplate.gov</a>.</div><div class=\"graphic_footnotes\">* Low fat products are not recommended for children under the age of 2.<br />¶ May be a choking hazard for children under the age of 3.<br />Δ Children should be encouraged to consume whole fruits. Recommend limiting fruit juice to 4 to 6 ounces (120 to 180 mL) for children 4 through 6 years of age. Recommend limiting fruit juice to 8 ounces (240 mL)&nbsp;for children 7 to 18 years of age. <br />◊ Discretionary kilocalories are those available for consumption as added sugars or solid fats after essential daily nutrient requirements are met.</div><div class=\"graphic_reference\">Adapted with permission from: Texas Children's Hospital Pediatric Nutrition Reference Guide 2010, 9<SUP>th</SUP> ed, Bunting KD, Mills J, Phillips S, et al (Eds). Copyright © 2010 Texas Children's Hospital. All rights reserved.<br />Additional data from: <br /><OL>&#xD;&#xA;<LI>Vos MB, Kaar JL, Welsh JA, et al. Added sugars and cardiovascular disease risk in children: A scientific statement from the American Heart Association. Circulation 2016.</LI>&#xD;&#xA;<LI>Heyman MB, Abrams SA, AAP Section on Gastroenterology, Hepatology, and Nutrition, Committee on Nutrition. Fruit juice in infants, children, and adolescents: Current recommendations. Pediatrics 2017; 139:e20170967.</LI></OL>​</div><div id=\"graphicVersion\">Graphic 60734 Version 16.0</div></div></div>"},"60735":{"type":"graphic_picture","displayName":"Inflamed ingrown toenail","title":"Ingrown toenail postoperatively","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ingrown toenail postoperatively</div><div class=\"cntnt\"><img style=\"width:297px; height:247px;\" src=\"images/PC/60735_Inflamedingrowntoenail.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Significant erythema is evident; the involved nail wedge was removed.</div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 60735 Version 1.0</div></div></div>"},"60736":{"type":"graphic_figure","displayName":"Measurement right atrial volume","title":"Right atrial volume","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Right atrial volume</div><div class=\"cntnt\"><img style=\"width:326px; height:423px;\" src=\"images/CARD/60736_Measurementrightatrialvo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The right atrial (RA) volume is measured from single plane area length algorithm computed from digitizing the chamber in the four chamber view. The volume of this very large atrium is 153 mL.</div><div class=\"graphic_footnotes\">RV: right ventricle; LV: left ventricle; LA: left atrium.</div><div id=\"graphicVersion\">Graphic 60736 Version 2.0</div></div></div>"},"60737":{"type":"graphic_figure","displayName":"MRP 2 gene mutations","title":"Map of mutations detected in the MRP2 gene in patients with Dubin-Johnson syndrome","html":"<div class=\"graphic\"><div style=\"width: 599px\" class=\"figure\"><div class=\"ttl\">Map of mutations detected in the MRP2 gene in patients with Dubin-Johnson syndrome</div><div class=\"cntnt\"><img style=\"width:579px; height:162px;\" src=\"images/GAST/60737_MRP_2_gene_mutations.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The vertical boxes represent the exons of the MRP2 gene. The numbers below the boxes mark the exons. 5' UTR and 3' UTR are the 5' and 3' untranslated regions. The inverted pointers labeled with alphabets, &quot;a&quot; through &quot;h&quot;, above the exons denote all the mutations detected to the date in this gene.</div><div class=\"graphic_footnotes\">(a) Exon-13:1669-1815del [42]. (b) IVS15, +2T&gt;C [43]. (c) Exon-18:2302C&gt;T (R368W) [42]. (d) Exon:18:2272-2439del [42]. (e) Exon 23: 3196 C&gt;T (R1066X) [41]. (f)Exon-25:3449G&gt;A (R1150H) [44] (g) Exon-25:3517A&gt;T (I1173F) [44] (h) Exon-30:4175-4180del [39].</div><div class=\"graphic_reference\">Note: Nomenclature of mutations in accordance with den Dunnen, JT, Antonarakis, SE. Hum Mutat 2000; 15:7.</div><div id=\"graphicVersion\">Graphic 60737 Version 2.0</div></div></div>"},"60739":{"type":"graphic_waveform","displayName":"Basic case 12","title":"Basic case 12","html":"<div class=\"graphic normal\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Basic case 12</div><div class=\"cntnt\"><img style=\"width:538px; height:322px;\" src=\"images/CARD/60739_Basic_case_12.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 60739 Version 2.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"60742":{"type":"graphic_figure","displayName":"QB QD and urea clearance during SLED","title":"Graph showing determinants of urea clearance during sustained low efficiency dialysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Graph showing determinants of urea clearance during sustained low efficiency dialysis</div><div class=\"cntnt\"><img style=\"width:392px; height:568px;\" src=\"images/NEPH/60742_QB_QD_and_urea_clearance.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship among urea clearance, blood flow rate (QB), and dialysate flow rate (QD) during sustained low efficiency dialysis (SLED). The flattening of the urea clearance curves describe the conditions in which increases in QB do not enhance clearance.</div><div class=\"graphic_footnotes\">QD: dialysate flow rate; QB: blood flow rate.</div><div class=\"graphic_reference\">Data from: Kudoh Y, Imura O. Slow continuous hemodialysis&mdash;new therapy for acute renal failure in critically ill patients&mdash;Part 1. Theoretical consideration and new technique. Jpn Circ J 1988; 52:1171.</div><div id=\"graphicVersion\">Graphic 60742 Version 3.0</div></div></div>"},"60743":{"type":"graphic_table","displayName":"Severity classification DLCO","title":"Severity classification of diffusing capacity of the lungs for carbon monoxide (DLCO) abnormality","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Severity classification of diffusing capacity of the lungs for carbon monoxide (DLCO) abnormality</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>High</td> <td>&#62;140 percent predicted*</td> </tr> <tr> <td>Normal</td> <td>76 to 140 percent*</td> </tr> <tr> <td>Mild decrease</td> <td>61 to 75 percent*</td> </tr> <tr> <td>Moderate decrease</td> <td>40 to 60 percent</td> </tr> <tr> <td>Severe decrease</td> <td>&#60;40 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The upper and lower limits of the normal range should be substituted for the 140 and 76 percent predicted cutpoints, if available from a reference study.</div><div id=\"graphicVersion\">Graphic 60743 Version 2.0</div></div></div>"},"60744":{"type":"graphic_table","displayName":"Approach to the diagnosis of NK cell deficiency","title":"Approach to the diagnosis of NK cell deficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to the diagnosis of NK cell deficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Evaluation</td> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Technique</td> <td class=\"subtitle1\">Abnormal result*</td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td>Identification</td> <td>Lymphocyte subset analysis</td> <td>FACS</td> <td>Absent or decreased</td> <td>Separate CD56 and CD16 evaluations<sup>&#182;</sup></td> </tr> <tr> <td>Ex vivo function</td> <td>NK cytotoxicity ADCC</td> <td>Cytotoxicity assay</td> <td>Absent or decreased<sup>&#916;</sup></td> <td>Always ship samples with an unrelated control<sup>&#9674;</sup></td> </tr> <tr> <td rowspan=\"2\">In vitro responsiveness</td> <td rowspan=\"2\">Cytokine induced cytotoxicity and cytokine production</td> <td>Cytotoxicity assay</td> <td rowspan=\"2\">Absent or decreased</td> <td rowspan=\"2\">Stimulants include IL-2, IL-12, and IFN-&#945;</td> </tr> <tr> <td>Intracellular FACS<sup>&#167;</sup></td> </tr> <tr> <td>Phenotype</td> <td>NK cell subset analysis</td> <td>FACS</td> <td>Missing/decreased activation receptor or increased inhibitory receptor</td> <td>&nbsp;</td> </tr> <tr> <td>Specific receptor function</td> <td>Redirected lysis and other antibody or ligand directed assays</td> <td>Cytotoxicity assay, granule release, Ca++ flux, and others</td> <td>Decreased activity after specific receptor ligation</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NK: natural killer; FACS: fluorescence activated cell sorting; ADCC: antibody-dependent cellular cytotoxicity; IL-2: interleukin-2; IL-12: interleukin-12; IFN-α: interferon-alfa; Ca++: calcium.<br />* Although it is difficult to interpret a decreased result, values that are persistently lower than the reference range for the laboratory experienced in the investigation may be of significance and worthy of further study.<br />¶ Many clinical laboratories use a reagent to identify NK cells that contain anti-CD3-FITC as well as both anti-CD56-PE and anti-CD16-PE. Although this reagent will identify NK cells, it will overlook all patients with an alteration of CD16. In suspected cases, both CD16 and CD56 should be evaluated separately. Anti-CD16 clone 3G8 will recognize variant receptors while clone B73.1 will not. Both reagents are commercially available.<br />Δ Decreased ex vivo NK cell function in total peripheral blood mononuclear cell (PBMC) preparations may be due to decreased NK cell numbers and thus may be a defect of NK cell production or survival, and not that particular function. If the patient possesses a small population of NK cells, this issue can be addressed using purified or enriched NK cells.<br /><FONT class=lozenge>◊</FONT> Extreme conditions during shipping can affect biological activity and thus a shipping control is necessary. It is important that the control be unrelated, as some NK deficiencies are present in families.<br />§ A major cytokine produced by NK cells that is presumably of biologic relevance is IFN-α. This factor can be measured intracellularly in NK cells most easily after short-term exposure to mitogen.</div><div id=\"graphicVersion\">Graphic 60744 Version 7.0</div></div></div>"},"60745":{"type":"graphic_algorithm","displayName":"Algorithm for evaluating children with bleeding symptoms","title":"Algorithm for identifying causes of bleeding symptoms in children based on results of coagulation screen","html":"<div class=\"graphic\"><div style=\"width: 635px\" class=\"figure\"><div class=\"ttl\">Algorithm for identifying causes of bleeding symptoms in children based on results of coagulation screen</div><div class=\"cntnt\"><img style=\"width:615px; height:291px;\" src=\"images/HEME/60745_Algoevlchlddsrhmst.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Refer to UpToDate topic on the evaluation of bleeding symptoms in children for additional details.</div><div class=\"graphic_footnotes\">PT: prothrombin time; INR: international normalized ratio; aPTT: activated partial thromboplastin time; vWD: von Willebrand disease; HMWK: high molecular weight kininogen; DIC: disseminated intravascular coagulation.</div><div id=\"graphicVersion\">Graphic 60745 Version 11.0</div></div></div>"},"60747":{"type":"graphic_picture","displayName":"Bedbugs","title":"Bedbugs","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bedbugs</div><div class=\"cntnt\"><img style=\"width:504px; height:328px;\" src=\"images/DERM/60747_Bedbugs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bedbugs are reddish brown, have six legs, and are similar in size to a dog tick. They have flat, oval bodies and needle-like, retroverted mouthparts. The eyes are widely separated.</div><div class=\"graphic_reference\">Courtesy of Dirk M Elston, MD.</div><div id=\"graphicVersion\">Graphic 60747 Version 4.0</div></div></div>"},"60748":{"type":"graphic_diagnosticimage","displayName":"Long axis MV annular calcium","title":"Mitral annular calcification","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mitral annular calcification</div><div class=\"cntnt\"><img style=\"width:284px; height:376px;\" src=\"images/CARD/60748_LongaxisMVannularcalciu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anatomic specimen (panel A) is sectioned along the long axis of the heart; the infiltrative calcific process just beneath the posterior mitral valve (pML) is called mitral annular calcification (MAC) or subannular calcification. The latter term is probably preferable because the process actually infiltrates the posterior wall (PW) myocardium. In this case, the infiltration extends nearly halfway through the basal myocardium and nearly one-third of the way to the papillary muscle (PM). The long axis echocardiogram from a patient with MAC (panel B) shows that the image faithfully represents the pathologic process; MAC extends at least one-third of the way from the mitral annulus to the PM base.</div><div id=\"graphicVersion\">Graphic 60748 Version 6.0</div></div></div>"},"60749":{"type":"graphic_picture","displayName":"Pemphigus vulgaris biopsy","title":"Pemphigus vulgaris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pemphigus vulgaris</div><div class=\"cntnt\"><img style=\"width:392px; height:261px;\" src=\"images/PC/60749_Pemhigus_vulgaris_light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histologic specimen of a bullous lesion in a patient with pemphigus vulgaris demonstrates the characteristic loss of cohesion between epidermal cells (acantholysis) with an intact basement membrane.</div><div class=\"graphic_reference\">Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.</div><div id=\"graphicVersion\">Graphic 60749 Version 3.0</div></div></div>"},"60750":{"type":"graphic_picture","displayName":"Bennett lipseal","title":"Lipseal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lipseal</div><div class=\"cntnt\"><img style=\"width:286px; height:228px;\" src=\"images/PULM/60750_Bennett_lipseal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bennett Lipseal used for mouthpiece ventilator (Nellcor Puritan Bennett, Inc).</div><div id=\"graphicVersion\">Graphic 60750 Version 3.0</div></div></div>"},"60751":{"type":"graphic_diagnosticimage","displayName":"Langerhans histiocytosis PA II","title":"Pulmonary Langerhans cell histiocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary Langerhans cell histiocytosis</div><div class=\"cntnt\"><img style=\"width:326px; height:360px;\" src=\"images/PULM/60751_Lngrhns_hstcyts_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph reveals reticular and nodular opacities in mid-lung zones, cysts, costophrenic angle sparing, and increased lung volumes in a 58-year-old man with pulmonary LCH.</div><div class=\"graphic_footnotes\">LCH: Langerhans cell histiocytosis.</div><div class=\"graphic_reference\">Courtesy of Talmadge E King Jr, MD.</div><div id=\"graphicVersion\">Graphic 60751 Version 4.0</div></div></div>"},"60753":{"type":"graphic_figure","displayName":"Lyme sxs frequency","title":"Percentage of symptoms reported among Lyme disease patients,* by year - United States, 1992-2006","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Percentage of symptoms reported among Lyme disease patients,* by year - United States, 1992-2006</div><div class=\"cntnt\"><img style=\"width:515px; height:400px;\" src=\"images/ID/60753_Lyme_sxs_frequency.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* N = 150,829.</div><div class=\"graphic_reference\">Bacon, RM, Kugeler, KJ, Mead, PS. Surveillance for Lyme disease--United States, 1992-2006. MMWR Surveill Summ 2008; 57:1.</div><div id=\"graphicVersion\">Graphic 60753 Version 1.0</div></div></div>"},"60754":{"type":"graphic_diagnosticimage","displayName":"Renal abscess CT","title":"Renal abscess on computed tomography scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Renal abscess on computed tomography scan</div><div class=\"cntnt\"><img style=\"width:360px; height:242px;\" src=\"images/NEPH/60754_Renal_abscess_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan showing a large renal abscess with internal echoes in the right kidney (arrow).</div><div class=\"graphic_reference\">Courtesy of Alain Meyrier, MD.</div><div id=\"graphicVersion\">Graphic 60754 Version 3.0</div></div></div>"},"60755":{"type":"graphic_table","displayName":"Classification of PN tumors","title":"Classification of peripheral nerve tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of peripheral nerve tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Benign</td> </tr> <tr> <td class=\"subtitle2_left\">Non-neoplasms</td> </tr> <tr> <td class=\"indent1\">Neuroma</td> </tr> <tr> <td class=\"indent1\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Morton neuroma</td> </tr> <tr> <td class=\"indent1\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Solitary circumscribed neuroma</td> </tr> <tr> <td class=\"indent1\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mucosal neuroma</td> </tr> <tr> <td class=\"indent1\">Ganglion cyst, mucous cyst</td> </tr> <tr> <td class=\"indent1\">Heterotopic ossification</td> </tr> <tr> <td class=\"indent1\">Sarcoid granuloma</td> </tr> <tr> <td class=\"indent1\">Leprosy</td> </tr> <tr> <td class=\"indent1\">Localized hypertrophic neuropathy</td> </tr> <tr> <td class=\"indent1\">Lipofibromatous hamartoma</td> </tr> <tr> <td class=\"indent1\">Benign triton tumor (aka neuromuscular choristoma)</td> </tr> <tr> <td class=\"subtitle2_left\">Nerve sheath neoplasms</td> </tr> <tr> <td class=\"indent1\">Neurofibroma</td> </tr> <tr> <td class=\"indent1\">&nbsp;&nbsp;&nbsp;&nbsp;Cutaneous neurofibroma</td> </tr> <tr> <td class=\"indent1\">&nbsp;&nbsp;&nbsp;&nbsp;Intraneural neurofibroma</td> </tr> <tr> <td class=\"indent1\">&nbsp;&nbsp;&nbsp;&nbsp;Plexiform neurofibroma</td> </tr> <tr> <td class=\"sublist2_start\">Schwannoma (aka neurilemmoma)</td> </tr> <tr> <td class=\"sublist2\">Cellular</td> </tr> <tr> <td class=\"sublist2\">Plexiform</td> </tr> <tr> <td class=\"sublist2\">Microcystic/reticular</td> </tr> <tr> <td class=\"sublist2\">Ancient</td> </tr> <tr> <td class=\"sublist2\">Melanotic</td> </tr> <tr> <td class=\"sublist2\">Psammomatous melanotic</td> </tr> <tr> <td class=\"indent1\">Perineurioma</td> </tr> <tr> <td class=\"indent1\">Hybrid nerve sheath tumors&nbsp;</td> </tr> <tr> <td class=\"indent1\">Dermal nerve sheath myxoma (previously aka myxoid neurothekeoma)</td> </tr> <tr> <td class=\"indent1\">Cellular and mixed-type neurothekeoma</td> </tr> <tr> <td class=\"indent1\">Paraganglioma</td> </tr> <tr> <td class=\"indent1\">Hemangioblastoma</td> </tr> <tr> <td class=\"subtitle1_single\">Malignant</td> </tr> <tr> <td class=\"subtitle2_left\">Tumors of peripheral nerve sheath origin</td> </tr> <tr> <td class=\"indent1\">Malignant peripheral nerve sheath tumor (aka neurogenic sarcoma)</td> </tr> <tr> <td class=\"indent1\">Malignant granular cell tumor</td> </tr> <tr> <td class=\"subtitle2_left\">Tumors of nonperipheral nerve sheath origin</td> </tr> <tr> <td class=\"indent1\">Cancer</td> </tr> <tr> <td class=\"indent1\">Neurolymphomatosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of John E Donahue, MD and James M Gilchrist, MD.</div><div id=\"graphicVersion\">Graphic 60755 Version 3.0</div></div></div>"},"60757":{"type":"graphic_diagnosticimage","displayName":"Calcified cephalohematoma","title":"Five-week-old with calcifying cephalohematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Five-week-old with calcifying cephalohematoma</div><div class=\"cntnt\"><img style=\"width:368px; height:504px;\" src=\"images/PEDS/60757_Calcified_cephalohematoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Rajvee Shah, MD.</div><div id=\"graphicVersion\">Graphic 60757 Version 4.0</div></div></div>"},"60758":{"type":"graphic_picture","displayName":"Tenaculum apple extraction","title":"Tenaculum use for apple extraction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tenaculum use for apple extraction</div><div class=\"cntnt\"><img style=\"width:432px; height:389px;\" src=\"images/GAST/60758_Tenaculum_apple_extraction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transanal extraction of a rectal foreign body. Note use of a Richardson retractor.</div><div class=\"graphic_reference\">Courtesy of Scott Steele, MD.</div><div id=\"graphicVersion\">Graphic 60758 Version 1.0</div></div></div>"},"60759":{"type":"graphic_figure","displayName":"Subacromial bursa injection","title":"Subacromial bursa injection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subacromial bursa injection</div><div class=\"cntnt\"><img style=\"width:339px; height:273px;\" src=\"images/PC/60759_Subacromial_bursa_injection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lateral or posterior approach can be used to inject the subacromial bursa; the lateral approach shown here is safer to perform, since injection into the rotator cuff tendons is nearly impossible with this technique. The patient is to be sitting up, with the hands placed in the lap. The patient is asked to relax the shoulder and neck muscles. Traction applied to the flexed elbow may be necessary to open the subacromial space. The lateral edge of the acromion is located and its midpoint marked. The point of entry is 1 to 1.5 inches&nbsp;(about 2.5 to 4 cm) below the marked midpoint. The angle of entry should parallel the patient's own acromial angle (averaging 50 to 65 degrees). The depth will vary according to the patient's weight and muscle development (1.5 inches&nbsp;[about 4 cm] in an asthenic patient and up to 3.5 inches [about 9 cm]&nbsp;in an obese patient over 30 percent ideal body weight). Ethyl chloride is sprayed on the skin. Local anesthetic is placed in the deltoid muscle (1 mL) and the deep deltoid fascia (0.5 mL). The needle is advanced through the subcutaneous tissue and the deltoid muscle until the subtle resistance of the deep deltoid fascia is encountered. If firm or hard tissue resistance is encountered (deltoid tendon or periosteum, often painful), then the needle is withdrawn&nbsp;0.5 inch (about 1.5 cm)&nbsp;and the angle is redirected 5 to 10 degrees either up or down. A \"giving way\" or \"popping\" sensation is often appreciated when the subacromial bursa is entered. Following 1 to 2 mL of anesthesia and leaving the needle in position, the patient strength is tested again. If pain is reduced by 50 percent and the strength of abduction and external rotation are 75 to 80 percent of the unaffected side, then 1 mL of depo-medrol (80 mg/mL) is injected. Note, never inject under moderate to high pressure. If high injection pressure is encountered, first try rotating the syringe 180 degrees. If tension is still high and the patient obviously anxious, ask the patient to take a deep breath and try to relax the shoulder muscles. If tension remains high, reposition the needle by&nbsp;0.25 inch&nbsp;(about 0.5 cm)&nbsp;increments or by altering the angle of entry by 5 to 10 degrees. The subacromial bursa will accept only 2 to 3 mL of total volume before rupturing.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 60759 Version 4.0</div></div></div>"},"60760":{"type":"graphic_table","displayName":"Indications TTO2","title":"Potential benefits and indications for transtracheal oxygen","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential benefits and indications for transtracheal oxygen</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Potential benefits compared to standard nasal cannula\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Improved compliance with 24 hr/day oxygen use</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Eliminate tenderness and irritation caused by the nasal cannula</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Decreased oxygen flow requirement, greater portability</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Less dyspnea, improved exercise endurance</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Cosmetically more acceptable</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Adequate oxygenation despite refractory baseline hypoxemia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Specific indications\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Suboptimal compliance or oxygenation with nasal cannula delivery</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Complications caused by the nasal cannula</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Desire for greater mobility</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Patient preference</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Refractory hypoxemia</td>\r\n  \r\n   </tr>\r\n\r\n   <tr>\r\n  \r\n   <td>Nocturnal hypoxemia despite nasal cannula</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Ideal candidate\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Low nasal cannula flow requirement (1 to 4 L/min)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Strong desire to remain active (eg, spend less than 12 hours per day in bed and leave house routinely for shopping, socializing, or work)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Willing and able to follow care protocol</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Disease process \"stable\"</td>\r\n  \r\n   </tr>\r\n\r\n   <tr>\r\n  \r\n   <td>Demonstrates good adherence to medical regimen</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Additional important considerations\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Care partner willing to be part of the team or close support from significant other</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Lives within one hour of institution, or equivalent follow up available elsewhere</td>\r\n  \r\n   </tr>\r\n   \r\n   <tr>\r\n  \r\n   <td>Has dependable transportation</td>\r\n  \r\n   </tr>\r\n\r\n </table></div><div id=\"graphicVersion\">Graphic 60760 Version 1.0</div></div></div>"},"60761":{"type":"graphic_diagnosticimage","displayName":"Trans-ethmoidal encephalocele","title":"Trans-ethmoidal encephalocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trans-ethmoidal encephalocele</div><div class=\"cntnt\"><img style=\"width:413px; height:222px;\" src=\"images/PEDS/60761_Trans_ethmoidal_encephaloc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Metrizamide CT cisternography images show a trans-ethmoidal encephalocele.<br />(A) Sagittal view.<br />(B) Coronal view.</div><div class=\"graphic_reference\">Courtesy of Dr. Tadanori Tomita.</div><div id=\"graphicVersion\">Graphic 60761 Version 3.0</div></div></div>"},"60762":{"type":"graphic_picture","displayName":"Pediculosis ciliaris","title":"Pediculosis ciliaris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pediculosis ciliaris</div><div class=\"cntnt\"><img style=\"width:428px; height:336px;\" src=\"images/DERM/60762_Pediculosis_ciliaris.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 36-year-old woman developed itching in the pubic area and eye lids. Nits are visible on the eyelashes.</div><div class=\"graphic_reference\">Copyright © Samuel Freire da Silva, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 60762 Version 6.0</div></div></div>"},"60763":{"type":"graphic_figure","displayName":"Decline HAV incidence","title":"Incidence* of reported acute hepatitis A cases, by county — National Notifiable Diseases Surveillance System, United States, 1987 to 1997<sup>¶</sup> (pre-vaccine) and 2007","html":"<div class=\"graphic\"><div style=\"width: 833px\" class=\"figure\"><div class=\"ttl\">Incidence* of reported acute hepatitis A cases, by county &mdash; National Notifiable Diseases Surveillance System, United States, 1987 to 1997<sup>&para;</sup> (pre-vaccine) and 2007</div><div class=\"cntnt\"><img style=\"width:813px; height:312px;\" src=\"images/ID/60763_Dcln_HAV_incdnc.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Rate per 100,000 population.<br />&para; Annual average incidence.</div><div class=\"graphic_reference\">Reproduced from: Murphy TV, Denniston MM, Hill HA, et al. Progress Toward Eliminating Hepatitis A Disease in the United States. MMWR Suppl 2016; 65:29.</div><div id=\"graphicVersion\">Graphic 60763 Version 6.0</div></div></div>"},"60768":{"type":"graphic_picture","displayName":"Brand burn","title":"Brand burn","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brand burn</div><div class=\"cntnt\"><img style=\"width:216px; height:183px;\" src=\"images/EM/60768_Brandburn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the imprint in the shape of a clothes iron.</div><div class=\"graphic_reference\">Courtesy of Joan E Shook, MD.</div><div id=\"graphicVersion\">Graphic 60768 Version 2.0</div></div></div>"},"60769":{"type":"graphic_picture","displayName":"Crohns granuloma Light","title":"Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crohn disease</div><div class=\"cntnt\"><img style=\"width:396px; height:261px;\" src=\"images/PEDS/60769_Crohns_granuloma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Granulomatous inflammation in a biopsy from a patient with Crohn disease.</div><div class=\"graphic_reference\">Courtesy of Jonathan Glickman, MD.</div><div id=\"graphicVersion\">Graphic 60769 Version 1.0</div></div></div>"},"60770":{"type":"graphic_figure","displayName":"Graded benefit of fitness","title":"Graded survival benefit of physical fitness","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Graded survival benefit of physical fitness</div><div class=\"cntnt\"><img style=\"width:430px; height:262px;\" src=\"images/CARD/60770_Graded_benefit_of_fitness.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cumulative age-adjusted mortality from cardiovascular causes over 16 years of follow-up, according to fitness quartile in healthy, middle-aged, Norwegian men. Mortality varied inversely with fitness (estimated from total work performed on a bicycle ergometer), being lowest in those who were most fit (Quartile 4).</div><div class=\"graphic_reference\">Data from: Sandvik L, Erikssen J, Thaulow E, et al. N Engl J Med 1993; 328:533.</div><div id=\"graphicVersion\">Graphic 60770 Version 2.0</div></div></div>"},"60771":{"type":"graphic_picture","displayName":"Tracheoesophageal fistula Endo","title":"Tracheoesophageal fistula","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Tracheoesophageal fistula</div><div class=\"cntnt\"><img style=\"width:484px; height:237px;\" src=\"images/GAST/60771_Tracheoesophageal_fistula_E.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel shows a view into the esophagus during endoscopy revealing a tracheoesophageal fistula. A covered, self-expanding metal stent has been deployed covering the fistula (right panel).</div><div class=\"graphic_reference\">Courtesy of Todd H Baron, MD.</div><div id=\"graphicVersion\">Graphic 60771 Version 1.0</div></div></div>"},"60772":{"type":"graphic_picture","displayName":"Straddle injury3","title":"Straddle injury on picket fence","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Straddle injury on picket fence</div><div class=\"cntnt\"><img style=\"width:504px; height:339px;\" src=\"images/EM/60772_Straddle_injury3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note ecchymosis of inner thigh. Note bleeding out of proportion to size of laceration. Interrupted sutures were placed for hemostasis.</div><div class=\"graphic_reference\">Courtesy of Marc R. Laufer, MD.</div><div id=\"graphicVersion\">Graphic 60772 Version 5.0</div></div></div>"},"60776":{"type":"graphic_picture","displayName":"Mud dauber","title":"Mud dauber","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Mud dauber</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ALLRG/60776_Mud_dauber.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.</div><div id=\"graphicVersion\">Graphic 60776 Version 1.0</div></div></div>"},"60777":{"type":"graphic_algorithm","displayName":"Recommendations for imaging for infective endocarditis","title":"American Heart Association/American College of Cardiology recommendations for imaging for infective endocarditis","html":"<div class=\"graphic\"><div style=\"width: 785px\" class=\"figure\"><div class=\"ttl\">American Heart Association/American College of Cardiology recommendations for imaging for infective endocarditis</div><div class=\"cntnt\"><img style=\"width:765px; height:317px;\" src=\"images/CARD/60777_Guidelines_echocardiogr_IE.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Class I - There is evidence and/or general agreement that TTE or TEE should be performed in patients with native or prosthetic valve IE.<br />Class IIa - The weight of evidence or opinion is in favor of the usefulness of TTE or TEE in patients with native or prosthetic valve IE.<br />Class IIb - The weight of evidence or opinion is less well-established for the usefulness of TTE or TEE in patients with native or prosthetic valve IE.</div><div class=\"graphic_footnotes\">CT: computed tomography; IE: infective endocarditis; NVE: native valve endocarditis; PVE: prosthetic valve endocarditis; TEE: transesophageal echocardiography; TTE: transthoracic echocardiography.<br />* Repeat TEE and/or TTE recommended for re-evaluation of patients with IE and a change in clinical signs or symptoms and in patients at high risk of complications.</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; e130. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 60777 Version 8.0</div></div></div>"},"60778":{"type":"graphic_table","displayName":"Pneumatosis symptoms","title":"Symptoms of small and large bowel pneumatosis intestinalis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms of small and large bowel pneumatosis intestinalis</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">&nbsp;</td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Percent\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">\r\n  \r\n   Small Intestine\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   1. Vomiting\r\n  \r\n   </td>\r\n  \r\n   <td>60</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   2. Abdominal distention\r\n  \r\n   </td>\r\n  \r\n   <td>59</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   3. Weight loss\r\n  \r\n   </td>\r\n  \r\n   <td>55</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   4. Abdominal discomfort\r\n  \r\n   </td>\r\n  \r\n   <td>53</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   5. Diarrhea\r\n  \r\n   </td>\r\n  \r\n   <td>27</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   6. Anorexia\r\n  \r\n   </td>\r\n  \r\n   <td>14</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   7. Constipation\r\n  \r\n   </td>\r\n  \r\n   <td>12</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"2\" rowspan=\"1\" class=\"subtitle2_left\">\r\n  \r\n   Large Intestine\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   1. Diarrhea\r\n  \r\n   </td>\r\n  \r\n   <td>56</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   2. Hematochezia\r\n  \r\n   </td>\r\n  \r\n   <td>50</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   3. Abdominal discomfort\r\n  \r\n   </td>\r\n  \r\n   <td>32</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   4. Abdominal distention\r\n  \r\n   </td>\r\n  \r\n   <td>28</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   5. Constipation\r\n  \r\n   </td>\r\n  \r\n   <td>26</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   6. Weight loss\r\n  \r\n   </td>\r\n  \r\n   <td>16</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   7. Tenesmus\r\n  \r\n   </td>\r\n  \r\n   <td>10</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Adapted from: Jamart J, Acta Hepato Gastroenterol 1979; 26:419.</div><div id=\"graphicVersion\">Graphic 60778 Version 2.0</div></div></div>"},"60781":{"type":"graphic_waveform","displayName":"ECG epsilon wave and T wave inversions in ARVC","title":"12-lead electrocardiogram (ECG) showing epsilon wave and T wave inversions in arrhythmogenic right ventricular cardiomyopathy (ARVC)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) showing epsilon wave and T wave inversions in arrhythmogenic right ventricular cardiomyopathy (ARVC)</div><div class=\"cntnt\"><img style=\"width:386px; height:229px;\" src=\"images/CARD/60781_Epsilon_wave_T_inversions_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Twelve lead electrocardiogram in a patient with arrhythmogenic right ventricular cardiomyopathy (ARVC) showing deep T wave inversions in V2 to V4, compatible with right ventricular disease, and epsilon waves representing delayed right ventricular depolarization just after the QRS complex (arrows).</div><div class=\"graphic_reference\">Data from: Jaoude S, Leclercq JF, Coumel P. Eur Heart J 1996; 17:1717.</div><div id=\"graphicVersion\">Graphic 60781 Version 8.0</div></div></div>"},"60782":{"type":"graphic_table","displayName":"Paget dz breast surg XRT","title":"Treatment of Paget disease of the breast with breast conserving surgery and radiation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of Paget disease of the breast with breast conserving surgery and radiation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Study </td> <td class=\"subtitle1\">N </td> <td class=\"subtitle1\">Presentation </td> <td class=\"subtitle1\">Treatment </td> <td class=\"subtitle1\">Local Recurrence </td> <td class=\"subtitle1\">Median F/U (mos) </td> </tr> <tr> <td>Fourquet A; 1987</td> <td>17</td> <td> <p>No mass</p> <p>Normal mammogram</p> </td> <td>Biopsy + radiation</td> <td>3 (18 percent)</td> <td>90</td> </tr> <tr> <td>Bulens P; 1990</td> <td>13</td> <td>No mass</td> <td>Biopsy + radiation</td> <td>0 (0 percent)</td> <td>52</td> </tr> <tr> <td rowspan=\"2\">Stockdale AD; 1989 </td> <td>19</td> <td> <p>No mass</p> <p>Normal mammogram</p> </td> <td>Biopsy + radiation</td> <td>3 (16 percent)</td> <td>63</td> </tr> <tr> <td>6</td> <td> <p>No mass</p> <p>Abnormal/unknown mammogram</p> </td> <td>Biopsy + radiation</td> <td>5 (8 percent)</td> <td>63</td> </tr> <tr> <td>Rissanen PM; 1969</td> <td>8</td> <td>&nbsp;</td> <td>Local surgery + radiation</td> <td>3 (38 percent)</td> <td>&nbsp;</td> </tr> <tr> <td>Bijker N; 2001</td> <td>61</td> <td> <p>No mass, 97 percent</p> <p>Normal mammogram, 84 percent</p> </td> <td>Complete nipple-areolar resection + radiation</td> <td>4 (6 percent)</td> <td>77</td> </tr> <tr> <td>Marshall JK; 2003</td> <td>36</td> <td> <p>No mass</p> <p>Normal mammogram</p> </td> <td>Partial nipple-areolar resection + radiation (n = 9); complete nipple-areolar resection + radiation (n = 25)</td> <td>4 (11 percent)</td> <td>113</td> </tr> </tbody></table></div><div class=\"graphic_reference\"><OL>&#xD;&#xA;<LI>Fourquet A, Campana F, Vielh P, et al. Paget's disease of the nipple without detectable breast tumor: conservative management with radiation therapy. Int J Radiat Oncol Biol Phys 1987; 13:1463. </LI>&#xD;&#xA;<LI>Bulens P, Vanuytsel L, Rijnders A, van der Schueren E. Breast conserving treatment of Paget's disease. Radiother Oncol 1990; 17:305. </LI>&#xD;&#xA;<LI>Stockdale AD, Brierley JD, White WF, et al. Radiotherapy for Paget's disease of the nipple: a conservative alternative. Lancet 1989; 2:664.</LI>&#xD;&#xA;<LI>Rissanen PM, Holsti P. Paget's disease of the breast: the influence of the presence or absence of an underlying palpable tumor on the prognosis and on the choice of treatment. Oncology 1969; 23:209.</LI>&#xD;&#xA;<LI>Bijker N, Rutgers EJ, Duchateau L, et al. Breast-conserving therapy for Paget disease of the nipple: a prospective European Organization for Research and Treatment of Cancer study of 61 patients. Cancer 2001: 91:472.</LI>&#xD;&#xA;<LI>Marshall JK, Griffith KA, Haffty BG, et al. Conservative management of Paget disease of the breast with radiotherapy: 10- and 15-year results. Cancer 2003; 97:2142.</LI></OL></div><div id=\"graphicVersion\">Graphic 60782 Version 3.0</div></div></div>"},"60784":{"type":"graphic_figure","displayName":"CDC BMI for age boys 2 to 20 years","title":"Body mass index-for-age percentiles, boys, 2 to 20 years, CDC growth charts: United States","html":"<div class=\"graphic\"><div style=\"width: 577px\" class=\"figure\"><div class=\"ttl\">Body mass index-for-age percentiles, boys, 2 to 20 years, CDC growth charts: United States</div><div class=\"cntnt\"><img style=\"width:557px; height:669px;\" src=\"images/PEDS/60784_BMI_age_boys_2_20_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BMI: body mass index; CDC: Centers for Disease Control and Prevention.</div><div class=\"graphic_reference\">Developed by the National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).</div><div id=\"graphicVersion\">Graphic 60784 Version 5.0</div></div></div>"},"60786":{"type":"graphic_picture","displayName":"Keratosis pilaris light skin","title":"Keratosis pilaris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Keratosis pilaris</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/60786_Keratosispilarisfairskin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Keratosis pilaris. Multiple mildly erythematous follicularly-based papules.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60786 Version 6.0</div></div></div>"},"60787":{"type":"graphic_figure","displayName":"Cross-reactivity patterns in OAS (PFAS)","title":"Cross-reactivity patterns in oral allergy syndrome (pollen-food allergy syndrome)","html":"<div class=\"graphic\"><div style=\"width: 636px\" class=\"figure\"><div class=\"ttl\">Cross-reactivity patterns in oral allergy syndrome (pollen-food allergy syndrome)</div><div class=\"cntnt\"><img style=\"width:616px; height:784px;\" src=\"images/ALLRG/60787_OAS_related_poll_fruits_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical patterns of cross-reactivity between pollens and fruits and vegetables. Individual foods are grouped by their taxonomical families.</div><div class=\"graphic_reference\">Adapted and extended from: Sicherer SH. Clinical implications of cross-reactive food allergens. J Allergy Clin Immunol 2001; 108:881.</div><div id=\"graphicVersion\">Graphic 60787 Version 7.0</div></div></div>"},"60788":{"type":"graphic_diagnosticimage","displayName":"Stage II lateral condyle fracture","title":"Stage II fracture of the lateral condyle","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Stage II fracture of the lateral condyle</div><div class=\"cntnt\"><img style=\"width:468px; height:314px;\" src=\"images/EM/60788_StageIILCfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Anteroposterior radiograph shows 4 mm of displacement of the metaphyseal segment; however, the fracture was stable by stress examination and arthrography.<br />(B) Four weeks after percutaneous pinning, the fracture is healed.</div><div class=\"graphic_reference\">Reproduced with permission from: Skaggs DL, Flynn JM. The elbow: Physeal fractures, apophyseal injuries of the distal humerus, osteonecrosis of the trochlea, and T-condylar fractures. In: Rockwood and Wilkins' Fractures in Children, 7th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2009.&nbsp;Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 60788 Version 15.0</div></div></div>"},"60789":{"type":"graphic_figure","displayName":"Types of splicing mutations","title":"Types of splicing mutations and correction with antisense morpholino oligonucleotides","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Types of splicing mutations and correction with antisense morpholino oligonucleotides</div><div class=\"cntnt\"><img style=\"width:521px; height:667px;\" src=\"images/ALLRG/60789_Types_of_splicing_mutations.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Type I refers to the classical splicing mutation that causes the deletion of an entire exon during pre-mRNA splicing. B) Type II splicing mutations occur in the mid-intron and result in the insertion of a pseudoexon at the cDNA level. C) Type III mutations lie within the coding region, resulting in the partial deletion of an exon. D) Type IV mutations lie within the intron and lead to partial deletion of an exon. E) Type V mutations disturb the lariat branch point and result in deletion of an exon.</div><div class=\"graphic_reference\">Reproduced with permission from: Hu H, Gatti R. New approaches to treatment of primary immunodeficiencirs fixing mutations with chemicals. Curr Opin Allergy Clin Immunol 2008; 8:540. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60789 Version 9.0</div></div></div>"},"60790":{"type":"graphic_waveform","displayName":"ECG atrial fibrillation in WPW","title":"12-lead electrocardiogram (ECG) showing atrial fibrillation and preexcitation in the Wolff-Parkinson-White (WPW) syndrome","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) showing atrial fibrillation and preexcitation in the Wolff-Parkinson-White (WPW) syndrome</div><div class=\"cntnt\"><img style=\"width:383px; height:333px;\" src=\"images/CARD/60790_AF_in_WPW.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The surface 12-lead ECG shows atrial fibrillation with a rapid ventricular response. The QRS complexes are widened due to antegrade conduction over a left lateral accessory pathway. However, the QRS complexes vary in morphology and duration because of variability in the degree of preexcitation; there is one QRS complex (*) that is conducted without preexcitation.</div><div id=\"graphicVersion\">Graphic 60790 Version 4.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"60791":{"type":"graphic_figure","displayName":"Functional class outcome AR","title":"Preoperative functional class predicts outcome after valve replacement for aortic regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Preoperative functional class predicts outcome after valve replacement for aortic regurgitation</div><div class=\"cntnt\"><img style=\"width:376px; height:480px;\" src=\"images/CARD/60791_FunctionalclassoutcomeAR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients who preoperatively have functional class III or IV symptoms have a lower survival rate compared&nbsp;with those with functional class I or II regardless of whether the left ventricular ejection fraction (LVEF) is ≥50 percent (upper panel) or &lt;50 percent (lower panel).</div><div class=\"graphic_reference\">Data from: Klodas E, Enriquez-Sarano M, Tajik AJ, et al. J Am Coll Cardiol 1997; 30:746.</div><div id=\"graphicVersion\">Graphic 60791 Version 2.0</div></div></div>"},"60793":{"type":"graphic_table","displayName":"Priorities for management of cerebral palsy","title":"Priorities for management of individuals with cerebral palsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Priorities for management of individuals with cerebral palsy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td> Communication</td>\n</tr>\n<tr>\n<td> Social and emotional development</td>\n</tr>\n<tr>\n<td> Education</td>\n</tr>\n<tr>\n<td> Maximal independence in activities of daily living</td>\n</tr>\n<tr>\n<td> As near-normal appearance as possible</td>\n</tr>\n<tr>\n<td> Nutrition</td>\n</tr>\n<tr>\n<td> Mobility</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Miller G. Cerebral palsies. In: Static Encephalopathies of Infancy and Childhood, Miller G, Ramer JC (Eds), Raven, New York 1992. Copyright © 1992 Lippincott Williams &amp; Wilkins.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 60793 Version 7.0</div></div></div>"},"60795":{"type":"graphic_algorithm","displayName":"Special management LUTS","title":"Specialized management of persistent, bothersome LUTS after basic management","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Specialized management of persistent, bothersome LUTS after basic management</div><div class=\"cntnt\"><img style=\"width:577px; height:853px;\" src=\"images/PC/60795_SpecialmanagementLUTS.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LUTS: lower urinary tract symptoms; OAB: overactive bladder; BOO: bladder outlet obstruction; MIST: minimally invasive surgical treatment.<br />* PSA &lt;1.5 ng.<br />&para; PSA &gt;1.5 ng.</div><div class=\"graphic_reference\">Reproduced with permission from: Abrams, P, Chapple, C, Khoury, S, et al. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2009; 181:1779. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 60795 Version 2.0</div></div></div>"},"60796":{"type":"graphic_diagnosticimage","displayName":"MRI of AC joint degeneration","title":"MRI of AC joint degeneration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of AC joint degeneration</div><div class=\"cntnt\"><img style=\"width:342px; height:360px;\" src=\"images/EM/60796_MRI_AC_jt_degeneration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The MRI image of acromioclavicular (AC) joint above shows narrowing of the joint space (arrow) and a subchondral cyst of the acromion (bright circular lesion adjacent to joint space). The AC joint of this 41-year-old patient was asymptomatic.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 60796 Version 4.0</div></div></div>"},"60800":{"type":"graphic_picture","displayName":"Placenta accreta","title":"Placenta accreta","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Placenta accreta</div><div class=\"cntnt\"><img style=\"width:518px; height:361px;\" src=\"images/OBGYN/60800_Placentaaccreta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Villi have implanted in scar tissue (arrows) which replaced the endometrium in an area of thinned myometrium. Placenta accretas often occur at the site of prior cesarian sections.<br />(B) Note the layer of dense pink fibrinoid covering the scar (dashed arrow). The presence of fibrinoid material between villi and myometrial tissue does not exclude a diagnosis of placenta accreta.<br />(C) Villi are immediately adjacent to underlying myometrium without any intervening decidua.<br />(D) Villi in direct contact with myometrium (thick arrow). Note the implantation site trophoblast (arrowhead) which can be mistaken for decidua.</div><div class=\"graphic_reference\">Courtesy of Miriam D Post, MD.</div><div id=\"graphicVersion\">Graphic 60800 Version 2.0</div></div></div>"},"60801":{"type":"graphic_picture","displayName":"Inflammatory breast ca Light","title":"Inflammatory carcinoma of the breast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Inflammatory carcinoma of the breast</div><div class=\"cntnt\"><img style=\"width:360px; height:226px;\" src=\"images/ONC/60801_Inflammatory_breast_ca_Ligh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The skin of the breast with an inflammatory carcinoma shows dermal lymphatic invasion by carcinoma cells (arrows).</div><div class=\"graphic_reference\">Courtesy of Stuart Schnitt, MD.</div><div id=\"graphicVersion\">Graphic 60801 Version 1.0</div></div></div>"},"60803":{"type":"graphic_table","displayName":"Example of conservative schedule for very sensitive patients","title":"Aeroallergen subcutaneous immunotherapy (SCIT) - Example of conservative schedule for very sensitive patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Aeroallergen subcutaneous immunotherapy (SCIT) - Example of conservative schedule for very sensitive patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Concentration: 1:1000 v/v dilution of maintenance vial</td> </tr> <tr> <td class=\"subtitle2_single\">Dose</td> </tr> <tr> <td class=\"indent1\">0.05 mL</td> </tr> <tr> <td class=\"indent1\">0.10 mL</td> </tr> <tr> <td class=\"indent1\">0.20 mL</td> </tr> <tr> <td class=\"indent1\">0.40 mL</td> </tr> <tr> <td class=\"subtitle1_single\">Concentration: 1:100 v/v</td> </tr> <tr> <td class=\"subtitle2_single\">Dose</td> </tr> <tr> <td class=\"indent1\">0.05 mL</td> </tr> <tr> <td class=\"indent1\">0.10 mL</td> </tr> <tr> <td class=\"indent1\">0.20 mL</td> </tr> <tr> <td class=\"indent1\">0.30 mL</td> </tr> <tr> <td class=\"indent1\">0.40 mL</td> </tr> <tr> <td class=\"indent1\">0.50 mL</td> </tr> <tr> <td class=\"subtitle1_single\">Concentration: 1:10 v/v</td> </tr> <tr> <td class=\"subtitle2_single\">Dose</td> </tr> <tr> <td class=\"indent1\">0.05 mL</td> </tr> <tr> <td class=\"indent1\">0.07 mL</td> </tr> <tr> <td class=\"indent1\">0.10 mL</td> </tr> <tr> <td class=\"indent1\">0.15 mL</td> </tr> <tr> <td class=\"indent1\">0.25 mL</td> </tr> <tr> <td class=\"indent1\">0.35 mL</td> </tr> <tr> <td class=\"indent1\">0.40 mL</td> </tr> <tr> <td class=\"indent1\">0.45 mL</td> </tr> <tr> <td class=\"indent1\">0.50 mL</td> </tr> <tr> <td class=\"subtitle1_single\">Maintenance concentration</td> </tr> <tr> <td class=\"subtitle2_single\">Dose</td> </tr> <tr> <td class=\"indent1\">0.05 mL</td> </tr> <tr> <td class=\"indent1\">0.07 mL</td> </tr> <tr> <td class=\"indent1\">0.10 mL</td> </tr> <tr> <td class=\"indent1\">0.15 mL</td> </tr> <tr> <td class=\"indent1\">0.20 mL</td> </tr> <tr> <td class=\"indent1\">0.25 mL</td> </tr> <tr> <td class=\"indent1\">0.30 mL</td> </tr> <tr> <td class=\"indent1\">0.35 mL</td> </tr> <tr> <td class=\"indent1\">0.40 mL</td> </tr> <tr> <td class=\"indent1\">0.45 mL</td> </tr> <tr> <td class=\"indent1\">0.50 mL</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">v/v: volume/volume.</div><div class=\"graphic_reference\">Original figure modified for this publication. Cox L, Nelson H, Lockey R. Allergen immunotherapy: A practice parameter third update. J Allergy Clin Immunol 2011; 127(1 Supp):S1. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 60803 Version 10.0</div></div></div>"},"60804":{"type":"graphic_diagnosticimage","displayName":"Congenital toxoplasmosis intracranial calcifications","title":"Congenital toxoplasmosis intracranial calcifications","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital toxoplasmosis intracranial calcifications</div><div class=\"cntnt\"><img style=\"width:207px; height:260px;\" src=\"images/PEDS/60804_Congtoxintracrcalc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brain computed tomographic scan showing small, calcified lesions.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics in Review, Vol. 18, Pages 75-83, Copyright © 1997 by the AAP.</div><div id=\"graphicVersion\">Graphic 60804 Version 13.0</div></div></div>"},"60805":{"type":"graphic_table","displayName":"Perioperative anaphylaxis agents and proposed mechanisms","title":"Some agents capable of causing perioperative anaphylaxis and proposed mechanisms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some agents capable of causing perioperative anaphylaxis and proposed mechanisms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Agents</td> <td class=\"subtitle1\" colspan=\"2\">Immunologic reactions</td> <td class=\"subtitle1\" rowspan=\"2\">Nonimmunologic</td> </tr> <tr> <td class=\"subtitle2\">IgE-mediated</td> <td class=\"subtitle2\">Non-IgE-mediated</td> </tr> <tr> <td>Neuromuscular-blocking agents</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> </tr> <tr> <td>Latex</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Antibiotics</td> <td class=\"centered\"> <p>+</p> (eg, beta-lactams)</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\"> <p>+</p> (eg, vancomycin)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Hypnotic induction agents:</td> </tr> <tr> <td class=\"indent1\">Barbiturates</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Nonbarbiturates</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>Opioids</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> </tr> <tr> <td>Colloids and plasma expanders</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>Chlorhexidine</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">+/–: agent may cause anaphylaxis by this mechanism.</div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.</div><div id=\"graphicVersion\">Graphic 60805 Version 15.0</div></div></div>"},"60806":{"type":"graphic_waveform","displayName":"Advanced case 2 with answer","title":"Bidirectional ventricular tachycardia","html":"<div class=\"graphic\"><div style=\"width: 485px\" class=\"figure\"><div class=\"ttl\">Bidirectional ventricular tachycardia</div><div class=\"cntnt\"><img style=\"width:465px; height:128px;\" src=\"images/CARD/60806_Advanced_case_2_with_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rhythm strip showing bidirectional ventricular tachycardia which may be a manifestation of digitalis toxicity. This rare, life-threatening tachyarrhythmia is characterized by beat-to-beat changes in the polarity of consecutive premature ventricular complexes. It may also occur in other settings, including catecholaminergic polymorphic ventricular tachycardia.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 60806 Version 3.0</div></div></div>"},"60812":{"type":"graphic_diagnosticimage","displayName":"Proximal humerus fracture-dislocation","title":"Proximal humerus fracture-dislocation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proximal humerus fracture-dislocation</div><div class=\"cntnt\"><img style=\"width:278px; height:348px;\" src=\"images/EM/60812_Proxhumerfracdisloc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The antero-posterior radiograph above shows a fracture dislocation of the proximal humerus. The glenoid and a large fragment of the greater tuberosity are easily seen adjacent to the humeral head. Fracture dislocations require urgent orthopedic referral.</div><div class=\"graphic_reference\">Reproduced with permission from: Robinson CM. Proximal humerus fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 60812 Version 10.0</div></div></div>"},"60813":{"type":"graphic_table","displayName":"History skin lesions after OLT","title":"Evolution of skin lesions after liver transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evolution of skin lesions after liver transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Dermatologic condition</td> <td class=\"subtitle1\">Liver disease</td> <td class=\"subtitle1\">Evolution after liver transplantation</td> </tr> <tr> <td>Acanthosis nigricans</td> <td>Primary biliary cholangitis</td> <td>Improvement.</td> </tr> <tr> <td>Alopecia areata</td> <td>Autoimmune hepatitis</td> <td>Frequently improvement in the 4 to 12 weeks following transplantation. Occasionally, new alopecia spots appear with immunosuppression.</td> </tr> <tr> <td>Pressure alopecia</td> <td>Living donor</td> <td>Reported in living donors<sup>[1,2]</sup>.</td> </tr> <tr> <td>Azure lunules (blue discoloration of the bases of the fingernails)</td> <td>Wilson disease</td> <td>Discoloration disappears as the metabolic defect is corrected.</td> </tr> <tr> <td>Lichen planus</td> <td> <p>Hepatitis C virus</p> Primary biliary cholangitis</td> <td>Improves after liver transplantation. Chronic graft-versus-host-disease and parakeratosis occurring after liver transplantation may have a lichenoid appearance.</td> </tr> <tr> <td>Livedo reticularis</td> <td>Primary hyperoxaluria</td> <td>Improvement; livedo reticularis can appear months after transplantation<sup>[3]</sup>.</td> </tr> <tr> <td>Panniculitis</td> <td>Alpha-1 antitrypsin deficiency</td> <td>Improvement; panniculitis has been reported to occur in a patient who acquired a PiZZ phenotype and resolve after transplantation<sup>[4]</sup>.</td> </tr> <tr> <td>Photosensitivity</td> <td>Erythropoietic protoporphyria</td> <td>Improvement, but it may take months or even years. Recurrence has been described<sup>[5]</sup>. Intraoperative protection from phototoxic injury with a filter omitting wavelengths below 470 nm is recommended during liver transplantation<sup>[6]</sup>.</td> </tr> <tr> <td>Vasculitis</td> <td>Hepatitis C with cryoglobulinemia</td> <td>May worsen after transplantation as the viremia increases. Antiviral therapy may be beneficial<sup>[7]</sup>.</td> </tr> <tr> <td>Raynaud phenomenon</td> <td>Primary biliary cholangitis</td> <td>Improvement.</td> </tr> <tr> <td>Vitiligo</td> <td>Autoimmune hepatitis</td> <td>Improvement; vitiligo occurring after transplantation due to the destruction of melanocytes by donor-derived immune reaction has been reported<sup>[8]</sup>.</td> </tr> <tr> <td>Xanthomas and xanthelasmas</td> <td>Chronic cholestatic diseases, such as primary biliary cholangitis, Alagille syndrome, familial hypercholesterolemia</td> <td>Improvement<sup>[9]</sup>.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Tomioka T, Hayashida M, Hanaoka K. Pressure alopecia in living donors for liver transplantation. Can J Anaesth 2004; 51:186.</li>&#xD;&#xA;    <li>Khalaf H, Negmi H, Hassan G, Al-Sebayel M. Postoperative alopecia areata: is pressure-induced ischemia the only cause to blame? Transplant Proc 2004; 36:2158.</li>&#xD;&#xA;    <li>Rubenstein MC, Martinelli PT, Bayer-Garner IB, et al. Persistent cutaneous manifestations of hyperoxaluria after combined hepatorenal transplantation. Dermatol Online J 2004; 10:10.</li>&#xD;&#xA;    <li>Fernandez-Torres R, Garcia-Silva J, Robles O, et al. Alfa-1-antitrypsin deficiency panniculitis acquired after liver transplant and successfully treated with retransplant. J Am Acad Dermatol 2009; 60:715.</li>&#xD;&#xA;    <li>Dowman JK, gunson BK, Mirza DF, et al. UK experience of liver transplantation for erythropoietic protoporphyria. J Inherit Metab Dis 2011; 34:539.</li>&#xD;&#xA;    <li>Wahlin S, Srikanthan N, Hamre B, et al. Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria. Liver Transpl 2008; 14:1340.</li>&#xD;&#xA;    <li>Francesca Donata M, Banfi G, Cresseri D, et al. Antiviral therapy of symptomatic HCV-mixed \u2028cryoglobulinemia after liver transplant: Case \u2028report and literature review. Int J Artif Organs. 2013 Feb 28 [Epub ahead of print].</li>&#xD;&#xA;    <li>Bradle V, Kemp EH, Dickinson C, et al. Vitiligo following a combined liver-kidney transplant. Nephrol Dial Transplant 2009; 24:686.</li>&#xD;&#xA;    <li>Maiorana A, Nobil V, Calandra S, et al. Preemptive liver transplantation in a child with familial hypercholesterolemia. Pediatr Transplant 2011; 15:E25.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 60813 Version 6.0</div></div></div>"},"60816":{"type":"graphic_table","displayName":"Infections and inflammatory causes of tonic pupil","title":"Infectious and inflammatory etiologies of a tonic pupil","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infectious and inflammatory etiologies of a tonic pupil</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td class=\"indent1\">Campylobacter jejuni enteritis</td> </tr> <tr> <td class=\"indent1\">Cellulitis</td> </tr> <tr> <td class=\"indent1\">Chickenpox</td> </tr> <tr> <td class=\"indent1\">Choroiditis</td> </tr> <tr> <td class=\"indent1\">Diphtheria</td> </tr> <tr> <td class=\"indent1\">Herpes simplex virus</td> </tr> <tr> <td class=\"indent1\">Herpes zoster virus</td> </tr> <tr> <td class=\"indent1\">HTLV- II</td> </tr> <tr> <td class=\"indent1\">Influenza</td> </tr> <tr> <td class=\"indent1\">Measles</td> </tr> <tr> <td class=\"indent1\">Parvovirus B19</td> </tr> <tr> <td class=\"indent1\">Pertussis</td> </tr> <tr> <td class=\"indent1\">Scarlet fever</td> </tr> <tr> <td class=\"indent1\">Sinusitis</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> </tr> <tr> <td class=\"indent1\">Varicella virus</td> </tr> <tr> <td class=\"indent1\">Viral hepatitis</td> </tr> <tr> <td class=\"subtitle1_single\">Inflammation</td> </tr> <tr> <td class=\"indent1\">Iritis or uveitis causing damage to ciliary ganglion</td> </tr> <tr> <td class=\"indent1\">Rheumatoid arthritis</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Vogt-Koyanagi-Harada syndrome</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 60816 Version 3.0</div></div></div>"},"60817":{"type":"graphic_picture","displayName":"Inv perineur panc adenoCA","title":"Histologic appearance of pancreatic ductal adenocarcinoma with perineural invasion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic appearance of pancreatic ductal adenocarcinoma with perineural invasion</div><div class=\"cntnt\"><img style=\"width:432px; height:238px;\" src=\"images/ONC/60817_Inv_perineur_panc_adenoCA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pancreatic ductal adenocarcinoma invading perineurally at the retroperitoneal resection margin (right) Hematoxylin and Eosin-stained section.</div><div class=\"graphic_reference\">Courtesy of Daniel S Longnecker, MD.</div><div id=\"graphicVersion\">Graphic 60817 Version 3.0</div></div></div>"},"60819":{"type":"graphic_table","displayName":"Causes of hypergastrinemia","title":"Causes of hypergastrinemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hypergastrinemia</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td class=\"subtitle1\">Cause</td>\n\t\t\t\t\t<td class=\"subtitle1\">Relative gastrin level</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"2\">Elevated antral pH</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist2_start\" colspan=\"2\">Chronic atrophic gastritis - type A</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist2\">Pernicious anemia</td>\n\t\t\t\t\t<td class=\"sublist_other\">++++</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist2\">Other immunologic associations (eg, vitiligo, rheumatoid arthritis, Sjogren's syndrome, diabetes mellitus)</td>\n\t\t\t\t\t<td class=\"sublist_other\">+</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Chronic atrophic gastritis - type B (eg, H. pylori-induced)</td>\n\t\t\t\t\t<td>++</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Renal insufficiency</td>\n\t\t\t\t\t<td>+</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Massive small bowel resection</td>\n\t\t\t\t\t<td>+ or ++</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Gastrin cell hyperplasia</td>\n\t\t\t\t\t<td>+ or ++</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist2_start\" colspan=\"2\">Antisecretory therapy</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist2\">H2 blockers</td>\n\t\t\t\t\t<td class=\"sublist_other\">+</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist2\">Proton pump inhibitors</td>\n\t\t\t\t\t<td class=\"sublist_other\">++</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Truncal vagotomy</td>\n\t\t\t\t\t<td>+</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\">Gastrinoma</td>\n\t\t\t\t\t<td>++++</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"subtitle2_left\" colspan=\"2\">Other tumors</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Ovarian cancer</td>\n\t\t\t\t\t<td>+</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"indent1\">Pheochromocytoma</td>\n\t\t\t\t\t<td>+ or ++</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 60819 Version 1.0</div></div></div>"},"60820":{"type":"graphic_figure","displayName":"Vaginal pull through procedure","title":"Vaginal pull through procedure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vaginal pull through procedure</div><div class=\"cntnt\"><img style=\"width:336px; height:308px;\" src=\"images/OBGYN/60820_Vaginalpullthroughproced.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After drainage of obstructed lower vagina, the normal upper vaginal tissue is pulled through to the perineum to create a normal vagina.</div><div class=\"graphic_reference\">Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 60820 Version 10.0</div></div></div>"},"60821":{"type":"graphic_figure","displayName":"Neonate step pain therapy","title":"Proposed steps for neonatal analgesia","html":"<div class=\"graphic\"><div style=\"width: 788px\" class=\"figure\"><div class=\"ttl\">Proposed steps for neonatal analgesia</div><div class=\"cntnt\"><img style=\"width:768px; height:508px;\" src=\"images/PEDS/60821_Neonate_step_pain_therapy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the stepwise approach to providing preemptive analgesia in neonates undergoing procedures that may cause pain or discomfort. The level of analgesia provided is based upon the degree of anticipated procedural pain. However, with the escalation of intervention with increasing pain, it is important to remember that interventions from earlier steps should still be provided. For example, when a central line is placed, the neonate should receive subcutaneous administration of local anesthestic (Step 5), along with oral sucrose (Step 1), and topical anesthetic for the skin (Step 2).</div><div class=\"graphic_reference\">From: Anand KJS. International Evidence-Based Group for Neonatal Pain. Consensus statement for the prevention and management of pain in the newborn. Arch Pediatr Adolesc Med 2001; 155:173&ndash;80. This figure has been reproduced with permission of the International Association for the Study of Pain&reg; (IASP). The figure may not be reproduced for any other purpose without permission.</div><div id=\"graphicVersion\">Graphic 60821 Version 3.0</div></div></div>"},"60823":{"type":"graphic_figure","displayName":"Auditory pathways","title":"Current concept of the auditory pathways","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Current concept of the auditory pathways</div><div class=\"cntnt\"><img style=\"width:572px; height:441px;\" src=\"images/PC/60823_Auditory_pathways.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Elizabeth Dinces, MD.</div><div id=\"graphicVersion\">Graphic 60823 Version 1.0</div></div></div>"},"60824":{"type":"graphic_figure","displayName":"Four-flap Z-plasty","title":"Four-flap Z-plasty","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Four-flap Z-plasty</div><div class=\"cntnt\"><img style=\"width:510px; height:499px;\" src=\"images/SURG/60824_Four-flap_z-plasty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A four-flap Z-plasty has two additional limbs (forming A and D).</div><div id=\"graphicVersion\">Graphic 60824 Version 2.0</div></div></div>"},"60825":{"type":"graphic_table","displayName":"Pharmacokinetics of second generation antipsychotics","title":"Pharmacokinetics of second generation antipsychotics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacokinetics of second generation antipsychotics</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Therapeutic peak plasma level, h</td> <td class=\"subtitle1\">Half-Life, h, therapeutic</td> <td class=\"subtitle1\">Protein binding, percent</td> <td class=\"subtitle1\">Vol. of distribuion, L/kg </td> <td class=\"subtitle1\">Route of metabloism</td> <td class=\"subtitle1\">Active metabolite </td> </tr> <tr> <td>Traditional agents</td> <td>2-5</td> <td>8-36</td> <td>90-95</td> <td>7-62</td> <td> <p>CYP2D6</p> <p>CYP1A2</p> <p>CYP3A4</p> </td> <td>Variable</td> </tr> <tr> <td>Clozapine</td> <td>1-4</td> <td>7-13</td> <td>92-95</td> <td>2-5</td> <td> <p>CYP1A2</p> <p>CYP3A4</p> </td> <td>Norclozapine</td> </tr> <tr> <td>Olanzapine</td> <td>5-6</td> <td>20-30</td> <td>93</td> <td>10-20</td> <td> <p>CYP1A2</p> <p>CYP2D6</p> </td> <td>NO</td> </tr> <tr> <td>Quetiapine</td> <td>1-2</td> <td>4-10</td> <td>83</td> <td>10</td> <td>CYP3A4</td> <td>7-hydroxyquetiapine</td> </tr> <tr> <td>Risperadone</td> <td>1-2</td> <td>3-24</td> <td>90</td> <td>1-1.5</td> <td>CYP2D6</td> <td>9-hydroxyrisperidone</td> </tr> <tr> <td>Ziprasidone</td> <td>4-5</td> <td>4-10</td> <td>&#62;99</td> <td>2</td> <td>CYP3A4</td> <td>NO</td> </tr> <tr> <td>Aripiprazole</td> <td>3-5</td> <td>75-146</td> <td>&#62;99</td> <td>4.9</td> <td> <p>CYP2D6</p> <p>CYP3A4</p> </td> <td>Dehydroaripiprazole</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 60825 Version 4.0</div></div></div>"},"60827":{"type":"graphic_table","displayName":"Interpretation of the hepatitis B panel","title":"Interpretation of the hepatitis B serologic panel","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interpretation of the hepatitis B serologic panel</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tests</td> <td class=\"subtitle1\">Results</td> <td class=\"subtitle1\">Interpretation</td> </tr> <tr> <td>HBsAg</td> <td>Negative</td> <td class=\"divider_bottom\" rowspan=\"3\">Susceptible</td> </tr> <tr> <td>anti-HBc</td> <td>Negative</td> </tr> <tr class=\"divider_bottom\"> <td>anti-HBs</td> <td>Negative</td> </tr> <tr> <td>HBsAg</td> <td>Negative</td> <td class=\"divider_bottom\" rowspan=\"3\">Immune due to natural infection</td> </tr> <tr> <td>anti-HBc</td> <td>Positive</td> </tr> <tr class=\"divider_bottom\"> <td>anti-HBs</td> <td>Positive</td> </tr> <tr> <td>HBsAg</td> <td>Negative</td> <td class=\"divider_bottom\" rowspan=\"3\">Immune due to hepatitis B vaccination*</td> </tr> <tr> <td>anti-HBc</td> <td>Negative</td> </tr> <tr class=\"divider_bottom\"> <td>anti-HBs</td> <td>Positive</td> </tr> <tr> <td>HBsAg</td> <td>Positive</td> <td class=\"divider_bottom\" rowspan=\"4\">Acutely infected</td> </tr> <tr> <td>anti-HBc</td> <td>Positive</td> </tr> <tr> <td>IgM anti-HBc</td> <td>Positive</td> </tr> <tr class=\"divider_bottom\"> <td>anti-HBs</td> <td>Negative</td> </tr> <tr> <td>HBsAg</td> <td>Positive</td> <td class=\"divider_bottom\" rowspan=\"4\">Chronically infected</td> </tr> <tr> <td>anti-HBc</td> <td>Positive</td> </tr> <tr> <td>IgM anti-HBc</td> <td>Negative</td> </tr> <tr class=\"divider_bottom\"> <td>anti-HBs</td> <td>Negative</td> </tr> <tr> <td>HBsAg</td> <td>Negative</td> <td rowspan=\"3\">Four interpretations possible<sup>&#182;</sup></td> </tr> <tr> <td>anti-HBc</td> <td>Positive</td> </tr> <tr> <td>anti-HBs</td> <td>Negative</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HBsAg: hepatitis B surface antigen; anti-HBc: hepatitis B core antibody; anti-HBs: hepatitis B surface antibody; IgM: immunoglobulin M; HBV: hepatitis B virus.<br />* Antibody response (anti-HBs) can be measured quantitatively or qualitatively. A protective antibody response is reported quantitatively as 10 or more milliinternational units (≥10 milliint. unit/mL) or qualitatively as positive. Postvaccination testing should be completed one to two months after the third vaccine dose for results to be meaningful.<br />¶ Four interpretations: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Might be recovering from acute HBV infection.</LI>&#xD;&#xA;<LI>Might be distantly immune and test not sensitive enough to detect very low level of anti-HBs in serum.</LI>&#xD;&#xA;<LI>Might be susceptible with a false positive anti-HBc.</LI>&#xD;&#xA;<LI>Might be undetectable level of HBsAg present in the serum, and the person is actually chronically infected.</LI></OL></div><div class=\"graphic_reference\">Centers for Disease Control and Prevention, Hepatitis B information for health professionals: Interpretation of hepatitis B serologic test results. Available from the CDC website.</div><div id=\"graphicVersion\">Graphic 60827 Version 5.0</div></div></div>"},"60828":{"type":"graphic_picture","displayName":"Indeterminate leprosy","title":"Indeterminate leprosy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Indeterminate leprosy</div><div class=\"cntnt\"><img style=\"width:302px; height:357px;\" src=\"images/ID/60828_Indeterminate_leprosy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Indeterminate disease with the typical hypopigmented to slightly erythematous macule (white arrow), which has diminished sensation.</div><div class=\"graphic_reference\">Reproduced with permission from McDougall AC, Yuasa Y. A New Atlas of leprosy, Sasakawa Memorial Health Foundation, Tokyo, 2000, and Guinto RS, Abalos RM, Cellopna RV, Fajardo TT. An Atlas of Leprosy, Sasakawa Memorial Health Foundation, Tokyo, 1983.</div><div id=\"graphicVersion\">Graphic 60828 Version 3.0</div></div></div>"},"60830":{"type":"graphic_figure","displayName":"Transcellular cation exchange","title":"Cation shifts in hypokalemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cation shifts in hypokalemia</div><div class=\"cntnt\"><img style=\"width:312px; height:226px;\" src=\"images/NEPH/60830_Transcellular_cation_exchan.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reciprocal cation shifts of K<SUP>+</SUP>, H<SUP>+</SUP>, and Na<SUP>+</SUP> between the cells, including renal tubular cells, and the extracellular fluid. In the presence of hypokalemia, K<SUP>+</SUP> moves out of the cells down a concentration gradient. Since the cell anions (primarily, proteins and organic phosphates) are unable to cross the cell membrane, electroneutrality is primarily maintained by the entry of Na<SUP>+</SUP> and H<SUP>+</SUP> into the cell. The increase in cell H<SUP>+</SUP> concentration may be responsible for the increased H<SUP>+</SUP> secretion and HCO<SUB>3</SUB><SUP>–</SUP> reabsorption seen with hypokalemia. On the other hand, hyperkalemia causes H<SUP>+</SUP> and Na<SUP>+</SUP> to leave the cells, resulting in a fall in H<SUP>+</SUP> secretion and HCO<SUB>3</SUB><SUP>–</SUP> reabsorption.</div><div id=\"graphicVersion\">Graphic 60830 Version 3.0</div></div></div>"},"60831":{"type":"graphic_figure","displayName":"Headache and vomiting in stroke","title":"Headache and vomiting in stroke subtypes","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Headache and vomiting in stroke subtypes</div><div class=\"cntnt\"><img style=\"width:452px; height:258px;\" src=\"images/NEURO/60831_Headache_and_vomiting_in_st.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The frequency of sentinel headache, onset headache, and vomiting in three subtypes of stroke: subarachnoid hemorrhage (SAH), intraparenchymal (intracerebral) hemorrhage (IPH), and ischemic stroke (IS). Onset headache was present in virtually all patients with SAH and about one-half of those with IPH; all of these symptoms were infrequent in patients with IS.</div><div class=\"graphic_reference\">Data from: Gorelick PB, Hier DB, Caplan LR, et al, Neurology 1986; 36:1445.</div><div id=\"graphicVersion\">Graphic 60831 Version 3.0</div></div></div>"},"60832":{"type":"graphic_table","displayName":"WHO MEC for reproductive tract infections and disorders","title":"World Health Organization medical eligibility for contraceptive use: Reproductive tract infections and disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization medical eligibility for contraceptive use: Reproductive tract infections and disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">COC</td> <td class=\"subtitle1\">CIC</td> <td class=\"subtitle1\">P/R</td> <td class=\"subtitle1\">POP</td> <td class=\"subtitle1\"> <p>DMPA</p> <p>NET-EN</p> </td> <td class=\"subtitle1\"> <p>LNG/ETG</p> <p>Implants</p> </td> <td class=\"subtitle1\">Cu-IUD</td> <td class=\"subtitle1\">LNG-IUD</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Vaginal bleeding patterns</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Irregular pattern without heavy bleeding</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">2</td> <td rowspan=\"2\">2</td> <td rowspan=\"2\">2</td> <td rowspan=\"2\">1</td> <td>Initiation: 1</td> </tr> <tr> <td>Continuation: 1</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Heavy or prolonged bleeding (includes regular and irregular patterns)</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">2</td> <td rowspan=\"2\">2</td> <td rowspan=\"2\">2</td> <td rowspan=\"2\">2</td> <td>Initiation: 1</td> </tr> <tr> <td>Continuation: 2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Unexplained vaginal bleeding (suspicious for serious condition)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Before evaluation</td> <td rowspan=\"2\">2</td> <td rowspan=\"2\">2</td> <td rowspan=\"2\">2</td> <td rowspan=\"2\">2</td> <td rowspan=\"2\">3</td> <td rowspan=\"2\">3</td> <td>Initiation: 4</td> <td>Initiation: 4</td> </tr> <tr> <td>Continuation: 2</td> <td>Continuation: 2</td> </tr> <tr> <td class=\"subtitle2_left\">Endometriosis</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>2</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\">Benign ovarian tumors (including cysts)</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\">Severe dysmenorrhoea</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>2</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Gestational trophoblastic disease</td> </tr> <tr> <td class=\"indent1\">Decreasing or undetectable human chorionic gonadotropin levels</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>3</td> <td>3</td> </tr> <tr> <td class=\"indent1\">Persistently elevated human chorionic gonadotropin levels or malignant disease</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>4</td> <td>4</td> </tr> <tr> <td class=\"subtitle2_left\">Cervical ectropion</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\">Cervical intraepithelial neoplasia (CIN)</td> <td>2</td> <td>2</td> <td>2</td> <td>1</td> <td>2</td> <td>2</td> <td>1</td> <td>2</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">Cervical cancer (awaiting treatment)</td> <td rowspan=\"2\">2</td> <td rowspan=\"2\">2</td> <td rowspan=\"2\">2</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">2</td> <td rowspan=\"2\">2</td> <td>Initiation: 4</td> <td>Initiation: 4</td> </tr> <tr> <td>Continuation: 2</td> <td>Continuation: 2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Breast disease</td> </tr> <tr> <td class=\"indent1\">Undiagnosed mass</td> <td>2</td> <td>2</td> <td>2</td> <td>2</td> <td>2</td> <td>2</td> <td>1</td> <td>2</td> </tr> <tr> <td class=\"indent1\">Benign breast disease</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"indent1\">Family history of cancer</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"indent1\" colspan=\"9\">Cancer</td> </tr> <tr> <td class=\"indent2\">Current</td> <td>4</td> <td>4</td> <td>4</td> <td>4</td> <td>4</td> <td>4</td> <td>1</td> <td>4</td> </tr> <tr> <td class=\"indent2\">Past and no evidence of current disease for&nbsp;five years</td> <td>3</td> <td>3</td> <td>3</td> <td>3</td> <td>3</td> <td>3</td> <td>1</td> <td>3</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">Endometrial cancer</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td>Initiation: 4</td> <td>Initiation: 4</td> </tr> <tr> <td>Continuation: 2</td> <td>Continuation: 2</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"2\">Ovarian cancer</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td>Initiation: 3</td> <td>Initiation: 3</td> </tr> <tr> <td>Continuation: 2</td> <td>Continuation: 2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Uterine fibroids</td> </tr> <tr> <td class=\"indent1\">Without distortion of the uterine cavity</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> </tr> <tr> <td class=\"indent1\">With distortion of the uterine cavity</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>4</td> <td>4</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Anatomical abnormalities</td> </tr> <tr> <td class=\"indent1\">That distort the uterine cavity</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>4</td> <td>4</td> </tr> <tr> <td class=\"indent1\">That do not distort the uterine cavity</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>2</td> <td>2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">Pelvic inflammatory disease (PID)</td> </tr> <tr> <td class=\"indent1\" colspan=\"9\">Past PID (assuming no current risk factors of STIs)</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\">With subsequent pregnancy</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td>Initiation: 1</td> <td>Initiation: 1</td> </tr> <tr> <td>Continuation: 1</td> <td>Continuation: 1</td> </tr> <tr> <td class=\"indent2\" rowspan=\"2\">Without subsequent pregnancy</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td>Initiation: 2</td> <td>Initiation: 2</td> </tr> <tr> <td>Continuation: 2</td> <td>Continuation: 2</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">PID - current or within last three months</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td>Initiation: 4</td> <td>Initiation: 4</td> </tr> <tr> <td>Continuation: 2</td> <td>Continuation: 2</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">STIs (sexually transmitted infections)</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Current purulent cervicitis or chlamydial infection or gonorrhoea</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td>Initiation: 4</td> <td>Initiation: 4</td> </tr> <tr> <td>Continuation: 2</td> <td>Continuation: 2</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Other STIs (excluding HIV and hepatitis)</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td>Initiation: 2</td> <td>Initiation: 2</td> </tr> <tr> <td>Continuation: 2</td> <td>Continuation: 2</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Vaginitis (including trichomonas vaginalis and bacterial vaginosis)</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td>Initiation: 2</td> <td>Initiation: 2</td> </tr> <tr> <td>Continuation: 2</td> <td>Continuation: 2</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Increased risk of STIs</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td rowspan=\"2\">1</td> <td>Initiation: 2/3</td> <td>Initiation: 2/3</td> </tr> <tr> <td>Continuation: 2</td> <td>Continuation: 2</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">1: A condition for which there is no restriction for the use of the contraceptive method.<BR>2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks.<BR>3: A condition where the theoretical or proven risks usually outweigh the advantages of using the method.<BR>4: A condition which represents an unacceptable health risk if the contraceptive method is used.</div><div class=\"graphic_footnotes\">COC: low-dose combined oral contraceptive; CIC: combined injectable contraceptives; P: combined patch; R: combined vaginal ring; POP: progestogen-only pill; DMPA: depot medroxyprogesterone acetate; NET-EN: norethisterone enantate; LNG: levonorgestrel; ETG: etonogestrel; ECP: emergency contraceptive pill; Cu-IUD: copper intrauterine device; LNG-IUD: levonorgestrel-releasing IUDs; E-IUD: copper-IUD for emergency contraception; BARR: barrier methods; FAB: fertility awareness-based methods; LAM: lactational amenorrhoea method; CI: coitus interruptus; STER: female and male sterilization.</div><div class=\"graphic_reference\">Reproduced with permission from: http://www.who.int/reproductive-health/publications/mec/summary.html. Copyright © 2006 World Health Organization. Updated and revised 2009.</div><div id=\"graphicVersion\">Graphic 60832 Version 5.0</div></div></div>"},"60833":{"type":"graphic_picture","displayName":"Acute paronychia toe","title":"Acute paronychia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute paronychia</div><div class=\"cntnt\"><img style=\"width:396px; height:266px;\" src=\"images/DERM/60833_Acute_paronychia_toe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute paronychia. Note erythema and edema of the proximal nail fold. The absence of nail dystrophy is indicative of the acute nature of the disorder.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60833 Version 1.0</div></div></div>"},"60836":{"type":"graphic_diagnosticimage","displayName":"Neuroendocrine tumor of the ileum UGI","title":"Neuroendocrine tumor of the ileum, as seen on an upper gastrointestinal (UGI) study with small bowel follow through","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neuroendocrine tumor of the ileum, as seen on an upper&nbsp;gastrointestinal&nbsp;(UGI) study with small bowel follow through</div><div class=\"cntnt\"><img style=\"width:219px; height:360px;\" src=\"images/GAST/60836_CarcinoidileumUGI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small bowel follow through examination shows a polypoid eccentric mass arising from the wall of the terminal ileum (arrow).</div><div class=\"graphic_reference\">Courtesy of Norman Joffe, MD.</div><div id=\"graphicVersion\">Graphic 60836 Version 3.0</div></div></div>"},"60838":{"type":"graphic_picture","displayName":"Aspiration of knee effusion","title":"Aspiration of a knee effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aspiration of a knee effusion</div><div class=\"cntnt\"><img style=\"width:342px; height:297px;\" src=\"images/PC/60838_Aspiration_of_knee_effusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lateral approach is preferred since the synovial cavity distends laterally in 75 percent of patients. Landmarks include the lateral patella, superior patellar pole, and the iliotibial band.&nbsp;A 1.5 inch (4 cm)&nbsp;22-gauge&nbsp;needle is inserted at an angle of approximately 70 degrees, halfway between the undersurface of the patella and the middle of the iliotibial band. One mL of local anesthetic is placed in the lateral retinaculum and intraarticularly. The needle is advanced to a depth of&nbsp;1.5 to 3&nbsp;inches (4 to 8 cm) and joint fluid is aspirated.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 60838 Version 2.0</div></div></div>"},"60840":{"type":"graphic_figure","displayName":"Internal herniations","title":"Internal hernias","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Internal hernias</div><div class=\"cntnt\"><img style=\"width:413px; height:526px;\" src=\"images/SURG/60840_Internal_herniations.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Internal hernias have been described in up to 5 percent of patients undergoing laparoscopic bariatric surgery. Hernias through the transverse mesocolon are the most common and require operative treatment. The arrows show the common areas of herniation. To reduce the incidence of internal hernias, all areas of potential herniation should be closed.</div><div class=\"graphic_reference\">Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury, Connecticut 2010. Copyright &#169; 2010 Cine-Med.</div><div id=\"graphicVersion\">Graphic 60840 Version 4.0</div></div></div>"},"60841":{"type":"graphic_algorithm","displayName":"CDC algorithm for screening for GBS in preterm PROM ","title":"CDC algorithm for screening for GBS in PROM before 37 weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CDC algorithm for screening for GBS in PROM before 37 weeks of gestation</div><div class=\"cntnt\"><img style=\"width:423px; height:390px;\" src=\"images/OBGYN/60841_Algo_screen_GBS_PROM_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CDC: Centers for Disease Control and Prevention; GBS: group B streptococcus; PROM: premature rupture of membranes.<br />* If patient has undergone vaginal-rectal GBS culture within the preceding 5 weeks, the results of that culture should guide management. GBS-colonized women should receive intrapartum antibiotic prophylaxis. No antibiotics are indicated for GBS prophylaxis if a vaginal-rectal screen within 5 weeks was negative.<br /><FONT class=bullet>•</FONT> Antibiotics given for latency in the setting of pPROM that include ampicillin 2 g intravenously (IV) once, followed by 1 g IV every 6 hours for at least 48 hours are adequate for GBS prophylaxis. If other regimens are used, GBS prophylaxis should be initiated in addition.<br />Δ GBS prophylaxis should be discontinued at 48 hours for women with pPROM who are not in labor. If results from a GBS screen performed on admission become available during the 48-hour period and are negative, GBS prophylaxis should be discontinued at that time.<br /><FONT class=lozenge>◊</FONT> Unless subsequent GBS culture prior to delivery is positive.<br />§ A negative GBS screen is considered valid for 5 weeks. If a patient with pPROM is entering labor and had a negative GBS screen &gt;5 weeks prior, she should be rescreened and managed according to this algorithm at that time.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Prevention of Perinatal Group B Streptococcal Disease. Revised Guidelines from CDC, 2010. MMWR 2010; 59:No. RR-10.</div><div id=\"graphicVersion\">Graphic 60841 Version 7.0</div></div></div>"},"60843":{"type":"graphic_table","displayName":"Cardioaortic sources embolism","title":"Cardioaortic sources of cerebral embolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cardioaortic sources of cerebral embolism</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Sources with high primary risk for ischemic stroke</td> </tr> <tr> <td class=\"indent1\">Atrial fibrillation</td> </tr> <tr> <td class=\"indent1\">Paroxysmal atrial fibrillation </td> </tr> <tr> <td class=\"indent1\">Left atrial thrombus</td> </tr> <tr> <td class=\"indent1\">Left ventricular thrombus</td> </tr> <tr> <td class=\"indent1\">Sick sinus syndrome</td> </tr> <tr> <td class=\"indent1\">Atrial flutter</td> </tr> <tr> <td class=\"indent1\">Recent myocardial infarction (within one month prior to stroke)</td> </tr> <tr> <td class=\"indent1\">Mitral stenosis or rheumatic valve disease</td> </tr> <tr> <td class=\"indent1\">Bioprosthetic and mechanical heart valves</td> </tr> <tr> <td class=\"indent1\">Chronic myocardial infarction together with low ejection fraction (&#60;28 percent)</td> </tr> <tr> <td class=\"indent1\">Dilated cardiomyopathy (prior established diagnosis or left ventricular dilatation with an ejection fraction of &#60;40 percent or fractional shortening of &#60;25 percent)</td> </tr> <tr> <td class=\"indent1\">Nonbacterial thrombotic endocarditis</td> </tr> <tr> <td class=\"indent1\">Infective endocarditis</td> </tr> <tr> <td class=\"indent1\">Papillary fibroelastoma</td> </tr> <tr> <td class=\"indent1\">Left atrial myxoma</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Sources with low or uncertain primary risk for ischemic stroke</td> </tr> <tr> <td class=\"subtitle2_single\">Cardiac sources of embolism</td> </tr> <tr> <td class=\"indent1\">Mitral annular calcification</td> </tr> <tr> <td class=\"indent1\">Patent foramen ovale</td> </tr> <tr> <td class=\"indent1\">Atrial septal aneurysm</td> </tr> <tr> <td class=\"indent1\">Atrial septal aneurysm and patent foramen ovale</td> </tr> <tr> <td class=\"indent1\">Left ventricular aneurysm without thrombus</td> </tr> <tr> <td class=\"indent1\">Left atrial spontaneous echo contrast (\"smoke\")</td> </tr> <tr> <td class=\"indent1\">Congestive heart failure with ejection fraction &#60;30 percent</td> </tr> <tr> <td class=\"indent1\">Apical akinesia</td> </tr> <tr> <td class=\"indent1\">Wall motion abnormalities (hypokinesia, akinesia, dyskinesia) other than apical akinesia</td> </tr> <tr> <td class=\"indent1\">Hypertrophic cardiomyopathy</td> </tr> <tr> <td class=\"indent1\">Left ventricular hypertrophy</td> </tr> <tr> <td class=\"indent1\">Left ventricular hypertrabeculation/non-compaction</td> </tr> <tr> <td class=\"subtitle2_single\">Aortic sources of embolism</td> </tr> <tr> <td class=\"indent1\">Complex atheroma in the ascending aorta or proximal arch (protruding with &#62;4 mm thickness, or mobile debris, or plaque ulceration)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The high and low risk cardioaortic sources in this table are separated using an arbitrary 2 percent annual or one-time primary stroke risk threshold.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Ay H, Benner T, Arsava EM, et al. A computerized algorithm for etiologic classification of ischemic stroke: the Causative Classification of Stroke System. Stroke 2007; 38:2979. </li>&#xD;&#xA;    <li>Ay H, Furie KL, Singhal A, et al. An evidence-based causative classification system for acute ischemic stroke. Ann Neurol 2005; 58:688. </li>&#xD;&#xA;    <li>Arsava EM, Ballabio E, Benner T, et al. The Causative Classification of Stroke system: an international reliability and optimization study. Neurology 2010; 75:1277. </li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced and modified with permission from: Ay H, Furie KL, Singhal A, et al. An evidence-based causative classification system for acute ischemic stroke. Ann Neurol 2005; 58:688. Copyright &copy; 2005 American Neurological Association.</div><div id=\"graphicVersion\">Graphic 60843 Version 10.0</div></div></div>"},"60844":{"type":"graphic_diagnosticimage","displayName":"FLAIR MRI CADASIL","title":"Brain MRI in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Brain MRI in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)</div><div class=\"cntnt\"><img style=\"width:504px; height:308px;\" src=\"images/NEURO/60844_FLAIR_MRI_CADASIL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial images of the brain with fluid-attenuated inversion-recovery (FLAIR) MRI in representative patients with biopsy-proved CADASIL show a typical pattern of brain lesions. Note the symmetry of the lesions and their extension into the superficial white matter (arrows).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reprinted with permission from: Auer, D, Putz, B, Gossl, C, et al. Differential Lesion Patterns in CADASIL and Sporadic Subcortical Arteriosclerotic Encephalopathy: MR Imaging Study with Statistical Parametric Group Comparison. Radiology 2001; 218:443. Copyright &copy;2001 Radiological Society of North America.</div><div id=\"graphicVersion\">Graphic 60844 Version 3.0</div></div></div>"},"60845":{"type":"graphic_table","displayName":"Misoprostol-only protocol","title":"Misoprostol-only protocol for medical termination of pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Misoprostol-only protocol for medical termination of pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"3\">Contraindications</td> </tr> <tr> <td colspan=\"3\">Suspected or confirmed ectopic pregnancy</td> </tr> <tr> <td colspan=\"3\">Gestational trophoblastic disease (GTD)</td> </tr> <tr> <td colspan=\"3\">High risk of uterine rupture (more than one prior hysterotomy, a prior classical or T-shaped uterine incision, or extensive transfundal uterine surgery [eg, myomectomy])</td> </tr> <tr> <td colspan=\"3\">Pregnancy - intrauterine device (IUD; must be removed before misoprostol is administered)</td> </tr> <tr> <td colspan=\"3\">Allergy to prostaglandins</td> </tr> <tr> <td colspan=\"3\">Other contraindications to medical or surgical uterine evacuations (eg, hemodynamically unstable, coagulopathy)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"3\">Relative contraindications</td> </tr> <tr> <td colspan=\"3\">Moderate risk of uterine rupture (one prior low transverse or low vertical hysterotomy, multigravidity, or uterine anomaly)</td> </tr> <tr> <td colspan=\"3\">Breastfeeding (women should be counseled to pump and discard all milk produced within 5 hours after each dose)</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"3\">Pretreatment evaluation and preparation</td> </tr> <tr> <td colspan=\"3\">Medical history and physical examination</td> </tr> <tr> <td colspan=\"3\">Confirmation of pregnancy, gestational age, pregnancy location, and absence of GTD (via history and physical with serum or urine human chorionic gonadotropin testing and/or transvaginal ultrasound)</td> </tr> <tr> <td colspan=\"3\">Complete blood count</td> </tr> <tr> <td colspan=\"3\">Blood group and Rh(D) typing; give anti Rh(D) immune globulin 300 mcg IM, if indicated</td> </tr> <tr> <td colspan=\"3\">Remove IUD, if present</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"3\">Treatment effects and patient counseling</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Bleeding - usually commences within 24 hours, lasting 7 to 10 days. Women should be counseled about bleeding and to call or return to the clinic for the following:</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">&#8226; 48 hours have passed and bleeding has been less than a normal menstrual period</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">&#8226; Soaks more than 2 pads per hour for 2 consecutive hours</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">&#8226; Bleeding persists for more than 2 weeks</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">&#8226; Heavy bleeding recurs 2 or more weeks after treatment</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\">&#8226; Feels dizzy or lightheaded</td> </tr> <tr> <td colspan=\"3\">Cramping and pain - symptoms are often more intense than a menstrual period. Non-steroidal inflammatory medications or other analgesia can be used without decreasing treatment effectiveness. Women should be instructed to call if pain greatly exceeds menstrual cramps and/or persists after products of conception have been expelled or &#8805;24 hours after last misoprostol dose. Women with severe or persistent pain should be evaluated for uterine rupture, particularly if risk factors are present.</td> </tr> <tr> <td colspan=\"3\">Chills and fever - common, but generally transient. Women should be instructed to call if a temperature of &#8805;100.4&#176;F (&#8805;38&#176;C) persists for &#8805;24 hours after taking misoprostol.</td> </tr> <tr> <td colspan=\"3\">Diarrhea, nausea and vomiting - misoprostol may exacerbate pregnancy-related nausea or vomiting and may cause diarrhea; symptoms are generally transient. Anti-emetic or -diarrheal medications can be given. Women should be instructed to call if symptoms persist for 48 hours or more after last dose.</td> </tr> <tr> <td class=\"subtitle1\">Gestational age, weeks of amenorrhea</td> <td class=\"subtitle1\">Treatment location</td> <td class=\"subtitle1\">Misoprostol regimen</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Clinical regimen</td> </tr> <tr> <td class=\"indent1\">&#8804;9</td> <td>Home or clinic</td> <td> <p>800 mcg PV every 3 to 12 hours (2 doses, a 3rd dose may be given if complete abortion has not occurred 48 hours after 2nd dose) <strong>OR</strong></p> <p>800 mcg SL every 3 hours (max 3 doses) <strong>OR</strong></p> <p><span style=\"font-family: verdana; font-size: 13px;\">800 mcg buccally every 3 to 2 hours</span></p> </td> </tr> <tr> <td class=\"indent1\">10 to 12</td> <td>Clinic advised</td> <td>800 mcg PV every 12 hours (max 3 doses)</td> </tr> <tr> <td class=\"indent1\">13 to 22</td> <td>Clinic (immediate access to emergency surgery and blood transfusion are required)</td> <td> <p>400 mcg PV or SL every 3 to 6 hours (max 5 doses) <strong>OR</strong></p> <p>600 mcg PV every 12 hours</p> <p>Either protocol may be repeated after 24 hours if induction is not complete</p> </td> </tr> <tr> <td class=\"indent1\">23 to 26</td> <td>Clinic (immediate access to emergency surgery and blood transfusion are required)</td> <td>No established regimen; it may be prudent to use a lower dose than used at 13 to 22 weeks, due to increased uterine sensitivity to prostaglandins with increasing gestational age</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PV: per vaginal route; SL: sublingual route; max: maximum.</div><div id=\"graphicVersion\">Graphic 60845 Version 4.0</div></div></div>"},"60846":{"type":"graphic_table","displayName":"Antipsychotics for management of acute agitation","title":"Antipsychotics for initial management of the acutely agitated adult patient with psychosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antipsychotics for initial management of the acutely agitated adult patient with psychosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"6\" width=\"10%\"></colgroup><colgroup width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Formulation</td> <td class=\"subtitle1\">Route</td> <td class=\"subtitle1\">Initial dose (mg)</td> <td class=\"subtitle1\">Frequency (hours)</td> <td class=\"subtitle1\">Maximum initial dose per 24 hours (mg)</td> <td class=\"subtitle1\">Time to peak plasma concentration (hours)</td> <td class=\"subtitle1\">Notes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">First-generation agents</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Haloperidol</td> <td>Short-acting lactate injection</td> <td>IM, IV</td> <td>2 to 5</td> <td>0.5 to 2*</td> <td>20<sup>&#182;</sup></td> <td>0.5 to 1</td> <td class=\"divider_bottom\" rowspan=\"2\">Sedation, hypotension and prolongation of QTc interval more pronounced with injection. &#8593; EPS risk.</td> </tr> <tr class=\"divider_bottom\"> <td>Oral solution</td> <td>PO</td> <td>0.5 to 5</td> <td>6</td> <td>30</td> <td>2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Droperidol</td> <td>Injection (short-acting)</td> <td>IM, IV</td> <td>2.5 to 5</td> <td>2 to 4*</td> <td>40</td> <td>0.5</td> <td>Rapid onset of 3 to 10 minutes advantageous in severely agitated violent patients. Dose related QTc prolongation and risk of cardiac arrhythmias. &#8593; EPS risk.</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Fluphenazine</td> <td>Short-acting hydrochloride injection</td> <td>IM</td> <td>1.25</td> <td>6</td> <td>10</td> <td>ND</td> <td class=\"divider_bottom\" rowspan=\"2\">1 mg short-acting IM injection is equivalent to approximately 2.5 mg oral. &#8593; EPS risk.</td> </tr> <tr class=\"divider_bottom\"> <td>Oral solution</td> <td>PO</td> <td>1 to 2.5</td> <td>6</td> <td>10</td> <td>3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Chlorpromazine</td> <td>Injection (short-acting)</td> <td>IM, IV</td> <td>25</td> <td>1 to 4</td> <td>200</td> <td>0.5</td> <td>Hypotension, sedation and injection site pain are limiting side effects. Not a first-line agent.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Second-generation agents</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Aripiprazole</td> <td>Disintegrating tablet, oral solution</td> <td>PO</td> <td>10 to 15</td> <td>2</td> <td>30</td> <td>3 to 5</td> <td>Less sedating. Minimal prolongation of QTc interval or orthostatic hypotension.</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Olanzapine</td> <td>Injection (short-acting)</td> <td>IM</td> <td>5 to 10</td> <td>2 to 4</td> <td>30</td> <td>0.25 to 0.75</td> <td class=\"divider_bottom\" rowspan=\"2\">Decreased clearance in female and/or non-smoking patients.</td> </tr> <tr class=\"divider_bottom\"> <td>Disintegrating tablet</td> <td>PO</td> <td>5 to 10</td> <td>0.5 to 2</td> <td>20</td> <td>5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Risperidone</td> <td>Disintegrating tablet, oral solution</td> <td>PO</td> <td>1 to 2</td> <td>0.5 to 2</td> <td>4</td> <td>1.5</td> <td>Decreased clearance in renal and/or hepatic impairment.</td> </tr> <tr> <td class=\"indent1\">Ziprasidone</td> <td>Short-acting mesylate injection</td> <td>IM</td> <td>10 to 20</td> <td>2 to 4</td> <td>40</td> <td>0.5 to 1</td> <td>Dose related QTc prolongation and risk of cardiac arrhythmias.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>The approach to pharmacologic treatment of the acutely agitated patient, including specific medication choices and combinations depending upon presentation (eg, toxic ingestion, withdrawal syndrome, or known psychiatric history) is provided in the accompanying topic reviews and in an algorithm.</LI>&#xD;&#xA;<LI>Dose reduction by one-half is needed for older adults, debilitated patients, and if used in combination with other sedation. Refer to accompanying text for discussion of electrocardiograph and other monitoring for agents known to cause prolongation of the QTc interval.</LI></UL></div><div class=\"graphic_footnotes\">IM: intramuscular; IV: intravenous; EPS: extrapyramidal symptoms; PO: per os (by mouth); ND: no data.<br />* It may be necessary to repeat initial dose or fraction thereof after 15 to 20 minutes in patients with severe agitation until desired level of sedation attained.<br />¶ Selected patients without schizophrenia may need a higher cumulative haloperidol dose (eg, up to 30 mg) during the first 24 hours of treatment to achieve and maintain adequate sedation.</div><div id=\"graphicVersion\">Graphic 60846 Version 12.0</div></div></div>"},"60848":{"type":"graphic_diagnosticimage","displayName":"Lymphomatoid gran CT II","title":"48-year-old woman who presented with hypercalcemia and multiple pulmonary nodules","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">48-year-old woman who presented with hypercalcemia and multiple pulmonary nodules</div><div class=\"cntnt\"><img style=\"width:506px; height:199px;\" src=\"images/PULM/60848_Lymphomatoid_gran_CT_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) CT image reveals multiple large conglomerated masses with air bronchogram. Numerous small nodules have aggregated to form well-defined irregularly marginated nodules of variable size.<br />(B) CT image at same level as A, obtained after patient underwent treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone for six months, reveals nodules and masses are smaller and have almost disappeared. However, coarse linear opacities along bronchovascular bundle have become more abundant.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">From: Lee JS, Tuder R, Lynch DA. Lymphomatoid granulomatosis: Radiologic features and pathologic correlations. Am J Roentgenol 2000; 175:1335. Reprinted with permission from the American Journal of Roentgenology.</div><div id=\"graphicVersion\">Graphic 60848 Version 11.0</div></div></div>"},"60849":{"type":"graphic_picture","displayName":"Scabies axilla","title":"Scabies axilla","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Scabies axilla</div><div class=\"cntnt\"><img style=\"width:380px; height:506px;\" src=\"images/DERM/60849_Scabies_axilla.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules are present in the axilla of this patient with scabies.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60849 Version 10.0</div></div></div>"},"60854":{"type":"graphic_picture","displayName":"Pathologic skin picking","title":"Acne excoriée","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acne excoriée</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/60854_Pathologic_skin_pick.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Excoriated papules with erosions and multiple hyperpigmented macules in a 25-year-old young woman who had developed acne papules a few years before. Chronic picking of papules resulted in erosions, scarring, and postinflammatory hyperpigmentation.</div><div class=\"graphic_reference\">Copyright © Shahbaz A Janjua, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 60854 Version 7.0</div></div></div>"},"60855":{"type":"graphic_figure","displayName":"Stress test PI","title":"Person having a stress test","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Person having a stress test</div><div class=\"cntnt\"><img style=\"width:505px; height:568px;\" src=\"images/PI/60855_Stress_test_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows a person having a stress test. During a stress test, you either exercise (such as on a treadmill, shown here) or take medicine to make your heart pump faster. A test called an ECG (also called an electrocardiogram or EKG) is done during the stress test. For an ECG, patches (called \"electrodes\")&nbsp;are stuck to&nbsp;your chest. Wires run from the patches to the ECG machine to measure the electrical activity in your heart. Your blood pressure&nbsp;is also&nbsp;checked&nbsp;during a stress test.</div><div class=\"graphic_reference\">Modified from: NHLBI Diseases and Conditions&nbsp;Index.&nbsp;Stress testing: What to expect during stress testing. National Heart Lung and Blood Institute. Available at: <A href=\"http://www.nhlbi.nih.gov/health/dci/Diseases/stress/stress_during.html\">http://www.nhlbi.nih.gov/health/dci/Diseases/stress/stress_during.html</A>.</div><div id=\"graphicVersion\">Graphic 60855 Version 4.0</div></div></div>"},"60856":{"type":"graphic_diagnosticimage","displayName":"Spine anatomy MRI","title":"Spine anatomy MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Spine anatomy MRI</div><div class=\"cntnt\"><img style=\"width:338px; height:640px;\" src=\"images/EM/60856_SpineanatomyMRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This sagittal MRI study shows the primary contents of the vertebral canal. The medullary cone (L. conus medullaris) is the cone-shaped inferior end of the spinal cord, which typically ends at the L1–L2 level in adults. The dura mater, the external overing of the spinal cord (gray), is separated from the spinal cord by a fluid-filled space (black) and from the wall of the vertebral canal by fat (white) and thin-walled veins (not visible here).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 60856 Version 8.0</div></div></div>"},"60859":{"type":"graphic_figure","displayName":"Central cord syndrome","title":"Location of lesion in central cord syndrome","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Location of lesion in central cord syndrome</div><div class=\"cntnt\"><img style=\"width:542px; height:353px;\" src=\"images/NEURO/60859_Central_cord_syndrome.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 60859 Version 3.0</div></div></div>"},"60860":{"type":"graphic_algorithm","displayName":"Categorize chronic diarrhea","title":"Algorithm for the evaluation and classification of chronic diarrhea in children","html":"<div class=\"graphic\"><div style=\"width: 999px\" class=\"figure\"><div class=\"ttl\">Algorithm for the evaluation and classification of chronic diarrhea in children</div><div class=\"cntnt\"><img style=\"width:979px; height:801px;\" src=\"images/PEDS/60860_Categorizechronicdiarrhea.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Adapted with permission from: Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116:1464. Copyright &copy; 1999 Elsevier.</div><div id=\"graphicVersion\">Graphic 60860 Version 3.0</div></div></div>"},"60861":{"type":"graphic_figure","displayName":"Child protection process","title":"Overview of the child protection process","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Overview of the child protection process</div><div class=\"cntnt\"><img style=\"width:543px; height:695px;\" src=\"images/EM/60861_Child_protection_process.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CPS: child protective services.</div><div class=\"graphic_reference\">Reproduced with permission from: Goldman, J, Salus, MK, Wolcott, D, Kennedy, KY. A Coordinated Response to Child Abuse and Neglect: The Foundation for Practice. Office on Child Abuse and Neglect (DHHS), Washington, DC 2003.</div><div id=\"graphicVersion\">Graphic 60861 Version 2.0</div></div></div>"},"60862":{"type":"graphic_figure","displayName":"Lateral recumbent position for lumbar puncture","title":"Lateral recumbant position","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lateral recumbant position</div><div class=\"cntnt\"><img style=\"width:410px; height:324px;\" src=\"images/PEDS/60862_Lateral_recumbent_position.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The child is positioned near the edge of the examining table. The assistant places one arm around the posterior aspect of the child's neck and the other arm under the child's knees to hold the child in optimal position. The child's hips and shoulders should be kept perpendicular to the table in order to maintain spinal alignment without rotation. The assistant can maintain adequate restraint by holding onto his or her own wrists.</div><div class=\"graphic_reference\">Adapted from Cronan, KM, Wiley, JF. Lumbar puncture. In: Henretig, FM, King, C, (Eds), Textbook of Pediatric Emergency Procedures, Williams and Wilkins, Baltimore, 1997.</div><div id=\"graphicVersion\">Graphic 60862 Version 2.0</div></div></div>"},"60863":{"type":"graphic_table","displayName":"Needle length IM shots","title":"Suggested needle length for intramuscular injection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested needle length for intramuscular injection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age group, sex, weight</td> <td class=\"subtitle1\">Needle length, inches</td> <td class=\"subtitle1\">Needle length, millimeters</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Anterolateral thigh muscle injections</td> </tr> <tr> <td class=\"indent1\">0 to 28 days (term or preterm)</td> <td>5/8*</td> <td>16*</td> </tr> <tr> <td class=\"indent1\">1 through 11 months</td> <td>1</td> <td>25</td> </tr> <tr> <td class=\"indent1\">1 through 10 years</td> <td>1 to 1 1/4</td> <td>25 to 32</td> </tr> <tr> <td class=\"indent1\">11 through 18 years</td> <td>1 to 1 1/2</td> <td>25 to 38</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Deltoid muscle injections</td> </tr> <tr> <td class=\"subtitle3_left\">1 through 18 years</td> <td>5/8* to 1</td> <td>16* to 25</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"3\">&#8805;19 years</td> </tr> <tr> <td class=\"indent2\">&#60;70 kg (152 lbs) (male or female)</td> <td>1<sup>&#182;</sup></td> <td>25<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"3\">Female</td> </tr> <tr> <td class=\"sublist3\">70&nbsp;to 90 kg (152 to 200 lbs)</td> <td class=\"sublist_other\">1 to 1 1/2</td> <td class=\"sublist_other\">25 to 38</td> </tr> <tr> <td class=\"sublist3\">&#62;90 kg (200 lbs)</td> <td class=\"sublist_other\">1 1/2</td> <td class=\"sublist_other\">38</td> </tr> <tr> <td class=\"sublist3_start\" colspan=\"3\">Male</td> </tr> <tr> <td class=\"sublist3\">70&nbsp;to 118 kg (152 to 260 lbs)</td> <td class=\"sublist_other\">1 to 1 1/2</td> <td class=\"sublist_other\">25 to 38</td> </tr> <tr> <td class=\"sublist3\">&#62;118 kg (260 lbs)</td> <td class=\"sublist_other\">1 1/2</td> <td class=\"sublist_other\">38</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* If skin is stretched tightly and&nbsp;subcutaneous tissues are not bunched.<br />¶ Some experts recommend a 5/8-inch (16-millimeter) needle for men and women who weigh &lt;60 kg (130 lbs).</div><div class=\"graphic_reference\">Data from: Kroger AT, Duchin J, Vázquez M. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Available at:&nbsp;<A spellcheck=true href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html\" target=_blank>https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html</A> (Accessed on April 27, 2017). </div><div id=\"graphicVersion\">Graphic 60863 Version 8.0</div></div></div>"},"60864":{"type":"graphic_figure","displayName":"Placement of intrauterine balloon catheter","title":"Placement of an intrauterine balloon catheter","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Placement of an intrauterine balloon catheter</div><div class=\"cntnt\"><img style=\"width:487px; height:401px;\" src=\"images/OBGYN/60864_Intrauterine-balloon.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 60864 Version 2.0</div></div></div>"},"60865":{"type":"graphic_table","displayName":"Sex reassignment surgery eligibility and readiness criteria","title":"Sex reassignment surgery eligibility and readiness criteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sex reassignment surgery eligibility and readiness criteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Individuals treated with cross-sex hormones are considered eligible for sex reassignment surgery if they:</td> </tr> <tr> <td class=\"indent1\">1. Are of the legal age of majority in their nation.</td> </tr> <tr> <td class=\"indent1\">2. Have used cross-sex hormones continuously and responsibly during 12 months (if they have no medical contraindication).</td> </tr> <tr> <td class=\"indent1\">3. Had a successful continuous full-time real life experience (RLE) during 12 months.</td> </tr> <tr> <td class=\"indent1\">4. Have (if required by the mental health professional [MHP]) regularly participated in psychotherapy throughout the RLE at a frequency determined jointly by the patient and the MHP.</td> </tr> <tr> <td class=\"indent1\">5. Have shown demonstrable knowledge of all practical aspects of surgery (eg, cost, required lengths of hospitalizations, likely complications, postsurgical rehabilitation, etc).</td> </tr> <tr> <td class=\"subtitle1_single\">Individuals treated with cross-sex hormones should fulfill the following readiness criteria prior to sex reassignment surgery:</td> </tr> <tr> <td class=\"indent1\">1. Demonstrable progress in consolidating one's gender identity.</td> </tr> <tr> <td class=\"indent1\">2. Demonstrable progress in dealing with work, family, and interpersonal issues, resulting in a significantly better state of mental health.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94:3132. Copyright © 2009 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 60865 Version 3.0</div></div></div>"},"60866":{"type":"graphic_picture","displayName":"Pityriasis alba 1","title":"Pityriasis alba","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pityriasis alba</div><div class=\"cntnt\"><img style=\"width:310px; height:263px;\" src=\"images/DERM/60866_Pityriasisalba1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypopigmented macules are present on the face of this young girl with pityriasis alba.</div><div class=\"graphic_reference\">Copyright © Nicole Sorensen, RN, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 60866 Version 7.0</div></div></div>"},"60868":{"type":"graphic_picture","displayName":"Vulvar abscess","title":"Vulvar abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vulvar abscess</div><div class=\"cntnt\"><img style=\"width:324px; height:324px;\" src=\"images/OBGYN/60868_Vulvar_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This diabetic woman has a left vulvar abscess involving the labium majus. Note the increased size when compared with the right labium. There is also a background of erythema about the vulva and perianal area from chronic superficial candidiasis.</div><div class=\"graphic_reference\">Courtesy of Andrea R Thurman, MD.</div><div id=\"graphicVersion\">Graphic 60868 Version 1.0</div></div></div>"},"60869":{"type":"graphic_table","displayName":"WHO classification malnutrition","title":"Classification of malnutrition according to the World Health Organization (WHO)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of malnutrition according to the World Health Organization (WHO)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Clinical term</td> <td class=\"subtitle1\" rowspan=\"2\">Clinical measure</td> <td class=\"subtitle1\" colspan=\"2\">Classification</td> </tr> <tr> <td class=\"subtitle2\">Moderate malnutrition</td> <td class=\"subtitle2\">Severe malnutrition<br /> </td> </tr> <tr> <td rowspan=\"2\">Wasting*</td> <td>Mid-upper arm circumference (MUAC)</td> <td>11.5 to 12.4 cm</td> <td>&#60;11.5 cm</td> </tr> <tr> <td>Weight-for-height Z-score (WHZ)<sup>&#182;</sup></td> <td>&ndash;2 to &ndash;3</td> <td>&#60;&ndash;3</td> </tr> <tr> <td>Kwashiorkor</td> <td>Symmetrical pitting edema</td> <td>Absent</td> <td>Present<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Children should be classified based on their most \"severe\" criterion. For example, if a child is moderately malnourished by WHZ but severely malnourished by MUAC, the child should be classified as severely malnourished.</div><div class=\"graphic_footnotes\">SD: standard deviations.<br />* Severe wasting is also known as marasmus. Either WHZ or MUAC criteria can be used independently to diagnose moderate and severe malnutrition. <br />¶ The Z-score (SD-score) is defined as the deviation of the value for an individual from the median value of the reference population, divided by the standard deviation of the reference population. In this case, the reference population is defined by WHO growth standards.<br />Δ All children with kwashiorkor (edematous malnutrition) are considered to have severe malnutrition regardless of other anthropometric measurements. The edema can be further&nbsp;classified as 1<SUP>+</SUP> if it is only located in the feet or lower legs; 2<SUP>+</SUP> if edema extends to the arms or upper body; or 3<SUP>+</SUP> if it extends to the face.</div><div class=\"graphic_reference\">Adapted from: WHO child growth standards and the identification of severe acute malnutrition in infants and children. A Joint Statement by the World Health Organization and the United Nations Children's Fund. World Health Organization and UNICEF, 2009. Copyright © 2009.</div><div id=\"graphicVersion\">Graphic 60869 Version 10.0</div></div></div>"},"60870":{"type":"graphic_picture","displayName":"IPH macrophages High","title":"Pathology of idiopathic pulmonary hemosiderosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathology of idiopathic pulmonary hemosiderosis</div><div class=\"cntnt\"><img style=\"width:398px; height:263px;\" src=\"images/PULM/60870_IPH_macrophages_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transbronchial lung biopsy from a 55-year-old woman with idiopathic pulmonary hemosiderosis and hemoptysis for six months. Combined staining for iron (Perls' Prussian blue) and nuclear counterstaining (Kernechtrot) demonstrates alveoli filled with hemosiderin-laden macrophages and thickening of the alveolar walls.</div><div class=\"graphic_reference\">Courtesy of Per Praetorius Clausen, MD.</div><div id=\"graphicVersion\">Graphic 60870 Version 1.0</div></div></div>"},"60871":{"type":"graphic_table","displayName":"Lung transplant pathogens","title":"Common fungal pathogens in lung transplantation and their usual clinical manifestations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common fungal pathogens in lung transplantation and their usual clinical manifestations</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Pathogen\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Usual clinical manifestation\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"3\">\r\n  \r\n   <em>Aspergillus</em> spp\r\n  \r\n   </td>\r\n  \r\n   <td>Airway colonization</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Tracheobronchitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pulmonary disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   <em>Blastomycosis</em>\r\n  \r\n   </td>\r\n  \r\n   <td>Pulmonary disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Disseminated disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><em>Candida</em> spp</td>\r\n  \r\n   <td>Candidemia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   Coccidioidomycosis\r\n  \r\n   </td>\r\n  \r\n   <td>Pulmonary disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Disseminated disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"3\">\r\n  \r\n   <em>Cryptococcus neoformans</em>\r\n  \r\n   </td>\r\n  \r\n   <td>Pulmonary disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Meninigitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Cellulitis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   Dematiaceous molds*\r\n  \r\n   </td>\r\n  \r\n   <td>Skin and soft tissue infection</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Brain abscess</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td><em>Fusarium</em> spp</td>\r\n  \r\n   <td>Skin and soft tissue infection</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"3\">\r\n  \r\n   Histoplasmosis\r\n  \r\n   </td>\r\n  \r\n   <td>Fever of unknown origin</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Pulmonary disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Disseminated disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"2\">\r\n  \r\n   <em>Scedosporium</em> spp\r\n  \r\n   </td>\r\n  \r\n   <td>Pulmonary disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Disseminated disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  rowspan=\"3\">\r\n  \r\n   Zygomycetes\r\n  \r\n   </td>\r\n  \r\n   <td>Pulmonary disease</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Rhinocerebral infection</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Disseminated disease</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">14.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Media_Notes msdt:dt=\"string\">5/9/2009--Permission granted via Rightslink; figures to Terrence (JD). 6/6/2010--Renewal granted via Rightslink (JD).</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=66142&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Lung_transplant_pathogens.htm</title></head></div><div class=\"graphic_footnotes\">* <EM>Exophiala</EM>, <EM>Alternaria</EM>, <EM>Curvularia</EM>, <EM>Dactylaria</EM>, <EM>Cladophialophora,</EM> and others.</div><div class=\"graphic_reference\">Reproduced with permission from: Silveira FP, Husain S. Fungal infections in lung transplant recipients. Curr Opin Pulm Med 2008; 14:211. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60871 Version 10.0</div></div></div>"},"60872":{"type":"graphic_picture","displayName":"Tumor embolus High","title":"Pulmonary tumor embolus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary tumor embolus</div><div class=\"cntnt\"><img style=\"width:362px; height:234px;\" src=\"images/PULM/60872_Tumor_embolus_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph shows a small pulmonary artery with a partially organized tumor embolus within the lumen (arrow).</div><div class=\"graphic_reference\">From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.</div><div id=\"graphicVersion\">Graphic 60872 Version 1.0</div></div></div>"},"60874":{"type":"graphic_picture","displayName":"Sclerosing keratitis","title":"Sclerosing keratitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sclerosing keratitis</div><div class=\"cntnt\"><img style=\"width:504px; height:387px;\" src=\"images/ID/60874_Sclerosing_keratitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sclerosing keratitis affecting entire cornea.</div><div class=\"graphic_reference\">Reproduced with permission from: Murdoch ME, Murdoch IE. Onchocerciasis. In: Principles of Medicine in Africa, 3rd Ed, Parry E, Godfrey R, Mabey D, Gill G (Eds), Cambridge University Press 2004. Copyright &copy; 2004 Cambridge University Press.</div><div id=\"graphicVersion\">Graphic 60874 Version 1.0</div></div></div>"},"60875":{"type":"graphic_diagnosticimage","displayName":"Complete CBD transection I","title":"Complete transection of the common bile duct after cholecystectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Complete transection of the common bile duct after cholecystectomy</div><div class=\"cntnt\"><img style=\"width:231px; height:432px;\" src=\"images/GAST/60875_Complete_CBD_transection_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ERCP demonstrating complete transection of the common bile duct.</div><div class=\"graphic_reference\">Courtesy of Michael J Bourke, MBBS, FRACP.</div><div id=\"graphicVersion\">Graphic 60875 Version 3.0</div></div></div>"},"60877":{"type":"graphic_figure","displayName":"Peak influenza activity","title":"Peak month of influenza activity 1982-1983 through 2015-2016, United States","html":"<div class=\"graphic\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Peak month of influenza activity 1982-1983 through 2015-2016, United States</div><div class=\"cntnt\"><img style=\"width:704px; height:330px;\" src=\"images/ID/60877_Peak_influenza_actvty_edit2.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Influenza: The flu season. Available at: <a href=\"http://www.cdc.gov/flu/about/season/flu-season.htm\" target=\"_blank\">www.cdc.gov/flu/about/season/flu-season.htm</a> (Accessed on September 8, 2016).</div><div id=\"graphicVersion\">Graphic 60877 Version 5.0</div></div></div>"},"60878":{"type":"graphic_figure","displayName":"ACEI in diabetic nephropathy","title":"ACE inhibitor slows progression of diabetic nephropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">ACE inhibitor slows progression of diabetic nephropathy</div><div class=\"cntnt\"><img style=\"width:424px; height:255px;\" src=\"images/NEPH/60878_ACEI_in_diabetic_nephropath.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The effect of the administration of placebo or captopril to patients with type 1 diabetes with overt proteinuria and a Pcr equal to or greater than 1.5 mg/dL (132 µmol/L). The likelihood of a doubling of the Pcr was reduced by more than 50 percent in the captopril group.</div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme; Pcr: plasma creatinine concentration.</div><div class=\"graphic_reference\">Data from: Lewis EJ, Hunsicker LG, Bain RP,&nbsp;Rohde RD.&nbsp;The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.&nbsp;N Engl J Med 1993; 329:1456.</div><div id=\"graphicVersion\">Graphic 60878 Version 4.0</div></div></div>"},"60880":{"type":"graphic_figure","displayName":"Low NH4 excretion in CKD","title":"Impaired ammonium excretion in chronic kidney disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Impaired ammonium excretion in chronic kidney disease</div><div class=\"cntnt\"><img style=\"width:386px; height:233px;\" src=\"images/NEPH/60880_Low_NH4_excretion_in_CRF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urinary excretion of ammonium (NH4) in normals (solid line) and patients with chronic kidney disease (CKD, dashed line) at baseline and after an acid load. The plasma bicarbonate concentration fell from 27 to 22 meq/L in normals and from 22 to 14 meq/L in CKD following the acid load. Ammonium excretion rose markedly in normal subjects but was low at baseline and did not increase in the patients with CKD despite a greater degree of metabolic acidosis.</div><div class=\"graphic_reference\">Data from: Welbourne T, Weber M, Bank N. J Clin Invest 1972; 51:1852.</div><div id=\"graphicVersion\">Graphic 60880 Version 3.0</div></div></div>"},"60881":{"type":"graphic_table","displayName":"Causes elevated D-dimer","title":"Disorders associated with increased plasma levels of fibrin D-dimer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders associated with increased plasma levels of fibrin D-dimer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Arterial thromboembolic disease </td> </tr> <tr> <td class=\"sublist1\">Myocardial infarction </td> </tr> <tr> <td class=\"sublist1\">Stroke </td> </tr> <tr> <td class=\"sublist1\">Acute limb ischemia </td> </tr> <tr> <td class=\"sublist1\">Atrial fibrillation </td> </tr> <tr> <td class=\"sublist1\">Intracardiac thrombus </td> </tr> <tr> <td class=\"sublist1_start\">Venous thromboembolic disease </td> </tr> <tr> <td class=\"sublist1\">Deep vein thrombosis </td> </tr> <tr> <td class=\"sublist1\">Pulmonary embolism </td> </tr> <tr> <td>Disseminated intravascular coagulation</td> </tr> <tr> <td>Preeclampsia and eclampsia</td> </tr> <tr> <td>Abnormal fibrinolysis; use of thrombolytic agents</td> </tr> <tr> <td>Cardiovascular disease, congestive failure</td> </tr> <tr> <td>Severe infection/sepsis/inflammation</td> </tr> <tr> <td>Surgery/trauma (eg, tissue ischemia, necrosis)</td> </tr> <tr> <td>Systemic inflammatory response syndrome</td> </tr> <tr> <td>Vaso-occlusive episode of sickle cell disease</td> </tr> <tr> <td>Severe liver disease (decreased clearance)</td> </tr> <tr> <td>Malignancy</td> </tr> <tr> <td class=\"sublist1_start\">Renal disease </td> </tr> <tr> <td class=\"sublist1\">Nephrotic syndrome (eg, renal vein thrombosis) </td> </tr> <tr> <td class=\"sublist1\">Acute renal failure </td> </tr> <tr> <td class=\"sublist1\">Chronic renal failure and underlying cardiovascular disease </td> </tr> <tr> <td> <p>Normal pregnancy</p> <p>Venous malformations</p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 60881 Version 2.0</div></div></div>"},"60882":{"type":"graphic_picture","displayName":"Liver in sideroblastic anemia","title":"Iron overload in the liver in sideroblastic anemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Iron overload in the liver in sideroblastic anemia</div><div class=\"cntnt\"><img style=\"width:390px; height:527px;\" src=\"images/HEME/60882_Liver_in_sideroblastic_anem.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Liver biopsy sections from a 26-year-old man with autosomal recessive&#160;congenital sideroblastic anemia and moderate iron overload.<br> (Top panel) Hematoxylin and eosin stain.<br> (Bottom panel) Prussian blue (iron) stain.</div><div class=\"graphic_reference\">Courtesy of Sylvia Bottomley, MD.</div><div id=\"graphicVersion\">Graphic 60882 Version 5.0</div></div></div>"},"60883":{"type":"graphic_table","displayName":"Adjusting cyclophosphamide dose","title":"Algorithm for adjusting oral cyclophosphamide dose for adult patients with renal insufficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Algorithm for adjusting oral cyclophosphamide dose for adult patients with renal insufficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Creatinine clearance* (mL/minute)</td> <td class=\"subtitle1\">Cyclophosphamide (CYC) oral dose (mg/kg/day)<sup>&#182;</sup></td> </tr> <tr> <td>&#62;100</td> <td>2</td> </tr> <tr> <td>50 to 99</td> <td>1.5</td> </tr> <tr> <td>25 to 49</td> <td>1.2</td> </tr> <tr> <td>15 to 24</td> <td>1</td> </tr> <tr> <td>&#60;15 or dialysis<sup>&#916;</sup></td> <td>0.8</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Initial 2 mg/kg per day dose and adjustments for renal insufficiency are for daily oral administration of \"low-dose\" cyclophosphamide therapy in rheumatic diseases. For approach, other dose adjustments that may be needed, and duration of therapy, refer to UpToDate topics&nbsp;on the use of cyclophosphamide in rheumatic diseases.</div><div class=\"graphic_footnotes\">CYC: cyclophosphamde; Clcr: creatinine clearance.<br />* Can be estimated by using the Cockroft-Gault equation. Clcr = [140-age] * weight (kg)/serum Cr in mg/dL * 72. Multiply result by 0.85 for women. Separate calculators for creatinine clearance using conventional and SI units are available in UpToDate.<br />¶ Usual maximum daily dose is 200 mg. For patients who are overweight or obese, an estimate of ideal or lean body weight is used for estimating Clcr and determining daily CYC weight-based dose. Calculators are available in UpToDate.<br />Δ CYC is variably dialyzable (approximately 20 to 50 percent). Dose may require further adjustment depending upon type of dialysis. For intermittent hemodialysis, give dose after session on dialysis days.</div><div class=\"graphic_reference\">Adapted with permission from: Rheumatic Disease Clinics of North America 2001. 27(4):863. Copyright &copy; 2001 Elsevier Science. Additional information from de Groot et al. Ann Intern Med 2009. 150(10):670.</div><div id=\"graphicVersion\">Graphic 60883 Version 8.0</div></div></div>"},"60884":{"type":"graphic_diagnosticimage","displayName":"First trimester ultrasound image of umbilical cord","title":"First trimester ultrasound image of umbilical cord","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">First trimester ultrasound image of umbilical cord</div><div class=\"cntnt\"><img style=\"width:514px; height:241px;\" src=\"images/OBGYN/60884_First_trim_us_umbil_cord.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Three-dimensional rendered image of a first-trimester fetus and its umbilical cord. Both the placental and abdominal insertion sites are shown. Note that the umbilical cord length at this gestational age is approximately the same as the crown rump length.<br> (Panel B) Transvaginal two-dimensional ultrasound shows a transverse view of the fetal abdomen (a), the entire length of the umbilical cord (uc) including its placental and fetal insertion sites, and the physiologic midgut herniation (arrow) at the base of the fetal insertion site.</div><div id=\"graphicVersion\">Graphic 60884 Version 2.0</div></div></div>"},"60885":{"type":"graphic_figure","displayName":"S shape supracondylar fracture","title":"S-shaped supracondylar fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">S-shaped supracondylar fracture</div><div class=\"cntnt\"><img style=\"width:396px; height:352px;\" src=\"images/EM/60885_SshapeSCfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clinical appearance. The S-shaped configuration is created by the prominence of the spike of the proximal fragment (A), flexion of the distal fragment (B), and the posterior prominence of the olecranon (C).</div><div class=\"graphic_reference\">Reproduced with permission from: Kasser JR, Beaty JH. Supracondylar fractures of the distal humerus. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 60885 Version 13.0</div></div></div>"},"60887":{"type":"graphic_figure","displayName":"Billroth II anatomy","title":"Billroth II gastrectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Billroth II gastrectomy</div><div class=\"cntnt\"><img style=\"width:357px; height:431px;\" src=\"images/GAST/60887_Billroth_II_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the relationship between the afferent and efferent limbs of the gastrojejunostomy and the ampulla of Vater following Billroth II reconstruction. During endoscopic retrograde cholangiopancreatography, the landmarks of the ampulla are inverted by 180&#186; compared to their location in native anatomy.</div><div id=\"graphicVersion\">Graphic 60887 Version 1.0</div></div></div>"},"60888":{"type":"graphic_figure","displayName":"DeLancey levels pelvic support","title":"DeLancey levels of female pelvic floor support: Level 1 (apical suspension) and level 2 (lateral attachment)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">DeLancey levels of female pelvic floor support: Level 1 (apical suspension) and level 2 (lateral attachment)</div><div class=\"cntnt\"><img style=\"width:439px; height:345px;\" src=\"images/OBGYN/60888_DeLancey_levels_pelvic_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Level 1: paracolpium suspends the vaginal apex from the lateral pelvic sidewall via the uterosacral-cardinal complex.<br> Level 2: the anterior vaginal wall is attached laterally to arcus tendinous fascia pelvis and the posterior vaginal wall is attached laterally to the facia overlying the levator ani muscle.</div><div class=\"graphic_reference\">Reproduced with permission from: DeLancey, JO. Anatomic aspects of vaginal eversion after hysterectomy. Am J Obstet Gynecol 1992; 166(6 Pt 1):1717. Copyright &#169; 1992 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 60888 Version 4.0</div></div></div>"},"60890":{"type":"graphic_figure","displayName":"Paravaginal defect repair","title":"Transvaginal paravaginal defect repair","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Transvaginal paravaginal defect repair</div><div class=\"cntnt\"><img style=\"width:537px; height:602px;\" src=\"images/OBGYN/60890_Paravaginal_defect_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal paravaginal repair - After complete sharp dissection of the anterior vaginal mucosa, the endopelvic fascia is sharply incised using Metzenbaum scissors, thereby entering the retropubic space. Medial retraction allows visualization of the pelvic sidewall and the arcus tendineus fascia pelvis (Image A). The lateral vagina is then reattached to the pelvic sidewall with a series of interrupted permanent sutures through the lateral vagina and arcus tendineus fascia pelvis (Image B). The interrupted sutures are not tied until all have been placed (Image C). Tying of the sutures results in closure of the lateral vaginal support defect.</div><div id=\"graphicVersion\">Graphic 60890 Version 2.0</div></div></div>"},"60893":{"type":"graphic_diagnosticimage","displayName":"Pancreatocele","title":"Endoscopic retrograde cholangiopancreatography (ERCP) showing pancreatocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic retrograde cholangiopancreatography (ERCP) showing pancreatocele</div><div class=\"cntnt\"><img style=\"width:432px; height:347px;\" src=\"images/PEDS/60893_Pancreatocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: ERCP in Paediatric Practice: Diagnosis and Treatment, Isis Medical Media LTD, Oxford University Press, UK 1997. Copyright ©1997 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 60893 Version 3.0</div></div></div>"},"60900":{"type":"graphic_table","displayName":"Developmental milestones 4 through 8 years","title":"Developmental milestones: 4 years, 0 months through 7 to 8 years","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Developmental milestones: 4 years, 0 months through 7 to 8 years</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"4\">Approximate chronologic age</td> </tr> <tr> <td class=\"subtitle2\">4 to 5 years</td> <td class=\"subtitle2\">5 to 6 years</td> <td class=\"subtitle2\">6 to 7 years</td> <td class=\"subtitle2\">7 to 8 years</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Gross motor</strong></td> <td> <ul> <li>Balances on one foot: Four to eight seconds </li> <li>Hops on one foot: Two to three times </li> <li>Standing broad jump: One to two feet </li> <li>Gallops </li> <li>Throws ball overhand: 10 feet </li> <li>Catches bounced ball </li> </ul> </td> <td> <ul> <li>Walks down stairs, alternating feet, without using rail </li> <li>Balances on one foot: More than eight seconds </li> <li>Hops on one foot: 15 feet </li> <li>Skips </li> <li>Running broad jump: Two to three feet </li> <li>Walks backward heel-toe </li> <li>Jumps backward </li> </ul> </td> <td> <ul> <li>Tandem walks </li> <li>Skips </li> </ul> </td> <td> <ul> <li>Rides bicycle independently </li> <li>Bats ball placed on cone </li> <li>Does somersaults </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Fine motor/writing</strong></td> <td> <ul> <li>Copies square </li> <li>Imitates making a complex gate with cubes </li> <li>Ties single knot </li> <li>Cuts five inch circle </li> <li>Uses tongs to transfer </li> <li>Writes part of first name </li> <li>Works from left to right, top to bottom </li> </ul> </td> <td> <ul> <li>Copies triangle </li> <li>Builds stairs with cubes from model </li> <li>Puts paper clip on paper </li> <li>Can use clothespins to transfer small objects </li> <li>Cuts with scissors </li> <li>Writes first name </li> </ul> </td> <td> <ul> <li>Builds stairs with cubes from memory </li> <li>Draws diamond </li> <li>Copies flag </li> <li>Writes first and last name </li> <li>Creates and writes short stories </li> <li>Forms letters with down-going and counter-clockwise strokes </li> </ul> </td> <td> <ul> <li>Writing rate increases </li> <li>Stays on line when writing </li> <li>Spaces between words </li> <li>Size of letters becomes uniform </li> <li>Letter reversals disappear </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Self-help</strong></td> <td> <ul> <li>Goes to toilet alone </li> <li>Wipes after BM </li> <li>Washes face/hands </li> <li>Brushes teeth alone </li> <li>Buttons </li> <li>Uses fork well </li> </ul> </td> <td> <ul> <li>Spreads with knife </li> <li>Independent dressing </li> </ul> </td> <td> <ul> <li>Ties shoes </li> <li>Combs hair </li> <li>Remembers to bring belongings </li> </ul> </td> <td> <ul> <li>Sticks with tasks (with television off) for up to 20 minutes </li> <li>Pays attention to teacher when in a group </li> <li>Completes homework on own </li> <li>Answers and delivers phone messages </li> <li>Completes household chores (with reminders) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Cognitive/academic</strong></td> <td> <ul> <li>Draws a four- to six-part person </li> <li>Can give amounts (usually less than five) correctly </li> <li>Completes simple analogies (eg, dad/boy:mother/___, ice/cold:fire/___, ceiling/up:floor/___) </li> <li>Points to five to six colors </li> <li>Points to letters/numerals when named </li> <li>Rote counts to four </li> <li>\"Reads\" several common signs/store names </li> </ul> </td> <td> <ul> <li>Draws an 8- to 10-part person </li> <li>Gives amounts (less than 10) </li> <li>Identifies coins </li> <li>Names letters/numerals out of order </li> <li>Rote counts to 10 </li> <li>Names 10 colors </li> <li>Uses letter names as sounds to invent spelling (eg, \"N-D-N\" for \"Indian\") </li> <li>By end of kindergarten: Knows sounds of consonants and short vowels </li> <li>Reads 25 words </li> </ul> </td> <td> <ul> <li>Draws a 12- to 14-part person </li> <li>Number concepts to 20 </li> <li>Simple addition/subtraction </li> <li>Understands seasons </li> <li>Sounds out regularly spelled words </li> <li>By end of first grade: Reads 250 words </li> </ul> </td> <td> <ul> <li>Knows sounds of consonant digraphs (eg, \"ch,\" \"sh\") </li> <li>Knows sounds of vowel diphthongs (eg, \"oo,\" \"ou\") </li> <li>Reads words with r-controlled vowels (eg, bird, burn) </li> <li>Starts \"reading to learn\" not just \"learning to read\" </li> <li>Two-place addition/subtraction </li> <li>Enjoys reading independently </li> <li>Remembers spelling words </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Social/emotional</strong></td> <td> <ul> <li>Deception: Interested in tricking others and concerned about being tricked by others </li> <li>Has a preferred friend </li> <li>Labels happiness, sadness, fear, and anger in self </li> <li>Group play </li> </ul> </td> <td> <ul> <li>Has a group of friends </li> <li>Apologizes for mistakes </li> <li>Responds verbally to good fortune of others </li> </ul> </td> <td> <ul> <li>Has best friend of same sex </li> <li>Plays board games </li> <li>Distinguishes fantasy from reality </li> <li>Wants to be like friends and please them&nbsp; </li> </ul> </td> <td> <ul> <li>Avoids hurting others in play </li> <li>Learns from mistakes </li> <li>Helps younger children </li> <li>Strong notions about what is fair </li> <li>Takes turns in conversations </li> <li>Delays gratification and waits to take turn </li> <li>Interested in the opinions of peers </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Receptive language</strong></td> <td> <ul> <li>Follows three-step commands </li> <li>Points to things that are the same versus different </li> <li>Names things when actions are described (eg, it swims in water, you cut with it, it is something you read, it tells time) </li> </ul> </td> <td> <ul> <li>Knows right and left on self </li> <li>Points to different one in a series </li> <li>Understands \"er\" endings (eg, batter, skater) </li> <li>Understands adjectives (eg, bushy, long, thin, pointed) </li> <li>Enjoys rhyming words and alliterations </li> <li>Produces words that rhyme </li> <li>Points correctly to \"side,\" \"middle,\" and \"corner\" </li> </ul> </td> <td> <ul> <li>Asks what unfamiliar words mean </li> <li>Can tell which words do not belong in a group </li> </ul> </td> <td> <ul> <li>Understands opposites and word analogies </li> <li>Knows right and left on others </li> <li>Understands days and months </li> </ul> </td> </tr> <tr> <td><strong>Expressive language</strong></td> <td> <ul> <li>Repeats four- to six-syllable sentences </li> <li>Uses 300 to 1000 words </li> <li>Tells stories </li> <li>100% intelligibility with few articulation errors </li> <li>Uses \"feeling\" words </li> <li>Uses words that tell about time </li> </ul> </td> <td> <ul> <li>Repeats six- to eight-syllable sentences </li> <li>Defines simple words </li> <li>2000 word vocabulary </li> <li>Knows telephone number </li> <li>Responds to \"why\" questions </li> <li>Retells stories with clear beginning, middle, and end </li> </ul> </td> <td> <ul> <li>Repeats 8- to 10-word sentences </li> <li>Describes events in an orderly way </li> <li>Knows days of the week </li> <li>10,000 word vocabulary </li> </ul> </td> <td> <ul> <li>Masters \"r\" sound in speech </li> <li>Tells time </li> <li>Uses complex and compound sentences </li> <li>Talks about a range of topics </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BM: bowel movement.<br />* Refer to UpToDate content on fine motor milestones.</div><div class=\"graphic_reference\">© 2007 Chris Johnson, MD, AAP Council on Children with Disabilities. Adapted with permission and contributions from: Frances Page Glascoe, PhD and Nicholas Robertshaw, authors of PEDS: Developmental Milestones; Franklin Trimm, MD, Vice Chair of Pediatrics, USA/APA Education Committee; the Center for Disease Control \"Act Early\" Initiative; the National Institute for Literacy/Reach Out and Read; and the Inventory of Early Development by Albert Brigance published by Curriculum Associates, Inc. Permission is granted to reproduce these pages on the condition that they are only used as guide to average development and not as a substitute for standardized validated screening for developmental-behavioral problems.</div><div id=\"graphicVersion\">Graphic 60900 Version 11.0</div></div></div>"},"60901":{"type":"graphic_table","displayName":"Sources of iodine","title":"Iodine content of some iodine-containing medications and radiographic contrast agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Iodine content of some iodine-containing medications and radiographic contrast agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Substance</td> <td class=\"subtitle1\">Amount of iodine</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Potassium iodides (thyroprotectant and prethyroidectomy agents)</td> </tr> <tr> <td class=\"indent1\">Potassium iodide oral tablet</td> <td>50 mg iodine per 65 mg potassium iodide tablet; 100 mg iodine per 130 mg potassium iodide tablet</td> </tr> <tr> <td class=\"indent1\">Potassium iodide oral solution</td> <td>50 mg iodine per mL of 65 mg/mL potassium iodide solution</td> </tr> <tr> <td class=\"indent1\">Potassium iodide oral saturated solution (SSKI)</td> <td>770 mg iodine per mL (approximately 20 drops) of 1000 mg/mL potassium iodide saturated solution</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Potassium iodide and iodine mixture (Lugol solution, Strong iodine solution)</td> <td>Total 127 mg iodine per mL (approximately 20 drops) of 100 mg/mL potassium iodide and 50 mg/mL iodine mixture</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Antiarrhythmic drugs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Amiodarone</td> <td>75 mg iodine per 200 mg amiodarone*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Radiographic preparations</td> </tr> <tr> <td class=\"indent1\">Iodinated contrast agents</td> <td>Significant source of short-term iodine exposure. Typical oral preparations may contain 300 to 480 mg iodine per mL or tablet.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Intravenous preparations</td> <td>140 to 400 mg/mL</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Topical antiseptic agents</td> </tr> <tr> <td class=\"indent1\">Povidone-iodine solution 10%</td> <td>10 mg iodine per mL solution</td> </tr> <tr> <td class=\"indent1\">Iodine tinctures 2 and 7%</td> <td>20 mg iodine per mL of 2% tincture; 70 mg iodine per mL of 7% tincture</td> </tr> <tr> <td class=\"indent1\">Cadexomer-iodine dressings, ointment, powder, paste</td> <td>9 mg iodine per gram of cadexomer-iodine ointment, powder or paste</td> </tr> <tr> <td class=\"indent1\">Iodoquinol cream 1%</td> <td>6.4 mg iodine per gram of 1% cream (preparation may include 1 or 2% hydrocortisone)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Clioquinol cream<sup>&#182;</sup> 3%</td> <td>12 mg iodine per gram of 3% cream</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Amebicidal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Iodoquinol (Yodoxin, Diodoquin)</td> <td>134 mg iodine per 210 mg iodoquinol oral capsule; 415 mg iodine per 650 mg iodoquinol oral capsule</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Douches</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Povidone-iodine</td> <td>10 mg iodine per mL solution</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Iodine containing expectorants</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Iodinated glycerol, calcium iodide</td> <td>Iodine has largely been discontinued as an ingredient of expectorants due to safety concerns. Typical preparations formerly available in the United States contained approximately 6 to 25 mg iodine per mL.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Kelp or seaweed containing supplements</td> </tr> <tr> <td class=\"indent1\">Oral kelp (wrack, bladderwrack)</td> <td>Up to 6 mg of iodine may be contained in a 600 mg serving of kelp<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Cellasene (anti-cellulite supplement)</td> <td>720 mcg of iodine per serving</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Approximately 10% is released as free inorganic iodine. Accumulation of amiodarone in body tissue results in a prolonged iodine exposure half-life (months or more) after discontinuation.<br />¶ Clioquinol cream is not available as a single ingredient or combination product in the United States. It is available in combinations with flumethasone as a topical cream and as otic in Canada.<br />Δ Iodine content is variable due to variability in source kelp and preparation.</div><div id=\"graphicVersion\">Graphic 60901 Version 6.0</div></div></div>"},"60902":{"type":"graphic_table","displayName":"Accelerated phase CML criteria","title":"Diagnostic criteria: accelerated phase of chronic myelogenous leukemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria: accelerated phase of chronic myelogenous leukemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">MD Anderson*</td> <td class=\"subtitle1\">Sokal et al<sup>&#182;</sup></td> <td class=\"subtitle1\">WHO<sup>&#916;</sup></td> </tr> <tr> <td> <p>PB blasts &#8805;15%</p> PB blasts + pro &#8805;30%</td> <td>PB or BM blasts &#8805;5%</td> <td>PB or BM blasts 10 to 19%</td> </tr> <tr> <td>PB baso &#8805;20%</td> <td>PB basophils &#8805;20%</td> <td>PB basophils &#8805;20%</td> </tr> <tr> <td>Platelets &#60;100,000/microL not related to therapy</td> <td>Thrombocytopenia, not related to therapy</td> <td>Platelets &#60;100,000/microL, unrelated to therapy</td> </tr> <tr> <td rowspan=\"8\">Cytogenetic evolution</td> <td>Cytogenetic evolution</td> <td>Cytogenetic evolution or additional clonal chromosomal abnormalities in Ph+ cells at diagnosis that include \"major route\" abnormalities, complex karyotype, or abnormalities of 3q26.2</td> </tr> <tr> <td>Platelets &#62;1 million/microL despite adequate therapy</td> <td>Platelets &#62;1,000,000/microL unresponsive to therapy</td> </tr> <tr> <td>Marrow collagen fibrosis</td> <td>&nbsp;</td> </tr> <tr> <td>Anemia, unrelated to Rx</td> <td>&nbsp;</td> </tr> <tr> <td>Progressive splenomegaly</td> <td>Progressive splenomegaly and increasing WBC unresponsive to therapy</td> </tr> <tr> <td>WBC doubling time &#60;5 days</td> <td>&nbsp;</td> </tr> <tr> <td>Unexplained fever</td> <td>&nbsp;</td> </tr> <tr> <td>Pelger-Huett-like neutrophils, nucleated RBCs, megakaryocyte fragments</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Examples of \"major route\" abnormalities defined by the WHO include second Ph, trisomy 8, isochromosome 17q, and trisomy 19. The WHO includes provisional response-to-tyrosine kinase inhibitor criteria for accelerated phase disease.</div><div class=\"graphic_footnotes\">WHO: World Health Organization; PB: peripheral blood; BM: bone marrow; pro: promyelocytes; baso: basophils; WBC: white blood cell count; RBC: red blood cells.<br />* Kantarjian, HM, et al. Cancer 1988; 61:1441.<br />¶ Sokal, JE, et al. Semin Hematol 1988; 25:49.<br />Δ Arber, DA, et al. Blood 2016; 127:2391.</div><div class=\"graphic_reference\">For each of the three sets of criteria, the accelerated phase of chronic myelogenous leukemia is diagnosed if one or more of the listed features is present. Adapted from O'Dwyer, ME, et al. Blood 2002; 100:1628.</div><div id=\"graphicVersion\">Graphic 60902 Version 4.0</div></div></div>"},"60904":{"type":"graphic_picture","displayName":"Superfic puncuate keratitis","title":"Punctate keratitis from toxic chemical","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Punctate keratitis from toxic chemical</div><div class=\"cntnt\"><img style=\"width:338px; height:257px;\" src=\"images/PC/60904_Superfic_puncuate_keratitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chemicals in contact lens solutions may produce toxic or immune reactions on the corneal epithelium.</div><div id=\"graphicVersion\">Graphic 60904 Version 2.0</div></div></div>"},"60907":{"type":"graphic_diagnosticimage","displayName":"Chance fracture of the lumbar spine","title":"Chance fracture of the lumbar spine","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Chance fracture of the lumbar spine</div><div class=\"cntnt\"><img style=\"width:527px; height:502px;\" src=\"images/RADIOL/60907_Chancefraclumbarspine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plain film of the lumbar spine in the lateral projection shows a transverse fracture of the third lumbar (L3) vertebral body. Chance fracture is often due to seatbelt injury. Note the wide radiolucent gap between the two fracture segments (arrows). Associated fractures of the lamina, pedicles, and interspinous ligament have splayed the posterior elements (double arrow).</div><div id=\"graphicVersion\">Graphic 60907 Version 4.0</div></div></div>"},"60908":{"type":"graphic_table","displayName":"Criteria for thyroid storm","title":"Diagnostic criteria for thyroid storm*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for thyroid storm*</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Thermoregulatory dysfunction</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Temperature (&#176;F | &#176;C)</td> </tr> <tr> <td class=\"indent2\">99 to 99.9 | 37.2&nbsp;to 37.7</td> <td>5</td> </tr> <tr> <td class=\"indent1\">100&nbsp;to 100.9 | 37.8&nbsp;to 38.2</td> <td>10</td> </tr> <tr> <td class=\"indent1\">101&nbsp;to 101.9 | 38.3&nbsp;to 38.8</td> <td>15</td> </tr> <tr> <td class=\"indent1\">102&nbsp;to 102.9 | 38.9&nbsp;to 39.4</td> <td>20</td> </tr> <tr> <td class=\"indent1\">103&nbsp;to 103.9 | 39.4&nbsp;to 39.9</td> <td>25</td> </tr> <tr> <td class=\"indent2\">&#8805;104.0 | &#62;40.0</td> <td>30</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Central nervous system effects</td> </tr> <tr> <td class=\"subtitle2_left\">Mild</td> <td rowspan=\"2\">10</td> </tr> <tr> <td class=\"indent1\">Agitation</td> </tr> <tr> <td class=\"subtitle2_left\">Moderate</td> <td rowspan=\"4\">20</td> </tr> <tr> <td class=\"indent1\">Delirium</td> </tr> <tr> <td class=\"indent1\">Psychosis</td> </tr> <tr> <td class=\"indent1\">Extreme lethargy</td> </tr> <tr> <td class=\"subtitle2_left\">Severe</td> <td rowspan=\"3\">30</td> </tr> <tr> <td class=\"indent1\">Seizure</td> </tr> <tr> <td class=\"indent1\">Coma</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Gastrointestinal-hepatic dysfunction</td> </tr> <tr> <td class=\"subtitle2_left\">Moderate</td> <td rowspan=\"4\">10</td> </tr> <tr> <td class=\"indent1\">Diarrhea</td> </tr> <tr> <td class=\"indent1\">Nausea/vomiting</td> </tr> <tr> <td class=\"indent1\">Abdominal pain</td> </tr> <tr> <td class=\"subtitle2_left\">Severe</td> <td rowspan=\"2\">20</td> </tr> <tr> <td class=\"indent1\">Unexplained jaundice</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Cardiovascular dysfunction</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Tachycardia</td> </tr> <tr> <td class=\"indent1\">99&nbsp;to 109</td> <td>5</td> </tr> <tr> <td class=\"indent1\">110&nbsp;to 119</td> <td>10</td> </tr> <tr> <td class=\"indent1\">120&nbsp;to 129</td> <td>15</td> </tr> <tr> <td class=\"indent1\">130&nbsp;to 139</td> <td>20</td> </tr> <tr> <td class=\"indent1\">&#8805;140</td> <td>25</td> </tr> <tr> <td><strong>Atrial fibrillation</strong></td> <td>10</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Heart failure</td> </tr> <tr> <td class=\"subtitle2_left\">Mild</td> <td rowspan=\"2\">5</td> </tr> <tr> <td class=\"indent1\">Pedal edema</td> </tr> <tr> <td class=\"subtitle2_left\">Moderate</td> <td rowspan=\"2\">10</td> </tr> <tr> <td class=\"indent1\">Bibasilar rales</td> </tr> <tr> <td class=\"subtitle2_left\">Severe</td> <td rowspan=\"2\">15</td> </tr> <tr> <td class=\"indent1\">Pulmonary edema</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Precipitant history</td> </tr> <tr> <td>Negative</td> <td>0</td> </tr> <tr> <td>Positive</td> <td>10</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* A score of 45 or more is highly suggestive of thyroid storm, a score of 25 to 44 supports the diagnosis, and a score below 25 makes thyroid storm unlikely.</div><div class=\"graphic_reference\">Adapted from: Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am 1993; 22:263.</div><div id=\"graphicVersion\">Graphic 60908 Version 7.0</div></div></div>"},"60909":{"type":"graphic_table","displayName":"Echo views for valves","title":"Commonly used views to evaluate cardiac valves","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly used views to evaluate cardiac valves</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Valve</td>\n\n      <td class=\"subtitle1\">View</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Aortic valve</td>\n\n      <td>PLA, PSA (base), apical long axis, apical 5-chamber</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mitral valve</td>\n\n      <td>PLA, PSA (mid), apical long axis, subcostal 4-chamber</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Tricuspid valve</td>\n\n      <td>Parasternal RV inflow, PSA (mid), apical 4-chamber, apical long axis, subcostal 4-chamber, subcostal short axis</td>\n\n    </tr>\n\n\n    <tr>\n\n      <td>Pulmonic\nvalve</td>\n\n      <td>Parasternal RV outflow, PSA (base), subcostal short axis</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">PLA: parasternal long axis; PSA: parasternal short axis.</div><div id=\"graphicVersion\">Graphic 60909 Version 1.0</div></div></div>"},"60910":{"type":"graphic_table","displayName":"Causes of high T4","title":"Conditions associated with hyperthyroxinemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with hyperthyroxinemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"7\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"8\">Thyroid function tests</td> </tr> <tr> <td class=\"subtitle2\">Defect</td> <td class=\"subtitle2\">T<sub>4</sub></td> <td class=\"subtitle2\">T<sub>3</sub></td> <td class=\"subtitle2\">rT<sub>3</sub></td> <td class=\"subtitle2\">TSH</td> <td class=\"subtitle2\">FT<sub>4</sub> direct</td> <td class=\"subtitle2\">FT<sub>4</sub> dialysis</td> <td class=\"subtitle2\">Prevalence*</td> </tr> <tr> <td>Increased T4 binding globulin</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">N</td> <td class=\"centered\">N</td> <td class=\"centered\">N</td> <td class=\"centered\">Common</td> </tr> <tr> <td>Increased transthyretin<sup>&#182;</sup></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">N</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">N</td> <td class=\"centered\">N</td> <td class=\"centered\">N</td> <td class=\"centered\">Rare</td> </tr> <tr> <td>Familial dysalbuminemic hyperthyroxinemia (FDH)</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593; or N</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">N</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">N</td> <td class=\"centered\">Rare or common<sup>&#916;</sup></td> </tr> <tr> <td>Resistance to thyroid hormone (RTH)<br /> (usually due to a mutation in the thyroid hormone beta gene [RTH beta])</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593; or N</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">sl &#8593; or N</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">Uncommon</td> </tr> <tr> <td>TSH-producing pituitary adenoma</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">sl &#8593; or N</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">Rare</td> </tr> <tr> <td>SBP2/SECISBP2 mutation<br /> (causes a thyroid hormone metabolism defect)</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">sl &#8593; or N</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">Unknown</td> </tr> <tr> <td>Acute nonthyroidal illness</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8595; &#8595;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">N</td> <td class=\"centered\">&#8593; or N</td> <td class=\"centered\">N</td> <td class=\"centered\">Common</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SBP2: selenocysteine insertion binding sequence protein; sl: slight; N: normal; &uarr;: increased; &darr;: decreased.<br />* \"Common\" indicates &gt;1:300; \"Uncommon\" indicates &gt;1:50,000; \"Rare\" indicates &lt;1:50,000.<br />&para; Refers to transthyretin with increased affinity for T<sub>4</sub> and rT<sub>3</sub>.<br />&Delta; Depending on the ethnic origin.</div><div id=\"graphicVersion\">Graphic 60910 Version 7.0</div></div></div>"},"60912":{"type":"graphic_figure","displayName":"Metaphyseal lesions","title":"Metaphyseal lesions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metaphyseal lesions</div><div class=\"cntnt\"><img style=\"width:289px; height:392px;\" src=\"images/PEDS/60912_Metaphyseal_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diagrammatic representation of the relationship of the subperiosteal bone collar to a metaphyseal lesion. A: A tangential view of the metaphyseal margin, demonstrating a fracture line that extends adjacent to the chondro-osseous junction centrally. Peripherally, the fracture line (arrows) veers away from the growth plate to undermine a larger peripheral fragment, incorporating the subperiosteal bone collar. B: When the fracture line (arrows) is projected obliquely, the thicker peripheral fragment, including the subperiosteal bone collar, is projected as a curvilinear fragment or a bucket-handle lesion. C: When the fracture line (arrow) is incomplete (it extends across only a portion of the metaphysis), the appearance suggests a focal, triangularly shaped peripheral fragment encompassing the subperiosteal bone collar. D: When the fracture line (arrow) is tipped obliquely, the peripheral margin of the fragment is projected as curvilinear density.</div><div class=\"graphic_reference\">Reproduced with permission from: Kleinman, PK, Marks, SC Jr. Relationship of the subperiosteal bone collar to metaphyseal lesions in abused infants. J Bone Joint Surg Am 1995; 77:1471. Copyright &#169; 1995 The Journal of Bone and Joint Surgery, Inc.</div><div id=\"graphicVersion\">Graphic 60912 Version 1.0</div></div></div>"},"60914":{"type":"graphic_picture","displayName":"Tuboovarian abscess","title":"Tuboovarian abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuboovarian abscess</div><div class=\"cntnt\"><img style=\"width:389px; height:252px;\" src=\"images/PC/60914_Tuboovarian_abscess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross intraoperative photograph of a left tuboovarian abscess in a patient with pelvic inflammatory disease.</div><div class=\"graphic_reference\">Courtesy of Mitchel Hoffman, MD.</div><div id=\"graphicVersion\">Graphic 60914 Version 1.0</div></div></div>"},"60915":{"type":"graphic_figure","displayName":"Supraclavicular brachial plexus block","title":"Supraclavicular brachial plexus block","html":"<div class=\"graphic\"><div style=\"width: 936px\" class=\"figure\"><div class=\"ttl\">Supraclavicular brachial plexus block</div><div class=\"cntnt\"><img style=\"width:916px; height:305px;\" src=\"images/SURG/60915_Sprclvcbrchlplxblck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound probe is placed in a transverse position just above the clavicle. The needle insertion site is guided by the ultrasound image, and is usually approximately where the red dot appears in the middle panel. The brachial plexus appears as a \"bag of grapes\" just lateral to the subclavian artery, as in the ultrasound image in the right panel. For further details, refer to the UpToDate content on supraclavicular block.</div><div class=\"graphic_footnotes\">a.: artery.</div><div id=\"graphicVersion\">Graphic 60915 Version 4.0</div></div></div>"},"60917":{"type":"graphic_figure","displayName":"Simvastatin heart transplant","title":"Simvastatin improves survival in cardiac transplant recipients","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Simvastatin improves survival in cardiac transplant recipients</div><div class=\"cntnt\"><img style=\"width:453px; height:390px;\" src=\"images/CARD/60917_Simvastatin_heart_transplan.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Seventy-two heart transplant recipients were randomly assigned to simvastatin or placebo and followed for four years; then all patients were maintained on simvastatin for another four years. Survival at eight years was significantly better for those patients who were treated with simvastatin throughout the eight-year course (89 versus 60 percent).</div><div class=\"graphic_reference\">Data from Wenke K, Meiser B, Thiery J, et al. Circulation 2003; 107:93.</div><div id=\"graphicVersion\">Graphic 60917 Version 3.0</div></div></div>"},"60918":{"type":"graphic_table","displayName":"Maintenance agents for lung transplant","title":"Agents for maintenance of immunosuppression following lung transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Agents for maintenance of immunosuppression following lung transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup width=\"25%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug*</td> <td class=\"subtitle1\">Mechanism of action</td> <td class=\"subtitle1\">Suggested dose*</td> <td class=\"subtitle1\">Drug monitoring</td> <td class=\"subtitle1\">Metabolism/transporter effects with selected drug interactions<sup>&#182;</sup></td> <td class=\"subtitle1\">Common major adverse effects</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Glucocorticoids</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Methylprednisolone, prednisone</td> <td> <p>Inhibits humoral and cell-mediated immunity</p> Binds with DNA sequences (+/&ndash; nuclear factor-kB) to inhibit production of inflammatory cytokines</td> <td> <p>At time of transplant: 500 to 1000 mg methylprednisolone intravenously</p> <p>Maintenance oral prednisone dose: 0.5 to 1 mg/kg per day initially after transplant with taper to a goal of 5 to 10 mg per day over several months to one year</p> Protocols may vary by institution</td> <td>N/A</td> <td> <p>Cytochrome P450 3A4 substrate</p> Numerous clinically relevant interactions in transplant patients<sup>&#9674;</sup></td> <td> <p>Diabetes</p> <p>GERD, PUD</p> <p>Osteoporosis</p> <p>Skeletal muscle wasting</p> <p>Hypertension</p> <p>Hypercholesterolemia</p> <p>Change in appetite</p> Weight gain</td> <td>Do not stop abruptly; may be taken with food to reduce dyspepsia</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Calcineurin inhibitors</td> </tr> <tr> <td class=\"indent1\">Cyclosporine<sup>&#916;</sup></td> <td>Prevents T cell activation and proliferation by inhibiting the production of interleukins and other cytokines</td> <td> <p>2 to 3 mg/kg per day intravenously at time of transplantation given in a 24 hour infusion or 1 to 1.5 mg/kg in two or more four hour infusions and until patient can tolerate oral intake. Adjust dose to target trough concentration of 250 to 350 ng/mL and two hour post dose (C2) concentration of 900 to 1200 ng/mL</p> Maintenance oral dose: 3 to 5 mg/kg twice per day 12 hours apart at a consistent time each day in relation to meals and adjusted according to trough or C2 concentration as above</td> <td> <p>Monitor BUN, Cr, magnesium, potassium</p> Trough levels typically used but levels drawn two hours post dose (C2) are most accurate</td> <td> <p>Metabolized by cytochrome P450 enzyme system</p> <p>Cytochrome P450 3A4 substrate/inhibitor, p-glycoprotein substrate/inhibitor</p> <p>Marked increase in levels of statin drugs when co-administered</p> Numerous clinically relevant interactions in transplant patients<sup>&#9674;</sup></td> <td> <p>Renal dysfunction including acute nephrotoxicity</p> <p>Hypertension</p> <p>Hypercholesterolemia</p> <p>Gingival hyperplasia</p> <p>Neurotoxicity (tremor, headache, encephalopathy, focal deficits)</p> Hirsutism</td> <td> <p>High inter- and intra-individual absorption variability</p> Blood concentration monitoring is necessary for any change in formulation (including switch between generics or brands) to determine need for dose alteration. The microemulsion form, which is also known as \"modified\" (Neoral) is generally better absorbed than the non-modified form (Sandimmune)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tacrolimus<sup>&#916;</sup></td> <td>Prevents T cell activation and proliferation by inhibiting the production of interleukins and other cytokines</td> <td> <p>Initial dose sublingually: 0.04 to 0.05 mg/kg per day in two divided doses (eg, 1 to 2 mg sublingually every 12 hours)<sup>[1,2]<sup><span style=\"font-size: 13px;\">&#167;</span></sup></sup>; OR</p> <p>Initial dose intravenously: 0.03 to 0.05 mg/kg per day by continuous infusion over 24 hours; risk of infusion reactions and other&nbsp;toxicities (refer to accompanying text)</p> <p>Maintenance oral dose: 0.05 mg/kg twice daily taken 12 hours apart at a consistent time each day in relation to meals. </p> <p>Initial and maintenance: Adjust dose to target whole blood concentration of 8 to 15 ng/mL</p> </td> <td> <p>Monitor glucose, LFTs, BUN, Cr, calcium, magnesium, potassium</p> Monitor trough levels</td> <td> <p>Metabolized by cytochrome P450 enzyme system</p> <p>Cytochrome P450 3A4 substrate</p> Numerous clinically relevant interactions in transplant patients<sup>&#9674;</sup></td> <td> <p>Renal dysfunction</p> <p>Diabetes</p> <p>Hypertension (less than cyclosporine)</p> <p>Hypercholesterolemia</p> <p>Altered mental status</p> <p>Headache</p> Focal neurological deficits</td> <td> <p>High inter- and intra-individual absorption variability</p> Blood concentration monitoring is necessary for change in formulation (including switch between generics or brands) and between methods of administration (eg, sublingual, oral, and IV administration)&nbsp;to determine need for dose alteration</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Antimetabolites</td> </tr> <tr> <td class=\"indent1\">Mycophenolate mofetil (CellCept)</td> <td> <p>Nucleotide blocking agent</p> Inhibits T cell proliferation by blocking nucleotide synthesis</td> <td> <p>IV equivalent to oral</p> <p>Starting dose: 250 mg twice daily within 72 hours after transplantation</p> <p>Gradually increase dose by 250 mg twice daily to a goal dose of 1000 mg twice daily (with tacrolimus) or 1500 mg twice daily (with cyclosporine)</p> <p>Alternatively, patients may be initiated at goal dose</p> <p>Oral doses should be taken on an empty stomach or at a consistent time each day in relation to meals if taken with food to improve tolerability</p> Giving total daily dose in three or four equally divided doses might improve GI tolerability</td> <td> <p>Monitor WBC</p> <p>Dose adjusted for leukopenia</p> <p>Serum concentration monitoring not routinely performed<sup>&#165;</sup></p> </td> <td>Levels decreased by:<sup><span style=\"font-size: 13px;\">&#165;</span></sup> <ul class=\"decimal_heading\"> <li>Antacids </li> <li>Aluminum hydroxide </li> <li>Magnesium (oral) </li> <li>Bile acid sequestrants (eg, cholestyramine) </li> <li>Cyclosporine (but not tacrolimus) </li> <li>Magnesium (oral) </li> <li>Proton pump inhibitors </li> <li>Rifamycins (eg, rifampin) </li> </ul> Levels increased by:<sup><span style=\"font-size: 13px;\">&#165;</span></sup> <ul class=\"decimal_heading\"> <li>Acyclovir&nbsp; </li> <li>Probenecid </li> </ul> <p>May inactivate protein bound drugs, especially hormonal contraceptives (use nonhormonal method of contraception)</p> </td> <td> <p>Nausea, vomiting, diarrhea, abdominal pain</p> <p>Diarrhea may occur after months of treatment</p> <p>GI tolerability may improve with more frequent dosing (same total daily dose) or by changing to enteric-coated mycophenolate sodium (below)&nbsp;</p> <p>Myelosuppression, anemia</p> Increased risk of CMV disease</td> <td> <p>Serum&nbsp;concentration monitoring&nbsp;is not routinely performed<sup>&#165;</sup></p> <p>&nbsp;</p> </td> </tr> <tr> <td class=\"indent1\">Mycophenolate sodium, enteric coated (Myfortic)</td> <td> <p>Nucleotide blocking agent</p> Inhibits T cell proliferation by blocking nucleotide synthesis</td> <td> <p>360 to 720 mg orally twice per day on an empty stomach</p> To convert from mycophenolate mofetil 1000 mg every 12 hours, switch to mycophenolate sodium enteric coated 720 mg every 12 hours</td> <td> <p>Monitor WBC</p> <p>Dose adjusted for leukopenia</p> <p>Serum concentration monitoring not routinely performed<sup>&#165;</sup></p> </td> <td>Levels decreased by:<sup><span style=\"font-size: 13px;\">&#165;</span></sup> <ul class=\"decimal_heading\"> <li>Antacids&nbsp;&nbsp; </li> <li>Aluminum hydroxide </li> <li>Bile acid sequestrants (eg, cholestyramine) </li> <li>Cyclosporine (but not tacrolimus) </li> <li>Magnesium (oral) </li> <li>Rifamycins (eg, rifampin) </li> </ul> Levels increased by:<sup><span style=\"font-size: 13px;\">&#165;</span></sup> <ul class=\"decimal_heading\"> <li>Acyclovir </li> <li>Probenecid </li> </ul> <p>May inactivate protein bound drugs, especially hormonal contraceptives (use nonhormonal method of contraception)</p> </td> <td> <p>Nausea, vomiting</p> <p>Diarrhea</p> <p>Myelosuppression, anemia</p> Increased risk of CMV disease</td> <td> <p>Serum&nbsp;concentration monitoring&nbsp;is not routinely performed<sup><span style=\"font-size: 13px;\">&#165;</span></sup></p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Azathioprine</td> <td> <p>Nucleotide blocking agent</p> Inhibits T and B cell proliferation by blocking nucleotide synthesis</td> <td> <p>IV equivalent to oral</p> Starting dose: 1 to 2 mg/kg daily and adjusted to prevent development of leukopenia</td> <td> <p>Monitor WBC</p> <p>Dose adjusted for leukopenia</p> Monitor LFTs</td> <td>Levels increased by: <ul class=\"decimal_heading\"> <li>Allopurinol (Preferably avoid co-administration. If co-administration required, reduce azathioprine by up to 70 percent.) </li> </ul> <p>Use with febuxostat is contraindicated</p> May diminish anticoagulant effects of warfarin</td> <td> <p>Nausea, vomiting</p> <p>Diarrhea</p> <p>Bone marrow suppression</p> Liver abnormality</td> <td>Requires TPMT enzyme for metabolism. Individuals with profound initial side effects may be deficient in this enzyme</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">mTOR inhibitors </td> </tr> <tr> <td class=\"indent1\">Sirolimus</td> <td>Inhibits T cell proliferation by cell cycle arrest in G1 phase</td> <td> <p>Sirolimus is initiated at least three months post-transplantation, due to effects on wound healing</p> <p>Administer sirolimus four hours after cyclosporine, when both medications are being used</p> <p>Liquid and tablet form</p> Starting dose: 2 mg orally per day. Adjusted to maintain a trough target between 8 and 12 ng/mL when used without calcineurin inhibitor. Adjust to maintain trough level between 4 and 8 ng/mL when used with calcineurin inhibitor.</td> <td> <p>Monitor CBC, LFTs</p> Obtain trough level three to four days after initiation and seven days after any change in dose</td> <td> <p>Metabolized by cytochrome P450 3A enzyme system</p> <p>Cytochrome P450 3A4 substrate, p-glycoprotein substrate</p> <p>Cyclosporine dose should be decreased by one-half to two-thirds when co-administered with sirolimus</p> Numerous clinically relevant interactions in transplant patients<sup>&#9674;</sup></td> <td> <p>Delayed wound healing</p> <p>Fatal airway anastomotic dehiscence if administered early after lung transplantation</p> <p>Myelosuppression</p> <p>Hypercholesterolemia</p> <p>Pulmonary toxicity</p> <p>LFT abnormalities</p> <p>Diarrhea</p> Nausea</td> <td>Associated with increased incidence of deep venous thrombosis<sup>[3]</sup></td> </tr> <tr> <td class=\"indent1\">Everolimus</td> <td>Inhibits T cell proliferation by cell cycle arrest in G1 phase</td> <td> <p>Everolimus is initiated at least three months post-transplantation, due to effects on wound healing</p> <p>Starting dose: 1.5 mg orally every 12 hours and adjusted to maintain a trough target between 3 and 12 ng/mL in combination with cyclosporine and a glucocorticoid</p> In combination with tacrolimus, higher doses of everolimus may be needed to maintain trough levels within target range compared to doses when used with cyclosporine</td> <td> <p>Monitor CBC, LFTs, BUN, Cr, glucose</p> Monitor trough levels; steady state levels are reached four to five days after a dose change</td> <td> <p>Metabolized by cytochrome P450 3A enzyme system</p> <p>Cytochrome P450 3A4 substrate, p-glycoprotein substrate/inhibitor</p> <p>Cyclosporine dose should be decreased by one-half to two-thirds when co-administered with everolimus</p> Numerous clinically relevant interactions in transplant patients<sup>&#9674;</sup></td> <td> <p>Delayed wound healing</p> <p>Bone marrow suppression</p> <p>Hypercholesterolemia</p> <p>Pulmonary toxicity</p> <p>Diarrhea</p> Nausea</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GERD: gastroesophageal reflux disease; PUD: peptic ulcer disease; Cr: creatinine; LFT: liver function tests; BUN: blood urea nitrogen; ECG: electrocardiogram; WBC: white blood cell count; CMV: cytomegalovirus; MPA: mycophenolic acid (active metabolite of mycophenolate);&nbsp;TPMT: thiopurine methyltransferase; mTOR: mechanistic target of rapamycin; CBC: complete blood count.<br />* Initial immunosuppressant doses shown should be adjusted based upon patient-specific factors including organ function and potential drug interactions. Drug therapy should be managed by transplant specialists with expertise in therapeutic drug monitoring and doses should be adjusted based upon measurement of immunosuppressant concentrations. The US Food and Drug Administration has not approved any medications specifically for lung transplantation, so the doses are suggested based on the experience of large lung transplantation centers. Dosing protocols vary by institution.<br />¶ Immunosuppressants are subject to numerous drug interactions, particularly with drugs or foods that inhibit or induce cytochrome CYP 450 3A4 and/or P-glycoprotein transporters (P-gp). Drug therapy should be managed by transplant specialists with expertise in therapeutic drug monitoring and doses adjusted based upon measurement of immunosuppressant concentrations, particularly whenever drug therapy is altered. The table is NOT a complete list of all possible interactions. To determine specific drug interactions and suggestions for management,&nbsp;the Lexi-Interact program included within UpToDate may be used.<br />Δ For additional information, refer to UpToDate topic on pharmacology and side effects of cyclosporine and tacrolimus.<br /><FONT class=lozenge>◊</FONT> For additional information, refer to UpToDate table on major drug interactions with immunosuppressants: cyclosporine, tacrolimus, sirolimus, or everolimus.<br />§ Sublingual administration of tacrolimus may be an alternative for lung transplant recipients who are unable to swallow capsules<SUP>[1,2]</SUP>.<br />¥ Serum levels of mycophenolate active metabolite&nbsp;(MPA) can be altered by&nbsp;some drug interactions. However, adjustment of mycophenolate dose&nbsp;may not be necessary depending upon&nbsp;the expected&nbsp;effect of the interaction&nbsp;and patient factors (eg, rejection risk); single MPA serum levels are not reliable for&nbsp;determining mycophenolate exposure or predicting efficacy and&nbsp;are not routinely performed (refer to accompanying text).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Tsapepas D, Saal S, Benkert S, et al. Sublingual tacrolimus: a pharmacokinetic evaluation pilot study. Pharmacotherapy 2013; 33:31.</LI>&#xD;&#xA;<LI>Watkins KD, Boettger RF, Hanger KM, et al. Use of sublingual tacrolimus in lung transplant recipients. J Heart Lung Transplant 2012; 31:127.</LI>&#xD;&#xA;<LI>Ahya VN, McShane PJ, Baz MA, et al. Increased risk of venous thromboembolism with a sirolimus based immunosuppression regimen in lung transplantation. J Heart Lung Transplant 2011; 30:175.</LI></OL>Prepared with data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Bhorade SM, Stern E. Immunosuppression for lung transplantation. Proc Am Thorac Soc 2009; 6:47.</LI>&#xD;&#xA;<LI>Korom S, Boehler A, Weder W. Immunosuppressive therapy in lung transplantation: state of the art. Eur J Cardiothorac Surg 2009; 35:1045.</LI>&#xD;&#xA;<LI>Floreth T, Bhorade SM. Current trends in immunosuppression for lung transplantation. Semin Respir Crit Care Med 2010; 31:172.</LI></OL></div><div id=\"graphicVersion\">Graphic 60918 Version 8.0</div></div></div>"},"60919":{"type":"graphic_table","displayName":"Breath tests chronic diarrhea","title":"Breath tests that may be applied to patients with chronic diarrhea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Breath tests that may be applied to patients with chronic diarrhea</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Agent administered</td> <td class=\"subtitle1\">Substance measured in breath</td> <td class=\"subtitle1\">Condition assessed</td> </tr> <tr> <td>Lactose</td> <td>H2</td> <td>Lactase deficiency</td> </tr> <tr> <td>Sucrose</td> <td>H2</td> <td>Sucrase deficiency</td> </tr> <tr> <td>Glucose</td> <td>H2</td> <td>Bacterial overgrowth of small intestine</td> </tr> <tr> <td>Lactulose</td> <td>H2</td> <td>Bacterial overgrowth of small intestine; determination of orocecal transit time</td> </tr> <tr> <td>14C-xylose</td> <td>14C</td> <td>Bacterial overgrowth of small intestine</td> </tr> <tr> <td>14C-glycocholate</td> <td>14C</td> <td>Bacterial overgrowth of small intestine</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission from: Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116:1464.</div><div id=\"graphicVersion\">Graphic 60919 Version 3.0</div></div></div>"},"60921":{"type":"graphic_table","displayName":"Vehicle selection","title":"Topical therapy: Vehicle selection for specific body sites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Topical therapy: Vehicle selection for specific body sites</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Vehicle</td> <td class=\"subtitle1\">Smooth, nonhairy skin; thick, hyperkeratotic lesions</td> <td class=\"subtitle1\">Hairy areas</td> <td class=\"subtitle1\">Palms, soles</td> <td class=\"subtitle1\">Infected areas</td> <td class=\"subtitle1\">Between skin folds; moist, macerated lesions</td> </tr> <tr> <td>Ointment</td> <td class=\"centered\">+++</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+++</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Cream</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> </tr> <tr> <td>Lotion</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">++</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> </tr> <tr> <td>Solution</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+++</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+++</td> <td class=\"centered\">++</td> </tr> <tr> <td>Gel</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">++</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>Foam</td> <td class=\"centered\">++</td> <td class=\"centered\">+++</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> <td class=\"centered\">++</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">+: infrequently used; ++: acceptable vehicle; +++: preferred vehicle.</div><div class=\"graphic_reference\">Adapted from: Goldstein BG, Goldstein AO. Practical Dermatology 2nd ed, Mosby-Year Book, Inc, St. Louis, MO, 1997.</div><div id=\"graphicVersion\">Graphic 60921 Version 4.0</div></div></div>"},"60922":{"type":"graphic_table","displayName":"Animal handling antigens in HP","title":"Hypersensitivity pneumonitides associated with veterinary work and animal handling","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypersensitivity pneumonitides associated with veterinary work and animal handling</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">Environmental source</td>\n\n      <td class=\"subtitle1\">Major causative antigen</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Laboratory worker's lung (rats, gerbils)</td>\n\n      <td>Urine, serum, pelts, proteins</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pituitary snuff taker's disease</td>\n\n      <td>Dried, powdered neurohypophysis (bovine and porcine pituitary proteins)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Furrier's lung (sewing furs; animal fur dust)</td>\n\n      <td>Animal pelts</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Bat lung (bat droppings)</td>\n\n      <td>Bat serum protein</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Fish meal worker's lung</td>\n\n      <td>Fish meal</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Coptic lung (mummy handler's lung) </td>\n\n      <td>Cloth wrappings of mummies</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mollusc shell HP</td>\n\n      <td>Sea-snail shell</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pearl oyster shell pneumonitis</td>\n\n      <td>Oyster shells</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 60922 Version 1.0</div></div></div>"},"60923":{"type":"graphic_table","displayName":"Avoidance measures for dust mites","title":"Avoidance measures for dust mites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Avoidance measures for dust mites</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">First: Bedrooms</td> </tr> <tr> <td class=\"indent1\">Cover pillows and mattresses with zippered covers, which are impermeable to mites and mite allergens.</td> </tr> <tr> <td class=\"indent1\">Wash sheets, pillowcases, and blankets in hot or warm water with detergent or dry in an electric dryer on the hot setting weekly. When necessary, blankets should be replaced with those that can be washed. Comforters (or duvets) should be removed or covered with fine woven covers.</td> </tr> <tr> <td class=\"indent1\">Use washable, vinyl, or roll-type window covers.</td> </tr> <tr> <td class=\"indent1\">Remove clutter, soft toys, and upholstered furniture.</td> </tr> <tr> <td class=\"indent1\">Where possible, carpets should be removed or replaced with area rugs that can be cleaned/washed.</td> </tr> <tr> <td class=\"subtitle1_single\">Second: Rest of house</td> </tr> <tr> <td class=\"indent1\">Reduce upholstered furniture, particularly old sofas.</td> </tr> <tr> <td class=\"indent1\">Replace carpets with polished flooring where possible. Carpets on concrete slabs or over poorly-ventilated crawl spaces are a problem and should be replaced with polished flooring, if possible.</td> </tr> <tr> <td class=\"indent1\">Vacuum weekly using a cleaner with a high-efficiency particulate air (HEPA) filtration system.</td> </tr> <tr> <td class=\"indent1\">Window coverings should be washable, vinyl, or roll-type.</td> </tr> <tr> <td class=\"indent1\">Control humidity to &#60;50% relative humidity at normal temperatures (ie, 68 to 72&#176;F).</td> </tr> <tr> <td class=\"subtitle1_single\">Third: Changing houses*</td> </tr> <tr> <td class=\"indent1\">In general, allergy sufferers should not be encouraged to move from their home except in those cases where they are living in basements or overtly damp housing.</td> </tr> <tr> <td class=\"indent1\">Individuals who are allergic to mites (or molds) should be advised about the potential benefit of moving to an apartment (second floor or higher) or a house with second floor bedrooms and wooden floors.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The average family in the United States moves approximately every four years.</div><div id=\"graphicVersion\">Graphic 60923 Version 6.0</div></div></div>"},"60924":{"type":"graphic_table","displayName":"Hemodyn pulm thromboend II","title":"Hemodynamics after pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hemodynamics after pulmonary thromboendarterectomy for chronic thromboembolic pulmonary hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">Preoperative</td>\n\n      <td class=\"subtitle1\">Postoperative</td>\n\n      <td class=\"subtitle1\">Follow-up</td>\n\n    </tr>\n\n    <tr>\n\n      <td>PA mean pressure (mmHg)</td>\n\n      <td>48 &plusmn; 12</td>\n\n      <td>27 &plusmn; 8*</td>\n\n      <td>24 &plusmn; 10</td>\n\n    </tr>\n\n    <tr>\n\n      <td>PA systolic pressure (mmHg)</td>\n\n      <td>80 &plusmn; 21</td>\n\n      <td>44 &plusmn; 15*</td>\n\n      <td>39 &plusmn; 17*</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiac output (L/min)</td>\n\n      <td>3.7 &plusmn; 1.2</td>\n\n      <td>6.0 &plusmn; 1.1*</td>\n\n      <td>4.8 &plusmn; 1.0*</td>\n\n    </tr>\n\n    <tr>\n\n      <td>PVR (dynes x sec x cm-5)</td>\n\n      <td>971 &plusmn; 551</td>\n\n      <td>232 &plusmn; 111*</td>\n\n      <td>282 &plusmn; 251</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_lgnd\">Immediate and late pulmonary hemodynamic results in 47 of the first 150 patients in whom postoperative values were obtained 48 to 72 hours after admission to the intensive care unit, off all vasoactive drugs, and who returned for follow-up catheterization 6 to 24 months after surgery. After significant improvements in all parameters after surgery, there were highly significant reductions in pulmonary artery (PA) systolic pressure and cardiac output at late follow-up.</div><div class=\"graphic_footnotes\">* Statistically significant compared to preoperative values.</div><div id=\"graphicVersion\">Graphic 60924 Version 1.0</div></div></div>"},"60926":{"type":"graphic_figure","displayName":"Cutaneous innervation of the lower extremity","title":"Cutaneous innervation of the lower extremity","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Cutaneous innervation of the lower extremity</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/SURG/60926_Lowerextcutaneousinnerv.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">n.: nerve.</div><div id=\"graphicVersion\">Graphic 60926 Version 4.0</div></div></div>"},"60927":{"type":"graphic_table","displayName":"Antiretroviral drugs","title":"Classification of antiretroviral drugs (agents listed alphabetically)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of antiretroviral drugs (agents listed alphabetically)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug (abbreviations)</td> <td class=\"subtitle1\">Brand name in the United States</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs)</td> </tr> <tr> <td class=\"indent1\">Abacavir (ABC)</td> <td>Ziagen</td> </tr> <tr> <td class=\"indent1\">Didanosine (ddI)</td> <td>Videx, Videx EC</td> </tr> <tr> <td class=\"indent1\">Emtricitabine (FTC)</td> <td>Emtriva</td> </tr> <tr> <td class=\"indent1\">Lamivudine (3TC)</td> <td>Epivir</td> </tr> <tr> <td class=\"indent1\">Stavudine (d4T)</td> <td>Zerit</td> </tr> <tr> <td class=\"indent1\">Tenofovir alafenamide (TAF)&nbsp;</td> <td>Vemlidy&nbsp;</td> </tr> <tr> <td class=\"indent1\">Tenofovir <span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-bidi;\">disoproxil fumarate&nbsp;</span>(TDF)</td> <td>Viread*</td> </tr> <tr> <td class=\"indent1\">Zalcitabine (ddC) (no longer marketed in most countries)</td> <td>Hivid</td> </tr> <tr> <td class=\"indent1\">Zidovudine (ZDV, AZT)</td> <td>Retrovir</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Non-nucleoside reverse transcriptase inhibitors (NNRTIs)</td> </tr> <tr> <td class=\"indent1\">Delavirdine (DLV)</td> <td>Rescriptor</td> </tr> <tr> <td class=\"indent1\">Efavirenz (EFV)</td> <td>Sustiva</td> </tr> <tr> <td class=\"indent1\">Etravirine (ETR)</td> <td>Intelence</td> </tr> <tr> <td class=\"indent1\">Nevirapine (NVP)</td> <td>Viramune, Viramune XR</td> </tr> <tr> <td class=\"indent1\">Rilpivirine (RPV)</td> <td>Edurant</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Protease inhibitors (PIs)</td> </tr> <tr> <td class=\"indent1\">Amprenavir (APV) (no longer marketed in most countries)</td> <td>Agenerase</td> </tr> <tr> <td class=\"indent1\">Atazanavir (ATV)</td> <td>Reyataz</td> </tr> <tr> <td class=\"indent1\">Atazanavir-cobicistat (ATV/COBI)</td> <td>Evotaz</td> </tr> <tr> <td class=\"indent1\">Darunavir (DRV)</td> <td>Prezista</td> </tr> <tr> <td class=\"indent1\">Darunavir-cobicistat (DRV/COBI)</td> <td>Prezcobix</td> </tr> <tr> <td class=\"indent1\">Fosamprenavir (FPV)</td> <td>Lexiva</td> </tr> <tr> <td class=\"indent1\">Indinavir (IDV)</td> <td>Crixivan</td> </tr> <tr> <td class=\"indent1\">Lopinavir/ritonavir boosting (LPV/r)</td> <td>Kaletra</td> </tr> <tr> <td class=\"indent1\">Nelfinavir (NFV)</td> <td>Viracept</td> </tr> <tr> <td class=\"indent1\">Ritonavir (RTV) (used as a pharmacokinetic boosting agent)</td> <td>Norvir</td> </tr> <tr> <td class=\"indent1\">Saquinavir (SQV)</td> <td>Invirase</td> </tr> <tr> <td class=\"indent1\">Tipranavir (TPV)</td> <td>Aptivus</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Fusion inhibitor</td> </tr> <tr> <td class=\"indent1\">Enfuvirtide (T-20)</td> <td>Fuzeon</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Integrase strand transfer inhibitors (INSTIs)</td> </tr> <tr> <td class=\"indent1\">Dolutegravir (DTG)</td> <td>Tivicay</td> </tr> <tr> <td class=\"indent1\">Elvitegravir (EVG)</td> <td><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif'; color: #000000; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;\">Vitekta</span></td> </tr> <tr> <td class=\"indent1\">Raltegravir (RAL)</td> <td>Isentress</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">CCR5 antagonist</td> </tr> <tr> <td class=\"indent1\">Maraviroc (MVC)</td> <td>Selzentry</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Fixed-dose combinations</td> </tr> <tr> <td class=\"indent1\">Abacavir-lamivudine (ABC/3TC)</td> <td>Epzicom</td> </tr> <tr> <td class=\"indent1\">Abacavir-lamivudine-zidovudine (ABC/3TC/ZDV)</td> <td>Trizivir</td> </tr> <tr> <td class=\"indent1\">Bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF)</td> <td>Biktarvy</td> </tr> <tr> <td class=\"indent1\">Dolutegravir-abacavir-lamivudine (DTG/ABC/3TC)</td> <td>Triumeq</td> </tr> <tr> <td class=\"indent1\">Dolutegravir-rilpivirine (DTG/RPV)</td> <td>Juluca</td> </tr> <tr> <td class=\"indent1\">Efavirenz-<span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-bidi;\">emtricitabine-</span>tenofovir <span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-bidi;\">disoproxil fumarate</span> (EFV/FTC/TDF)</td> <td>Atripla</td> </tr> <tr> <td class=\"indent1\">Elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide (ECF/TAF or EVG/COBI/FTC/TAF)</td> <td>Genvoya&nbsp;</td> </tr> <tr> <td class=\"indent1\">Elvitegravir-cobicistat-<span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-bidi;\">emtricitabine-</span>tenofovir <span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-bidi;\">disoproxil fumarate</span> (ECF/TDF or EVG/COBI/FTC/TDF)</td> <td>Stribild</td> </tr> <tr> <td class=\"indent1\">Rilpivirine-emtricitabine-tenofovir alafenamide (RPV/FTC/TAF)</td> <td>Odefsey</td> </tr> <tr> <td class=\"indent1\">Rilpivirine-emtricitabine-tenofovir <span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-bidi;\">disoproxil fumarate </span>(RPV/FTC/TDF)</td> <td>Complera</td> </tr> <tr> <td class=\"indent1\">Tenofovir alafenamide-emtricitabine (TAF/FTC)</td> <td>Descovy</td> </tr> <tr> <td class=\"indent1\">Tenofovir <span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-theme-font: minor-bidi;\">disoproxil fumarate</span>-emtricitabine (TDF/FTC)</td> <td>Truvada</td> </tr> <tr> <td class=\"indent1\">Zidovudine-lamivudine (ZDV/3TC)</td> <td>Combivir</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Brand names shown are for preparations available in United States and some other countries.<br />* Nucleotide reverse transcriptase inhibitor.</div><div id=\"graphicVersion\">Graphic 60927 Version 21.0</div></div></div>"},"60928":{"type":"graphic_picture","displayName":"Optic disc Frisen grade 5","title":"Optic disc Frisén grade V","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Optic disc Fris&#233;n grade V</div><div class=\"cntnt\"><img style=\"width:450px; height:341px;\" src=\"images/NEURO/60928_Optic_disc_Frisen_grade_5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fris&#233;n Grade V showing complete obscuration of a major vessel on the optic disc and partial obscuration of all major vessels.</div><div class=\"graphic_reference\">Courtesy of Michael Wall, MD.</div><div id=\"graphicVersion\">Graphic 60928 Version 2.0</div></div></div>"},"60929":{"type":"graphic_table","displayName":"Trials cervical cerclage","title":"Summary of randomized trials on cervical cerclage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of randomized trials on cervical cerclage</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Delivery before 33 completed weeks</td> <td class=\"subtitle1\" rowspan=\"2\">Significance</td> </tr> <tr> <td class=\"subtitle2\">n</td> <td class=\"subtitle2\">Percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">MRC/RCOG</td> </tr> <tr> <td class=\"indent1\">Cerclage (n = 647)</td> <td class=\"centered\">83</td> <td class=\"centered\">13</td> <td class=\"centered\" rowspan=\"2\">p&#8804;0.05</td> </tr> <tr> <td class=\"indent1\">No cerclage (n = 645)</td> <td class=\"centered\">110</td> <td class=\"centered\">17</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Rush et al, (1984)</td> </tr> <tr> <td class=\"indent1\">Cerclage (n = 96)</td> <td class=\"centered\">12</td> <td class=\"centered\">13</td> <td class=\"centered\" rowspan=\"2\">NS</td> </tr> <tr> <td class=\"indent1\">No cerclage (n = 98)</td> <td class=\"centered\">10</td> <td class=\"centered\">10</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Lazar et al, (1984)</td> </tr> <tr> <td class=\"indent1\">Cerclage (n = 268)</td> <td class=\"centered\">4</td> <td class=\"centered\">1</td> <td class=\"centered\" rowspan=\"2\">NS</td> </tr> <tr> <td class=\"indent1\">No cerclage (n = 238)</td> <td class=\"centered\">1</td> <td class=\"centered\">&#60;1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Dor et al, (1982)</td> </tr> <tr> <td class=\"indent1\">Cerclage (n = 25)</td> <td class=\"centered\">6</td> <td class=\"centered\">24</td> <td class=\"centered\" rowspan=\"2\">NS</td> </tr> <tr> <td class=\"indent1\">No cerclage (n = 25)</td> <td class=\"centered\">5</td> <td class=\"centered\">20</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRC/RCOG: Medical Research Council/Royal College of Obstetricians and Gynecologists; NS: no significant difference between cerclage and no cerclage.</div><div class=\"graphic_reference\">Adapted from data in MRC/RCOG, Br J Obstet Gynecol 1993; 100:516.</div><div id=\"graphicVersion\">Graphic 60929 Version 3.0</div></div></div>"},"60930":{"type":"graphic_table","displayName":"GIST progn site size mit","title":"Rates of progression-free survival for gastrointestinal stromal tumors (GISTs) of stomach, small intestine, and rectum grouped by mitotic rate and tumor size*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rates of progression-free survival for gastrointestinal stromal tumors (GISTs) of stomach, small intestine, and rectum grouped by mitotic rate and tumor size*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Tumor size<br /> (cm)</td> <td class=\"subtitle1\" rowspan=\"2\">Mitotic rate<br /> (HPFs)</td> <td class=\"subtitle1\" colspan=\"4\"> <p>Percent of patients progression-free during long-term follow-up</p> <p>Primary site</p> </td> </tr> <tr> <td class=\"subtitle2\">Gastric</td> <td class=\"subtitle2\">Jejunum/ileum</td> <td class=\"subtitle2\">Duodenum</td> <td class=\"subtitle2\">Rectum</td> </tr> <tr> <td>&#8804;2</td> <td>&#8804;5/50</td> <td>100</td> <td>100</td> <td>100</td> <td>100</td> </tr> <tr> <td>2 to 5</td> <td>&#8804;5/50</td> <td>98.1</td> <td>95.7</td> <td>91.7</td> <td>91.5</td> </tr> <tr> <td>5 to 10</td> <td>&#8804;5/50</td> <td>96.4</td> <td>76</td> <td rowspan=\"2\">66*</td> <td rowspan=\"2\">43*</td> </tr> <tr> <td>&#62;10</td> <td>&#8804;5/50</td> <td>88</td> <td>48</td> </tr> <tr> <td class=\"sublist_other\" colspan=\"6\">&nbsp;</td> </tr> <tr> <td>&#8804;2</td> <td>&#62;5/50</td> <td>100<sup>&#182;</sup></td> <td>50<sup>&#182;</sup></td> <td>&ndash;</td> <td>46</td> </tr> <tr> <td>2 to 5</td> <td>&#62;5/50</td> <td>84</td> <td>27</td> <td>50</td> <td>48</td> </tr> <tr> <td>5 to 10</td> <td>&#62;5/50</td> <td>45</td> <td>15</td> <td rowspan=\"2\">14*</td> <td rowspan=\"2\">29*</td> </tr> <tr> <td>10</td> <td>&#62;5/50</td> <td>14</td> <td>10</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Based on long-term follow-up studies on 1055 gastric, 629 small intestinal, 144 duodenal, and 111 rectal cancers.</div><div class=\"graphic_footnotes\">HPFs: high power fields.<br />* Data are combined for tumors &gt;5 cm.<br />¶ Small number of cases.</div><div class=\"graphic_reference\">Adapted from: Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites.&nbsp;Semin Diagn Pathol 2006; 23:70.</div><div id=\"graphicVersion\">Graphic 60930 Version 6.0</div></div></div>"},"60931":{"type":"graphic_table","displayName":"Properties of topical agents and dressing materials","title":"Properties of topical agents and dressing materials","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Properties of topical agents and dressing materials</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Actions</td> <td class=\"subtitle1\">Indications/use</td> <td class=\"subtitle1\">Precautions/contraindications</td> </tr> <tr class=\"divider_bottom\"> <td>Alginates/CMC*</td> <td> <ul> <li>Absorb fluid. </li> <li>Promote autolytic debridement. </li> <li>Moisture control. </li> <li>Conformability to wound bed. </li> </ul> </td> <td> <ul> <li>Moderate to high exuding wounds. </li> <li>Special cavity presentations in the form of rope or ribbon. </li> <li>Combined presentation with silver for antimicrobial activity. </li> </ul> </td> <td> <ul> <li>Do not use on dry/necrotic wounds. </li> <li>Use with caution on friable tissue (may cause bleeding). </li> <li>Do not pack cavity wounds tightly. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Foams</td> <td> <ul> <li>Absorb fluid. </li> <li>Moisture control. </li> <li>Conformability to wound bed. </li> </ul> </td> <td> <ul> <li>Moderate to high exuding wounds. </li> <li>Special cavity presentations in the form of strips or ribbon. </li> <li>Low-adherent versions available for patients with fragile skin. </li> <li>Combined presentation with silver or PHMB for antimicrobial activity. </li> </ul> </td> <td> <ul> <li>Do not use on dry/necrotic wounds or those with minimal exudate. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Honey</td> <td> <ul> <li>Rehydrate wound bed. </li> <li>Promote autolytic debridement. </li> <li>Antimicrobial action. </li> </ul> </td> <td> <ul> <li>Sloughy, low to moderate exuding wounds. </li> <li>Critically colonized wounds or clinical signs of infection. </li> </ul> </td> <td> <ul> <li>May cause \"drawing\" pain (osmotic effect). </li> <li>Known sensitivity. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Hydrocolloids</td> <td> <ul> <li>Absorb fluid. </li> <li>Promote autolytic debridement. </li> </ul> </td> <td> <ul> <li>Clean, low to moderate exuding wounds. </li> <li>Combined presentation with silver for antimicrobial activity. </li> </ul> </td> <td> <ul> <li>Do not use on dry/necrotic wounds or high exuding wounds. </li> <li>May encourage overgranulation. </li> <li>May cause maceration. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Hydrogels</td> <td> <ul> <li>Rehydrate wound bed. </li> <li>Moisture control. </li> <li>Promote autolytic debridement. </li> <li>Cooling. </li> </ul> </td> <td> <ul> <li>Dry/low to moderate exuding wounds. </li> <li>Combined presentation with silver for antimicrobial activity. </li> </ul> </td> <td> <ul> <li>Do not use on highly exuding wounds or where anaerobic infection is suspected. </li> <li>May cause maceration. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Iodine</td> <td> <ul> <li>Antimicrobial action. </li> </ul> </td> <td> <ul> <li>Critically colonized wounds or clinical signs of infection. </li> <li>Low to high exuding wounds. </li> </ul> </td> <td> <ul> <li>Do not use on dry necrotic tissue. </li> <li>Known sensitivity to iodine. </li> <li>Short-term use recommended (risk of systemic absorption). </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Low-adherent wound contact layer (silicone)</td> <td> <ul> <li>Protect new tissue growth. </li> <li>Atraumatic to periwound skin. </li> <li>Conformable to body contours. </li> </ul> </td> <td> <ul> <li>Low to high exuding wounds. </li> <li>Use as contact layer on superficial low exuding wounds. </li> </ul> </td> <td> <ul> <li>May dry out if left in place for too long. </li> <li>Known sensitivity to silicone. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>PHMB</td> <td> <ul> <li>Antimicrobial action. </li> </ul> </td> <td> <ul> <li>Low to high exuding wounds. </li> <li>Critically colonized wounds or clinical signs of infection. </li> <li>May require secondary dressing. </li> </ul> </td> <td> <ul> <li>Do not use on dry/necrotic wounds. </li> <li>Known sensitivity. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Odor control (eg, activated charcoal)</td> <td> <ul> <li>Odor absorption. </li> </ul> </td> <td> <ul> <li>Malodorous wounds (due to excess exudate). </li> <li>May require antimicrobial if due to increased bioburden. </li> </ul> </td> <td> <ul> <li>Do not use on dry wounds. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Protease modulating</td> <td> <ul> <li>Active or passive control of wound protease levels. </li> </ul> </td> <td> <ul> <li>Clean wounds that are not progressing despite correction of underlying causes, exclusion of infection, and optimal wound care. </li> </ul> </td> <td> <ul> <li>Do not use on dry wounds or those with leathery eschar. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Silver</td> <td> <ul> <li>Antimicrobial action. </li> </ul> </td> <td> <ul> <li>Critically colonized wounds or clinical signs of infection. </li> <li>Low to high exuding wounds. </li> <li>Combined presentation with foam and alginates/CMC for increased absorbency. Also in paste form. </li> </ul> </td> <td> <ul> <li>Some may cause discoloration. </li> <li>Known sensitivity. </li> <li>Discontinue after 2 weeks if no improvement and reevaluate. </li> </ul> </td> </tr> <tr> <td>Polyurethane film</td> <td> <ul> <li>Moisture control. </li> <li>Breathable bacterial barrier. </li> <li>Transparent (allow visualization of wound). </li> </ul> </td> <td> <ul> <li>Primary dressing over superficial low exuding wounds. </li> <li>Secondary dressing over alginate or hydrogel for rehydration of wound bed. </li> </ul> </td> <td> <ul> <li>Do not use on patients with fragile/compromised periwound skin. </li> <li>Do not use on moderate to high exuding wounds. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Other more advanced dressings (eg, collagen and bioengineered tissue products) may be considered for wounds that are hard to heal<sup>[1]</sup>.</div><div class=\"graphic_footnotes\">CMC: carboxymethylcellulose; PHMB: polyhexamethylene biguanide.<br />* Wound dressings may contain alginates or CMC only; alginates may also be combined with CMC.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>International Consensus. Acellular matrices for the treatment of wounds. An expert working group review. Wounds International 2010. Available at http://woundsinternational.com (Accessed on March 2013).</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: McCardle J, Chadwick P, Edmonds M, et al. International Best Practice Guidelines: Wound Management in Diabetic Foot Ulcers. Wounds International, 2013. Copyright &copy; 2013 Schofield Healthcare Media LTD. Available from: <a href=\"http://www.woundsinternational.com/\" target=\"_blank\">www.woundsinternational.com</a>.</div><div id=\"graphicVersion\">Graphic 60931 Version 6.0</div></div></div>"},"60933":{"type":"graphic_picture","displayName":"Cecal villous adenoma Endosc","title":"Cecal adenoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cecal adenoma</div><div class=\"cntnt\"><img style=\"width:319px; height:313px;\" src=\"images/GAST/60933_Cecal_villous_adenoma_Endos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, multilobuluated polyp in the cecum with the endoscopic appearance of a villous adenoma, which was confirmed by histology.</div><div class=\"graphic_reference\">Courtesy of Eric D Libby, MD.</div><div id=\"graphicVersion\">Graphic 60933 Version 1.0</div></div></div>"},"60935":{"type":"graphic_diagnosticimage","displayName":"Cystic bronchiectasis","title":"Cystic bronchiectasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystic bronchiectasis</div><div class=\"cntnt\"><img style=\"width:432px; height:293px;\" src=\"images/PULM/60935_Cystic_bronchiectasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest CT shows left lower lobe dilated and thickened airways (arrow). Arrowhead shows clusters of airways forming cysts destroying lung.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Alan Barker, MD.</div><div id=\"graphicVersion\">Graphic 60935 Version 3.0</div></div></div>"},"60938":{"type":"graphic_table","displayName":"Etiology of urethral stricture","title":"Etiology of urethral stricture","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiology of urethral stricture</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Location</td> <td class=\"subtitle1\">Etiology of stricture</td> </tr> <tr> <td rowspan=\"3\">Anterior urethra</td> <td>Meatus</td> <td>Instrumentation, iatrogenic, hypospadias, skin disorders (lichen sclerosus)</td> </tr> <tr> <td>Pendulous urethra</td> <td>Instrumentation, iatrogenic, hypospadias, skin disorders (lichen sclerosus), sexually transmitted infections, crush injury</td> </tr> <tr> <td>Bulbar urethra</td> <td>Instrumentation, iatrogenic, skin disorders (lichen sclerosus), sexually transmitted infections, crush injury, straddle-type injury</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Posterior urethra</td> <td>Membranous urethra</td> <td>Instrumentation, pelvic fracture with urethral distraction defects</td> </tr> <tr> <td>Prostatic urethra</td> <td>Instrumentation, radiation therapy for prostate cancer (external beam radiation therapy, brachytherapy)</td> </tr> <tr> <td>Bladder neck</td> <td>Instrumentation, radiation therapy for prostate cancer (external beam radiation therapy, brachytherapy)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 60938 Version 4.0</div></div></div>"},"60939":{"type":"graphic_picture","displayName":"Leukoplakia - palate","title":"Leukoplakia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leukoplakia</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/60939_Leukoplakia_palate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A white plaque is present on the hard palate and gingiva.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60939 Version 3.0</div></div></div>"},"60941":{"type":"graphic_table","displayName":"Active TB risk factors","title":"Risk factors for the development of active tuberculosis among persons infected with <em>Mycobacterium tuberculosis</em>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for the development of active tuberculosis among persons infected with <em>Mycobacterium tuberculosis</em></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"42%\"></colgroup><colgroup width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk factor</td> <td class=\"subtitle1\">Estimated risk for TB relative to persons with no known risk factor</td> <td class=\"subtitle1\">References</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">High risk</td> </tr> <tr> <td class=\"indent1\">Acquired immunodeficiency syndrome (AIDS)</td> <td>110 to 170</td> <td>1,2</td> </tr> <tr> <td class=\"indent1\">Human immunodeficiency virus infection (HIV)</td> <td>50 to 110</td> <td>3,4</td> </tr> <tr> <td class=\"indent1\">Transplantation (related to immune-suppressant therapy)</td> <td>20 to 74</td> <td>5 to 8</td> </tr> <tr> <td class=\"indent1\">Silicosis</td> <td>30</td> <td>9,10</td> </tr> <tr> <td class=\"indent1\">Chronic renal failure requiring hemodialysis</td> <td>10 to 25</td> <td>11 to 14</td> </tr> <tr> <td class=\"indent1\">Carcinoma of head and neck</td> <td>16.0</td> <td>15</td> </tr> <tr> <td class=\"indent1\">Recent tuberculosis (TB) infection (&#8804;2 years)</td> <td>15.0</td> <td>16,17</td> </tr> <tr> <td class=\"indent1\">Abnormal chest radiograph with apical fibronodular changes typical of healed TB (not granuloma)</td> <td>6 to 19</td> <td>18 to 20</td> </tr> <tr> <td class=\"indent1\">Tumor necrosis factor (TNF)-alpha inhibitors</td> <td>1.7 to 9</td> <td>21,22,35,36</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Moderate risk</td> </tr> <tr> <td class=\"indent1\">Treatment with glucocorticoids</td> <td>4.9</td> <td>23</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus (all types)</td> <td>2 to 3.6</td> <td>24 to 27,37</td> </tr> <tr> <td class=\"indent1\">Young age when infected (&#8804;4 years)</td> <td>2.2 to 5</td> <td>28</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Slightly increased risk</td> </tr> <tr> <td class=\"indent1\">Underweight (&#60;85 percent of ideal body weight); for most individuals this is equivalent to body mass index (BMI) &#8804;20</td> <td>2 to 3</td> <td>29</td> </tr> <tr> <td class=\"indent1\">Cigarette smoker (1 pack/day)</td> <td>2 to 3</td> <td>30,31</td> </tr> <tr> <td class=\"indent1\">Chest radiograph with solitary granuloma</td> <td>2</td> <td>20,32</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Low risk</td> </tr> <tr> <td class=\"indent1\">Infected person, no known risk factor, normal chest radiograph (\"low-risk reactor\")</td> <td>1</td> <td>33</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Very low risk</td> </tr> <tr> <td class=\"indent1\">Positive booster (two-step test) with no other known risk factor and normal chest radiograph)</td> <td>0.5</td> <td>Extrapolated from 33 and 34</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Guelar A, Gatell JM, Verdejo J, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 1993; 7:1345.</LI>&#xD;&#xA;<LI>Antonucci G, Girardi E, Raviglione MC, et al. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. JAMA 1995; 274:143.</LI>&#xD;&#xA;<LI>Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1 - Infected adults from communities with low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 2000; 23:75.</LI>&#xD;&#xA;<LI>Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. New Engl J Med 1989; 320:545.</LI>&#xD;&#xA;<LI>Sakhuja V, Jha V, Varma PP, et al. The high incidence of tuberculosis among renal transplant recipients in India. Transplantation 1996; 61:211.</LI>&#xD;&#xA;<LI>Aguado JM, Herrero JA, Gavalda J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation 1997; 63:1278.</LI>&#xD;&#xA;<LI>Miller RA, Lanza LA, Kline JN, Geist LJ. Mycobacterium tuberculosis in lung transplant recipients. Am J Respir Crit Care Med 1995; 152:374.</LI>&#xD;&#xA;<LI>Meyers BR, Halpern M, Sheiner P, et al. Tuberculosis in liver transplant patients. Transplantation 1994; 58:301.</LI>&#xD;&#xA;<LI>Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A Double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145:36.</LI>&#xD;&#xA;<LI>Cowie RL. The epidemiology of tuberculosis in gold miners with silicosis. Am J Respir Crit Care Med 1994; 150:1460.</LI>&#xD;&#xA;<LI>Malhotra KK, Parashar MK, Sharma RK, et al. Tuberculosis in maintenance haemodialysis patients. Study from an endemic area. Postgrad Med J 1981; 57:492.</LI>&#xD;&#xA;<LI>Lundin AP, Adler AJ, Berlyne GM, Friedman EA. Tuberculosis in patients undergoing maintenance hemodialysis. Am J Med 1979; 67:597.</LI>&#xD;&#xA;<LI>Andrew OT, Schoenfeld PY, Hopewell PC, Humphreys MH. Tuberculosis in patients with end-stage renal disease. Am J Med 1980; 68:59.</LI>&#xD;&#xA;<LI>Pradhan RP, Katz LA, Nidus BD, et al. Tuberculosis in dialyzed patients. JAMA 1974; 229:798.</LI>&#xD;&#xA;<LI>Rieder HL, Cauthen GM, Comstock GW, Snider DE Jr. Epidemiology of tuberculosis in the United States. Epidemiol Rev 1989; 11:79.</LI>&#xD;&#xA;<LI>Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res 1976; 19:1.</LI>&#xD;&#xA;<LI>Sutherland I. The evolution of clinical tuberculosis in adolescents. Tuberc 1966; 47:308.</LI>&#xD;&#xA;<LI>Nolan CM, Elarth AM. Tuberculosis in a cohort of Southeast Asian refugees: A five-year surveillance study. Am Rev Resp Dis 1988; 137:805.</LI>&#xD;&#xA;<LI>Grzybowksi S, McKinnon NE, Tuters L, et al. Reactivations in inactive pulmonary tuberculosis. Am Rev Resp Dis 1966; 93:352. </LI>&#xD;&#xA;<LI>Grzybowski S, Fishaut H, Rowe J, Brown A. Tuberculosis among patients with various radiologic abnormalities, followed by the chest clinic service. Am Rev Resp Dis 1971; 104:605. </LI>&#xD;&#xA;<LI>Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor ? - neutralizing agent. N Engl J Med 2001; 345:1098. </LI>&#xD;&#xA;<LI>Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006; 43:717. </LI>&#xD;&#xA;<LI>Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006; 55:19. </LI>&#xD;&#xA;<LI>Kim SJ, Hong YP, Lew WJ, et al. Incidence of pulmonary tuberculosis among diabetics. Tuber Lung Dis 1995; 76:529. </LI>&#xD;&#xA;<LI>Silwer H, Oscarsson PN. Incidence and coincidence of diabetes mellitus and pulmonary tuberculosis in a Swedish county. Acta Med Scand 1958; 161:1. </LI>&#xD;&#xA;<LI>Pablos-Mendez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 1997; 87:574. </LI>&#xD;&#xA;<LI>Boucot KR. Diabetes mellitus and pulmonary tuberculosis. J Chronic Dis 1957; 6:256. </LI>&#xD;&#xA;<LI>Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974; 99:131. </LI>&#xD;&#xA;<LI>Comstock GW. Frost Revisited: The modern epidemiology of tuberculosis. Am J Epidemiol 1975; 101:263. </LI>&#xD;&#xA;<LI>Maurya V, Vijayan VK, Shah A. Smoking and tuberculosis: an association overlooked. Int J Tuberc Lung Dis 2002; 6:942. </LI>&#xD;&#xA;<LI>Gajalakshmi V, Peto R, Kanaka T, Jha P. Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43000 adult male deaths and 35000 controls. Lancet 2003; 362:507. </LI>&#xD;&#xA;<LI>Horwitz O, Wilbek E, Erickson PA. Epidemiological basis of tuberculosis eradication. Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area. Bull World Health Organ 1969; 41:95.</LI>&#xD;&#xA;<LI>Comstock GW, Edwards LB, Livesay VT. Tuberculosis morbidity in the US Navy: its distribution and decline. Am Rev Respir Dis 1974; 110:572. </LI>&#xD;&#xA;<LI>Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. Adv Tuberc Res 1969; 17:28. </LI>&#xD;&#xA;<LI>Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50:372. </LI>&#xD;&#xA;<LI>Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52:1766.</LI>&#xD;&#xA;<LI>Lee MR, Huang YP, Kuo YT, et al. Diabetes mellitus and latent tuberculosis infection: a systemic review and meta-analysis. Clin Infect Dis 2016; pii:ciw836.</LI></OL></div><div id=\"graphicVersion\">Graphic 60941 Version 7.0</div></div></div>"},"60942":{"type":"graphic_table","displayName":"Occupational HIV infection","title":"Healthcare personnel with documented and possible occupationally acquired HIV infection, by occupation, United States, 1981-2013","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Healthcare personnel with documented and possible occupationally acquired HIV infection, by occupation, United States, 1981-2013</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Occupation</td> <td class=\"subtitle1\">Documented</td> <td class=\"subtitle1\">Possible</td> </tr> <tr> <td>Nurse</td> <td class=\"centered\">24</td> <td class=\"centered\">37</td> </tr> <tr> <td>Laboratory worker, clinical</td> <td class=\"centered\">16</td> <td class=\"centered\">21</td> </tr> <tr> <td>Physician, nonsurgical</td> <td class=\"centered\">6</td> <td class=\"centered\">13</td> </tr> <tr> <td>Laboratory technician, nonclinical</td> <td class=\"centered\">4</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Housekeeper/maintenance worker</td> <td class=\"centered\">2</td> <td class=\"centered\">14</td> </tr> <tr> <td>Technician, surgical</td> <td class=\"centered\">2</td> <td class=\"centered\">2</td> </tr> <tr> <td>Embalmer/morgue technician</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> </tr> <tr> <td>Health aide/attendant</td> <td class=\"centered\">1</td> <td class=\"centered\">16</td> </tr> <tr> <td>Respiratory therapist</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> </tr> <tr> <td>Technician, dialysis</td> <td class=\"centered\">1</td> <td class=\"centered\">3</td> </tr> <tr> <td>Dental worker, including dentist</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">6</td> </tr> <tr> <td>Emergency medical technician/paramedic</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">13</td> </tr> <tr> <td>Physician, surgical</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">6</td> </tr> <tr> <td>Other technician/therapist</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">9</td> </tr> <tr class=\"divider_bottom\"> <td>Other healthcare occupation</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">6</td> </tr> <tr> <td><strong>Total</strong></td> <td class=\"centered\"><strong>58</strong></td> <td class=\"centered\"><strong>150</strong></td> </tr> </tbody></table></div><div class=\"graphic_reference\">Joyce MP, Kuhar D, Brooks JT. Notes from the field: occupationally acquired HIV infection among health care workers - United States, 1985-2013. MMWR Morb Mortal Wkly Rep. 2015 Jan 9; 63(53):1245-6.</div><div id=\"graphicVersion\">Graphic 60942 Version 5.0</div></div></div>"},"60944":{"type":"graphic_figure","displayName":"Mortality risk among dialysis pts according to baseline albumin","title":"Risk of mortality among dialysis patients according to baseline albumin at initiation of dialysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Risk of mortality among dialysis patients according to baseline albumin at initiation of dialysis</div><div class=\"cntnt\"><img style=\"width:410px; height:245px;\" src=\"images/NEPH/60944_HD_and_PD_survival_by_album.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Correlation of the risk of mortality according to the plasma albumin concentration, obtained within six weeks of starting maintenance dialysis in 2897 patients receiving hemodialysis and 666 patients treated with CAPD. Hypoalbuminemia was associated with increased mortality, particularly at plasma concentrations below 3.0 g/dL (30 g/L).</div><div class=\"graphic_footnotes\">CAPD: continuous ambulatory peritoneal dialysis.</div><div class=\"graphic_reference\">Data from Held PJ, Port FK.</div><div id=\"graphicVersion\">Graphic 60944 Version 6.0</div></div></div>"},"60945":{"type":"graphic_figure","displayName":"Anterior cerebral artery territory","title":"Anterior cerebral artery distribution and signs and symptoms of occlusion","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Anterior cerebral artery distribution and signs and symptoms of occlusion</div><div class=\"cntnt\"><img style=\"width:535px; height:578px;\" src=\"images/NEURO/60945_Ant_cerebral_artery_territo.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from Kistler, JP, et al, Cerebrovascular Diseases, Harrison's Principles of Internal Medicine, 13th ed. McGraw-Hill, New York 1994. Copyright 1994 McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 60945 Version 2.0</div></div></div>"},"60946":{"type":"graphic_picture","displayName":"Condyloma acuminatum 1","title":"Perianal condyloma acuminatum","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Perianal condyloma acuminatum</div><div class=\"cntnt\"><img style=\"width:400px; height:513px;\" src=\"images/OBGYN/60946_Condyloma_acuminatum1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 60946 Version 7.0</div></div></div>"},"60949":{"type":"graphic_table","displayName":"Causes of acute pericarditis ","title":"Acute pericarditis etiologies: Data from published clinical studies with unselected populations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Acute pericarditis etiologies: Data from published clinical studies with unselected populations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Permanyer-Miralda G. et al.<br /> (n = 231)</td> <td class=\"subtitle1\">Zayas R. et al.<br /> (n = 100) </td> <td class=\"subtitle1\">Imazio M. et al.<br /> (n = 453) </td> <td class=\"subtitle1\"> <p>Reuter H. et al.<br /> (n = 233) </p> </td> <td class=\"subtitle1\"> <p>Gouriet F. et al.<br /> (n = 933) </p> </td> </tr> <tr> <td>Years</td> <td>1977-1983</td> <td>1991-1993 </td> <td>1996-2004</td> <td>1995-2001</td> <td>2007-2012</td> </tr> <tr> <td>Location</td> <td>Spain</td> <td>Spain</td> <td>Italy</td> <td>Africa</td> <td>Western Europe&nbsp;</td> </tr> <tr> <td>Idiopathic</td> <td>199 (86.0 percent)</td> <td>78 (78.0 percent)</td> <td>377 (83.2 percent)</td> <td>32 (13.7 percent)</td> <td>516 (55.0 percent)&nbsp;</td> </tr> <tr> <td>Specific etiology</td> <td>32 (14.0 percent)</td> <td>22 (22.0 percent)</td> <td>76 (16.8 percent)</td> <td>201 (86.3 percent)</td> <td>417 (46.0 percent)&nbsp;</td> </tr> <tr> <td>Neoplastic</td> <td>13 (5.6 percent)</td> <td>7 (7.0 percent)</td> <td>23 (5.1 percent)</td> <td>22 (9.4 percent)</td> <td>85 (8.9 percent)&nbsp;</td> </tr> <tr> <td>Tuberculosis</td> <td>9 (3.9 percent)</td> <td>4 (4.0 percent)</td> <td>17 (3.8 percent)</td> <td>161 (69.5 percent)</td> <td>4 (&#60;1.0 percent)</td> </tr> <tr> <td>Autoimmune etiologies</td> <td>4 (1.7 percent)</td> <td>3 (3.0 percent)</td> <td>33 (7.3 percent)</td> <td>12 (5.2 percent)</td> <td>197 (21 percent)&nbsp;</td> </tr> <tr> <td>Purulent</td> <td>2 (0.9 percent)</td> <td>1 (1.0 percent)</td> <td>3 (0.7 percent)</td> <td>5&nbsp;(2.1 percent)</td> <td>29 (3.0 percent)&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Permanyer-Miralda G, Sagrista-Sauleda J, Soler-Soler J. Primary acute pericardial disease: A prospective series of 231 consecutive patients. Am J Cardiol 1985; 56:623.</LI>&#xD;&#xA;<LI>Zayas R, Anguita M, Torres F, et al. Incidence of specific etiology and role of methods for specific etiologic diagnosis of primary acute pericarditis. Am J Cardiol 1995; 75:378.</LI>&#xD;&#xA;<LI>Imazio M, Cecchi E, Demichelis B, et al. Indicators of poor prognosis of acute pericarditis. Circulation 2007; 115:2739.</LI>&#xD;&#xA;<LI>Reuter H, Burgess LJ, Louw VJ, et al. The management of tuberculous pericardial effusion: experience in 233 consecutive patients. Cardiovasc J S Afr 2007; 18:20.</LI>&#xD;&#xA;<LI>Gouriet F, Levy PY, Casalta JP, et al. Etiology of&nbsp;pericarditis&nbsp;in a prospective cohort of 1162 cases. Am J Med 2015; 128:784.</LI></OL></div><div id=\"graphicVersion\">Graphic 60949 Version 5.0</div></div></div>"},"60950":{"type":"graphic_table","displayName":"Treatment studies BV preg","title":"Treatment regimens used in studies demonstrating a reduction in preterm birth in treated high-risk patients with bacterial vaginosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment regimens used in studies demonstrating a reduction in preterm birth in treated high-risk patients with bacterial vaginosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Metronidazole 400 mg orally twice daily for two consecutive days. Repeat if a second test four weeks post-treatment is positive.<sup>[1]</sup></td> </tr> <tr> <td>Metronidazole 250 mg orally three times daily for seven days plus erythromycin base 333 mg orally three times daily for 14 days. Repeat test at 28 weeks of gestation and repeat treatment if test is positive.<sup>[2]</sup></td> </tr> <tr> <td>Metronidazole 250 mg orally three times daily for seven days. No second treatment.<sup>[3]</sup></td> </tr> <tr> <td>Clindamycin 300 mg orally twice daily for five days. No second treatment.<sup>[4]</sup></td> </tr> <tr> <td>Clindamycin 5 grams of 2% vaginal cream nightly for three nights. Repeat test three weeks after initial diagnosis; if still positive, give a seven-day course of the same treatment.<sup>[5]</sup></td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>McDonald HM, O'Loughlin JA, Vigneswaran R, et al. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial. Br J Obstet Gynaecol 1997; 104:1391. </LI>&#xD;&#xA;<LI>Hauth JC, Goldenberg RL, Andrews WW, et al. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med 1995; 333:1732. </LI>&#xD;&#xA;<LI>Morales WJ, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am J Obstet Gynecol 1994; 171:345. </LI>&#xD;&#xA;<LI>Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet 2003; 361:983. </LI>&#xD;&#xA;<LI>Lamont RF, Duncan SL, Mandal D, Bassett P. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstet Gynecol 2003; 101:516. </LI></OL></div><div id=\"graphicVersion\">Graphic 60950 Version 6.0</div></div></div>"},"60952":{"type":"graphic_picture","displayName":"Papules in Cowden syndrome","title":"Trichilemmomas and verrucous papules, as well as oral papillomas on the mucosa are characteristic of Cowden syndrome ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trichilemmomas and verrucous papules, as well as oral papillomas on the mucosa are characteristic of Cowden syndrome </div><div class=\"cntnt\"><img style=\"width:392px; height:262px;\" src=\"images/ONC/60952_Cowdens_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichilemmomas (multiple skin-colored warty papules) on the face, as well as the mucosa of the lower lip.</div><div class=\"graphic_reference\">Reproduced with permission from: Color Atlas and Synopsis of Clinical Dermatology, 3rd edition, Fitzpatrick, et al (Eds), McGraw-Hill, New York 1997. Copyright © 1997 The McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 60952 Version 6.0</div></div></div>"},"60954":{"type":"graphic_picture","displayName":"Thoracic ultrasound transducer","title":"Thoracic ultrasound transducer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracic ultrasound transducer</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PULM/60954_ThoracicUStransducer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 3.5 MHz convex array transducer is shown over the right lateral chest wall, just below the angle of the clavicle. The arrows indicate the directions the transducer may be moved during a systematic examination. Transducer movement should be in only one direction at a time until the entire area of interest has been imaged. The purpose of the examination is to outline the craniocaudal and lateral extents of the pleural effusion, determine whether the effusion is free-flowing or septated, and identify adjacent structures.</div><div id=\"graphicVersion\">Graphic 60954 Version 3.0</div></div></div>"},"60955":{"type":"graphic_figure","displayName":"Air plethysmography","title":"Air plethysmography","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Air plethysmography</div><div class=\"cntnt\"><img style=\"width:598px; height:398px;\" src=\"images/SURG/60955_Air_plethysmography.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Air plethysmography indirectly measures changes in leg volume by quantifying air displacement within a polyurethane cuff wrapped around the calf.<br />(A) The test begins with the patient supine. The limb being evaluated is elevated to drain the venous system. The cuff is placed on the lower leg and inflated to a low pressure to calibrate the equipment.<br />(B) The patient is asked to stand, which fills the veins. The maximum volume achieved is the functional venous volume (VV). The time needed to fill 90 percent of the functional venous volume (90%VV) is the venous filling time (VFT90). The venous filling index (VFI) is 90%VV/VFT90.<br />(C) With the limb filled with blood, the patient is asked to dorsiflex at the ankle (toe-up) which ejects blood from the leg (measured as the ejection volume [EV]). The ejection fraction (EF) is the ratio of ejection volume to the functional venous volume (EV/VV x 100%).<br />(D) Next, the patient is asked to perform a series of consecutive dorsiflexion movements (toe-ups), which empties blood from the leg allowing the calculation of the residual volume (RV). The residual volume fraction is the ratio of the residual volume to the functional venous volume (RV/VV x 100%).<br />(E) With the limb dependent and resting, the leg refills with blood.</div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Reproduced from: Perrin M, Gillet JL, Guex JJ. Syndrome post-thrombotique. In: Encyclop&eacute;die M&eacute;dico-Chirurgicale, Elsevier, 2003. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 60955 Version 2.0</div></div></div>"},"60957":{"type":"graphic_diagnosticimage","displayName":"Esophageal perforation PA","title":"Esophageal perforation","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal perforation</div><div class=\"cntnt\"><img style=\"width:276px; height:324px;\" src=\"images/GAST/60957_Esophageal_perforation_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest film from a patient with Boerhaave syndrome reveals air under both diaphragmatic leaflets.</div><div class=\"graphic_reference\">Courtesy of Robert E Mindelzun, MD, Department of Radiology, Stanford University.</div><div id=\"graphicVersion\">Graphic 60957 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal chest radiograph</div><div class=\"cntnt\"><img style=\"width:371px; height:324px;\" src=\"images/PULM/65576_Normal_chest_film_PA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior view of a normal chest radiograph.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD.</div><div id=\"graphicVersion\">Graphic 65576 Version 1.0</div></div></div>"},"60960":{"type":"graphic_picture","displayName":"Lichen sclerosus early adult","title":"Lichen sclerosus early adult","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lichen sclerosus early adult</div><div class=\"cntnt\"><img style=\"width:213px; height:432px;\" src=\"images/OBGYN/60960_LS_early_adult.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">40-year-old woman with vulvar lichen sclerosus. She has had itching and irritation for two years. Note loss of clitoris, most of labia minora, a periclitoral white plaque, and erythema from scratching.</div><div class=\"graphic_reference\">Reproduced with permission from: F William Danby, MD, FRCPC, FAAD,&nbsp;and Lynne J Margesson, MD.</div><div id=\"graphicVersion\">Graphic 60960 Version 4.0</div></div></div>"},"60962":{"type":"graphic_diagnosticimage","displayName":"Newborn with natal teeth","title":"Natal teeth radiograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Natal teeth radiograph</div><div class=\"cntnt\"><img style=\"width:399px; height:256px;\" src=\"images/PEDS/60962_Newborn_with_natal_teeth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This radiograph of a newborn with natal teeth confirms they are the normal primary central incisors and not supernumerary teeth.</div><div class=\"graphic_reference\">Reproduced with permission from: Wright JT. Normal formation and development defects of the human dentition. Pediatr Clin North Am 2000; 47:975. Copyright &copy; WB Saunders 2000.</div><div id=\"graphicVersion\">Graphic 60962 Version 5.0</div></div></div>"},"60963":{"type":"graphic_table","displayName":"Eating attitudes test","title":"Eating attitudes test","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Eating attitudes test</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"7\" width=\"7%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Always</td> <td class=\"subtitle1\">Usually</td> <td class=\"subtitle1\">Often</td> <td class=\"subtitle1\">Sometimes</td> <td class=\"subtitle1\">Rarely</td> <td class=\"subtitle1\">Never</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td>1. Am terrified about being overweight</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>2. Avoid eating when I am hungry</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>3. Find myself preoccupied with food</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>4. Have gone on eating binges where I feel that I may not be able to stop</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>5. Cut my food into small pieces</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>6. Aware of the calorie content of foods that I eat</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>7. Particularly avoid foods with high carbohydrate content (ie, bread, rice, potatoes, etc)</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>8. Feel that others would prefer if I ate more</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>9. Vomit after I have eaten</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>10. Feel extremely guilty after eating</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>11. Am preoccupied with a desire to be thinner</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>12. Think about burning up calories when I exercise</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>13. Other people think that I am too thin</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>14. Am preoccupied with the thought of having fat on my body</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>15. Take longer than others to eat my meals</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>16. Avoid foods with sugar in them</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>17. Eat diet foods</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>18. Feel that food controls my life</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>19. Display self-control around food</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>20. Feel that others pressure me to eat</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>21. Give too much time and thought to food</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>22. Feel uncomfortable after eating sweets</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>23. Engage in dieting behavior</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>24. Like my stomach to be empty</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td>25. Enjoy trying new rich foods</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr class=\"divider_bottom\"> <td>26. Have the impulse to vomit after meals</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">0</td> <td class=\"centered\">___</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">For all items except #25, responses receive the following value:</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Always = 3</td> <td>Usually = 2</td> <td>Often = 1</td> <td>Sometimes = 0</td> <td>Rarely = 0</td> <td>Never = 0</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">For item #25, the responses receive these values:</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Always = 0</td> <td>Usually = 0</td> <td>Often = 0</td> <td>Sometimes = 1</td> <td>Rarely = 2</td> <td>Never = 3</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The cutoff score in screening patients for the presence of a DSM-IV eating disorder is 20<sup>[1]</sup>.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Mintz LB, O'Halloran MS. The Eating Attitudes Test: validation with DSM-IV eating disorder criteria. J Pers Assess 2000; 74:489.</li>&#xD;&#xA;</ol>&#xD;&#xA;<br />Reproduced with permission from: Garner DM, Garfinkel PE. Psychol Med 1979; 9:273. Copyright &copy; 1979 Cambridge University Press.</div><div id=\"graphicVersion\">Graphic 60963 Version 6.0</div></div></div>"},"60965":{"type":"graphic_diagnosticimage","displayName":"Impacted common bile duct stone","title":"Impacted common bile duct stone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Impacted common bile duct stone</div><div class=\"cntnt\"><img style=\"width:432px; height:403px;\" src=\"images/SURG/60965_Impacted_bileduct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Impacted common bile duct stone (arrow). Characteristic smooth, concave intraluminal filling defect.</div><div class=\"graphic_reference\">Reproduced with permission from: Eisenberg, RL. An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright © 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60965 Version 2.0</div></div></div>"},"60967":{"type":"graphic_figure","displayName":"Inferior skull anatomy","title":"Inferior skull anatomy","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Inferior skull anatomy</div><div class=\"cntnt\"><img style=\"width:604px; height:418px;\" src=\"images/EM/60967_Skull_anat_inf.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inferior view of the external aspect of the skull.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, PhD, FRSM, FIAC &amp; Dalley AF II, PhD. Clinical Oriented Anatomy (4th ed.). Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60967 Version 2.0</div></div></div>"},"60968":{"type":"graphic_picture","displayName":"Recluse spider eye pattern","title":"Eye pattern of a recluse spider","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eye pattern of a recluse spider</div><div class=\"cntnt\"><img style=\"width:396px; height:396px;\" src=\"images/ALLRG/60968_Recluse_eye_pattern.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Richard S Vetter, MS.</div><div id=\"graphicVersion\">Graphic 60968 Version 2.0</div></div></div>"},"60971":{"type":"graphic_picture","displayName":"Enamel hypoplasia","title":"Enamel hypoplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Enamel hypoplasia</div><div class=\"cntnt\"><img style=\"width:284px; height:212px;\" src=\"images/PEDS/60971_Enamel_hypoplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dennis J McTigue, MD.</div><div id=\"graphicVersion\">Graphic 60971 Version 2.0</div></div></div>"},"60974":{"type":"graphic_figure","displayName":"Billroth reconstruction following gastrectomy","title":"Billroth reconstruction following gastrectomy","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Billroth reconstruction following gastrectomy</div><div class=\"cntnt\"><img style=\"width:538px; height:520px;\" src=\"images/SURG/60974_Billroth_I_and_II_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This illustration depicts the Billroth I and Billroth II methods of reconstruction following vagotomy and antrectomy. The Billroth I consists of an end-to-end gastrodoudenal anastomosis; in contrast, the Billroth II consists of an end-to-side gastrojejunal anastomosis.</div><div class=\"graphic_reference\">Sedgwick CE. Gastrectomy. In: Atlas of Abdominal Surgery, Braasch JW, Sedgwick CE, Veidenheimer MC, Ellis FH (Eds), WB Saunders Company, Philadelphia 1991. p.33.</div><div id=\"graphicVersion\">Graphic 60974 Version 8.0</div></div></div>"},"60975":{"type":"graphic_picture","displayName":"Degenerated uterine leiomyoma","title":"Uterine leiomyoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterine leiomyoma</div><div class=\"cntnt\"><img style=\"width:372px; height:247px;\" src=\"images/PC/60975_Degenerated_uterine_leiomyo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross intraoperative photograph of a degenerated uterine leiomyoma. This benign neoplasm can mimic an ovarian tumor.</div><div class=\"graphic_reference\">Courtesy of Mitchel Hoffman, MD.</div><div id=\"graphicVersion\">Graphic 60975 Version 1.0</div></div></div>"},"60977":{"type":"graphic_picture","displayName":"Lunge PI","title":"Lunge","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lunge</div><div class=\"cntnt\"><img style=\"width:387px; height:432px;\" src=\"images/PI/60977_Lunge_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stand with the feet together. Step the right foot approximately 36 inches in front of the body. The right knee should be over the right ankle. Hold for 5 seconds. Step the right foot back so that the feet are together. Rest as needed. Repeat with the left leg. Repeat 10 to 15 times (one set). Perform a total of 3 sets.</div><div id=\"graphicVersion\">Graphic 60977 Version 3.0</div></div></div>"},"60979":{"type":"graphic_figure","displayName":"Penile blood flow in erection","title":"Penile blood flow in erection","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Penile blood flow in erection</div><div class=\"cntnt\"><img style=\"width:494px; height:317px;\" src=\"images/ENDO/60979_Penile_blood_flow_in_erecti.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cross-section of corpora cavernosae illustrating penile blood flow in the flaccid and erect state. As intracavernosal pressure rises, emissary veins are occluded to maintain erectile function.</div><div id=\"graphicVersion\">Graphic 60979 Version 1.0</div></div></div>"},"60981":{"type":"graphic_movie","displayName":"Traction-countertraction with axillary pressure","title":"Traction-countertraction technique for shoulder reduction","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traction-countertraction technique for shoulder reduction</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/60981_Tractioncountertraction.mp4\" style=\"width:448px;height:352px\"></div><img style=\"width:432px; height:324px;\" src=\"images/EM/60981_Tractioncountertraction.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Simon and Sherman, Emergency Orthopedics, 6th edition. DVD © Scott Sherman. All rights reserved.</div><div id=\"graphicVersion\">Graphic 60981 Version 3.0</div></div></div>"},"60985":{"type":"graphic_picture","displayName":"Lichen planus penis","title":"Penile lichen planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Penile lichen planus</div><div class=\"cntnt\"><img style=\"width:396px; height:269px;\" src=\"images/DERM/60985_Lichen_planus_penis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lichen planus. Wickham's striae are visible.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 60985 Version 2.0</div></div></div>"},"60988":{"type":"graphic_figure","displayName":"Single breath DLCO","title":"Single breath DLCO maneuver","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Single breath DLCO maneuver</div><div class=\"cntnt\"><img style=\"width:455px; height:250px;\" src=\"images/PULM/60988_Single_breath_DLCO.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient quickly inhales a deep breath of test gas, holds his or her breath for 10 seconds, and then exhales quickly. The Jones method measures breathhold time (BHT) starting at 30 percent of inspiratory time (t<sub>I</sub>) and extending to half of sampling time.</div><div class=\"graphic_footnotes\">RV: residual volume; TLC: total lung capacity.</div><div class=\"graphic_reference\">Adapted from Am J Respir Crit Care Med 1995; 152:2185.</div><div id=\"graphicVersion\">Graphic 60988 Version 1.0</div></div></div>"},"60989":{"type":"graphic_diagnosticimage","displayName":"Tracheal hamartoma","title":"Tracheal hamartoma","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Tracheal hamartoma</div><div class=\"cntnt\"><img style=\"width:506px; height:420px;\" src=\"images/PULM/60989_Tracheal_hamartoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple images obtained from a patient with a tracheal hamartoma. This lesion, visible on the lateral radiograph (A), is further characterized using axial (B) and coronal (C) computed tomographic images and a computer generated shaded surface reformatting (D).</div><div class=\"graphic_reference\">Courtesy of Lawrence Goodman, MD.</div><div id=\"graphicVersion\">Graphic 60989 Version 3.0</div></div></div>"},"60990":{"type":"graphic_diagnosticimage","displayName":"Normal and torn labrum CT","title":"Computerized tomographic (CT) arthrography of the shoulder","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computerized tomographic (CT) arthrography of the shoulder</div><div class=\"cntnt\"><img style=\"width:358px; height:566px;\" src=\"images/RHEUM/60990_Normal_and_torn_labrum_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The upper panel illustrates a normal double contrast CT arthrogram (air and radiopaque contrast). The anterior glenoid labrum (arrows) and the normal extent of the anterior glenohumeral joint capsule (arrowhead) are seen in this axial image. In the lower panel, a tear of the anterior glenoid labrum is seen (air and contrast abuts the bone of the glenoid); the fibrocartilaginous labrum has been avulsed.</div><div class=\"graphic_reference\">Courtesy of Douglas H Brown, MD.</div><div id=\"graphicVersion\">Graphic 60990 Version 3.0</div></div></div>"},"60995":{"type":"graphic_figure","displayName":"Normal mesenteric fixation","title":"Normal small bowel mesenteric attachment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal small bowel mesenteric attachment</div><div class=\"cntnt\"><img style=\"width:360px; height:387px;\" src=\"images/PEDS/60995_Normal_mesenteric_fixation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal mesenteric fixation. Normal rotation and fixation results in a wide-based mesentery (demonstrated by the red line) that extends from the ligament of Treitz in the left upper quadrant to the ileocecal valve in the right lower quadrant.</div><div id=\"graphicVersion\">Graphic 60995 Version 1.0</div></div></div>"},"60997":{"type":"graphic_table","displayName":"Indications for DLCO","title":"Indications for performing a diffusing capacity of the lungs for carbon monoxide (DLCO) test","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for performing a diffusing capacity of the lungs for carbon monoxide (DLCO) test</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Evaluation of dyspnea or hypoxemia</td> </tr> <tr> <td>Evaluation of emphysema</td> </tr> <tr> <td>Evaluation for presence of interstitial lung disease</td> </tr> <tr> <td>Monitoring of known interstitial lung disease</td> </tr> <tr> <td>Differential diagnosis of lung volume restriction</td> </tr> <tr> <td>Detection of pulmonary vascular disease</td> </tr> <tr> <td>Pulmonary disability/impairment evaluation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ILD: interstitial lung disease; COPD: chronic obstructive pulmonary disease.</div><div id=\"graphicVersion\">Graphic 60997 Version 4.0</div></div></div>"},"60998":{"type":"graphic_figure","displayName":"Anatomic relationship of colon to surrounding structures","title":"Anatomic relationship of colon to surrounding structures","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Anatomic relationship of colon to surrounding structures</div><div class=\"cntnt\"><img style=\"width:531px; height:586px;\" src=\"images/SURG/60998_Colon-relationships.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the relationship of the large intestine to the overlying and underlying organs and vessels.</div><div id=\"graphicVersion\">Graphic 60998 Version 1.0</div></div></div>"},"60999":{"type":"graphic_diagnosticimage","displayName":"Thoracic aorta dilation","title":"Mildly dilated thoracic aorta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mildly dilated thoracic aorta</div><div class=\"cntnt\"><img style=\"width:314px; height:246px;\" src=\"images/CARD/60999_Thoracic_aorta_dilation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The long axis precordial view shows slight dilation of the thoracic aorta (Th Ao).</div><div class=\"graphic_footnotes\">CS: coronary sinus.</div><div id=\"graphicVersion\">Graphic 60999 Version 2.0</div></div></div>"}};